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Preface
Capsaicin, the hot principle of red peppers or chilli (paprika) is a favorite spice in culinary
practice.
Since the time man started gathering food, the additional of small amounts of some plan
materials may have been used for the powerful impact they had on the appearance or eating
quantity. Initially, these additions were valued for masking the off-flavor of stored, decom‐
posing foods; late on, in medieval Europe, they were imported as rural spices for their ca‐
pacity to slow down deterioration during storage. Gradually, when definitve ethnic cuisines
developed, the individual spices came to be valued in the modern sense for their contribu‐
tion, which is to flavor generally insipid meat and cereal foods and to make more acceptable
and preferred. Spices have became indispensable in the modern kitchens on individual
homes, institutions, and the food manufactoring industries. They provide individually to
the dishes and distinquishing gourmet foods.
Among the spices, capsicums are the most colorful in appearance, and are important in
terms of their history, antiquity, and influence on many cuisines of the world.
During the first expedition, Colombus (1492-1493) observed that the natives of the New
World used a colorful red fred fruit calls aji or axe with most of their foods. This additive
was found to be much stronger than the black pepper of Asia (Piper nigrum L.) in search of
which he had undertaken this expedition. He took samples of this fruit back to Spain and
named it „red pepper”. De Cuneo, who accompanied Colombus on the second voyage to the
New World in 1495, made the more definitive observations that „rose-like bushes have
fruits as long as cinnamon, full of small grains, as biting as pepper; those Caribes and Indi‐
ans eat that fruit like we eat apple”.
Chanca, the physician with expedition, observed that the natives used this food additive bot
has a condiment and in medicine. Other travelers, who extensively traveled in Spanish
America in the 16th and 17th centruries, decribed the popular use of Uchu , a colorful fiery
pod of a plant, in the food of Peruvian Indians. Since early Indians of northern Guatemala
has been recorded. The highly irritating smoke from the burning dried fruit is reported to
have used by the native Indians against Spanish invaders.
The chilli pepper (paprika) is one of the very old domesticated plants of Middle America.
The Valle de Tehuacan (Puebra) which is one of the best documented examples on an early
settlement in Mesoamerica, archeological evidence for the consumption of chilli pepper
dates back to the seventth millennium B.C., long before the cultivation of maize and beans.
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Capsicum has been known since the beginning of civilization in the Western Hemisphere. It
has been a part of the human diet since about 7500 B.C. It was the ancient ancestors of the
native people, who took the wild chilli piguin and selected the values types known today.
The Capsicum is a genus of the family of Solanaceae and is closely related to another genus,
Solanum, which covers many economically important plants such as potato (Solanum tuber‐
osum L.), eggplant (S. melengere L.), tomato (Lycopersieon esculentum Mill.), and tobacco
(Nicotiana tobacum L.).
Some 20 to 30 species of Capsicum are reported in the world. The following five major species are
mophologically definable: Capsicum annuum var. Annuum L., Capsicum frutescences L., Capsaicum
chinense Jacq, Capsicum baccatum var. Pendulum wild, Capsaicum pubescens Riuz and Pav).
Seven capsaicinoids (capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydro-cap‐
saicin, homocapsaicin, nonanoic acid vanillylamide and decanoid acid vanillylamide) can be
extracted from the different Capsicum species. The first five compounds represent capsaicin
homologues, meanwhile the last two represent capsaicin analogues.
In physiological and pharmacological basic research, the term of „capsaicin” as „one” chem‐
ical compound” is generally used, meanswhile the fine chemical trading firms (including
Sigma Aldrich and all of others) obtain the capsaicin from plants (Capsicum ). According to
the chemotaxonomic key, the different species of Capsicums contain different amounts of
capsaicin homologues and analogues. So, the commercially available natural capsaicin prep‐
aration are mixtures of capsaicin and natural capsaicinoids.
The capsaicin preparation can be used as an active pharmaceutical ingredient (Capsaicin
Natural) is described by the United States Pharmacopeia (USP). The 2006 edition of USP30-
NF25 described its definition, identification, melting range and the content of capsaicin, di‐
hydrocapsaicin and other capsaicinoids. According to the USP requirements Capsaicin
Natural should contain not less than 90 percent of total capsaicinoids. The content of capsai‐
cin and dihydrocapsaicin should not less than 75 percent, and the content of other capsaici‐
noids should not more than 15 percent calculated on dried basis (USP30-NF25 Page 1609).
The principal requirements of the European Authorities capsaicinoid content of natural cap‐
saicin preparations for medical therapy are the as those of USP30-NF25.
The capsaicin (capsaicinoids) modify the functions of capsaicin-sensitive afferent nerves,
however, this (these) action(s) is(are) on dose-dependent manner. This (these) compound (s)
stimulates (stimulate) in smaller doses and inhibits (inhibit) in higher doses of capsaicin-sen‐
sitive afferent nerves. The capsaicin-.induced actions on capsaicin-sensitive afferent nerves
are associated with changes of vascular microcirculation, relaese of different neuropeptides,
modifications of functions of immune cells, hormonal system, etc. Consequently the the cap‐
saicin(oids) is (are) able to produce gastrointestinal mucosal protection and mucosal dam‐
age.
Because of capsaicin(oids), the hot principle of red peppers or chill is (are) a favorite spice in
culinary practice and therefore it’s (their) role in gastrointestinal tract has (have) been tested
in animal experiments and in human observations. The obtained results were contradictory
ones in gastrointestinal tract of animals and of humans (patiensts). The capsaicin was given
in very different ( from small to extremely high) doses of capsaicin int he different observa‐
tions.
XIV Preface
Szolcsányi and Barthó (1981) firstly demonstrated that the capsaicin given in 5-50 µg/mL
(given intragastrically) prevents the development of gastric mucosal damage in rats, mean‐
while it enhances the gastric mucosal damage given in higher doses. It was important dis‐
covery that the gastroprotection produced by small doses of capsaicin does not associated
with the decrease of gastric acid secretion (volume and Hst output) and of pepsin secretion
(details in a book chapter of this book).
Robert el al. (1979) described the phenomenon of „cytoprotection” to prostaglandins. The
essetial point of this discovery was that the small doses of prostaglandins are able to protect
the gastric mucosal damage produced by intragastric administration of 96% ethanol, 0.2 M
NaOH, 0.6 M HCl and 25% saline sulution in rats, without presence of any decrease of gas‐
tric acid secretion.
The capsaicin-induced gastroprotection differs from the „classical cytoprotection”, beacuse
the mechanism of gastroprotection by capsaicin mediated by subepithelial enhanced of mi‐
crocirculation, meanwhile in case of the „classic cyoptoprotection” produced by different
chemicals produce in fact a destroy the superficial protective layer of the stomach (mainly
mediated by prostaglandins). In many other observations indicated that the chemicals-in‐
duced mucosal damage (produced according to the method of Robert et al.,1979) can be pro‐
tected by many other compounds (SH-inhibitors, retinoids, carotenoids, etc ) as the
prostaglandin system.
Prior to these basic observations in animal models we had previously performed studies in
humans with anticholinergic agents. We employed conventional clinical pharmacological
studies using methods that were then established in our group in time period of 1962 to
1970. Our attention was focussed on the changes of gastric secretory responses in patients
with duodenal ulcer during a chronic atropine treatment. We were very surprised to find
that the patients with duodenal ulcer healed following chronic (2 to 4 weeks) treatment with
atropine. However, the gastric secretory responses of patients were not decreased (as basal
acid output, BAO, and after application of superliminal (but submaximal) of dose of hista‐
mine (0.5 mg given s.c.), thus showing that the duodenal protection could be obtained inde‐
pendent of effects on acid secretion (Mózsik et al., 1965). In 1978, we found that the
gastrointestinal anti-ulcer effects of atropine, cimetidine and carbenoxolone were superior to
that of placebo in a multicentre, randomized, prospective and comparative study in duode‐
nal ulcer patients. However, no significant difference was obtained in the beneficial effects
of atropine vs. cimetidine vs. cabenoxolone (Tárnok et al., 1978). Since carbenoxolone, has no
inhibitory action of gastric acid secretion in DU patients could be considered independent of
any effects on acid secretion. We did not know anything about the „classical cytoprotec‐
tion”, and we gave a clinical pharmacological explanation (namely the development of toler‐
ance to drug used in the treatment and together development of „pharmacological
denervation”) for the first our observation, and in the second case, we suggested that the
increase of mucus secretion (and no the gastric acid secretion) took place in the duodenal
protection in DU patients.
Discoveries of both of these two kinds of gastroprotective mechanims in rats opened new
gates of research in the gastrointestinal tract. These studies run, in some meaning, in differ‐
ent and separated ways, meanwhile these studies have been combined together in our days.
Many new pathways were found in the field of „classical cytoprotection „in our days, and
as well as in the field of capsaicin research. There are no questions that the principal regula‐
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as well as in the field of capsaicin research. There are no questions that the principal regula‐
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tory functions exist in basic research of animals and in humans. However, there are some
differences between the results (and explanations) of basic research and human observations
in the GI tract in human beings.
Many observations with capsaicin were carried out from last decades in the animal experi‐
ments and in human observations. It’s true that number of capsaicin studies much more
higher in animals and than in humans.
The explanations for the small number of human observations are complex, namely. 1. the
solution of the ethical problems of human observations; 2. permission from the national and
international Authorities for investigating compound (presently the capsaicin) based on the
internationally accepted laws; 3. of course, the grants to help the carried out of observations;
4. existence of special internationally accepted institutes (wards) for doing these types of ob‐
servations.
It is also important to mention that the different extractions of Capsaicums (without exact
knowledge of their chemical composions) were used (instead of pure chemical composions)
in the earlier periods of the human studies.
To receive permission for human use - for orally given as a drug substance - of capsaicin
preparation from the National and Inteernational Regulatory Authorities we have to present
the following details: 1. specification of the Capsaicum species; 2. climatic regulations of pla‐
ces of Capsicum cultivation; 3. chemical treatments of Capsicum plants during their cultiva‐
tion; 4. details of treatment of Capsicum plants (their collection, drying, extractions,
storages, etc.); 5. analytical results supporting the chemical composition of the plant origin
capsaicinoids extract; 7.the chemical stability of the natural capsaicin (capsaicinoids); 7. ana‐
lytical results showing the (possible) contamination of the capsaicin product with organic
phosphates, pesticides, fusariums, aflatoxin; 8. international certification (including Food
and Drug Administration, FDA) on capsaicin (capsaicinoids) content of the natural prepara‐
tion. Data above mentioned fact given by internationally accredited laboratories. These data
are collected in Drug Master File (DMF).
In our case we found only one natural capsaicin preparation with Drug Master File (DMF)
(Asian Herbex Ltd., Asdhra Pradesh, India ), which is signed in the documentation of Food
and Drug Administration (FDA) in USA („ 17856 A II 26.10.2004 Asian Herbex Ltd: Capsi‐
cum USP as manufactured in Andhra Pradesh, India”) for orally applicable drug substance
in healthy human subjects and in patients.
The fine chemical trading firms (concerning capsaicin supply) had no DMF for their capsai‐
cin preparation. Independently., several trade firms keep the natural capsaicin(oids) prepa‐
ration on the market they can not have, however , exact knowledge on the circumstances of
cultivation, details of preparation extract, stability of the product. They have no exact infor‐
mation on the quantities of residues of organic phosphates, pesticides, fusariums, aflatoxin
in the preparation of origin capsaicin (proved by certification of different internationally ac‐
credited laboratories).
We wanted to use this (these) capsaicin(oids) as the only component or one of the compo‐
nents for orally applicable drug or drug combinations for in human healthy beings and pa‐
tients.
We compiled the documentations for the National Institute of Pharmacy to ask permission
for human clinical pharmacological studies with this capsaicin preparation: 1. expert’s opin‐
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ion; 2. results of all toxicological studies; 3.chemical stability of the natural capsaicin prepa‐
ration; 4. results of pharmaceutical formulation from the natural capsaicin; 5. different
permissions from University; 6. documentation of health insurance of volunteers; 7. preclini‐
cal dossier; 8. documented valid permission on the accreditation of Clinical Pharmacological
Unit for human phase I and II examinations – which accreditaion controlled by the National
Insitute in Hungary – were prepared for the National Instutute of Pharmacy in Hungary; 9.
exact protocols for human clinical pharmacological studies; 10. written informations on the
planned examinations, for volunteers; 11. request for authorization of a clinical trial on med‐
ical product for human use the competent authorities and for of opinion of the ethical com‐
mittees in the community; 12. lists of investigators (together with their CV), places institutes
(departments) participating in the study.
Of course, after receiving all of the permissions from the authorities, the human observa‐
tions with capsaicin were carried out respected the conditions of Good Clinical Practice
(GPC).
This book gives a special collection of our update knowledges in the capsaicin research in
the gastrointestinal ttract: from bench to the human bedside [including the main mecha‐
nisms of gastroprotection, available methods for measurements of capsaicin(oids) from dif‐
ferent spices of Capsicums and their necessary regulatory chemical qualification required by
the international authorities,observations with isolated gastic cells from rats, main lines on
animal capsaicin research and finally approach of capsaicin action in the human gastrointes‐
tinal tract and clinical pharmacological requirements for development and pharmaceutical
production of capsaicin containing and orally applicable drug or drug combinations in the
human healthy subjects and in patients].
The authors of the different book chapters are internationally well known and accepted re‐
searchers (chemists, pharmaceutist, pharmacologist, internist, gastroenterologist, clinical
pharmacologist, pharmaceutical industrial expert, who are working in the basic and clinical
research).
The editors wishes to express their thankfulness for the excellent work of the contributing
authors.
The editors are specilally thankful on the excellent support given by Ms.Danijela Duric
(Head of Book Publishing) from the Intech Open Access Publisher. Without her help this
book would not be possible.
Gyula Mózsik, MD, PhD, ScD
First Department of Medicine, Medical and Health Centre,
University of Pécs, Hungary
Omar M.E.Abdel-Salam, MD, PhD
Head of the Department of Toxicology and Narcotics, Medical Division,
National Research Centre, Cairo, Egypt
Koji Takeuchi, PhD
Kyoto Pharmaceutical University, Japan
Doshisha Women’s College of Liberal Arts, Japan
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1. Introduction
Capsaicin, the hot principle of red peppers or chilli is a favorite spice in culinary practice and
therefore it’s role in gastric ulcerations has been tested since a long time. In early clinical
practice sudies in this line using intake of pungent pepper flavoured foods resulted in
contradictory conclusions and for patients having peptic ulcers intake of hot spicy foods was
forbidden (Schneider et al., 1956, Lennard-Jones and Babouris, 1965, Viranuvatti et al., 1972,
Solanke, 1973). Furthermore, animal experiments (Sanchez-Palomera 1951, Makara et al.,
1965) were neither conclusive. In the latter study aggravation of gastric ulceration in rats was
observed by capsaicin application into the stomach while pungent paprika extract in oil
inhibited the reserpine-induced gastric ulcerations in the rat. The authors supposed that
protective effect of carotenoids in the extract counteracted the ulcerogenic effect of capsaicin
(Makara et al 1965).
Studies in our laboratories on the actions of capsaicin in the guinea-pig isolated ileum revealed
that capsaicin acting in a highly selective way elicits in low concentration a new type of neural
contraction which after higher doses are completely abolished (Barthó and Szolcsányi 1978,
Szolcsányi and Barthó 1978). This effect was elicited by neuropeptides as substance P released
from the sensory nerve terminals in response to capsaicin. The neuroselective action of
capsaicin was shown by it’s lack of effect on function of cholinergic, adrenergic, purinergic,
enteric peptidergic neural responses (Szolcsányi 1984, 1996). These capsaicin-sensitive
unorthodox sensory nerve terminals served as nerve endings mediating both afferent sensory
and mediator releasing efferent functions. On "capsaicin-sensitive” neural elements the
presence of a ˝capsaicin receptor” was predicted (Szolcsányi and Jancsó-Gábor 1975) which
was later cloned (Caterina et al 1997) and is now named as Transient Receptor Potential
Vanilloid Type-1 (TRPV1). TRPV1 is a nonselective cation channel gated by long list of
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exogenous and endogenous chemical agents including H+as well as noxious heat (Jordt et al.
2000, Szolcsányi and Sándor 2012).
The capsaicin-sensitive cutaneous and visceral sense organs correspond to the C-and Aδ –
polymodal nociceptor group of primary afferent neurons (Szolcsányi 1996, 2014).
Capsaicin elicits cutaneous enhancement of microcirculation which can be elicited also by
antidromic dorsal root stimulation. Antidromic vasodilatation evoked by dorsal root stimu‐
lation was known since over a century (Bayliss 1901) but our recent laser-Doppler results
revealed that it can be activated at subnoxious level of stimulation applying very low frequency
of discharges (0.1Hz or less). Thus this highly efficient efferent function of these sense organs
elicits maximum cutaneous vasodilatation from lower level of stimulation than it causes
sensation (Szolcsányi 1996, 2004). These fibers with “sensory-efferent” functions differ from
the theoretical so called “nocifensor” nerves of the posterior root system proposed by Sir
Thomas Lenis (1937) since he predicted that they have only efferent but no sensory function.
(Szolcsányi 2013).
On the basis of our results with the “sensory-efferent” function of TRPV1-expressing “capsai‐
cin-sensitive” sense organs of the skin it was tempting to test whether it could operate also in
the stomach mucosa where the acidity of the gastric juice, spicy foods or drugs like acetyl
salicylic acid seemed a rational site where this local neuroregulatory vasodilator system might
operate and play an important role in gastroprotection. On this ground we started to analyze
from the late seventies the effect of blocking or stimulation these capsaicin-sensitive nerve
endings on gastric ulcer formation in the rat.
2. First evidence for the gastroprotective role of capsaicin-sensitive nerves
In the first series of experiments on rats (Szolcsányi and Barthó 1981) gastric ulcers were
provoked by pylorus ligation (Shay et al 1945) or by acid distension (Gáti and Guth 1976). In
rats pretreated with capsaicin (50+100mg/kg s.c 6-8 days before the experiment) a systemic
blockade of capsaicin-sensitive nerve endings was achieved. These rats did not react to
capsaicin if it was instilled into the eye and as revealed earlier this state of loss of nociceptive
function was coupled with ablation of sensory nerve-mediated neurogenic inflammation
(Jancsó et al 1967) or other sensory-efferent responses (Szolcsányi 1996). Fig 1A shows the effect
of this capsaicin-induced blockade of sensory nerve endings on gastric ulcer formation in the
Shay ulcer model. In the pretreated group mucosal lesions appeared as early as at the 7th hour
after pylorus ligation and at the 9th hour deep extensive nearly perforating lesions were
observed in the forestomach. On the contrary out of the 20 control rats terminated 7-9 hours
after ligation petechial and minimal mucosal lesions appeared only in two animals. At the
14th hour incidence of perforation was only 13% in the control group and 75% in the group of
capsaicin-pretreated rats. Differences at 7th, 9th and 14th hours in ulcer indexes of Fig 1A were
highly significant (P< 0.01; n=8-11 of each group).
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside4
Figure 1. Effect of blockade of capsaicin-sensitive sensory neurons on gastric ulceration in rats evoked by pylorus liga‐
tion (A), on volume of gastric juice (C) as well as on gastric acid (D) and pepsin secretion (E) at different time points
after pylorus ligation. Gastric ulcers of control rats and that of rats which received by oral application low dose of cap‐
saicin (0.5 μg/0.5 ml and 4 hours later 50 μg/0.5 ml) given into pylorus ligated rats (B).
Aggravation of gastric ulcer formation was not due to enhancement of aggressive factors
responsible for mucosal damage. Gastric secretion of the capsaicin pretreated group of animals
did not differ from that of the controls as shown on Fig 1C, D and E. The volume, acidity and
pepsin concentration of the gastric juice as measured at different time points were similar.
Since at the 7th hour petechiae appeared in the capsaicin pretreated group the pepsin concen‐
tration was determined only at the 4th hour. Thus it has been concluded that in rats where the
function of capsaicin-sensitive nerve endings were abolished in the stomach the gastropro‐
tection is severely impaired against the injurious effect of secreted gastric content inducing H
+ back-diffusion and distension. This conclusion was supported also in another model when
constant acid-distension was used (Gáti and Guth 1976). In these experiments the animals
under pentobarbitone anaesthesia (40mg/kg ip) received 0.1M HCl in 6ml/100g volume
through the duodenum and thereafter both the esophagus and the duodenum were ligated.
The animals were sacrificed one hour later and mucosal lesions of the removed stomach was
determined. In 17 control rats the incidence of lesions was 59% and the area of damaged
mucosa (ulcer index) was 19±7mm2. In 15 rats where the functions of capsaicin-sensitive
sensory nerve ending were abolished all rats had mucosal erosions and the gastric ulcer index
was 41±11mm2 (p<0.002).
On the basis of these remarkable clear results it has been concluded that capsaicin-sensitive
nerve endings of the stomach have a gastroprotective effect in peptic ulcer models of the rat.
Mechanism of Capsaicin-Induced Gastroprotection
http://dx.doi.org/10.5772/58684
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In another series of experiments it was also revealed, that this gastroptective sensory-efferent
mechanism is enhanced in rats where sensory stimulating low concentration of capsaicin was
applied in the Shay model of gastric ulcer. Since it had been shown earlier (Szolcsányi and
Jancsó-Gábor 1976) that topical application of capsaicin up to a concentration of 10 µg/ml
stimulates the sensory nerve endings in the conjunctiva without causing desensitization this
concentration was applied: 5µg capsaicin in 0.5ml was introduced into the stomach after
pylorus ligation and 50µg four hours later when the volume of gastric juice was shown to be
enhanced to 5ml (Fig 1C). 18 hours after pylorus ligation all control rats had severe forestomach
lesions (ulcer index 84.1±9.5), while in the group of rats where low concentration of capsaicin
was introduced into the stomach for stimulation of the nerve endings clear gastroprotective
effect was observed (ulcer index 17.8±8.0 mm2). The difference between the two groups was
highly significant (p=0.002).
Threshold concentration of capsaicin on the human tongue which elicits recognizable slight
warm sensation is about 0.2µg/ml and a concentration of 1-2µg/ml causes the well known hot
spicy sensation (Szolcsányi 1977). Thus, in this range of culinary practice commonly used
slightly hot foods capsaicin is gastroprotective and inhibits the development of mucosal
erosions. Capsaicin content of pungent chilli pods varies between 0.2-1.4%. Thus, regular
intake of very hot foods can produce 1) local desensitization of gastric TRPV1-expressing
capsaicin-sensitive sensory nerve endings; 2) enhance vagal reflexes causing smooth muscle
contractions and producing gastric discomfort or even pain if gastric ulcers are already present;
and 3) induce focal oedema with mucosal inchaemia (Viranuvatti et al 1972) probably mediated
by neurogenic inflammation (Jancsó et al 1967, Szolcsányi 1996).
On the basis of the first results and considerations the effect of capsaicin on gastroprotection
had been presented in a shematic way as shown on Fig 3. Acid back-diffusion activates both
the capsaicin-sensitive sensory nerve endings and release vasodilator mediators from mast
cells which enhance mucosal microcirculation and protect the epithelial barrier against
erosions which could produce peptic ulcer formation. This natural protective mechanism can
be enhanced by low concentration of capsaicin present e.g in spicy flavoured foods. The
significance of the capsaicin-sensitive neural part in this protective hyperaemic response is
underlined by the fact that if these nerve endings are not functioning under experimental
conditions described above severe ulcerations will develop in acid-back diffusion models of
gastric ulcers. It is important to note, however, that no erosions in the stomach develop after
capsaicin-induced sensory blockade under control conditions. Thus without aggressive factors
TRPV1-expressing capsaicin-sensitive nerve endings are not required for gastroprotection.
It is worthy to emphasize, that the mechanism of gastroprotection mediated by subepithelial
enhancement of microcirculation clearly differs from the cytoprotection of the epithelial cells
described by Robert et al (1979). Cytoprotection is mediated by the release of prostaglandins
mainly PGE2 which inhibit ulcerations induced by tissue damaging necrotic agents (96%
ethanol, 0.6M HCl, 0.2 M NaOH, 25% NaCl) which in fact destroy the superficial protective
layer of the stomach. Using these aggressive treatments in rats where the capsaicin-sensitive
nerve endings were blocked by capsaicin pretreatment no difference in number of lesions, but
a significant reduction in the severity of the mucosal damage was observed (Szolcsányi and
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Mózsik 1984), just in contrast to the H+back-diffusion models discussed earlier. It has been
concluded that in this case ulcerations evoked by profound tissue damaging chemical agents
resulted in inflammatory reaction and part of it was mediated by the release of substance P
(Sharkey et al 1984) released from the capsaicin-sensitive nerve endings (neurogenic inflam‐
mation) which are released at higher frequencies of stimulation than the release of CGRP which
induces gastroprotective enhancement of microcirculation (Szolcsányi 1996, 2004).
3. Gastroprotection induced by capsaicin-sensitive nerves in animal
experiments
Five years after we described the first data and a proposed mechanism for explaining the effect
of capsaicin on gastric ulcer formations other groups also supported our results on the
gastroprotective effect of capsaicin. Holzer and Sametz (1986) reported that in adult rats treated
in the neonatal age by capsaicin which induces a permanent loss of sensory neurons including
also a major group of TRPV1 –expressing neurons for ref (Szolcsányi and Pintér 2013) gastric
ulcers evoked by indomethacin is aggravated although the release of prostaglandin E2
remained unchanged. Proposal for the involvement of the adrenals in this capsaicin-sensitive
gastroprotective effect in the indomethacin-induced ulceration was raised by another group
(Evangelista et al 1986). One year later it has been revealed by immunohistochemistry that in
the digestive tract of rats the highest concentration of the potent vasodilator neuropeptide,
calcitonin gene-related peptide (CGRP) is present in the stomach (45±2.8pmol/g wet weight).
Figure 2. Gastric ulcers of rats induced by ethanol (50%) containing capsaicin, piperine or resiniferatoxin (RTX) in
doses indicated. Number of rats in each groups in brackets. Significance ***: P<0.01, **<0.02, *<0.05 from the values
obtained on rats which received ethanol with solvent as control.
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After neonatal capsaicin pretreatment the peptide content was reduced by greater than 95%
(Sternini et al 1987). Subsequently our data about the gastroprotective effect of intragastric low
concentration of capsaicin was supported in case of the ulcerogenic effect of 25% ethanol
(Holzer and Lippe 1988). This study provided also evidence against the involvement of
autonomic nervous system in the gastroprotective effect of capsaicin and subsequently this
group described that intragastric capsaicin (62-640µM) had no effect on nonstimulated acid
output of the rat stomach and by light and scanning electron microscopy no signs of mucosal
damage was observed (Lippe et al 1989). It is worthy to mention here, that in 1988 it was also
reported that in humans using videoendoscopy no visible mucosal damage was observed in
individuals who have eaten hot Mexican meal with chili but in those subjects who was taken
bland meal plus aspirin multiple erosions developed (Graham et al 1988).
Beyond capsaicin other TRPV1 agonists also induced gastroprotection (Szolcsányi 1990). Fig
2 shows that in these experiments 50% ethanol was given through a stomach tube to conscious
rats which evoked mucosal lesions in almost all rats as detected one hour after ethanol
exposure (first two columns of Fig 2). Capsaicin, piperine, the pungent principle of black
pepper and resiniferatoxin (RTX), the highly potent irritant of Euphorbia resinifera as TRPV1
agonists (Szállási and Blumberg 1999, Szolcsányi 2004) were dissolved in the ethanol and given
to three groups of rats (n=9-11). Fig 2 shows that the three TRPV1 agonists given in similar
pungent potency ranges induced similar significant gastroprotection against ethanol-induced
mucosal ulcerations (Szolcsányi 1990). RTX similarly as capsaicin induces enhanced blood flux
of the stomach wall as detected by laser-Dappler flowmetry (Abdel-Salam et al 1996).
Figure 3. Schematic representation of the hypothetical role of capsaicin-sensitive sensory nerve endings in response
to acid distension models which induced gastric mucosal erosions and ulcerations (reproduced from Szolcsányi and
Barthó, 1981 with kind permission of the Akadémiai Kiadó, Budapest). A. H+back-diffusion through the epithelial bar‐
rier activates both capsaicin-sensitive chemoceptive nerve endings and mast cells which release vasodilator mediators
and enhance mucosal microcirculation. B. Low concentration of capsaicin in the stomach enhances the gastroprotec‐
tive vasodilatation. C. Blockade of capsaicin-sensitive nerve terminals induces depletion of the sensory neuropeptides.
In these rats the natural gastroprotective mucosal vasodilatation is impaired.
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4. Mechanism of action of gastroprotection of capsaicin
In the defense mechanism to maintain the structural integrity of the gastric mucosa unstirred
layer of mucosa-bicarbonate-phospholipid barrier (Fig 4) and the surface epithelial cell layer
with tight and gap junctions form the superficial layers of gastroprotection including cyto‐
protection (Robert et al 1979, Whittle 1993, Abdel-Salam et al. 1999, 2001, Mózsik et al. 2007).
Subendothelial enhanced microcirculation proposed to be the main site where capsaicin and
TRPV1 agonists (Fig 3) induce the gastroprotective effect was supported by several lines of
evidence beyond the opposite effect of capsaicin desensitization on H+back-diffusion models
and on ulcers provoked by epithelial necrotizing agents suitable to be inhibited by the
cytoprotective prostaglandins.
Figure 4. Mechanism of capsaicin-sensitive sensory-effector nerve terminals in gastroprotection depicted on a modi‐
fied scheme of Whittle (1993). Black arrows: H+backflow through the epithelial barrier damaged by nonsteroid anti-
inflammatory drugs (NSAID), ethanol or other aggressive agents. White arrows release of CGRP from capsaicin-
sensitive nerve endings or other vasodilator mediators released during degranulation of mast cells (MC). The released
mediators induce enhancement of mucosal microcirculation. Thick black arrow: action potentials of sensory message
to the central nervous system.
TRPV1 is a non-selective cation channel with preferential gating to Ca++over Na+(Caterina
1997, Szolcsányi and Sándor 2012) and there is firm evidence in the skin that both CGRP and
TRPV1 are coexpressed in the sensory receptors terminating in the epidermis (for ref see
Szolcsányiand Pintér 2013). Furthermore it has been shown that in vitro no inhibition of
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sensory neuropeptide release ensues in the presence of blockade of axon reflexes by tetrodo
toxin or lignocaine (for ret Szolcsányi 1996, 2013).
Thus CGRP is released from the sensory nerve ending which in an unorthodox way serve in
a bidirectional neuroregulatory sensory-efferent function. Nevertheless, capsaicin prevented
deep but not epithelial mucosal damage and local intra-arterial infusion of tetrodotoxin
prevented the capsaicin-induced gastroprotection (Holzer at el 1991).These results indicate,
that if the stomach mucosa was perfursed with capsaicin in 25% ethanol nerve terminals excites
the superficial layers and evoke axon reflexes (Fig 4). In this case mainly those sensory nerve
endings situated deeper near to the vessels are activated through branching axon collaterals
and mediators released by Ca++influx through the TRPV1 channel in the subepithelial sensory
nerve endings play minor role in enhancement of mucosal microcirculation. There is, however,
no evidence to suppose that in axon reflex arrangement in the periphery some nerve endings
of primary sensory neurons might have nerve terminals specialized for efferent, mediator
releasing function in antidromic vasodilation (Szolcsányi 1996, 2013).
Recently another hypothesis for gastroprotection (Holzer and Maggi 1988), in fact a revival of
Lewis’s “nocifensor” fiber theory was raised according to which vasodilator mediators are
released from nerve endings of capsaicin-sensitive DRG fibers which have only efferent
function without mediating messages to the central nervous system. In other words these
authors in this paper proposed that peripheral release of neuropeptides in the stomach mucosa
takes place from effector nerve terminals of a subset of DRG neurons which have only efferent
function. They showed that acid challenge of the mucosa elicited rapid c-fos mRNA activation
in the nucleus tractus solitarii but not in the spinal cord, while capsaicin-induced mucosal
vasodilation was abolished by splanchnic nerve denervation but remained intact after
vagotomy. (Holzer and Maggi 1998). Subsequent data (Blackshaw et al 2000) indicated that
most of the vagal afferents excited by low pH are capsaicin-insensitive fibers from where
neuropeptides are not released (Szolcsányi 2004). Thus they could mediate the c-fos activation
in the nucleus tractus solitarii. It has been shown earlier that for release of sensory neuropep‐
tides a very low frequency of activity is already maximal (see Introduction and Szolcsányi
1996 2013). Therefore pronounced mucosal vasodilatation without c-fos activation can be
evoked (Szolcsányi and Barthó 2001). More recent data of Peter Holzer’s group seems to
support our conclusion, since the lack of c-fos activation in the dorsal half of the spinal cord
by mucosal HCl application was in contrast to the effect of capsaicin which evoked c-fos
activation both in the nucleus tractus solitarii and particularly in the lamina I of dorsal horn
of the spinal cord (Holzer et al 2005). Distension of the stomach enhanced c-fos expression and
CGRP expression both in the spinal cord and medulla oblongata (Zhang et al 2006).
The pivotal role of CGRP in gastroprotection due to an enhancement of mucosal microcircu‐
lation (Peskar et al 1993) in response to stimulation of peptidergic capsaicin-sensitive vagal
and spinal sensory neurons are supported by several further lines of evidence. Gastric
hyperemia to intragastric capsaicin or acid back diffusion (0.15M HCl +15% ethanol) was
blocked by the CGRP antagonist hCGRP 8-37 (Li et al 1991, 1992). Some data indicate that
beyond the vascular effect of CGRP it induces also release of somatostatin (Inui et al 1991).
Furthermore a subpopulation of capsaicin-sensitive vagal sensory neurons contain also
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somatostatin which is released by electrical nerve stimulation of the nerves both from the
thoracic and abolominal parts of the nerves (Than et al 2000).
Recently it has been shown, that TRPV1 and neuronal nitric oxide synthase (nNOS) are
coexpressed in sensory fibers around the vessels of the gastric mucosa and the capsaicin-
induced enhancement of mucosal blood flow appeared to be diminished by nNOS inhibition
(Raimara et al 2013). Epidermal growth factor (EGF) reduces gastric mucosal lesions evoked
by ethanol by activating capsaicin-sensitive sensory nerve terminals (Matsumoto et al 2001).
The role of prostaglandin E2 and its receptors EP1 in cytoprotection against necrotizing agents
is well established and has been discussed to be different from the effects of capsaicin. Recent
data using EP1 and prostacyclin (IP) knockout mice showed that capsaicin-induced gastro‐
protection is present in gene-deleted mice of EP1 but disappeared in IP knockout mice
(Takeuchi, 2014). The role of prostacyclin in capsaicin-induced gastroprotection seems to be
interesting for further research. For further reviews see Abdel-Salam 2001, Pawlik et al 2001,
Evangelista 2009, Mózsik et al 2007, 2014, Luo et al 2013).
It is important to note that stimulation of capsaicin-sensitive perivascular nerve terminals in
vitro elicits slow inhibitory junction potential (IJP) and dilator response on mesenteric smooth
muscle cells. IJP evoked by capsaicin or electrical stimulation was unaffected by endothelial
removal or pharmacological blockade of autonomic neuroeffector mechanism by pharmaco‐
logical treatments with guanethidine, 6-hydroxydopamine, propranolol, atropine, α, β-
methylene ATP (Meehan et al. 1991).
The role of mast cells in gastric mucosal injury evoked by H+back-diffusion, NSAID, ethanol
and other aggressive chemicals has been described since a long time (Fig 3, 4) (Szolcsányi and
Barthó 1981, Takeuchi et al 1997, Rydning et al. 2004). Recently it has been reported, that mast
cell deficient Sash mice are highly susceptible to piroxicam-induced gastric ulceration. Thus,
it seems that beyond the potent gastroprotective effect of capsaicin-sensitive nerve endings
described earlier and presented in humans (Mózsik et al.,2014 in this volume) mast cells play
also role through releasing vasodilator mediators (Rydning et al., 2002), but by releasing
histamine it enhances on H2 receptors gastric acid secretion which in these mice did not
interfere with the ulcer formation (Hampton and Hale, 2013).
5. Conclusions
CGRP release from the capsaicin-sensitive TRPV1-expressing sensory nerve endings induces
potent enhancement of submucosal microcirculation which results in marked gastroprotective
effect. CGRP, substance P and somatostatin are released from these nerve endings which by
arborizations could induce effector tissue responses also by axon reflexes.
Capsaicin-sensitive sensory nerve-mediated vasodilation together with mast cell degranula‐
tion participate in the gastroprotective effect against mucosal injuries induced by aggressive
agents as H+back-diffusion, ethanol or nonsteroid anti-inflammatory drugs (NSAID) and
provide therapeutic means for gastroprotection.
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1. Introduction
Capsicum fruits contain coloring pigments, pungent principles, resin, protein, cellulose, pentosans,
mineral elements and a small amount of volatile oil, while seeds contain fixed (non-volatile) oil.
Besides these organic constituents Capsicum fruits also contain inorganic constituents, mostly
potassium and sodium, calcium, phosphorus, iron, copper and manganese.
Paprikas derive their color in the ripe state mainly from carotenoid pigments, which range from
bright red (capsanthin, capsorubin) to yellow (cucurbitene). The pungent principles capsaicin
and its structurally closely related homologs (so-called capsaicinoids) and analogues, are
contained only in small amounts, as low as 0.001 to 0.005% in “mild” and 0.1% in “hot”
cultivars. The characteristic aroma and flavor of the fresh fruit is imparted by the volatile oil
containing a range of alkylmethoxypyrazines and a structurally diverse group (alcohols,
aldehydes, ketones, carboxylic acids, and esters of carboxylic acids) of oxygenated hydrocar‐
bons. Apart from capsaicinoids, the taste of paprika is mostly due to the fixed oil which is
comprised mainly of triglycerides of which linoleic, linolic, stearinic and other unsaturated
fatty acids predominate.
The first part of the chapter summarizes the chemical characterization of the three classes of
Capsicum ingredients (coloring pigments, pungent principles, and volatile oils), the most important
analytical methods used in pharmacobotanical studies or acknowledged by different regula‐
tory bodies.
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aldehydes, ketones, carboxylic acids, and esters of carboxylic acids) of oxygenated hydrocar‐
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comprised mainly of triglycerides of which linoleic, linolic, stearinic and other unsaturated
fatty acids predominate.
The first part of the chapter summarizes the chemical characterization of the three classes of
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analytical methods used in pharmacobotanical studies or acknowledged by different regula‐
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Capsicum extracts are frequently used as active pharmaceutical ingredients (API) in manufac‐
turing pharmaceutical products. For such applications Capsicum extract should be qualified
not only on the basis of the amount of API(s) but on the basis of the amounts of possible
impurities/contaminants as well. Among the most important impurities/contaminants (a) toxic
metals, (b) pesticides, (c) mycotoxins, (d) foreign organic matters, and (e) radioactivity (if there is
cause for concern) should be mentioned.
The second part of the chapter describes the Pharmacopoeial and other internationally
recognized methods for determination of pesticides in Capsicum fruits and extracts.
2. Structure and biosynthetic pathways of the most important ingredients
of capsicum fruits
Capsicum is a versatile plant used as vegetable, pungent food additive, colorant and raw
material for pharmaceutical products. The genus Capsicum, which is commonly known as
“chili”, “red chili”, “tabasco”, “paprika”, “cayenne”, etc., is a member of the family Solana‐
ceae, and closely related to eggplant, potato, petunia, tomato and tobacco. After much work by
taxonomists concerning the classification of the presently domesticated species, they have been
considered to belong to one of five species, namely Capsicum annuum, Capsicum frutescens,
Capsicum baccatum, Capsicum chinense and Capsicum pubescens (Bosland, 1994).
Capsicum types are usually classified by fruit characteristics, i.e. pungency, color, fruit shape, as
well as by their use. Capsicum species are commonly divided into two groups, pungent and
non-pungent, also called hot and sweet.
The word “paprika” was borrowed from Hungarian (paprika). It entered a great number of
languages, in many cases probably via German. In the end, also “paprika” is derived from a
name of black pepper, in this case Serbian pepper. In most languages, “paprika” denotes the
dried spice only, though in some (e.g., German) it is commonly used for the vegetable bell
pepper.
Capsicum fruits contain coloring pigments, pungent principles, resin, protein, cellulose, pentosans,
mineral elements and a small amount of volatile oil, while seeds contain fixed (non-volatile)
oil. Besides these organic constituents Capsicum fruits also contain inorganic constituents,
mostly potassium and sodium, calcium, phosphorus, iron, copper and manganese (Thresh,
1846; Brawer and Schoen, 1962; Brash et al., 1988; Pruthi, 2003).
The pungent principles capsaicin and its structurally closely related homologs (so-called
capsaicinoids) and analogues, are contained only in small amounts, as low as 0.001 to 0.005%
in “mild” and 0.1% in “hot” cultivars. Apart from capsaicin, the taste of paprika is mostly due
to the fixed oil which is comprised mainly of triglycerides of which linoleic, linolic, stearinic
and other unsaturated fatty acids predominate. The fixed oil content of the Capsicum seeds also
play an important role in the visual sensing of the paprika powder since it can dissolve and
homogeneously distribute the colored substances during grinding of the dried fruits. The
characteristic aroma and flavor of the fresh fruit is imparted by the volatile oil containing a
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range of alkylmethoxypyrazines (e.g., 2-methoxy-3-isobutylpyrazine, the “earthy” flavor) and
a structurally diverse group (alcohols, aldehydes, ketones, carboxylic acids, and esters of
carboxylic acids) of oxygenated hydrocarbons.
Furthermore, the fresh ripe paprika contains sizable amounts (0.1%) of vitamin C (ascorbic
acid). It was the Hungarian biochemist Albert Szent-Györgyi who discovered that the
Hungarian paprika is a rich source of vitamin C. Later (1937) he won the Nobel Prize “for his
discoveries in connection with the biological combustion processes, with special reference to
vitamin C and the catalysis of fumaric acid” (Encyclopedia Britannica).
Paprikas derive their color in the ripe state mainly from carotenoid pigments, which range
from bright red (capsanthin, capsorubin) to yellow (cucurbitene); the total carotenoid content
in dried paprika is 0.1 to 0.5%.
2.1. Volatiles
The characteristic flavor and aroma of the fresh fruits is due to their volatile oil content. The
fruits of Capsicum species have relative low volatile oil content, ranging from about 0.1% to
2.6% in paprika. The total volatiles are generally isolated by steam distillation. In the case of
heat-sensitive compounds present, vacuum distillation-continuous solvent extraction can be
used. The pure volatile oil and concentrated extracts were analyzed by GC-MS methods. Most
compounds of odor significance have been tentatively identified by their mass spectra, and
the identification was confirmed by checking the retention time and mass spectra of authentic
reference compounds. When Buttery et al. (1969a,b) identified 3-isobutyl-2-methoxypyrazine
(1) (Fig 1) as a characteristic aroma compound, the alkylmethoxypyrazines aroused great
interest among flavor chemists. The alkylmethoxypyrazines have been shown to be widely
distributed in vegetables and with a greenish sweet smell that possibly plays a significant role
in the aroma of salad vegetables (Murray, and Whitfield, 1975).
Volatiles have been identified in fresh, homogenized, cooked and stir-fried bell peppers and
the effects of ripening and tissue disruption on the composition of volatiles have been
determined (Wu and Liou, 1986; Whitfield and Last, 1991; Cremer and Eichner, 2000). About
60 volatile compounds have been identified in green California bell pepper using a vacuum
Liken-Nickerson (Buttery et al., 1969a,b). Luning et al. (1994a,b) have identified 64 volatile
compounds in fresh bell pepper at three ripening stages (green, turning, red) with dynamic
headspace. The composition of volatile compounds indicated that the majority of green related
odour volatile compounds decreased or even disappeared during maturation and fruity and
sweet odour were higher at the turning and red stages.
There are common aroma compounds amongst the different species of the different fresh
pepper, namely, 2,3-butanedione (caramel), 1-penten-3-one (pungent/spicy), hexanal (2)
(grassy, herbal), 3-carene (red bell pepper, rubbery), trans-beta-ocimene (rancid), octanal
(fruity), trans-2-hexenal (3) (sweet) and 2-isobutyl-3-methoxypyrazine (1) (green bell pepper).
Keller et al. (1981) reported that volatiles of fresh red Jalapeno pepper extracts had a pleasant
floral aroma (3-carene). Likewise, trans-2-hexenal (3) and trans-2-hexenol (4), which have an
almond, fruity and spicy odour, were found to increase during maturation.
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range of alkylmethoxypyrazines (e.g., 2-methoxy-3-isobutylpyrazine, the “earthy” flavor) and
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carboxylic acids) of oxygenated hydrocarbons.
Furthermore, the fresh ripe paprika contains sizable amounts (0.1%) of vitamin C (ascorbic
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odour volatile compounds decreased or even disappeared during maturation and fruity and
sweet odour were higher at the turning and red stages.
There are common aroma compounds amongst the different species of the different fresh
pepper, namely, 2,3-butanedione (caramel), 1-penten-3-one (pungent/spicy), hexanal (2)
(grassy, herbal), 3-carene (red bell pepper, rubbery), trans-beta-ocimene (rancid), octanal
(fruity), trans-2-hexenal (3) (sweet) and 2-isobutyl-3-methoxypyrazine (1) (green bell pepper).
Keller et al. (1981) reported that volatiles of fresh red Jalapeno pepper extracts had a pleasant
floral aroma (3-carene). Likewise, trans-2-hexenal (3) and trans-2-hexenol (4), which have an
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Study by Chitwood et al. (1983) suggested that trans-3-hexenol, 2-sec-butyl-3-methoxypyrazine
and 2-isobutyl-3-methoxypyrazine are responsible for the frequent use of green descriptors in
the aroma descriptive analysis of three C. annuum cultivar (Anaheim, Jalapeno and Fresno).
Based on GC-MS and sensory analysis of volatiles of three cultivars of C. annuum – Jalapeno,
Fresno, and Anaheim – twelve odor significant compounds were identified that had been found
in one or the other of the earlier studies: 2,3-butadienone (caramel), 1-penten-3-one (pungent/
spicy), hexanal (grassy, herbal), 3-carene (red bell pepper, rubbery), trans-3-hexenol (4),
trans-3-hexenyl isopentanoate (6) (associated with green and green-fruity odors); 3-isobutyl-
(1) and 3-sec-butyl-2-methoxypyrazine (7) (with green vegetable and green bell capsicum
odors); beta-ionone (5) (only in Jalapeno), linalool (both with floral character); and the aromatic
compounds benzaldehyde (8) and methyl salicylate (9) (with sweetish, penetrating odors)
(Chitwood et al., 1983).
The analysis of volatile compounds has been a challenge to many researchers. Many different
analytical methods have been developed to determine fresh and processed chilli flavour, such
as solvent extraction-simultaneous distillation extraction (Chitwood et al., 1983; Wu and Liou,
1986; Korany et al., 2002) and dynamic headspace (Luning et al., 1994a,b). However, these
methods are time-consuming, expensive and likely to introduce artifact resulting from sample
preparation and solvent interaction steps. Moreover they cannot represent the total composi‐
tion of volatile chemicals in equilibrium as found in the aroma of intact, fresh chilli. Solid phase
microextraction (SPME) is a method that approaches the ideal extraction method and has been
applied to the analysis of various aroma and flavour compound in samples (Peppard and Yang,
1994; Penton, 1996; Steffen and Pawliszyn, 1996; Ibanez et al., 1998; Sides et al., 2000). SPME
has been recommended for the quantitative analysis of flavour and fragrance compounds
(Zhang and Pawliszyn, 1993). The main advantages of SPME are simplicity, speed, solvent-
free, high sensitivity, small sample volume, lower cost and simple automation (Kataoka et al.,
2000).
2.2. Coloring pigments
The coloring pigments of red peppers are comprised of carotenoids. The term “carotenoid”
encompasses not only the carotenes (C40 hydrocarbons), but also their oxygenated derivatives,
the xanthophylls. Carotenoids are widely distributed groups of natural pigments, responsible
for the yellow, orange, and red colors of fruits, roots, flowers, fish, invertebrates, and birds.
Only bacteria, algae, fungi, and green plants can synthesize carotenoids, but humans incor‐
porate them from the diet. Especially bacterial carotenoids are most diverse. Carotenoid
extracts and fruits rich in carotenoids are now being used in the food industry to color foods,
thus such foods are also representing carotenoid sources of the human diet. The nutritional
importance of carotenoids is mostly associated with the provitamin A activity of beta-carotene
and others. Besides its well-established provitamin A activity, research is under way to study
the relationship between beta-carotene intake and occurrence of atherosclerosis, cardiovascular
diseases, in particular degree of LDL oxidation (Poppel and von Goldbochm, 1995; Hinds et
al., 1997; Rodriguez-Amaya, 1997; Woodall et al., 1997; Maillard et al., 1998; Manirakiza et al.,
1999, 2003).
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The basic carotenoid structure is a symmetrical, linear, 40-carbon tetraterpene built from eight
carbon isoprenoid units joined in such a way that the order is reversed at the center. Fig 2
shows the structure of beta-carotene (10), one of the most typical carotenoid components of
Capsicum fruits.
Carotenoids were for a long time assumed being synthesized by the mevalonate pathway for
isoprenoid biosynthesis. This view was prevalent up until the mid-nineties when it was
discovered that the carotenoid precursor isopentenyl-pyrophosphate (IPP) was synthetized
by two independent metabolic pathways in plants (Lichtenthaler et al., 1997).
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Figure 1. Main components of volatile oils of Capsicum furits.
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The first pathway occurs in the cytoplasmic compartment from mevalonic acid and gives rise
to compounds such as sterols and cytokinins. In fungi, carotenoids are derived via the
mevalonate biosynthetic pathway. The second pathway, effective in bacteria and plastids of
plants, is responsible for biosynthesis of gibberellins, carotenoids, abscisic acid, and also
contributes to the biosynthesis of tocopherols as well as chlorophyll A and B. This plastidial
pathway of isoprenoid synthesis is named after its first metabolite 1-deoxyxylulose 5-phos‐
phate (DOXP) and has pyruvate and glycerinaldehyde-3-phosphate as precursors. Further
details can be obtained from a number of review articles, (Davies, 1980; Spurgeon, and Porter,
1983; Britton, 1991).
Carotenoids can be extracted from natural sources by lipid solvents. With fresh material,
ethanol or acetone act both as dehydrating agent and extracting solvents. When lipids and
esterified xantophylls are present (hydroxylated carotenoids generally occur as esters of fatty
acids), the extracts are saponified and the free carotenoids extracted for analysis. Most
carotenoids are unstable in oxygen atmosphere and light thus careful extractions and separa‐
tions are generally carried out under inert atmosphere, subdued light and low temperature
(Rodriguez-Amaya, 1997; Deli and Molnár, 2002). High performance liquid chromatography
(HPLC) is the most powerful chromatographic technique to separate and – coupled with mass
spectrometry (MS) – identify carotenoids. Recent reviews on the field provide up-to-date
summary of carotenoid analysis (Rodriguez-Amaya, 1997; Wall and Bosland, 1998; Deli and
Molnár, 2002; Felt et al., 2005).
The composition of carotenoid pigments produced by paprika has been investigated in detail.
Some twenty carotenoids have been isolated so far with capsanthin (11) and capsorubin (12)
(Figure 3) representing the most abundant (Deli and Molnár, 2002). The ripening process is
marked by the disappearance of chlorophyll and a rapid rise in the colored carotenoids
(Rodriguez-Amaya, 1997; Rahman, and Buckle, 1980; Hornero-Mendez et al., 2000; Gnayfeed
et al., 2001; Deli and Molnár, 2002). A small number of cultivars do not produce significant
amounts of carotenoids; when chlorophyll levels decrease in the last stages of ripening, these
chilies develop a pale hue often referred to as “white”. Due to small amounts of chlorophyll
and/or yellow carotenoids, the “white” is, however, more precisely described as a pale
greenish-yellow.
Some varieties of paprika contain pigments of anthocyanin type and develop dark purple,
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cyanins get decomposed, and the unusual darkness thus gives way to normal orange or red
colors. The same anthocyanins cause the dark spots which are sometimes seen on unripe fruits
or particularly the stems of paprika plants and which almost all paprika varieties can develop.










Figure 3. Structure of capsanthin (11) and capsorubin (12).
2.3. Capsaicinoids
Capsicum fruits have been valued for over a thousand of years for the piquant taste they added
to the flavorless foods, as well as for the therapeutic effects as a stimulant and counter irritant.
These effects have been related to the components stimulating pungency.
The degree of pungency (heat or bite) is determined by the amount of compounds called
capsaicinoids. These substances produce the characteristic sensations associated with inges‐
tion of spicy cuisine as well as the agents responsible for causing severe irritation, inflamma‐
tion, erythema, and transient hypo-and hyperalgesia at sites exposed to paprika extracts.
Capsaicinoids are particulary irritating to the eyes, skin, nose, tongue and respiratory tract.
The nature of the causal components in the spice has been established as a mixture of acid
amides of vanillylamine and C8 to C13 fatty acids, which are known generally as capsaicinoids.
The major capsaicinoids in red peppers are capsaicin (13), dihydrocapsaicin (17) and nordihydro‐
capsaicin (16) (Table 1). In commercial Capsicums, capsaicin generally comprises 33-59%,
dihydrocapsaicin accounts for 30-51%, nordihidrocapsaicin is 7-15% and the remainder is less than
5% of the capsaicinoids (Reineccius, 1994).
The seven homologous branched-chain alkyl vanillylamides are capsaicin (13), homocapsaicin
I (14), homocapsaicin II (15), nordihydrocapsaicin (16), dihydrocapsaicin (17), homodihydrocapsaicin
I (18) and homodihydrocapsaicin II (19). (Hoffman et al., 1983; Reilly et al., 2001a, Karnka et al.,
2002). In addition, three straight-chain analogs, octanoyl vanillylamide (20), nonoyl vanilly‐
lamide (nonivamide) (21) and decyl vanillylamide (22), have also been shown to occur in
Capsicum fruits (Govindarajan, 1986d).
Each capsaicinoid possesses a 3-hydroxy-4-methoxybenzylamide (vanilloid) pharmacophore,
but differ from capsaicin from their hydrophobic alkyl side chain. Differences in the side chain
moiety include saturation of the carbon-carbon double bond, deletion of a methyl group, and
changes in the length of the hydrocarbon chain. The structures of capsaicin as well as its
homologs and analogs are given in Table 1.
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The first pathway occurs in the cytoplasmic compartment from mevalonic acid and gives rise
to compounds such as sterols and cytokinins. In fungi, carotenoids are derived via the
mevalonate biosynthetic pathway. The second pathway, effective in bacteria and plastids of
plants, is responsible for biosynthesis of gibberellins, carotenoids, abscisic acid, and also
contributes to the biosynthesis of tocopherols as well as chlorophyll A and B. This plastidial
pathway of isoprenoid synthesis is named after its first metabolite 1-deoxyxylulose 5-phos‐
phate (DOXP) and has pyruvate and glycerinaldehyde-3-phosphate as precursors. Further
details can be obtained from a number of review articles, (Davies, 1980; Spurgeon, and Porter,
1983; Britton, 1991).
Carotenoids can be extracted from natural sources by lipid solvents. With fresh material,
ethanol or acetone act both as dehydrating agent and extracting solvents. When lipids and
esterified xantophylls are present (hydroxylated carotenoids generally occur as esters of fatty
acids), the extracts are saponified and the free carotenoids extracted for analysis. Most
carotenoids are unstable in oxygen atmosphere and light thus careful extractions and separa‐
tions are generally carried out under inert atmosphere, subdued light and low temperature
(Rodriguez-Amaya, 1997; Deli and Molnár, 2002). High performance liquid chromatography
(HPLC) is the most powerful chromatographic technique to separate and – coupled with mass
spectrometry (MS) – identify carotenoids. Recent reviews on the field provide up-to-date
summary of carotenoid analysis (Rodriguez-Amaya, 1997; Wall and Bosland, 1998; Deli and
Molnár, 2002; Felt et al., 2005).
The composition of carotenoid pigments produced by paprika has been investigated in detail.
Some twenty carotenoids have been isolated so far with capsanthin (11) and capsorubin (12)
(Figure 3) representing the most abundant (Deli and Molnár, 2002). The ripening process is
marked by the disappearance of chlorophyll and a rapid rise in the colored carotenoids
(Rodriguez-Amaya, 1997; Rahman, and Buckle, 1980; Hornero-Mendez et al., 2000; Gnayfeed
et al., 2001; Deli and Molnár, 2002). A small number of cultivars do not produce significant
amounts of carotenoids; when chlorophyll levels decrease in the last stages of ripening, these
chilies develop a pale hue often referred to as “white”. Due to small amounts of chlorophyll
and/or yellow carotenoids, the “white” is, however, more precisely described as a pale
greenish-yellow.
Some varieties of paprika contain pigments of anthocyanin type and develop dark purple,
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cyanins get decomposed, and the unusual darkness thus gives way to normal orange or red
colors. The same anthocyanins cause the dark spots which are sometimes seen on unripe fruits
or particularly the stems of paprika plants and which almost all paprika varieties can develop.
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tion, erythema, and transient hypo-and hyperalgesia at sites exposed to paprika extracts.
Capsaicinoids are particulary irritating to the eyes, skin, nose, tongue and respiratory tract.
The nature of the causal components in the spice has been established as a mixture of acid
amides of vanillylamine and C8 to C13 fatty acids, which are known generally as capsaicinoids.
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capsaicin (16) (Table 1). In commercial Capsicums, capsaicin generally comprises 33-59%,
dihydrocapsaicin accounts for 30-51%, nordihidrocapsaicin is 7-15% and the remainder is less than
5% of the capsaicinoids (Reineccius, 1994).
The seven homologous branched-chain alkyl vanillylamides are capsaicin (13), homocapsaicin
I (14), homocapsaicin II (15), nordihydrocapsaicin (16), dihydrocapsaicin (17), homodihydrocapsaicin
I (18) and homodihydrocapsaicin II (19). (Hoffman et al., 1983; Reilly et al., 2001a, Karnka et al.,
2002). In addition, three straight-chain analogs, octanoyl vanillylamide (20), nonoyl vanilly‐
lamide (nonivamide) (21) and decyl vanillylamide (22), have also been shown to occur in
Capsicum fruits (Govindarajan, 1986d).
Each capsaicinoid possesses a 3-hydroxy-4-methoxybenzylamide (vanilloid) pharmacophore,
but differ from capsaicin from their hydrophobic alkyl side chain. Differences in the side chain
moiety include saturation of the carbon-carbon double bond, deletion of a methyl group, and
changes in the length of the hydrocarbon chain. The structures of capsaicin as well as its
homologs and analogs are given in Table 1.



































































Table 1. Chemical structures of capsaicin homologs and analogs.
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Capsaicin and its natural homologs are always found in the trans (E) form because in the cis
(Z) isomer, the-CH(CH3)2 and the longer chain on the other side of the ∆6,7 carbon-carbon
double bond will be too close to each other which causes strong repulsive force. This steric





































Figure 4. Simplifies biochemical pathway of synthesis of capsaicinoids.
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Figure 4. Simplifies biochemical pathway of synthesis of capsaicinoids.
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The capsaicin biosynthetic pathway has two distinct branches, one of which utilizes L-
phenylalanine (23) as the precursor of aromatic residue of capsaicinoids, presumably via
trans-cinnamic acid (24) and its hydroxylated derivatives trans-caffeic acid (26) and trans-
ferulic acid (27) following the well-established pathways in other plants (Ishikawa, 2003).
Vanillylamine (28) as precursor showed a high level of incorporation into the capsaicinoids
and possibly the immediate progenitor of natural capsaicinoids (Figure 4). The enzymes
involved in the formation of the precursors, phenolics, and fatty acids, are similar to those
studied for long in other biological systems. The second group of enzymes form the branched-
chained fatty acids by elongation of deaminated valine (Figure 4). The capsaicinoids synthe‐
tase, however, has been found to have narrow specificity in accepting only the iso-C(9:0) to
C(11:0) fatty acids and in the fruit system forming predominantly the vanillylamides of even-
number branched fatty acids, capsaicin (13) and dihydrocapsaicin (17), in all the cultivated
varieties of the Capsicum species (Ravishankar et al., 2003). In the isolated systems, however,
the synthethase favors formation of capsaicin (13) and nordihydrocapsaicin (16), while the
light induced activation of the synthase in Capsicum annuum cv. grossum, results in higher
formation of nordihydrocapsaicin (16) and dihydrocapsaicin (17) (Govindarajan, 1986a,b).
Synthesis of capsaicinoids by means of recent development of biotechnological methods has
been reviewed in deatails (Ravishankar et al., 2003).
3. Quality control
Capsicum is now one of the two most widely used spices. Quality of food should fulfill the
consumers’ expectations – not necessarily the maximum of each attribute, but the optimal level
and combination appropriate for each food. Thus a range of quality attributes is required to
make different foods of optimal quality. Quality control which can be exercised through
measurement of the physical and chemical properties of the component stimuli needs to be
validated by a relationship with sensoryly perceived responses individually and in combina‐
tion. It is obvious that the accuracy and reproducibility of any instrumental method meaning‐
ful for food quality measure is that which correlates with the sensoryly perceivable differences
(Kramer, 1966).
Besides the sensory attributes, capsicum like other products used as foods and food additives,
should also have certain functional properties for its optimal use in the industrial sectors,
which also have to be considered. The standards of the importing countries are based on the
requirements of the food processing industries and include additional emphasis on cleanliness,
which progressively cover, in addition to insects and rodent parts, limits of chemical and
microbiological contaminations, and freedom of health-hazard organisms. These specifica‐
tions assure genuiness, purity and cleanliness, but they do not give information on the sensory
attributes which the consumers require. In the case of some processed products, e.g., ground
paprika and oleoresin, specifications for total color and capsaicinoid content are found in
standards and manufacturer literature, these being the main selling factors in this increasing
competitive market (Govindarajan, 1986c).
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Herbs and fruits that are used as spice, active pharmaceutical ingredients of drugs, or constit‐
uents of food additives should also fulfill even more special requirements described by the
Pharmacopoeias and/or other international organizations like EC, FAO, WHO, ISO, ASTA,
etc., and national bodies, which guide the industry concerned in the respective activities such
as manufacturing or trade. The standards are the results of conscientious efforts in standard‐
ization. In the lack of space, it is not possible to cover all such standards. Only those have been
listed that are closely related to the quality of Capsicum and Capsicum-originated products that
can be used for the pharmaceutical industry.
3.1. Capsicum fruits
3.1.1. Capsicum (Ph. Eur. 7.0)
The 2011 edition of the European Pharmacopoeia Edition 7.0 (Ph. Eur. 7.0) lists Capsicum
fruit (Capsici fructus) and describes its Definition, Identification, Nonivamid Test, and Assay as
follows.
DEFINITION: Dried ripe fruits of Capsicum annuum L. var. minimum (Miller) Heise and small-
fruited varieties of Capsicum frutescens L.
CONTENT: Minimum 0,4 per cent of total capsaicinoids expressed as capsaicin (C18H27NO3;
Mr 305.4) (dried drug).
IDENTIFICATION
a. The fruit is yellowish-orange to reddish-brown, oblong conical with an obtuse apex, about
1 cm to 3 cm long and up to 1 cm in diameter at the widest part, occasionally attached to
a 5-toothed inferior calyx and a straight pedicel. Pericarp somewhat shrivelled, glabrous,
enclosing about 10 to 20 flat, reniform seeds 3 mm to 4 mm long, either loose or attached
to a reddish dissepiment.
b. Reduce to a powder. The powder is orange. Examine under a microscope using chloral
hydrate solution R. The powder shows the following diagnostic characters: fragments of
the pericarp having an outer epicarp with cells often arranged in rows of 5 to 7, cotucle
uniformly striated: parenchymatous cells frequently containing droplets of red oil,
occasionally containing misrosphenoidal crystals of calcium oxalabe; endocarp with
characteristic island groups of sclerenchymatous cells, the groups being separated by thin-
walled parenchymatous cells. Fragments of the seeds having an episperm composed of
large, greenish-yellow, sinuous-walled sclereids with thin outer walls and strongly and
unevenly thickened radial and inner walls which are conspicuously pitted; endosperm
parenchymatous cells with drops of fixed oil and aleurone grains 3 µm to 6 µm in diameter.
Occassional fragments from the calyx having an outer epidermis with anisocytis stomata,
inner epidermis with many trichomes but no stomata; trichomes glandular, with uniseri‐
ate stalks and multicellular heads; mesophyll with many idioblasts containing micro‐
sphenoidal crystals of calcium oxalate.
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The capsaicin biosynthetic pathway has two distinct branches, one of which utilizes L-
phenylalanine (23) as the precursor of aromatic residue of capsaicinoids, presumably via
trans-cinnamic acid (24) and its hydroxylated derivatives trans-caffeic acid (26) and trans-
ferulic acid (27) following the well-established pathways in other plants (Ishikawa, 2003).
Vanillylamine (28) as precursor showed a high level of incorporation into the capsaicinoids
and possibly the immediate progenitor of natural capsaicinoids (Figure 4). The enzymes
involved in the formation of the precursors, phenolics, and fatty acids, are similar to those
studied for long in other biological systems. The second group of enzymes form the branched-
chained fatty acids by elongation of deaminated valine (Figure 4). The capsaicinoids synthe‐
tase, however, has been found to have narrow specificity in accepting only the iso-C(9:0) to
C(11:0) fatty acids and in the fruit system forming predominantly the vanillylamides of even-
number branched fatty acids, capsaicin (13) and dihydrocapsaicin (17), in all the cultivated
varieties of the Capsicum species (Ravishankar et al., 2003). In the isolated systems, however,
the synthethase favors formation of capsaicin (13) and nordihydrocapsaicin (16), while the
light induced activation of the synthase in Capsicum annuum cv. grossum, results in higher
formation of nordihydrocapsaicin (16) and dihydrocapsaicin (17) (Govindarajan, 1986a,b).
Synthesis of capsaicinoids by means of recent development of biotechnological methods has
been reviewed in deatails (Ravishankar et al., 2003).
3. Quality control
Capsicum is now one of the two most widely used spices. Quality of food should fulfill the
consumers’ expectations – not necessarily the maximum of each attribute, but the optimal level
and combination appropriate for each food. Thus a range of quality attributes is required to
make different foods of optimal quality. Quality control which can be exercised through
measurement of the physical and chemical properties of the component stimuli needs to be
validated by a relationship with sensoryly perceived responses individually and in combina‐
tion. It is obvious that the accuracy and reproducibility of any instrumental method meaning‐
ful for food quality measure is that which correlates with the sensoryly perceivable differences
(Kramer, 1966).
Besides the sensory attributes, capsicum like other products used as foods and food additives,
should also have certain functional properties for its optimal use in the industrial sectors,
which also have to be considered. The standards of the importing countries are based on the
requirements of the food processing industries and include additional emphasis on cleanliness,
which progressively cover, in addition to insects and rodent parts, limits of chemical and
microbiological contaminations, and freedom of health-hazard organisms. These specifica‐
tions assure genuiness, purity and cleanliness, but they do not give information on the sensory
attributes which the consumers require. In the case of some processed products, e.g., ground
paprika and oleoresin, specifications for total color and capsaicinoid content are found in
standards and manufacturer literature, these being the main selling factors in this increasing
competitive market (Govindarajan, 1986c).
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Herbs and fruits that are used as spice, active pharmaceutical ingredients of drugs, or constit‐
uents of food additives should also fulfill even more special requirements described by the
Pharmacopoeias and/or other international organizations like EC, FAO, WHO, ISO, ASTA,
etc., and national bodies, which guide the industry concerned in the respective activities such
as manufacturing or trade. The standards are the results of conscientious efforts in standard‐
ization. In the lack of space, it is not possible to cover all such standards. Only those have been
listed that are closely related to the quality of Capsicum and Capsicum-originated products that
can be used for the pharmaceutical industry.
3.1. Capsicum fruits
3.1.1. Capsicum (Ph. Eur. 7.0)
The 2011 edition of the European Pharmacopoeia Edition 7.0 (Ph. Eur. 7.0) lists Capsicum
fruit (Capsici fructus) and describes its Definition, Identification, Nonivamid Test, and Assay as
follows.
DEFINITION: Dried ripe fruits of Capsicum annuum L. var. minimum (Miller) Heise and small-
fruited varieties of Capsicum frutescens L.
CONTENT: Minimum 0,4 per cent of total capsaicinoids expressed as capsaicin (C18H27NO3;
Mr 305.4) (dried drug).
IDENTIFICATION
a. The fruit is yellowish-orange to reddish-brown, oblong conical with an obtuse apex, about
1 cm to 3 cm long and up to 1 cm in diameter at the widest part, occasionally attached to
a 5-toothed inferior calyx and a straight pedicel. Pericarp somewhat shrivelled, glabrous,
enclosing about 10 to 20 flat, reniform seeds 3 mm to 4 mm long, either loose or attached
to a reddish dissepiment.
b. Reduce to a powder. The powder is orange. Examine under a microscope using chloral
hydrate solution R. The powder shows the following diagnostic characters: fragments of
the pericarp having an outer epicarp with cells often arranged in rows of 5 to 7, cotucle
uniformly striated: parenchymatous cells frequently containing droplets of red oil,
occasionally containing misrosphenoidal crystals of calcium oxalabe; endocarp with
characteristic island groups of sclerenchymatous cells, the groups being separated by thin-
walled parenchymatous cells. Fragments of the seeds having an episperm composed of
large, greenish-yellow, sinuous-walled sclereids with thin outer walls and strongly and
unevenly thickened radial and inner walls which are conspicuously pitted; endosperm
parenchymatous cells with drops of fixed oil and aleurone grains 3 µm to 6 µm in diameter.
Occassional fragments from the calyx having an outer epidermis with anisocytis stomata,
inner epidermis with many trichomes but no stomata; trichomes glandular, with uniseri‐
ate stalks and multicellular heads; mesophyll with many idioblasts containing micro‐
sphenoidal crystals of calcium oxalate.




Test solution. To 0.50 g of the powdered drug (500) add 5.0 ml of ether R, shake for 5 min and
filter.
Reference solution. Dissolve 2 mg of capsaicin R and 2 mg of dihidrocapsaicin R in 5.0 ml of ether
R.
Plate: TLC octadecylsilyl silica gel plate R. Mobile phase: water R, methanol R (20:80 V/V).
Aplication: 20 µl, as bands.
Development: over a path of 12 cm.
Drying: in air.
Detection: spray with a 5 g/l solution of dichloroquinonechlorimide R in methanol R.
Expose the plate to ammonia vapour until blue zones appear. Examine in daylight.
Results: see below the sequence of the zones present in the chromatograms obtained with the
reference solution and the test solution. Furthermore, other zones may be present in the





Dried ripe fruits of Capsicum annuum L. var. minimum (Miller) Heise and small-fruited varieties of Capsicum frutescens L. 2 
CONTENT 3 
Minimum 0,4 per cent of total capsaicinoids expressed as capsaicin (C18H27NO3; Mr 305.4) (dried drug). 4 
IDENTIFICATION 5 
A. The fruit is yellowish-orange to reddish-brown, oblong conical with an obtuse apex, about 1 cm to 3 cm long and up to 1 6 
cm in diameter at the widest part, occasionally attached to a 5-toothed inferior calyx and a straight pedicel. Pericarp somewhat 7 
shrivelled, glabrous, enclosing about 10 to 20 flat, reniform seeds 3 mm to 4 m  long, either loose or attached to a reddish 8 
dissepiment. 9 
B. Reduce to a powder. The powder is orange. Examine under a microscope using chloral hydrate solution R. The powder 10 
shows the following diagnostic characters: fragments of the pericarp having an outer epicarp with cells often arranged in rows of 5 to 11 
7, cotucle uniformly striated: parenchymatous cells frequently containing droplets of red oil, occasionally containing misrosphenoidal 12 
crystals of calcium oxalabe; endocarp with characteristic island groups of sclerenchymatous cells, the groups being separated by thin-13 
walled parenchymatous cells. Fragments of the seeds having an episperm composed of large, greenish-yellow, sinuous-walled 14 
sclereids with thin outer walls and strongly and unevenly thickened radial and inner walls which are conspicuously pitted; endosperm 15 
parenchymatous cells with drops of fixed oil and aleurone grains 3 μm to 6 μm in diameter. Occassional fragments from the calyx 16 
having an outer epidermis with anisocytis stomata, inner epidermis with many trichomes but no stomata; trichomes glandular, with 17 
uniseriate stalks and multicellular heads; mesophyll with many idioblasts containing microsphenoidal crystals of calcium oxalate.  18 
C. Thin-layer chromatography. 19 
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Nonivamide. Liquid chromatography. 33 
Test solution. To 2.5 g of the powdered drug add 100 ml of methanol R. Allow to macerate for 30 min. Place in an ultrasonic bath for 34 
15 min. Filter into a 100 ml volumetric flask, rinse the flask and filter with methanol R. Dilute to 100,0 ml with methanol R. 35 
Reference solution. Dissolve 20.0 mg of capsaicin R and 4.0 mg of nonivamide R in 100.0 ml of methanol R.  36 
Column: size: l = 0.25 m,  = 4.6 mm; stationary phase: phenylsilyl silica gel for chromatography R (5 μm); temperature: 30 oC. 37 
Figure 5 Characterization of the top of the TLC plate (Ph. Eur. 7.0)
TESTS
Nonivamide. Liquid chromatography.
Test solution. To 2.5 g of the powdered drug add 100 ml of methanol R. Allow to macerate for
30 min. Place in an ultrasonic bath for 15 min. Filter into a 100 ml volumetric flask, rinse the
flask and filter with methanol R. Dilute to 100,0 ml with methanol R.
Reference solution. Dissolve 20.0 mg of capsaicin R and 4.0 mg of nonivamide R in 100.0 ml of
methanol R.
Column: size: l=0.25 m, ∅=4.6 mm; stationary phase: phenylsilyl silica gel for chromatography R
(5 µm); temperature: 30 oC.
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Mobile phase: mixture of 40 volumes of acetonitril R and 60 volumes of a 1 g/l solution of
phosphoric acid R.
Flow rate: 1.0 ml/min.; Detection: spectrophotometer at 225 nm.; Injection: 10 µl.
System suitability: reference solution:
• resolution: minimum 3.0 between the peaks due to capsaicin and nonivamide.
Limit: calculate the percentage content of nonivamide
• nonivamide: maximum 5.0 per cent of the total capsaicinoid content.
ASSAY: Liquid chromatography as described in the test for nonivamide.
3.2. Capsicum extracts
Presently, virtually all commercial spice extraction is carried out by one of two methods. One
the methods is solvent extraction, wich involves treating a ground dry spice with an organic
solvent such as hexane, acetone, methanol, ethanol or methylene chloride. Pursuant to this
method, the spice extract is recovered by removal of the solvent, usually by distillation with
heat under vacuum. The spice extract recovered in this way is known as an “Oleoresin”
(Eisvale, 1981; Pruthi, 2003). In the case of oleoresin from Capsicum, the oleoresin is further
treated with polar solvent, methanol, in order to separate the pungent component Oleoresin
Capsicum from the color component Oleoresin paprika. Oleoresins are used almost exclusively
by the food and pharmaceutical industries as a substitute of ground spices and spice tinctures.
The composition of an oleoresin is affected by the choice of organic solvent used in the
extraction, but typically will include phospholipids, oils, waxes, sterols, resins, and a range of
non-volatile and volatile compounds which make up much of the aroma and flavor of the
original spice. In its use as food additive, the best oleoresin of Capsicum is that which contains
the color and flavor components and that which truly recreates, when appropriately diluted
in food formulations, the sensory qualities of fresh materials (Govindarajan, 1986c).
The other commercial method of spice extraction is the aqueous distillation of the whole or
ground, fresh or dried spice using either boiling water or steam. This method recovers only
the steam volatile components of the spice; i.e., the “Essential oil” which is high in aroma and
flavor compounds (Simon, 1990). Many variations of these two methods are possible. The
essential oil may be prepared by distillation from the original spice, or by distillation from a
previously prepared solvent extracted oleoresin.
These traditional processes have a number of disadvantages. Most organic solvents are toxic,
and government food regulations dictate that their residues must be reduced in the oleoresin
to very small concentrations, generally in the range of 25-30 ppm or less (Pruthi, 2003). The
distillation processes used to remove the solvents, or to recover essential oils, lowers the
content of the very light volatiles which contribute to aroma and flavor. Of more importance
is the growing consumer demand for food ingredients which are completely natural and free
of contact with synthetic chemicals.




Test solution. To 0.50 g of the powdered drug (500) add 5.0 ml of ether R, shake for 5 min and
filter.
Reference solution. Dissolve 2 mg of capsaicin R and 2 mg of dihidrocapsaicin R in 5.0 ml of ether
R.
Plate: TLC octadecylsilyl silica gel plate R. Mobile phase: water R, methanol R (20:80 V/V).
Aplication: 20 µl, as bands.
Development: over a path of 12 cm.
Drying: in air.
Detection: spray with a 5 g/l solution of dichloroquinonechlorimide R in methanol R.
Expose the plate to ammonia vapour until blue zones appear. Examine in daylight.
Results: see below the sequence of the zones present in the chromatograms obtained with the
reference solution and the test solution. Furthermore, other zones may be present in the





Dried ripe fruits of Capsicum annuum L. var. minimum (Miller) Heise and small-fruited varieties of Capsicum frutescens L. 2 
CONTENT 3 
Minimum 0,4 per cent of total capsaicinoids expressed as capsaicin (C18H27NO3; Mr 305.4) (dried drug). 4 
IDENTIFICATION 5 
A. The fruit is yellowish-orange to reddish-brown, oblong conical with an obtuse apex, about 1 cm to 3 cm long and up to 1 6 
cm in diameter at the widest part, occasionally attached to a 5-toothed inferior calyx and a straight pedicel. Pericarp somewhat 7 
shrivelled, glabrous, enclosing about 10 to 20 flat, reniform seeds 3 mm to 4 m  long, either loose or attached to a reddish 8 
dissepiment. 9 
B. Reduce to a powder. The powder is orange. Examine under a microscope using chloral hydrate solution R. The powder 10 
shows the following diagnostic characters: fragments of the pericarp having an outer epicarp with cells often arranged in rows of 5 to 11 
7, cotucle uniformly striated: parenchymatous cells frequently containing droplets of red oil, occasionally containing misrosphenoidal 12 
crystals of calcium oxalabe; endocarp with characteristic island groups of sclerenchymatous cells, the groups being separated by thin-13 
walled parenchymatous cells. Fragments of the seeds having an episperm composed of large, greenish-yellow, sinuous-walled 14 
sclereids with thin outer walls and strongly and unevenly thickened radial and inner walls which are conspicuously pitted; endosperm 15 
parenchymatous cells with drops of fixed oil and aleurone grains 3 μm to 6 μm in diameter. Occassional fragments from the calyx 16 
having an outer epidermis with anisocytis stomata, inner epidermis with many trichomes but no stomata; trichomes glandular, with 17 
uniseriate stalks and multicellular heads; mesophyll with many idioblasts containing microsphenoidal crystals of calcium oxalate.  18 
C. Thin-layer chromatography. 19 
Test solution. To 0.50 g of the powdered drug (500) add 5.0 ml of ether R, shake for 5 min and filter.  20 
Reference solution. Dissolve 2 mg of capsaicin R and 2 mg of dihidrocapsaicin R in 5.0 ml of ether R. 21 
Plate: TLC octadecylsilyl silica gel plate R. Mobile phase: water R, methanol R (20:80 V/V). 22 
Aplication: 20 μl, as bands.  23 
Development: over a path of 12 cm. 24 
Drying: in air. 25 
 Detection: spray with a 5 g/l olution of dichloroquinonechlorimide R i  methanol R. 26 
Expose the plate to ammonia vapour until blue zones appear. Examin  in daylight.  27 
Results: see below the sequence of the zones present in the chromatograms obtained with the reference solution and the test solution. 28 
Furthermore, other zones may be present in the chromatogram obtained with the test solution (Figure 5). 29 
Figure 5. Characterization of the top of the TLC plate (Ph. Eur. 6.0.) 30 
Top of the plate 
 
Capsaicin: a blue zone 
 
Dyhidrocapsaicin: a blue zone 
 
 
A blue zone (capsaicin) 
 
A blue zone (dihydrocapsaicin) 
 
Reference Solution Test solution 
 31 
TESTS 32 
Nonivamide. Liquid chromatography. 33 
Test solution. To 2.5 g of the powdered drug add 100 ml of methanol R. Allow to macerate for 30 min. Place in an ultrasonic bath for 34 
15 min. Filter into a 100 ml volumetric flask, rinse the flask and filter with methanol R. Dilute to 100,0 ml with methanol R. 35 
Reference solution. Dissolve 20.0 mg of capsaicin R and 4.0 mg of nonivamide R in 100.0 ml of methanol R.  36 
Column: size: l = 0.25 m,  = 4.6 mm; stationary phase: phenylsilyl silica gel for chromatography R (5 μm); temperature: 30 oC. 37 
Figure 5 Characterization of the top of the TLC plate (Ph. Eur. 7.0)
TESTS
Nonivamide. Liquid chromatography.
Test solution. To 2.5 g of the powdered drug add 100 ml of methanol R. Allow to macerate for
30 min. Place in an ultrasonic bath for 15 min. Filter into a 100 ml volumetric flask, rinse the
flask and filter with methanol R. Dilute to 100,0 ml with methanol R.
Reference solution. Dissolve 20.0 mg of capsaicin R and 4.0 mg of nonivamide R in 100.0 ml of
methanol R.
Column: size: l=0.25 m, ∅=4.6 mm; stationary phase: phenylsilyl silica gel for chromatography R
(5 µm); temperature: 30 oC.
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Mobile phase: mixture of 40 volumes of acetonitril R and 60 volumes of a 1 g/l solution of
phosphoric acid R.
Flow rate: 1.0 ml/min.; Detection: spectrophotometer at 225 nm.; Injection: 10 µl.
System suitability: reference solution:
• resolution: minimum 3.0 between the peaks due to capsaicin and nonivamide.
Limit: calculate the percentage content of nonivamide
• nonivamide: maximum 5.0 per cent of the total capsaicinoid content.
ASSAY: Liquid chromatography as described in the test for nonivamide.
3.2. Capsicum extracts
Presently, virtually all commercial spice extraction is carried out by one of two methods. One
the methods is solvent extraction, wich involves treating a ground dry spice with an organic
solvent such as hexane, acetone, methanol, ethanol or methylene chloride. Pursuant to this
method, the spice extract is recovered by removal of the solvent, usually by distillation with
heat under vacuum. The spice extract recovered in this way is known as an “Oleoresin”
(Eisvale, 1981; Pruthi, 2003). In the case of oleoresin from Capsicum, the oleoresin is further
treated with polar solvent, methanol, in order to separate the pungent component Oleoresin
Capsicum from the color component Oleoresin paprika. Oleoresins are used almost exclusively
by the food and pharmaceutical industries as a substitute of ground spices and spice tinctures.
The composition of an oleoresin is affected by the choice of organic solvent used in the
extraction, but typically will include phospholipids, oils, waxes, sterols, resins, and a range of
non-volatile and volatile compounds which make up much of the aroma and flavor of the
original spice. In its use as food additive, the best oleoresin of Capsicum is that which contains
the color and flavor components and that which truly recreates, when appropriately diluted
in food formulations, the sensory qualities of fresh materials (Govindarajan, 1986c).
The other commercial method of spice extraction is the aqueous distillation of the whole or
ground, fresh or dried spice using either boiling water or steam. This method recovers only
the steam volatile components of the spice; i.e., the “Essential oil” which is high in aroma and
flavor compounds (Simon, 1990). Many variations of these two methods are possible. The
essential oil may be prepared by distillation from the original spice, or by distillation from a
previously prepared solvent extracted oleoresin.
These traditional processes have a number of disadvantages. Most organic solvents are toxic,
and government food regulations dictate that their residues must be reduced in the oleoresin
to very small concentrations, generally in the range of 25-30 ppm or less (Pruthi, 2003). The
distillation processes used to remove the solvents, or to recover essential oils, lowers the
content of the very light volatiles which contribute to aroma and flavor. Of more importance
is the growing consumer demand for food ingredients which are completely natural and free
of contact with synthetic chemicals.
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Extraction of spices with supercritical fluid carbon dioxide has been proposed as a means of
eliminating the use of organic solvents and providing the prospect of simultaneous fractiona‐
tion of the extract. The use of supercritical fluids (SCF) for extraction purposes was introduced
in the late nineteenth century. A supercritical fluid is a substance at temperatures and pressures
beyond its critical point at which the liquid phase of the substance will not exist. At these
temperatures and pressures, the supercritical fluid has properties between gas-and liquid-
phase characteristics. These properties make supercritical fluids efficient extraction solvents
with high mass transfer characteristics (McHugh and Krukonis, 1986;; Krukonis, 1988).
Consequently, supercritical fluids are often used to selectively extract or separate specific
compounds from a mixture by varying fluid density through changes in pressure and
temperature. In food technology, the use of supercritical fluids is essentially limited to
supercritical carbon dioxide (SCF-CO2) extraction since carbon dioxide has the advantages of
being inexpensive and nontoxic and because its critical point is easily reached.
Oleoresins have several advantages over ground spices, e.g., elimination of microbial con‐
tamination, uniformity of color and flavor strenght and optimal utilization. The Essential Oil
Association of America has detailed specifications for three types of Capsicum oleoresins (Table
2). Oleoresin paprika is mainly used as food coloring in meats, dairy products, soups, sauces
and snacks. Oleoresin red pepper is used for both coloring and pungency, mainly in canned
meats, sausages, in some snacks and in a dispersed form in some drinks such as ginger ale.
Oleoresin Capsicum is the most pungent and is used for its counter-irritant properties in plasters
and some pharmaceutical preparations.
Type of oleoresin
Capsicum




























40,000-100,000 Deep red Nil or negligible
Table 2. Nomenclature of oleoresins of Capsicums (Essential Oils Association, 1975).
3.2.1. Capsicum Oleoresin
The 2012 edition of the United States Pharmacopoeia-National Formulary (USP36-NF31) lists
Capsicum Oleoresin and describes its Capsicum Oleoresin as follows.
3.2.1.1. Capsicum Oleoresin (USP30-NF25)
DEFINITION: Capsicum Oleoresin is an alcoholic extract of the dried ripe fruits of Capsicum
annum var. minimum and small fruited varieties of C. frutescens (Solanaceae). It contains not
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less than 8.0 percent of total capsaicins [capsaicin (C18H27NO3), dihydrocapsaicin (C18H29NO3),
and nordihydrocapsaicin (C17H27NO3)].
IDENTIFICATION: To about 0.5 g of it in a beaker add 5 mL of water and 10 mL of a mixture
of water, 0.2 M potassium chloride, and 0.2 N hydrochloric acid, and mix. Add 5.0 mL of 0.5
M sodium nitrite and 5.0 mL of 0.02 M sodium tungstate, and mix. Heat at 55o to 60o for 15
minutes, allow to cool, and filter. To the filtrate add 10 mL of 1 N sodium hydroxide: a bright
yellow color is produced (presence of capsaicin).
ASSAY
Mobile phase— Prepare a mixture of methanol and 2% acetic acid (56:44), filter through a 0.5-
µm or finer porosity filter, and degas.
Standard preparation— Prepare a solution of USP Capsaicin RS in methanol having a known
concentration of about 0.5 mg per mL. Filter a portion of this solution through a 0.2-µm porosity
filter, and use the filtrate as the Standard preparation.
Assay preparation— Transfer about 1000 mg of Capsicum Oleoresin, accurately weighed, to a 100-
mL volumetric flask, dissolve in and dilute with methanol to volume, and mix. Filter a portion
of this solution through a 0.2-µm porosity filter, and use the filtrate as the Assay preparation.
Chromatographic system— The liquid chromatograph is equipped with a 280-nm detector and
a 3.9-mm × 30-cm column that contains packing L1. The flow rate is about 2 mL per minute.
Chromatograph the Standard preparation, and record the peak responses as directed for
Procedure: the tailing factor is not more than 2.0; and the relative standard deviation for replicate
injections is not more than 2.0%. Chromatograph the Assay preparation, and record the peak
responses as directed for Procedure: the relative retention times are about 0.9 for nordihydro‐
capsaicin, 1.0 for capsaicin, and 1.6 for dihydrocapsaicin; and the resolution, R, between the
nordihydrocapsaicin peak and the capsaicin peak is not less than 1.2.
Procedure— Separately inject equal volumes (about 10 µL) of the Standard preparation and the
Assay preparation into the chromatograph, record the chromatograms, and measure the
responses for the three major peaks. Calculate the percentage of total capsaicins in the portion
of Capsicum Oleoresin taken by the formula:
(CP / W)(r U / r S)
in which
C is the concentration, in mg per mL, of USP Capsaicin RS in the Standard preparation;
P is the designated purity, in percentage, of USP Capsaicin RS,
W is the weight, in mg, of Capsicum Oleoresin taken to prepare the Assay preparation;
r U is the sum of the peak responses for nordihydrocapsaicin, capsaicin, and dihydrocapsaicin
obtained from the Assay preparation; and
r S is the peak response obtained from the Standard preparation.
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Extraction of spices with supercritical fluid carbon dioxide has been proposed as a means of
eliminating the use of organic solvents and providing the prospect of simultaneous fractiona‐
tion of the extract. The use of supercritical fluids (SCF) for extraction purposes was introduced
in the late nineteenth century. A supercritical fluid is a substance at temperatures and pressures
beyond its critical point at which the liquid phase of the substance will not exist. At these
temperatures and pressures, the supercritical fluid has properties between gas-and liquid-
phase characteristics. These properties make supercritical fluids efficient extraction solvents
with high mass transfer characteristics (McHugh and Krukonis, 1986;; Krukonis, 1988).
Consequently, supercritical fluids are often used to selectively extract or separate specific
compounds from a mixture by varying fluid density through changes in pressure and
temperature. In food technology, the use of supercritical fluids is essentially limited to
supercritical carbon dioxide (SCF-CO2) extraction since carbon dioxide has the advantages of
being inexpensive and nontoxic and because its critical point is easily reached.
Oleoresins have several advantages over ground spices, e.g., elimination of microbial con‐
tamination, uniformity of color and flavor strenght and optimal utilization. The Essential Oil
Association of America has detailed specifications for three types of Capsicum oleoresins (Table
2). Oleoresin paprika is mainly used as food coloring in meats, dairy products, soups, sauces
and snacks. Oleoresin red pepper is used for both coloring and pungency, mainly in canned
meats, sausages, in some snacks and in a dispersed form in some drinks such as ginger ale.
Oleoresin Capsicum is the most pungent and is used for its counter-irritant properties in plasters
and some pharmaceutical preparations.
Type of oleoresin
Capsicum




























40,000-100,000 Deep red Nil or negligible
Table 2. Nomenclature of oleoresins of Capsicums (Essential Oils Association, 1975).
3.2.1. Capsicum Oleoresin
The 2012 edition of the United States Pharmacopoeia-National Formulary (USP36-NF31) lists
Capsicum Oleoresin and describes its Capsicum Oleoresin as follows.
3.2.1.1. Capsicum Oleoresin (USP30-NF25)
DEFINITION: Capsicum Oleoresin is an alcoholic extract of the dried ripe fruits of Capsicum
annum var. minimum and small fruited varieties of C. frutescens (Solanaceae). It contains not
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less than 8.0 percent of total capsaicins [capsaicin (C18H27NO3), dihydrocapsaicin (C18H29NO3),
and nordihydrocapsaicin (C17H27NO3)].
IDENTIFICATION: To about 0.5 g of it in a beaker add 5 mL of water and 10 mL of a mixture
of water, 0.2 M potassium chloride, and 0.2 N hydrochloric acid, and mix. Add 5.0 mL of 0.5
M sodium nitrite and 5.0 mL of 0.02 M sodium tungstate, and mix. Heat at 55o to 60o for 15
minutes, allow to cool, and filter. To the filtrate add 10 mL of 1 N sodium hydroxide: a bright
yellow color is produced (presence of capsaicin).
ASSAY
Mobile phase— Prepare a mixture of methanol and 2% acetic acid (56:44), filter through a 0.5-
µm or finer porosity filter, and degas.
Standard preparation— Prepare a solution of USP Capsaicin RS in methanol having a known
concentration of about 0.5 mg per mL. Filter a portion of this solution through a 0.2-µm porosity
filter, and use the filtrate as the Standard preparation.
Assay preparation— Transfer about 1000 mg of Capsicum Oleoresin, accurately weighed, to a 100-
mL volumetric flask, dissolve in and dilute with methanol to volume, and mix. Filter a portion
of this solution through a 0.2-µm porosity filter, and use the filtrate as the Assay preparation.
Chromatographic system— The liquid chromatograph is equipped with a 280-nm detector and
a 3.9-mm × 30-cm column that contains packing L1. The flow rate is about 2 mL per minute.
Chromatograph the Standard preparation, and record the peak responses as directed for
Procedure: the tailing factor is not more than 2.0; and the relative standard deviation for replicate
injections is not more than 2.0%. Chromatograph the Assay preparation, and record the peak
responses as directed for Procedure: the relative retention times are about 0.9 for nordihydro‐
capsaicin, 1.0 for capsaicin, and 1.6 for dihydrocapsaicin; and the resolution, R, between the
nordihydrocapsaicin peak and the capsaicin peak is not less than 1.2.
Procedure— Separately inject equal volumes (about 10 µL) of the Standard preparation and the
Assay preparation into the chromatograph, record the chromatograms, and measure the
responses for the three major peaks. Calculate the percentage of total capsaicins in the portion
of Capsicum Oleoresin taken by the formula:
(CP / W)(r U / r S)
in which
C is the concentration, in mg per mL, of USP Capsaicin RS in the Standard preparation;
P is the designated purity, in percentage, of USP Capsaicin RS,
W is the weight, in mg, of Capsicum Oleoresin taken to prepare the Assay preparation;
r U is the sum of the peak responses for nordihydrocapsaicin, capsaicin, and dihydrocapsaicin
obtained from the Assay preparation; and
r S is the peak response obtained from the Standard preparation.
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3.3. Quantitation of capsicum pigments
Appearance and color, the first of the percieved attributes, directly provide a basis for a
decision of appropriateness. Size, shape, and maximum percentage of defects are easily
measured specifications are given in standards. Color of Capsicum fruits is basicly determined
by the nature and distribution of the above described carotenoids of which can be hidden or
modified by other pigments such as chlorophylls and anthocyanins. The major coloring
pigments in paprika are capsanthin and capsorubin, comprising majority of the total carote‐
noids. Other pigments are beta-carotene, zeaxanthin, violaxanthin, neoxantin and lutein (Anu
and Peter, 2000). It is also worth repatedly mentioning that the relative amounts of the colored
pigments are changing during the ripening period according to a rather well investigated
biochemical pathways (Rodriguez-Amaya, 1997; Rahman and Buckle, 1980; Hornero-Mendez
et al., 2000; Gnayfeed et al., 2001; Deli and Molnár, 2002).
It is also worth mentioning that carotenoid research in the field of plant and food chemistry is
a very extensive area. The interested readers can consult recent reviews to learn the analytical
methods that are currently used to analyse plant and food samples for their carotenoid contents
(Rodriguez-Amaya, 1997; Wall and Bosland, 1998; Deli and Molnár, 2002; Felt et al., 2005).
Some of the methods to measure coloring parameters of paprika and oleoresins currently
accepted as official are summarized below.
3.3.1. The color matching method
This early method for total pigments expressed as Nesslerimeter color value used in the
industry was standardized and adopted by the Essential Oils Association of America (EOA)
for Oleoresin Capsicum (Essential Oil Association (1975): Specification of oleoresin paprika –
EOA No. 239, Oleoresin Capsicum – EOA No. 244, Oleoresin red pepper – EOA No. 245,
Essential Oil Association, New York). The method is based on matching the color of the
properly diluted oleoresin acetone solution with that of a potasium dichromate (K2Cr2O7) and
cobaltous chloride (CoCl2 x 6H2O) containing reference solutions.
3.3.2. Spectrophotometric methods
The alternative method uses the spectrophotometer to measure the total carotenoid pigments.
3.3.2.1. The EOA method
(Essential Oil Association (1975): Specification of oleoresin paprika – EOA No. 239, Oleoresin
Capsicum – EOA No. 244, Oleoresin red pepper – EOA No. 245, Essential Oil Association, New
York)
The absorbance of a 0.01% acetone solution of oleoresin is measured at 458 nm. The absorbance
value is multiplied by 61,000 (an empirical factor worked out to relate the data from the color
matching method) gives the total pigment as the Nesslerimeter color value.
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside36
3.3.2.2. The American Spice Trade Association (ASTA) method
By the above spectrophotometric method, results from different laboratories were not directly
comparable due to differences in the spectrophotometers. In the new ASTA 20.1 Method
(ASTA, 1968) a reference solution of inorganic salts (potassium dichromate and cobaltous
ammonium sulfate in 1.8 M sulfuric acid solution) absorbing in the same region as the
carotenoids is used to calculate an instrument factor which makes interlaboratory comparison
possible. In the ASTA Method 20.1 for extractable color (pigments) in Capsicums absorbance
of acetone extract of ground paprika and other capsicums is measured at 460 nm. The color
value (in ASTA) is calculated using the determined instrument correction factor.
A direct correlation between the earlier ASTA Method 19, measuring absorbance at 450 nm,
and the new Method 20.1 can not be established, an empirical factor (16.4) in the formula to
give values nearly equal to those obtained by the earlier Method No. 19.
3.3.2.3. The Hungarian standard method
In Hungary, where specified grades of ground paprika are produced (csípős, csemege, édes‐
nemes), the total pigments are determined by similar absorbtion measurements. Earlier, the
total pigment concentration in ground capsicums or in oleoresins was calculated by using the
extinction coefficient in benzene of the major pigment capsanthin (1%E477nm=1826). The results
were expressed in grams of capsanthin per kilograms of dry matter (Hungarian Standard.
Examination of Ground Paprika Spice. Determination of Pigment Content, MSZ 9681/5-76.).
At present, the measurements are performed using acetone extracts similar to the ASTA
Method 20.1 (MSZ 9681-5:2002)
3.4. Quantitation of pungent principles
For the major portion of Capsicum species pruduced and traded, pungency is the important
quality attribute. The nature of the causal components in the spice has been established as a
mixture of seven homologous branched-chain alkyl vanillylamides, named capsaicinoids. Smal
amounts of three straight-chain analogues have also been shown to occure. The chemistry of
these compounds has been reviewed (Suzuki and Iwai, 1984). The structures are given in
Table 1.
The average composition of these related vanillylamides in the videly traded chillis (Capsicum
annuum var. annuum) varieties is capsaicin 33 to 59%; dihydrocapsaicin, 30 to 51%; nordihy‐
drocapsaicin, 7 to 15%; and others, in the range of 0 to 5% each. Fruits of the species Capsicum
frutescens, stimulating high pungency and mostly used in the pharmaceutical industry, have
higher capsaicin (63 to 77%) and dihydrocapsaicin (20 to 32%) with other homologues and
analogues making up around 10% (Jurenitsch et al., 1978). The total capsaicinoids varied
greatly (0.001 to 0.01% in paprika and 0.1 to >1% in chillis), but the proportion of capsaicin and
dihydrocapsain ranged from 77 to 90% int he fruits of the species C. annuum and from 89 to
98% in those from species C. frutescens (Govindarajan et al., 1987).
The pungency stimulated by the different alkyl acyl vanillylamides varied greatly, all much
lower compared to capsaicin and dihydrocapsaicin, which were equal (Govindarajan et al.,
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3.3. Quantitation of capsicum pigments
Appearance and color, the first of the percieved attributes, directly provide a basis for a
decision of appropriateness. Size, shape, and maximum percentage of defects are easily
measured specifications are given in standards. Color of Capsicum fruits is basicly determined
by the nature and distribution of the above described carotenoids of which can be hidden or
modified by other pigments such as chlorophylls and anthocyanins. The major coloring
pigments in paprika are capsanthin and capsorubin, comprising majority of the total carote‐
noids. Other pigments are beta-carotene, zeaxanthin, violaxanthin, neoxantin and lutein (Anu
and Peter, 2000). It is also worth repatedly mentioning that the relative amounts of the colored
pigments are changing during the ripening period according to a rather well investigated
biochemical pathways (Rodriguez-Amaya, 1997; Rahman and Buckle, 1980; Hornero-Mendez
et al., 2000; Gnayfeed et al., 2001; Deli and Molnár, 2002).
It is also worth mentioning that carotenoid research in the field of plant and food chemistry is
a very extensive area. The interested readers can consult recent reviews to learn the analytical
methods that are currently used to analyse plant and food samples for their carotenoid contents
(Rodriguez-Amaya, 1997; Wall and Bosland, 1998; Deli and Molnár, 2002; Felt et al., 2005).
Some of the methods to measure coloring parameters of paprika and oleoresins currently
accepted as official are summarized below.
3.3.1. The color matching method
This early method for total pigments expressed as Nesslerimeter color value used in the
industry was standardized and adopted by the Essential Oils Association of America (EOA)
for Oleoresin Capsicum (Essential Oil Association (1975): Specification of oleoresin paprika –
EOA No. 239, Oleoresin Capsicum – EOA No. 244, Oleoresin red pepper – EOA No. 245,
Essential Oil Association, New York). The method is based on matching the color of the
properly diluted oleoresin acetone solution with that of a potasium dichromate (K2Cr2O7) and
cobaltous chloride (CoCl2 x 6H2O) containing reference solutions.
3.3.2. Spectrophotometric methods
The alternative method uses the spectrophotometer to measure the total carotenoid pigments.
3.3.2.1. The EOA method
(Essential Oil Association (1975): Specification of oleoresin paprika – EOA No. 239, Oleoresin
Capsicum – EOA No. 244, Oleoresin red pepper – EOA No. 245, Essential Oil Association, New
York)
The absorbance of a 0.01% acetone solution of oleoresin is measured at 458 nm. The absorbance
value is multiplied by 61,000 (an empirical factor worked out to relate the data from the color
matching method) gives the total pigment as the Nesslerimeter color value.
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3.3.2.2. The American Spice Trade Association (ASTA) method
By the above spectrophotometric method, results from different laboratories were not directly
comparable due to differences in the spectrophotometers. In the new ASTA 20.1 Method
(ASTA, 1968) a reference solution of inorganic salts (potassium dichromate and cobaltous
ammonium sulfate in 1.8 M sulfuric acid solution) absorbing in the same region as the
carotenoids is used to calculate an instrument factor which makes interlaboratory comparison
possible. In the ASTA Method 20.1 for extractable color (pigments) in Capsicums absorbance
of acetone extract of ground paprika and other capsicums is measured at 460 nm. The color
value (in ASTA) is calculated using the determined instrument correction factor.
A direct correlation between the earlier ASTA Method 19, measuring absorbance at 450 nm,
and the new Method 20.1 can not be established, an empirical factor (16.4) in the formula to
give values nearly equal to those obtained by the earlier Method No. 19.
3.3.2.3. The Hungarian standard method
In Hungary, where specified grades of ground paprika are produced (csípős, csemege, édes‐
nemes), the total pigments are determined by similar absorbtion measurements. Earlier, the
total pigment concentration in ground capsicums or in oleoresins was calculated by using the
extinction coefficient in benzene of the major pigment capsanthin (1%E477nm=1826). The results
were expressed in grams of capsanthin per kilograms of dry matter (Hungarian Standard.
Examination of Ground Paprika Spice. Determination of Pigment Content, MSZ 9681/5-76.).
At present, the measurements are performed using acetone extracts similar to the ASTA
Method 20.1 (MSZ 9681-5:2002)
3.4. Quantitation of pungent principles
For the major portion of Capsicum species pruduced and traded, pungency is the important
quality attribute. The nature of the causal components in the spice has been established as a
mixture of seven homologous branched-chain alkyl vanillylamides, named capsaicinoids. Smal
amounts of three straight-chain analogues have also been shown to occure. The chemistry of
these compounds has been reviewed (Suzuki and Iwai, 1984). The structures are given in
Table 1.
The average composition of these related vanillylamides in the videly traded chillis (Capsicum
annuum var. annuum) varieties is capsaicin 33 to 59%; dihydrocapsaicin, 30 to 51%; nordihy‐
drocapsaicin, 7 to 15%; and others, in the range of 0 to 5% each. Fruits of the species Capsicum
frutescens, stimulating high pungency and mostly used in the pharmaceutical industry, have
higher capsaicin (63 to 77%) and dihydrocapsaicin (20 to 32%) with other homologues and
analogues making up around 10% (Jurenitsch et al., 1978). The total capsaicinoids varied
greatly (0.001 to 0.01% in paprika and 0.1 to >1% in chillis), but the proportion of capsaicin and
dihydrocapsain ranged from 77 to 90% int he fruits of the species C. annuum and from 89 to
98% in those from species C. frutescens (Govindarajan et al., 1987).
The pungency stimulated by the different alkyl acyl vanillylamides varied greatly, all much
lower compared to capsaicin and dihydrocapsaicin, which were equal (Govindarajan et al.,
Pharmacobotanical Analysis and Regulatory Qualification of Capsicum Fruits and Capsicum Extracts — A Survey
http://dx.doi.org/10.5772/58812
37
1987). Thus, the estimation of total capsaicinoids, reproducibly and accurately correlating with
the determined pungency, should be sufficient for quality control. Where the minor capsaicin-
related vanillylamides make up a larger portion (above 20%), however, their individual
estimation could become necessary because they stimulate much lower pungency. It is also
known for a long time that synthetic nonoyl vanillylamide (pelargonyl vanillylamide) has
considearable pungency and heat (Kulka, 1967). and has been found in varying amounts in
commercial oleoresins. Therefore, it was necessary to determine the upper limits of the straight
chain analogs to determine adulteration.
3.4.1. Official methods for organoleptic determination of pungency
3.4.1.1. The Scoville method
A number of methods have been reported from time to time since 1912 for assaying the
pungency or capsaicin content of Capsicum fruits and/or the processed fruits (Pruthi, 2003).
The basic principle of pungency evaluation using an organoleptic method was eshtablished
in 1912 by W. L. Scoville (Scoville, 1912). The method is based on sensory evaulation deter‐
mining the amount of sugar to neutralize the heat from the pepper. A solution of the pepper
extract is variably diluted with sugar solution are tested in increasing concentration. The
highest dilution at wich pungency is just detected is taken as a measure of the heat value. The
dilution value, in milliliters per gram has since then been called Scoville Heat Units (SHU).
The SHU for pure capsaicin is reported as 16-17 x 106. The Scoville Heat Units of various chilli
pepper varieties are shown in Table 3. The greatest weakness of the Scoville organoleptic test
is its imprecision, because it relies on human subjectivity.
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Table 3. The Scoville Heat Units of various chilli pepper varieties.
3.4.1.2. The EOA method
This method (Essential Oil Association (1975): Specification of oleoresin paprika – EOA No.
239, Oleoresin Capsicum – EOA No. 244, Oleoresin red pepper – EOA No. 245, Essential Oil
Association, New York) is the codification of the procedure that was in use by the spice
processing industry to check the constancy of pungency of a usual trade variety and source.
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The method, based on the approach of the original Scoville method, specified for oleoresins of
capsicum as follows.
A standard solution for testing is made by diluting a stock alcoholic solution of the oleoresin
and it is tested by five trained panelists. If three of the five on a panel agree on just perceptible
pungency at the given dilution (which is equivalent to 240,000 ml/g), this value is called the
SHU of pungency of the sample. If the pungency response is strong, this first diluted standard
is further diluted and the panel testing is repeated to find the dilution at which three of the
five judge the pungency just perceptible. The Scoville test run shows a rather high correlation
to total capsaicinoids content (1,500,000 Scoville units=1% capsaicin).
3.4.1.3. The British standard method
The British Standard Institution adapted the above industry procedure except that dilutions
were rationalized in more convenient volumes (British Standards Institution (1979): Methods
for testing spices and condiments: Determination of Scoville index of chillies, BS 4548 (Part 7),
BSI, London)
3.4.1.4. The International Standard Organization (ISO) method
The British Standard Method adopted and improved by the International Standards Organi‐
zation (ISO) requires the testing of a series of dilutions around the anticipated value by
individuals experienced in recognizing pungency (International Standards Organization
(1997): Spices and condiments – chillies: Determination of Scoville index, ISO 3513:1977E, ISO,
Geneva). Testing of dilutions should be done from the weekest to the strongest until a level at
which three of five panelists agree on recognition pungency. There is no published reports on
the extensive use and efficiency of these latter two methods, except a few which reported
comparison of experimentally determined SHU values with that of calculated based on
capsaicinoid content of oleoresin capsicum samples. (Suzuki et al., 1957).
3.4.1.5. The ASTA method
The ASTA adopted as early as 1968 Method No. 21.0 as an official method for pungency
evaluation which took care of many variables that were to be controlled for good reproduci‐
bility (ASTA (1968): Method 21.0, Pungency of capsicum spices and oleoresins (Scoville heat
test), In: Official Analytical Methods, ASTA, Englewood Cliffs, N.J.). The procedure followed
in the industry and EOA was thoroughly revised by designing it as a general method applicable
to samples of a large range of capsaicinoids content by careful steps for determining the
recognition threshold using an ascending concentration series.
3.5. Quantitation of capsaicinoids
In addition to pungency, as a bulk characteristics of total capsaicinoids, estimation of individ‐
ual level of each capsaicinoid is also an important quality attribute of Capsicum fruits. There
are over a hundred papers published on the estimation of total capsaicinoids in Capsicum fruits,
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1987). Thus, the estimation of total capsaicinoids, reproducibly and accurately correlating with
the determined pungency, should be sufficient for quality control. Where the minor capsaicin-
related vanillylamides make up a larger portion (above 20%), however, their individual
estimation could become necessary because they stimulate much lower pungency. It is also
known for a long time that synthetic nonoyl vanillylamide (pelargonyl vanillylamide) has
considearable pungency and heat (Kulka, 1967). and has been found in varying amounts in
commercial oleoresins. Therefore, it was necessary to determine the upper limits of the straight
chain analogs to determine adulteration.
3.4.1. Official methods for organoleptic determination of pungency
3.4.1.1. The Scoville method
A number of methods have been reported from time to time since 1912 for assaying the
pungency or capsaicin content of Capsicum fruits and/or the processed fruits (Pruthi, 2003).
The basic principle of pungency evaluation using an organoleptic method was eshtablished
in 1912 by W. L. Scoville (Scoville, 1912). The method is based on sensory evaulation deter‐
mining the amount of sugar to neutralize the heat from the pepper. A solution of the pepper
extract is variably diluted with sugar solution are tested in increasing concentration. The
highest dilution at wich pungency is just detected is taken as a measure of the heat value. The
dilution value, in milliliters per gram has since then been called Scoville Heat Units (SHU).
The SHU for pure capsaicin is reported as 16-17 x 106. The Scoville Heat Units of various chilli
pepper varieties are shown in Table 3. The greatest weakness of the Scoville organoleptic test
is its imprecision, because it relies on human subjectivity.
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Table 3. The Scoville Heat Units of various chilli pepper varieties.
3.4.1.2. The EOA method
This method (Essential Oil Association (1975): Specification of oleoresin paprika – EOA No.
239, Oleoresin Capsicum – EOA No. 244, Oleoresin red pepper – EOA No. 245, Essential Oil
Association, New York) is the codification of the procedure that was in use by the spice
processing industry to check the constancy of pungency of a usual trade variety and source.
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The method, based on the approach of the original Scoville method, specified for oleoresins of
capsicum as follows.
A standard solution for testing is made by diluting a stock alcoholic solution of the oleoresin
and it is tested by five trained panelists. If three of the five on a panel agree on just perceptible
pungency at the given dilution (which is equivalent to 240,000 ml/g), this value is called the
SHU of pungency of the sample. If the pungency response is strong, this first diluted standard
is further diluted and the panel testing is repeated to find the dilution at which three of the
five judge the pungency just perceptible. The Scoville test run shows a rather high correlation
to total capsaicinoids content (1,500,000 Scoville units=1% capsaicin).
3.4.1.3. The British standard method
The British Standard Institution adapted the above industry procedure except that dilutions
were rationalized in more convenient volumes (British Standards Institution (1979): Methods
for testing spices and condiments: Determination of Scoville index of chillies, BS 4548 (Part 7),
BSI, London)
3.4.1.4. The International Standard Organization (ISO) method
The British Standard Method adopted and improved by the International Standards Organi‐
zation (ISO) requires the testing of a series of dilutions around the anticipated value by
individuals experienced in recognizing pungency (International Standards Organization
(1997): Spices and condiments – chillies: Determination of Scoville index, ISO 3513:1977E, ISO,
Geneva). Testing of dilutions should be done from the weekest to the strongest until a level at
which three of five panelists agree on recognition pungency. There is no published reports on
the extensive use and efficiency of these latter two methods, except a few which reported
comparison of experimentally determined SHU values with that of calculated based on
capsaicinoid content of oleoresin capsicum samples. (Suzuki et al., 1957).
3.4.1.5. The ASTA method
The ASTA adopted as early as 1968 Method No. 21.0 as an official method for pungency
evaluation which took care of many variables that were to be controlled for good reproduci‐
bility (ASTA (1968): Method 21.0, Pungency of capsicum spices and oleoresins (Scoville heat
test), In: Official Analytical Methods, ASTA, Englewood Cliffs, N.J.). The procedure followed
in the industry and EOA was thoroughly revised by designing it as a general method applicable
to samples of a large range of capsaicinoids content by careful steps for determining the
recognition threshold using an ascending concentration series.
3.5. Quantitation of capsaicinoids
In addition to pungency, as a bulk characteristics of total capsaicinoids, estimation of individ‐
ual level of each capsaicinoid is also an important quality attribute of Capsicum fruits. There
are over a hundred papers published on the estimation of total capsaicinoids in Capsicum fruits,
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the oleoresins and products containing their extracts. The methods can be grouped into four
sets as follows:
3.5.1. Early direct and methods
As early as 1931, von Fodor used vanadium oxytrichloride or ammonium vanadate and
hydrochloric acid to react with the phenolic hydroxyl group of capsaicinoids and measured
the blue color formed. The accuracy of determinations based on color formation reactions of
the phenolic moiety could be conveniently used when the color produced with the chromo‐
genic reagent had absorption maxima far removed from the absorption range (300 to 550 nm)
of the red and yellow carotenoids of Capsicum fruits. Thus the blue colors formed when the
phenolic moiety of the capsaicinoids reacted with reagents such as vanadium oxychloride
(Palacio, 1977) and phosphomolybdic or phosphotungstic reagents (Jentzsch et al., 1969) had
their absorption maxima around 725 nm. On the other and, the chromophore produced by the
more specific 2,6-dichloro-p-benzoquinone-4-chlorimide (Gibb’s phenol reagent), depending
on the reaction conditions, absorbed maximally at 590 or 615 nm (Jentzsch et al., 1969; Rajpoot
and Govindarajan, 1981). The extinction coefficients for the blue colours using different
reagents varied greately and affected sensitivity. There are also reports using potassium
ferricianide plus ferric chloride (Spanyar and Blazovich, 1969) sodium nitrite molybdate
reagent (Bajaj, 1980) and Folin-Ciocalteu reagent (Kosuge and Inagaki, 1959) as chromogenic
reagents for determination of total capsaicinoids. It is worth mentioning that the color reactions
could also be applied for visualization of thin layer chromatography (TLC) spots of separated
capsaicinoids.
3.5.2. Methods based on separation of capsaicinoids
The specificity and accuracy of determination of capsaicinoids were improved by a prelimi‐
nary separation of interfering pigments and other substances. In the early methods separation
of capsaicinoids from the pigments was accomplished by solvent partition. Several combina‐
tion of partition system has been found in the literature (Spanya et al., 1957; Benedek, 1959;
Chem. Abstr. 1963a; Tirimanna, 1972) none of the methods, however, was validated by
pungency tests, without which the accuracy of the determination can not be ascertained.
There have been several methods developed for preliminary separation of capsaicinoids from
the Capsicum pigments using short column clean-up methods. The purified capsaicinoids were
quantitated by colorimetry after reacting with chromogenic reagents (Hollo et al., 1957, Chem.
Abstr., 1958; Bajaj, 1980) or directly at the absorption maxima (282 nm) of pure capsaicin
(Suzuki et al., 1957; Brawer and Schoen, 1962; Chem. Abstr., 1963b). Suzuki et al. determined
pungency values for a number of chilli and oleoresin samples by threshold testing and
validated the capsaicinoids values determined by the proposed method (Suzuki et al., 1957).
After several reviews, the Joint committe (Pharmaceutical Society/Society of Analytical
Chemistry) recommended the diethyl ether-alkali partition method for separation and the
spectrophotometric difference method or the method using the Gibb’s reagent for measure‐
ment (Joint Committee (PS/SAC) 1964). The method has been adopted by both the British
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside40
Standards (BS) and International Standards Institutions (ISO) for estimation of capsaicinoids
(International Standards Organization, 1981).
3.5.2.1. Thin layer chromatography
As newer separation methods emerged (e.g., paper chromatography and TLC) which gave
rapid and more efficient separation, they were quickly used in the determination of total and
later the individual capsaicinoids. The main body of papers in the 1960s practically relegated
the earlier solvent partition and column methods to the past and published reliable, rapid
micromethods. Most of the early thin layer chromatography (TLC) methods used silica gel
plates with a wide range of variations in the developing solvents. The versatility of TLC method
for separation of complex mixture of compounds could be further improved, however, by
using reversed-phase plates and polar developing solvents containing silver nitrate (Todd et
al., 1975). Methods of visualization applied UV light or chromogenic reagents. The estimation
method also varied: visual comparison of size and intensity of spots, direct densitometry on
the plate, collection of the marked spot into a tube, development of color with a chromogenic
reagent and absorption measurements. Quantitation was by reference to a standard curve
using pure capsaicinoids treated under the same conditions. A comprehensive listing of the
methods can be found in some reviews on capsaicinoids (Suzuki, and Iwai, 1984; Govindarajan
et al., 1987).
3.5.2.2. Gas chromatography
Gas chromatography (GC) was early used to detect adulteration of capsaicinoids with
synthetic vanillylamides and individual components in crystalline capsaicinoids through the
analysis of methyl esters of fatty acids derived from them (see Table 2). As early as 1967,
Morrison demonstrated that capsaicinoids can be analyzed by gas chromatography without
derivatization (Morrison, 1967). In order to improve peak symmetry, prevent degradation of
column and improve reproducibility of measurements, however, most of the GC methods need
derivatization step to increase volatility of the capsaicinoids, and, furthermore, an efficient
clean-up step is necessary (Todd et al., 1977; Iwai et al., 1979; Krajewska and Powers, 1987;
Manirakiza et al., 1999). Two types of derivatization procedures have been reported: trime‐
thylsilylation of capsaicinoids (Lee et al., 1976; Todd et al., 1977; Iwai et al., 1979; Fung et al.,
1982) and hydrolysis of capsaicinoids to yield fatty acids and subsequent esterification
(Jurenitsch et al., 1978; Jurenitsch and Leinmueller, 1980). To overcome the problem of tailing
peaks and to avoid the use of derivatization step, Thomas et al. (Thomas et al., 1998) and Hawer
et al. (Hawer et al., 1994) have recognized the use of polar capillary column for interaction with
polar functional group of the molecules. In an earlier work Di Cecco also used stable polar
analytical column (Carbowax-Teflon) to analyse column purified capsaicinoids from ground
capsicum (Di Cecco, 1976). Furthermore, the use of a thermoionic selective detector (TSD)
instead of flame ionization detection allowed the elimination of sample clean-up (Thomas et
al., 1998)
Although direct analysis of capsaicinoids could be disandvantageous direct GC-MS analysis
of commercially available natural capsainoids has been proved to be a proper method to
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the oleoresins and products containing their extracts. The methods can be grouped into four
sets as follows:
3.5.1. Early direct and methods
As early as 1931, von Fodor used vanadium oxytrichloride or ammonium vanadate and
hydrochloric acid to react with the phenolic hydroxyl group of capsaicinoids and measured
the blue color formed. The accuracy of determinations based on color formation reactions of
the phenolic moiety could be conveniently used when the color produced with the chromo‐
genic reagent had absorption maxima far removed from the absorption range (300 to 550 nm)
of the red and yellow carotenoids of Capsicum fruits. Thus the blue colors formed when the
phenolic moiety of the capsaicinoids reacted with reagents such as vanadium oxychloride
(Palacio, 1977) and phosphomolybdic or phosphotungstic reagents (Jentzsch et al., 1969) had
their absorption maxima around 725 nm. On the other and, the chromophore produced by the
more specific 2,6-dichloro-p-benzoquinone-4-chlorimide (Gibb’s phenol reagent), depending
on the reaction conditions, absorbed maximally at 590 or 615 nm (Jentzsch et al., 1969; Rajpoot
and Govindarajan, 1981). The extinction coefficients for the blue colours using different
reagents varied greately and affected sensitivity. There are also reports using potassium
ferricianide plus ferric chloride (Spanyar and Blazovich, 1969) sodium nitrite molybdate
reagent (Bajaj, 1980) and Folin-Ciocalteu reagent (Kosuge and Inagaki, 1959) as chromogenic
reagents for determination of total capsaicinoids. It is worth mentioning that the color reactions
could also be applied for visualization of thin layer chromatography (TLC) spots of separated
capsaicinoids.
3.5.2. Methods based on separation of capsaicinoids
The specificity and accuracy of determination of capsaicinoids were improved by a prelimi‐
nary separation of interfering pigments and other substances. In the early methods separation
of capsaicinoids from the pigments was accomplished by solvent partition. Several combina‐
tion of partition system has been found in the literature (Spanya et al., 1957; Benedek, 1959;
Chem. Abstr. 1963a; Tirimanna, 1972) none of the methods, however, was validated by
pungency tests, without which the accuracy of the determination can not be ascertained.
There have been several methods developed for preliminary separation of capsaicinoids from
the Capsicum pigments using short column clean-up methods. The purified capsaicinoids were
quantitated by colorimetry after reacting with chromogenic reagents (Hollo et al., 1957, Chem.
Abstr., 1958; Bajaj, 1980) or directly at the absorption maxima (282 nm) of pure capsaicin
(Suzuki et al., 1957; Brawer and Schoen, 1962; Chem. Abstr., 1963b). Suzuki et al. determined
pungency values for a number of chilli and oleoresin samples by threshold testing and
validated the capsaicinoids values determined by the proposed method (Suzuki et al., 1957).
After several reviews, the Joint committe (Pharmaceutical Society/Society of Analytical
Chemistry) recommended the diethyl ether-alkali partition method for separation and the
spectrophotometric difference method or the method using the Gibb’s reagent for measure‐
ment (Joint Committee (PS/SAC) 1964). The method has been adopted by both the British
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Standards (BS) and International Standards Institutions (ISO) for estimation of capsaicinoids
(International Standards Organization, 1981).
3.5.2.1. Thin layer chromatography
As newer separation methods emerged (e.g., paper chromatography and TLC) which gave
rapid and more efficient separation, they were quickly used in the determination of total and
later the individual capsaicinoids. The main body of papers in the 1960s practically relegated
the earlier solvent partition and column methods to the past and published reliable, rapid
micromethods. Most of the early thin layer chromatography (TLC) methods used silica gel
plates with a wide range of variations in the developing solvents. The versatility of TLC method
for separation of complex mixture of compounds could be further improved, however, by
using reversed-phase plates and polar developing solvents containing silver nitrate (Todd et
al., 1975). Methods of visualization applied UV light or chromogenic reagents. The estimation
method also varied: visual comparison of size and intensity of spots, direct densitometry on
the plate, collection of the marked spot into a tube, development of color with a chromogenic
reagent and absorption measurements. Quantitation was by reference to a standard curve
using pure capsaicinoids treated under the same conditions. A comprehensive listing of the
methods can be found in some reviews on capsaicinoids (Suzuki, and Iwai, 1984; Govindarajan
et al., 1987).
3.5.2.2. Gas chromatography
Gas chromatography (GC) was early used to detect adulteration of capsaicinoids with
synthetic vanillylamides and individual components in crystalline capsaicinoids through the
analysis of methyl esters of fatty acids derived from them (see Table 2). As early as 1967,
Morrison demonstrated that capsaicinoids can be analyzed by gas chromatography without
derivatization (Morrison, 1967). In order to improve peak symmetry, prevent degradation of
column and improve reproducibility of measurements, however, most of the GC methods need
derivatization step to increase volatility of the capsaicinoids, and, furthermore, an efficient
clean-up step is necessary (Todd et al., 1977; Iwai et al., 1979; Krajewska and Powers, 1987;
Manirakiza et al., 1999). Two types of derivatization procedures have been reported: trime‐
thylsilylation of capsaicinoids (Lee et al., 1976; Todd et al., 1977; Iwai et al., 1979; Fung et al.,
1982) and hydrolysis of capsaicinoids to yield fatty acids and subsequent esterification
(Jurenitsch et al., 1978; Jurenitsch and Leinmueller, 1980). To overcome the problem of tailing
peaks and to avoid the use of derivatization step, Thomas et al. (Thomas et al., 1998) and Hawer
et al. (Hawer et al., 1994) have recognized the use of polar capillary column for interaction with
polar functional group of the molecules. In an earlier work Di Cecco also used stable polar
analytical column (Carbowax-Teflon) to analyse column purified capsaicinoids from ground
capsicum (Di Cecco, 1976). Furthermore, the use of a thermoionic selective detector (TSD)
instead of flame ionization detection allowed the elimination of sample clean-up (Thomas et
al., 1998)
Although direct analysis of capsaicinoids could be disandvantageous direct GC-MS analysis
of commercially available natural capsainoids has been proved to be a proper method to
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separate the main capsaicinoids and quantitate capsaicin and dihydrocapsaicin in Capsicum
extracts as well (Kuzma et al., 2006) A typical gas chromatogram of a commercially available
natural capsaicin is shown on Figure 6.
Figure 6. Gas chromatogram of a commercially available natural capsaicin preparation (Mózsik et al., 2009). Retention
times: 16.8 min (not shown): nordihydrocapsaicin; 17.4 min capsaicin; 17.6 min: dihydrocapsaicin.
Lee et al. (Lee et al., 1976) used selective ion monitoring to identify and quantify individual
capsaicinoids at the nanogram level in partially or fully separated and even mixed peaks from
GC of trimethylsylilated capsaicinoids. Aliquots of fruit extracts were subjected to TLC or
reversed phase (RP) HPLC to separate the capsaicinoids from other components of the extracts.
Iwai et al. (Iwai et al, 1979) developed a similar method for determining all homologs in total
extracts of Capsicum fruits. By this analysis, similar to other GC-MS methods (Fung et al.,
1982; Reilly et al., 2001a, b) the straight-chain homologs (octanoyl, nonoyl and decyl vanilly‐
lamides – identified in minor amounts in other analyzes (Jurenitsch et al., 1978; Jurenitsch and
Leinmueller, 1980) – were not found in any of the samples. This was the case because the
analysis was based on selected m/e values but not on monitoring the mass of octanoyl vanil‐
lylamide, and the method could not differentiate between nonoyl vanillylamide and nordi‐
hydrocapsaicin eluting in the same area. Pena-Alvarez et al. (Pena-Alvarez et al., 2009) used
solid phase microextraction (SPME)–gas chromatography–mass spectrometry for the analysis
of capsaicin and dihydrocapsaicin in peppers and pepper sauces. In addition to capsaicin and
dihydrocapsaicin, the method could differentiate several straight-chain analogs (e.g. nordi‐
hydrocapsaicin, nonoyl vanillylamide, homodihydrocapsaicin I and homodihydrocapsaicin
II) in the different peppers and pepper sauces.
3.5.2.3. High performance liqiud chromatography
This chromatographic technique has superior and rapid separation capabilities arising from
the use of very fine and highly uniform particles, newer solid phases, and high pressure to
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move the eluting solvent and fractions. With all its advantages, high performance liquid
chromatographic analysis is being increasingly used for routine analyses in both industrial
and research laboratories. HPLC has superior separation capabilities for closely related
compounds typically occuring in the case of extract of natural sources. Combined with
additional operational parametres, e.g., reversed-phase systems, silver-ion complexing of
olefinic compounds, optical as well as mass selective detectors, the separation efficiency,
sensitivity, and quantification at submicrogram levels of capsaicinoids have been demonstrat‐
ed in the recent years.
There has been published several HPLC methods for determination of capsaicin homologs and
analogs. Since there is no space to summarize all the methods published so far, attention of
interested readers is drawn to recent reviews to get a comprehensive knowledge on the field
(e.g., Govindarajan et al., 1987; Wall and Bosland, 1998; Pruthi, 2003; Manirakiza et al., 2003).
Here only selective papers are summarized with data obtained. A typical HPLC chromatogram
of a commercially available natural capsaicin is shown on Figure 7.
Lee et al (Lee et al., 1976) and Iwai and colleagues (Iwai et al., 1979) early used HPLC for
separation of capsaicinoids in one or two fractions from total extracts for the subsequents
analysis by mass spectrometry. Sticher et al. (Sticher et al., 1978) reported separation of four
homologs of capsaicin in purified capsaicinoids using a reversed-phase system. Jurenitsch at
al. (Jurenitsch et al., 1979a,b) accomplished separation of the capsaicin homologs and analogs
directly from ground fruit extracts on a reversed-phase system. Detection and quantitation
were done by absorbance at 280 nm. Four samples of Capsicum fruits were analyzed by this
HPLC method and also by the TMS-GC method earlier used by the group (Jurenitsch et al.,
1978) for comparison.
Nonoyl vanillyamide content has assumed importance since more than 3 to 4% of this analog
in a natural sample is considered adulteration unless declared. The method developed by
Figure 7. HPLC chromatogram of a commercially available capsaicin preparation (Mózsik et al., 2009). Retention
times: 9.3 min: nordihydrocapsaicin; 10.3 min: capsaicin; 15.6 min: dihydrocapsaicin; 17.0 min: homocapsaicin.
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separate the main capsaicinoids and quantitate capsaicin and dihydrocapsaicin in Capsicum
extracts as well (Kuzma et al., 2006) A typical gas chromatogram of a commercially available
natural capsaicin is shown on Figure 6.
Figure 6. Gas chromatogram of a commercially available natural capsaicin preparation (Mózsik et al., 2009). Retention
times: 16.8 min (not shown): nordihydrocapsaicin; 17.4 min capsaicin; 17.6 min: dihydrocapsaicin.
Lee et al. (Lee et al., 1976) used selective ion monitoring to identify and quantify individual
capsaicinoids at the nanogram level in partially or fully separated and even mixed peaks from
GC of trimethylsylilated capsaicinoids. Aliquots of fruit extracts were subjected to TLC or
reversed phase (RP) HPLC to separate the capsaicinoids from other components of the extracts.
Iwai et al. (Iwai et al, 1979) developed a similar method for determining all homologs in total
extracts of Capsicum fruits. By this analysis, similar to other GC-MS methods (Fung et al.,
1982; Reilly et al., 2001a, b) the straight-chain homologs (octanoyl, nonoyl and decyl vanilly‐
lamides – identified in minor amounts in other analyzes (Jurenitsch et al., 1978; Jurenitsch and
Leinmueller, 1980) – were not found in any of the samples. This was the case because the
analysis was based on selected m/e values but not on monitoring the mass of octanoyl vanil‐
lylamide, and the method could not differentiate between nonoyl vanillylamide and nordi‐
hydrocapsaicin eluting in the same area. Pena-Alvarez et al. (Pena-Alvarez et al., 2009) used
solid phase microextraction (SPME)–gas chromatography–mass spectrometry for the analysis
of capsaicin and dihydrocapsaicin in peppers and pepper sauces. In addition to capsaicin and
dihydrocapsaicin, the method could differentiate several straight-chain analogs (e.g. nordi‐
hydrocapsaicin, nonoyl vanillylamide, homodihydrocapsaicin I and homodihydrocapsaicin
II) in the different peppers and pepper sauces.
3.5.2.3. High performance liqiud chromatography
This chromatographic technique has superior and rapid separation capabilities arising from
the use of very fine and highly uniform particles, newer solid phases, and high pressure to
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move the eluting solvent and fractions. With all its advantages, high performance liquid
chromatographic analysis is being increasingly used for routine analyses in both industrial
and research laboratories. HPLC has superior separation capabilities for closely related
compounds typically occuring in the case of extract of natural sources. Combined with
additional operational parametres, e.g., reversed-phase systems, silver-ion complexing of
olefinic compounds, optical as well as mass selective detectors, the separation efficiency,
sensitivity, and quantification at submicrogram levels of capsaicinoids have been demonstrat‐
ed in the recent years.
There has been published several HPLC methods for determination of capsaicin homologs and
analogs. Since there is no space to summarize all the methods published so far, attention of
interested readers is drawn to recent reviews to get a comprehensive knowledge on the field
(e.g., Govindarajan et al., 1987; Wall and Bosland, 1998; Pruthi, 2003; Manirakiza et al., 2003).
Here only selective papers are summarized with data obtained. A typical HPLC chromatogram
of a commercially available natural capsaicin is shown on Figure 7.
Lee et al (Lee et al., 1976) and Iwai and colleagues (Iwai et al., 1979) early used HPLC for
separation of capsaicinoids in one or two fractions from total extracts for the subsequents
analysis by mass spectrometry. Sticher et al. (Sticher et al., 1978) reported separation of four
homologs of capsaicin in purified capsaicinoids using a reversed-phase system. Jurenitsch at
al. (Jurenitsch et al., 1979a,b) accomplished separation of the capsaicin homologs and analogs
directly from ground fruit extracts on a reversed-phase system. Detection and quantitation
were done by absorbance at 280 nm. Four samples of Capsicum fruits were analyzed by this
HPLC method and also by the TMS-GC method earlier used by the group (Jurenitsch et al.,
1978) for comparison.
Nonoyl vanillyamide content has assumed importance since more than 3 to 4% of this analog
in a natural sample is considered adulteration unless declared. The method developed by
Figure 7. HPLC chromatogram of a commercially available capsaicin preparation (Mózsik et al., 2009). Retention
times: 9.3 min: nordihydrocapsaicin; 10.3 min: capsaicin; 15.6 min: dihydrocapsaicin; 17.0 min: homocapsaicin.
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Jurenitsch et al. (1979a,b) was modified with the inclusion of silver nitrate in the mobile phase
to selectively shorten the retention time of capsaicin, thus separating it from the coeluting
nonoyl vanillylamide (Jurenitsch and Kampelmuehler, 1980). Constant and coworkers
(Constant et al., 1995) also used complexation chromatography (AgNO3) to separate norcap‐
saicin, zucapsaicin (civamide), capsaicin, nordihydrocapsaicin, nonivamide, homocapsaicin,
dihydrocapsaicin and homodihydrocapsaicin-I.
Kawada et al. performed microdetermination of capsaicin by high-performance liquid
chromatography with electrochemical detection (Kawada et al., 1985). Karnka et al. has
reported an optimized HPLC method for sample preparation, separation, detection and
identification of the major capsaicinoid compounds in various capsicum samples (Karnka et
al., 2002). Isocratic reversed phase HPLC analysis performed in the author’s laboratory allowed
separation of five main capsaicinoids of a commercially available capsaicin preparation. The
validated analytical method has been successfully applied to quantitate capsaicin and
dihydrocapsaicin in industrial Capsicum extracts (Kuzma et al., 2014). Isocratic HPLC method
with fluorimetric detection was used to determine capsaicin in rat tissues after acetone
extraction (Saria et al., 1981).
HPLC analysis has made possible the accurate determination of the homologs and analogs of
capsaicin and, combined with mass spectral analysis, has led to identification of structural
isomers of some minor components (Govindarajan, 1986b; Reilly et al., 2001; Schweiggert et
al., 2006; Singh et al., 2009; González-Zamora et al., 2013) and has made possible determination
of nanogram levels of the individual capsaicinoids as is required in biosynthetic and metabolic
studies (Reilly et al., 2002; Kozukue et al., 2005; Thompson et al., 2005; Zhang et al., 2010). The
use of HPLC-MS (Reilly et al., 2001a) has been reported to differentiate nonivamide and
capsaicin by mass-to-charge (m/e) ratio. The same authors have reported the use of LC-MS-MS
with electrospray ionization source operating at selective ion monitoring mode (Reilly et al.,
2001b). The quantification of capsaicinoids using LC-MS-MS was more sensitive (in the ng/ml
range) and exhibited greater accuracy, even at low analyte concentrations. HPLC coupled with
atmospheric pressure chemical ionization masss spectrometry has been reported to be a
method of choice for separation and identification of the three groups of capsaicinoids:
capsaicins possessing a methyl branched acyl residue with a carbon-carbon double bond,
dihydrocapsaicins analogous to the previous class, but beeing saturated compounds, and
capsaicin analogs (N-vanillyl-N-acylamides) composed of saturated, unbranched alkyl chains
(Schweiggert et al., 2006).
In summary, HPLC analysis for total capsaicinoids or individual capsaicinoids is certainly
rapid, reproducible, sensitive, and convenient for analysis of capsaicinoids in various capsai‐
cinoid containing matrices.
3.5.3. Official methods for determination of capsaicinoids
3.5.3.1. The ASTA method for determination of capsaicinoids
In the 1980’s it became clear that a more accurate and reproducible method of determining
“heat” in peppers and pepper products was necessary. Under the auspices of the American
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Spice Trade Association (ASTA), a new High Pressure Liquid Chromatography (HPLC)
Method was adopted as ASTA Method 21.1. The HPLC measurement of capsaicin has evolved
over the years as new and better instrumentation has allowed of greater accuracy of analysis.
In 1996 AOAC issued Method 995.03: Capsaicinoids in Capsicums and their Extractives. In
1998, in a collaborative effort with AOAC, ASTA issued a revised method of analysis, ASTA
Method 21.3 (HPLC Method). Using the revised method, the accepted pungency of pure
capsaicin was re-stated from 15,000,000 to 16,000,000 SHU. AOAC revised its method to
coincided with ASTA Method 21.3, in 1999, and in 2003 AOAC revised the method once more.
3.5.3.2. The United States Pharmacopoeia (USP) method
The 2012 edition of the USP36-NF31 lists Capsaicin and describes its Definition, Identification,
Melting range, and Content of capsaicin, dihydrocapsaicin, and other capsaicinoids as follows.




Capsaicin contains not less than 90.0 percent and not more than 110.0 percent of the labeled
percentage of total capsaicinoids. The content of capsaicin (C18H27NO3) is not less than 55
percent, and the sum of the contents of capsaicin and dihydrocapsaicin (C18H27NO3) is not less
than 75 percent, and the content of other capsaicinoids is not more than 15 percent, all
calculated on the dried basis.
Packaging and storage— Preserve in tight containers, protected from light, and store in a cool
place
Caution—Handle Capsaicin with care. Prevent inhalation of particles of it and prevent its
contact with any part of the body.
Solubility – It does not dissolve in water. It well dissolves in alcohols (methanol, ethanol 96%),
ethylacetate and acetonitrile.
IDENTIFICATION: Prepare a test solution of Capsaicin in methanol containing 1 mg per mL.
Prepare a Standard solution of USP Capsaicin RS in methanol containing 1 mg per mL.
Separately apply 10-µL portions of the test solution and the Standard solution to a thin-layer
chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture.
Develop the chromatograms in a solvent system consisting of a mixture of ether and methanol
(19:1) until the solvent front has moved about three-fourths of the length of the plate. Remove
the plate from the chamber, and allow it to air-dry. Spray the plate with a 0.5% solution of 2,6-
dibromoquinone-chlorimide in methanol, allow to stand in a chamber containing ammonia
fumes, and examine the chromatograms: the blue color and the Rf value of the principal spot
obtained from the test solution correspond to those properties of the principal spot obtained
from the Standard solution.
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Jurenitsch et al. (1979a,b) was modified with the inclusion of silver nitrate in the mobile phase
to selectively shorten the retention time of capsaicin, thus separating it from the coeluting
nonoyl vanillylamide (Jurenitsch and Kampelmuehler, 1980). Constant and coworkers
(Constant et al., 1995) also used complexation chromatography (AgNO3) to separate norcap‐
saicin, zucapsaicin (civamide), capsaicin, nordihydrocapsaicin, nonivamide, homocapsaicin,
dihydrocapsaicin and homodihydrocapsaicin-I.
Kawada et al. performed microdetermination of capsaicin by high-performance liquid
chromatography with electrochemical detection (Kawada et al., 1985). Karnka et al. has
reported an optimized HPLC method for sample preparation, separation, detection and
identification of the major capsaicinoid compounds in various capsicum samples (Karnka et
al., 2002). Isocratic reversed phase HPLC analysis performed in the author’s laboratory allowed
separation of five main capsaicinoids of a commercially available capsaicin preparation. The
validated analytical method has been successfully applied to quantitate capsaicin and
dihydrocapsaicin in industrial Capsicum extracts (Kuzma et al., 2014). Isocratic HPLC method
with fluorimetric detection was used to determine capsaicin in rat tissues after acetone
extraction (Saria et al., 1981).
HPLC analysis has made possible the accurate determination of the homologs and analogs of
capsaicin and, combined with mass spectral analysis, has led to identification of structural
isomers of some minor components (Govindarajan, 1986b; Reilly et al., 2001; Schweiggert et
al., 2006; Singh et al., 2009; González-Zamora et al., 2013) and has made possible determination
of nanogram levels of the individual capsaicinoids as is required in biosynthetic and metabolic
studies (Reilly et al., 2002; Kozukue et al., 2005; Thompson et al., 2005; Zhang et al., 2010). The
use of HPLC-MS (Reilly et al., 2001a) has been reported to differentiate nonivamide and
capsaicin by mass-to-charge (m/e) ratio. The same authors have reported the use of LC-MS-MS
with electrospray ionization source operating at selective ion monitoring mode (Reilly et al.,
2001b). The quantification of capsaicinoids using LC-MS-MS was more sensitive (in the ng/ml
range) and exhibited greater accuracy, even at low analyte concentrations. HPLC coupled with
atmospheric pressure chemical ionization masss spectrometry has been reported to be a
method of choice for separation and identification of the three groups of capsaicinoids:
capsaicins possessing a methyl branched acyl residue with a carbon-carbon double bond,
dihydrocapsaicins analogous to the previous class, but beeing saturated compounds, and
capsaicin analogs (N-vanillyl-N-acylamides) composed of saturated, unbranched alkyl chains
(Schweiggert et al., 2006).
In summary, HPLC analysis for total capsaicinoids or individual capsaicinoids is certainly
rapid, reproducible, sensitive, and convenient for analysis of capsaicinoids in various capsai‐
cinoid containing matrices.
3.5.3. Official methods for determination of capsaicinoids
3.5.3.1. The ASTA method for determination of capsaicinoids
In the 1980’s it became clear that a more accurate and reproducible method of determining
“heat” in peppers and pepper products was necessary. Under the auspices of the American
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Spice Trade Association (ASTA), a new High Pressure Liquid Chromatography (HPLC)
Method was adopted as ASTA Method 21.1. The HPLC measurement of capsaicin has evolved
over the years as new and better instrumentation has allowed of greater accuracy of analysis.
In 1996 AOAC issued Method 995.03: Capsaicinoids in Capsicums and their Extractives. In
1998, in a collaborative effort with AOAC, ASTA issued a revised method of analysis, ASTA
Method 21.3 (HPLC Method). Using the revised method, the accepted pungency of pure
capsaicin was re-stated from 15,000,000 to 16,000,000 SHU. AOAC revised its method to
coincided with ASTA Method 21.3, in 1999, and in 2003 AOAC revised the method once more.
3.5.3.2. The United States Pharmacopoeia (USP) method
The 2012 edition of the USP36-NF31 lists Capsaicin and describes its Definition, Identification,
Melting range, and Content of capsaicin, dihydrocapsaicin, and other capsaicinoids as follows.




Capsaicin contains not less than 90.0 percent and not more than 110.0 percent of the labeled
percentage of total capsaicinoids. The content of capsaicin (C18H27NO3) is not less than 55
percent, and the sum of the contents of capsaicin and dihydrocapsaicin (C18H27NO3) is not less
than 75 percent, and the content of other capsaicinoids is not more than 15 percent, all
calculated on the dried basis.
Packaging and storage— Preserve in tight containers, protected from light, and store in a cool
place
Caution—Handle Capsaicin with care. Prevent inhalation of particles of it and prevent its
contact with any part of the body.
Solubility – It does not dissolve in water. It well dissolves in alcohols (methanol, ethanol 96%),
ethylacetate and acetonitrile.
IDENTIFICATION: Prepare a test solution of Capsaicin in methanol containing 1 mg per mL.
Prepare a Standard solution of USP Capsaicin RS in methanol containing 1 mg per mL.
Separately apply 10-µL portions of the test solution and the Standard solution to a thin-layer
chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture.
Develop the chromatograms in a solvent system consisting of a mixture of ether and methanol
(19:1) until the solvent front has moved about three-fourths of the length of the plate. Remove
the plate from the chamber, and allow it to air-dry. Spray the plate with a 0.5% solution of 2,6-
dibromoquinone-chlorimide in methanol, allow to stand in a chamber containing ammonia
fumes, and examine the chromatograms: the blue color and the Rf value of the principal spot
obtained from the test solution correspond to those properties of the principal spot obtained
from the Standard solution.
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Melting range: between 57° and 66°, but the range between beginning and end of melting does
not exceed 5°.
3.5.3.3. Content of capsaicin, dihydrocapsaicin and other capsaicinoids
Mobile phase— Prepare a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile
(600:400). Filter through a filter having a porosity of 0.5 µm or finer, and degas.
Standard capsaicin solution— Dissolve an accurately weighed quantity of USP Capsaicin RS
quantitatively in methanol to obtain a solution having a known concentration of about 0.1 mg
per mL.
Standard dihydrocapsaicin solution— Dissolve an accurately weighed quantity of USP Dihydro‐
capsaicin RS quantitatively in methanol to obtain a solution having a known concentration of
about 0.025 mg per mL.
Test solution— Transfer about 25 mg of Capsaicin, accurately weighed, to a 250-mL volumetric
flask, dilute with methanol to volume, and mix.
Chromatographic system— The liquid chromatograph is equipped with a 281-nm detector and
a 4.6-mm × 25-cm column that contains 5-µm packing L11 and is maintained at a constant
temperature of about 30°. Adjust the flow rate to obtain a retention time of about 20 minutes
for the main capsaicin peak. Chromatograph the Standard capsaicin solution, and record the
peak responses as directed for Procedure: the relative standard deviation for replicate injections
is not more than 2%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard capsaicin solution, the
Standard dihydrocapsaicin solution, and the Test solution into the chromatograph, record the
chromatogram for a period of time that is twice that of the retention time of capsaicin, and
measure the areas of the responses for all of the peaks.
Calculate the percentage of capsaicin (C18H27NO3) in the portion of Capsaicin taken by the
formula:
25,000(C / W)(rU / rS)
in which
C is the concentration, in mg per mL, of USP Capsaicin RS in the Standard capsaicin solution,
W is the weight, in mg, of Capsaicin taken to prepare the Test solution, and
rU and rS are the capsaicin peak responses obtained from the Test solution and the Standard
capsaicin solution, respectively.
Not less than 55% is found.
Calculate the percentage of dihydrocapsaicin (C18H29NO3) in the portion of Capsaicin taken by
the formula:
25,000(C / W)(rU / rS)
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in which
C is the concentration, in mg per mL, of USP Dihydrocapsaicin RS in the Standard capsaicin
solution,
W is the weight, in mg, of Capsaicin taken to prepare the Test solution, and
rU and rS are the dihydrocapsaicin peak responses obtained from the Test solution and the
Standard dihydrocapsaicin solution, respectively.
The sum of the percentage of capsaicin found and of the percentage of dihydrocapsaicin found
is not less than 75%. Using the chromatograms obtained from the Standard capsaicin solution
and the Test solution, calculate the percentage of other capsaicinoids in the portion of Capsai‐
cin taken by the formula
25,000(C / W)(rT / rS)
in which
C is the concentration, in mg per mL, of USP Capsaicin RS in the Standard capsaicin solution,
W is the weight, in mg, of Capsaicin taken to prepare the Test solution,
rT is the sum of the peak responses of the capsaicinoids other than capsaicin and dihydrocap‐
saicin in the chromatogram obtained from the Test solution, and
rS is the capsaicin peak response obtained from the Standard capsaicin solution.
Not more than 15% of other capsaicinoids is found.
4. Pesticide control
Quality is a mandatory requirement in the materials to accomplish the Pharmaceutical Good
Manufacturing Practices. Nowadays, the presence of pesticides in animal and vegetal (herbal)
commodities is a topic of public concern for the potential health hazards derived from them
(WHO, 1998). The presence of pesticide residues in vegetal raw materials can be originated in
agricultural practices, environmental contamination or cross contamination.
Table 1 shows examples of potentially hazardous contaminants and residues that may occur
in herbal products (WHO, 1998). The summary table includes information on possible sources
of contaminants and residues, as well as the manufacturing stages at which they may be
detectable. Some of them are considered as unavoidable contaminants or residues of herbal
medicines.
4.1. Classification of contaminants
Contaminants in herbal medicines are classified into chemical contaminants and biological
contaminants. A variety of agrochemical agents and some organic solvents may be important
residues in herbal medicines (WHO, 1998).
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Melting range: between 57° and 66°, but the range between beginning and end of melting does
not exceed 5°.
3.5.3.3. Content of capsaicin, dihydrocapsaicin and other capsaicinoids
Mobile phase— Prepare a mixture of diluted phosphoric acid (1 in 1000) and acetonitrile
(600:400). Filter through a filter having a porosity of 0.5 µm or finer, and degas.
Standard capsaicin solution— Dissolve an accurately weighed quantity of USP Capsaicin RS
quantitatively in methanol to obtain a solution having a known concentration of about 0.1 mg
per mL.
Standard dihydrocapsaicin solution— Dissolve an accurately weighed quantity of USP Dihydro‐
capsaicin RS quantitatively in methanol to obtain a solution having a known concentration of
about 0.025 mg per mL.
Test solution— Transfer about 25 mg of Capsaicin, accurately weighed, to a 250-mL volumetric
flask, dilute with methanol to volume, and mix.
Chromatographic system— The liquid chromatograph is equipped with a 281-nm detector and
a 4.6-mm × 25-cm column that contains 5-µm packing L11 and is maintained at a constant
temperature of about 30°. Adjust the flow rate to obtain a retention time of about 20 minutes
for the main capsaicin peak. Chromatograph the Standard capsaicin solution, and record the
peak responses as directed for Procedure: the relative standard deviation for replicate injections
is not more than 2%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard capsaicin solution, the
Standard dihydrocapsaicin solution, and the Test solution into the chromatograph, record the
chromatogram for a period of time that is twice that of the retention time of capsaicin, and
measure the areas of the responses for all of the peaks.
Calculate the percentage of capsaicin (C18H27NO3) in the portion of Capsaicin taken by the
formula:
25,000(C / W)(rU / rS)
in which
C is the concentration, in mg per mL, of USP Capsaicin RS in the Standard capsaicin solution,
W is the weight, in mg, of Capsaicin taken to prepare the Test solution, and
rU and rS are the capsaicin peak responses obtained from the Test solution and the Standard
capsaicin solution, respectively.
Not less than 55% is found.
Calculate the percentage of dihydrocapsaicin (C18H29NO3) in the portion of Capsaicin taken by
the formula:
25,000(C / W)(rU / rS)
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in which
C is the concentration, in mg per mL, of USP Dihydrocapsaicin RS in the Standard capsaicin
solution,
W is the weight, in mg, of Capsaicin taken to prepare the Test solution, and
rU and rS are the dihydrocapsaicin peak responses obtained from the Test solution and the
Standard dihydrocapsaicin solution, respectively.
The sum of the percentage of capsaicin found and of the percentage of dihydrocapsaicin found
is not less than 75%. Using the chromatograms obtained from the Standard capsaicin solution
and the Test solution, calculate the percentage of other capsaicinoids in the portion of Capsai‐
cin taken by the formula
25,000(C / W)(rT / rS)
in which
C is the concentration, in mg per mL, of USP Capsaicin RS in the Standard capsaicin solution,
W is the weight, in mg, of Capsaicin taken to prepare the Test solution,
rT is the sum of the peak responses of the capsaicinoids other than capsaicin and dihydrocap‐
saicin in the chromatogram obtained from the Test solution, and
rS is the capsaicin peak response obtained from the Standard capsaicin solution.
Not more than 15% of other capsaicinoids is found.
4. Pesticide control
Quality is a mandatory requirement in the materials to accomplish the Pharmaceutical Good
Manufacturing Practices. Nowadays, the presence of pesticides in animal and vegetal (herbal)
commodities is a topic of public concern for the potential health hazards derived from them
(WHO, 1998). The presence of pesticide residues in vegetal raw materials can be originated in
agricultural practices, environmental contamination or cross contamination.
Table 1 shows examples of potentially hazardous contaminants and residues that may occur
in herbal products (WHO, 1998). The summary table includes information on possible sources
of contaminants and residues, as well as the manufacturing stages at which they may be
detectable. Some of them are considered as unavoidable contaminants or residues of herbal
medicines.
4.1. Classification of contaminants
Contaminants in herbal medicines are classified into chemical contaminants and biological
contaminants. A variety of agrochemical agents and some organic solvents may be important
residues in herbal medicines (WHO, 1998).




4.1.1.1. Toxic metals and non-metals
Contamination of herbal materials with toxic substances such as arsenic can be attributed to
many causes. These include environmental pollution (i.e. contaminated emissions from
factories and leaded petrol and contaminated water including runoff water which finds its
way into rivers, lakes and the sea, and some pesticides), soil composition and fertilizers. This
contamination of the herbal material leads to contamination of the products during various
stages of the manufacturing process.
4.1.1.2. Persistent organic pollutants
Persistent organic pollutants include organic chemicals, such as the synthetic aromatic
chlorinated hydrocarbons, which are only slightly soluble in water and are persistent or stable
in the presence of sunlight, moisture, air and heat. In the past, they were extensively used in
agriculture as pesticides. The use of persistent pesticides, such as DDT and benzene hexa‐
chloride (BHC), in agriculture has been banned for many years in many countries. However
they are still found in the areas where they were previously used and often contaminate
medicinal plants growing nearby.
4.1.1.3. Radioactive contamination
A certain amount of exposure to ionizing radiation is unavoidable because many sources,
including of radionuclides occur naturally in the ground and the atmosphere. Dangerous
contamination may be the consequence of a nuclear accident or may arise from other sources.
WHO, in close collaboration with several other international organizations, has developed
guidelines for use in the event of widespread contamination by radionuclides resulting from
a major nuclear accident.
4.1.1.4. Mycotoxins
The presence of mycotoxins in plant material can pose both acute and chronic risks to health..
Mycotoxins produced by species of fungi including Aspergillus, Fusarium and Penicillium are
the most commonly reported. Mycotoxins comprise four main groups, namely, aflatoxins,
ochratoxins, fumonisins and tricothecenes, all of which have toxic effects. Aflatoxins have been
extensively studied and are classifi ed as Group 1 human carcinogens by the International
Agency for Research on Cancer.
4.1.2. Biological contaminants
4.1.2.1. Microbiological contaminants
Herbs and herbal materials normally carry a large number of bacteria and moulds, often
originating in soil or derived from manure. While a large range of bacteria and fungi form the
naturally occurring microflora of medicinal plants, aerobic spore-forming bacteria frequently
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predominate.. The presence of Escherichia coli, Salmonella spp. and moulds may indicate poor
quality of production and harvesting practices.
4.1.2.2. Parasitic contamination
Parasites such as protozoa and nematoda, and their ova, may be introduced during cultivation
and may cause zoonosis, especially if uncomposted animal excreta are used. Contamination
with parasites may also arise during processing and manufacturing if the personnel carrying
out these processes have not taken appropriate personal hygiene measures.
4.1.3. Agrochemical residues
The main agrochemical residues in herbal medicines are derived from pesticides and fumi‐
gants.
Pesticides may be classified on the basis of their intended use, for example as follows:
• insecticides;
• fungicides and nematocides;
• herbicides; and
• other pesticides (e.g. ascaricides, molluscicides and rodenticides).
Examples of fumigants include ethylene oxide, ethylene chlorohydrin, methyl bromide and
sulfur dioxide.
4.1.3.1. Pesticide residues
Medicinal plant materials may contain pesticide residues, which accumulate as a result of
agricultural practices, such as spraying, treatment of soils during cultivation and administra‐
tion of fumigants during storage. It is therefore recommended that every country producing
medicinal plant materials should have at least one control laboratory capable of performing
the determination of pesticides using a suitable method.
4.1.3.2. Classification of pesticides
Different classifications of pesticides exist. A classification based on the chemical composition
or structure of the pesticide is the most useful for analytical chemists, for example:
• chlorinated hydrocarbons and related pesticides: hexachlorocyclohexane (HCH) or benzene
hexachloride (BHC), lindane, methoxychlor
• chlorinated phenoxyalkanoic acid herbicides: 2,4-D, 2,4,5-T
• organophosphorus pesticides: carbophenothion (carbofenotion), chlorpyrifos and methyl‐
chlorpyrifos, coumaphos (coumafos), demeton, dichlorvos, dimethoate, ethion, fenchlor‐
phos (fenclofos), malathion, methyl parathion, parathion
• carbamate insecticides: carbaryl (carbaril)




4.1.1.1. Toxic metals and non-metals
Contamination of herbal materials with toxic substances such as arsenic can be attributed to
many causes. These include environmental pollution (i.e. contaminated emissions from
factories and leaded petrol and contaminated water including runoff water which finds its
way into rivers, lakes and the sea, and some pesticides), soil composition and fertilizers. This
contamination of the herbal material leads to contamination of the products during various
stages of the manufacturing process.
4.1.1.2. Persistent organic pollutants
Persistent organic pollutants include organic chemicals, such as the synthetic aromatic
chlorinated hydrocarbons, which are only slightly soluble in water and are persistent or stable
in the presence of sunlight, moisture, air and heat. In the past, they were extensively used in
agriculture as pesticides. The use of persistent pesticides, such as DDT and benzene hexa‐
chloride (BHC), in agriculture has been banned for many years in many countries. However
they are still found in the areas where they were previously used and often contaminate
medicinal plants growing nearby.
4.1.1.3. Radioactive contamination
A certain amount of exposure to ionizing radiation is unavoidable because many sources,
including of radionuclides occur naturally in the ground and the atmosphere. Dangerous
contamination may be the consequence of a nuclear accident or may arise from other sources.
WHO, in close collaboration with several other international organizations, has developed
guidelines for use in the event of widespread contamination by radionuclides resulting from
a major nuclear accident.
4.1.1.4. Mycotoxins
The presence of mycotoxins in plant material can pose both acute and chronic risks to health..
Mycotoxins produced by species of fungi including Aspergillus, Fusarium and Penicillium are
the most commonly reported. Mycotoxins comprise four main groups, namely, aflatoxins,
ochratoxins, fumonisins and tricothecenes, all of which have toxic effects. Aflatoxins have been
extensively studied and are classifi ed as Group 1 human carcinogens by the International
Agency for Research on Cancer.
4.1.2. Biological contaminants
4.1.2.1. Microbiological contaminants
Herbs and herbal materials normally carry a large number of bacteria and moulds, often
originating in soil or derived from manure. While a large range of bacteria and fungi form the
naturally occurring microflora of medicinal plants, aerobic spore-forming bacteria frequently
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predominate.. The presence of Escherichia coli, Salmonella spp. and moulds may indicate poor
quality of production and harvesting practices.
4.1.2.2. Parasitic contamination
Parasites such as protozoa and nematoda, and their ova, may be introduced during cultivation
and may cause zoonosis, especially if uncomposted animal excreta are used. Contamination
with parasites may also arise during processing and manufacturing if the personnel carrying
out these processes have not taken appropriate personal hygiene measures.
4.1.3. Agrochemical residues
The main agrochemical residues in herbal medicines are derived from pesticides and fumi‐
gants.
Pesticides may be classified on the basis of their intended use, for example as follows:
• insecticides;
• fungicides and nematocides;
• herbicides; and
• other pesticides (e.g. ascaricides, molluscicides and rodenticides).
Examples of fumigants include ethylene oxide, ethylene chlorohydrin, methyl bromide and
sulfur dioxide.
4.1.3.1. Pesticide residues
Medicinal plant materials may contain pesticide residues, which accumulate as a result of
agricultural practices, such as spraying, treatment of soils during cultivation and administra‐
tion of fumigants during storage. It is therefore recommended that every country producing
medicinal plant materials should have at least one control laboratory capable of performing
the determination of pesticides using a suitable method.
4.1.3.2. Classification of pesticides
Different classifications of pesticides exist. A classification based on the chemical composition
or structure of the pesticide is the most useful for analytical chemists, for example:
• chlorinated hydrocarbons and related pesticides: hexachlorocyclohexane (HCH) or benzene
hexachloride (BHC), lindane, methoxychlor
• chlorinated phenoxyalkanoic acid herbicides: 2,4-D, 2,4,5-T
• organophosphorus pesticides: carbophenothion (carbofenotion), chlorpyrifos and methyl‐
chlorpyrifos, coumaphos (coumafos), demeton, dichlorvos, dimethoate, ethion, fenchlor‐
phos (fenclofos), malathion, methyl parathion, parathion
• carbamate insecticides: carbaryl (carbaril)
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• carbamoyl benzimidazoles: benomyl, carbendazim
• dithiocarbamate fungicides: ferbam, maneb, nabam, thiram, zineb, ziram
• amino acid herbicides: glyphosate
• inorganic pesticides: aluminium phosphide, calcium arsenate
• miscellaneous: bromopropylate, chloropicrin, ethylene dibromide, ethylene oxide, methyl
bromide, sulfur dioxide
• pesticides of plant origin: tobacco leaf extract, pyrethrum flower, and pyrethrum extract;
derris and Lonchocarpus root and rotenoids.
Only the chlorinated hydrocarbons and related pesticides (e.g. HCH) and a few organophos‐
phorus pesticides (e.g. carbophenothion) have a long residual action. Although the use of many
persistent pesticides has been widely discontinued, residues may still remain in the environ‐
ment (e.g. DDT). Thus the recording of all pesticide usage in countries should be strongly
encouraged so as to enable cost-effective quality control of medicinal plants and of their
products. The Stockholm Convention on Persistent Organic Pollutants currently includes DDT
and 11 other POPs including dioxin (a potent carcinogen), aldrin, chlordane, dieldrin, endrin,
heptachlor, mirex, toxaphene and hexachlorobenzene.
Most other pesticides have very short residual actions. Therefore it is suggested that, where
the length of exposure to pesticides is unknown, the herbal materials should be tested for the
presence of organically bound chlorine and phosphorus as a preliminary screening method
which can be useful in predicting where a pesticide might be used.
4.1.4. Residual solvents
A range of organic solvents are used for manufacturing herbal medicines, and can be detected
as residues of such processing in herbal preparations and finished herbal products. They
should be controlled through GMP and quality control.
Solvents are classifi ed by ICH (Q3C (R5), according to their potential risk, into:
• class 1 (solvents to be avoided such as benzene);
• class 2 (limited toxic potential such as methanol or hexane); and
• class 3 (low toxic potential such as ethanol).
4.2. Pesticide analysis
One area of chemical testing of growing concern is pesticide analysis. Pesticides and their
degradation products migrate from their intended point of application and spread through
the air, water, soil, plants, microorganisms, and animals, including birds and fish. While many
of the chemicals used in pesticide formulations are harmless, others may have toxic properties
or could even form toxic by-products, potentially causing risks to human and animal health
and/or environmental damage.There are over 1,000 pesticides available for use, many of which
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are regulated by government agencies. As a result, powerful and rapid analytical methods are
needed to detect very low concentrations of pesticides and their degradation products in
diverse sample matrices.
4.2.1. Analytical advances
Scientific advances in the field of application of natural products with pharmaceutical
relevance has been focused on analysis of (a) the actice constituents, and (b) the potentially
hazardous contaminats. Methods for quantitative determination of the above mentioned
contaminations varies for different classes of contaminants. Comprehensive review of the
different methodologies is out of scope ofthe present monograph. Since pesticide residue
analysis has been appeared as the most seriuus issue in connection with our Capsicum
extracts, here we concentrate on regulatory requirements on this class of possible hasardous
contaminants of herbal products.
Several modern multiresidue precedures employing different (a) extraction methods, (b) clean-up
techniques and (c) a variety of determination methods have been reported for quantitation of
pesticide residues in natural products with pharmaceutical applications. One of the cruitial
point of these methods is to extract and isolate the target pesticides from the matrix. The
optimal sample treatment hevealy depends on the complexicity of the matrix.
Not going into details, the most imortant ad frequntly used extraction techniques as follows:
• Liquid phase extraction,
• Solid phase extraction,
• Solid phase micro extraction,
• Microvawe assisted solvent extraction, and
• Supercritical fluid extraction
During extraction, the solvent comes in contact with the substrate matrix, to enable extraction
of the pesticide along with some of the constituents of the substrate matrix also get solubilized.
The extract not only contains pesticide residues but also other constituents, which are called
co-extractives. The removal of interfering co-extractives from extract is called clean up. After
removal of moisture, the other coextractives are removed by using various separation
techniques.




• Thin layer chromatography
• Ion exchange chromatography
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• carbamoyl benzimidazoles: benomyl, carbendazim
• dithiocarbamate fungicides: ferbam, maneb, nabam, thiram, zineb, ziram
• amino acid herbicides: glyphosate
• inorganic pesticides: aluminium phosphide, calcium arsenate
• miscellaneous: bromopropylate, chloropicrin, ethylene dibromide, ethylene oxide, methyl
bromide, sulfur dioxide
• pesticides of plant origin: tobacco leaf extract, pyrethrum flower, and pyrethrum extract;
derris and Lonchocarpus root and rotenoids.
Only the chlorinated hydrocarbons and related pesticides (e.g. HCH) and a few organophos‐
phorus pesticides (e.g. carbophenothion) have a long residual action. Although the use of many
persistent pesticides has been widely discontinued, residues may still remain in the environ‐
ment (e.g. DDT). Thus the recording of all pesticide usage in countries should be strongly
encouraged so as to enable cost-effective quality control of medicinal plants and of their
products. The Stockholm Convention on Persistent Organic Pollutants currently includes DDT
and 11 other POPs including dioxin (a potent carcinogen), aldrin, chlordane, dieldrin, endrin,
heptachlor, mirex, toxaphene and hexachlorobenzene.
Most other pesticides have very short residual actions. Therefore it is suggested that, where
the length of exposure to pesticides is unknown, the herbal materials should be tested for the
presence of organically bound chlorine and phosphorus as a preliminary screening method
which can be useful in predicting where a pesticide might be used.
4.1.4. Residual solvents
A range of organic solvents are used for manufacturing herbal medicines, and can be detected
as residues of such processing in herbal preparations and finished herbal products. They
should be controlled through GMP and quality control.
Solvents are classifi ed by ICH (Q3C (R5), according to their potential risk, into:
• class 1 (solvents to be avoided such as benzene);
• class 2 (limited toxic potential such as methanol or hexane); and
• class 3 (low toxic potential such as ethanol).
4.2. Pesticide analysis
One area of chemical testing of growing concern is pesticide analysis. Pesticides and their
degradation products migrate from their intended point of application and spread through
the air, water, soil, plants, microorganisms, and animals, including birds and fish. While many
of the chemicals used in pesticide formulations are harmless, others may have toxic properties
or could even form toxic by-products, potentially causing risks to human and animal health
and/or environmental damage.There are over 1,000 pesticides available for use, many of which
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are regulated by government agencies. As a result, powerful and rapid analytical methods are
needed to detect very low concentrations of pesticides and their degradation products in
diverse sample matrices.
4.2.1. Analytical advances
Scientific advances in the field of application of natural products with pharmaceutical
relevance has been focused on analysis of (a) the actice constituents, and (b) the potentially
hazardous contaminats. Methods for quantitative determination of the above mentioned
contaminations varies for different classes of contaminants. Comprehensive review of the
different methodologies is out of scope ofthe present monograph. Since pesticide residue
analysis has been appeared as the most seriuus issue in connection with our Capsicum
extracts, here we concentrate on regulatory requirements on this class of possible hasardous
contaminants of herbal products.
Several modern multiresidue precedures employing different (a) extraction methods, (b) clean-up
techniques and (c) a variety of determination methods have been reported for quantitation of
pesticide residues in natural products with pharmaceutical applications. One of the cruitial
point of these methods is to extract and isolate the target pesticides from the matrix. The
optimal sample treatment hevealy depends on the complexicity of the matrix.
Not going into details, the most imortant ad frequntly used extraction techniques as follows:
• Liquid phase extraction,
• Solid phase extraction,
• Solid phase micro extraction,
• Microvawe assisted solvent extraction, and
• Supercritical fluid extraction
During extraction, the solvent comes in contact with the substrate matrix, to enable extraction
of the pesticide along with some of the constituents of the substrate matrix also get solubilized.
The extract not only contains pesticide residues but also other constituents, which are called
co-extractives. The removal of interfering co-extractives from extract is called clean up. After
removal of moisture, the other coextractives are removed by using various separation
techniques.




• Thin layer chromatography
• Ion exchange chromatography
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• Gel permeation chromatography, and
• Adsorption column chromatography
In accordance to the official methodologies, capillary gas-liquid chromatography (GC) is the
most used separation technique in residue analysis of non-polar and semi-polar pesticides.
Majos attantion has paid for determination of organochlorine, organophosphorus and
pyrethroid pesticides. Most reports focuses on selective detection of pesticied using electron
capture (ECD), nitrogen-phosphorous (NPD), thermal conductivity (TCD) and flame photo‐
metric (FPD) detectors. In spite of the increased selectivity and sensitivity of the GC-coupled
detectors, the use of mass spectrometry is being compulsory induced in order to obtain relaible
identification and confirmation of residues.
As a result of searching for non-persistent and biodegradable pesticides, which kill both
detrimental and beneficial insects, introduction of more polar (and less volatile) agrochemical
has been recognized. Such compounds have promted the use of high presuure liquid chro‐
matography coupled with mass spectrometry (HPLC-MS), which at the moment is a widely
accepted technique for monitoring of polar and most semipolar pesticeds as well as for
regulatory isuues.
Recent advances of modern multiresidue precedures including application of different GC-
and HPLC-based methodologies have been summarized in several review articles. Readers
interested in the field can consult this literature (Hirahara et al., 2005, Abd El-Moneim et al.,
2010, Perez-Parada et al., 2011, Niell et al., 2014).
4.2.2. Regulatory methods for pestice analysis of herbal products of pharmaceutical use
4.2.2.1. The European Pharmacopoeia (Ph.Eur.)
In the seventh edition of the European Pharmacopoeia (Ph. Eur. 7.0) pesticide residues are
described under chapter 02 „Methods of analysis“. The Ph.Eur. Monograph „2.8.13. Pesticide
residues“ contains „Definition“, „Limits“, „Sampling“ and „Qualitative and quantitative
analysis of pesticide residues“ of herbal drugs. The requirements for “Herbal Drugs” and
“Extracts”, as well as “Herbal Drugs for Homoeopathic Preparations” and “Mother Tinctures
for Homoeopathic Preparations” are refered within the scope of their monographs in chapter
05 „General texts“:
For the purposes of the European Pharmacopoeia Pharmacopoeia, a pesticide is any substance
or mixture of substances intended for preventing, destroying or controlling any pest, unwant‐
ed species of plants or animals causing harm during or otherwise interfering with the pro‐
duction, processing, storage, transport or marketing of vegetable drugs. The item includes
substances intended for use as growth-regulators, defoliants or desiccants and any substance
applied to crops either before or after harvest to protect the commodity from deterioration
during storage and transport.
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4.2.2.1.1. Limits
Unless otherwise indicated in the monograph, the drug to be examined at least complies with
the limits indicated in Table 4. The limits applying to pesticides that are not listed in the table
and whose presence is suspected for any reason comply with the limits set by European
Community directives 76/895 and 90/642, including their annexes and successive updates.
Limits for pesticides that are not listed in Table 4 nor in EC directives are calculated using the
following expression:
ADI  x  M
MDD x  100
where
ADI=acceptable daily intake, as published by FAO-WHO, in milligrams per kilogram of body
mass,
M=body mass in kilograms (60 kg),
MDD=daily dose of the drug, in kilograms.
If the drug is intended for the preparation of extracts, tinctures or other pharmaceutical forms
whose preparation method modifies the content of pesticides in the finished product, the limits
are calculated using the following expression:
ADI  x  M  x  E
MDD x  100
where
E=extraction factor of the method of preparation, determined experimentally, and
ADI, M, and MDD are as defined above.
Higher limits can also be authorised, in exceptional cases, especially when a plant requires a
particular cultivation method or has a metabolism or a structure that gives rise to a higher than
normal content of pesticides. The competent authority may grant total or partial exemption
from the test when the complete history (nature and quantity of the pesticides used, date of
each treatment during cultivation and after the harvest) of the treatment of the batch is known





Aldrin and Dieldrin (sum of) 0.05
Azinphos-methyl 1.0
Bromopropylate 3.0
Chlordane (sum of cis-, trans- and Oxythlordane) 0.05
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• Gel permeation chromatography, and
• Adsorption column chromatography
In accordance to the official methodologies, capillary gas-liquid chromatography (GC) is the
most used separation technique in residue analysis of non-polar and semi-polar pesticides.
Majos attantion has paid for determination of organochlorine, organophosphorus and
pyrethroid pesticides. Most reports focuses on selective detection of pesticied using electron
capture (ECD), nitrogen-phosphorous (NPD), thermal conductivity (TCD) and flame photo‐
metric (FPD) detectors. In spite of the increased selectivity and sensitivity of the GC-coupled
detectors, the use of mass spectrometry is being compulsory induced in order to obtain relaible
identification and confirmation of residues.
As a result of searching for non-persistent and biodegradable pesticides, which kill both
detrimental and beneficial insects, introduction of more polar (and less volatile) agrochemical
has been recognized. Such compounds have promted the use of high presuure liquid chro‐
matography coupled with mass spectrometry (HPLC-MS), which at the moment is a widely
accepted technique for monitoring of polar and most semipolar pesticeds as well as for
regulatory isuues.
Recent advances of modern multiresidue precedures including application of different GC-
and HPLC-based methodologies have been summarized in several review articles. Readers
interested in the field can consult this literature (Hirahara et al., 2005, Abd El-Moneim et al.,
2010, Perez-Parada et al., 2011, Niell et al., 2014).
4.2.2. Regulatory methods for pestice analysis of herbal products of pharmaceutical use
4.2.2.1. The European Pharmacopoeia (Ph.Eur.)
In the seventh edition of the European Pharmacopoeia (Ph. Eur. 7.0) pesticide residues are
described under chapter 02 „Methods of analysis“. The Ph.Eur. Monograph „2.8.13. Pesticide
residues“ contains „Definition“, „Limits“, „Sampling“ and „Qualitative and quantitative
analysis of pesticide residues“ of herbal drugs. The requirements for “Herbal Drugs” and
“Extracts”, as well as “Herbal Drugs for Homoeopathic Preparations” and “Mother Tinctures
for Homoeopathic Preparations” are refered within the scope of their monographs in chapter
05 „General texts“:
For the purposes of the European Pharmacopoeia Pharmacopoeia, a pesticide is any substance
or mixture of substances intended for preventing, destroying or controlling any pest, unwant‐
ed species of plants or animals causing harm during or otherwise interfering with the pro‐
duction, processing, storage, transport or marketing of vegetable drugs. The item includes
substances intended for use as growth-regulators, defoliants or desiccants and any substance
applied to crops either before or after harvest to protect the commodity from deterioration
during storage and transport.
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4.2.2.1.1. Limits
Unless otherwise indicated in the monograph, the drug to be examined at least complies with
the limits indicated in Table 4. The limits applying to pesticides that are not listed in the table
and whose presence is suspected for any reason comply with the limits set by European
Community directives 76/895 and 90/642, including their annexes and successive updates.
Limits for pesticides that are not listed in Table 4 nor in EC directives are calculated using the
following expression:
ADI  x  M
MDD x  100
where
ADI=acceptable daily intake, as published by FAO-WHO, in milligrams per kilogram of body
mass,
M=body mass in kilograms (60 kg),
MDD=daily dose of the drug, in kilograms.
If the drug is intended for the preparation of extracts, tinctures or other pharmaceutical forms
whose preparation method modifies the content of pesticides in the finished product, the limits
are calculated using the following expression:
ADI  x  M  x  E
MDD x  100
where
E=extraction factor of the method of preparation, determined experimentally, and
ADI, M, and MDD are as defined above.
Higher limits can also be authorised, in exceptional cases, especially when a plant requires a
particular cultivation method or has a metabolism or a structure that gives rise to a higher than
normal content of pesticides. The competent authority may grant total or partial exemption
from the test when the complete history (nature and quantity of the pesticides used, date of
each treatment during cultivation and after the harvest) of the treatment of the batch is known





Aldrin and Dieldrin (sum of) 0.05
Azinphos-methyl 1.0
Bromopropylate 3.0
Chlordane (sum of cis-, trans- and Oxythlordane) 0.05









Cypermethrin (and isomers) 1.0




Dithiocarbamates (as CS2) 2.0






Heptachlor (sum of Heptachlor and Heptachlorepoxide) 0.05
Hexachlorobenzene 0.1










Pyrethrins (sum of) 3.0
Quintozene (sum of quintozene, pentachloroaniline and methyl
pentachlorophenyl sulphide)
1.0
Table 4. Limits for pesticide residues (Ph. Eur. 7.0).
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4.2.2.1.2. Qualitative and quantitative analysis of pesticide residues
The analytical procedures used are validated according to the regulations in force. In partic‐
ular, they satisfy the following criteria:
• the chosen method, especially the purification steps, are suitable for the combination
pesticide residue/substance to be analysed, and not susceptible to interference from co-
extractives; the limits of detection and quantification are measured for each pesticide-matrix
combination to be analysed,
• between 70 per cent to 110 per cent of each pesticide is recovered,
• the repeatability of the method is not less than the values indicated in Table 5,
• the reproducibility of the method is not less than the values indicated in Table 5,
• the concentration of test and reference solutions and the setting of the apparatus are such
that a linear response is obtained from the analytical detector.









Table 5. Repeatibility and reproducibility limits of determination of pesticides (Ph. Eur. 7.0).
Detailed description of qualitative and quantitative determination of organochlorine, organo‐





To 10 g of the substance being examined, coarsely powdered, add 100 ml of acetone R and allow
to stand for 20 min. Add 1 ml of a solution containing 1.8 µg/ml of carbophenothion R in toluene
R. Homogenise using a high-speed blender for 3 min. Filter and wash the filter cake with two
quantities, each of 25 ml, of acetone R. Combine the filtrate and the washings and heat using a
rotary evaporator at a temperature not exceeding 40 °C until the solvent has almost completely
evaporated. To the residue add a few millilitres of toluene R and heat again until the acetone
is completely removed. Dissolve the residue in 8 ml of toluene R. Filter through a membrane
filter (45 µm), rinse the flask and the filter with toluene R and dilute to 10.0 ml with the same
solvent (solution A).
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Heptachlor (sum of Heptachlor and Heptachlorepoxide) 0.05
Hexachlorobenzene 0.1










Pyrethrins (sum of) 3.0
Quintozene (sum of quintozene, pentachloroaniline and methyl
pentachlorophenyl sulphide)
1.0
Table 4. Limits for pesticide residues (Ph. Eur. 7.0).
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4.2.2.1.2. Qualitative and quantitative analysis of pesticide residues
The analytical procedures used are validated according to the regulations in force. In partic‐
ular, they satisfy the following criteria:
• the chosen method, especially the purification steps, are suitable for the combination
pesticide residue/substance to be analysed, and not susceptible to interference from co-
extractives; the limits of detection and quantification are measured for each pesticide-matrix
combination to be analysed,
• between 70 per cent to 110 per cent of each pesticide is recovered,
• the repeatability of the method is not less than the values indicated in Table 5,
• the reproducibility of the method is not less than the values indicated in Table 5,
• the concentration of test and reference solutions and the setting of the apparatus are such
that a linear response is obtained from the analytical detector.









Table 5. Repeatibility and reproducibility limits of determination of pesticides (Ph. Eur. 7.0).
Detailed description of qualitative and quantitative determination of organochlorine, organo‐





To 10 g of the substance being examined, coarsely powdered, add 100 ml of acetone R and allow
to stand for 20 min. Add 1 ml of a solution containing 1.8 µg/ml of carbophenothion R in toluene
R. Homogenise using a high-speed blender for 3 min. Filter and wash the filter cake with two
quantities, each of 25 ml, of acetone R. Combine the filtrate and the washings and heat using a
rotary evaporator at a temperature not exceeding 40 °C until the solvent has almost completely
evaporated. To the residue add a few millilitres of toluene R and heat again until the acetone
is completely removed. Dissolve the residue in 8 ml of toluene R. Filter through a membrane
filter (45 µm), rinse the flask and the filter with toluene R and dilute to 10.0 ml with the same
solvent (solution A).




4.2.2.1.4.1. Organochlorine, organophosphorus and pyrethroid insecticides
Purificationis to be accomplished by means of size-exclusion chromatography.
The chromatographic procedure may be carried out using:
• a stainless steel column 0.30 m long and 7.8 mm in internal diameter packed with styrene-
divinylbenzene copolymer R (5 µm),
• as mobilephase toluene R at a flow rate of 1 ml/min.
Performance of the column. Inject 100 µl of a solution containing 0.5 g/l of methyl red R and 0.5 g/
l of oracet blue2R R in toluene R and proceed with the chromatography. The column is not
suitable unless the colour of the eluate changes from orange to blue at an elution volume of
about 10.3 ml. If necessary calibrate the column, using a solution containing, in toluene R, at a
suitable concentration, the insecticide to be analysed with the lowest molecular mass (for
example, dichlorvos) and that with the highest molecular mass (for example, deltamethrin).
Determine which fraction of the eluate contains both insecticides.
Purification of the test solution. Inject a suitable volume of solution A (100 µl to 500 µl) and
proceed with the chromatography. Collect the fraction as determined above (solution B).
Organophosphorus insecticides are usually eluted between 8.8 ml and 10.9 ml. Organochlorine
and pyrethroid insecticides are usually eluted between 8.5 ml and 10.3 ml.
4.2.2.1.4.2. Organochlorine and pyrethroid insecticides
In a chromatography column, 0.10 m long and 5 mm in internal diameter, introduce a piece of
defatted cotton and 0.5 g of silica gel treated as follows : heat silica gel for chromatography R in
an oven at 150 °C for at least 4 h. Allow to cool and add dropwise a quantity of water R
corresponding to 1.5 per cent of the mass of silica gel used; shake vigorously until agglomerates
have disappeared and continue shaking for 2 h using a mechanical shaker. Condition the
column using 1.5 ml of hexane R. Prepacked columns containing about 0.50 g of a suitable silica
gel may also be used provided they are previously validated. Concentrate solution B in a
current of helium for chromatography R or oxygen-free nitrogen R almost to dryness and dilute to
a suitable volume with toluene R (200 µl to 1 ml according to the volume injected in the
preparation of solution B). Transfer quantitatively onto the column and proceed with the
chromatography using 1.8 ml of toluene R as the mobile phase. Collect the eluate (solution C).
4.2.2.1.5. Quantitative analysis
4.2.2.1.5.1. Organophosphorus insecticides
Quantitative determination to be accomplished by means of gas chromatography, using
carbophenothion R as internal standard. It may be necessary to use a second internal standard
to identify possible interference with the peak corresponding to carbophenothion.
Test solution. Concentrate solution B in a current of helium for chromatography R almost to
dryness and dilute to 100 µl with toluene R.
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Reference solution. Prepare at least three solutions in toluene R containing the insecticides to be
determined and carbophenothion at concentrations suitable for plotting a calibration curve.
The chromatographic procedure may be carried out using:
• a fused-silica column 30 m long and 0.32 mm in internal diameter the internal wall of which
is covered with a layer 0.25 µm thick of poly(dimethyl)siloxane R,
• hydrogen for chromatography R as the carrier gas. Other gases such as helium for chromatography
R or nitrogen for chromatography R may also be used provided the chromatography is suitably
validated.
• a phosphorus-nitrogen flame-ionisation detector or a atomic emission spectrometry
detector, maintaining the temperature of the column at 80 °C for 1 min, then raising it at a
rate of 30 °C/min to 150 °C, maintaining at 150 °C for 3 min, then raising the temperature at
a rate of 4 °C/min to 280 °C and maintaining at this temperature for 1 min, and maintaining
the temperature of the injector port at 250 °C and that of the detector at 275 °C. Inject the
chosen volume of each solution. Calculate the content of each insecticide from the peak areas
and the concentrations of the solutions.
4.2.2.1.5.2. Organochlorine and pyrethroid insecticides
Quantitative determination to be accomplished by means of gas chromatography, using
carbophenothion R as internal standard. It may be necessary to use a second internal standard
to identify possible interference with the peak corresponding to carbophenothion.
Test solution. Concentrate solution C in a current of helium for chromatography R or oxygen-free
nitrogen R almost to dryness and dilute to 500 µl with toluene R.
Reference solution. Prepare at least three solutions in toluene R containing the insecticides to be
determined and carbophenothion at concentrations suitable for plotting a calibration curve
The chromatographic procedure may be carried out using:
• a fused silica column 30 m long and 0.32 mm in internal diameter the internal wall of which
is covered with a layer 0.25 µm thick of poly(dimethyl)(diphenyl)siloxane R,
• hydrogen for chromatography R as the carrier gas. Other gases such as helium for chromatography
R or nitrogen for chromatography R may also be used, provided the chromatography is suitably
validated,
• an electron-capture detector,
• a device allowing direct cold on-column injection, maintaining the temperature of the
column at 80 °C for 1 min, then raising it at a rate of 30 °C/min to 150 °C, maintaining at 150
°C for 3 min, then raising the temperature at a rate of 4 °C/min to 280 °C and maintaining
at this temperature for 1 min, and maintaining the temperature of the injector port at 250 °C
and that of the detector at 275 °C. Inject the chosen volume of each solution. Calculate the
content of each insecticide from the peak areas and the concentrations of the solutions.




4.2.2.1.4.1. Organochlorine, organophosphorus and pyrethroid insecticides
Purificationis to be accomplished by means of size-exclusion chromatography.
The chromatographic procedure may be carried out using:
• a stainless steel column 0.30 m long and 7.8 mm in internal diameter packed with styrene-
divinylbenzene copolymer R (5 µm),
• as mobilephase toluene R at a flow rate of 1 ml/min.
Performance of the column. Inject 100 µl of a solution containing 0.5 g/l of methyl red R and 0.5 g/
l of oracet blue2R R in toluene R and proceed with the chromatography. The column is not
suitable unless the colour of the eluate changes from orange to blue at an elution volume of
about 10.3 ml. If necessary calibrate the column, using a solution containing, in toluene R, at a
suitable concentration, the insecticide to be analysed with the lowest molecular mass (for
example, dichlorvos) and that with the highest molecular mass (for example, deltamethrin).
Determine which fraction of the eluate contains both insecticides.
Purification of the test solution. Inject a suitable volume of solution A (100 µl to 500 µl) and
proceed with the chromatography. Collect the fraction as determined above (solution B).
Organophosphorus insecticides are usually eluted between 8.8 ml and 10.9 ml. Organochlorine
and pyrethroid insecticides are usually eluted between 8.5 ml and 10.3 ml.
4.2.2.1.4.2. Organochlorine and pyrethroid insecticides
In a chromatography column, 0.10 m long and 5 mm in internal diameter, introduce a piece of
defatted cotton and 0.5 g of silica gel treated as follows : heat silica gel for chromatography R in
an oven at 150 °C for at least 4 h. Allow to cool and add dropwise a quantity of water R
corresponding to 1.5 per cent of the mass of silica gel used; shake vigorously until agglomerates
have disappeared and continue shaking for 2 h using a mechanical shaker. Condition the
column using 1.5 ml of hexane R. Prepacked columns containing about 0.50 g of a suitable silica
gel may also be used provided they are previously validated. Concentrate solution B in a
current of helium for chromatography R or oxygen-free nitrogen R almost to dryness and dilute to
a suitable volume with toluene R (200 µl to 1 ml according to the volume injected in the
preparation of solution B). Transfer quantitatively onto the column and proceed with the
chromatography using 1.8 ml of toluene R as the mobile phase. Collect the eluate (solution C).
4.2.2.1.5. Quantitative analysis
4.2.2.1.5.1. Organophosphorus insecticides
Quantitative determination to be accomplished by means of gas chromatography, using
carbophenothion R as internal standard. It may be necessary to use a second internal standard
to identify possible interference with the peak corresponding to carbophenothion.
Test solution. Concentrate solution B in a current of helium for chromatography R almost to
dryness and dilute to 100 µl with toluene R.
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Reference solution. Prepare at least three solutions in toluene R containing the insecticides to be
determined and carbophenothion at concentrations suitable for plotting a calibration curve.
The chromatographic procedure may be carried out using:
• a fused-silica column 30 m long and 0.32 mm in internal diameter the internal wall of which
is covered with a layer 0.25 µm thick of poly(dimethyl)siloxane R,
• hydrogen for chromatography R as the carrier gas. Other gases such as helium for chromatography
R or nitrogen for chromatography R may also be used provided the chromatography is suitably
validated.
• a phosphorus-nitrogen flame-ionisation detector or a atomic emission spectrometry
detector, maintaining the temperature of the column at 80 °C for 1 min, then raising it at a
rate of 30 °C/min to 150 °C, maintaining at 150 °C for 3 min, then raising the temperature at
a rate of 4 °C/min to 280 °C and maintaining at this temperature for 1 min, and maintaining
the temperature of the injector port at 250 °C and that of the detector at 275 °C. Inject the
chosen volume of each solution. Calculate the content of each insecticide from the peak areas
and the concentrations of the solutions.
4.2.2.1.5.2. Organochlorine and pyrethroid insecticides
Quantitative determination to be accomplished by means of gas chromatography, using
carbophenothion R as internal standard. It may be necessary to use a second internal standard
to identify possible interference with the peak corresponding to carbophenothion.
Test solution. Concentrate solution C in a current of helium for chromatography R or oxygen-free
nitrogen R almost to dryness and dilute to 500 µl with toluene R.
Reference solution. Prepare at least three solutions in toluene R containing the insecticides to be
determined and carbophenothion at concentrations suitable for plotting a calibration curve
The chromatographic procedure may be carried out using:
• a fused silica column 30 m long and 0.32 mm in internal diameter the internal wall of which
is covered with a layer 0.25 µm thick of poly(dimethyl)(diphenyl)siloxane R,
• hydrogen for chromatography R as the carrier gas. Other gases such as helium for chromatography
R or nitrogen for chromatography R may also be used, provided the chromatography is suitably
validated,
• an electron-capture detector,
• a device allowing direct cold on-column injection, maintaining the temperature of the
column at 80 °C for 1 min, then raising it at a rate of 30 °C/min to 150 °C, maintaining at 150
°C for 3 min, then raising the temperature at a rate of 4 °C/min to 280 °C and maintaining
at this temperature for 1 min, and maintaining the temperature of the injector port at 250 °C
and that of the detector at 275 °C. Inject the chosen volume of each solution. Calculate the
content of each insecticide from the peak areas and the concentrations of the solutions.
Pharmacobotanical Analysis and Regulatory Qualification of Capsicum Fruits and Capsicum Extracts — A Survey
http://dx.doi.org/10.5772/58812
57
4.2.2.2. United States Pharmacopoea-National Formulary (USP-NF)
In the 2012 edition of the United States Pharmacopoea-National Formulary (USP36–NF31)
pesticide residues are described under General Chapters „<561> Articles of Botanical Origin
USP“. The „General Method for Pesticide Residues Analysys” section of the USP Monograph
„„<561> Articles of Botanical Origin USP“ contains „Definition“, „Limits“, „Qualitative and
quantitative analysis of pesticide residues“ and „Test for Pesticides” of herbal drugs.
For the purposes of the United States Pharmacopoea the designation pesticide applies to any
substance or mixture of substances intended to prevent, destroy, or control any pest, unwanted
species of plants or animals causing harm during or otherwise interfering with the production,
processing, storage, transport, or marketing of pure articles. The designation includes sub‐
stances intended for use as growth regulators, defoliants, or desiccants, and any substance
applied to crops before or after harvest to protect the product from deterioration during storage
and transport.
4.2.2.2.1. Limits
Within the United States, many botanicals are treated as dietary supplements and are subject
to the statutory provisions that govern foods but not drugs in the Federal Food, Drug, and
Cosmetic Act. Limits for pesticides for foods are determined by the Environmental Protection
Agency (EPA) as indicated in the Code of Federal Regulations (40 CFR Part 180) or the Federal
Register (FR). For pesticide chemicals without EPA-established tolerance levels, the limits
should be below the detection limit of the specified method. Result less than the EPA detection
limits are considered zero values. The limits contained in the USP, therefore, are not applicable
in the United States when articles of botanical origins are labeled for food purposes. The limits,
however, may be applicable in other countries where the presence of pesticide residues is
permitted.
Unless otherwise indicated in the monograph, the article to be examined complies with the
limits indicated in Table 6. The limits for suspected pesticides that are not listed in Table 6
must comply with the regulations of the EPA. For instances in which a pesticide is not listed
in Table 6 or in EPA regulations, calculate the limit by the formula:
A x  M
100 x  B
where
A is the acceptable daily intake (ADI), as published by FAO-WHO, in mg/kg of body weight;
M is body weight, in kg (60 kg); and
B is the daily dose of the article, in kg.
If the article is intended for the preparation of extracts, tinctures, or other pharmaceutical forms
of which the preparation method modifies the content of pesticides in the finished product,
calculate the limits by the formula:
A x  M  x  E
100 x  B
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where
E is the extraction factor of the preparation method, determined experimentally; and
A, M, and B are as defined above.
A total or partial exemption from the test may be granted when the complete history (nature
and quantity of the pesticides used, date of each treatment during cultivation and after harvest)
of the treatment of the batch is known and can be checked precisely according to good




Aldrin and dieldrin (sum of) 0.05
Azinphos-ethyl 0.1
Azinphos-methyl 1









Cyfluthrin (sum of) 0.1
λ-Cyhalothrin 1
Cypermethrin and isomers (sum of) 1








Dimethoate and omethoate (sum of) 0.1
Dithiocarbamates (expressed as CS2) 2
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limits are considered zero values. The limits contained in the USP, therefore, are not applicable
in the United States when articles of botanical origins are labeled for food purposes. The limits,
however, may be applicable in other countries where the presence of pesticide residues is
permitted.
Unless otherwise indicated in the monograph, the article to be examined complies with the
limits indicated in Table 6. The limits for suspected pesticides that are not listed in Table 6
must comply with the regulations of the EPA. For instances in which a pesticide is not listed
in Table 6 or in EPA regulations, calculate the limit by the formula:
A x  M
100 x  B
where
A is the acceptable daily intake (ADI), as published by FAO-WHO, in mg/kg of body weight;
M is body weight, in kg (60 kg); and
B is the daily dose of the article, in kg.
If the article is intended for the preparation of extracts, tinctures, or other pharmaceutical forms
of which the preparation method modifies the content of pesticides in the finished product,
calculate the limits by the formula:
A x  M  x  E
100 x  B
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside58
where
E is the extraction factor of the preparation method, determined experimentally; and
A, M, and B are as defined above.
A total or partial exemption from the test may be granted when the complete history (nature
and quantity of the pesticides used, date of each treatment during cultivation and after harvest)
of the treatment of the batch is known and can be checked precisely according to good
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Fensulfothion(sum of fensulfothion, fensulfothion-oxon,
fensulfothion-oxonsulfon, and fensulfothion-sulfon)
0.05
Fenthion (sum of fenthion, fenthion-oxon, fenthion-oxon-











Hexachlorocyclohexane (sum of isomers α-, β-, δ-, and ε-) 0.3
Lindan (γ-hexachlorocyclohexane) 0.6








Parathion-ethyl and Paraoxon-ethyl (sum of) 0.5
Parathion-methyl and Paraoxon-methyl (sum of) 0.2
Pendimethalin 0.1
Pentachloranisol 0.01
Permethrin and isomers(sum of) 1
Phosalone 0.1











Pyrethrum (sum of cinerin I, cinerin II, jasmolin I, jasmolin II,
pyrethrin I, and pyrethrin II)
3
Quinalphos 0.05







Table 6. Limits for pesticide residues (USP36–NF31).
4.2.2.2.2. Qualitative and quantitative analysis of pesticide residues
Use validated analytical procedures (e.g., FDA Pesticide Analytical Manual (PAM) [http://
www.fda.gov/Food/FoodScienceResearch/LaboratoryMethods/ucm2006955.htm], or other
analytical procedures validated in accordance with EU guideline [Document No. SANCO/
10684/2009, http://ec.europa.eu/food/plant/protection/resources/qualcontrol_en.pdf] or the
USP Validation of Compendial Procedures <1225>) that satisfy the following criteria:
• the method, especially with respect to its purification steps, is suitable for the combination
of pesticide residue and substance under test, and is not susceptible to interference from co-
extractives;
• the limits of detection and quantification for each pesticide matrix combination to be
analyzed;
• the method is shown to recover between 70% and 110% of each pesticide;
• the repeatability and reproducibility of the method are NLT the appropriate values
indicated in Table 7; and
• the concentrations of test and reference solutions and the setting of the apparatus are such
that a linear response in obtained from the analytical detector.
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• the method, especially with respect to its purification steps, is suitable for the combination
of pesticide residue and substance under test, and is not susceptible to interference from co-
extractives;
• the limits of detection and quantification for each pesticide matrix combination to be
analyzed;
• the method is shown to recover between 70% and 110% of each pesticide;
• the repeatability and reproducibility of the method are NLT the appropriate values
indicated in Table 7; and
• the concentrations of test and reference solutions and the setting of the apparatus are such
that a linear response in obtained from the analytical detector.
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Concentration Range of the
Pesticide (mg/kg)





Table 7. Repeatibility and reproducibility limits of determination of pesticides (USP36–NF31).
4.2.2.2.3. Test for pesticides
Unless otherwise specified in the individual monograph, the following methods may be used
for the analysis of pesticides. Depending on the substance being examined, it may be necessary
to modify, sometimes extensively, the procedure described hereafter. Additionally, it may be
necessary to perform another method with another (e.g. mass spectrometry), or a different
method (e.g. immunochemical method) to confirm the results.
Description of qualitative and quantitative determination of organochlorine, organophospho‐





To 10 g of the coarsely powdered substance under test add 100 ml of acetone, and allow to
stand for 20 min. add 1 ml of a solution in toluene containing 1.8 µg of carbophenothion per
ml. Mix in a high-speed blender for 3 min. Filter this solution, and wash the residue with two
25-ml portions of acetone. Combine the filtrate and the washings, and heat, in a rotary
evaporator, maintaining the temperature of the bath below 40° until the solvent has almost
completely removed. Dissolve the residue in 8 ml of toluene. Pass through a membrane filter
of 45 µm pore size, rinse the flask and the filter with toluene, dilute with toluene to 10 ml
(Solution A), and mix. [NOTE – Use the above procedure for the analysis of samples of articles
having a water content of less than 15%. Samples having a higher water content may be dried,
provided that the drying procedure does not significantly affect the pesticide content.]
4.2.2.2.5. Purification
4.2.2.2.5.1. Organochlorine, organophosphorus, and pyrethroid
Purification is to be accomplished by means of size-exclusion chromatography. The size-
exclusion chromatograph is equipped with a 7.8 mm x 30 cm stainless steel column containing
5 µm packing L21. Toluene is used as the mobile phase at a flow rate of about 1 ml/min.
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Performance of the Column – Inject 100 µl of a solution in toluene containing, in each ml, 0.5 mg
of methyl red and 0.5 mg of oracet blue or equivalent. The column is not suitable unless the
color of the eluate changes from orange to blue at an elution volume of about 10.3 ml. If
necessary, calibrate the column, using a solution in toluene containing suitable concentrations
of the pesticide of interest having the lowest molecular weight (for example, dichlorvos) and
that having the highest molecular weight (for example, deltamethrin). Determine which
fraction of the eluate contains both pesticides.
Purification of the Test Solution – Inject a suitable volume (100 to 500 µl) of Solution A into the
chromatograph. Collect the fraction (Solution B) as determined above under Performance of the
Column. Organophosphorus pesticide elute between 8.8 and 10.9 ml. Organochlorine and
pyrethroid pesticides elute between 8.5 and 10.3 ml.
Organochlorine and Pyrethroid Insecticides – Into a 5 mm x 10 cm chromatographic column,
introduce a piece of fat-free cotton and 0.5 g of silica gel treated as follows. Heat chromato‐
graphic silica gel in oven 150° for at least 4 h. Allow to cool, and add dropwise a quantity of
water corresponding to 1.5% of the weight of silica gel used. Shake vigorously until agglom‐
erates have disappeared, and continue shaking by mechanical means for 2 h. Condition the
column with 1.5 ml of hexane. [NOTE – Prepacked columns containing about 0.50 g of suitable
silica gel may also be used, provided they have been previously validated.] Concentrate
Solution B almost to dryness, with the aid of a stream of helium or oxygen-free nitrogen, and
dilute with toluene to a suitable volume (200 µl to 1 ml, according to the volume injected in
the preparation of Solution B). Quantitatively transfer this solution to the column, and proceed
with the chromatography, using 1.8 ml of toluene as the mobile phase. Collect the eluate
(Solution C).
4.2.2.2.6. Quantitative analysis
4.2.2.2.6.1. Quantitative analysis of organophosphorus insecticides
Test Solution – Concentrate Solution B almost to dryness, with the aid of a stream of helium,
dilute with toluene to 100 µl, and mix.
Standard Solution – Prepare at least three solutions in toluene containing each of the pesticides
of interest and carbophenothion at concentrations suitable for plotting a calibration curve.
Chromatographic System-The gas chromatograph is equipped with an alkali flame-ionization
detector or flame photometric detector and a 0.32 mm x 30 m fused silica column coated with
a 0.25 µm layer of phase G1. Hydrogen is used as the carrier gas. Other gases, such as helium
or nitrogen, may also be used. The injection port temperature is maintained at 250°, and the
detector is maintained at 275°. The column temperature is maintained at 80° for 1 min, then
increased to 150° at a rate of 30°/min, maintained at 150° for 3 min, then increased to 280° at a
rate of 4°/min, and maintained at this temperature for 1 min. Use carbophenothion as the
internal standard. [NOTE – If necessary, use a second internal standard to identify any possible
interference with the peak corresponding to carbophenothion.] inject the chosen volume of
each solution, record the chromatograms, and measure the peak responses. Calculate the
content of each pesticide from the peak areas and the concentrations of the solution.
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Table 7. Repeatibility and reproducibility limits of determination of pesticides (USP36–NF31).
4.2.2.2.3. Test for pesticides
Unless otherwise specified in the individual monograph, the following methods may be used
for the analysis of pesticides. Depending on the substance being examined, it may be necessary
to modify, sometimes extensively, the procedure described hereafter. Additionally, it may be
necessary to perform another method with another (e.g. mass spectrometry), or a different
method (e.g. immunochemical method) to confirm the results.
Description of qualitative and quantitative determination of organochlorine, organophospho‐





To 10 g of the coarsely powdered substance under test add 100 ml of acetone, and allow to
stand for 20 min. add 1 ml of a solution in toluene containing 1.8 µg of carbophenothion per
ml. Mix in a high-speed blender for 3 min. Filter this solution, and wash the residue with two
25-ml portions of acetone. Combine the filtrate and the washings, and heat, in a rotary
evaporator, maintaining the temperature of the bath below 40° until the solvent has almost
completely removed. Dissolve the residue in 8 ml of toluene. Pass through a membrane filter
of 45 µm pore size, rinse the flask and the filter with toluene, dilute with toluene to 10 ml
(Solution A), and mix. [NOTE – Use the above procedure for the analysis of samples of articles
having a water content of less than 15%. Samples having a higher water content may be dried,
provided that the drying procedure does not significantly affect the pesticide content.]
4.2.2.2.5. Purification
4.2.2.2.5.1. Organochlorine, organophosphorus, and pyrethroid
Purification is to be accomplished by means of size-exclusion chromatography. The size-
exclusion chromatograph is equipped with a 7.8 mm x 30 cm stainless steel column containing
5 µm packing L21. Toluene is used as the mobile phase at a flow rate of about 1 ml/min.
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Performance of the Column – Inject 100 µl of a solution in toluene containing, in each ml, 0.5 mg
of methyl red and 0.5 mg of oracet blue or equivalent. The column is not suitable unless the
color of the eluate changes from orange to blue at an elution volume of about 10.3 ml. If
necessary, calibrate the column, using a solution in toluene containing suitable concentrations
of the pesticide of interest having the lowest molecular weight (for example, dichlorvos) and
that having the highest molecular weight (for example, deltamethrin). Determine which
fraction of the eluate contains both pesticides.
Purification of the Test Solution – Inject a suitable volume (100 to 500 µl) of Solution A into the
chromatograph. Collect the fraction (Solution B) as determined above under Performance of the
Column. Organophosphorus pesticide elute between 8.8 and 10.9 ml. Organochlorine and
pyrethroid pesticides elute between 8.5 and 10.3 ml.
Organochlorine and Pyrethroid Insecticides – Into a 5 mm x 10 cm chromatographic column,
introduce a piece of fat-free cotton and 0.5 g of silica gel treated as follows. Heat chromato‐
graphic silica gel in oven 150° for at least 4 h. Allow to cool, and add dropwise a quantity of
water corresponding to 1.5% of the weight of silica gel used. Shake vigorously until agglom‐
erates have disappeared, and continue shaking by mechanical means for 2 h. Condition the
column with 1.5 ml of hexane. [NOTE – Prepacked columns containing about 0.50 g of suitable
silica gel may also be used, provided they have been previously validated.] Concentrate
Solution B almost to dryness, with the aid of a stream of helium or oxygen-free nitrogen, and
dilute with toluene to a suitable volume (200 µl to 1 ml, according to the volume injected in
the preparation of Solution B). Quantitatively transfer this solution to the column, and proceed
with the chromatography, using 1.8 ml of toluene as the mobile phase. Collect the eluate
(Solution C).
4.2.2.2.6. Quantitative analysis
4.2.2.2.6.1. Quantitative analysis of organophosphorus insecticides
Test Solution – Concentrate Solution B almost to dryness, with the aid of a stream of helium,
dilute with toluene to 100 µl, and mix.
Standard Solution – Prepare at least three solutions in toluene containing each of the pesticides
of interest and carbophenothion at concentrations suitable for plotting a calibration curve.
Chromatographic System-The gas chromatograph is equipped with an alkali flame-ionization
detector or flame photometric detector and a 0.32 mm x 30 m fused silica column coated with
a 0.25 µm layer of phase G1. Hydrogen is used as the carrier gas. Other gases, such as helium
or nitrogen, may also be used. The injection port temperature is maintained at 250°, and the
detector is maintained at 275°. The column temperature is maintained at 80° for 1 min, then
increased to 150° at a rate of 30°/min, maintained at 150° for 3 min, then increased to 280° at a
rate of 4°/min, and maintained at this temperature for 1 min. Use carbophenothion as the
internal standard. [NOTE – If necessary, use a second internal standard to identify any possible
interference with the peak corresponding to carbophenothion.] inject the chosen volume of
each solution, record the chromatograms, and measure the peak responses. Calculate the
content of each pesticide from the peak areas and the concentrations of the solution.
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4.2.2.2.6.2. Quantitative analysis organochlorine and pyrethroid insecticides
Test solution – Concentrate Solution C almost to dryness, with the aid of a stream of helium or
oxygen-free nitrogen, dilute with toluene to 500 µl, and mix.
Standard Solution – Prepare at least three solutions in toluene containing each of the pesticides
of interest and carbophenothion at concentrations suitable for plotting a calibration curve.
Chromatographic System – The gas chromatograph is equipped with an electron-capture
detector, a device allowing direct on-column cold injection, and a 0.32 mm x 30 m fused silica
column coated with a 0.25 µm layer of phase G1. Hydrogen is used as the carrier gas. Other
gases, such as helium or nitrogen, may also be used. The injection port temperature is main‐
tained at 275°, and the detector is maintained at 300°. The column temperature is maintained
at 80° for 1 min, then increased to 150° at a rate of 30°/min, maintained at 150° for 3 min, then
increased to 280° at a rate of 4°/min, and maintained at this temperature for 1 min. Use
carbophenothion as the internal standard. [NOTE – If necessary, use a second internal standard
to identify any possible interference with the peak corresponding to carbophenothion.] Inject
the chosen volume of each solution, record the chromatograms, and measure the peak
responses. Calculate the content of each pesticide from the peak areas and the concentrations
of the solutions.
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spice paprika (Capsicum annuum) powder. Journal of Agricultural and Food Chem‐
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[18] Davies, B.H. (1980): Carotenoid biosynthesis, In: Czygan, F.C. (ed): Pigments in
Plants, 2nd Ed. Gustav Fischer, Stuttgart. pp. 31–56.
Pharmacobotanical Analysis and Regulatory Qualification of Capsicum Fruits and Capsicum Extracts — A Survey
http://dx.doi.org/10.5772/58812
65
4.2.2.2.6.2. Quantitative analysis organochlorine and pyrethroid insecticides
Test solution – Concentrate Solution C almost to dryness, with the aid of a stream of helium or
oxygen-free nitrogen, dilute with toluene to 500 µl, and mix.
Standard Solution – Prepare at least three solutions in toluene containing each of the pesticides
of interest and carbophenothion at concentrations suitable for plotting a calibration curve.
Chromatographic System – The gas chromatograph is equipped with an electron-capture
detector, a device allowing direct on-column cold injection, and a 0.32 mm x 30 m fused silica
column coated with a 0.25 µm layer of phase G1. Hydrogen is used as the carrier gas. Other
gases, such as helium or nitrogen, may also be used. The injection port temperature is main‐
tained at 275°, and the detector is maintained at 300°. The column temperature is maintained
at 80° for 1 min, then increased to 150° at a rate of 30°/min, maintained at 150° for 3 min, then
increased to 280° at a rate of 4°/min, and maintained at this temperature for 1 min. Use
carbophenothion as the internal standard. [NOTE – If necessary, use a second internal standard
to identify any possible interference with the peak corresponding to carbophenothion.] Inject
the chosen volume of each solution, record the chromatograms, and measure the peak
responses. Calculate the content of each pesticide from the peak areas and the concentrations
of the solutions.
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1. Introduction
Patients with peptic ulcer and functional dyspepsia avoid food intake of chilies, wasabi, and
mustard oil by advised medical staffs, because the prevalent notion is that those condiments
would lead to the aggravation of gastric ulcers or stomach pain. However, chilies, wasabi, and
mustard oil are known to have pharmacological effects such as the ability to improve apatite
and digestion traditionally. It was reported that capsaicin, a pungent ingredient of chilies,
induced gastric mucosal protection, accelerated gastric healing, and regulated gastric acid
secretion via capsaicin-sensitive sensory neurons from animal and human studies [1-5].
Recently, it has been shown that allyl isothiocyanate, a pungent ingredient of wasabi and
mustard oil, has the protective and the aggravating effects of gastric mucosal damages in rats
[6-8]. Although the underlying mechanism was investigated, it remained to be inconsistent
effects of allyl isothiocyanate on gastric mucosal defense mechanisms.
Gastric mucosal defense mechanisms are essential for preventing potentially harmful elements
such as acid, pepsin, and Helicobacter pylori (H. pylori), present in the gastric lumen from gaining
access to the gastric mucosa. Tight junctions, which is classified as epithelial barrier in gastric
mucosal defense [9], are dynamic structures located at the most apical region of cell-cell contact
points. Interconnected by tight junctions, gastric epithelial cells form tight junction barrier,
preventing back diffusion of acid and pepsin. Tight junction proteins are comprised of ZO-1,
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occludin, claudins, and junctional adhesion molecules (JAMs) [10, 11]. Occludin was the first
identified transmembrane protein of tight junctions. Recently, the claudin family is supposedly
composed of at least 24 members in mice and human. In the stomach, it has been reported that
ZO-1, occludin, claudin-3, 4, 7, and 11 are expressed [12-14]. In addition, electrical resistance,
which is an indicator for tight junction barrier, in gastric mucosa was shown the highest in the
gastrointestinal tract, suggesting that tight junction barrier play critical roles in gastric mucosal
defenses [11]. Indeed, it was reported that the disruption of tight junction complexes were
attributed to gastric mucosal damages induced by aspirin in animal model and cell culture
studies [14, 15].
1.1. Aim
The aim of the present study is (1) to develop primary cultures of gastric epithelial cells from
rats that enable to investigate tight junction barrier, (2) to examine the influence of allyl
isothiocyanate (AITC) on tight junction barrier using primary cultures from the rat stomachs,
as compared with action of capsaicin. In this paper, it is suggested that allyl isothiocyanate
breaks gastric tight junction barrier. In addition, we have established confluent primary
cultures from rat stomachs for investigating tight junction barrier of gastric mucosa.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley strain rats (SLC, Hamamatsu, Japan) weighing 180-220 g were used.
Animals were housed under controlled environmental conditions (temperature at 24±2℃ and
light on 7:00 am to 7:00 pm) and fed commercial mouse chow MF (Oriental Yeast, Tokyo,
Japan). Animal experiments were performed in compliance with the “Guiding Principles for
the Care and Use of Laboratory Animals” approved by the Japanese Pharmacological Society
and the guidelines approved by the Ethical Committee on Animal Care and Animal Experi‐
mentation of Josai International University (#12). Animals were anesthetized using sodium
pentobarbital before the isolation of tissues, and euthanized by over dose of sodium pento‐
barbital.
2.2. Buffers for cell isolation
Medium A contained (in mM) 0.5 NaH2PO4, 1.0 Na2HPO4, 20 NaHCO3, 70 NaCl, 5 KCl, 11
glucose, 50 HEPES, 2 Na2EDTA, and 20 mg/ml BSA (fraction V). Medium B contained (in mM)
0.5 NaH2PO4, 1.0 Na2HPO4, 20 NaHCO3, 70 NaCl, 5 KCl, 11 glucose, 50 HEPES, 20 mg/ml BSA
(fraction V), 1.0 CaCl2, and 1.5 MgCl2. Medium C contained (in mM) 0.5 NaH2PO4, 1.0
Na2HPO4, 20 NaHCO3, 70 NaCl, 5 KCl, 11 glucose, 50 HEPES, 1 mg/ml BSA (fraction V), 1.0
CaCl2, 1.5 MgCl2, and 0.5 dithiothreitol [16, 17].
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2.3. Cell isolation
Cell isolation from the rat stomach was according to the methods described by Tani. et al.
[16, 18] and modified by us to collect parietal cells and chief cells [19], where were located
at  the  middle  and  bottom of  gastric  glands,  from the  rat  stomach.  In  brief,  three  non-
fasted rats were anesthetized using sodium pentobarbital. The stomach was excised, everted,
and tied at both esophagus and pylorus. The everted sac was filled with 2 ml of Medium
A, containing 2.5 mg/ml of protease E and placed in Medium A for 30 min (fraction 1),
followed by Medium B for 120 min in a shaking water bath at 37ºC (fractions 2-4). Isolated
cells  from digestion  fractions  4  were  pelleted  at  240x  g  in  a  TOMY EIX-136  centrifuge
(Tokyo, Japan), re-suspended in Medium C. The cells were centrifuged at 500x g at room
temperature for 10 min and then re-suspended in 1:1 mixture of Ham’s F-12 and Dulbec‐
co’s minimum essential medium (DMEM/F-12), supplemented with heat-inactivated 10 %
fetal bovine serum (FBS), 8 µg/ml insulin, 1 µg/ml hydrocortisone, 100 U/mL penicillin, 100
U/ mL streptomycin, and 0.25 µg/ml amphotericin B.
2.4. Primary cultured gastric epithelial cells
Isolated cells from rat stomachs were plated at density of 3.6 x 105 cells/cm2 in collagen-coated
Transwell filters, 35 mm-cultures dishes, and 60 mm-culture dishes. Those cells were incubated
in DMEM/F12 supplemented with 10% FBS, 8 µg/ml insulin, 1 µg/ml hydrocortisone, 100 U/
mL penicillin, 100 U/ mL streptomycin, and 0.25 µg/ml amphotericin B under 5 % CO2 in air
at 37 °C by 4 days.
2.5. RGM-1 cells culture
RGM-1 cells, established by Dr. Matsui et al. [Institute of Physical and Chemical Science
(RIKEN) Cell Bank and Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan],
are non-transformed gastric surface epithelial cells [20]. RGM-1 cells were cultured in DMEM/
F-12 supplemented with 10 % FBS, 100 U/mL penicillin, 100 U/mL streptomycin, and 0.25 µg/
ml amphotericin B. RGM-1 cells were plated at density of 2.8 x 104 cells/cm2 in non-coated
Transwell filters and incubated in 5 % CO2 in air at 37 °C by 14-15 days.
2.6. Immunofluorescence microscopy
For  histochemical  identification  of  the  isolated  and  4  day-cultured  cells,  periodic  acid-
Sciff reaction (for mucus surface cells), succinic dehydrogenase activity (for parietal cells),
and immunofluorescense test for pepsinogen II (for chief cells) were used [21]. Dispersed
cells immediately after isolation were pelleted, re-suspended in OCT compound, and then
frozen in isopentane cooled with liquid nitrogen. Frozen dispersed cells were sectioned on
a cryostat (Leica, Bannockbum, IL, USA) at a thickness of 4 µm. The sections were thaw-
mounted on slides glasses. Surface cells were identified by red color (neutral mucins) of
the large granules when stained with periodic acid-Sciff stain [22]. Succinic dehydrogen‐
ase  activity  was  determined  by  the  methods  of  Nachlas  et  al  [23].  The  sections  were
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incubated in the medium containing 0.2 M phosphate buffer, 0.25 M succinic acid (disodi‐
um salt),  and nitro-blue tetrazolium (1 mg/ml)  for  50 min at  37℃. After  incubation,  the
sections were counterstained cell nuclei by 2 % methyl green for 15 min at 60 min. Parietal
cells  containing an unusual  number of  mitochondria among gastric  epithelial  cells  were
identified  by  bluish  purple  [24].  For  immunofluorescence  study  of  pepsinogen  II  for
identification  of  chief  cells,  the  section  was  incubated  for  1  hr  with  blocking  buffer
containing (in mM) 150 NaCl, 10 NaH2PO4, 2 mg/ml of gelatin, 0.5 % fish gelatin, and 2 %
BSA (globulin-free). Antibody staining was done at room temperature for 2 hr with anti-
pepsinogen II  antibody (BioDesign,  Saco,  ME).  Evaluation of  staining was done using a
Nikon  TE300  microscope  (MicroVideo  Instruments,  Avon,  MA)  outfitted  with  an  Orca
charge-coupled device camera (Hamamatus Photonics) and IP Lab (Scanalytics, Fairfax, VA)
image processing software. In contrast, cells grown on the 35 mm-dish were fixed for 10
min at room temperature with 4 % formaldehyde in 0.2 M phosphate buffer (pH 7.4). Fixed
cells  were washed with PBS,  permeabilized with 0.25 % Triton X-100 containing 0.02 %
saponin for 4 min at  4 °C,  and then the above procedure were conducted from incuba‐
tion  with  blocking  buffer  to  do  immunostaining  and  identification  of  each  cell  type.
Antibody  staining  was  done  at  room  temperature  for  2  hr  with  anti-cytokeratine  8/18
antibody (Novocastra, Newcastle, UK) for identification of epithelial cells and anti-vimen‐
tin antibody for fibroblasts (Novocastra, Newcastle, UK) [25, 26]. Evaluation of cell purity
was done by counting the total cell  number, as identified by methyl green and propidi‐
um iodide staining of nuclei, against the number of cells stained with periodic acid-Sciff,
nitro blue tetrazolium, and above specific antibodies. Approximately 1,000 cells/slide were
evaluated.
2.7. Electrophysiological analysis of primary cultures and RGM-1 cells
Transepithelial electrical resistance (TER) was measured in Transwell filter chambers using a
“Milli-cell” ERS system (Millipore, Billerica, MA, USA). The background resistance of cham‐
bers containing medium alone was subtracted from the value of all experimental conditions.
TER was evaluated 1) at 1-4 days after seeding in primary cultured epithelial cells from the rat
stomach and at 4, 7, 10, 14 days after seeding in RGM-1 cells, and 2) when capsaicin, allyl
isothiocyanate, cinnamaldehyde, and icilin were applied into apical compartment at every 30
min for 3 hr after apical application in 4 day-primary cultures.
2.8. Measurement of permeability in confluent primary cultures and RGM-1 cells
Mucosal (Apical or top well) to serosal (nutrient or bottom well) fluxes of mannitol were done
using Transwell filters containing confluent monolayers at day 4. For these studies, 3 mM
mannitol was added to the luminal solution and 3 mM D-glucose to the serosal solution. After
equilibration for 30 min, 2 mCi of [3H]-mannitol (15-30 Ci.mmol, NEM Life Science Products,
Boston, MA) was added to the mucosal solution and the cells were returned to 37℃ in the
incubator. Triplicate wells were sampled for each treatment at 1 to 3 hr after the addition of
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labeled mannitol. The concentration of mannitol in the serosal solution was determined by
liquid scintillation as described previously in detail [26].
2.9. Fluorescence microscopy and confocal microscope for occludin, ZO-1, and claudin 4
Gastric epithelial cells grown on Transwell filters were fixed for 10 min at room temperature
with 4 % formaldehyde in 0.2 M phosphate buffer (pH 7.4). Fixed cells were washed with PBS,
permeabilized with 0.25 % Triton X-100 containing 0.02 % saponin for 4 min at 4 °C. Samples
were then labeled with either rabbit anti-occludin antibody, rabbit anti-ZO-1 antibody, or
mouse anti-claudin 4 antibody, these were followed by incubation with Gel-PBS containing
with 1:200 diluted secondary FITC-conjugated goat anti-rabbit IgG or FITC-conjugated donkey
anti-mouse IgG. These samples were mounted in Vectashield (Vector Labs, CA, USA).
Fluorescence images were collected using an Axioskop 2 plus microscope with a plan-
NEOFLUAR 40x objective. The data was analyzed using AxioVision LE Rel 4.6.3 software (Carl
Zeiss Vision, Germany). Images were converted to TIFF format and composites of images were
prepared using Adobe Photoshop Elements 2.0 (Adobe Co., CA, USA).
2.10. Measurement of cell viability
Cell viability was evaluated by a colorimetric assay using crystal violet [28]. In brief, primary
cultured epithelial cells after apical application of pungent ingredients such as capsaicin and
allyl isothiocyanate were washed with PBS to remove dead cells, fixed with methanol, air-
dried, and stained with crystal violet. Stained cells were solubilized and the absorbance was
measured at 590 nm using 1420 Multilabel Counter (Perkin Elmer, Shelton, CT, USA).
2.11. Reverse transcription-polymerase chain reaction
Total RNA was isolated by using an RNeasy kit (Qiagen, CA, USA) according to the manu‐
facturer’s protocol. In brief, either the confluent monolayer of primary cultured rat gastric
epithelial cells, which were grown for 4 days after platting, the confluent monolayer of RGM-1
cells, or freshly isolated rat dorsal root ganglia was immediately submerged in Buffer RLT
(Qiagen), which inhibited RNase activation, and was homogenized by using a Multi-beads
shocker (Yasui Kikai, Osaka, Japan). Reverse transcription-polymerase chain reaction (RT-
PCR) was performed by using a one-step RT-PCR Kit (Qiagen) and a thermal cycler GeneAmp
PCR System 9700 (Applied Biosystems, CA, USA) for 35 cycles (TRPA1, TRPV1, and GAPDH)
under the following conditions: reverse transcription at 50°C for 30 min, initial denaturation;
15 min at 95°C and then 30 sec at 94°C, followed by a 30 sec annealing step at 56°C for TRPA1,
TRPV1, and GAPDH and 1 min elongation at 72°C. The primers sequences were 5’-CCC CAC
TAC ATT GGG CTG CA-3’ and 5’-CCG CTG TCC AGG CAC ATC TT-3’ for rat TRPA1, 5’-
TCG TCT ACC TCG TGT TCT TGT TTG-3’ and 5’-CCA GAT GTT CTT GCT CTC TTG TGC-3’
for rat TRPV1, and 5’-TCC CTC AAG ATT GTC AGC AA-3’ and 5’-AGA TCC ACA ACG GAT
ACA TT-3’ for rat GAPDH. The PCR products were separated on 3% (wt/vol) agarose gel in
Tris-acetate EDTA buffer, stained with ethidium bromide, and analyzed by LAS 3000 (FUJI‐
FILM, Tokyo, Japan). The sequence of the PCR product was analyzed using the BLAST
program (NCBI).
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allyl isothiocyanate were washed with PBS to remove dead cells, fixed with methanol, air-
dried, and stained with crystal violet. Stained cells were solubilized and the absorbance was
measured at 590 nm using 1420 Multilabel Counter (Perkin Elmer, Shelton, CT, USA).
2.11. Reverse transcription-polymerase chain reaction
Total RNA was isolated by using an RNeasy kit (Qiagen, CA, USA) according to the manu‐
facturer’s protocol. In brief, either the confluent monolayer of primary cultured rat gastric
epithelial cells, which were grown for 4 days after platting, the confluent monolayer of RGM-1
cells, or freshly isolated rat dorsal root ganglia was immediately submerged in Buffer RLT
(Qiagen), which inhibited RNase activation, and was homogenized by using a Multi-beads
shocker (Yasui Kikai, Osaka, Japan). Reverse transcription-polymerase chain reaction (RT-
PCR) was performed by using a one-step RT-PCR Kit (Qiagen) and a thermal cycler GeneAmp
PCR System 9700 (Applied Biosystems, CA, USA) for 35 cycles (TRPA1, TRPV1, and GAPDH)
under the following conditions: reverse transcription at 50°C for 30 min, initial denaturation;
15 min at 95°C and then 30 sec at 94°C, followed by a 30 sec annealing step at 56°C for TRPA1,
TRPV1, and GAPDH and 1 min elongation at 72°C. The primers sequences were 5’-CCC CAC
TAC ATT GGG CTG CA-3’ and 5’-CCG CTG TCC AGG CAC ATC TT-3’ for rat TRPA1, 5’-
TCG TCT ACC TCG TGT TCT TGT TTG-3’ and 5’-CCA GAT GTT CTT GCT CTC TTG TGC-3’
for rat TRPV1, and 5’-TCC CTC AAG ATT GTC AGC AA-3’ and 5’-AGA TCC ACA ACG GAT
ACA TT-3’ for rat GAPDH. The PCR products were separated on 3% (wt/vol) agarose gel in
Tris-acetate EDTA buffer, stained with ethidium bromide, and analyzed by LAS 3000 (FUJI‐
FILM, Tokyo, Japan). The sequence of the PCR product was analyzed using the BLAST
program (NCBI).




BSA (globulin-free), crystal violet, deoxyribonuclease 1, ethidium bromide, fish gelatin,
hydrocortisone, insulin, methyl green, nitro blue tetrazolium, periodic acid, protease, and icilin
were from Sigma-Aldrich (MO, USA). Absolute ethanol, allyl isothiocyanate, BSA (fraction V),
capsaicin, cell culture media, cinnamaldehyde, and dimethyl sulfoxide (DMSO) were from
Wako Pure Chemical Industries, Inc. (Osaka, Japan). Rabbit polyclonal anti-occludin antibody,
rabbit polyclonal anti-ZO-1 antibody, and monoclonal anti-claudin 4 antibody were from
Zymed Laboratories (CA, USA). FITC-conjugated goat anti-rabbit IgG, FITC-conjugated
donkey anti-mouse IgG, normal goat serum, and normal donkey serum were from Jackson
Immune Research Laboratories (PA, USA). Serum was from GibcoBRL (CA, USA). Propidium
iodide was from Molecular Probes (OR, USA). Sodium pentobarbital was from Dainippon
Sumitomo Pharma Co. (Osaka, Japan). The 35 mm-and 60 mm-dish, and a collagen type I from
rat tail were from Beckton Dickenson Biosciences (MA, USA). Transwell with filter (0.4 µm)
was from Corning (MA, USA). Allyl isothiocyanate, capsaicin, and cinnamaldehyde were
dissolved in absolute ethanol prior to dilution in cell culture medium, respectively. Icilin was
dissolved in DMSO, followed by absolute ethanol prior to dilution in cell culture medium. The
final concentrations of either ethanol or DMSO in the apical compartment of Transwell were
less than 0.1%. The vehicles used had no pharmacological effects on the epithelial barrier in
cell cultures.
2.13. Statistics
Values are presented as means±S.E.M. for three or more independent experiments.. Statistical
analysis of data were done with SigmaStat software (Jandel Scientific Software, CA, USA)
using a two-tailed Student’s t-test between two groups, and multiple comparisons against a
single control group were made by one-way analysis of variance (ANOVA) with Dunnett’s
multiple comparisons test. P < 0.05 was considered statistically significant.
3. Results
3.1. Identification of isolated cells from the rat gastric mucosa
Isolated cells from the rat stomach were prepared as described in methods and suspend‐
ed in medium C. The identification of isolated fraction consisted of chief cells (35.6 ± 5.8
%), parietal cells (31.8 ± 2.6 %), and surface cells (10.3 ± 0.9 %) determined by fluorescent
and light microscopy (Table 1). The remaining ~23 % of the cells are likely to be the non-
identified  immature  cell,  including  proliferative  cells  and  occasional  endocrine  cells.  In
addition, those isolated cells became a confluent cultures on the collagen-coating dishes by
4  days  after  seeding,  whose  cells  were  stained  with  anti-cytokeratine  8/18  antibody,  a
epithelial marker (data not shown), and with no staining anti-vimentin antibody, a fibroblast
marker (0.11 ± 0.11 %). These results suggested that primary cultures from the rat stom‐
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Table 1. Quantification of each cell type (%) in rat gastric epithelial cells after isolation
35.6±5.8









Table 1. Quantification of each cell type (%) in isolated cells from the rat stomach
3.2. Tight junction barrier is formed in primary cultures from the rat stomach
When isolated gastric epithelial cells were plated, cells attached to Transwell filters by 2
days after seeding. Primary cultured epithelial cells completely covered the Transwell filters
by 4 days after seeding, which were similar morphological features when cells were grown
on plastic dishes (data not shown). In contrast, RGM-1 cells, which are widely used for the
investigation of gastric epithelial physiology as a non-transformed gastric surface epithe‐
lial  cell  lines,  were  also  attached  and  proliferated  on  Transwell  filters,  and  formed  a
confluent monolayer by 4 to 5 days after seeding. Therefore, to determine whether those
cultures  were  an  appropriate  model  to  investigate  tight  junction  barrier,  we  first  con‐
firmed to  form functional  tight  junctions.  Transepithelial  electrical  resistance  (TER)  was
quantified.  We  found  that  as  primary  cultures  reached  confluence  at  3  to  4  days  after
seeding, there was a progressive increase in TER (Fig. 1A). TER at 4 days after seeding was
3069.6±582.0 Ohm.cm2. However, RGM-1 cells did not show any increased TER, even though
confluence was observed after 4 days after seeding. TER was less than about 60.0 Ohm.cm2
throughout the experiment (Fig. 1B).
To investigate why primary cultured epithelial cells, but not RGM-1 cells, have a great high
TER, we examined the localization of occludin and ZO-1 for tight junctions in the both cultures.
Interestingly, it was found that the localization of occludin and ZO-1 were continuously
observed at the cell-cell contact region in primary cultures from the rat stomach (Fig. 2A and
B). In RGM-1 cells, occludin was no expressed at the tight junction region, although ZO-1 was
only continuously expressed at the cell-cell contact point (Fig. 2C and D). It is suggested that
primary cultures from the rat stomach, but not RGM-1 cells, form functional tight junction
barrier.
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Figure 1. Progressive increased TER in primary cultures from the rat stomach, but not RGM-1 cells. Isolated cells from
the rat stomach and RGM-1 cells were grown on Transwell filters. TER was measured from 1 to 4 days after seeding of
primary cultures (A) and at 4, 7, 10, 14 days after seeding of RGM-1 cells (B). Data represent means±S.E.M. from 4 inde‐
pendent experiments. Note that primary cultures from the rat stomach produced a great high TER after 3 to 4 days
after seeding, when they formed a confluent monolayer.





Figure 2. Immunolocalization of occludin and ZO-1 in primary cultures from the rat stomach and RGM-1 cells. The
expression is anti-occludin staining (A, C) and anti-ZO-1 staining (B, D) for tight junction. Primary cultures were grown
to confluent by 4 days after seeding (A, B), and RGM-1 cells were grown confluent enough by 14 days after seeding on
Transwell filters (C, D). Those cells were fixed directly on the filter, incubated with each specific antibody, and evaluat‐
ed by a fluorescence microscope. Note that the localization of the both occludin and ZO-1 was observed at the entire
region of cell-cell contact in primary cultures from the rat stomach, yet occludin, but not ZO-1, did not localize at the
cell-cell contact region in RGM-1 cells. Bar (A, B, C, D)=20 μm.
3.3. Allyl isothiocyanate alters tight junction barrier in primary cultures from rat stomachs
To determine the effects of pungent ingredients such as allyl isothiocyanate and capsaicin on
tight junction barrier, we next examined TER and the mannitol flux using confluent cultures
at 4 days after seeding. Allyl isothiocyanate and capsaicin are applied into the apical side
(luminal or top compartment), because the apical side of gastric epithelial cells would be
exposed to those pungent ingredients when people intake condiments such as wasabi, mustard
oil, chili etc. It was found that 100 µM of allyl isothiocyanate induced a progressive decreased
in TER in a time-dependent manner as compared with control (Fig. 3A). TER loss was apparent
within 1 hr and fell by about 60 % following 3 hr of application. However, the lower concen‐
tration of allyl isothiocyanate (1 and 10 µM) did not affect TER. In contrast, capsaicin failed to
affect TER in primary cultures from the rat stomach, even at high concentration (300 µM) of
capsaicin (Fig.3C). Permeability was inversely correlated to TER, where cells applied with 100
µM of allyl isothiocyanate produced most permeable cultures among all groups (Fig. 4A and
B). Permeability is no change when the lower concentration of allyl isothiocyanate (10 µM)
and 300 µM of capsaicin were applied.
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Figure 1. Progressive increased TER in primary cultures from the rat stomach, but not RGM-1 cells. Isolated cells from
the rat stomach and RGM-1 cells were grown on Transwell filters. TER was measured from 1 to 4 days after seeding of
primary cultures (A) and at 4, 7, 10, 14 days after seeding of RGM-1 cells (B). Data represent means±S.E.M. from 4 inde‐
pendent experiments. Note that primary cultures from the rat stomach produced a great high TER after 3 to 4 days
after seeding, when they formed a confluent monolayer.
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Figure 3. Effect of allyl isothicyanate and capsaicin on TER and cell viability in primary cultures from the rat stomach.
Transwell-grown primary cultures from the rat stomach were incubated for 3 hr with allyl-isothiocyanate (A, B) and
capsaicin (C, D) each at the indicated concentrations in the apical side. Data for the time-course analysis of TER (A, C)
and cell vability (B, D) represent means ± S.E.M. from 3~6 independent experiments. *P<0.05 by ANOVA with Dun‐
nett’s multiple comparisons test compared with control. Note that the high dose (100 μM) of allyl-isothiocyanate in
the apical side produced a significant decrease in TER in primary cultures from the rat stomach with no affecting cell
viability, although the lower dose of allyl-isothiocyanate (1 and 10 μM) did not any alter in TER and cell viability. In
addition, notice that capsaicin did not affect TER and cell viability in primary cultures.
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Figure 4. Effect of capsaicin and allyl isothiocyanate on [3H]-mannitol flux in primary cultures from the rat stomach.
Isolated cells from the rat stomach were grown to confluence at 4 days after seeding on Transwell filters. The permea‐
bility of [3H]-mannitol (MW=182.17) was measured as the flux from the apical to basolateral chambers each hour for 3
hours. A: data indicate the [3H]-mannitol flux and presented as means ± S.E.M. of values determines every 1 hr after
apical application of capsaicin and allyl isothiocyanate from 3 independent experiments. *P<0.05 by ANOVA with
Dunnett’s multiple comparisons test compared with control. B: data show total [3H]-mannitol flux for 3 hr after apical
application of capsaicin and allyl isothiocyanate from 3 independent experiments. *P<0.05 by ANOVA with Dunnett’s
multiple comparisons test compared with control. Note that primary cultures from the rat stomach show a low perme‐
ability in nature, however the apical application of high concentration of AITC (100 μM), but not low concentration of
AITC (10 μM) and capsaicin, produced a high permeable monolayer in primary cultures from the rat stomach.
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Figure 5. Discontinuous expression of occludin in response to high concentration of allyl isothiocyanate (AITC) in pri‐
mary cultured epithelial cells from the rat stomach. The green label is anti-occludin antibody (A, B), anti-ZO-1 antibody
(C, D), or, anti-claudin 4 antibody (E,F) staining for tight junction. AITC (100 μM) or control (containing 0.1% ethanol)
was added for 3 hr in the apical side of transwell-grown primary cultures. Cells were fixed directly on the transwell
filter, followed by incubation with anti-occludin antibody, anti-ZO-1 antibody, or, anti-claudin 4 antibody, and evalu‐
ated by fluorescence microscope. Note that the continuous expression of occludin, ZO-1, and, claudin 4 at the cell-cell
contact region in primary cultures were observed in control, yet the application of AITC (100 mM) induced the discon‐
tinuous expression of occludin, but not ZO-1 and claudin 4, at the cell-cell contact region (arrows). Bar=20 mm.
To confirm the loss of tight junction barrier in response to allyl isothiocyanate, we assessed
localization  of  ZO-1,  occludin,  and claudin  4  for  tight  junctions  in  primary  cultures  by
immunocytochemistry. Those proteins are well-characterized tight junction components in
the stomach and has been reported that dislocation of tight junction proteins lead to the
pathogenesis of gastrointestinal tract such as H. pylori-induced gastritis [29]. When vehicle
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was applied for 3hr,  ZO-1,  occludin, and claudin 4 were located to the cellular margins
(Fig. 5A, C, and E). In contrast, the distribution of occludin was aberrant with discontinu‐
ous expression of the cell-cell contact point, when 100 µM of allyl isothiocyanate was applied
for  3  hr  (Fig.  5B).  However,  the  distribution  of  ZO-1  and  claudin  4  applied  by  allyl
isothiocyanate was found no deference as compared with vehicle-treated groups (Fig. 5D
and F).
To determine that the decreased TER and the mannitol flux were not due to allyl isothiocya‐
nate-induced alterations in cell viability, we measured the cell viability of primary cultures at
the end of each experiment. Fig. 3B and D demonstrate that primary cultures with allyl
isothicianate or capsaicin did not significantly alter cell viability, suggesting that in this system,
TER loss following application of allyl isothiocyanate is likely due to modulation of tight
junction barrier.
3.4. Allyl isothiocyanate-induced disruption of tight junction barrier is produced via
TRPA1-independent pathway
Recently,  allyl isothiocyanate is known as an activator of transient receptor potential A1
(TRPA1),  which is  considered to  be  a  chemosensor  in  several  sensory  tissues  including
gastrointestinal  tract  [30].  Additionally,  it  has  been  well  known  that  TRPA1  is  co-ex‐
pressed with TRPV1, which is ion channel targeted by capsaicin, on neuronal cells such as
dorsal root ganglia and trigeminal ganglia. Therefore, to investigate the possibility that loss
of  tight  junction  barrier  in  response  to  allyl  isothiocyanate  was  attributed  to  TRPA1 in
primary cultures from rat stomachs, we examined (1) the mRNA expression of TRPA1 and
TRPV1, and (2) the effect of cinnamaldehyde and icilin, other TRPA1 channel activators,
on TER in primary cultures  from rat  stomachs.  We found that  not  only TRPV1 mRNA
(predicted size: 347 bp) but also TRPA1 mRNA (predicted size: 487 bp) were expressed in
the primary cultures  from rat  stomachs (Fig.  6A).  By contrast,  TRPV1 mRNA was only
expressed in RGM-1 cells (Fig. 6B), which is agreement with previous reports [31, 32]. In
positive controls samples from the rat dorsal root ganglia, TRPA1 and TRPV1 mRNA were
also observed (data not shown).  The mRNA expression levels of glyceraldehyde-3-phos‐
phate-dehydroxgenase  were  unchanged  among  all  tested  samples  so  that  the  mRNA
expression analysis by using RT-PCR was done appropriately, suggesting that TRPA1 and
TRPV1 are periphery expressed at  mRNA levels in native gastric  epithelial  cells  in rats.
Therefore,  we  investigate  the  effect  of  cinnamaldehyde  and  icilin,  the  other  TRPA1
activators, on TER. When apical application of neither cinnamaldehyde (3-300 µM) nor icilin
(1-100 µM) for 3 hr induced decrease in TER (Fig. 7A, C) and cell viability (Fig. 7B, D) in
primary cultures from rat stomachs. In addition, TER reduction in response to100 µM of
allyl isothiocyanate was not inhibited in the presence of 10 µM of ruthenium red, which is
a nonselective TRP channel inhibitor (data not shown) [33].  These results suggested that
allyl isothiocyanate breaks tight junction barrier in primary cultures not via the pathway
of TRPA1 channels activation.
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Fig. 6
Figure 6. Expression of TRPV1, TRPA1, and, TRPM8 mRNA in primary cultures from the rat stomach, and the expres‐
sion of TRPV1 and TRPA1 mRNA in RGM-1 cells by RT-PCR. Total RNA was isolated from rat dorsal root ganglia, pri‐
mary cultures from the rat stomach, and RGM-1 cells. Data showed the mRNA expression of TRPV1 and TRPA1 in
primary cultures from the rat stomach (A), and in RGM-1 cells (B). The mRNA levels were analyzed by PCR (35 cycles)
using primers for TRPA1, TRPV1, and GAPDH. Rat DRG was used as positive control samples for TRPA1, TRPV1, and
TRPM8 mRNA. Predicted sizes of PCR products are TRPA1 (487 bp), TRPV1 (347 bp), and GAPDH (308 bp), respectively.
M: marker. GAPDH was the control for assay efficiency.
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Figure 7. Effect of cinnamaldehyde and icilin, the other TRPA1 antagonist, on TER and cell viability in primary cultures
from the rat stomach on AITC-induced TER reduction and cell viability in primary cultures from the rat stomach. Trans‐
well-grown primary cultures from the rat stomach were incubated for 3 hr with cinnamaldehyde (A, B) and icilin (C, D)
each at the indicated concentrations in the apical side. Data for the time-course analysis (A, C) and cell viability (B, D)
represent means ± S.E.M. from 3 independent experiments. Note that the application of cinnamaldehyde and icilin,
which are TRPA1 agonists, did not affect TER and cell viability.
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Previous investigations into mechanism by which noxious substances, including acid, H.
pylori, non-steroidal anti-inflammatory drugs (NSAIDs), and dietary nitrate, disrupts the tight
junctions barrier have been limited by the lack of testable gastric epithelial cells models that
form functional tight junction barrier. The present study has utilized a biologically relevant in
vitro model of the influence of condiments such as wasabi, mustard oil, and chilies on gastric
epithelial cell to demonstrate that exposure of allyl isothiocyanate, a pungent ingredient of
wasabi and mustard oil, induced a progressive loss of TER which is followed by disruption of
occludin at the levels of the tight junctions, but not capsaicin which is a pungent ingredient of
chilies. Our results have also identified TRPA1, which is activated by allyl isothiocyanate and
are expressed in native rat gastric epithelia cells, is not involved in tight junction barrier
dysfunction.
4.1. Confluent primary cultures with a great high TER
Isolated cells from the rat stomach, which are consisted of not only surface cells but also parietal
cells, chief cells, and non-identified immature cells, were grown a confluent monolayer with
a great high TER (>2000 Ohm.cm2), whose cultures are also identified as epithelial cells. In
previous reports, TER in gastric mucosa was shown the highest in the gastrointestinal tract
(>2000 Ohm.cm2) to prevent mucosal damages from exposure of luminal acid and pepsin [11],
suggesting that tight junction barrier plays critical roles in gastric mucosal defenses as
epithelial barriers. Although MDCK cells, T-84 cells, AGS cells, and MNK 28 cells [34] are
frequently used to study aspect tight junction barrier, those cells are not of gastric origin or
gastric adenocarcinoma cells so that those experimental data might not faithfully replicate the
physiology of gastric epithelial cells. In addition, RGM-1 cells as a non-transformed cell line
established from the rat stomach is a very useful cell culture models for investigation of gastric
epithelial physiology [20, 28]. However, we found that RGM-1 cells is not able to form tight
junction barrier with a high TER, although our results revealed that occludin expression was
not located at cell-cell contact region in RGM-1 cells, whereas ZO-1 expression was continu‐
ously located at tight junctions regions. It has been reported that occludin-/-mice produced
histological abnormalites in the gastric epithelium, which were complete loss of parietal and
mucus cell hyperplasia, suggesting that occludin is involved in not only epithelial barrier
formation but also epithelial differentiation in the stomach [35, 36]. It has been shown that the
expression of tight junction proteins are at the cell-cell contact points which is identified as
mature epithelial or endothelial cells in physiological condition, whereas down regulation of
tight junction proteins is associated with survival and metastatic potential in human gastric
cancer [37]. Shimokawa et al. [38] reported that RGM-1 cells had no secretory granules and the
abundance of polyribosomes by using electron microscopic analysis, suggesting that RGM-1
cells are undifferentiated and proliferating mucous progenitor cells, not mature and differen‐
tiated mucous neck cells. In agreement with those previous reports, the lock of occludin
expression at tight junction regions in RGM-1 cells is due to characterize as immature gastric
epithelial cell line such as proliferating mucus progenitor cells. So that primary cultures from
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the rat stomach was mimicked to the gastric epithelium, which is stand against noxious
substances such as gastric acid and pepsin.
4.2. Allyl isothiocyanate, but not capsaicin, breaks tight junction barrier, which is
independent on TRPA1
We next  explored the alteration of  tight  junction barrier  in  response to  allyl  isothiocya‐
nate and capsaicin in primary cultures from the rat  stomach. That is  because the diges‐
tive  properties  of  capsaicin  and  allyl  isothiocyanate  were  attributed  to  enhancement  of
digestive functions such as acid secretion [5], motility [39, 40], and mucosal blood flow [41,
42].  However,  little  is  known  those  pungent  ingredients  of  condiments  affect  gastric
epithelial barrier. Although some reports showed that very high concentration of capsai‐
cin (5 mM) in luminal side decreased in TER in the human intestinal epithelial  cell  line
HCT-8  [43],  there  is  no  report  about  allyl  isothiocyanate.  In  the  present  studies,  it  was
observed the luminal application of capsaicin (300 µM) did not have any changes in tight
junction barrier, whereas the luminal application of allyl isothiocyanate at high concentra‐
tion (100 µM) induced the decreased tight junction barrier in primacy cultures from the rat
stomach. Yet, the low concentration of allyl isothiocyanate (<10 µM) did not provide any
alteration  of  tight  junction  barrier  in  primary  cultures.  Indeed,  the  localization  of  tight
junction proteins including occludin, ZO-1, and claudin 4 were continuously expressed at
the cell-cell  region in control group. However, the discontinuous expression of occludin,
but not ZO-1 and claudin 4, was observed in the group treated with high concentration of
allyl isothiocyanate in primary cultures, suggesting that dislocation of occludin provide the
loss of tight junction barrier in response to allyl isothiocyanate.
It has been reported that TRPA1 is expressed primarily in small diameter, nociceptive neurons,
where its activation likely contributes to a variety of sensory processes, including thermal
nociception and inflammatory hyperalgesia [44]. TRPA1 is an excitatory ion channels targeted
by irritant compounds derived from plants including wasabi, mustard, and cinnamon [45].
TRPA1 expression has been demonstrated in gastrointestinal tract [40, 46], especially it was
showed that TRPA1 protein expression in gastric sensory neurons in rat using immunohisto‐
chemistry [47]. Although little was known about the expression of TRPA1 in non-neuronal
cells, Nozawa et al. [48] and Kono et al. [49] recently reported that TRPA1 was expressed in
serotonin-containing enterochromaffin cells in the rat small intestine and rat intestinal
epithelial cells. These findings let us speculate that gastric epithelial cells express TRPA1
functionally. Interestingly, in the present study, TRPA1 mRNA was also found to be clearly
expressed in primary cultures from the rat stomach which are epithelial cells identified with
the anti-cytokeratine 8/18 antibody, although there was no observation of the expression of
TRPA1 mRNA in RGM-1 cells. These data indicated that TRPA1 was located on not only gastric
sensory neuron but also native gastric epithelial cells. Therefore, we asked if the loss of tight
junction barrier in response to allyl isothiocyanate was mediated by TRPA1 in primary
cultures. It was analyzed by using the other TRPA1 activator cinnamaldehyde and icilin [50],
so that it was observed those TRPA1 activator did not provide the loss of tight junction barrier
at all. Additionally, it was also observed allyl isothiocyanate-induced tight junction’s alteration
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was not dose-dependently, and was not inhibited by the pretreatment of a non-selective TRP
blocker ruthenium red (data not shown), suggesting that the loss of tight junctions in response
to allyl isothiocyanate was not mediated by TRPA1 in primary cultures of the rat stomach.
5. Conclusion
In conclusion, it is suggested that allyl-isothiocyanate breaks gastric tight junction barrier via
TRPA1-independent pathways. In addition, we have established a unique technique to form
the confluent primary cultures from rat stomachs with a great high TER.
Terminology
TJ: tight junction
RGM-1 cells: rat gastric epithelial cell line
TER: Transepithelial electrical resistance
TRPV1: transient receptor potential vanilloid type 1
TRPA1: transient receptor potential ankyrin 1
ZO-1: zonula occludens-1
S.E.M: standard error of mean
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1. Introduction
1.1. Capsaicin-sensitive afferent nerves
Capsaicin-sensitive afferent nerves play an important role in maintaining the integrity of the
gastric mucosa. Stimulation of these nerves by capsaicin has been demonstrated to protect
gastric mucosa from a variety of noxious stimuli through increased gastric mucosal blood flow
(GMBF) [1, 2]. The binding site of capsaicin has been cloned, and named transient receptor
potential vanilloid type 1 (TRPV1), a nonselective cation channel [3]. It is reported that
capsaicin stimulates these afferent nerves through activation of TRPV1, resulting in gastric
mucosal protection [4] and gastric hyperemic response [5], which are mediated by both
calcitonin gene-related peptide (CGRP) and nitric oxide (NO) [6, 7]. Indeed, it has been shown
that gastric mucosal vasodilation induced by intragastric application of capsaicin was reduced
by the inhibitor of NO synthase (NOS), NG-nitro-L-arginine methyl ester (L-NAME) [8].
1.2. Nitric oxide synthase
NO has been reported to affect gastric mucosal blood flow [9]. In mammals, three isoforms of
NOS encoded by different genes have been identified [10]. The constitutively expressed
isoforms include neuronal NOS (nNOS) present in the neuron and endothelial NOS (eNOS)
present in the endothelium lining the vasculature. Inducible NOS (iNOS) requires a stimulus
(cytokines and lipopolysaccharides) for expression in specific cell types such as macrophages,
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neutrophils, and epithelial cells. Therefore, eNOS-derived NO is assumed to contribute to the
gastric hyperemic response to capsaicin although the gastric mucosa has been shown to contain
not only eNOS [11, 12] but also nNOS [11] and iNOS [13].
Interestingly, Chen et al. [14] speculated that NO comes from not only endothelium but also
nitroxidergic nerves in the submucosa in gastric vasodilation response to capsaicin. However,
it has not been studied which NOS isoforms contribute to gastric hyperemic responses to
capsaicin thus far.
1.3. Aim
In the present report, we examined to determine the roles of NOS isoforms on gastric hypere‐
mic response to capsaicin in urethane-anesthetized rats by using pharmacological tools,
including N5-[imino (propylamino) methyl]-L-ornithine, (NPLA; a selective nNOS inhibitor),
N5-(l-iminoethyl)-L-ornithine (L-NIO; a selective eNOS inhibitor), and 1400W (a selective iNOS
inhibitor). In addition, we investigated the localization relationship of nNOS and TRPV1-
expressing nerves in rat stomachs by using immunohistochemical analysis.
2. Material and methods
2.1. Animals
Male Sprague–Dawley strain rats (SLC, Hamamatsu, Japan) weighing 180–220 g were used.
Animals were housed under controlled environmental conditions (temperature, 24 ± 2°C and
lights on 7:00 am to 7:00 pm) and fed commercial rat chow MF (Oriental Yeast, Tokyo, Japan).
The animals were kept in individual cages with raised mesh bottoms to prevent coprophagy,
and they were deprived of food but allowed free access to tap water for 18 h before the
experiments. Animal experiments were performed according to the “Guiding Principles for
the Care and Use of Laboratory Animals” approved by the Japanese Pharmacological Society
and the guidelines approved by the Ethical Committee on Animal Care and Animal Experi‐
mentation of Josai International University (#52). The number of animals used was kept to the
minimum necessary for meaningful interpretation of the data.
2.2. Preparations and drugs used
Atenolol, capsaicin, CMC, dimethyl sulfoxide (DMSO), dl-isoproterenol, and urethane (ethyl
carbamate) were obtained from Wako Pure Chemical Industries (Osaka, Japan). L-arginine, L-
NAME, and omeprazole were from Sigma-Aldrich (St. Louis, MO, USA). NPLA and L-NIO
came from Tocris Cookson (Ellisville, MO, USA). N-(4-t-Butylphenyl)-4-(3-chlopyridin-2-yl)
tetrahydropyrazine-1(2H)-carboxamide (BCTC) was purchased from BIOMOL (Plymouth
Meeting, PA, USA). Capsaicin was dissolved in Tween 80-ethanol solution (10% ethanol, 10%
Tween 80, and 80% saline) for s.c. injection or suspended in 0.5% CMC for mucosal application.
Omeprazole was suspended in 0.5% CMC for i.p. injection. BCTC was dissolved in DMSO
prior to dilution in saline, and the final concentration of DMSO was less than 1.0%. Other drugs
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were dissolved in saline with no organic solvent or detergent. Each drug was prepared
immediately before use and was given in a volume of 0.5 ml/100 g of body wt. in the case of
i.p. and s.c. administration or in a volume of 0.1 ml/100 g of body wt. in case of i.v. adminis‐
tration. Control animals received the vehicle alone.
2.3. Gastric mucosal blood flow
The measurement of gastric blood flow was carried out as described previously [15]. The
animals were anesthetized with urethane (1.25 g/kg, i.p.). The stomach was exposed through
a midline incision, delivered onto the abdominal surface by gentle traction on the spleen, and
pylorus was ligated. The lucite chamber was used for maintaining ex vivo conditions of gastric
mucosa. The lucite chamber, known as the ex vivo chamber, consists of two parts: one part is
a lucite base and the other is plastic rim which has two holes on the side wall. Two holes are
cannulated for perfusing the mucosa with saline (154 mmol/l NaCl, 37°C) at a flow rate of 1
ml/min. The lucite base was lowered over the animals, and the stomach was drawn though
the center hole with the forceps applied only to the forestomach. The stomach was then opened
along the greater curvature from the middle part of the forestomach to the area where the
epiploic artery is terminated, and the edges were pinned out by gently stretching the glandular
mucosa. The plastic rim was then applied and tightened down on the mucosa. Under these
conditions, the exposed area was exclusively the glandular mucosa, mostly consisting of
corpus region. The chamber was set at the level of the abdominal wall so that the external wall
of the stomach remained inside the abdominal cavity. The body temperature was maintained
at a temperature similar to that of the rectum at around 37°C by using a small animal warmer
and thermometer (Bio Research Center, Model BWT-100, Nagoya, Japan). Gastric mucosal
blood flow was measured by laser-Doppler flowmetry (Advance, Model ALF-21N, Tokyo,
Japan) and by a non-touching probe (1 mm in diameter) on the surface of the corpus mucosa.
After gastric mucosal blood flow was well stabilized, the perfusion was discontinued, the
luminal solution was removed, and then the mucosa was exposed to 2 ml of capsaicin for 10
min. After application, the mucosa was rinsed with saline, another 2 ml of saline was instilled,
and the perfusion resumed. Changes in the gastric mucosal blood flow were continuously
monitored and recorded for 2-h test periods by using the PowerLab system (Model ML845;
AD Instruments, Bella Vista, NSW, Australia).
2.4. Experimental procedures
A TRPV1 antagonist N-(4-t-butylphenyl)-4-(3-chlopyridin-2-yl) tetrahydropyrazine-1(2H)-
carboxamide (BCTC) (0.8 mmol/L, i.g.) [16], a non-selective NOS inhibitor NG-nitro-L-arginine
methyl ester (L-NAME; 5 and 10 mg/kg, i.v.), a nNOS selective inhibitor NPLA (0.02 and 0.2
mg/kg, i.v.), an eNOS selective inhibitor L-NIO (3 and 10 mg/kg, i.v.), and an iNOS selective
inhibitor 1400W (3 and 10 mg/kg, i.v.) were administered 20 min before exposing the stomach
to 2 ml of capsaicin for 10 min. In one group, L-arginine (300 mg/kg, i.v.) was administered
twice 40 min and 60 min before the application of capsaicin.
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neutrophils, and epithelial cells. Therefore, eNOS-derived NO is assumed to contribute to the
gastric hyperemic response to capsaicin although the gastric mucosa has been shown to contain
not only eNOS [11, 12] but also nNOS [11] and iNOS [13].
Interestingly, Chen et al. [14] speculated that NO comes from not only endothelium but also
nitroxidergic nerves in the submucosa in gastric vasodilation response to capsaicin. However,
it has not been studied which NOS isoforms contribute to gastric hyperemic responses to
capsaicin thus far.
1.3. Aim
In the present report, we examined to determine the roles of NOS isoforms on gastric hypere‐
mic response to capsaicin in urethane-anesthetized rats by using pharmacological tools,
including N5-[imino (propylamino) methyl]-L-ornithine, (NPLA; a selective nNOS inhibitor),
N5-(l-iminoethyl)-L-ornithine (L-NIO; a selective eNOS inhibitor), and 1400W (a selective iNOS
inhibitor). In addition, we investigated the localization relationship of nNOS and TRPV1-
expressing nerves in rat stomachs by using immunohistochemical analysis.
2. Material and methods
2.1. Animals
Male Sprague–Dawley strain rats (SLC, Hamamatsu, Japan) weighing 180–220 g were used.
Animals were housed under controlled environmental conditions (temperature, 24 ± 2°C and
lights on 7:00 am to 7:00 pm) and fed commercial rat chow MF (Oriental Yeast, Tokyo, Japan).
The animals were kept in individual cages with raised mesh bottoms to prevent coprophagy,
and they were deprived of food but allowed free access to tap water for 18 h before the
experiments. Animal experiments were performed according to the “Guiding Principles for
the Care and Use of Laboratory Animals” approved by the Japanese Pharmacological Society
and the guidelines approved by the Ethical Committee on Animal Care and Animal Experi‐
mentation of Josai International University (#52). The number of animals used was kept to the
minimum necessary for meaningful interpretation of the data.
2.2. Preparations and drugs used
Atenolol, capsaicin, CMC, dimethyl sulfoxide (DMSO), dl-isoproterenol, and urethane (ethyl
carbamate) were obtained from Wako Pure Chemical Industries (Osaka, Japan). L-arginine, L-
NAME, and omeprazole were from Sigma-Aldrich (St. Louis, MO, USA). NPLA and L-NIO
came from Tocris Cookson (Ellisville, MO, USA). N-(4-t-Butylphenyl)-4-(3-chlopyridin-2-yl)
tetrahydropyrazine-1(2H)-carboxamide (BCTC) was purchased from BIOMOL (Plymouth
Meeting, PA, USA). Capsaicin was dissolved in Tween 80-ethanol solution (10% ethanol, 10%
Tween 80, and 80% saline) for s.c. injection or suspended in 0.5% CMC for mucosal application.
Omeprazole was suspended in 0.5% CMC for i.p. injection. BCTC was dissolved in DMSO
prior to dilution in saline, and the final concentration of DMSO was less than 1.0%. Other drugs
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were dissolved in saline with no organic solvent or detergent. Each drug was prepared
immediately before use and was given in a volume of 0.5 ml/100 g of body wt. in the case of
i.p. and s.c. administration or in a volume of 0.1 ml/100 g of body wt. in case of i.v. adminis‐
tration. Control animals received the vehicle alone.
2.3. Gastric mucosal blood flow
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mucosa. The lucite chamber, known as the ex vivo chamber, consists of two parts: one part is
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cannulated for perfusing the mucosa with saline (154 mmol/l NaCl, 37°C) at a flow rate of 1
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the center hole with the forceps applied only to the forestomach. The stomach was then opened
along the greater curvature from the middle part of the forestomach to the area where the
epiploic artery is terminated, and the edges were pinned out by gently stretching the glandular
mucosa. The plastic rim was then applied and tightened down on the mucosa. Under these
conditions, the exposed area was exclusively the glandular mucosa, mostly consisting of
corpus region. The chamber was set at the level of the abdominal wall so that the external wall
of the stomach remained inside the abdominal cavity. The body temperature was maintained
at a temperature similar to that of the rectum at around 37°C by using a small animal warmer
and thermometer (Bio Research Center, Model BWT-100, Nagoya, Japan). Gastric mucosal
blood flow was measured by laser-Doppler flowmetry (Advance, Model ALF-21N, Tokyo,
Japan) and by a non-touching probe (1 mm in diameter) on the surface of the corpus mucosa.
After gastric mucosal blood flow was well stabilized, the perfusion was discontinued, the
luminal solution was removed, and then the mucosa was exposed to 2 ml of capsaicin for 10
min. After application, the mucosa was rinsed with saline, another 2 ml of saline was instilled,
and the perfusion resumed. Changes in the gastric mucosal blood flow were continuously
monitored and recorded for 2-h test periods by using the PowerLab system (Model ML845;
AD Instruments, Bella Vista, NSW, Australia).
2.4. Experimental procedures
A TRPV1 antagonist N-(4-t-butylphenyl)-4-(3-chlopyridin-2-yl) tetrahydropyrazine-1(2H)-
carboxamide (BCTC) (0.8 mmol/L, i.g.) [16], a non-selective NOS inhibitor NG-nitro-L-arginine
methyl ester (L-NAME; 5 and 10 mg/kg, i.v.), a nNOS selective inhibitor NPLA (0.02 and 0.2
mg/kg, i.v.), an eNOS selective inhibitor L-NIO (3 and 10 mg/kg, i.v.), and an iNOS selective
inhibitor 1400W (3 and 10 mg/kg, i.v.) were administered 20 min before exposing the stomach
to 2 ml of capsaicin for 10 min. In one group, L-arginine (300 mg/kg, i.v.) was administered
twice 40 min and 60 min before the application of capsaicin.




Chemical deafferentation was performed two weeks before the experiment by successive
injections of capsaicin subcutaneously once daily for 3 d (20, 30, and 50 mg/kg) [17]. All
capsaicin injections were performed under ether anesthesia, and the rats were pretreated with
the beta-adrenergic receptor agonist isoproterenol (0.01 mg/kg, i.m.) and the selective beta 1-
adrenergic antagonist atenolol (0.01 mg/kg, i.m.) to counteract the respiratory impairment
associated with capsaicin injection. To check for the effectiveness of the treatment, a drop of a
0.1 mg/ml solution of capsaicin in 0.5% carboxymethyl cellulose solution (CMC) was instilled
into one eye of each rat, and the protective wiping movements were counted [18].
2.6. Immunohistochemical study
The immunohistochemical procedures were performed as described previously [4]. The
corpora of rat stomachs were fixed by immersion in fresh 4% paraformaldehyde in 0.1 mol/l
phosphate buffer (pH 7.4) for 2 h at 4°C, and washed three times with phosphate-buffered
saline (PBS). They were cryoprotected overnight in 0.1 mol/l phosphate buffer containing 20%
sucrose. The tissues were frozen in OCT mounting medium (Sakura Finetek Europe, Zoeter‐
woude, The Netherlands), and sectioned on a cryostat (Leica, Hemel Hempstead, UK) at a
thickness of 60 µm. The tissue sections were thaw-mounted onto Superfrost Plus slides (BDH
Laboratory Supplies, Poole, UK). Prior to staining, the slide-mounted sections were incubated
in PBS containing 0.3% hydrogen peroxide for 30 min to quench endogenous peroxidase
activity and washed with PBS. The sections were successively incubated in 10% normal donkey
serum containing 0.2% Triton X-100, 0.1% sodium azide in PBS for 1 h, and polyclonal anti-
TRPV1 antibody (1:15000) for 40 h at room temperature. TRPV1 immunoreactivity was
detected using a polyclonal antiserum raised in rabbit against the carboxy terminus of rat
TRPV1 provided by Dr. David Julius. After washes in PBS, the sections were incubated with
biotinylated donkey anti-rabbit immounoglobulin G (1:400; Jackson Immunoresearch Labo‐
ratories, West Grove, PA, USA) for 90 min at room temperature. After further washes, the
sections were incubated in stretavidin biotin-peroxidase complex (1:5 in PBS; Vectastain Elite
ABC kit, Vector Laboratories, Peterborough, UK) for 1 h at room temperature followed by
fluorescein tyramide (1:75; TSA kit, PerkinElmer Life Sciences, Boston, MA, USA). In control
experiments, the TRPV1 antibody was omitted from the staining procedures to verify the
specificity of the staining. No immunolabeling was observed in these controls.
Double staining of the section with TRPV1 antiserum combined with protein gene product 9.5
(PGP 9.5) and nNOS antisera was also performed. TRPV1 staining was carried out first using
the TSA procedure with FITC, following by PGP 9.5 or nNOS staining using indirect labeling
procedure as described below. The sections were incubated for 40 h at room temperature in
the PGP 9.5 or nNOS primary antibody solution, and then washed three times for 10 min each
in PBS. To visualize the labeling, sections were then incubated for 4 h with the corresponding
secondary antibody linked to tetramethyl rhodamine isothiocyanate (TRITC, 1:400; Jackson
Immunoresearch Laboratories). Antisera were diluted in PBS containing 0.2% Triton X-100
and 0.1% sodium azide. Two sets of controls were processed for this double labeling. First, the
primary antibodies in the first and second stainings were omitted from the staining procedures.
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No immunolabeling was observed in this control. Second, only the primary antibody in the
second staining was omitted from the staining procedures. In this control, FITC labeling of
TRPV1 fibers was seen, but TRITC labeling was not.
2.7. Microscopy
Sections were viewed on either a Leica epifluorescence microscope using Y3 (TRITC) and L4
(FITC) filter blocks, or on a upright Zeiss confocal laser scanning microscope system (LSM510)
and ×20, ×40 Plan Neofluar objectives. On the latter system, single tracking mode was used for
single FITC labeling. Sections were scanned in multitracking mode (to avoid channel cross
talk) when double labeling was done with FITC (488 nm) and TRITC (543 nm). Each image
was produced by projecting all the slices of the stack onto one plane. Final plates were prepared
using Adobe Photoshop.
2.8. Statistics
The data are presented as the means ± S.E.M. from 3–7 rats per group. The statistical signifi‐
cance of differences between two groups was assessed using Student’s t-test. Multiple
comparisons against a single control group were made by a one-way analysis of variance
ANOVA with Bonferroni correction. The level of significance was set at 0.05. Sigma Stat 3.1
software (Jandel Scientific Software, San Rafael, CA, USA) procedure was applied for statistical
analysis.
3. Results
3.1. Effects of intragastric capsaicin on gastric mucosal blood flow
Intragastric capsaicin (0.33, 1, and 3.3 mmol/l) induced gastric hyperemic responses in a
concentration-dependent manner: a significant effect was observed at concentrations greater
than 1 mmol/l (Fig. 1B). The response of gastric mucosal blood flow to capsaicin (0.33, 1, and
3.3 mmol/l) during intragastric application for 10 min was 121.5 ± 2.6%, 146.4 ± 8.9%, and 178.6
± 12.9%, respectively. Interestingly, gastric mucosal blood flow in response to 3.3 mmol/l
capsaicin remained significantly high despite the removal of capsaicin from the chamber (Fig.
1A). At 20 and 50 minutes after removal of capsaicin, gastric mucosal blood flow showed a
persistent increase (about ~120–130%) as compared to pre-application values (Fig. 1C).
Mucosal application of the control solution (0.5% CMC) did not increase gastric mucosal blood
flow. Since the effect of capsaicin on gastric mucosal blood flow reached the maximum values
during the application and remained significantly elevated after removal of capsaicin at 3.3
mmol/l, this concentration was used in the following experiments for examining the effects of
various agents on the gastric mucosal blood flow in response to capsaicin.




Chemical deafferentation was performed two weeks before the experiment by successive
injections of capsaicin subcutaneously once daily for 3 d (20, 30, and 50 mg/kg) [17]. All
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activity and washed with PBS. The sections were successively incubated in 10% normal donkey
serum containing 0.2% Triton X-100, 0.1% sodium azide in PBS for 1 h, and polyclonal anti-
TRPV1 antibody (1:15000) for 40 h at room temperature. TRPV1 immunoreactivity was
detected using a polyclonal antiserum raised in rabbit against the carboxy terminus of rat
TRPV1 provided by Dr. David Julius. After washes in PBS, the sections were incubated with
biotinylated donkey anti-rabbit immounoglobulin G (1:400; Jackson Immunoresearch Labo‐
ratories, West Grove, PA, USA) for 90 min at room temperature. After further washes, the
sections were incubated in stretavidin biotin-peroxidase complex (1:5 in PBS; Vectastain Elite
ABC kit, Vector Laboratories, Peterborough, UK) for 1 h at room temperature followed by
fluorescein tyramide (1:75; TSA kit, PerkinElmer Life Sciences, Boston, MA, USA). In control
experiments, the TRPV1 antibody was omitted from the staining procedures to verify the
specificity of the staining. No immunolabeling was observed in these controls.
Double staining of the section with TRPV1 antiserum combined with protein gene product 9.5
(PGP 9.5) and nNOS antisera was also performed. TRPV1 staining was carried out first using
the TSA procedure with FITC, following by PGP 9.5 or nNOS staining using indirect labeling
procedure as described below. The sections were incubated for 40 h at room temperature in
the PGP 9.5 or nNOS primary antibody solution, and then washed three times for 10 min each
in PBS. To visualize the labeling, sections were then incubated for 4 h with the corresponding
secondary antibody linked to tetramethyl rhodamine isothiocyanate (TRITC, 1:400; Jackson
Immunoresearch Laboratories). Antisera were diluted in PBS containing 0.2% Triton X-100
and 0.1% sodium azide. Two sets of controls were processed for this double labeling. First, the
primary antibodies in the first and second stainings were omitted from the staining procedures.
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No immunolabeling was observed in this control. Second, only the primary antibody in the
second staining was omitted from the staining procedures. In this control, FITC labeling of
TRPV1 fibers was seen, but TRITC labeling was not.
2.7. Microscopy
Sections were viewed on either a Leica epifluorescence microscope using Y3 (TRITC) and L4
(FITC) filter blocks, or on a upright Zeiss confocal laser scanning microscope system (LSM510)
and ×20, ×40 Plan Neofluar objectives. On the latter system, single tracking mode was used for
single FITC labeling. Sections were scanned in multitracking mode (to avoid channel cross
talk) when double labeling was done with FITC (488 nm) and TRITC (543 nm). Each image
was produced by projecting all the slices of the stack onto one plane. Final plates were prepared
using Adobe Photoshop.
2.8. Statistics
The data are presented as the means ± S.E.M. from 3–7 rats per group. The statistical signifi‐
cance of differences between two groups was assessed using Student’s t-test. Multiple
comparisons against a single control group were made by a one-way analysis of variance
ANOVA with Bonferroni correction. The level of significance was set at 0.05. Sigma Stat 3.1
software (Jandel Scientific Software, San Rafael, CA, USA) procedure was applied for statistical
analysis.
3. Results
3.1. Effects of intragastric capsaicin on gastric mucosal blood flow
Intragastric capsaicin (0.33, 1, and 3.3 mmol/l) induced gastric hyperemic responses in a
concentration-dependent manner: a significant effect was observed at concentrations greater
than 1 mmol/l (Fig. 1B). The response of gastric mucosal blood flow to capsaicin (0.33, 1, and
3.3 mmol/l) during intragastric application for 10 min was 121.5 ± 2.6%, 146.4 ± 8.9%, and 178.6
± 12.9%, respectively. Interestingly, gastric mucosal blood flow in response to 3.3 mmol/l
capsaicin remained significantly high despite the removal of capsaicin from the chamber (Fig.
1A). At 20 and 50 minutes after removal of capsaicin, gastric mucosal blood flow showed a
persistent increase (about ~120–130%) as compared to pre-application values (Fig. 1C).
Mucosal application of the control solution (0.5% CMC) did not increase gastric mucosal blood
flow. Since the effect of capsaicin on gastric mucosal blood flow reached the maximum values
during the application and remained significantly elevated after removal of capsaicin at 3.3
mmol/l, this concentration was used in the following experiments for examining the effects of
various agents on the gastric mucosal blood flow in response to capsaicin.
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Figure 1. Effect of mucosal application of capsaicin on gastric mucosal blood flow (GMBF) in the ex vivo stomach of
anesthetized rats. Figure A shows the time course of analysis for GMBF in response to capsaicin (3.3 mmol/l) in anes‐
thetized rats. Capsaicin was topically applied to the mucosa for 10 min from time 0, and the stomach was perfused
with saline before and after the application. The data are expressed as a % increase of baseline values and represent
the means ± S.E. of values obtained every 2 or 10 min from 4 to 7 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with control (0.5% CMC). Figure B shows the maximum GMBF response during
capsaicin (0.33–3.3 mmol/l) application, and figure C shows the GMBF response at 20 and 50 min after removal of
capsaicin (0.33–3.3 mmol/l). The data are expressed as a % increase of baseline values, and represent the means ± S.E.
from 4 to 7 rats. * indicates statistically significant difference at P<0.05 compared to the group treated with control
(0.5% CMC). Note that GMBF in response to capsaicin (3.3 mmol/l) was significantly increased during application, and
remained moderately elevated even after removal of capsaicin from the chamber.
The increased gastric mucosal blood flow in animals in response to capsaicin (3.3 mmol/l) was
totally abolished in the animals when the mucosa was exposed to a TRPV1 antagonist BCTC
(0.8 mmol/l) (Fig. 2). The maximum response of gastric mucosal blood flow induced by 3.3
mmol/l capsaicin in the presence of BCTC was 102.4 ± 6.1% throughout the experiment. A
similar phenomenon was observed in the animals following chemical deafferentation by
consecutive injections of capsaicin (neurotoxic dose: total 100 mg/kg, s.c.) at two weeks before
the experiment (Fig. 2). In those animals, the gastric mucosal blood flow remained unchanged
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during and after exposure of the mucosa to capsaicin (3.3 mmol/l), the maximum response was
103.1 ± 4.2%. It was found that intragastric capsaicin produced a significant and persistent
increase in gastric mucosal blood flow via activation of TRPV1 expressed in capsaicin-sensitive
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Figure 2. Effects of BCTC, a TRPV1 antagonist, and sensory deafferentation on gastric mucosal blood flow (GMBF) in‐
duced by mucosal application of capsaicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course
of analysis for GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats treated with BCTC or sensory deafferenta‐
tion. Capsaicin was topically applied to the mucosa for 10 min and the stomach was perfused with saline before and
after the application. BCTC (0.8 mmol/l) was applied to the chamber for 30 min, starting at 20 min before the capsai‐
cin application. Chemical deafferentation (capsaicin pretreatment) was performed 2 weeks before the experiment by
consecutive injections of capsaicin s.c. once daily for 3 days (total dose: 100 mg/kg). The data are expressed as a %
increase of baseline values and represent the mean ± S.E. of values obtained every 2 or 10 min from 3 to 4 rats. * indi‐
cates statistically significant difference at P<0.05 compared to the group treated with vehicle. Figure B shows a maxi‐
mum response of GMBF induced by mucosal application of capsaicin (3.3 mmol/l). The data are expressed as a %
increase of baseline values and represent the mean ± S.E. from 3 to 4 rats. * indicates statistically significant difference
at P<0.05 compared to the group treated with vehicle. Note that increased GMBF in response to capsaicin was com‐
pletely abolished by BCTC and sensory deafferentation.
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Figure 1. Effect of mucosal application of capsaicin on gastric mucosal blood flow (GMBF) in the ex vivo stomach of
anesthetized rats. Figure A shows the time course of analysis for GMBF in response to capsaicin (3.3 mmol/l) in anes‐
thetized rats. Capsaicin was topically applied to the mucosa for 10 min from time 0, and the stomach was perfused
with saline before and after the application. The data are expressed as a % increase of baseline values and represent
the means ± S.E. of values obtained every 2 or 10 min from 4 to 7 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with control (0.5% CMC). Figure B shows the maximum GMBF response during
capsaicin (0.33–3.3 mmol/l) application, and figure C shows the GMBF response at 20 and 50 min after removal of
capsaicin (0.33–3.3 mmol/l). The data are expressed as a % increase of baseline values, and represent the means ± S.E.
from 4 to 7 rats. * indicates statistically significant difference at P<0.05 compared to the group treated with control
(0.5% CMC). Note that GMBF in response to capsaicin (3.3 mmol/l) was significantly increased during application, and
remained moderately elevated even after removal of capsaicin from the chamber.
The increased gastric mucosal blood flow in animals in response to capsaicin (3.3 mmol/l) was
totally abolished in the animals when the mucosa was exposed to a TRPV1 antagonist BCTC
(0.8 mmol/l) (Fig. 2). The maximum response of gastric mucosal blood flow induced by 3.3
mmol/l capsaicin in the presence of BCTC was 102.4 ± 6.1% throughout the experiment. A
similar phenomenon was observed in the animals following chemical deafferentation by
consecutive injections of capsaicin (neurotoxic dose: total 100 mg/kg, s.c.) at two weeks before
the experiment (Fig. 2). In those animals, the gastric mucosal blood flow remained unchanged
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during and after exposure of the mucosa to capsaicin (3.3 mmol/l), the maximum response was
103.1 ± 4.2%. It was found that intragastric capsaicin produced a significant and persistent
increase in gastric mucosal blood flow via activation of TRPV1 expressed in capsaicin-sensitive
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Figure 2. Effects of BCTC, a TRPV1 antagonist, and sensory deafferentation on gastric mucosal blood flow (GMBF) in‐
duced by mucosal application of capsaicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course
of analysis for GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats treated with BCTC or sensory deafferenta‐
tion. Capsaicin was topically applied to the mucosa for 10 min and the stomach was perfused with saline before and
after the application. BCTC (0.8 mmol/l) was applied to the chamber for 30 min, starting at 20 min before the capsai‐
cin application. Chemical deafferentation (capsaicin pretreatment) was performed 2 weeks before the experiment by
consecutive injections of capsaicin s.c. once daily for 3 days (total dose: 100 mg/kg). The data are expressed as a %
increase of baseline values and represent the mean ± S.E. of values obtained every 2 or 10 min from 3 to 4 rats. * indi‐
cates statistically significant difference at P<0.05 compared to the group treated with vehicle. Figure B shows a maxi‐
mum response of GMBF induced by mucosal application of capsaicin (3.3 mmol/l). The data are expressed as a %
increase of baseline values and represent the mean ± S.E. from 3 to 4 rats. * indicates statistically significant difference
at P<0.05 compared to the group treated with vehicle. Note that increased GMBF in response to capsaicin was com‐
pletely abolished by BCTC and sensory deafferentation.
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3.2. Effects of L-NAME, a non-selective NOS inhibitor, and combined treatment with L-
arginine on gastric mucosal blood flow in response to capsaicin
Gastric mucosal blood flow was temporarily increased after the injection of L-NAME was
injected but immediately returned to the baseline value (Fig. 3A). The increase in gastric
mucosal blood flow in response to capsaicin (3.3 mmol/l) seen in control rats apparently
attenuated by L-NAME in a dose-dependent manner. The maximum response of gastric
mucosal blood flow in response to capsaicin in animals treated with L-NAME (5 and 10
mg/kg) was 138.8 ± 11.6% and 125.6 ± 11.6%, respectively (Fig.3B). The administration of 300
mg/kg L-arginine, a substrate for NOS, twice reversed the inhibitory effects of L-NAME (10
mg/kg) on gastric hyperemic response both during and after removal of capsaicin (Fig. 3).
Thus, gastric hyperemia in response to capsaicin was attributable to both NO-dependent
hyperemia during the application, followed by NO-dependent hyperemia alone after removal
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Figure 3. Effects of L-NAME, a non-selective NOS inhibitor, and combined treatment with L-arginine (300 mg/kg, x2)
on gastric mucosal blood flow (GMBF) induced by mucosal application of capsaicin in the ex vivo stomach of anesthe‐
tized rats. Figure A shows the time course of analysis for GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats
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pretreated with L-NAMA and L-arginine. Capsaicin (3.3 mmol/l) was topically applied to the mucosa for 10 min and
the stomach was perfused with saline before and after the application. L-NAME (5 and 10 mg/kg) was given via intra‐
venous injection 20 min before capsaicin application. L-NAME by itself showed the temporary increase of GMBF when
was injected, but immediately returned to baseline value. L-arginine (300 mg/kg) was given via intravenous injection
40 and 60 min before capsaicin application. The data are expressed as a % increase of baseline values and represent
the means ± S.E. of values obtained every 2 or 10 min from 4 to 5 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum response of GMBF during
capsaicin (3.3 mmol/l) application in animals with L-NAME (5 and 10 mg/kg) or L-NAME (10 mg/kg) plus L-arginine
(300 mg/kg, x2). Figure C shows a response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with L-
NAME (5 and 10 mg/kg) or L-NAME (10 mg/kg) plus L-arginine (300 mg/kg, x2). The data are expressed as a % in‐
crease of baseline values and represent the mean ± S.E. from 4 to 5 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with vehicle (saline). Note that increased GMBF during and after removal of
capsaicin was significantly inhibited by L-NAME (10 mg/kg), whose response was reversed by pretreatment with L-
arginine (300 mg/kg, x2).
3.3. Effect of NPLA, a selective nNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
The roles of different isoforms of NOS in the gastric hyperemia induced by capsaicin were
investigated by using selective NOS inhibitors including a nNOS inhibitor NPLA, an eNOS
inhibitor L-NIO, and an iNOS inhibitor 1400W. Administration of the nNOS-specific inhibitor
NPLA alone did not significantly affect gastric mucosal blood flow (Fig. 4A). Interestingly, the
increase in gastric mucosal blood flow in response to capsaicin (3.3 mmol/l) during the
application, but not after removal, was apparently decreased by 0.2 mg/kg NPLA. The
maximum responses of gastric mucosal blood flow during capsaicin application in animals
treated with NPLA (0.02 and 0.2 mg/kg) were 182.1 ± 26.6% and 141.9 ± 8.9%, respectively (Fig.
4B). In contrast, the persistent increase in gastric mucosal blood flow after removal of capsaicin
was not affected by NPLA (0.2 mg/kg), with the responses being 138.3 ± 17.3% and 126.5 ±
15.1%, respectively (Fig. 4C).
3.4. Effect of L-NIO, a selective eNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
Administration of the selective eNOS inhibitor L-NIO (10 mg/kg) by itself temporarily
increased gastric mucosal blood flow, but the gastric mucosal blood flow immediately returned
to the baseline value (Fig. 5A). The gastric hyperemic response after treatment with capsaicin
during the application was not significantly affected by L-NIO (3 and 10 mg/kg), and the
maximum responses being 158.7 ± 8.4% and 160.0 ± 9.6%, respectively (Fig. 5B). However, the
persistent increase in gastric mucosal blood flow after removal of capsaicin was obviously
attenuated by L-NIO (10 mg/kg) (Fig. 5A, C). In treatment with L-NIO (10 mg/kg), the gastric
mucosal blood flow responses at 20 and 50 min after removal of capsaicin were 96.2 ± 7.2%
and 89.5 ± 6.2%, respectively.
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3.2. Effects of L-NAME, a non-selective NOS inhibitor, and combined treatment with L-
arginine on gastric mucosal blood flow in response to capsaicin
Gastric mucosal blood flow was temporarily increased after the injection of L-NAME was
injected but immediately returned to the baseline value (Fig. 3A). The increase in gastric
mucosal blood flow in response to capsaicin (3.3 mmol/l) seen in control rats apparently
attenuated by L-NAME in a dose-dependent manner. The maximum response of gastric
mucosal blood flow in response to capsaicin in animals treated with L-NAME (5 and 10
mg/kg) was 138.8 ± 11.6% and 125.6 ± 11.6%, respectively (Fig.3B). The administration of 300
mg/kg L-arginine, a substrate for NOS, twice reversed the inhibitory effects of L-NAME (10
mg/kg) on gastric hyperemic response both during and after removal of capsaicin (Fig. 3).
Thus, gastric hyperemia in response to capsaicin was attributable to both NO-dependent
hyperemia during the application, followed by NO-dependent hyperemia alone after removal
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Figure 3. Effects of L-NAME, a non-selective NOS inhibitor, and combined treatment with L-arginine (300 mg/kg, x2)
on gastric mucosal blood flow (GMBF) induced by mucosal application of capsaicin in the ex vivo stomach of anesthe‐
tized rats. Figure A shows the time course of analysis for GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats
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pretreated with L-NAMA and L-arginine. Capsaicin (3.3 mmol/l) was topically applied to the mucosa for 10 min and
the stomach was perfused with saline before and after the application. L-NAME (5 and 10 mg/kg) was given via intra‐
venous injection 20 min before capsaicin application. L-NAME by itself showed the temporary increase of GMBF when
was injected, but immediately returned to baseline value. L-arginine (300 mg/kg) was given via intravenous injection
40 and 60 min before capsaicin application. The data are expressed as a % increase of baseline values and represent
the means ± S.E. of values obtained every 2 or 10 min from 4 to 5 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum response of GMBF during
capsaicin (3.3 mmol/l) application in animals with L-NAME (5 and 10 mg/kg) or L-NAME (10 mg/kg) plus L-arginine
(300 mg/kg, x2). Figure C shows a response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with L-
NAME (5 and 10 mg/kg) or L-NAME (10 mg/kg) plus L-arginine (300 mg/kg, x2). The data are expressed as a % in‐
crease of baseline values and represent the mean ± S.E. from 4 to 5 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with vehicle (saline). Note that increased GMBF during and after removal of
capsaicin was significantly inhibited by L-NAME (10 mg/kg), whose response was reversed by pretreatment with L-
arginine (300 mg/kg, x2).
3.3. Effect of NPLA, a selective nNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
The roles of different isoforms of NOS in the gastric hyperemia induced by capsaicin were
investigated by using selective NOS inhibitors including a nNOS inhibitor NPLA, an eNOS
inhibitor L-NIO, and an iNOS inhibitor 1400W. Administration of the nNOS-specific inhibitor
NPLA alone did not significantly affect gastric mucosal blood flow (Fig. 4A). Interestingly, the
increase in gastric mucosal blood flow in response to capsaicin (3.3 mmol/l) during the
application, but not after removal, was apparently decreased by 0.2 mg/kg NPLA. The
maximum responses of gastric mucosal blood flow during capsaicin application in animals
treated with NPLA (0.02 and 0.2 mg/kg) were 182.1 ± 26.6% and 141.9 ± 8.9%, respectively (Fig.
4B). In contrast, the persistent increase in gastric mucosal blood flow after removal of capsaicin
was not affected by NPLA (0.2 mg/kg), with the responses being 138.3 ± 17.3% and 126.5 ±
15.1%, respectively (Fig. 4C).
3.4. Effect of L-NIO, a selective eNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
Administration of the selective eNOS inhibitor L-NIO (10 mg/kg) by itself temporarily
increased gastric mucosal blood flow, but the gastric mucosal blood flow immediately returned
to the baseline value (Fig. 5A). The gastric hyperemic response after treatment with capsaicin
during the application was not significantly affected by L-NIO (3 and 10 mg/kg), and the
maximum responses being 158.7 ± 8.4% and 160.0 ± 9.6%, respectively (Fig. 5B). However, the
persistent increase in gastric mucosal blood flow after removal of capsaicin was obviously
attenuated by L-NIO (10 mg/kg) (Fig. 5A, C). In treatment with L-NIO (10 mg/kg), the gastric
mucosal blood flow responses at 20 and 50 min after removal of capsaicin were 96.2 ± 7.2%
and 89.5 ± 6.2%, respectively.
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Figure 4. Effect of NPLA, a selective neuronal NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by capsai‐
cin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of the effect of NPLA (0.2 mg/kg) on
GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was topically applied to the mu‐
cosa for 10 min and the stomach was perfused with saline before and after the application. NPLA (0.2 mg/kg) was
given via intravenous injection 20 min before capsaicin application. The data are expressed as a % increase of baseline
values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. * indicates statistically signifi‐
cant difference at P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum response
of GMBF response during capsaicin (3.3 mmol/l) application in animals with NPLA (0.02 and 0.2 mg/kg). Figure C
shows a response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with NPLA (0.02 and 0.2 mg/kg).
The data are expressed as a % increase of baseline values and represent the means ± SE from 4 to 5 rats. * indicates
statistically significant difference at P<0.05 compared to the group treated with vehicle (saline). Note that increased
GMBF during capsaicin application was inhibited by NPLA, yet persistent increase in GMBF after removal of capsaicin
was not affected by NPLA.
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Figure 5. Effect of L-NIO, a selective endothelial NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by cap‐
saicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of analysis for the effect of L-NIO (10
mg/kg) on GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was applied topically
to the mucosa for 10 min and the stomach was perfused with saline before and after the application. L-NIO (10
mg/kg) was injected intravenously 20 min before capsaicin application. L-NIO by itself induced a temporary increase
of GMBF when injected, but it immediately returned to baseline value. The data are expressed as a % increase of base‐
line values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. * indicates statistically
significant difference at P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum re‐
sponse of GMBF response during capsaicin (3.3 mmol/l) application in animals with L-NIO (3 and 10 mg/kg). Figure C
shows the response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with L-NIO (3 and 10 mg/kg).
The data are expressed as a % increase of baseline values and represent the means ± S.E. from 4–5 rats. * indicates
statistically significant difference at P<0.05 compared to the group treated with the vehicle (saline). Note that L-NIO
significantly inhibited persistent increase of GMBF after removal of capsaicin, although GMBF response during capsai‐
cin application was not affected by L-NIO.
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Figure 4. Effect of NPLA, a selective neuronal NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by capsai‐
cin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of the effect of NPLA (0.2 mg/kg) on
GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was topically applied to the mu‐
cosa for 10 min and the stomach was perfused with saline before and after the application. NPLA (0.2 mg/kg) was
given via intravenous injection 20 min before capsaicin application. The data are expressed as a % increase of baseline
values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. * indicates statistically signifi‐
cant difference at P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum response
of GMBF response during capsaicin (3.3 mmol/l) application in animals with NPLA (0.02 and 0.2 mg/kg). Figure C
shows a response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with NPLA (0.02 and 0.2 mg/kg).
The data are expressed as a % increase of baseline values and represent the means ± SE from 4 to 5 rats. * indicates
statistically significant difference at P<0.05 compared to the group treated with vehicle (saline). Note that increased
GMBF during capsaicin application was inhibited by NPLA, yet persistent increase in GMBF after removal of capsaicin
was not affected by NPLA.
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Figure 5. Effect of L-NIO, a selective endothelial NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by cap‐
saicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of analysis for the effect of L-NIO (10
mg/kg) on GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was applied topically
to the mucosa for 10 min and the stomach was perfused with saline before and after the application. L-NIO (10
mg/kg) was injected intravenously 20 min before capsaicin application. L-NIO by itself induced a temporary increase
of GMBF when injected, but it immediately returned to baseline value. The data are expressed as a % increase of base‐
line values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. * indicates statistically
significant difference at P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum re‐
sponse of GMBF response during capsaicin (3.3 mmol/l) application in animals with L-NIO (3 and 10 mg/kg). Figure C
shows the response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with L-NIO (3 and 10 mg/kg).
The data are expressed as a % increase of baseline values and represent the means ± S.E. from 4–5 rats. * indicates
statistically significant difference at P<0.05 compared to the group treated with the vehicle (saline). Note that L-NIO
significantly inhibited persistent increase of GMBF after removal of capsaicin, although GMBF response during capsai‐
cin application was not affected by L-NIO.
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3.5. Effect of 1400W, a selective iNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
Gastric mucosal blood flow remained unchanged by the administration of an iNOS selective
inhibitor 1400W (10 mg/kg) (Fig. 6). In addition, the increased gastric mucosal blood flow I
response to capsaicin was not also affected by 1400W (3 and 10 mg/kg) (Fig. 6).
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Figure 6. Effect of 1400W, a selective inducible NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by cap‐
saicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of analysis for the effect of 1400W
(10 mg/kg) on GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was topically ap‐
plied to the mucosa for 10 min and the stomach was perfused with saline before and after the application. 1400W (3
and 10 mg/kg) was given via intravenous injection 20 min before capsaicin application. The data are expressed as a %
increase of baseline values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. Figure B
shows the maximum response of GMBF response during capsaicin (3.3 mmol/l) application in animals treated with
1400W (3 and 10 mg/kg). Figure C shows the responses of GMBF (3.3 mmol/l) at 20 and 50 min after removal of cap‐
saicin. The data are expressed as a % increase of baseline values and represent the mean ± S.E. from 4 to 5 rats. Note
that increased GMBF in response to capsaicin was not affected by 1400W.
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3.6. TRPV1-immunoreactivity in corpus and antrum of stomach
Extensive TRPV1-immunoreactivity was detected in fundus, corpus and antrum of the
stomach [4, 19]. Immunoreactivity was present in all layers of the corpus and in all cases
appeared axon-like in nature (Fig. 7A). This identification was confirmed by double labeling
with the pan axonal marker PGP 9.5, which confirmed that all TRPV1 immunoreactive
structures were also PGP 9.5 immunoreactive (Figure 7C). However, not all PGP 9.5-immu‐
noreactive fibers were TRPV1-immunoreactive, reflecting the fact that only a subpopulation
of neural elements in the stomach expresses TRPV1. TRPV1 immunoreactivity was also not
seen in the PGP 9.5 immunoreactive cell bodies of the myenteric plexus or submucosal plexus.
In control experiments, TRPV1-immunoreactivity was not observed in any corpus sections
processed without the primary antibody. Similar observation was obtained in all layers of















Figure 7. Distribution of TRPV1-immunoreactivity in corpus of rat stomach. mu: mucosa; su: submucosa; cm: circular
muscle. (A) A low magnification image showing that TRPV1-immunoractivity is present in all layers of corpus. Asterisk
indicates a blood vessel. (B) A high magnification image showing that TRPV1-immunoractivity is present in submucos‐
al and muscular layers of corpus. TRPV1-immunoreactive fibers are observed associated with small blood vessels (as‐
terisk) or along and in the lamina muscularis mucosae. Numerous TRPV1-immunoreactive fibers are found around
blood vessels (asterisks) in the submucosal layer. TRPV1-immunoreactive axons are sparse in longitudinal smooth mus‐
cle but isolated varicose fibers are present. Fibers are abundant in circular muscle layer where they run parallel to mus‐
cle fibers. A large number of nerve fibers are seen in circular smooth muscle layer and in the myenteric nerve plexus.
(C) Co-localization of TRPV1-positive neurons with protein gene product 9.5 (PGP 9.5) in corpus submucosa. Rat stom‐
ach sections were dual-labelled with TRPV1 in green and PGP 9.5 in red. Merged image is shown in (C). Arrows indi‐
cate the co-localization of TRPV1 immunoreactivity with PGP 9.5 immunoreactivity. All TRPV1 immunoreactive
structures are PGP 9.5 immunoreactive. Note that in circular smooth muscle, the TRPV1 immunoreactive axons repre‐
sent a relatively small population of the total population of PGP 9.5 immunoreactive axons. Scale bars are 100 µm in
(A) and 50 µm in (B), (C).
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3.5. Effect of 1400W, a selective iNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
Gastric mucosal blood flow remained unchanged by the administration of an iNOS selective
inhibitor 1400W (10 mg/kg) (Fig. 6). In addition, the increased gastric mucosal blood flow I
response to capsaicin was not also affected by 1400W (3 and 10 mg/kg) (Fig. 6).
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Figure 6. Effect of 1400W, a selective inducible NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by cap‐
saicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of analysis for the effect of 1400W
(10 mg/kg) on GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was topically ap‐
plied to the mucosa for 10 min and the stomach was perfused with saline before and after the application. 1400W (3
and 10 mg/kg) was given via intravenous injection 20 min before capsaicin application. The data are expressed as a %
increase of baseline values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. Figure B
shows the maximum response of GMBF response during capsaicin (3.3 mmol/l) application in animals treated with
1400W (3 and 10 mg/kg). Figure C shows the responses of GMBF (3.3 mmol/l) at 20 and 50 min after removal of cap‐
saicin. The data are expressed as a % increase of baseline values and represent the mean ± S.E. from 4 to 5 rats. Note
that increased GMBF in response to capsaicin was not affected by 1400W.
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The TRPV1-immunoreactive varicose fibers were present in the mucosa along gastric glands
of corpus and antrum, although Ward et al. (2003) did not observe TRPV1 immunoreactive
fibers that penetrate the mucosa [20]. A few TRPV1-immunoreactive varicose nerve fibers were
observed in the lamina propria, mainly in association with small vessels or along the muscu‐
laris mucosae of antrum and corpus [4, 19]. Numerous TRPV1-immunoreactive axons were
also found around arterioles in the submucosal layer. A dense TRPV1-innervation of the
submucosal blood vessels was seen running along the major arterioles (Fig. 7B). Occasionally
fibers formed baskets around the vessels [4].
3.7. Coexistence of TRPV1 and nNOS
Many TRPV1 axons were also observed to be immunoreactive for nNOS (Figure 8). A few
axons of this type were present in the mucosa and smooth muscle layers but were particularly
abundant in the vicinity of blood vessels in the submucosa [21]. Numerous TRPV1-immunor‐





Figure 8. Confocal images showing co-localization of TRPV1-and neuronal NOS-immnuoreactivities in corpus submu‐
cosa and muscle. Labeling for TRPV1 (A: green) and neuronal NOS (B: red) is shown separately, and merged in (C).
Double immunolabeling for TRPV1 and neuronal NOS demonstrated co-localization in many but not all axons. This
photo shows abundant TRPV1 axons containing neuronal NOS in the submucosa, with a high density of immounor‐
eactive axons around blood vessels (asterisk). mu: mucosa; sm: submucosa; cm: circular muscle. Scale bars is 100 µm.
4. Discussion
This report showed that intragastric application of capsaicin facilitates an initial increase in
gastric mucosal blood flow by NO mainly derived from nNOS after stimulating capsaicin-
sensitive sensory nerves, and also the persistent increase in gastric mucosal blood flow after
removal of capsaicin is attributed to eNOS/NO in the rat stomach.
Topical application of capsaicin causes dilatation of the submucosal and mucosal arterioles in
the rat stomach [22, 23], but it has not been fully elucidated how capsaicin really activates
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primary afferent vasodilator neurons in the stomach. Primary afferent neurons express TRPV
1 channels, which mediates the gastrointestinal vasodilator effect of capsaicin. By the use of
the TRPV1 blocker BCTC, it was found that this TRPV1 channels appear to participate in the
capsaicin-induced hyperemia in the rat stomach [21]. Nerve-selective ablation of capsaicin-
sensitive afferent neurons has revealed that the mucosal hyperemic response to local capsaicin
administration in the rat stomach is mediated by primary afferent vasodilator neurons that
originate in the dorsal root ganglia. It was inferred that the capsaicin-induced increase of blood
flow is relayed entirely by a peripheral reflex circuit via the TRPV1 activation. The gastric
hyperemic response to capsaicin results from an axon reflex between mucosal and submucosal
collaterals of afferent neurons [24]. Evidence for an axon reflex-type innervation has been
found in submucosal arterioles of the guinea pig ileum in which focal application of capsaicin
evokes vasodilatation that spreads beyond the application site [25].
It is known that NO, the endothelium-derived vasodilator, plays an important role in the
regulation of the resting gastric mucosal microcirculation [26, 27]. Indeed, an increase in both
systemic arterial blood pressure and gastric mucosal blood flow was observed under physio‐
logical conditions in rats after a bolus administration of L-NAME.
The gastric mucosal blood flow responses to capsaicin were markedly inhibited by a non-
selective NOS inhibitor L-NAME, which indicated that NO is mainly involved in those
hyperemic responses. However, L-NAME did not completely inhibit the increases in gastric
mucosal blood flow as much as BCTC. This result suggests that gastric mucosal hyperemia in
response to capsaicin is attributable not only to NO but also to other mediators including CGRP
and prostaglandins (PGs). Several studies have shown that endogenous PGs, contributes to
gastric hyperemic responses to capsaicin by sensitizing TRPV1-expressing afferent nerves,
which was revealed by the treatment of indomethacin (5 mg/kg, s.c.) and the animals lacking
IP receptors [28]. In addition, Chen et al. reported the interaction of NO and CGRP in gastric
vasodilation through sensory nerves [14]. Our results can be explained on the basis of the
previous findings that BCTC functionally antagonizes the action of capsaicin at the peripheral
terminals of sensory nerves and inhibits the release of some transmitters such as CGRP and
NO from capsaicin-sensitive afferent nerves. Further, the submucosal application of CGRP
induced dose-dependent dilation of gastric submucosal arterioles, which was significantly
decreased by L-NAME [23]. However, the dilation induced by submucosal CGRP was
decreased to a much lesser degree by inhibition of NO synthesis than that induced with
intragastric capsaicin [14]. This indicates that NO released by CGRP is not the only source of
submucosal NO in capsaicin-induced vasodilation, and there may be other source of submu‐
cosal NO, such as from nitroxidergic nerves that has not been determined thus far [29]. The
existence of capsaicin-sensitive nitroxidergic nerves is hypothesized by some reports, but it
was not proved [6].
NO is synthesized from L-arginine by NOS in various cells. NOS is present not only in vascular
endothelial cells (eNOS) but also in perivascular nerves (nNOS) [10, 30]. It is well known that
NO is a vasodilator that increases gastric mucosal blood flow, and this gas mediator is
important in the modulation of gastric mucosal integrity through interaction with sensory
nerves [6]. The increase in gastric mucosal blood flow responses to capsaicin is mitigated by
Cooperative Effects of Neuronal Nitric Oxide Synthase and Endothelial Nitric Oxide Synthase on Gastric Hyperemic
http://dx.doi.org/10.5772/58557
117
The TRPV1-immunoreactive varicose fibers were present in the mucosa along gastric glands
of corpus and antrum, although Ward et al. (2003) did not observe TRPV1 immunoreactive
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observed in the lamina propria, mainly in association with small vessels or along the muscu‐
laris mucosae of antrum and corpus [4, 19]. Numerous TRPV1-immunoreactive axons were
also found around arterioles in the submucosal layer. A dense TRPV1-innervation of the
submucosal blood vessels was seen running along the major arterioles (Fig. 7B). Occasionally
fibers formed baskets around the vessels [4].
3.7. Coexistence of TRPV1 and nNOS
Many TRPV1 axons were also observed to be immunoreactive for nNOS (Figure 8). A few
axons of this type were present in the mucosa and smooth muscle layers but were particularly
abundant in the vicinity of blood vessels in the submucosa [21]. Numerous TRPV1-immunor‐





Figure 8. Confocal images showing co-localization of TRPV1-and neuronal NOS-immnuoreactivities in corpus submu‐
cosa and muscle. Labeling for TRPV1 (A: green) and neuronal NOS (B: red) is shown separately, and merged in (C).
Double immunolabeling for TRPV1 and neuronal NOS demonstrated co-localization in many but not all axons. This
photo shows abundant TRPV1 axons containing neuronal NOS in the submucosa, with a high density of immounor‐
eactive axons around blood vessels (asterisk). mu: mucosa; sm: submucosa; cm: circular muscle. Scale bars is 100 µm.
4. Discussion
This report showed that intragastric application of capsaicin facilitates an initial increase in
gastric mucosal blood flow by NO mainly derived from nNOS after stimulating capsaicin-
sensitive sensory nerves, and also the persistent increase in gastric mucosal blood flow after
removal of capsaicin is attributed to eNOS/NO in the rat stomach.
Topical application of capsaicin causes dilatation of the submucosal and mucosal arterioles in
the rat stomach [22, 23], but it has not been fully elucidated how capsaicin really activates
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside116
primary afferent vasodilator neurons in the stomach. Primary afferent neurons express TRPV
1 channels, which mediates the gastrointestinal vasodilator effect of capsaicin. By the use of
the TRPV1 blocker BCTC, it was found that this TRPV1 channels appear to participate in the
capsaicin-induced hyperemia in the rat stomach [21]. Nerve-selective ablation of capsaicin-
sensitive afferent neurons has revealed that the mucosal hyperemic response to local capsaicin
administration in the rat stomach is mediated by primary afferent vasodilator neurons that
originate in the dorsal root ganglia. It was inferred that the capsaicin-induced increase of blood
flow is relayed entirely by a peripheral reflex circuit via the TRPV1 activation. The gastric
hyperemic response to capsaicin results from an axon reflex between mucosal and submucosal
collaterals of afferent neurons [24]. Evidence for an axon reflex-type innervation has been
found in submucosal arterioles of the guinea pig ileum in which focal application of capsaicin
evokes vasodilatation that spreads beyond the application site [25].
It is known that NO, the endothelium-derived vasodilator, plays an important role in the
regulation of the resting gastric mucosal microcirculation [26, 27]. Indeed, an increase in both
systemic arterial blood pressure and gastric mucosal blood flow was observed under physio‐
logical conditions in rats after a bolus administration of L-NAME.
The gastric mucosal blood flow responses to capsaicin were markedly inhibited by a non-
selective NOS inhibitor L-NAME, which indicated that NO is mainly involved in those
hyperemic responses. However, L-NAME did not completely inhibit the increases in gastric
mucosal blood flow as much as BCTC. This result suggests that gastric mucosal hyperemia in
response to capsaicin is attributable not only to NO but also to other mediators including CGRP
and prostaglandins (PGs). Several studies have shown that endogenous PGs, contributes to
gastric hyperemic responses to capsaicin by sensitizing TRPV1-expressing afferent nerves,
which was revealed by the treatment of indomethacin (5 mg/kg, s.c.) and the animals lacking
IP receptors [28]. In addition, Chen et al. reported the interaction of NO and CGRP in gastric
vasodilation through sensory nerves [14]. Our results can be explained on the basis of the
previous findings that BCTC functionally antagonizes the action of capsaicin at the peripheral
terminals of sensory nerves and inhibits the release of some transmitters such as CGRP and
NO from capsaicin-sensitive afferent nerves. Further, the submucosal application of CGRP
induced dose-dependent dilation of gastric submucosal arterioles, which was significantly
decreased by L-NAME [23]. However, the dilation induced by submucosal CGRP was
decreased to a much lesser degree by inhibition of NO synthesis than that induced with
intragastric capsaicin [14]. This indicates that NO released by CGRP is not the only source of
submucosal NO in capsaicin-induced vasodilation, and there may be other source of submu‐
cosal NO, such as from nitroxidergic nerves that has not been determined thus far [29]. The
existence of capsaicin-sensitive nitroxidergic nerves is hypothesized by some reports, but it
was not proved [6].
NO is synthesized from L-arginine by NOS in various cells. NOS is present not only in vascular
endothelial cells (eNOS) but also in perivascular nerves (nNOS) [10, 30]. It is well known that
NO is a vasodilator that increases gastric mucosal blood flow, and this gas mediator is
important in the modulation of gastric mucosal integrity through interaction with sensory
nerves [6]. The increase in gastric mucosal blood flow responses to capsaicin is mitigated by
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NG-monomethyl L-arginine, and the gastroprotection induced by capsaicin is also decreased
by the NOS inhibitor [8, 31]. Previous studies have shown that gastric hyperemia caused by
acid back-diffusion or exogenous CGRP is mediated partly by NO, but which NOS isoform is
involved in those hyperemic responses has not been investigated in any of the studies thus far.
In addition, the source of NO involved in the actions of capsaicin was not identified [29]. That
is because highly selective inhibitors for NOS isoforms had not been developed at that time.
We investigated which NOS isoform mediates the increased gastric mucosal blood flow in
response to capsaicin by using newly developed NOS inhibitors.
In this study, NPLA and L-NIO were adopted as selective nNOS and eNOS inhibitors,
respectively. It was reported that the potency of inhibition for nNOS by NPLA is 3158 times
that for iNOS and 149-fold that for eNOS, whose selectivity for nNOS/iNOS and nNOS/eNOS
are ratio of the inverse of IC50 values [32, 33]. L-NIO and 1400W were also reported to be as
selective inhibitors for eNOS and iNOS, respectively [34, 35].
Intravenous injection of L-NIO alone of L-NAME alone produced a temporary increase in
gastric mucosal blood flow, although intravenous injection of NPLA did not affect the gastric
mucosal blood flow. Therefore, eNOS-derived NO homeostatically regulates gastric mucosal
blood flow under physiological conditions. In the increased gastric mucosal blood flow in
responses to capsaicin, NPLA significantly decreased the maximum response of gastric
mucosal blood flow during the application of capsaicin, but NPLA did not affect the increase
in gastric mucosal blood flow after removal of capsaicin. In contrast, L-NIO significantly
decreased gastric mucosal blood flow responses after removal of capsaicin, but did not affect
the maximum response of gastric mucosal blood flow induced by capsaicin during the
application. These results suggested that nNOS/NO, which may be released from TRPV1-
expressing nerves stimulated by capsaicin, plays an important role in gastric hyperemia during
the luminal application of capsaicin (as in the early phase). eNOS/NO plays a role in regulating
gastric mucosal blood flow responses after removal of capsaicin (as in the late phase). On the
other hand, intravenous injection of 1400W did not affect the baseline value of gastric mucosal
blood flow as well as the increase in gastric mucosal blood flow in response to capsaicin.
Our results were consistent with those reported previously that eNOS was expressed mostly
in the vasculature throughout the gastric mucosa in rats, but the expression of iNOS was hardly
observed in the gastric mucosa of normal rats by using immunohistochemical analysis [11,
12]. These findings support our hypothesis that eNOS/NO plays a role in the resting state
responses of gastric mucosal blood flow in the late phase, while iNOS/NO plays no role in the
increased GMBF in response to capsaicin.
In our immunohistochemical studies, TRPV1 immunoreactivity was detected in mucosal and
submucosal layers of the corpus of the rat stomach. Many TRPV1 nerve fibers contain nNOS,
but not all axons do. In addition, numerous TRPV1-immunoreactive axons were also found
around arterioles in the submucosal layer. These data led us to speculate that the capsaicin-
induced increase in gastric mucosal blood flow could be attributed to the time-dependent
interaction of both nNOS/NO and eNOS/NO. Namely, it is suggested that capsaicin stimulates
TRPV1 nerves and releases CGRP and NO from the sensory nerve endings. The NO is
immediately provided by nNOS and dilates the blood vessels in the early phase. On the other
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hand, NO derived from eNOS, but not nNOS, maintains the persistent dilation of the blood



















Figure 9. Putative mechanism underlying increase of gastric mucosal blood flow due to activation of TRPV1 channels.
Capsaicin increases blood flow in the rat stomach by a peripheral axon reflex-like circuit. Capsaicin excites primary af‐
ferent neurons that originate in the dorsal root ganglia and that arborize into several branches that innervate mucosa
and submucosal arterioles. The reflex hyperemia is mediated by calcitonin gene-related peptide (CGRP) and nitric ox‐
ide (NO) that form most likely in the endothelium. The involvement of NO derived from nNOS in hyperemia is newly
clarified. The primary afferent neurons release NO/nNOS to dilate blood vessels.
Stimulation of sensory nerves leads to gastric hyperemic response, which is mediated partly
by NO formation, but it is not clear whether the NO is derived solely from endothelial cells or
is also released directly by extrinsic and/or intrinsic nerves [6, 14]. We have reported that
abundant TRPV1 axons containing nNOS in the submucosa with a high density of immunor‐
eactive axons around blood vessels [21]. Therefore, our study suggests that capsaicin is likely
to induce vasodilatation by inducing NO release from TRPV1-expressing sensory fibers.
5. Conclusion
The mucosal application of capsaicin increased gastric mucosal blood flow by releasing NO
derived from nNOS after stimulating capsaicin-sensitive sensory nerves. The contribution of
nNOS-derived NO in gastric hyperemic responses to the activation of TRPV1 by capsaicin has
been reported using not only pharmacological but also immunohistochemical techniques. We
also demonstrated the interaction between nNOS/NO and eNOS/NO on the increased gastric
mucosal blood flow by capsaicin in time-dependently, whose hyperemic responses were
composed of the both nNOS/NO in the early phase and eNOS/NO in the late phase.
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in the vasculature throughout the gastric mucosa in rats, but the expression of iNOS was hardly
observed in the gastric mucosa of normal rats by using immunohistochemical analysis [11,
12]. These findings support our hypothesis that eNOS/NO plays a role in the resting state
responses of gastric mucosal blood flow in the late phase, while iNOS/NO plays no role in the
increased GMBF in response to capsaicin.
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1. Introduction
Gastric mucosal integrity is maintained by multiple factors, including both paracrine and
neuronal factors [1-4]. The former includes prostaglandins (PGs) [1] and nitric oxide (NO) [2],
while capsaicin-sensitive afferent neurons play a central role in neuronal protection in the
stomach [3]. Previous studies demonstrated that capsaicin, a selective stimulator of these
afferent neurons, protected the gastric mucosa against various ulcerogenic stimuli such as
nectrotizing agents [3]. The protective effects of capsaicin were shown to be mediated by these
afferent neurons because they were completely attenuated by the chemical ablation of these
neurons following a pretreatment with a large dose of capsaicin [3, 5]. The binding site of
capsaicin has been cloned and named the transient receptor potential vaniloid type 1 receptor
(TRPV1), a nonselective cationic channel [6]. Capsaicin is assumed to stimulate these afferent
neurons by activating TRPV1, which results in the liberation of the neurotransmitter, calcitonin
gene-related peptide (CGRP) and gastric protection.
Several studies, including our own, have showed that the protective effects of capsaicin were
mitigated by the prior administration of indomethacin, which indicated the involvement of
endogenous PGs in this action [6-9]. Endogenous PGs were previously shown to sensitize
sensory neurons to nociceptive stimuli [10, 11]. Therefore, endogenous PGs are assumed to
play a supportive role in the mechanism underlying capsaicin-induced gastric protection,
possibly by sensitizing these afferent neurons, because capsaicin-induced gastric cytoprotec‐
tion was shown to be attenuated by indomethacin.
On the other hand, recent pharmacological studies have classified PGE2 receptors into four
specific G protein-coupled subtypes, EP1 to EP4 [12]. The distribution of these receptors is
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considered to explain the multiple effects of PGE2 in various tissues including the gastroin‐
testinal tract. Mice lacking various receptors for prostanoids have been established [13, 14],
and the roles of specific PG receptors in the various biological actions of PGs have been
demonstrated using these "knockout mice" [15]. We performed a series of experiments to
identify the EP receptor subtypes mediating the gastrointestinal protection afforded by PGE2
using various models in both rats and EP receptor knockout mice, and found that PGE2,
administered exogenously or generated endogenously, provided gastric protection against
HCl/ethanol mediated by EP1 receptors [16, 17]. However, the relationship between the EP
receptor subtype and facilitation of capsaicin-induced gastric protection by PGs remains
unknown.
We here investigated the role of endogenous PGs in the gastric protective action of capsaicin
against HCl/ethanol-induced damage in rats, mainly in relation to PGE2 and EP receptors.
Furthermore, because an animal model lacking various receptors for prostanoids is now
available [13, 15, 18], we also evaluated the protective activity of capsaicin in knockout mice
lacking EP1 or EP3 receptors and also in some cases IP receptors. In addition, we also examined
the gastric hyperemic response to capsaicin in these knockout mice in order to provide
functional evidence for the modulatory role of PGs in capsaicin-induced protective effects.
2. Methods
ANIMALS: Male Sprague-Dawley rats (200-220 g) and C57BL/6 mice (25-30 g) were used. Mice
lacking the EP1, EP3, or IP receptors were generated as described previously [13, 15, 19, 20].
In brief, the mouse genes encoding the EP1, EP3, and IP receptors were individually disrupted,
and chimaeric mice were generated. These animals were then back crossed with C57BL/6 mice,
and the resulting heterozygous litter mates [EP1 (+/-), EP3 (+/-) or IP (+/-), ] were bred to
produce homozygous EP1 (-/-), EP3 (-/-), or IP (-/-) mice. Homozygous mice were born at the
predicted Mendelian frequency, grew normally, lived longer than 1 year and were fertile. The
distribution of the EP1, EP3, and IP receptor genes was verified by northern blot hybridization,
which failed to detect messenger RNAs encoding the respective receptors in EP1 (-/-), EP3 (-/-),
and IP (-/-) mice. These knockout mice were deprived of food, but allowed free access to tap
water for 18 hr before the experiments. All studies were performed using 4~8 animals per
group.
INDUCTION OF GASTRIC LESIONS: Rats were administered 1 ml of HCl/ethanol (60% in
150 mM HCl) p.o. through esophageal intubation, and killed 1 hr later under deep ether
anesthesia. The stomachs were removed, inflated by injecting 10 ml of 1% formalin for 10 min
to fix the tissue walls, and opened along the greater curvature. The area (mm2) of hemorrhagic
lesions that developed in the stomach was measured under a dissecting microscope with a
square grid (x10). Capsaicin (1-10 mg/kg) was given p.o. 30 min before the administration of
HCl/ethanol. PGE2 (0.3 mg/kg) was given i.v. 10 min prior to the HCl/ethanol treatment. In
some cases, indomethacin (5 mg/kg) or ONO-AE-829 (5 and 10 mg/kg), the EP1 receptor
antagonist [20], was given s.c. 30 min before the administration of PGE2 or capsaicin. In
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addition, the protective effects of PGE2 and capsaicin on HCl/ethanol were also examined in
rats with the chemical ablation of capsaicin-sensitive sensory neurons. Chemical deafferenta‐
tion was induced by s.c. injections of capsaicin once a day for three consecutive days (total
dose: 100 mg/kg) 2 weeks before the experiment [5]. All capsaicin injections were performed
under ether anesthesia, and rats were pretreated with terbutaline (0.1 mg/kg, i.m.) and
aminophylline (10 mg/kg, i.m.) to counteract the respiratory impairment associated with
capsaicin injections. The effectiveness of the treatment was tested by examining protective
wiping movements of the eye. In a separate experiment, we examined the rescue effect of
various subtype-specific EP agonists on the protective effects of capsaicin in indomethacin-
treated rats. Animals were first administered indomethacin (5 mg/kg) s.c., followed by
capsaicin p.o. 30 min later, and were then given HCl/ethanol p.o. 30 min following the capsaicin
treatment. Butaprost (an EP2 agonist: 3 mg/kg), ONO-NT-012 (an EP3 agonist: 3 mg/kg) or 11-
deoxy PGE1 (an EP3/EP4 agonist: 1 mg/kg) was administered i.v. 10 min before the capsaicin
treatment. Animals were killed 1 hr after the administration of HCl/ethanol. In another
experiment, wild-type mice and EP1, EP3, or IP receptor knockout mice were administered
HCl/ethanol p.o. in a volume of 0.3 ml, and killed 1 hr later [16]. The stomach was then removed
and treated with formalin, and the mucosa was examined for hemorrhagic lesions under a
dissecting microscope, as described previously. Capsaicin (10 mg/kg) was given p.o. to half of
the animals in each group 30 min before the administration of HCl/ethanol. In addition,
indomethacin (5 mg/kg) or ONO-AE-829 (10 mg/kg) was given s.c. 30 min before the admin‐
istration of capsaicin in wild-type mice.
MEASUREMENT OF GASTRIC MUCOSAL BLOOD FLOW (GMBF): GMBF was measured
in both wild type mice and EP1-, EP3-, or IP-receptor knockout mice according to methods
described in our previous study [21, 22]. Under urethane anesthesia, the abdomen was opened
through a midline incision, and the stomach exposed, mounted on an ex-vivo chamber (the
exposed area; 0.7 mm2), and superfused at a rate of 0.5 ml/min. Gastric mucosal blood flow
was measured by a laser Doppler flowmeter (ALF-21, Advance, Tokyo, Japan) and by placing
a probe gently on the surface of the corpus mucosa using a balance (Medical Agent, Kyoto,
Japan). Changes in mucosal blood flow were monitored on a recorder (U-228, Tokai-irika,
Tokyo, Japan). After mucosal blood flow had stabilized, the solution in the chamber was
withdrawn, and the mucosa was then exposed to 0.2 ml of cicaprost, a PGI2 analogue (5 µg/
ml), or capsaicin (1 mg/ml) for 10 min. After the application of these agents, the mucosa was
rinsed with saline, another 0.2 ml of saline was instilled, and perfusion was resumed. Indo‐
methacin (5 mg/kg) was given s.c. to some of wild type mice 30 min before the application of
capsaicin.
MEASUREMENT OF MUCOSAL PGE2 AND 6-keto PGF1< LEVELS: PGE2 levels in the rat
gastric mucosa and those of 6-keto PGF1α in the mouse stomach were measured 30 min after
the p.o. administration of capsaicin (10 mg/kg). Some of the rats used were pretreated with
caspsaicin for sensory deafferentation. In some cases, indomethacin (5 mg/kg) was adminis‐
tered s.c. 30 min before the capsaicin treatment. Under ether anesthesia, the stomachs were
quickly removed, opened along the greater curvature, and rinsed with ice-cold saline. To
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with a rubber band, and placed in hexane-frozen Dry Ice and acetone. These glasses were
separated, and the mucosa was collected, weighed, and put in a tube containing 100% ethanol
plus 0.1 M indomethacin [17, 23]. The samples were then homogenized, and centrifuged for
10 min at 12000 g at 4°C. The supernatant of each sample was used to determine PGE2 and 6-
keto PGF1α levels by EIA using PGE2-and 6-keto PGF1<-kits, respectively (Cayman Chemical
Co., Ann Arbor, MI).
PREPARATION OF DRUGS: The drugs used in the present study were capsaicin (Nakarai
Tesque, Kyoto, Japan), prostaglandin E2 (PGE2), 11-deoxy prostaglandin E1 (11-deoxy PGE1)
(Funakoshi, Tokyo, Japan), ONO-AE-829, butaprost, and ONO-NT-012 (Ono, Osaka, Japan),
terbutaline (Fujisawa, Osaka, Japan), aminophylline (Eisai, Tokyo, Japan), and indomethacin
(Sigma Chemicals, St. Louis, Mo). Capsaicin was dissolved in Tween 80-ethanol solution (10%
ethanol, 10% Tween 80, 80% saline, w/w) for s.c. injections, while indomethacin was suspended
in saline with a drop of Tween 80 (Wako, Osaka, Japan). ONO-AE-829 was dissolved in saline.
PGE2 and other EP receptor ligands were first dissolved in absolute ethanol and then diluted
with saline to the desired concentration. Each agent was prepared immediately before use and
given in a volume of 0.5 ml per 100 g body weight (rat) or 0.1 ml per 10 g body weight (mouse)
for its p.o. and s.c. administration, respectively, and given i.v. in a volume of 0.1 ml per 100 g
body weight (rat). Control animals received saline instead of the active agent.
STATISTICS: Data are presented as the mean±SE for 4~8 animals per group. Statistical
analyses were performed using a two-tailed Dunnett's multiple comparison test, and values
of P<0.05 were regarded as significant.
3. Results
3.1. Effect of capsaicin on HCl/ethanol-induced gastric lesions in rats
The oral administration of HCl/ethanol (60% in 150 mM HCl) produced multiple lesions in the
glandular mucosa, along the long axis of the rat stomach. These lesions were dose-dependently
prevented in animals pretreated with capsaicin (1-10 mg/kg) p.o. before the challenge with
HCl/ethanol, and a significant effect was obtained at doses over 3 mg/kg, with the inhibition
at 10 mg/kg being 81.6% (Figure 1A). The protective effects of capsaicin (10 mg/kg) were
completely attenuated by the chemical ablation of sensory neurons as well as prior adminis‐
tration of indomethacin (5 mg/kg), but not by ONO-AE-829 (10 mg/kg)(Figure 1B). The severity
of HCl/ethanol-induced gastric lesions was also significantly reduced by the prior i.v. admin‐
istration of PGE2 (0.03 mg/kg), with the inhibition being 82.1% (Figure 2). The protective effects
of PGE2 were significantly mitigated by the pretreatment with the EP1 antagonist, ONO-
AE-829 (10 mg/kg), but not by chemical deafferentation. The degree of protection afforded by
PGE2 in the presence of ONO-AE-829 at 10 mg/kg was 19.8%, which was significantly less than
that observed in vehicle-treated normal rats.
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Figure 1. Dose-response relationship for the protective effects of capsaicin against HCl/ethanol-induced gastric le‐
sions in rats (A), and the effects of indomethacin (5 mg/kg), ONO-AE-829 (10 mg/kg), or sensory deafferentation on
the mucosal protective effects of capsaicin (B). Animals were administered 1 ml of HCl/ethanol (60% in 150 mM HCl),
and killed 1 hr later. Capsaicin (1-10 mg/kg) was administered p.o. 30 min before HCl/ethanol. Indomethacin (5
mg/kg) or ONO-AE-829 (10 mg/kg) was given s.c. 30 min before capsaicin. Sensory deafferentation was achieved with
3 consecutive s.c. injections of capsaicin (total 100 mg/kg) 2 weeks before the experiment. Data are presented as




with a rubber band, and placed in hexane-frozen Dry Ice and acetone. These glasses were
separated, and the mucosa was collected, weighed, and put in a tube containing 100% ethanol
plus 0.1 M indomethacin [17, 23]. The samples were then homogenized, and centrifuged for
10 min at 12000 g at 4°C. The supernatant of each sample was used to determine PGE2 and 6-
keto PGF1α levels by EIA using PGE2-and 6-keto PGF1<-kits, respectively (Cayman Chemical
Co., Ann Arbor, MI).
PREPARATION OF DRUGS: The drugs used in the present study were capsaicin (Nakarai
Tesque, Kyoto, Japan), prostaglandin E2 (PGE2), 11-deoxy prostaglandin E1 (11-deoxy PGE1)
(Funakoshi, Tokyo, Japan), ONO-AE-829, butaprost, and ONO-NT-012 (Ono, Osaka, Japan),
terbutaline (Fujisawa, Osaka, Japan), aminophylline (Eisai, Tokyo, Japan), and indomethacin
(Sigma Chemicals, St. Louis, Mo). Capsaicin was dissolved in Tween 80-ethanol solution (10%
ethanol, 10% Tween 80, 80% saline, w/w) for s.c. injections, while indomethacin was suspended
in saline with a drop of Tween 80 (Wako, Osaka, Japan). ONO-AE-829 was dissolved in saline.
PGE2 and other EP receptor ligands were first dissolved in absolute ethanol and then diluted
with saline to the desired concentration. Each agent was prepared immediately before use and
given in a volume of 0.5 ml per 100 g body weight (rat) or 0.1 ml per 10 g body weight (mouse)
for its p.o. and s.c. administration, respectively, and given i.v. in a volume of 0.1 ml per 100 g
body weight (rat). Control animals received saline instead of the active agent.
STATISTICS: Data are presented as the mean±SE for 4~8 animals per group. Statistical
analyses were performed using a two-tailed Dunnett's multiple comparison test, and values
of P<0.05 were regarded as significant.
3. Results
3.1. Effect of capsaicin on HCl/ethanol-induced gastric lesions in rats
The oral administration of HCl/ethanol (60% in 150 mM HCl) produced multiple lesions in the
glandular mucosa, along the long axis of the rat stomach. These lesions were dose-dependently
prevented in animals pretreated with capsaicin (1-10 mg/kg) p.o. before the challenge with
HCl/ethanol, and a significant effect was obtained at doses over 3 mg/kg, with the inhibition
at 10 mg/kg being 81.6% (Figure 1A). The protective effects of capsaicin (10 mg/kg) were
completely attenuated by the chemical ablation of sensory neurons as well as prior adminis‐
tration of indomethacin (5 mg/kg), but not by ONO-AE-829 (10 mg/kg)(Figure 1B). The severity
of HCl/ethanol-induced gastric lesions was also significantly reduced by the prior i.v. admin‐
istration of PGE2 (0.03 mg/kg), with the inhibition being 82.1% (Figure 2). The protective effects
of PGE2 were significantly mitigated by the pretreatment with the EP1 antagonist, ONO-
AE-829 (10 mg/kg), but not by chemical deafferentation. The degree of protection afforded by
PGE2 in the presence of ONO-AE-829 at 10 mg/kg was 19.8%, which was significantly less than
that observed in vehicle-treated normal rats.
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Figure 1. Dose-response relationship for the protective effects of capsaicin against HCl/ethanol-induced gastric le‐
sions in rats (A), and the effects of indomethacin (5 mg/kg), ONO-AE-829 (10 mg/kg), or sensory deafferentation on
the mucosal protective effects of capsaicin (B). Animals were administered 1 ml of HCl/ethanol (60% in 150 mM HCl),
and killed 1 hr later. Capsaicin (1-10 mg/kg) was administered p.o. 30 min before HCl/ethanol. Indomethacin (5
mg/kg) or ONO-AE-829 (10 mg/kg) was given s.c. 30 min before capsaicin. Sensory deafferentation was achieved with
3 consecutive s.c. injections of capsaicin (total 100 mg/kg) 2 weeks before the experiment. Data are presented as




Figure 2. Effects of ONO-AE-829 or sensory deafferentation on the protective action of PGE2 against HCl/ethanol in
the rat stomach. Animals were administered 1 ml of HCl/ethanol (60% in 150 mM HCl), and killed 1 hr later. PGE2 (0.3
mg/kg) was given i.v. 10 min before HCl/ethanol. ONO-AE-829 (10 mg/kg) was administered s.c. 30 min before PGE2.
Sensory deafferentation was induced with 3 consecutive s.c. injections of capsaicin (total 100 mg/kg) 2 weeks before
the experiment. Data are presented as means±SE from 6-8 rats. Significantly different at P<0.05: *from the control; #
from the vehicle.
The oral administration of capsaicin (10 mg/kg) did not affect the mucosal PGE2 content when
measured 0.5 hr after its administration (not shown). The prior administration of indomethacin
(5 mg/kg, s.c.) markedly reduced PGE2 levels in the presence of capsaicin. As in normal rats,
capsaicin did not significantly affect mucosal PGE2 levels in sensory deafferented animals.
3.2. Reversal of capsaicin-induced protection by EP agonists in indomehtacin-pretreated
rats
To investigate the roles of PGE2 and EP receptors in capsaicin-induced gastric protection, we
examined the rescue effects of various subtype-specific EP agonists on capsaicin in the presence
of indomethacin. The oral administration of capsaicin (10 mg/kg) markedly protected against
HCl/ethanol-induced gastric lesions (Figure 3A). This effect of capsaicin was significantly
mitigated by the prior administration of indomethacin (5 mg/kg), and the degree of inhibition
was reduced to 29.7%. When these animals were given various EP agonists i.v. 20 min after
indomethacin, the protective effects of capsaicin were again observed in rats pretreated with
butaprost (an EP2 agonist). Neither ONO-NT-012 (an EP3 agonist) nor 11-deoxy PGE1 (an EP3/
EP4 agonist) rescued the effects of capsaicin against HCl/ethanol in the presence of indome‐
thacin. None of the EP agonists (i.v.) used, including butaprost, significantly protected against
HCl/ethanol by themselves (Figure 3B).
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Figure 3. A: Effects of various EP agonists on the mucosal protective action of capsaicin against HCl/ethanol-induced
gastric lesions in the rat stomach in the presence of indomethacin. Animals were given 1 ml of HCl/ethanol (60% in
150 mM HCl) and killed 1 hr later. Capsaicin (10 mg/kg) was administered p.o. 30 min before HCl/ethanol. Indome‐
thacin (5mg/kg) was given s.c. 30 min before capsaicin. Various EP agonists were given i.v. 10 min before capsaicin.
Data are presented as means±SE from 6-8 rats. Significantly different at P<0.05: *from the control; # from the saline; $
from vehicle. B: Effects of various EP agonists on HCl/ethanol-induced gastric lesions in the rat stomach. Various EP
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3.3. Gastric cytoprotection against HCl/ethanol by capsaicin in mice
To further investigate the relationship between capsaicin-induced gastric protection and EP
receptor subtype, we examined the protective effects of capsaicin against HCl/ethanol in both
wild-type and knockout mice lacking EP1 or EP3 receptors. In addition, since other study
reported a role for PGI2 in the release of CGRP in the stomach following capsaicin stimulation
[19], the protective effect of capsaicin was also examined in IP receptor knockout mice. The
intragastric administration of HCl/ethanol (0.3 ml) also caused hemorrhagic lesions in the
mouse stomach (Figure 4). HCl/ethanol led to the development of gastric lesions in EP1, EP3,
and IP receptor knockout mice, similar to wild-type mice, and the severity of these lesions was
similar among these groups. The severity of these lesions in wild-type mice was also reduced
by the prior p.o. administration of capsaicin (10 mg/kg). This agent significantly reduced the
severity of these lesions in animals lacking either EP1 or EP3 receptors. However, capsaicin
failed to protect the stomach against HCl/ethanol in IP receptor knockout mice, and the lesion
score in these animals was not significantly different from that observed in IP receptor
knockout animals without the capsaicin pretreatment.
Figure 4. Effects of capsaicin on HCl/ethanol-induced gastric lesions in wild-type and knockout mice lacking EP1, EP3
or IP receptors. Animals were administered 0.3 ml of HCl/ethanol (60% ethanol in 150 mM HCl) p.o. and killed 1 hr
later. Capsaicin (10 mg/kg) was given p.o. 30 min before HCl/ethanol. In wild-type mice, indomethacin (5 mg/kg) was
given s.c. 30 min before administration of capsaicin. Data are presented as means±SE from 4-6 mice. Significantly dif‐
ferent at P<0.05; *from the vehicle in the corresponding group; # from saline.
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The oral administration of capsaicin (10 mg/kg) did not significantly affect 6-keto PGF1α levels,
which was similar to the effects observed on PGE2 content in the rat stomach (not shown).
Indomethacin (5 mg/kg) markedly decreased 6-keto PGF1α levels in the presence of capsaicin.
Similarly, capsaicin had no effect on 6-keto PGF1α levels in IP receptor knockout mice.
3.4. Effect of capsaicin on gastric mucosal blood flow in mice
Under urethane anesthesia, the chambered stomachs of both wild type mice and those lacking
EP1, EP3, or IP receptors showed a relatively constant GMBF during a 2-hr test period. The
mucosal application of capsaicin (1 mg/ml) for 10 min caused a marked increase in GMBF in
wild type mice, and this effect was significantly attenuated by the prior administration of
indomethacin (5 mg/ml) (Figure 5). A significant increase in GMBF by capsaicin was also
observed in both EP1 and EP3 receptor knockout mice. However, the gastric hyperemic
response to capsaicin was almost completely absent in animals lacking IP receptors, and GMBF
values were significantly lower than those in control wild type mice, at most of the time points
measured after the application of capsaicin.
Figure 5. Effects of capsaicin on GMBF in wild type mice and knockout mice lacking EP1, EP3 or IP receptors under
urethane anesthetized conditions. Capsaicin was applied to the chamber at a concentration of 1 mg/ml for 10 min
(100 µl), and GMBF was measured before and after its application. Indomethacin was administered s.c. at a dose of 5
mg/kg 30 min before capsaicin in wild-type mice. Data are expressed as an increase in GMBF (a % of basal values) and
presented as means±SE of values determined every 10 min from 5-6 mice per group. Significantly different at P<0.05:
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PGs, either endogenous or exogenous derivatives, have been shown to act on multiple
receptors [12]. Capsaicin affords gastric protection by stimulating afferent C-fibers [3], and this
action is partly dependent on endogenous PGs [5, 8, 9, 24]. We previously examined the
relationship between EP receptor subtypes and gastric protection against HCl/ethanol in rats
using various EP agonists and found that the gastroprotective action afforded by endogenous
or exogenous PGs was mediated by EP1 receptors [16, 17]. However, the EP receptor subtypes
or other prostanoid receptors responsible for this phenomenon has yet to be established. The
present study was conducted to determine the prostanoid receptor(s) involved in capsaicin-
induced gastric protection.
First, we confirmed that PGE2 prevented the development of HCl/ethanol-induced gastric
lesions, and this action was attenuated by the EP1 antagonist, ONO-AE-829 [16]. This result
was also verified in EP receptor knockout mice, with this protection being completely absent
in mice lacking EP1 receptors [16, 17]. These results strongly suggest that the protective effects
of exogenous PGE2 in the stomach were mainly mediated by the activation of EP1 receptors.
On the other hand, endogenous PGs play a role in the gastric cytoprotection induced by the
oral administration of capsaicin [5, 8, 9]. As shown in this study, the protective effects of
capsaicin against HCl/ethanol were dose-dependent, and were attenuated by the chemical
ablation of capsaicin-sensitive sensory neurons. The protective effects of capsaicin were also
significantly mitigated by the prior administration of indomethacin, which indicated the
involvement of endogenous PGs in these effects. However, in contrast to the adaptive
cytoprotection induced by a mild irritant [17], the effects of capsaicin were not affected by the
selective EP1 antagonist, ONO-AE-829. This was confirmed by the stimulatory effects of
capsaicin on gastric HCO3-secretion which were attenuated by indomethacin and capsazepine,
but not ONO-8711 (an EP1 antagonist) [25]. Furthermore, neither the stimulation of sensory
neurons by capsaicin nor sensory deafferentation affected mucosal PGE2 levels in the stomach.
Many studies have shown that mild irritants increased the production of PGE2 in the stomach
[14, 17]. These findings suggest that although endogenous PGs are involved in the gastric
cytoprotection induced by both mild irritants and capsaicin, the mode of action appears to be
different in these two cases. The stimulation of afferent neurons by capsaicin was assumed to
increase the production of PGs in the stomach, but exerted protective effects in the stomach,
that were partly dependent on endogenous PGs.
In the present study, we administered various EP agonists to indomethacin-treated animals,
to determine whether the inhibitory effect of indomethacin on capsaicin-induced gastric
protection was reversed by exogenous PGE2, and if so, which EP receptor subtype was
responsible for this action. The protective effects of capsaicin were significantly restored, even
in the presence of indomethacin, by the prior administration of butaprost, the EP2 agonist, but
not by the EP3 or EP4 agonist. In addition, the protective effects of capsaicin were significantly
enhanced in the presence of butaprost, which strongly suggested a supportive role for EP2
receptors in capsaicin-induced gastric protection. These results are supported by the findings
of Haupt et al [26], who reported the involvement of the EP2 receptor in the potentiation of
afferent neuronal discharges by PGE2 in the rat jejunum. Jenkins et al [27] also demonstrated
that the activation of DP, EP, and IP receptors could each cause the release of CGRP from
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trigeminal neurons, and that the predominant EP receptor subtype involved may be the EP2
receptor. In the present study, neither of these EP agonists, including butaprost, offered any
protection against HCl/ethanol-induced gastric damage by themselves. Furthermore, capsai‐
cin-induced gastric protection was not affected by the EP1 antagonist, which excluded the
involvement of EP1 receptors in the facilitation of this action by endogenous PGs. The
significant level of protection afforded by capsaicin was also observed in knockout mice
lacking EP1 and EP3 receptors, which confirmed that capsaicin-induced gastric protection did
not involve EP1 or EP3 receptors. We could not confirm the involvement of EP2 receptors in
this action because EP2 knockout mice were not available in our laboratory.
In contrast, we demonstrated that capsaicin failed to exhibit a cytoprotective effect against
HCl/ethanol-induced gastric lesions in IP-receptor knockout mice. We previously showed that
20 mM taurocholate, as a mild irritant, protected the stomach against HCl/ethanol even in IP
receptor knockout mice, which was similar to that observed in wild-type mice. These results
suggested the absence of the involvement of PGI2 in the mechanism responsible for adapative
cytoprotection [17]. We also reported that the adaptive cytoprotection induced by taurocholate
was attenuated by ONO-AE-829, the EP1 antagonist, as well as indomethacin, and was not
observed in EP1 receptor knockout mice [17]. The present results obtained in knockout mice
suggest that IP receptors are also involved in the protective effects of capsaicin in the stomach,
in addition to EP2 receptors. The exact mechanism by which endogenous PGs contributes to
the protective action of capsaicin is currently unknown. Previous studies have suggested that
endogenous PGs may sensitize sensory neurons to nociceptive stimuli [10, 11]. Boku et al. [19]
reported the lack of CGRP release in response to mild injuries in the stomachs of IP-receptor
knockout mice. Oishi et al. [10] demonstrated, using IP-receptor knockout mice, that PGI2 was
a major nociceptive mediator in the acetic acid-induced writhing reaction. Since capsaicin-
induced gastric cytoprotection was attenuated by indomethacin and was absent in IP-receptor
knockout mice, endogenous PGI2 may play a supportive role in the mechanism responsible
for capsaicin-induced gastric cytoprotection, possibly by sensitizing sensory neurons [17, 28].
However, capsaicin did not have any effect on either PGE2 production in the rat stomach or
PGI2 production in the mouse stomach. Thus, PGs generated constitutively may maintain the
sensitivity of these neurons to the capsaicin stimulation.
Intragastric capsaicin has been shown to increase GMBF in the rat stomach, and this effect was
attenuated by sensory deafferentation following a capsaicin pretreatment [9, 14, 29]. Although
gastric hyperemia is not the exclusive mechanism responsible for gastric cytoprotection
induced by PGE2 or the stimulation of capsaicin-sensitive afferent neurons [16, 30], GMBF is
considered to be a factor in capsaicin-induced gastric protection under certain experimental
conditions [7, 29]. We previously reported that the gastric hyperemic response to capsaicin
was also significantly mitigated by indomethacin, which suggested the involvement of
endogenous PGs in this response [14]. In the present study, we confirmed that intragastric
capsaicin markedly increased GMBF in wild type mice in an indomethacin-sensitive manner.
This effect was also observed in EP1 or EP3 receptor knockout mice, but was completely absent
in animals lacking IP receptors, similar to the gastroprotective effects of capsaicin. These results
may provide functional evidence for the modulatory role of IP receptors in the facilitation of
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The results of the present study suggest that capsaicin exhibits gastric cytoprotective effects
as well as gastric hyperemic response, essentially by stimulating sensory neurons, and this
partly depended on endogenous PG levels. The facilitative effects of endogenous PGs were
mediated by EP2 and IP receptors, which may have sensitized the sensory neurons to capsaicin,
even though capsaicin increased the production of PGI2 but not PGE2 in the gastric mucosa.
However, whether endogenous PGs modulated the effects of capsaicin by interacting with
TRPV1 remains unknown; however, capsaicin previously exhibited gastric protective effects
by activating TRPV1 [31]. Endogenous phosphatidyl-inositol-4, 5-bisphosphate (PtdIns(4, 5)
P2) was shown to inhibit TRPV1, and this was alleviated by agents that activated phospholipase
C [32, 33]. Therefore, PGs may sensitize these afferent neurons to capsaicin through EP2/IP
receptors by somehow releasing TRPV1 from PtdIns(4, 5)P2-mediated inhibition.
5. Summary
Capsaicin provided gastric cytoprotection essentially through the stimulation of sensory
neurons, and this partly depended on endogenous PGs. PGs facilitated the protective effects
of capsaicin, and this response was mediated by EP2 and IP receptors, possibly by sensitizing
the sensory neurons to capsaicin, even though capsaicin increased the production of PGI2 but
not PGE2 in the gastric mucosa (Figure 6). Although endogenous PGs are also known to be
involved in the adaptive cytoprotection induced by mild irritants, this is different from that of
capsaicin and is mediated by the activation of EP1 receptors with a concomitant increase in
the production of mucosal PGE2.
Figure 6. Mechanisms underlying the gastric cytoprotection induced by PGE2, mild irritants, and capsaicin. Exogenous
PGE2 provides direct gastric cytoprotection, and this was mediated by the activation of EP1 receptors and completely
blocked by the EP1 antagonist, ONO-AE-829. A mild irritant increased endogenous PGE2 production in the stomach
and exhibited adaptive gastric cytoprotection. This action was prevented by indomethacin as well as the EP1 antago‐
nist. On the other hand, capsaicin exhibited gastric cytoprotective effects, essentially mediated by capsaicin-sensitive
afferent neurons via the activation of TRPV1 receptors, and this effect was completely attenuated by the TRPV1 antag‐
onist, capsazepine. Although capsaicin increased the production of PGI2 but not PGE2 in the gastric mucosa, this pro‐
tective effect was facilitated by endogenous PGs through PGE2/EP2 and PGI2/IP receptors.
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The results of the present study suggest that capsaicin exhibits gastric cytoprotective effects
as well as gastric hyperemic response, essentially by stimulating sensory neurons, and this
partly depended on endogenous PG levels. The facilitative effects of endogenous PGs were
mediated by EP2 and IP receptors, which may have sensitized the sensory neurons to capsaicin,
even though capsaicin increased the production of PGI2 but not PGE2 in the gastric mucosa.
However, whether endogenous PGs modulated the effects of capsaicin by interacting with
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by activating TRPV1 [31]. Endogenous phosphatidyl-inositol-4, 5-bisphosphate (PtdIns(4, 5)
P2) was shown to inhibit TRPV1, and this was alleviated by agents that activated phospholipase
C [32, 33]. Therefore, PGs may sensitize these afferent neurons to capsaicin through EP2/IP
receptors by somehow releasing TRPV1 from PtdIns(4, 5)P2-mediated inhibition.
5. Summary
Capsaicin provided gastric cytoprotection essentially through the stimulation of sensory
neurons, and this partly depended on endogenous PGs. PGs facilitated the protective effects
of capsaicin, and this response was mediated by EP2 and IP receptors, possibly by sensitizing
the sensory neurons to capsaicin, even though capsaicin increased the production of PGI2 but
not PGE2 in the gastric mucosa (Figure 6). Although endogenous PGs are also known to be
involved in the adaptive cytoprotection induced by mild irritants, this is different from that of
capsaicin and is mediated by the activation of EP1 receptors with a concomitant increase in
the production of mucosal PGE2.
Figure 6. Mechanisms underlying the gastric cytoprotection induced by PGE2, mild irritants, and capsaicin. Exogenous
PGE2 provides direct gastric cytoprotection, and this was mediated by the activation of EP1 receptors and completely
blocked by the EP1 antagonist, ONO-AE-829. A mild irritant increased endogenous PGE2 production in the stomach
and exhibited adaptive gastric cytoprotection. This action was prevented by indomethacin as well as the EP1 antago‐
nist. On the other hand, capsaicin exhibited gastric cytoprotective effects, essentially mediated by capsaicin-sensitive
afferent neurons via the activation of TRPV1 receptors, and this effect was completely attenuated by the TRPV1 antag‐
onist, capsazepine. Although capsaicin increased the production of PGI2 but not PGE2 in the gastric mucosa, this pro‐
tective effect was facilitated by endogenous PGs through PGE2/EP2 and PGI2/IP receptors.
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1. Introduction
The gastric mucosa is maintained in an intact state by multiple protective mechanisms
including humoral and neuronal factors, in spite of its exposure to acid and other chemical
hazards [1]. Capsaicin-sensitive afferent neurons play a central role in neuronal mechanisms
taking place in the stomach [2]. These afferent neurons have been shown to regulate various
gastric functions such as secretion, mucosal blood flow (GMBF), and motility, and modulate
the mucosal integrity of the stomach [2-5]. Vanilloid type 1 receptor (VR1), a nonselective
cationic channel, has recently been cloned as the binding site of capsaicin [6], and more
recently, has been identified as a member of the transient receptor potential (TRP) family of
ion channels [7]. Although the TRP family is activated by a diverse range of stimuli, including
the depletion of intracellular Ca2+stores [6], the VR1 receptor remains the only channel
activated by vanilloids such as capsaicin and is now known as TRPV1 [8]. Capsaicin stimulates
these afferent neurons via TRPV1, resulting in the release of calcitonin gene-related peptide
(CGRP), the predominant neurotransmitter of spinal afferents in the rat stomach, and thus,
exerts a gastroprotective action [9]. CGRP has been shown to induce endothelial cells to release
nitric oxide (NO), and this molecule is known to strongly mediate the action of CGRP [2]. Other
studies have also demonstrated that activation of the bradykinin B2 receptor caused the
opening of TRPV1 and modified the action of capsaicin [10, 11].
The secretion of HCO3- from surface epithelial cells is a protective mechanism in the stomach,
with HCO3- working in collaboration with mucus gel, which adheres to the surface of mucosa
[1]. We previously reported that capsaicin increased duodenal HCO3- secretion mediated by
endogenous prostaglandins (PGs) and NO as well as capsaicin-sensitive afferent neurons [12,
13]. We also demonstrated that PGE2 stimulated HCO3- secretion through EP1 receptors in the
stomach and EP3/EP4 receptors in the duodenum [14, 15], while the action of capsaicin in the
duodenum required the presence of prostacyclin (PGI2) IP receptors [16]. However, few studies
have examined the mechanisms involved in gastric HCO3- secretion in response to capsaicin.
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1. Introduction
The gastric mucosa is maintained in an intact state by multiple protective mechanisms
including humoral and neuronal factors, in spite of its exposure to acid and other chemical
hazards [1]. Capsaicin-sensitive afferent neurons play a central role in neuronal mechanisms
taking place in the stomach [2]. These afferent neurons have been shown to regulate various
gastric functions such as secretion, mucosal blood flow (GMBF), and motility, and modulate
the mucosal integrity of the stomach [2-5]. Vanilloid type 1 receptor (VR1), a nonselective
cationic channel, has recently been cloned as the binding site of capsaicin [6], and more
recently, has been identified as a member of the transient receptor potential (TRP) family of
ion channels [7]. Although the TRP family is activated by a diverse range of stimuli, including
the depletion of intracellular Ca2+stores [6], the VR1 receptor remains the only channel
activated by vanilloids such as capsaicin and is now known as TRPV1 [8]. Capsaicin stimulates
these afferent neurons via TRPV1, resulting in the release of calcitonin gene-related peptide
(CGRP), the predominant neurotransmitter of spinal afferents in the rat stomach, and thus,
exerts a gastroprotective action [9]. CGRP has been shown to induce endothelial cells to release
nitric oxide (NO), and this molecule is known to strongly mediate the action of CGRP [2]. Other
studies have also demonstrated that activation of the bradykinin B2 receptor caused the
opening of TRPV1 and modified the action of capsaicin [10, 11].
The secretion of HCO3- from surface epithelial cells is a protective mechanism in the stomach,
with HCO3- working in collaboration with mucus gel, which adheres to the surface of mucosa
[1]. We previously reported that capsaicin increased duodenal HCO3- secretion mediated by
endogenous prostaglandins (PGs) and NO as well as capsaicin-sensitive afferent neurons [12,
13]. We also demonstrated that PGE2 stimulated HCO3- secretion through EP1 receptors in the
stomach and EP3/EP4 receptors in the duodenum [14, 15], while the action of capsaicin in the
duodenum required the presence of prostacyclin (PGI2) IP receptors [16]. However, few studies
have examined the mechanisms involved in gastric HCO3- secretion in response to capsaicin.
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We here described the regulatory mechanism underlying capsaicin-induced gastric HCO3-
secretion, in relation to sensory neurons, TRPV1, PGs, NO, and bradykinin B2 receptors, and
compared it to that of the acid-induced response. In addition, because we found that responses
to capsaicin and acid in the duodenum differed concerning PGI2/IP dependency [16], we also
examined these responses in the stomach using mice lacking EP1, EP3 or IP receptors.
2. Methods
ANIMALS: Male SD rats (220-260 g, Nippon Charles River, Shizuoka, Japan) and male C57BL/
6 mice (25-30 g) were used. Mice lacking the EP1, EP3, or IP receptors were generated as
described previously [17, 18]. These rats and knockout mice were deprived of food, but allowed
free access to tap water for 18 hr before the experiments. Studies were performed under
urethane anesthesia (1.25 g/kg, i.p.) using 4~8 animals per group.
DETERMINATION OF GASTRIC HCO3- SECRETION: The secretion of HCO3-was meas‐
ured in the chambered stomach as described previously [5]. The abdomen was incised and the
stomach was exposed, mounted on a chamber (exposed area, rat: 3.1 cm2, mouse: 0.7 cm2), and
superfused with saline that was gassed with 100% O2 and kept in a reservoir. The secretion of
HCO3- was measured at pH 7.0 using a pH-stat method (Hiranuma Comtite-8, Mito, Japan)
and by adding 2 mM HCl to the reservoir. Acid secretion was completely inhibited by
omeprazole given i.p. at a dose of 60 mg/kg to unmask HCO3- in the stomach. After basal
HCO3- secretion had stabilized, animals were subjected to the following treatment. Capsaicin
(0.03~0.3 mg/ml) or NOR-3 (a NO donor: 3 mg/ml) was topically applied to the chamber for
10 min, while PGE2 (1 mg/kg) or bradykinin (30 µg/kg) was given i.v. as a single injection. The
secretion of HCO3- was also stimulated by exposing the mucosa to 50~200 mM HCl (rat) or 50
mM HCl (mouse) for 10 min. The effects of indomethacin, NG-nitro L-arginine methyl ester (L-
NAME), ONO-8711 (an EP1 antagonist) (Aoi et al., 2004), FR172357 (a bradykinin B2 antago‐
nist) [19], capsazepine (a TRPV1 antagonist), or the chemical ablation of capsaicin-sensitive
afferent neurons were examined on the secretion of HCO3- induced by the above agents or
mucosal acidification. Indomethacin (5 mg/kg), ONO-8711 (10 mg/kg) or FR172357 (1 mg/kg)
was given s.c. 30 min or i.v. 15 min before each treatment, while L-NAME (20 mg/kg) was
given s.c. 3 hr before because this agent was previously shown to acutely increase HCO3-
secretion through a neural reflex due to an increase in blood pressure [20-22]. Capsazepine (2.5
mg/ml) was applied to the chamber for 20 min, starting from 10 min before the capsaicin or
acid treatment [13], or applied for 20 min followed by an i.v. injection of bradykinin 10 min
later. The chemical ablation of capsaicin-sensitive afferent neurons was achieved with repeated
s.c. injections of capsaicin (total dose; 100 mg/kg) once daily for 3 days, 2 weeks before the
experiment [3, 5].
MEASUREMENT OF MUCOSAL PGE2 AND PGI2 LEVELS: Mucosal PGE2 and PGI2 (6-keto
PGF1 a) levels in the stomach were measured after the application of capsaicin (0.3 mg/ml) for
10 min. The stomach was removed 30 later, weighed, and put in a tube containing 100%
methanol plus 0.1 M indomethacin [23]. The samples were then minced with scissors, homo‐
genized, and centrifuged at 12000 g for 10 min at 4˚C. The supernatant of each sample was
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used to measure PGE2 and 6-keto PGF1 α levels by EIA with PGE2- and 6-keto PGF1 α-kits
(Cayman Chemical Co., Ann Arbor, MI).
PREPARATION OF DRUGS: The drugs used in the present study were urethane (Tokyo
kasei, Tokyo, Japan), capsaicin and bradykinin (Nacalai Tesque, Kyoto, Japan), prostaglandin
E2 (PGE2: Funakoshi, Tokyo, Japan), capsazepine, NG-nitro L-arginine methyl ester (L-NAME),
and indomethacin (Sigma Chemicals, St. Louis, Mo, USA), ONO-8711 (Ono Pharmaceutical
Co., Osaka, Japan), NOR-3 [ (±)- (E)-ethyl-2- [ (E)-hydroxyimino]-5-nitro-3-hexeneamine]
(Dojindo, Kumamoto, Japan), omeprazole (Astra Zeneca, Möndal, Sweden), FR172357, and
terbutaline (BuricanylR, Fujisawa, Osaka, Japan), and aminophylline (NeophyllineR, Eizai,
Tokyo, Japan). Capsaicin was dissolved in a Tween 80-ethanol solution (10% ethanol, 10%
Tween, and 80% saline, w/w: Wako, Osaka, Japan) for the s.c. injection, while it was suspended
in a 0.5% carboxymethylcellulose solution (CMC: Nacalai Tesque) for the topical application.
PGE2 or NOR-3 was first dissolved in absolute ethanol or dimethyl sulfoxide (DMSO),
respectively, and diluted with saline to the desired concentrations. Omeprazole was suspend‐
ed in a 0.5% CMC solution. Other agents were dissolved in saline. Each agent was prepared
immediately before use and given in a volume of 0.5 ml per 100 g body weight in the case of
the i.p. or s.c. administration, in a volume of 0.1 ml per 100 g body weight in the case of the
i.v. administration, or applied topically to the chamber in a volume of 2 ml per rat or 0.7ml per
mice. Control animals received saline or CMC instead of active agents.
STATISTICS: Data are presented as the mean±SE from 4~8 rats or mice per group. Statistical
analyses were performed using a two-tailed Dunnett’s multiple comparison test, and values
of p<0.05 were regarded as significant.
3. Results
3.1. Stimulation by capsaicin and mucosal acidification of HCO3- secretion in the rat stomach
Capsaicin (0.03~0.3 mg/ml) applied to the chamber for 10 min increased the secretion of
HCO3- in a dose-dependent manner, and this effect was significant at a dose of 0.1 mg/ml or
greater (Figure 1). The stimulatory effect of capsaicin (0.3 mg/ml) on HCO3- was significantly
attenuated by the chemical ablation of capsaicin-sensitive afferent neurons as well as the prior
administration of indomethacin (5 mg/kg, s.c.) or L-NAME (20 mg/kg, s.c.) (Figure 2). The
action of capsaicin was also potently inhibited by the co-application of capsazepine, the TRPV1
antagonist. However, neither the EP1 antagonist, ONO-8711 (10 m/kg, s.c.) nor the bradykinin
B2 antagonist, FR172357 (1 mg/kg, i.v.) had any effect on HCO3- secretion in response to
capsaicin.
The secretion of HCO3- was also increased in a concentration-dependent manner when the
mucosa was acidified following its exposure to 50~200 mM HCl for 10 min (Figure 3). The
response to 200 mM HCl was significantly prevented by indomethacin, L-NAME, ONO-8711,
and capsaicin pretreatments (Figure 4). However, acid-induced HCO3- secretion in the stomach
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Figure 1. Effects of capsaicin on gastric HCO3- secretion in anesthetized rats. Capsaicin (0.03~0.3 mg/ml) was applied
to the chamber for 10 min. In Figure A, data are presented as a % of basal values and represent the mean±SE of values
determined every 10 minutes from 4~7 rats. Figure B shows the total net HCO3- output for 1 hr after the capsaicin
treatment, and data are presented as the mean±SE for 4~7 rats. *Significantly different from the control, at P<0.05.
Figure 2. Effects of the pretreatment with various agents and capsaicin on gastric HCO3- secretion induced by capsai‐
cin in anesthetized rats. Capsaicin (0.3 mg/ml) was applied to the chamber for 10 min. Indomethacin (5 mg/kg),
ONO-8711 (10 mg/kg), or L-NAME (10 mg/kg) was administered s.c. 1 or 3 hr before capsaicin, respectively. FR172357
(1 mg/kg) was administered i.v. 15 min before the mucosal application of capsaicin. Capsazepine (2.5 mg/ml) was ap‐
plied to the chamber for 20 min, starting 10 min before the capsaicin treatment. The chemical ablation of sensory
neurons (capsaicin pretreatment) was achieved with 3 consecutive s.c. injections of capsaicin (total dose: 100 mg/kg)
2 weeks before the experiment. The figure shows the total net HCO3- output for 1 hr after the capsaicin treatment,
and data are presented as the mean±SE from 4~6 rats. Significantly different at P<0.05; *from the control; # from sal‐
ine.
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Figure 3. Effects of mucosal acidification on gastric HCO3- secretion in anesthetized rats. Acidification was achieved by
exposing the mucosa to 50~200 mM HCl for 10 min. In Figure A, data are presented as a % of basal values and repre‐
sent the mean±SE of values determined every 10 minutes from 4~6 rats. Figure B shows the total net HCO3- output for
1 hr after acidification, and data are presented as the mean±SE for 4~6 rats. *Significantly different from the control,
at P<0.05.
Figure 4. Effects of the pretreatment with various agents and capsaicin on gastric HCO3- secretion induced by mucosal
acidification in anesthetized rats. Acidification was achieved by exposing the mucosa to 200 mM HCl for 10 min. Indo‐
methacin (5 mg/kg), ONO-8711 (10 mg/kg), or L-NAME (10 mg/kg) was administered s.c. 1 or 3 hr before acidifica‐
tion, respectively. FR172357 (1 mg/kg) was administered i.v. 15 min before mucosal acidification. Capsazepine (2.5
mg/ml) was applied to the chamber for 20 min, starting 10 min before the capsaicin treatment. The chemical ablation
of afferent neurons (capsaicin pretreatment) was achieved with 3 consecutive s.c. injections of capsaicin (total dose:
100 mg/kg) 2 weeks before the experiment. The figure shows the total net HCO3- output for 1 hr after the capsaicin
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Figure 4. Effects of the pretreatment with various agents and capsaicin on gastric HCO3- secretion induced by mucosal
acidification in anesthetized rats. Acidification was achieved by exposing the mucosa to 200 mM HCl for 10 min. Indo‐
methacin (5 mg/kg), ONO-8711 (10 mg/kg), or L-NAME (10 mg/kg) was administered s.c. 1 or 3 hr before acidifica‐
tion, respectively. FR172357 (1 mg/kg) was administered i.v. 15 min before mucosal acidification. Capsazepine (2.5
mg/ml) was applied to the chamber for 20 min, starting 10 min before the capsaicin treatment. The chemical ablation
of afferent neurons (capsaicin pretreatment) was achieved with 3 consecutive s.c. injections of capsaicin (total dose:
100 mg/kg) 2 weeks before the experiment. The figure shows the total net HCO3- output for 1 hr after the capsaicin





3.2. Effect of capsaicin and mucosal acidification on PGE2 and 6-keto PGF1 α levels in the
rat stomach
The intragastric application of capsaicin (0.3 mg/ml) for 10 min did not affect the amount of
PGE2, but significantly increased that of 6-keto PGF1 α to approximately 2.8-fold that of the
control level (data not shown). In contrast, the acidification of the gastric mucosa significantly
stimulated the production of PGs and increased PGE2 or 6-keto PGF1 α levels to approximately
2 or 3-fold that of basal levels, respectively.
3.3. Stimulation by PGE2, NOR-3, and bradykinin of HCO3-secretion in the rat stomach
The intravenous administration of PGE2 (1 mg/kg) increased the secretion of HCO3- in the
stomach, and this response was equivalent to that induced by capsaicin at 0.3 mg/ml (Figure
5). The NO donor, NOR-3 (3 mg/ml), which was applied topically to the mucosa for 10 min,
also increased HCO3- secretion. Neither indomethacin, L-NAME, nor FR172357 significantly
affected the increase in HCO3- secretion in response to PGE2 (data not shown). Gastric HCO3-
secretion was also stimulated by the i.v. administration of bradykinin (30 µg/kg), reached a
maximal value of 160% that of the basal level; however, this effect was less potent than that of
capsaicin or acidification and completely disappeared after 1 hr (Figure 6). The stimulatory
effect of bradykinin on HCO3- was significantly antagonized by FR172357 and attenuated by
the prior administration of indomethacin or L-NAME. In addition, the stimulatory effect of
bradykinin was almost completely blocked by the chemical ablation of capsaicin-sensitive
afferent neurons, but was not significantly affected by pretreatment with capsazepine.
Figure 5. Effects of PGE2 and NOR-3 on gastric HCO3- secretion in anesthetized rats. PGE2 (1 mg/kg) was administered
i.v., while NOR-3 (3 mg/ml) was applied to the chamber for 10 min. Data represent the total net HCO3- output for 1 hr
after the administration of PGE2 or NOR-3 and are presented as the mean±SE for 4-5 rats. *Significantly different from
the control, at P<0.05.
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside146
Figure 6. Effects of bradykinin on gastric HCO3- secretion in anesthetized rats. Bradykinin (30 µg/kg) was administered
i.v. after basal HCO3- secretion had been stabilized. Indomethacin (5 mg/kg) was administered s.c. 1 hr before bradyki‐
nin, while FR172357 (1 mg/kg) was given i.v. 15 min before. L-NAME (20 mg/kg) was administered s.c. 3 hr before
bradykinin. Capsazepine (2.5 mg/ml) was applied for 20 min to the chamber 10 min before the administration of bra‐
dykinin. The chemical ablation of sensory neurons (capsaicin pretreatment) was achieved with 3 consecutive s.c. injec‐
tions of capsaicin (total dose: 100 mg/kg) 2 weeks before the experiment. Data show the total net HCO3- output for 1
hr after the capsaicin treatment and are presented as the mean±SE for 4~5 rats. Significantly different at P<0.05;
*from the control; # from bradykinin+saline.
3.4. Effect of capsaicin on HCO3- secretion in wild-type and IP-receptor knockout mice
We previously demonstrated the importance of PGI2/IP receptors in the HCO3- stimulatory
action of capsaicin in the duodenum [16]. Since capsaicin also stimulated HCO3- secretion in
the stomach, in an indomethacin-inhibitable manner, we attempted to identify the type of
prostanoid receptor involved in capsaicin-induced responses in the stomach using EP1-, EP3-,
and IP-receptor knockout mice, in comparison with those induced by mucosal acidification.
The mouse stomach spontaneously secreted HCO3- at a rate of 0.1-0.3 µEq/10 min. Capsaicin
(0.3 mg/ml), which was applied to the chamber for 10 min, increased the gastric secretion of
HCO3- in wild-type mice, and the same effect was also observed in EP1-or EP3-receptor
knockout mice, but was absent in mice lacking IP receptors (Figure 7). HCO3- secretion was
also increased in wild-type mice following the exposure of the mucosa to 50 mM HCl for 10
min, and the same response was also observed in EP3 and IP, but not EP1 receptor knockout
animals (Figure 8). The response induced by either capsaicin or acidification in wild-type
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Figure 7. Effects of capsaicin on gastric HCO3- secretion in wild-type, and EP1-, EP3-, and IP-receptor knockout mice
under urethane anesthesia. Capsaicin (0.3 mg/ml) was applied to the chamber for 10 min. In some wild-type mice,
indomethacin (5 mg/kg) was given s.c. 1 hr before the capsaicin treatment. In Figure A, data are presented as a % of
basal values and represent the mean±SE of values determined every 10 minutes from 4~7 rats. Figure B shows the
total net HCO3- output for 1 hr after the capsaicin treatment, and data are presented as the mean±SE for 4~7 rats.
Significantly different at P<0.05; *from control wild-type mice; # from wild-type mice treated with capsaicin+saline.
4. Commentary
The gastroduodenal mucosa responds to acidification by significantly increasing the secretion
of HCO3-, which, in collaboration with mucus, contributes to the mucosal tolerance of luminal
acid [1]. We previously reported that the intraluminal application of capsaicin stimulated the
secretion of HCO3- in these tissues by activating capsaicin-sensitive afferent neurons [4, 5, 15,
16]. The present study confirmed that both acid and capsaicin increased HCO3- secretion in the
stomach, which was mediated by these afferent neurons, and clearly showed the difference in
their modes of action in terms of sensitivity to TRPV1 and prostanoid receptors. Furthermore,
we observed the involvement of endogenous PGs and NO in the stimulatory action of capsaicin
in the stomach, which was consistent with previous findings in the duodenum [21].
TRPV1 is a nonselective cation channel that responds to protons as well as capsaicin [6]. The
binding sites of capsaicin are located on the intracellular site of the receptor protein [24],
whereas the target of protons is thought to be located on the extracellular surface of the receptor
protein [25]. When the TRPV1 antagonist, capsazepine was applied to the mucosa together
with capsaicin or acid in the present study, it completely blocked the increase in gastric
HCO3- secretion induced by capsaicin, but not acid, in spite of both responses being mediated
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by capsaicin-sensitive afferent neurons. These results are consistent with our previous findings
in the duodenum, in which capsazepine significantly mitigated the response induced by
capsaicin, but not mucosal acidification [13]. Akiba et al [26] reported that acid in the lumen
induced a mucosal hyperemic response in the rat duodenum in a capsazepine-sensitive
manner, and suggested that luminal acid may be an endogenous ligand for duodenal TRPV1.
McIntyre et al [27] described pharmacological differences between the human and rat TRPV1
and demonstrated that capsazepine blocked the response of human, but not rat TRPV1 to low
pH. The reason for these different results between studies currently remains unclear. The
results of the present study do not exclude the involvement of TRPV1 in the acid-induced
secretion of HCO3-; however, the target site of acid may differ from that of capsaicin, ie., the
binding site inhibitable by capsazepine. Alternatively, acid may activate these afferent neurons
through acid-sensing ionic channels (ASICs). This proposal has been supported by the recent
findings in which the acid-induced duodenal HCO3- response was greater in female than male
rats, with the different responses being parallel with the intensity of the expression of ASIC3,
and ovariectomy suppressed the expression of ASIC3 in the duodenum and abolished such a
gender difference in the HCO3- response [28].
Endogenous PGs are known to be particularly important in the local regulation of HCO3-
secretion in the gastroduodenal mucosa. We previously demonstrated, using subtype-specific
EP agonists and antagonists, that PGE2 stimulated the secretion of HCO3- in the duodenum
Figure 8. Effects of mucosal acidification on gastric HCO3- secretion in wild-type, and EP1-, EP3-, and IP-receptor
knockout mice under urethane anesthesia. Acidification was achieved by exposing the mucosa to 50 mM HCl for 10
min. In some wild-type mice, indomethacin (5 mg/kg) was administered s.c. 1 hr before the capsaicin treatment. In
Figure A, data are presented as a % of basal values and represent the mean±SE of values determined every 10 minutes
from 4~8 rats. Figure B shows the total net HCO3- output for 1 hr after the capsaicin treatment, and data are presented
as the mean±SE for 4~8 rats. Significantly different at P<0.05; * from control wild-type mice; # from wild-type mice
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TRPV1 is a nonselective cation channel that responds to protons as well as capsaicin [6]. The
binding sites of capsaicin are located on the intracellular site of the receptor protein [24],
whereas the target of protons is thought to be located on the extracellular surface of the receptor
protein [25]. When the TRPV1 antagonist, capsazepine was applied to the mucosa together
with capsaicin or acid in the present study, it completely blocked the increase in gastric
HCO3- secretion induced by capsaicin, but not acid, in spite of both responses being mediated
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by capsaicin-sensitive afferent neurons. These results are consistent with our previous findings
in the duodenum, in which capsazepine significantly mitigated the response induced by
capsaicin, but not mucosal acidification [13]. Akiba et al [26] reported that acid in the lumen
induced a mucosal hyperemic response in the rat duodenum in a capsazepine-sensitive
manner, and suggested that luminal acid may be an endogenous ligand for duodenal TRPV1.
McIntyre et al [27] described pharmacological differences between the human and rat TRPV1
and demonstrated that capsazepine blocked the response of human, but not rat TRPV1 to low
pH. The reason for these different results between studies currently remains unclear. The
results of the present study do not exclude the involvement of TRPV1 in the acid-induced
secretion of HCO3-; however, the target site of acid may differ from that of capsaicin, ie., the
binding site inhibitable by capsazepine. Alternatively, acid may activate these afferent neurons
through acid-sensing ionic channels (ASICs). This proposal has been supported by the recent
findings in which the acid-induced duodenal HCO3- response was greater in female than male
rats, with the different responses being parallel with the intensity of the expression of ASIC3,
and ovariectomy suppressed the expression of ASIC3 in the duodenum and abolished such a
gender difference in the HCO3- response [28].
Endogenous PGs are known to be particularly important in the local regulation of HCO3-
secretion in the gastroduodenal mucosa. We previously demonstrated, using subtype-specific
EP agonists and antagonists, that PGE2 stimulated the secretion of HCO3- in the duodenum
Figure 8. Effects of mucosal acidification on gastric HCO3- secretion in wild-type, and EP1-, EP3-, and IP-receptor
knockout mice under urethane anesthesia. Acidification was achieved by exposing the mucosa to 50 mM HCl for 10
min. In some wild-type mice, indomethacin (5 mg/kg) was administered s.c. 1 hr before the capsaicin treatment. In
Figure A, data are presented as a % of basal values and represent the mean±SE of values determined every 10 minutes
from 4~8 rats. Figure B shows the total net HCO3- output for 1 hr after the capsaicin treatment, and data are presented
as the mean±SE for 4~8 rats. Significantly different at P<0.05; * from control wild-type mice; # from wild-type mice




through EP3/EP4 receptors and in the stomach through EP1 receptors [15, 16, 29]. Many
previous studies reported that mucosal acidification increased HCO3-secretion in these tissues,
with a concomitant rise in mucosal PGE2 levels [12, 13, 16]. Capsaicin also stimulated the
secretion of HCO3- in the stomach in an indomethacin-inhibitable manner, which suggested
the involvement of endogenous PGs. However, capsaicin was shown to increase PGE2
production in the duodenum, but not in the stomach [13, 30]. Notwithstanding, this agent
exhibited various effects in the stomach, such as mucosal protection and hyperemia, mediated
by capsaicin-sensitive afferent neurons that also depended on endogenous PGs [4, 5, 31]. We
confirmed that the intragastric application of capsaicin significantly enhanced the levels of 6-
keto PGF1α, the PGI2 metabolite, which was consistent with the findings reported in the mouse
stomach [21, 31]. We previously demonstrated that the gastroprotective effects of capsaicin
against HCl/ethanol were significantly attenuated by indomethacin in wild-type mice, but
were completely absent in animals lacking IP receptors [30]. In the present study, capsaicin
increased gastric HCO3- secretion in EP1-and EP3-receptor knockout mice, similar to wild-type
mice, but did not in animals lacking IP receptors. These results strongly suggest that endoge‐
nous PGI2 plays a supportive role in the action of capsaicin in the stomach, possibly by
sensitizing sensory neurons through IP receptors.
However, HCO3- secretion induced by acidification remained unchanged in IP receptor
knockout mice and was absent in animals lacking EP1 receptors. These results further support
the response of HCO3- induced in the stomach by acidification and capsaicin, but depending
on sensory neurons, being mediated by different mechanisms related to PG dependency; the
former is mainly mediated by PGE2 through EP1 receptors, while the latter depends on PGI2/
IP receptors. Similar results were obtained for the gastric hyperemic response induced by acid
or capsaicin [31]. Although gastric hyperemic responses to these treatments were mitigated
by the capsaicin pretreatment [2, 32], the response induced by acid required the presence of
EP1 receptors [33], while that evoked by capsaicin required the presence of IP receptors [29].
Thus, it is not unreasonable to assume that the presence of different prostanoid receptors may
be required for gastric HCO3-secretion in response to acid or capsaicin.
We found that capsaicin had no effect on the production of PGE2, but significantly increased
that of PGI2 in the stomach. Capsaicin-sensitive afferent neurons are known to be abundantly
at peri-vascular sites, and the stimulation by capsaicin releases CGRP/NO, resulting in an
increase in mucosal blood flow [2]. Harada et al. [34] reported that the activation of these
afferent neurons ameliorated ischemia/reperfusion-induced liver injury by limiting the
inflammatory response through an enhancement in endothelial PGI2 production, and sug‐
gested that the CGRP-induced activation of both endothelial NO synthase and cyclooxyge‐
nase-1 may be involved in this mechanism. Thus, it is possible that capsaicin increases
endothelial PGI2 production locally in the stomach when applied topically to the mucosa. The
reason why capsaicin had different effects on the production of PGE2 and PGI2 in the stomach
currently remains unknown.
The present study also showed that capsaicin-induced HCO3- secretion in the stomach was
significantly attenuated by L-NAME, which suggesed the involvement of endogenous NO in
this process, in addition to PGs. Several studies showed that CGRP, the dominant neurotrans‐
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mitter of spinal afferents, had various pharmacological actions, such as vasodilation, that were
mediated by endogenous NO [2, 3, 35]. We demonstrated that the NO donor, NOR-3 stimu‐
lated gastric HCO3- secretion in the present study, and this was consistent with our previous
findings in the duodenum [12]. Nishihara et al [36] reported that capsaicin increased the release
of CGRP and NO in the rat stomach. Although we did not measure NO release in the stomach
following the capsaicin treatment, it is assumed that capsaicin activated primary afferent
neurons, with the assistance of PGI2, to liberate CGRP, which in turn stimulated NO release,
resulting in an increase in gastric HCO3- secretion.
Bradykinin is also known to activate nociceptive-like afferent neurons through metabotropic
G protein-coupled bradykinin B2 receptors [37, 38]. A previous study showed that binding to
B2 receptors activated an intracellular signaling cascade, which led to the opening of TRPV1
channels [39]. We found that bradykinin itself stimulated the secretion of HCO3- in the stomach
in the present study. Furthermore, this response was attenuated not only by FR172357, the B2
antagonist, but also by indomethacin and L-NAME, which suggested the involvement of both
PGs and NO in the response of HCO3- to bradykinin. The stimulatory effect of bradykinin was
also significantly mitigated by the chemical ablation of capsaicin-sensitive afferent neurons,
but was not affected by capsazepine, a TRPV1 antagonist. The stimulatory effect of bradykinin
on HCO3- secretion is assumed to be partly mediated by sensory neurons via B2 receptors, but
not through the interaction with TRPV1, in addition to endogenous PGs. Since bradykinin also
potentiates the activation of TRPV1 by capsaicin through the hydrolysis of endogenous
posphatidylinositol-4, 5-bisphosphate in a phospholipase C-dependent manner [39, 40], it is
possible that capsaicin-induced gastric HCO3- secretion may be affected by the B2 receptor
antagonist. However, the present study showed that the responses induced by capsaicin and
acidification were not significantly affected by FR172357, which suggests that endogenous
bradykinin has no role in these responses. The reason for these results has yet to be elucidated
and is currently under investigation in our laboratory.
5. Summary
Capsaicin is assumed to stimulate the secretion of HCO3- in the stomach mediated by endog‐
enous PGs and NO, as well as capsaicin-sensitive afferent neurons, but not bradykinin B2
receptors. Mucosal acidification also increased gastric HCO3- secretion through sensory
neurons mediated by both PGs and NO, similar to capsaicin; however, their modes of action
differed in terms of capsazepine-sensitivity and prostanoid receptor-dependency (Figure 9).
Although luminal H+ played a modulator-type role in the physiological response mediated by
capsaicin-sensitive afferent neurons in the stomach, it is likely that this action was not due to
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by capsaicin-sensitive afferent neurons that also depended on endogenous PGs [4, 5, 31]. We
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keto PGF1α, the PGI2 metabolite, which was consistent with the findings reported in the mouse
stomach [21, 31]. We previously demonstrated that the gastroprotective effects of capsaicin
against HCl/ethanol were significantly attenuated by indomethacin in wild-type mice, but
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mice, but did not in animals lacking IP receptors. These results strongly suggest that endoge‐
nous PGI2 plays a supportive role in the action of capsaicin in the stomach, possibly by
sensitizing sensory neurons through IP receptors.
However, HCO3- secretion induced by acidification remained unchanged in IP receptor
knockout mice and was absent in animals lacking EP1 receptors. These results further support
the response of HCO3- induced in the stomach by acidification and capsaicin, but depending
on sensory neurons, being mediated by different mechanisms related to PG dependency; the
former is mainly mediated by PGE2 through EP1 receptors, while the latter depends on PGI2/
IP receptors. Similar results were obtained for the gastric hyperemic response induced by acid
or capsaicin [31]. Although gastric hyperemic responses to these treatments were mitigated
by the capsaicin pretreatment [2, 32], the response induced by acid required the presence of
EP1 receptors [33], while that evoked by capsaicin required the presence of IP receptors [29].
Thus, it is not unreasonable to assume that the presence of different prostanoid receptors may
be required for gastric HCO3-secretion in response to acid or capsaicin.
We found that capsaicin had no effect on the production of PGE2, but significantly increased
that of PGI2 in the stomach. Capsaicin-sensitive afferent neurons are known to be abundantly
at peri-vascular sites, and the stimulation by capsaicin releases CGRP/NO, resulting in an
increase in mucosal blood flow [2]. Harada et al. [34] reported that the activation of these
afferent neurons ameliorated ischemia/reperfusion-induced liver injury by limiting the
inflammatory response through an enhancement in endothelial PGI2 production, and sug‐
gested that the CGRP-induced activation of both endothelial NO synthase and cyclooxyge‐
nase-1 may be involved in this mechanism. Thus, it is possible that capsaicin increases
endothelial PGI2 production locally in the stomach when applied topically to the mucosa. The
reason why capsaicin had different effects on the production of PGE2 and PGI2 in the stomach
currently remains unknown.
The present study also showed that capsaicin-induced HCO3- secretion in the stomach was
significantly attenuated by L-NAME, which suggesed the involvement of endogenous NO in
this process, in addition to PGs. Several studies showed that CGRP, the dominant neurotrans‐
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mitter of spinal afferents, had various pharmacological actions, such as vasodilation, that were
mediated by endogenous NO [2, 3, 35]. We demonstrated that the NO donor, NOR-3 stimu‐
lated gastric HCO3- secretion in the present study, and this was consistent with our previous
findings in the duodenum [12]. Nishihara et al [36] reported that capsaicin increased the release
of CGRP and NO in the rat stomach. Although we did not measure NO release in the stomach
following the capsaicin treatment, it is assumed that capsaicin activated primary afferent
neurons, with the assistance of PGI2, to liberate CGRP, which in turn stimulated NO release,
resulting in an increase in gastric HCO3- secretion.
Bradykinin is also known to activate nociceptive-like afferent neurons through metabotropic
G protein-coupled bradykinin B2 receptors [37, 38]. A previous study showed that binding to
B2 receptors activated an intracellular signaling cascade, which led to the opening of TRPV1
channels [39]. We found that bradykinin itself stimulated the secretion of HCO3- in the stomach
in the present study. Furthermore, this response was attenuated not only by FR172357, the B2
antagonist, but also by indomethacin and L-NAME, which suggested the involvement of both
PGs and NO in the response of HCO3- to bradykinin. The stimulatory effect of bradykinin was
also significantly mitigated by the chemical ablation of capsaicin-sensitive afferent neurons,
but was not affected by capsazepine, a TRPV1 antagonist. The stimulatory effect of bradykinin
on HCO3- secretion is assumed to be partly mediated by sensory neurons via B2 receptors, but
not through the interaction with TRPV1, in addition to endogenous PGs. Since bradykinin also
potentiates the activation of TRPV1 by capsaicin through the hydrolysis of endogenous
posphatidylinositol-4, 5-bisphosphate in a phospholipase C-dependent manner [39, 40], it is
possible that capsaicin-induced gastric HCO3- secretion may be affected by the B2 receptor
antagonist. However, the present study showed that the responses induced by capsaicin and
acidification were not significantly affected by FR172357, which suggests that endogenous
bradykinin has no role in these responses. The reason for these results has yet to be elucidated
and is currently under investigation in our laboratory.
5. Summary
Capsaicin is assumed to stimulate the secretion of HCO3- in the stomach mediated by endog‐
enous PGs and NO, as well as capsaicin-sensitive afferent neurons, but not bradykinin B2
receptors. Mucosal acidification also increased gastric HCO3- secretion through sensory
neurons mediated by both PGs and NO, similar to capsaicin; however, their modes of action
differed in terms of capsazepine-sensitivity and prostanoid receptor-dependency (Figure 9).
Although luminal H+ played a modulator-type role in the physiological response mediated by
capsaicin-sensitive afferent neurons in the stomach, it is likely that this action was not due to





Figure 9. Mechanisms underlying stimulation of gastric HCO3- secretion induced by capsaicin and acid. Capsaicin
stimulated HCO3- secretion in the stomach, essentially through capsaicin-sensitive afferent neurons via the activation
of TRPV1, and this action was mediated with endogenous PGE2/EP1 receptors and NO. Mucosal acidification also in‐
creased HCO3- secretion through the activation of sensory neurons as well as endogenous PGs and NO; however, this
action did not result from an interaction between H+ and the capsazepine-sensitive site of TRPV1, and depended on
the PGI2/IP receptor.
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1. Introduction
How can gastric mucosa resist to wide variety of endogenous (e.g. acid, pepsin, H. pylori) and
exogenous (bacterial products, NSAIDs, alcohol, cytotoxic agents) mucosal challenges? Or
how can it be explained that while the incidence of mucosal injury related to acid secretion is
about 20% of the population, everybody secretes acid throughout the life [1]? And how can be
answered the classic question of Davenport: why the stomach does not digest itself [2]?
Though accumulating data strongly suggest an apparent redundancy in the processes of
gastric mucosal defense, several mediators, mechanisms, structural elements involved in
mucosal protection have been identified, the precious mechanism has not been completely
clarified yet and incompletely understood.
The aim of present work is to give a short overview on the protective mechanism of gastric
mucosal protection, particularly on capsaicin sensitive afferent pathways and mediators
released from sensory nerve endings and play a role in maintaining gastric mucosal integrity.
2. Gastric mucosal defense: mechanisms, mediators
Gastric mucosal defense to acid and other noxious stimulus involves both structural and
functional components. Gastric mucosal barrier consists of the pre-epithelial mucus bicarbon‐
ate layer, an epithelial layer, and a post-epithelial layer. The pre-epithelial mucus bicarbonate
layer consist of mucus gel, bicarbonat surfactant phospholipids, treofil peptides. Epithelial
layer, and a post-epithelial layer involve blood vessels, non-epithelial cells and enteric nerves
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play a role in generation of different substances which are essential in maintaining mucosal
integrity and gastric mucosal defense, e.g. bicarbonate, mucus, phospholipids, trefoil peptides,
prostaglandins (PGs), heat shock proteins [reviews 3-5].
2.1. Mucosal barrier
The pre-epitehlieal layer protects the gastric mucosa from microscopic damage. This layer
consists of mucus gel, bicarbonate and surfactant phospholipids, which cover the mucosal
surface. It retains bicarbonate secreted by surface epithelial cells to maintain a neutral micro‐
environment [5-7].
Trefoil factor family (TFF) proteins are able to enhance mucosal barrier functions by stabilizing
the mucus gel and promoting epithelial restitution [8, 9]. These small protease-resistant
proteins have been demonstrated to be protective demonstrated in various ulcer models [10,
11], the exact molecular mechanism has not been clarified yet.
2.2. Prostaglandin
Though the term „cytoprotection” has been used first by Chaudhury and Jacobson [12] the
classic definition of cytoprotection derives from Robert et al [13]; they suggested that cyto‐
protection refers to protection of gastric mucosa against chemically/ physically-induced acute
gastric ulceration in doses much smaller than that reduce gastric acid secretion. According to
their results prostaglandins fulfilled this criteria. Later Lacy and Ito [14] reported that the
superficial layer, that is supposed to be highly involved in maintenance of mucosal barrier, is
not preserved during prostaglandin-induced protective processes; this was the main argue
against the term “cytoprotection”.
Prostaglandins are synthesized from arachidonic acid by all nucleated cells, but the highest
concentrations are found in gastrointestinal mucosa. Continuous synthesis of prostaglandins
by gastrointestinal mucosa most likely represents a physiological process necessary to
maintain cellular integrity and for this process prostaglandins serve as trophic factors [15, 16].
Subsequent studies proved that the maintenance of gastric mucosal blood flow and thus the
prevention of ischemia are the key elements in the mucosal protective effect of prostaglandins
[17]. Takeuchi et al. [18] suggested recently, that endogenous PGs also contribute to maintain‐
ing mucosal integrity after barrier disruption through an increase in mucosal blood flow,
which occurs via sensory neurons by activation of the EP1 receptor.
Inhibition of leukocyte adherence to the vascular endothelium and inhibition of apoptosis are
additional actions that can result in prevention of gastric mucosal damage [19].
Different prostaglandin receptors are involved in different processes resulting in mucosal
defense. The effects of PGE2 on various gastric functions are mediated by different EP receptor
subtypes; such as inhibition of acid secretion (EP3) and motility (EP1), stimulation of mucus
secretion (EP4) and HCO3-secretion (EP1), and an increase in mucosal blood flow (EP2/EP4).
However, the presence of EP1 receptors is essential to the protective action of PGE2 [20].
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2.3. Nitric oxide
Nitric oxide (NO) is a freely diffusible molecule, synthetized from L-arginine by the enzyme
NO synthase, exerts its biological action on vascular smooth muscle by stimulating soluble
guanylate-cyclase and the subsequent formation of cyclic guanosine-monophosphate, which
results in vasodilation.
NO has been shown to participate in the regulation of gastric mucosal microcirculation both
under resting and stimulated conditions, since inhibition of NO synthase significantly reduced
both the resting and the gastric acid-induced increased gastric mucosal blood flow [21, 22]. In
addition, inhibition of NO synthase increases gastric mucosal injury [23, 24], and the constit‐
utive isoform of NO synthase is important in maintaining gastric mucosal integrity [25].
NO mediates the mucosal vasodilatation and gastroprotective effect of calcitonin gene-related
peptide (CGRP), which is released from nerve terminals of primary sensory neurons and plays
a crucial role in gastric emergency system [26-28].
2.4. Protein and non-protein sulfhydryls
Protein and non-protein sulfhydryls were suggested also as endogenous protective com‐
pounds [29, 30], and it was raised that the maintenance of a critical level of non-protein
sulfhydryls in the gastric mucosa is important for the gastroprotective action - besides nitric
oxide [31].
2.5. Hydrogen sulfid
H2S like NO, is an important gaseous mediator of gastric mucosal protection [32], and
inhibition of endogenous H2S synthesis increases the susceptibility of the gastric mucosa to
the damaging action of non-steroidal anti-inflammatory drugs (NSAIDs) [33]. On the other
hand, exogenous H2S donors can increase the resistance of the gastric mucosa to injury induced
by NSAIDs [34].
The gastroprotective effect of H2S involves several mechanisms, such as maintenance of gastric
mucosal blood flow, stimulation of bicarbonate secretion, inhibition of pro-inflammatory
cytokine expression/release stimulation of prostaglandin synthesis, reduced leukocyte-
endothelial adherence, decreased reactive oxygen metabolite production and enhanced tissue
repair [35].
2.6. Matrix metalloproteinases
Matrix metalloproteinases (MMPs) play a role both in the pathogenesis and in healing of peptic
ulcers. These endopeptidases degrade extracellular matrix proteins and are essential for
extracellular matrix remodeling and wound healing [36]. Experimentally their altered
expression have been demonstrated in gastric ulcers induced by NSAIDs (indomethacin,
naproxen) or ethanol [37, 38].
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3. Activation of gastric mucosal protective processes by noxious stimulus
Noxious stimulus results in both generation of endogenous substance(s) that may counteract
or attenuate the mucosal injury, and initiation of further protective mechanisms or formation
of additional protective mediators that stimulate repair and restore mucosal integrity.
3.1. Hypoxia-inducible factor-1
Early phase of mucosal lesions is characterized by decrease of mucosal blood flow and the
consequent hypoxia. However, activation of hypoxia-inducible factor-1, in response to
hypoxia, induces trefoil factor family (TFF) gene expression in rat and human gastric epithelial
cells. The consequent production of TFF peptides augment surface mucous barrier functions
(see above) and stimulate epithelial restitution by increasing mucosal blood flow, migration
of cells and restoration of barrier function [39, 40].
3.2. Antioxidant enzymes
Gastric mucosal injury is characterized by excessive production and/or decreased elimination
of reactive oxygen species (ROS), that can induce tissue damage by promoting lipid peroxi‐
dation and increasing the production of inflammatory mediators and proinflammatory
cytokines. Antioxidant enzymes, such as superoxide dismutase (SOD), catalase or glutathione
are able to counteract the oxidative stress, for example, SOD converts superoxide radical anion
(O2˙−) into less noxious hydrogen peroxide (H2O2) [39].
3.3. Heme oxygenase-1
Heme oxygenase-1 (HO-1), the inducible form of heme oxygenase, also exerts cytoprotective
effect and its generation may be induced by oxidative stress, inflammatory cytokines or heavy
metals [40]. HO-1 catalyzes the oxidative degradation of the pro-oxidant heme to antioxidant
and cytoprotective carbon monoxide and biliverdin [41, 42]. The activity of HO-1 is also
increased during the healing of gastric ulcers, which indicates its involvement in the mucosal
repair processes [43].
3.4. Growth factors
In addition, several genes, encoding peptides, are also upregulated after mucosal damage in
the gastrointestinal mucosa and stimulate the repair process. Epidermal growth factor (EGF) a
potent stimulant of growth and repair when infused systemically. It inhibits gastric acid
secretion, and has a cytoprotective effect on the gastrointestinal mucosa. On the other hand,
EGF is one of the main peptides secreted by repair lineages of the gastrointestinal tract [44].
Treofil factor family (TFF) has both cytoprotective and stimulant effect on repair. Three members
(TFF1/pS2, TFF2/SP, and TFF3/ITF) of the family are present in human gastrointestinal mucosa.
They are produced rapidly at sites of injury and stimulate the repair process. Exogenous TFF2/
SP exerts a cytoprotective action in indomethacin-induced ulcer model in rats [45]. Transform‐
ing growth factor α (TGF-α) is normally trophic both in vitro in different cell lines and in vivo
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in the intestine of rats [46]. TGF-α decreased the gastric damage induced by ethanol or stress
[47], and enhanced immunoreactive TGF-α was measured in gastric juice (within 30 minutes)
following gastric instillation of hydrochloric acid. Transforming growth factor β (TGF-ß) is also
involved in mucosal defense, but in contrast to other growth factors, it regulates the epithelial
proliferation, it halts the proliferation of epithelial cells once they have left the crypts or glands.
In addition, it is also a potent stimulant of cell migration [48-50]). Hepatocyte growth factor
(HGF) is secreted as inactive precursor and than converted to an active form. HGF receptor
was shown to be increased in the gastric mucosa after injury [51]. It was suggested that, the
active HGF, produced in the stomach after injury, may stimulate the proliferation of gastric
mucosal epithelial cells through increased number of HGF receptor. Basic fibroblast growth factor
(bFGF) a potent stimulant of angiogenesis, and accelerates the healing of experimental gastric
and duodenal ulcers in rats [52, 53]. In ulcerated human gastric mucosa, immunoreactive bFGF
is upregulated [54], thought additional data suggest that bFGF mRNA expression is an early
event after mucosal injury [55]. Platelet derived growth factor (PDGF) also stimulates angiogen‐
esis. It was shown that PDGF (and bFGF) accelerated the healing of cysteamine induced
duodenal ulcers in rats by stimulating angiogenesis and granulation tissue formation [56].
Furthermore, in experimental duodenal ulcer and colitis in rats (after a transitory reduction)
of the concentrations of bFGF and PDGF increased in the healing phases both experimental
lesions [57]. Vascular endothelial growth factor (VEGF) has dual role; in acute gastric ulcer it
induced gastroprotective effect surprisingly by enhancing vascular permeability and the
consequent perivascular dilution barrier towards gastric mucosal irritants [58]. On the other
hand, in chronic duodenal ulcer VEGF stimulates granulation tissue formation and angiogen‐
esis resulted in ulcer healing. In addition, upregulation of VEGF mRNA expression was
observed after ethanol challenge [59].
3.5. Capsaicin-sensitive primary afferent neurons
When the gastric epithelium is exposed to acid back diffusion or any irritant, one of the most
rapid and important responses is an increase in mucosal blood flow. The aim of this hyperemic
response is to remove, dilute and buffer any back-diffusing injurious agent or acid. This
response is mediated by primary sensory afferent neurons, namely if the mucosal barrier is
disturbed or disrupted in the presence of luminal acid, the acid reaching the lamina propria
stimulates spinal afferents. This stimulation will initiate the efferent-like function of primary
afferents resulting in CGRP and NO formation and release that induces a prompt hyperaemia
in the gastro-duodenal mucosa and bicarbonate (HCO3−) secretion [60-68].
3.5.1. Capsaicin-sensitive primary afferent neurons and transient receptor potential vanilloid-1
(TRVP1) receptors
Afferent neurons have a basic role in regulation of gastrointestinal functions, and also in gastric
mucosal defense. Beside intrinsic sensory neurons which have their cell body within the
gastrointestinal tract and originate in the myenteric or submucosal plexus, there are two
groups of extrinsic sensory neurons: vagal and spinal afferents. 75-90% of the axons in vagus
nerve are afferent fibers [69], and 9% of these afferent fibres are the capsaicin-sensitive afferent
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(bFGF) a potent stimulant of angiogenesis, and accelerates the healing of experimental gastric
and duodenal ulcers in rats [52, 53]. In ulcerated human gastric mucosa, immunoreactive bFGF
is upregulated [54], thought additional data suggest that bFGF mRNA expression is an early
event after mucosal injury [55]. Platelet derived growth factor (PDGF) also stimulates angiogen‐
esis. It was shown that PDGF (and bFGF) accelerated the healing of cysteamine induced
duodenal ulcers in rats by stimulating angiogenesis and granulation tissue formation [56].
Furthermore, in experimental duodenal ulcer and colitis in rats (after a transitory reduction)
of the concentrations of bFGF and PDGF increased in the healing phases both experimental
lesions [57]. Vascular endothelial growth factor (VEGF) has dual role; in acute gastric ulcer it
induced gastroprotective effect surprisingly by enhancing vascular permeability and the
consequent perivascular dilution barrier towards gastric mucosal irritants [58]. On the other
hand, in chronic duodenal ulcer VEGF stimulates granulation tissue formation and angiogen‐
esis resulted in ulcer healing. In addition, upregulation of VEGF mRNA expression was
observed after ethanol challenge [59].
3.5. Capsaicin-sensitive primary afferent neurons
When the gastric epithelium is exposed to acid back diffusion or any irritant, one of the most
rapid and important responses is an increase in mucosal blood flow. The aim of this hyperemic
response is to remove, dilute and buffer any back-diffusing injurious agent or acid. This
response is mediated by primary sensory afferent neurons, namely if the mucosal barrier is
disturbed or disrupted in the presence of luminal acid, the acid reaching the lamina propria
stimulates spinal afferents. This stimulation will initiate the efferent-like function of primary
afferents resulting in CGRP and NO formation and release that induces a prompt hyperaemia
in the gastro-duodenal mucosa and bicarbonate (HCO3−) secretion [60-68].
3.5.1. Capsaicin-sensitive primary afferent neurons and transient receptor potential vanilloid-1
(TRVP1) receptors
Afferent neurons have a basic role in regulation of gastrointestinal functions, and also in gastric
mucosal defense. Beside intrinsic sensory neurons which have their cell body within the
gastrointestinal tract and originate in the myenteric or submucosal plexus, there are two
groups of extrinsic sensory neurons: vagal and spinal afferents. 75-90% of the axons in vagus
nerve are afferent fibers [69], and 9% of these afferent fibres are the capsaicin-sensitive afferent
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nerves [70], that originate in the jugular and nodose ganglia and project to medullary brain
stem. The spinal afferents have their cell body in dorsal root ganglia and reach the stomach
via spinal and splanchnic nerves.
The first evidence that suggested the prominent role of sensory nerves in gastric mucosal
resistance was obtained by experiments when ablation of sensory nerve was shown to result
in aggravation of mucosal lesions induced by hydrochloric acid, aspirin, indomethacin [review
71]. Moreover, Szolcsányi and Barthó described that stimulation of afferent nerves by capsaicin
resulted in mucosal protection against acid induced mucosal injury [63, 71]. The role of sensory
nerves in gastric mucosal defense was confirmed by the findings that capsaicin induces
gastroprotective action following intragastric administration, both in experimental animals
[71, 72] and in humans [73].
The protective action of capsaicin is due to its stimulatory effect on capsaicin-sensitive primary
afferent neurons, since defunctionalisation of afferent neurons by high parenteral dose of
capsaicin [74] abolished the gastroprotective effect of capsaicin [67, 71].
The action of capsaicin is mediated by capsaicin receptor which was cloned and named as
transient receptor potential vanilloid-1 (TRVP1) [75], the specific sensor for capsaicin [76-79].
In the gastrointestinal tract, TRPV1 can be identified in intrinsic enteric neurons, extrinsic
sensory neurons, epithelial and endocrine cells [80-84].
The acid-evoked hyperemia in the esophageal and duodenal mucosa is inhibited by the TRPV1
antagonist capsazepine or sensory denervation, suggesting that acid activates TRPV1 on
sensory nerve fibers [85, 86]. As a result, activation of TRPV1-positive sensory nerve fibers are
able to protect the esophageal, gastric and intestinal mucosa from a variety of injurious by
stimulating mucosal microcirculation [61].
3.5.2. Peptide mediators of capsaicin sensitive primary afferent neurones
Apart from signaling to the CNS, TRPV1-expressing sensory nerve fibers when activated,
peptide transmitters, such as CGRP, somatostatin and the tachykinins substance P (SP) and
neurokinin, as well as well as nitrogen oxide (NO) and /or ATP can be released from the
peripheral nerve endings of afferents nerves and can influence the gastrointestinal function
[61, 87-89]. Peptide mediators of TRPV1-positive afferent neurons may induce wide variety of
actions.
CGRP and substance P fibers innervate the mucosal and submucosal microvasculature [78,
90]. CGRP in rat stomach are located exclusively in extrinsic afferent fibers, most if not all, in
spinal sensory afferent neurons [91-93]. Others also confirmed that CGRP, substance P,
somatostatin were characteristic of capsaicin-sensitive DRG neurons [77, 78, 93-95], while CGRP
was absent from vagal afferent neurons containing TRPV1 [91]. However, Suzuki et al. [96]
demonstrated that the density of CGRP-immunreactive fibers in the mucosa was largely
reduced also by vagotomy suggesting CGRP-immunreactive fibers to be of both vagal and
spinal origin. The CGRP-and SP-immunreactive fibers were less influenced by vagotomy in
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside162
the submucosal and muscular layers. Furthermore, major portion of SP-immunreactive fibers
in the mucosa is of vagal origin, and in contrast to CGRP, SP-immunreactive fibers are not
capsaicin sensitive. In contrast, others showed that capsaicin also induces the release of SP
from guinea pig and rat stomach [97]. Sternini et al [93] suggested that while CGRP-containing
nerve fibers arise exclusively from extrinsic neurons, SP-containing fibers are of both extrinsic
and intrinsic originl.
The gastroprotective effect of both CGRP and capsaicin was blocked by CGRP1 receptor
antagonist, CGRP 8-37 [98]. However, not only CGRP1 receptor may mediate gastroprotective
effects, since CGRP1 receptor antagonist failed to influence the effect of CGRP against aspirin-
induced lesions [99]. CGRP/NO released from the nerve terminal of sensory afferents, induces
gastroprotective effect not only by increasing mucosal microcirculation, but also by stimula‐
tion of mucin synthesis in the gastric corpus mucosa [100] and by reduction of myoelectrical
activity in gastric smooth muscle [101].
On the other hand, TRPV1 activation has been found to exacerbate inflammation and tissue
injury [76]. In addition, in the murine gastric mucosa, in ethanol-induced injury TRPV1-
mediated release of neuronal substance P and subsequent formation of reactive oxygen species
are involved in the development of mucosal damage
[102]. Moreover, colitis induced by dextran sulfate or trinitrobenzene sulfonic acid in ro‐
dents was attenuated by TRPV1 antagonist or TRPV1 knockout animals [103, 104]. TRPV1
receptors may also play a proinflammatory role in the ileitis elicited by C. difficile toxin A.
Formation of endocannabinoids is supposed to be involved in this process, and endocanna‐
binoids stimulate TRPV1, consequently, induce the release of substance P from sensory
nerve fibers. Substance P activates enteric neurons and immune cells, which finally results
in hypersecretion, inflammation, and mucosal damage [105].
How can CGRP mediate gastric mucosal protection? As mentioned above the gastric mucosa
and submucosa are densely innervated by CGRP, which is localized in capsaicin-sensitive
afferent fibers. The protective effect of CGRP was lost after blockade of the nitric oxide system,
but not the prostaglandin system indicating that the vasodilator and the consequent gastro‐
protective effect of CGRP is due to NO, but not to PG release [106]. However, the role of
prostaglandins in sensory nerve-mediated gastroprotection was suggested by the findings that
indomethacin inhibited the mucosal protective effect of capsaicin [107]. Takeuchi et al [108]
concluded that capsaicin exhibits gastric cytoprotection, essentially by stimulating sensory
neurons, and this action is facilitated by endogenous prostaglandins through EP2/IP receptors,
probably sensitizing the sensory neurons to capsaicin.
Substance P, released also from afferent nerve fibers, do not mediate vasodilation in the rats
stomach, neither the NK1 or NK2 antagonists influenced capsaicin-induced vasodilatation nor
tachykinins dilated the submucosal arteries and increased gastric mucosal blood flow; on the
contrary, substance P and neurokinin A induced constriction of submucosal veins [109, 110]
and substance P was supposed to be involved in the pathomechanism of ethanol-induced
gastric mucosal damage [111, 112]. However, others reported that substance P induce vaso‐
dilatation in vivo [113], and the effect could be attenuated by NG-monomethyl-L-arginine – a
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nerves [70], that originate in the jugular and nodose ganglia and project to medullary brain
stem. The spinal afferents have their cell body in dorsal root ganglia and reach the stomach
via spinal and splanchnic nerves.
The first evidence that suggested the prominent role of sensory nerves in gastric mucosal
resistance was obtained by experiments when ablation of sensory nerve was shown to result
in aggravation of mucosal lesions induced by hydrochloric acid, aspirin, indomethacin [review
71]. Moreover, Szolcsányi and Barthó described that stimulation of afferent nerves by capsaicin
resulted in mucosal protection against acid induced mucosal injury [63, 71]. The role of sensory
nerves in gastric mucosal defense was confirmed by the findings that capsaicin induces
gastroprotective action following intragastric administration, both in experimental animals
[71, 72] and in humans [73].
The protective action of capsaicin is due to its stimulatory effect on capsaicin-sensitive primary
afferent neurons, since defunctionalisation of afferent neurons by high parenteral dose of
capsaicin [74] abolished the gastroprotective effect of capsaicin [67, 71].
The action of capsaicin is mediated by capsaicin receptor which was cloned and named as
transient receptor potential vanilloid-1 (TRVP1) [75], the specific sensor for capsaicin [76-79].
In the gastrointestinal tract, TRPV1 can be identified in intrinsic enteric neurons, extrinsic
sensory neurons, epithelial and endocrine cells [80-84].
The acid-evoked hyperemia in the esophageal and duodenal mucosa is inhibited by the TRPV1
antagonist capsazepine or sensory denervation, suggesting that acid activates TRPV1 on
sensory nerve fibers [85, 86]. As a result, activation of TRPV1-positive sensory nerve fibers are
able to protect the esophageal, gastric and intestinal mucosa from a variety of injurious by
stimulating mucosal microcirculation [61].
3.5.2. Peptide mediators of capsaicin sensitive primary afferent neurones
Apart from signaling to the CNS, TRPV1-expressing sensory nerve fibers when activated,
peptide transmitters, such as CGRP, somatostatin and the tachykinins substance P (SP) and
neurokinin, as well as well as nitrogen oxide (NO) and /or ATP can be released from the
peripheral nerve endings of afferents nerves and can influence the gastrointestinal function
[61, 87-89]. Peptide mediators of TRPV1-positive afferent neurons may induce wide variety of
actions.
CGRP and substance P fibers innervate the mucosal and submucosal microvasculature [78,
90]. CGRP in rat stomach are located exclusively in extrinsic afferent fibers, most if not all, in
spinal sensory afferent neurons [91-93]. Others also confirmed that CGRP, substance P,
somatostatin were characteristic of capsaicin-sensitive DRG neurons [77, 78, 93-95], while CGRP
was absent from vagal afferent neurons containing TRPV1 [91]. However, Suzuki et al. [96]
demonstrated that the density of CGRP-immunreactive fibers in the mucosa was largely
reduced also by vagotomy suggesting CGRP-immunreactive fibers to be of both vagal and
spinal origin. The CGRP-and SP-immunreactive fibers were less influenced by vagotomy in
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the submucosal and muscular layers. Furthermore, major portion of SP-immunreactive fibers
in the mucosa is of vagal origin, and in contrast to CGRP, SP-immunreactive fibers are not
capsaicin sensitive. In contrast, others showed that capsaicin also induces the release of SP
from guinea pig and rat stomach [97]. Sternini et al [93] suggested that while CGRP-containing
nerve fibers arise exclusively from extrinsic neurons, SP-containing fibers are of both extrinsic
and intrinsic originl.
The gastroprotective effect of both CGRP and capsaicin was blocked by CGRP1 receptor
antagonist, CGRP 8-37 [98]. However, not only CGRP1 receptor may mediate gastroprotective
effects, since CGRP1 receptor antagonist failed to influence the effect of CGRP against aspirin-
induced lesions [99]. CGRP/NO released from the nerve terminal of sensory afferents, induces
gastroprotective effect not only by increasing mucosal microcirculation, but also by stimula‐
tion of mucin synthesis in the gastric corpus mucosa [100] and by reduction of myoelectrical
activity in gastric smooth muscle [101].
On the other hand, TRPV1 activation has been found to exacerbate inflammation and tissue
injury [76]. In addition, in the murine gastric mucosa, in ethanol-induced injury TRPV1-
mediated release of neuronal substance P and subsequent formation of reactive oxygen species
are involved in the development of mucosal damage
[102]. Moreover, colitis induced by dextran sulfate or trinitrobenzene sulfonic acid in ro‐
dents was attenuated by TRPV1 antagonist or TRPV1 knockout animals [103, 104]. TRPV1
receptors may also play a proinflammatory role in the ileitis elicited by C. difficile toxin A.
Formation of endocannabinoids is supposed to be involved in this process, and endocanna‐
binoids stimulate TRPV1, consequently, induce the release of substance P from sensory
nerve fibers. Substance P activates enteric neurons and immune cells, which finally results
in hypersecretion, inflammation, and mucosal damage [105].
How can CGRP mediate gastric mucosal protection? As mentioned above the gastric mucosa
and submucosa are densely innervated by CGRP, which is localized in capsaicin-sensitive
afferent fibers. The protective effect of CGRP was lost after blockade of the nitric oxide system,
but not the prostaglandin system indicating that the vasodilator and the consequent gastro‐
protective effect of CGRP is due to NO, but not to PG release [106]. However, the role of
prostaglandins in sensory nerve-mediated gastroprotection was suggested by the findings that
indomethacin inhibited the mucosal protective effect of capsaicin [107]. Takeuchi et al [108]
concluded that capsaicin exhibits gastric cytoprotection, essentially by stimulating sensory
neurons, and this action is facilitated by endogenous prostaglandins through EP2/IP receptors,
probably sensitizing the sensory neurons to capsaicin.
Substance P, released also from afferent nerve fibers, do not mediate vasodilation in the rats
stomach, neither the NK1 or NK2 antagonists influenced capsaicin-induced vasodilatation nor
tachykinins dilated the submucosal arteries and increased gastric mucosal blood flow; on the
contrary, substance P and neurokinin A induced constriction of submucosal veins [109, 110]
and substance P was supposed to be involved in the pathomechanism of ethanol-induced
gastric mucosal damage [111, 112]. However, others reported that substance P induce vaso‐
dilatation in vivo [113], and the effect could be attenuated by NG-monomethyl-L-arginine – a
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NO synthase inhibitor – suggesting the role of endogenous NO in the vasodilator response of
substance P.
3.5.3. Role of capsaicin sensitive afferent nerves in action of peripherally acting gastroprotective agents
Capsaicin sensitive afferent fibers are also involved in the mucosal protective action of several
gastroprotective agents. E.g. defunctionalisation of capsaicin-sensitive afferent nerves by
pretreatment with a neurotoxic dose of capsaicin aggravates gastric ulcers in rats and an‐
tagonised the gastroprotective effect of capsaicin (10 mg/kg p. os) and lafutidine indicating
that gastroprotective activity mediated by capsaicin-sensitive afferent nerves [114].
Similarly, the gastroprotective effect of different flavonoids against ethanol-lesions was
reduced by a neurotoxic dose of capsaicin, or by pretreatment with NO synthase inhibitor NG-
nitro-L arginine, indicating that plant-originated flavonoids-induced gastroprotection
probably due to enhancement of the expression of constitutive NO synthase and the release
of CGRP from sensory afferent nerves [115].
EGF was shown to exert a protective role against ethanol-induced gastric mucosal injury (10-30
µg, intragastrically), possibly by dilating the gastric mucosal arterioles via capsaicin-sensitive
afferent neurons involving CGRP and NO mechanisms. Namely, the protective effect of EGF
was significantly inhibited by pretreatment with capsaicin desensitization, human CGRP1
antagonist hCGRP 8-37, or the NO synthesis inhibitor, Nω-nitro-L-arginine methyl ester [116].
Mozsik et al [117] suggested participation of vanilloid/capsaicin receptors, CGRP and sub‐
stance P in gastric protection of omeprazole and omeprazole-like compounds.
Moreover, accumulating evidence indicates that capsaicin sensitive afferent fibers play a
pivotal role not only acutely in gastroprotection, but also in ulcer healing. In chronic ulcer
model, the acetic acid-induced model neurotoxic dose of capsaicin (100 mg/kg s.c.) signifi‐
cantly increased ulcer size, decreased gastric mucosal cell proliferation at the ulcer margin,
angiogenesis in the granulation tissue and also gastric mucus content. In addition, the dramatic
increase in elevation of EGF levels in salivary glands and serum was completely abolished by
neurotoxic dose of capsaicin. The results suggest that capsaicin sensitive nerves contribute to
gastroprotective and ulcer healing processes in the stomach probably by stimulation of EGF
expression in salivary glands [118].
3.5.4. Role of capsaicin sensitive afferent fibers and in the action of centrally acting gastroprotective
agents
Besides the periphery, gastric mucosal integrity can be regulated also by central mechanism.
In the last decades increasing number of evidence suggested that central nervous system (CNS)
has a pivotal role in regulation of gastric mucosal integrity. Different brain areas have been
suggested to be involved in centrally induced gastroprotection. Among them, hypothalamus
and dorsal vagal complex (DVC) seem to have a particularly important role and well defined
interconnections between neuroendocrine hypothalamus and the central autonomic system
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have been described. Descending hypothalamic efferents carry feedback signals to viscero‐
sensory and brainstem catecholaminergic neurons and regulatory inputs to parasympathetic
(dorsal vagal nucleus) and sympathetic (thoracolumbar intermediolateral cell column)
preganglionic neurons. These fibers arise mainly from neurons of the paraventricular, arcuate,
perifornical, and dorsomedial nuclei and the lateral hypothalamus. Pathways between the
hypothalamus and autonomic centers are bidirectional; the descending axons are mainly
peptidergic (corticotropin-releasing hormone, vasopressin, oxytocin, somatostatin, enkepha‐
lin, pro-opiomelanocortin), while the ascending fibers are both peptidergic (enkephalin,
neuropeptide Y, neurotensin, dynorphins) and catecholaminergic [119].
The first pharmacological evidence that neuropeptides by central mechanism are able to
influence gastric mucosal lesions was provided by the experiments with bombesin. Bombesin,
14-amino acid peptide, inhibited the gastric lesions induced by cold-restraint stress, aspirin,
indomethacin by intracisternal (i.c.) and/or intracerebroventricular (i.c.v.) injection [120, 121].
Several mechanism may be involved in the centrally induced mucosal protective effect of
bombesin, such as the antisecretory effect [122], inhibition of gastric motor activity, and
stimulation of protective processes (gastric mucus, bicarbonate secretion, gastric blood flow)
[123].
In addition, neurotensin, β-endorphin, substance P, and somatostatin proved to be also
protective given i.c. against cold restraint ulcer model. [124].
Cold restraint stress ulcer model is an acid dependent ulcer model [125]. As a next step, an
acid independent model, the ethanol-induced ulcer model has been used to examine the
gastroprotective effect of centally injected neuropeptides, where inhibiton of acid secretion is
not likely to contribute to the gastric mucosal protective action. Several neuropeptides were
injected either into dorsal motor nucleus of vagus (DMNV), i.c. or i.c.v. First, the effect of
thyreotropin-releasing hormon (TRH) or its stable analogue RX-77368, injected in low (0-5-1.5
ng), non-secretory dose into the cisterna magna or DMNV was shown to protect the gastric
mucosa against ethanol injury [126, 127].
Hereafter, additional neuropeptides proved to be gastroprotective given centrally, among
others adrenomedullin [128] peptide YY [129] amylin [130], leptin, cholecystokinin [131],
ghrelin [132], opioids, e.g. β-endorphin, deltorphin II, endomorphins [4, 133] nociceptin,
nocistatin [134], TLQP-21, a VGF-derived peptide [135], substance P [136] and angiotensin II
[137] (see reviews: [4, 127, 138]).
How can the centrally injected neuropeptide induce gastric mucosal protection in the periph‐
ery, in gastric mucosa? Convincing evidence suggest the role of vagal nerve in conveying the
central stimulus to the periphery. TRH or its stable analogue RX-77368, injected in non-
secretory dose into the cisterna magna or DMNV was the first peptide reported to protect the
gastric mucosa against ethanol injury through stimulation of vagal cholinergic pathways, since
both vagotomy and atropine reversed the gastroprotective effect. As a result of an intensive
research additional neuropeptides e.g. amylin, adrenomedullin, neurotensin, opioid peptides,
melatonin, ghrelin, leptin, as well as cannabinoids were shown to initiate gastroprotective
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NO synthase inhibitor – suggesting the role of endogenous NO in the vasodilator response of
substance P.
3.5.3. Role of capsaicin sensitive afferent nerves in action of peripherally acting gastroprotective agents
Capsaicin sensitive afferent fibers are also involved in the mucosal protective action of several
gastroprotective agents. E.g. defunctionalisation of capsaicin-sensitive afferent nerves by
pretreatment with a neurotoxic dose of capsaicin aggravates gastric ulcers in rats and an‐
tagonised the gastroprotective effect of capsaicin (10 mg/kg p. os) and lafutidine indicating
that gastroprotective activity mediated by capsaicin-sensitive afferent nerves [114].
Similarly, the gastroprotective effect of different flavonoids against ethanol-lesions was
reduced by a neurotoxic dose of capsaicin, or by pretreatment with NO synthase inhibitor NG-
nitro-L arginine, indicating that plant-originated flavonoids-induced gastroprotection
probably due to enhancement of the expression of constitutive NO synthase and the release
of CGRP from sensory afferent nerves [115].
EGF was shown to exert a protective role against ethanol-induced gastric mucosal injury (10-30
µg, intragastrically), possibly by dilating the gastric mucosal arterioles via capsaicin-sensitive
afferent neurons involving CGRP and NO mechanisms. Namely, the protective effect of EGF
was significantly inhibited by pretreatment with capsaicin desensitization, human CGRP1
antagonist hCGRP 8-37, or the NO synthesis inhibitor, Nω-nitro-L-arginine methyl ester [116].
Mozsik et al [117] suggested participation of vanilloid/capsaicin receptors, CGRP and sub‐
stance P in gastric protection of omeprazole and omeprazole-like compounds.
Moreover, accumulating evidence indicates that capsaicin sensitive afferent fibers play a
pivotal role not only acutely in gastroprotection, but also in ulcer healing. In chronic ulcer
model, the acetic acid-induced model neurotoxic dose of capsaicin (100 mg/kg s.c.) signifi‐
cantly increased ulcer size, decreased gastric mucosal cell proliferation at the ulcer margin,
angiogenesis in the granulation tissue and also gastric mucus content. In addition, the dramatic
increase in elevation of EGF levels in salivary glands and serum was completely abolished by
neurotoxic dose of capsaicin. The results suggest that capsaicin sensitive nerves contribute to
gastroprotective and ulcer healing processes in the stomach probably by stimulation of EGF
expression in salivary glands [118].
3.5.4. Role of capsaicin sensitive afferent fibers and in the action of centrally acting gastroprotective
agents
Besides the periphery, gastric mucosal integrity can be regulated also by central mechanism.
In the last decades increasing number of evidence suggested that central nervous system (CNS)
has a pivotal role in regulation of gastric mucosal integrity. Different brain areas have been
suggested to be involved in centrally induced gastroprotection. Among them, hypothalamus
and dorsal vagal complex (DVC) seem to have a particularly important role and well defined
interconnections between neuroendocrine hypothalamus and the central autonomic system
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have been described. Descending hypothalamic efferents carry feedback signals to viscero‐
sensory and brainstem catecholaminergic neurons and regulatory inputs to parasympathetic
(dorsal vagal nucleus) and sympathetic (thoracolumbar intermediolateral cell column)
preganglionic neurons. These fibers arise mainly from neurons of the paraventricular, arcuate,
perifornical, and dorsomedial nuclei and the lateral hypothalamus. Pathways between the
hypothalamus and autonomic centers are bidirectional; the descending axons are mainly
peptidergic (corticotropin-releasing hormone, vasopressin, oxytocin, somatostatin, enkepha‐
lin, pro-opiomelanocortin), while the ascending fibers are both peptidergic (enkephalin,
neuropeptide Y, neurotensin, dynorphins) and catecholaminergic [119].
The first pharmacological evidence that neuropeptides by central mechanism are able to
influence gastric mucosal lesions was provided by the experiments with bombesin. Bombesin,
14-amino acid peptide, inhibited the gastric lesions induced by cold-restraint stress, aspirin,
indomethacin by intracisternal (i.c.) and/or intracerebroventricular (i.c.v.) injection [120, 121].
Several mechanism may be involved in the centrally induced mucosal protective effect of
bombesin, such as the antisecretory effect [122], inhibition of gastric motor activity, and
stimulation of protective processes (gastric mucus, bicarbonate secretion, gastric blood flow)
[123].
In addition, neurotensin, β-endorphin, substance P, and somatostatin proved to be also
protective given i.c. against cold restraint ulcer model. [124].
Cold restraint stress ulcer model is an acid dependent ulcer model [125]. As a next step, an
acid independent model, the ethanol-induced ulcer model has been used to examine the
gastroprotective effect of centally injected neuropeptides, where inhibiton of acid secretion is
not likely to contribute to the gastric mucosal protective action. Several neuropeptides were
injected either into dorsal motor nucleus of vagus (DMNV), i.c. or i.c.v. First, the effect of
thyreotropin-releasing hormon (TRH) or its stable analogue RX-77368, injected in low (0-5-1.5
ng), non-secretory dose into the cisterna magna or DMNV was shown to protect the gastric
mucosa against ethanol injury [126, 127].
Hereafter, additional neuropeptides proved to be gastroprotective given centrally, among
others adrenomedullin [128] peptide YY [129] amylin [130], leptin, cholecystokinin [131],
ghrelin [132], opioids, e.g. β-endorphin, deltorphin II, endomorphins [4, 133] nociceptin,
nocistatin [134], TLQP-21, a VGF-derived peptide [135], substance P [136] and angiotensin II
[137] (see reviews: [4, 127, 138]).
How can the centrally injected neuropeptide induce gastric mucosal protection in the periph‐
ery, in gastric mucosa? Convincing evidence suggest the role of vagal nerve in conveying the
central stimulus to the periphery. TRH or its stable analogue RX-77368, injected in non-
secretory dose into the cisterna magna or DMNV was the first peptide reported to protect the
gastric mucosa against ethanol injury through stimulation of vagal cholinergic pathways, since
both vagotomy and atropine reversed the gastroprotective effect. As a result of an intensive
research additional neuropeptides e.g. amylin, adrenomedullin, neurotensin, opioid peptides,
melatonin, ghrelin, leptin, as well as cannabinoids were shown to initiate gastroprotective
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effect given centrally (i.c.v., i.c. or DMNV), mostly by a vagal dependent mechanism [139-142]
(see reviews: [4,127,138,143, 144]).
The mechanism of vagally mediated gastroprotective effect has been well documented by
pharmacological studies, demonstrating that activation of vagal cholinergic pathways
stimulates gastric prostaglandin and nitric oxide release and the effector function of capsaicin-
sensitive afferent fibers containing CGRP [72, 126, 128,129, 145-147, reviews, 4, 127, 143, 144].
In addition, TRH injected intracisternally at low, gastroprotective dose, stimulates gastric
splanchnic afferents as was shown by electrophysiological recording [148] and consequently
the local effector function of capsaicin-sensitive splanchnic afferent nerves containing CGRP
is activated [128, 149]. Pretreatment with high, neurotoxic dose of capsaicin (125 mg/kg sc.),
which induces ablation of primary sensory neurons and the depletion of CGRP-containing
fibers, pharmacological blockade of peripheral CGRP1 receptors by hCGRP 8-37 and NO
synthesis by NO-synthase inhibitor Nω-nitro-L-arginine methyl ester blocked the increased
gastric mucosal blood flow induced by i.c. injection of TRH [149-153]. The results indicate that
the intact function of sensory fibers containing CGRP and NO is basically important for
stimulation of gastric mucosal blood flow and the consequent gastroprotection [152], and the
CGRP/NO-mediated gastric hyperemia plays a crucial role to withstand gastric mucosal
damage [reviews 61, 154].
Moreover, additional action due to activation of vagal cholinergic pathway might contribute
to the mucosal protective effect. Namely, acetylcholine released from efferent nerve terminal
of vagal nerve in the periphery, activates α7 subunit-containing nicotinic receptors of macro‐
phages and other immune cells which results in inhibition of the release of proinflammatory
cytokines, consequently suppression of inflammation [155, 156].
As the above data suggest DVC has a basic role in the regulation of gastrointestinal functions.
We wondered if activation of different receptor populations identified in DVC. e.g. μ-opioid
receptors (in NTS and DMNV) [157], cannabinoid receptors (CB1-receptors in NTS and DMNV
and CB2-receptors in NTS and brain stem neurons) [158, 159] NK1-receptors in NTS and DMNV)
[160, 161], angiotensin AT1 receptors in in the NTS, area postrema and DMNV [162, 163] can
influence gastric mucosal homeostasis. Our experimental results demonstrated that opioid
peptides [4, 133], anandamide, 2-arachidonoyl glycerol (2-AG) endocannabinoids, ligands of
cannabinoid CB1 and CB2 receptors [137, 142], as well as (SP) [136] given i.c.v. induced gastric
mucosal protective effect against ethanol-induced lesions.
We wondered, if in the periphery, sensory neuropeptides, such as CGRP or somatostatin may
be involved in the centrally-induced mucosal protective effect of endomorphin-2, endocan‐
nabinoids, such as anandamide, 2-AG and SP.
Conclusions on the involvement of CGRP in gastric mucosal protection have been established
on pharmacological analysis by using a competitive peptide antagonist of CGRP1 receptor,
CGRP 8-37 or functional ablation of neuropeptides by neurotoxic dose of capsaicin [149, 152].
However, the gastric mucosal level of CGRP or somatostatin has not been determined
following central administration of gastroprotective agents.
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Therefore we aimed to determine how the gastric mucosal level of CGRP and somatostatin is
influenced by the mucosal damaging agent ethanol, and by endomorphin-2, endocannabi‐
noids and SP.
As Fig 1. shows that endomorphin-2 inhibited the ethanol-induced mucosal lesions in the rat,
the maximal effect was induced by 0.1 pmol. The mucosal levels of CGRP and somatostatin
were decreased in a significant manner following oral administration of ethanol (after 60 min),
while i.c.v. injection of endomorphin-2 reversed the decreased levels of both CGRP and
somatostatin.
Adapted from Gyires et al. [4].
Figure 1. Panel A: The inhibitory effect of endomorphin-2 (EM-2) on the formation of ethanol-induced mucosal le‐
sions in male Wistar rats. Acidified ethanol (2 ml concentrated HCl+98 ml absolute ethanol) was injected per os after
24 h food deprivation in a volume of 0.5 ml/rat. EM-2 was given intracerebroventricularly (i.c.v.) 10 minutes before the
ethanol challenge in a volume of 10 μl in conscious rats. Mucosal lesions were evaluated macroscopically one hour
after the administration of ethanol. Each column represents mean ± S.E.M., the number of rats was 5-10/group.
***p<0.001 compared to the respective control group (vehicle-treated rats) (One-way ANOVA, Newman-Keuls post
hoc test). Panels B and C: The effect of EM-2 on the mucosal levels of calcitonin gene-related peptide (CGRP) and so‐
matostatin. CGRP and somatostatin concentrations were determined from gastric mucosal tissue extract samples by
means of radioimmunoassay (RIA). Peptide concentrations were calculated as the measured amount of peptide per
wet tissue weight, expressed as fmol/mg. Detection limits of the assays were 2 fmol/ml (somatostatin) and 0.2
fmol/ml (CGRP). Each column represents mean ± S.E.M., the number of rats was 5/group. **p<0.01, ***p<0.001 com‐
pared to the absolute control group (no treatment), ##p<0.01, ###p<0.001 compared to vehicle (saline) i.c.v.+ethanol
p.os-treated group (One-way ANOVA, Newman-Keuls post hoc test).
Similarly, anandamide and 2-AG inhibited the mucosal lesions in a dose dependent manner
(though the protective effect of 2-AG was diminished in higher, 52.8 nmol dose), and both
anandamide and 2-AG increased the ethanol-induced dramatic reduction of the mucosal
CGRP and somatostatin levels in the gastroprotective doses (58, and 26 nmol, respectively)
(Fig 2. 3.).
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p.os-treated group (One-way ANOVA, Newman-Keuls post hoc test).
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(though the protective effect of 2-AG was diminished in higher, 52.8 nmol dose), and both
anandamide and 2-AG increased the ethanol-induced dramatic reduction of the mucosal
CGRP and somatostatin levels in the gastroprotective doses (58, and 26 nmol, respectively)
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Adapted from Gyires et al. [137].
Figure 2. Panel A: The inhibitory effect of anandamide (And) on the formation of ethanol-induced mucosal lesions in
male Wistar rats. Methods: see in the Legends of Fig. 1. Each column represents mean ± S.E.M., the number of rats was
5/group. *p<0.05, ***p<0.001 compared to the respective control group (vehicle-treated rats) (One-way ANOVA,
Newman-Keuls post hoc test). Panels B and C: The effect of anandamide on the mucosal levels of calcitonin gene-re‐
lated peptide (CGRP) and somatostatin. Methods: see in the Legends of Fig. 1. Each column represents mean ± S.E.M.,
the number of rats was 5/group. ***p<0.001 compared to the absolute control group (no treatment), ##p<0.01,
###p<0.001 compared to vehicle (ethanol diluted with saline) i.c.v.+ethanol p.os-treated group (One-way ANOVA,
Newman-Keuls post hoc test).
Adapted from Gyires et al. [137].
Figure 3. Panel A: The inhibitory effect of 2-arachidonoylglycerol (2-AG) on the formation of ethanol-induced mucosal
lesions in male Wistar rats. Methods: see in the Legends of Fig. 1. Each column represents mean ± S.E.M., the number
of rats was 5/group. *p<0.05, ***p<0.001 compared to the respective control group (vehicle-treated rats) (One-way
ANOVA, Newman-Keuls post hoc test). Panels B and C: The effect of 2-AG on the mucosal levels of calcitonin gene-
related peptide (CGRP) and somatostatin. Methods: see in the Legends of Fig. 1. Each column represents mean ±
S.E.M., the number of rats was 5/group. ***p<0.001 compared to the absolute control group (no treatment),
##p<0.01, ###p<0.001 compared to vehicle (acetonitrile diluted with saline) i.c.v.+ethanol p.os-treated group (One-
way ANOVA, Newman-Keuls post hoc test).
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SP in pmolar dose range exerted mucosal protective action, the dose response curve proved
to be bell shaped, similarly to 2-AG. However, though SP in gastroprotective doses also
reversed the ethanol-induced reduction of CGRP mucosal level, it failed to counteract the
reduced somatostatin level (Fig. 4.)
Adapted from Brancati et al. [136].
Figure 4. Panel A: The inhibitory effect of substance P (SP) on the formation of ethanol-induced mucosal lesions in
male Wistar rats. Methods: see in the Legends of Fig. 1.. Each column represents mean ± S.E.M., the number of rats
was 5/group. **p<0.01, ***p<0.001 compared to the respective control group (vehicle-treated rats) (One-way AN‐
OVA, Newman-Keuls post hoc test). Panels B and C: The effect of SP on the mucosal levels of calcitonin gene-related
peptide (CGRP) and somatostatin. Methods: see in the Legends of Fig. 1. Each column represents mean ± S.E.M., the
number of rats was 5/group. *p<0.05, ***p<0.001 compared to the absolute control group (no treatment), ##p<0.01
compared to vehicle (saline) i.c.v.+ethanol p.os-treated group (One-way ANOVA, Newman-Keuls post hoc test).
Our experimental results provided direct evidence on the role of sensory neuropeptides in
centrally initiated gastroprotective effect. It was shown that while ethanol decreased in a
significant manner the mucosal CGRP and somatostatin concentration, the centrally injected
endomorphin-2, endocannabinoids and SP were able to reverse the highly reduced mucosal
levels of sensory neuropeptides supporting the concept on the role of sensory neuropeptides
in centrally initiated gastroprotective effect.
4. Conclusion
The apparent redundancy in the mechanisms of gastric mucosal defense might be a potential
answer to the question raised above: how can gastric mucosa resist to wide variety of endog‐
enous and exogenous mucosal challenges. The redundancy can be observed in the wide scale
of mediators involved in mucosal defense, in generation of endogenous substance(s) to
noxious stimulus that may attenuate the mucosal injury and stimulate mucosal repair (for
instance, peptide gene expression in gastrointestinal mucosal ulceration [164]), and can induce
further protective mechanisms or formation of additional protective mediators.
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Our experimental results provided direct evidence on the role of sensory neuropeptides in
centrally initiated gastroprotective effect. It was shown that while ethanol decreased in a
significant manner the mucosal CGRP and somatostatin concentration, the centrally injected
endomorphin-2, endocannabinoids and SP were able to reverse the highly reduced mucosal
levels of sensory neuropeptides supporting the concept on the role of sensory neuropeptides
in centrally initiated gastroprotective effect.
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The apparent redundancy in the mechanisms of gastric mucosal defense might be a potential
answer to the question raised above: how can gastric mucosa resist to wide variety of endog‐
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of mediators involved in mucosal defense, in generation of endogenous substance(s) to
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In the early phase of mucosal injury when the gastric epithelium is exposed to acid or any
irritant, one of the most rapid and important responses is the increase in mucosal blood flow
to remove, dilute and buffer back-diffusing irritant or acid. In this process primary sensory
afferent neurons activated by the back-diffusing acid play a crucial role, since sensory nerve
endings can sense acid via acid sensing channel [60-68].
In addition, primary sensory afferent neurons are involved also in the actions of gastropro‐
tective agents. Intensive studies revealed that gastric mucosal defense can be initiated also by
central mechanism. Dorsal vagal complex is likely to have prominent role in centrally induced
gastroprotective effect. Several neuropeptides, and their receptors e.g. μ-opioid receptors
[157-159] NK1-receptors [160, 161] angiotensin AT1 receptors [162, 163] TRH receptors [126, 127,
165], neuropeptide Y receptors [166, 167] have been identified in this area, and activation of
these receptors result in mucosal protection. Accumulating data suggest that in the periphery
the final step in the chain of events of centrally initiated mucosal protective processes is the
release of sensory neuropeptides, such as CGRP and partly somatostatin, from the capsaicin
sensitive primary afferent neurons, as well as NO and prostaglandins. The process is likely to
be vagal dependent, and biochemical and pharmacological studies have shown that vagal
cholinergic pathway stimulates gastric prostaglandin and nitric oxide release. In addition,
vagal muscarinic mediated release of prostaglandins, histamine and serotonin [147, 150] evoke
sensory C-fiber excitation and a subsequent release of neuropeptides from sensory nerve
endings.
However, sympathetic nervous system may also be involved in the centrally induced gastro‐
protective effect, since e.g. the gastroprotective effect of opioid peptides markedly decreased
following i.c.v. administration of the catecholaminergic neurotoxin, 6-hydroxydopamine, that
reduced the noradrenaline concentration in a significant manner in the NTS[138].
Tache [165] raised that that the redundancy of brain peptides may be linked with different
pathophysiological conditions whereby they are recruited into the brain under stress, feeding
or damage of the gastric mucosa. Further studies focusing to clarify the role of neuropeptide-
interactions in gastroprotection, neuronal projections between brainstem autonomic centers
and upper brain areas, additional pathway(s) that may convey central stimulus to the periph‐
ery, identification of additional peripheral mechanisms, signaling of peripheral insults of
gastric mucosa to the CNS, are some of the opened questions that should be answered and
consequently, the better understanding of the central regulation of gastric mucosal homeostatis
may result in the development of new strategy and new concept in prevention/treatment of
gastric mucosal injuries.
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1. Introduction
Stable  gastric  pentadecapeptide  BPC 157  (GEPPPGKPADDAGLV,  M.  W.  1419,  a  partial
sequence of human gastric juice protein BPC, in all studies used peptide with 99% (HPLC)
purity, freely soluble in water at pH 7. 0 and in saline), was always given alone, without any
carrier, µg-ng dose ranges and ways of application, intraperitoneal, intragastrical, in drinking
water or topically, at the site of injury. Besides, tested in therapy of inflammatory bowel disease
(IBD) (PL 14736) in clinical phase II. (Ruenzi et al., 2005), and now in multiple sclerosis.
As prime importance, BPC 157 was found to be stable at least 24 hours in human gastric juice
and consequently, because of its anti-ulcerogenic potential in different, but relevant ulcer
models, suggested to be novel mediator of Robert’s cytoprotection and adaptive cytoprotection
(for review see, i. e., (Sikiric et al., 2010, 2011, 2012)), and thereby, exhibited a particular wound
healing effect, and cell protecting ability. At the general level this may likely explain its strong
effectiveness and LD1 not achieved.
Thereby, such kind of pathophysiologic importance along with unlimited applications of BPC
157 regimens contrasts with the evidence for standard peptides providing that regardless
commonly acknowledged pathophysiologic importance at least in many occasions they need
a carrier (one or more) to become effective and furthermore, that their application prefers to
be local, at the site of injury, given into the injury defect (for review see, i. e., (Urist, 1996)).
Therefore, pentadecapeptide BPC 157 certainly avoids a common scenario with standard
peptides where their limited application in pharmacology could hardly acknowledge their
suggested prime physiological importance (Sikiric et al., 2010, 2011, 2012, 2013, 2014; Seiwerth
et al., 2014)
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. Methods
With BPC 157 given alone, without a carrier, BPC 157 application strategy (for review see, i.
e., (Sikiric et al., 2010, 2011, 2012, 2013, 2014; Seiwerth et al., 2014)) considerably overrides the
standard peptides and their use with different carriers (i. e., peptide+carrier(s) complex) to
establish the therapeutic effect (thereby erroneously) ascribed to the given peptide. Therefore,
the activity – methodology dilemma whereby it is difficult to identify the real active part in
peptide+carrier complex (peptide, carrier, peptide+carrier complex or neither of them) or
specify their particular contribution is not applicable to BPC 157 (for review see, i. e., Urist,
1996). Finally, in BPC 157 – standard peptides relation, apart from the evidence that this anti-
ulcer peptide may be effective in both upper and lower GI tract injuries (for review see, i. e.,
(Sikiric et al., 2010, 2011, 2012)), and initial successful use in clinic (Ruenzi et al., 2005), involving
also a particular sphincter function control (Sikiric et al., 2010, 2011, 2012), the key difference
appears in the healing outside the GI tract. This may be also because since this evidence was
based on clear demonstration that it also may interact with the general systems, i. e., the NO-
system, providing endothelium protection and angiogenic effect (Seiwerth et al. 2014; Sikiric
et al., 2014). And even more, important to counteract severe complications of advanced and
poorly controlled IBD, this occurs even in severely impaired conditions. Notably, the final
background was that it stimulated expression of early growth response 1 gene (egr-1) respon‐
sible for cytokine and growth factor generation and early extracellular matrix (collagen)
formation (but also its repressor nerve growth factor 1-A binding protein-2 (naB2)) (Tkalcevic
et al., 2007).
To this point, it should be noted that BPC 157 markedly improves the healing of both traumatic
nerve (Gjurasin et al., 2010) and traumatic brain injury (Tudor et al., 2010), and therefore,
exhibits particular neuroprotective ability. Likewise, it ameliorates encephalopathies that
occur in severely intoxicated animals (Ilic et al., 2010, 2011, 2011).
In addition, BPC 157 has in general a very safe profile. As an illustration, single dose toxicity
studies in mice treated by oral and i. v. routes revealed a LD50 of PL 14736 higher than 2000
mg/kg. No mice died during both studies and transient sedation was the only finding in the
dose of 2000 mg/kg. In the 4-week repeated i. v. dosing toxicity studies in rats and dogs no
morphological findings related to PL 14736 administration were found at any of doses studied.
Macroscopical and histological examination of the organs and tissues sampled following 14-
day intracolonic administration in rats and dogs did not reveal changes that could be attributed
to treatment with PL 14736 (doses up to 25 mg/kg). The only finding, lesions at the area of
colon application site in rats, also seen in the control animals, was primarily caused by
mechanical trauma of the catheter used. No effect of PL 14736 on female fertility and early
embryonal development was noted. No effect of PL 14736 in sensitization study and in acute
eye irritation/corrosion study was noted. PL 14736 does not cause chromosomal aberrations
in cultures of human lymphocytes, nor it is mutagenic in the AMES test (doses up to 5 mg/
plate were tested). Repeated i. v. administration of 10-30 µg/kg/day to mice did not induce the
induction of microsomal liver enzymes in vitro. Safety pharmacology of PL 14736 has been
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studied in anaesthetised dogs following intraduodenal administration of 10 and 100 µg/kg,
with no significant effects on the cardiovascular and respiratory systems.
Based largely upon the use of neurotoxin capsaicin, peptidergic neurons have been postulated
to be involved in a physiological protective system (Holzer, 1991,1991). Protection of the gastric
mucosa from various forms of injury occurs with different peptides given centrally (Heiling
et al., 1987; Hernandez, 1986; Hernandez et al., 1987) and/or peripherally (Evangelista et al.,
1991; Takeuchi et al., 1979).
The integrity of capsaicin somatosensory neurons and their protection were suggested to be
related to BPC 157 activity in nociception (Sikiric et al., 1993). Capsaicin-sensitive afferent
neurons, regulators of vascular functions in many somatic and visceral tissues (Holzer, 1991,
1991), are involved in local blood flow regulation in gastrointestinal tract (Holzer, 1991, 1991;
Szabo et al., 1985). The population of capsaicin-sensitive neurons is heterogenous and com‐
prises most but not all primary afferent neurons with small cells body and unmyelinated (C
fiber) axons and some afferent neurons with thinly myelinated (A-δ) axons (Holzer, 1991,
1991). Low doses of capsaicin (micrograms per kilogram range) appear to be protective to the
mucosa (Holzer, 1991, 1991) since they induce a transient excitation. In contrast, systemic
administration of high doses of capsaicin (miligrams per kilogram range) is deleterious,
causing long-lasting damage to these neurons (Holzer, 1991). This effect is age-dependent,
being even more pronounced in the adult rat when capsaicin is given to newborn animals
(Jancsó et al., 1977).
Therefore, the possibility that BPC 157 causes mucosal protection trough capsaicin-sensitive
nerves was challenged. The effect of BPC 157 on gastroprotection, in rats treated with capsaicin,
was investigated. Because of the mentioned different susceptibility to capsaicin of the adult
and newborn animals (Holzer, 1991; Jancsó et al., 1977), and to achieve better insight into a
possible mechanism of BPC 157 activity against the background of near maximal neuronal
damage, it was necessary to use two different methods to deactivate sensory neurons by
capsaicin pretreatment (Holzer, 1991; Jancsó et al., 1977), one in adult rats, the other in newborn
rats. Likewise, since the importance of prostaglandins in organoprotection is well known
(Robert, 1979; Schmidt et al., 1991), these effects were investigated with and without prosta‐
glandin synthesis inhibition by indomethacin (Sikiric et al., 1988).
Stable gastric pentadecapeptide BPC 157 is an originally anti-ulcer peptide implemented in
inflammatory bowel disease trials, and now multiple sclerosis, LD1 could be not achieved
recently largely reviewed (Sikiric et al., 2010, 2011, 2012, 2013, 2014; Seiwerth et al., 2014).
The integrity of capsaicin somatosensory neurons and their protection were suggested to be
related to the activity of BPC 157 (Sikiric et al., 1996).
Therefore, from this viewpoint, the focus was on the gastroprotective effect of the pentadeca‐
peptide BPC 157, on gastric lesions produced in rats by 96% ethanol, restraint stress, and
indomethacin (Sikiric et al., 1996). The possible involvement of sensory neurons in the salutary
actions of BPC 157 (10 micrograms/kg, 10 ng/kg intraperitoneally) was studied with capsaicin,
which has differential effects on sensory neurons: a high dose in adult (125 mg/kg subcutane‐
ously, 3 months old) or administration (50 mg/kg subcutaneously) to neonatal animals (age of
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the 7 days) destroys sensory fibers, whereas a low dose (500 micrograms/kg intraperitoneally)
activates neurotransmitter release and protective effects on the mucosa (Table 1-4). In the
absence of capsaicin, BPC 157 protected gastric mucosa against ethanol, restraint, and indo‐
methacin application. In the presence of neurotoxic doses of capsaicin, the negative influence
of capsaicin on restraint, ethanol, or indomethacin lesions consistently affected salutary
activity of BPC 157. However, BPC 157 protection was still evident in the capsaicin-treated rats
(either treated as adults or as newborns) in all of these assays. Interestingly, after neonatal
capsaicin treatment, a complete abolition of BPC 157 gastroprotection was noted if BPC 157
was applied as a single nanogram-regimen, but the mucosal protection was fully reversed
when the same dose was used daily. In line with the excitatory dose of capsaicin the beneficial
effectiveness of BPC 157 appears to be increased as well (Table 4). Taken together, these data
provide evidence for complex synergistic interaction between the beneficial effectiveness of
BPC 157 and peptidergic sensory afferent neuron activity (Sikiric et al., 1996). In broader sense,
this should be a basis for further suitable generalization that was evidenced with transected
peripheral nerve, traumatic brain injury, and brain lesions and subsequent disturbances
(somatosensory disorientation, seizures, catalepsy/stereotypies) induced by various agents
applications (BobanBlagaic et al., 2005; Gjurasin et al., 2010;Ilic et al., 2010, 2011, 2011; Jelovac
et al., 1998, 1999; Klicek et al., 2013; Sikiric et al., 1999;Tohyama et al., 2004; Tudor et al., 2010).
Particularly, the evidence that it both protected somatosensory neurons against capsaicin
neurotoxicity and restored their function (Sikiric et al., 1996) suggests BPC 157 as an agent with
neuroprotective properties (Sikiric et al., 1996). One extension could be the healing of rat
transected sciatic nerve and improvement made by stable gastric pentadecapeptide BPC 157
(10 microg, 10ng/kg) applied shortly after injury intraperitoneally/ intragastrically /locally, at
the site of anastomosis, or after non-anastomozed nerve tubing (7 mm nerve segment resected)
(It is known that the spontaneous regenerative capabilities of the nerve stumps, as well as
Schwann cells abilities to provide a permissive environment for axonal elongation, are
insufficient when there is a 7 mm gap between nerve ends in rat, which also presents an obstacle
for the standard therapy (Gold, 2000)) directly into the tube) (Gjurasin et al., 2010). Improve‐
ment was shown clinically (autotomy), microscopically/morphometrically and functionally
(EMG, one or two months post-injury, walking recovery (sciatic functional index (SFI)) at
weekly intervals). BPC 157-rats exhibited faster axonal regeneration: histomorphometrically
(improved presentation of neural fascicles, homogeneous regeneration pattern, increased
density and size of regenerative fibers, existence of epineural and perineural regeneration,
uniform target orientation of regenerative fibers, and higher proportion of neural vs. connec‐
tive tissue, all fascicles in each nerve showed increased diameter of myelinated fibers, thickness
of myelin sheet, number of myelinated fibers per area and myelinated fibers as a percentage
of the nerve transected area and the increased blood vessels presentation), electrophysiologi‐
cally (increased motor action potentials), functionally (improved SFI), the autotomy absent.
Thus, BPC 157 markedly improved rat sciatic nerve healing with particular point that severe
autotomy – regularly present after transected sciatic nerve – was practically completely
avoided in BPC 157-treated rats (Gjurasin et al., 2010).
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The further extension could be the effect of BPC 157 after an induced traumatic brain injury
(TBI) in mice by a falling weight. BPC 157 regimens (10 micrograms/kg, 10 ng/kg intraperito‐
neally) demonstrated a marked attenuation of damage with an improved early outcome and
a minimal postponed mortality throughout a 24h post-injury period. Ultimately, the traumatic
lesions (subarachnoidal and intraventricularhaemorrhage, brain laceration, haemorrhagic
laceration) were less intense and consecutive brain edema had considerably improved. Given
prophylactically (30 min before TBI) the improved conscious/unconscious/death ratio in TBI-
mice was after force impulses of 0. 068 Ns, 0. 093 Ns, 0. 113 Ns, 0. 130 Ns, 0. 145 Ns, and 0. 159
Ns. Counteraction (with a reduction of unconsciousness, lower mortality) with both microg-
and ng-regimens included the force impulses of 0. 068-0. 145 Ns. A higher regimen presented
effectiveness also against the maximal force impulse (0. 159 Ns). Furthermore, BPC 157
application immediately prior to injury was beneficial in mice subjected to force impulses of
0. 093 Ns-TBI. For a more severe force impulse (0. 130 Ns, 0. 145 Ns, or 0159 Ns), the time-
relation to improve the conscious/unconscious/death ratio was: 5 min (0. 130 Ns-TBI), 20 min
(0. 145 Ns-TBI) or 30 min (0. 159 Ns-TBI) (Tudor et al., 2010)
3. Results
In conclusion, these results should be viewed with numerous compounds and neuroprotective
strategies more extensively discussed, evaluated and reviewed elsewhere (Maas et al., 2005;
Marklund et al., 2006). However, brain trauma results in brain damage and dysfunction from
both primary injury (due to biomechanical effects) and subsequent secondary damage due to
activation of pathophysiologic cascades (Muir, 2006), and this study with BPC 157 (Tudor et
al., 2010) evidenced the preserved consciousness and reduced mortality immediately after
trauma in pentadecapeptide BPC 157-mice and subsequently, markedly reduced mortality,
lowered brain edema, lowered the number and size of haemorrhagic traumatic lacerations,
and lowered the intensity of subarachnoidal bleeding with significantly less intraventricular‐
haemorrhage.
The additional extension could be the evidence that pentadecapeptide BPC 157 particularly
attenuated neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damage,
including mortality (Sikiric et al., 1999)(of note, neuroprotection by immunophillin ligands
lack the effect on MPTP-toxicity (Gold, 2000), significantly affected the dopamine system
(Jelovac et al., 1998, 1999; Sikiric et al., 1999)(a system also implicated in the traumatic brain
injury course) (Yan et al., 2001)and prevented/reversed catalepsy or stereotypy due to central
dopamine system failure induced by various procedures (Jelovac et al., 1998, 1999; Sikiric et
al., 1999). Accordingly, regional serotonin synthesis in the rat brain, assessed by α-methyl-L-
tryptophan autoradiographic measurements showed that, BPC 157 given peripherally may
readily cross the blood–brain barrier, affect region-specific brain 5-HT synthesis in rats leading
to significantly increased synthesis in the substantianigra (compacta and reticulata) structure
and counteract serotonin syndrome (BobanBlagaic et al., 2005; Tohyama et al., 2004). Very
recently, BPC 157 counteracts cuprizone-brain damage and motoric disability (Klicek et al.,
2013). An additional emphasize may be that BPC 157 largely interferes with different NSAIDs-
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toxicity, including their brain damages that appear subsequently their gastrointestinal and/or
liver toxicity (Ilic et al., 2010, 2011, 2011).
Also, in addition to several other effects of BPC 157 (such as counteraction of acute and chronic
gastric lesions, blood pressure modulation and prevention/reversal of chronic heart failure
(Balenovic et al. 2009, 2012; Barisic et al., 2013)), BPC 157's antagonization of acute and chronic
ethanol intoxication (Blagaic AB et al., 2004) was found to be an effect that is at least partly
NO-dependent (Boban-Blagaic et al., 2006; Klicek et al., 2008; Lovric-Bencic et al., 2004; Sikiric
et al., 1997).
One possible option of treatment (i. e., injury is often irreversible because inability of nerve
tissue to regenerate and no therapeutic solution of this problem to date) is protection of
secondary injury – zone of vascular and inflammatory reaction in nerve tissue to primary
injury.
Taken together, the data providing the protection and rescue of the capsaicin neurotoxicity,
and thereby, the evidence for complex synergistic interaction between the beneficial effective‐
ness of BPC 157 and peptidergic sensory afferent neuron activity (Sikiric et al., 1996) was
useful,in a broader sense, for the further experiments. We argue that the significance of these
beneficial effects (Sikiric et al., 1996) was confirmed by the healing effect of pentadecapeptide
BPC 157 on transected and anastomosed as well as non-anastomosed rat sciatic nerve (Gjurasin
et al., 2010). The final prove was provided from brain trauma studies resulting in brain damage
and dysfunction from primary injury and subsequent secondary damage due to activation of
pathophysiologic cascades, but the preserved consciousness and reduced mortality in
pentadecapeptide BPC 157 treated along with lowered brain edema, lessened number and size
of haemorrhagic traumatic lacerations, subarachnoidal bleeding and intraventricularhaemor‐
rhage (Tudor et al., 2010).




BPC 157 10ng +/-
BPC 157 10µg +/-
Capsaicin +++ +++++
BPC 157 10ng + Capsaicin ++ +++
BPC 157 10µg + Capsaicin + +
Table 1. Long-term somatosensory neuron damage. Gastric lesions in 3-month-old adult rats following 48 hours
restraint stress, treated with capsaicin two weeks (125 mg/kg subcutaneously) before or as neonates at 7 days old (50
mg/kg subcutaneously). BPC 157 (10 ng or 10 µg per kg intraperitoneally) treatment 1 hour before restraint; 16-20
rats per each experimental group.
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside190




BPC 157 10ng +/-
BPC 157 10µg +/-
Capsaicin 50mg +++++
BPC 157 10ng + Capsaicin 50mg ++
BPC 157 10µg + Capsaicin 50mg +
Table 2. Long-term somatosensory neuron damage. Gastric lesions in 3-month-old adult rats following subcutaneous
application of 30 mg/kg of indomethacin, treated with capsaicin as neonates at 7 days old (50 mg/kg
subcutaneously). BPC 157 (10 ng or 10 µg per kg intraperitoneally) treatment 1 hour before indomethacin
application; 16-20 rats per each experimental group.




BPC 157 10ng +
BPC 157 10µg +
Capsaicin +++ +++
BPC 157 10ng + Capsaicin + +++
BPC 157 10µg + Capsaicin + ++
Table 3. Long-term somatosensory neuron damage. Gastric lesions in 3-month-old adult rats 1 hour following
intragastric application of 96% ethanol, treated with capsaicin two weeks (125 mg/kg subcutaneously) before or as
neonates at 7 days old (50 mg/kg subcutaneously). BPC 157 (10 ng or 10 µg per kg intraperitoneally) treatment 1
hour before ethanol; 16-20 rats per each experimental group.
Excitation of somatosensory neurons in adult rats
Healthy +++++
BPC 157 10ng ++
BPC 157 10µg ++
Capsaicin 500µg ++++
BPC 157 10ng + Capsaicin 500µg +
BPC 157 10µg + Capsaicin 500µg +
Table 4. Excitation of somatosensory neurons. Gastric lesions in adult rats 1 hour following intragastric application of
96% ethanol, treated with capsaicin (low dose 500µg/kg, intraperitoneally) and/or BPC 157 (10 ng or 10 µg per kg
intraperitoneally) 1 hour before ethanol; 16-20 rats per each experimental group.
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1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin damage the small
intestine as well as the stomach, although the ulcerogenic dose is much lower in the former
[1-3]. Several factors such as intestinal hypermotility, enterobacteria, neutrophils, nitric oxide
(NO), and inducible NO synthase (iNOS) are involved in the pathogenesis of these intestinal
lesions [3-7], yet a deficiency of endogenous prostaglandins (PGs) due to cyclooxygenase
(COX) inhibition is most important in the background for the intestinal ulcerogenic response
to NSAIDs [8-10]. Recent clinical studies, using capsule endoscopes or double-balloon
endoscopes, confirmed that NSAIDs damage the small intestine in patients at a higher
incidence than previously thought. Unfortunately, antisecretory drugs such as proton pump
inhibitors and histamine H2 receptor antagonists are reported to be ineffective against NSAID-
induced small intestinal damage [11,12] and even worsen the severity of these lesions [12],
though these drugs prevent gastric ulcerogenic response to NSAIDs [13].
Capsaicin-sensitive sensory neurons are known to play an important role in modulating the
gastric mucosal integrity [14]. It has previously been reported that stimulation of these sensory
neurons by capsaicin prevented the occurrence of experimental colitis as well as indomethacin-
induced intestinal ulceration in rats, while sensory deafferentation increased both the degree
and incidence of the latter lesion model [11,15,16]. These findings suggest the role of capsaicin-
sensitive sensory neurons in maintaining the integrity of the intestinal mucosa, similar to the
gastric mucosa.
Lafutidine, a histamine H2-receptor antagonist, has been shown to exhibit a potent gastropro‐
tective activity in addition to gastric antisecretory action [17,18]. Onodera et al. [19] reported
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though these drugs prevent gastric ulcerogenic response to NSAIDs [13].
Capsaicin-sensitive sensory neurons are known to play an important role in modulating the
gastric mucosal integrity [14]. It has previously been reported that stimulation of these sensory
neurons by capsaicin prevented the occurrence of experimental colitis as well as indomethacin-
induced intestinal ulceration in rats, while sensory deafferentation increased both the degree
and incidence of the latter lesion model [11,15,16]. These findings suggest the role of capsaicin-
sensitive sensory neurons in maintaining the integrity of the intestinal mucosa, similar to the
gastric mucosa.
Lafutidine, a histamine H2-receptor antagonist, has been shown to exhibit a potent gastropro‐
tective activity in addition to gastric antisecretory action [17,18]. Onodera et al. [19] reported
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that the gastroprotective action of lafutidine was independent of its antisecretory effect and
partially mediated by capsaicin-sensitive sensory neurons.
In the present report, we described the protective effect of lafutidine against NSAID-induced
enteropathy and suggested the involvement of capsaicin-sensitive afferent neurons in this
action.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats (240~280 g; Nippon Charles River, Shizuoka, Japan) were used.
Studies were carried out using four to eight animals without fasting in a conscious state, unless
otherwise specified. All experimental procedures described here were approved by the
Experimental Animal Research Committee of Kyoto Pharmaceutical University.
2.2. Induction of small intestinal lesions
Animals were given loxoprofen (60 mg/kg, p.o.) and killed 24 h later under deep ether
anesthesia. The small intestine was excised, treated with 2% formalin for fixation of the tissue
wall for 10 min and opened along the antimesenteric attachment. The area of macroscopically
visible damage (mm2) was measured under a dissecting microscope with square grids (x10),
summed per tissue and used as a lesion score. Lafutidine (10 and 30 mg/kg), cimetidine (100
mg/kg) or famotidine (30 mg/kg) was given p.o. twice, 0.5 h before and 6 h after the adminis‐
tration of loxoprofen, while omeprazole (100 mg/kg) was given p.o. once, 0.5 h before loxo‐
profen. On the other hand, ablation of capsaicin-sensitive sensory neurons was performed by
s.c. injection of capsaicin once daily for 3 consecutive days (total dose 100 mg/kg) 2 weeks
before the experiment [20]. All capsaicin injections were done under ether anesthesia, and the
rats were pretreated with terbutaline (0.1 mg/kg, i.m.) and aminophylline (10 mg/kg, i.m.) to
prevent respiratory impairment. The effectiveness of the treatment was tested by examining
the protective wiping movements of the eye.
2.3. Determination of enterobacterial counts
Enterobacteria were enumerated according to a method described by Deitch et al. [21]. Twenty-
four hours after loxoprofen treatment (60 mg/kg, p.o.), the animals were killed under deep
diethyl ether anesthesia, and the small intestines were excised. Aliquots of the homogenate of
intestine were placed on blood agar and Gifu anaerobic medium agar (Nissui, Tokyo, Japan).
Blood agar plates were incubated at 37°C for 24 h under aerobic conditions, whereas Gifu
anaerobic medium agar plates were incubated for 24 h under standard anaerobic conditions
(BBL Gas Pack Pouch Anaerobic System; BD Biosciences, San Jose, CA). Plates containing 10
to 300 colony-forming units (CFU) were examined for numbers of enterobacteria, and the data
were expressed as log CFU per gram of tissue. Lafutidine (10 and 30 mg/kg) was given p.o.
twice, 0.5 h before and 6 h after the administration of loxoprofen.
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2.4. Determination of iNOS and Muc2 mRNA Expression by RT-PCR
Expression of iNOS and Muc2 mRNA in the small intestinal mucosa was measured by RT-
PCR. The animals were killed under deep ether anesthesia 6 h after the administration of
loxoprofen, and the small intestines were removed, frozen in acetone/dryice, and stored
at-80°C prior to use. Tissue samples were pooled from 2 to 3 rats for extraction of total RNA,
which was prepared by a single-step acid phenol-chloroform extraction procedure by use of
Sepasol RNA-I (Nacalai Tesque, Kyoto, Japan). Total RNA primed by random hexadeoxy
ribonucleotide was reverse-transcribed with the Rever Tra Ace-a (Toyobo, Osaka, Japan). An
aliquot of the RT reaction product served as a template in 35 cycles of PCR with 0.5 min of
denaturation at 95°C and 1 min of extension at 68°C by Advantage-2 (BD Biosciences, Palo
Alto, CA, USA) on a thermal cycler (PC806; ASTEC, Fukuoka, Japan). A portion of the PCR
mixture was electrophoresed in 1.8% agarose gel in TAE buffer, and the gel was stained with
ethidium bromide and photographed (Bio Doc-It Imaging System; UVP, Upland, CA, USA).
Lafutidine (30 mg/kg) was given p.o. twice, 0.5 h before and 6 h after the administration of
loxoprofen.
2.5. Determination of mucus secretion in small intestine
The amount of mucus secreted in the small intestine was determined by periodic acid-Schiff
(PAS) staining. Three hours after the administration of loxoprofen (60 mg/kg, p.o.), the animals
were killed under deep diethyl ether anesthesia, and the small intestines were removed. The
removed tissues were fixed in Carnoy's fluid (ethanol : acetic acid : chloroform=6 : 1 : 3) for 24
h, embedded in paraffin, and sectioned at a thickness of 6 µm. PAS staining was subsequently
performed according to the conventional method. Lafutidine (30 mg/kg) was given p.o. with
or without co-administration of loxoprofen. In the combined administration, this agent was
given p.o. 30 min before the administration of loxoprofen.
2.6. Preparation of drugs
The drugs used were lafutidine, cimetidine, famotidine, loxoprofen, ampicillin (Shigma
Chemicals, St. Louis, MO), and omeprazole. Lafutidine, cimetidine, famotidine, omeprazole
or loxoprofen was suspended in a 0.5% hydroxy propyl cellulose solution (Wako). All drugs
were prepared immediately before use and administered p.o. or s.c. in a volume of 0.5 ml/100
g body weight. Control animals received the vehicle alone.
2.7. Statistics
Data are presented as the mean±SE for four to eight rats per group. Statistical analyses were
performed using the two-tailed Dunnett’s multiple comparison test, and values of P<0.05 were
considered significant.
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before the experiment [20]. All capsaicin injections were done under ether anesthesia, and the
rats were pretreated with terbutaline (0.1 mg/kg, i.m.) and aminophylline (10 mg/kg, i.m.) to
prevent respiratory impairment. The effectiveness of the treatment was tested by examining
the protective wiping movements of the eye.
2.3. Determination of enterobacterial counts
Enterobacteria were enumerated according to a method described by Deitch et al. [21]. Twenty-
four hours after loxoprofen treatment (60 mg/kg, p.o.), the animals were killed under deep
diethyl ether anesthesia, and the small intestines were excised. Aliquots of the homogenate of
intestine were placed on blood agar and Gifu anaerobic medium agar (Nissui, Tokyo, Japan).
Blood agar plates were incubated at 37°C for 24 h under aerobic conditions, whereas Gifu
anaerobic medium agar plates were incubated for 24 h under standard anaerobic conditions
(BBL Gas Pack Pouch Anaerobic System; BD Biosciences, San Jose, CA). Plates containing 10
to 300 colony-forming units (CFU) were examined for numbers of enterobacteria, and the data
were expressed as log CFU per gram of tissue. Lafutidine (10 and 30 mg/kg) was given p.o.
twice, 0.5 h before and 6 h after the administration of loxoprofen.
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h, embedded in paraffin, and sectioned at a thickness of 6 µm. PAS staining was subsequently
performed according to the conventional method. Lafutidine (30 mg/kg) was given p.o. with
or without co-administration of loxoprofen. In the combined administration, this agent was
given p.o. 30 min before the administration of loxoprofen.
2.6. Preparation of drugs
The drugs used were lafutidine, cimetidine, famotidine, loxoprofen, ampicillin (Shigma
Chemicals, St. Louis, MO), and omeprazole. Lafutidine, cimetidine, famotidine, omeprazole
or loxoprofen was suspended in a 0.5% hydroxy propyl cellulose solution (Wako). All drugs
were prepared immediately before use and administered p.o. or s.c. in a volume of 0.5 ml/100
g body weight. Control animals received the vehicle alone.
2.7. Statistics
Data are presented as the mean±SE for four to eight rats per group. Statistical analyses were
performed using the two-tailed Dunnett’s multiple comparison test, and values of P<0.05 were
considered significant.




3.1. Effect of anti-secretory drugs on loxoprofen-induced small intestinal lesions
Orally administered loxoprofen (10-100 mg/kg) in normally fed rats dose-dependently
produced multiple hemorrhagic lesions in the small intestine, mainly in the jejunum and ileum.
The severity of these lesions induced by loxoprofen at 60 mg/kg was similar to that of the
lesions produced by indomethacin at 10 mg/kg. When animals were pretreated with lafutidine
(10 and 30 mg/kg) given p.o., this treatment dose-dependently prevented the development of
intestinal lesions in response to loxoprofen (60 mg/kg), and the effect was significant at 30 mg/
kg; the inhibition rate was around 50 % (Figure 1). By contrast, neither cimetidine (100 mg/kg)
nor famotidine (30 mg/kg), given p.o., had significant effect on the intestinal ulcerogenic
response to loxoprofen. Similarly, omeprazole (100 mg/kg, p.o.) did not affect the severity of
loxoprofen-induced intestinal lesions.
Figure 1. Effects of various agents on the intestinal lesions induced by loxoprofen in rats. Animals were given loxopro‐
fen (60 mg/kg) p.o. and killed 24 h later. Lafutidine (10 and 30 mg/kg), cimetidine (100 mg/kg) or famotidine (30
mg/kg) was given p.o. twice, 30 min before and 6 h after administration of loxoprofen, while omeprazole (100
mg/kg) was given p.o. once, 30 min before. Data are presented as the mean±SE from 5~8 rats. *Significant difference
from the corresponding control, at P<0.05. Data adapted after modification of ref. [26].
On the other hand, the severity of intestinal lesions induced by loxoprofen was significantly
aggravated by chemical ablation of capsaicin-sensitive sensory neurons, about 1.4 times
greater than the capsaicin nontreated animals (Figure 2). Lafutidine (30 mg/kg, p.o.) again
significantly suppressed the intestinal ulcerogenic response to loxoprofen, but this effect was
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totally attenuated by sensory deafferentation, the lesion score was almost equivalent to the
control value in the sensory deafferented animals.
Figure 2. Effect of lafutidine on the intestinal lesions induced by loxoprofen in normal and sensory deafferented rats.
Animals were given loxoprofen (60 mg/kg) p.o. and killed 24 h later. Sensory deafferentation was performed by 3
consecutive s.c. injections of capsaicin (total 100 mg/kg) 2 weeks before the experiment. Lafutidine (30 mg/kg) was
given p.o. twice, 30 min before and 6 h after loxoprofen. Data are presented as the mean±SE from 6~7 rats. *Signifi‐
cant difference from control in normal rats, at P<0.05. Data adapted after modification of ref. [26].
3.2. Effect of lafutidine on mucosal invasion of enterobacteria caused by loxoprofen
Following oral administration of loxoprofen (60 mg/kg), the bacterial counts in both aerobic
and anaerobic conditions were markedly increased compared to normal group, 24 h later
(Table 1). Pretreatment of the animals with lafutidine (30 mg/kg) significantly prevented
bacterial invasion in the mucosa following the administration of loxoprofen. The mucosal
invasion of enterobacteria was also increased after loxoprofen treatment in sensory deaffer‐
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totally attenuated by sensory deafferentation, the lesion score was almost equivalent to the
control value in the sensory deafferented animals.
Figure 2. Effect of lafutidine on the intestinal lesions induced by loxoprofen in normal and sensory deafferented rats.
Animals were given loxoprofen (60 mg/kg) p.o. and killed 24 h later. Sensory deafferentation was performed by 3
consecutive s.c. injections of capsaicin (total 100 mg/kg) 2 weeks before the experiment. Lafutidine (30 mg/kg) was
given p.o. twice, 30 min before and 6 h after loxoprofen. Data are presented as the mean±SE from 6~7 rats. *Signifi‐
cant difference from control in normal rats, at P<0.05. Data adapted after modification of ref. [26].
3.2. Effect of lafutidine on mucosal invasion of enterobacteria caused by loxoprofen
Following oral administration of loxoprofen (60 mg/kg), the bacterial counts in both aerobic
and anaerobic conditions were markedly increased compared to normal group, 24 h later
(Table 1). Pretreatment of the animals with lafutidine (30 mg/kg) significantly prevented
bacterial invasion in the mucosa following the administration of loxoprofen. The mucosal
invasion of enterobacteria was also increased after loxoprofen treatment in sensory deaffer‐
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ented animals. The inhibitory effect of lafutidine on bacterial invasion was totally attenuated
in the animals with sensory deafferentation.
The animals were given loxoprofen (60 mg/kg, p.o.) and killed 24 h later. Lafutidine (30
mg/kg, p.o.) was given twice, 30 min before and 6 hr after the administration of sodium
loxoprofen. Data are presented as the mean±SE from 4~5 rats. Significant difference at
P<0.05; a) from the corresponding control, b) from loxoprofen in the normal group. Data
adapted after modification of ref. [26].
Table 1. Effect of Lafutidine on Bacterial Counts in Rat Small Intestine
3.3. Changes in mucosal expression of iNOS and Muc2 mRNA
The iNOS mRNA expression  was  hardly  detected  in  the  normal  intestinal  mucosa,  but
markedly  up-regulated  after  the  administration  of  loxoprofen  (60  mg/kg,  p.o.)  when
examined 6 h later (Figure 3a). The up-regulation of iNOS expression following loxopro‐
fen was markedly suppressed by pretreatment of the animals with lafutidine (30 mg/kg).
Loxoprofen (60 mg/kg) similarly increased iNOS mRNA expression in sensory deafferent‐
ed animals.  In these animals,  however,  lafutidine did not  affect  the expression of  iNOS
mRNA in the small intestinal mucosa.
On the other hand, the expression of Muc2 mRNA was clearly detected in the normal intestinal
mucosa, but apparently down-regulated after the administration of loxoprofen (60 mg/kg)
when examined 6 h later (Figure 3b). The decrease in Muc2 expression caused by loxoprofen
was almost totally reverted by pretreatment of lafutidine (30 mg/kg), but this effect was not
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observed in the animals with sensory deafferentation, similar to the inhibitory effect on the
iNOS expression.
Figure 3. Effect of lafutidine on the expression of iNOS and Muc2 mRNAs in rat small intestine. Animals were given
loxoprofen (60 mg/kg) p.o. and killed 6 h later. Sensory deafferentation was performed by 3 consecutive s.c. injections
of capsaicin (total 100 mg/kg) 2 weeks before the experiment. Lafutidine (30 mg/kg) was given p.o. 30 min before the
administration of loxoprofen. Data adapted after modification of ref. [26].
3.4. Effect of Lafutidine on PAS-Positive Substances in Small Intestine
In the normal intestinal mucosa, PAS-positive substances were observed over the surface
epithelial cells and along the glands (Figure 4A). Loxoprofen (60 mg/kg, p.o.) apparently
reduced the amount of PAS-positive substances in the epithelial cells as well as the glands
(Figure 4B). However, the reduction in PAS staining was markedly restored when lafutidine
(30 mg/kg) was administered prior to loxoprofen treatment (Figure 4C). In addition, lafutidine
by itself increased the amount of PAS-positive substances in the mucosa compared to the
control mucosa (Figure 4D).
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3.4. Effect of Lafutidine on PAS-Positive Substances in Small Intestine
In the normal intestinal mucosa, PAS-positive substances were observed over the surface
epithelial cells and along the glands (Figure 4A). Loxoprofen (60 mg/kg, p.o.) apparently
reduced the amount of PAS-positive substances in the epithelial cells as well as the glands
(Figure 4B). However, the reduction in PAS staining was markedly restored when lafutidine
(30 mg/kg) was administered prior to loxoprofen treatment (Figure 4C). In addition, lafutidine
by itself increased the amount of PAS-positive substances in the mucosa compared to the
control mucosa (Figure 4D).
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Figure 4. Microscopic observations of the rat small intestinal mucosa. The animals were given loxoprofen (60 mg/kg)
p.o. and killed 3 h later. Lafutidine (30 mg/kg) was given p.o. 30 min before the administration of loxoprofen. Figures
show; a: normal; b: loxoprofen alone; c: lafutidine plus loxoprofen; d: lafutidine alone. (PAS; x100). Data adapted after
modification of ref. [26].
4. Commentary
The present study demonstrated that oral administration of loxoprofen induced multiple
hemorrhagic lesions in the small intestine, similar to indomethacin [5], and that lafutidine
protected these intestinal lesions, mediated by capsaicin-sensitive sensory neurons.
We confirmed that loxoprofen produced hemorrhagic lesions in the small intestine, and the
severity of these lesions at 60 mg/kg was almost equivalent to that of the lesions generated by
indomethacin. The onset of these lesions was accompanied by the mucosal invasion of
enterobacteria and the up-regulation of iNOS expression, those events being similarly
observed after indomethacin treatment. We also confirmed that the ulcerogenic response
induced by loxoprofen in the small intestine was significantly prevented by pretreatment of
the animals with dmPGE2 as a supplement for PG deficiency or ampicillin as an antibiotic, the
same was reported using the intestinal indomethacin-induced intestinal lesions [3-5].
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Lafutidine is a histamine H2-receptor antagonist with both antisecretory and gastroprotective
action [17,18]. Onodera et al. [19] reported that the mucosal protective action of lafutidine was
mediated by capsaicin-sensitive sensory neurons and independent of the antisecretory
activity, because the action was not mimicked by cimetidine, another H2-receptor antagonist,
and was totally abolished by chemical deafferentation of sensory neurons. In the present study
we observed that lafutidine protected the small intestine from loxoprofen-induced intestinal
lesions. Certainly, this effect is not brought about by inhibition of gastric acid secretion, since
omeprazole, an inhibitor of H+/K+ATPase, had no effect on this lesion model, similar to
cimetidine. These drugs at the doses used (100 mg/kg) reportedly caused nearly a complete
inhibition of acid secretion [22,23], supporting the idea that acid does not participate in the
pathogenesis of loxoprofen-induced small intestinal lesions.
Lafutidine has been previously shown to prevent indomethacin-induced enteropathy and this
effect was significantly attenuated by chemical ablation of capsaicin-sensitive sensory neurons
[11]. Consistent with these findings, we found that lafutidine dose-dependently reduced the
severity of intestinal lesions produced by loxoprofen and this action disappeared in the animals
with sensory deafferentation. The peptidergic afferent innervation of the intestine has been
demonstrated in various species of animals including the rat [14,24,25]. Several studies have
demonstrated that stimulation of sensory neurons by capsaicin significantly prevented the
occurrence of colitis as well as intestinal ulceration induced experimentally in rats [15,16]. We
also noted that the ulcerogenic response to loxoprofen in the rat intestine was significantly
aggravated by ablation of these sensory neurons. These results together with previous studies
[11,15,16] strongly suggest that capsaicin-sensitive sensory neurons play a role in maintaining
the mucosal integrity of the intestine against noxious stimuli, similarly in the stomach.
The intestinal ulcerogenic response to loxoprofen was also markedly suppressed by prior
administration of ampicillin, an antibiotics, similar to that induced by indomethacin [26]. These
findings were supported by the fact that NSAID-induced small intestinal lesions do not occur
in germ-free animals or fasting animals [5,27], suggesting a major pathogenic role for entero‐
bacteria in these lesions. Because lafutidine significantly mitigated the bacterial invasion in the
mucosa after loxoprofen treatment, this effect may account, at least partly, for the prophylactic
effect of this agent against the intestinal lesions produced by loxoprofen. As mentioned earlier,
the protective effect of lafutidine was almost totally attenuated by sensory deafferentation
following capsaicin pretreatment. We also found in the present study that the suppression by
lafutidine of the enterobacterial invasion following loxoprofen treatment was not observed in
the sensory deafferented animals. Since mucus plays an important part in the innate host
defense against intestinal pathogens and irritants, it is possible that a decreased mucus
production/ secretion plays a role in the pathogenic mechanism of NSAID-induced intestinal
damage by accelerating bacterial invasion in the mucosa. We have previously reported that
indomethacin at an ulcerogenic dose reduced the amount of mucus secreted in the small
intestine, in a PGE2-sensitive manner, and this effect preceded bacterial invasion [10]. Lafuti‐
dine increased mucus secretion in the stomach, at least partly mediated by capsaicin-sensitive
sensory neurons [28,29]. We observed in the present study that lafutidine by itself markedly
increased levels of PAS-positive materials in the intestinal mucosa and reverted the reduced
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Figure 4. Microscopic observations of the rat small intestinal mucosa. The animals were given loxoprofen (60 mg/kg)
p.o. and killed 3 h later. Lafutidine (30 mg/kg) was given p.o. 30 min before the administration of loxoprofen. Figures
show; a: normal; b: loxoprofen alone; c: lafutidine plus loxoprofen; d: lafutidine alone. (PAS; x100). Data adapted after
modification of ref. [26].
4. Commentary
The present study demonstrated that oral administration of loxoprofen induced multiple
hemorrhagic lesions in the small intestine, similar to indomethacin [5], and that lafutidine
protected these intestinal lesions, mediated by capsaicin-sensitive sensory neurons.
We confirmed that loxoprofen produced hemorrhagic lesions in the small intestine, and the
severity of these lesions at 60 mg/kg was almost equivalent to that of the lesions generated by
indomethacin. The onset of these lesions was accompanied by the mucosal invasion of
enterobacteria and the up-regulation of iNOS expression, those events being similarly
observed after indomethacin treatment. We also confirmed that the ulcerogenic response
induced by loxoprofen in the small intestine was significantly prevented by pretreatment of
the animals with dmPGE2 as a supplement for PG deficiency or ampicillin as an antibiotic, the
same was reported using the intestinal indomethacin-induced intestinal lesions [3-5].
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Lafutidine is a histamine H2-receptor antagonist with both antisecretory and gastroprotective
action [17,18]. Onodera et al. [19] reported that the mucosal protective action of lafutidine was
mediated by capsaicin-sensitive sensory neurons and independent of the antisecretory
activity, because the action was not mimicked by cimetidine, another H2-receptor antagonist,
and was totally abolished by chemical deafferentation of sensory neurons. In the present study
we observed that lafutidine protected the small intestine from loxoprofen-induced intestinal
lesions. Certainly, this effect is not brought about by inhibition of gastric acid secretion, since
omeprazole, an inhibitor of H+/K+ATPase, had no effect on this lesion model, similar to
cimetidine. These drugs at the doses used (100 mg/kg) reportedly caused nearly a complete
inhibition of acid secretion [22,23], supporting the idea that acid does not participate in the
pathogenesis of loxoprofen-induced small intestinal lesions.
Lafutidine has been previously shown to prevent indomethacin-induced enteropathy and this
effect was significantly attenuated by chemical ablation of capsaicin-sensitive sensory neurons
[11]. Consistent with these findings, we found that lafutidine dose-dependently reduced the
severity of intestinal lesions produced by loxoprofen and this action disappeared in the animals
with sensory deafferentation. The peptidergic afferent innervation of the intestine has been
demonstrated in various species of animals including the rat [14,24,25]. Several studies have
demonstrated that stimulation of sensory neurons by capsaicin significantly prevented the
occurrence of colitis as well as intestinal ulceration induced experimentally in rats [15,16]. We
also noted that the ulcerogenic response to loxoprofen in the rat intestine was significantly
aggravated by ablation of these sensory neurons. These results together with previous studies
[11,15,16] strongly suggest that capsaicin-sensitive sensory neurons play a role in maintaining
the mucosal integrity of the intestine against noxious stimuli, similarly in the stomach.
The intestinal ulcerogenic response to loxoprofen was also markedly suppressed by prior
administration of ampicillin, an antibiotics, similar to that induced by indomethacin [26]. These
findings were supported by the fact that NSAID-induced small intestinal lesions do not occur
in germ-free animals or fasting animals [5,27], suggesting a major pathogenic role for entero‐
bacteria in these lesions. Because lafutidine significantly mitigated the bacterial invasion in the
mucosa after loxoprofen treatment, this effect may account, at least partly, for the prophylactic
effect of this agent against the intestinal lesions produced by loxoprofen. As mentioned earlier,
the protective effect of lafutidine was almost totally attenuated by sensory deafferentation
following capsaicin pretreatment. We also found in the present study that the suppression by
lafutidine of the enterobacterial invasion following loxoprofen treatment was not observed in
the sensory deafferented animals. Since mucus plays an important part in the innate host
defense against intestinal pathogens and irritants, it is possible that a decreased mucus
production/ secretion plays a role in the pathogenic mechanism of NSAID-induced intestinal
damage by accelerating bacterial invasion in the mucosa. We have previously reported that
indomethacin at an ulcerogenic dose reduced the amount of mucus secreted in the small
intestine, in a PGE2-sensitive manner, and this effect preceded bacterial invasion [10]. Lafuti‐
dine increased mucus secretion in the stomach, at least partly mediated by capsaicin-sensitive
sensory neurons [28,29]. We observed in the present study that lafutidine by itself markedly
increased levels of PAS-positive materials in the intestinal mucosa and reverted the reduced
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response to loxoprofen. Furthermore, it was found that lafutidine increased the expression of
Muc2 mRNA in the small intestine and this response was totally mitigated by ablation of
capsaicin-sensitive sensory neurons. Muc2, one of important mucin genes, plays an important
role in the dimerization of secretory mucins, an essential step in the formation of the gastro‐
intestinal mucus-gels [30]. It is possible that lafutidine up-regulates Muc2 expression and
mucus secretion through a sensory neuron-dependent mechanism and thereby increases the
mucus gel thickness and hampers enterobacterial invasion in the mucosa.
Lafutidine prevented the up-regulation of iNOS expression in the small intestine, an important
event in the occurrence of intestinal lesions caused by NSAIDs [2,31]. Boughton-Smith et al.
[32] reported that bacterial endotoxin from E. coli enhanced the intestinal permeability though
up-regulation of iNOS and overproduction of NO in the mucosa. Since lafutidine was found
to prevent bacterial invasion, probably by up-regulating Muc2/mucus expression, it would be
understandable that this agent suppressed the increase of iNOS expression in the small
intestine following loxoprofen treatment. We previously reported that the mucosal protective
drugs, such as irsogladine, rebamipide and teprenone, all significantly increased mucus
secretion and suppressed bacterial invasion and iNOS expression, thereby reduced the severity
of intestinal lesions produced by indomethacin [33]. These results together support a cause-
effect relationship between changes in the above three events; ie., mucus secretion, bacterial
invasion, and iNOS expression.
5. Summary
Lafutidine protects the small intestine against loxoprofen-induced lesions. This effect is not
associated with inhibition of acid secretion due to the blockade of histamine H2-receptors and
appears to be mediated by capsaicin-sensitive sensory neurons. The exact mechanism under‐
lying the intestinal protection by lafutidine remains unknown, yet it is assumed that lafutidine
prevents the process of enterobacterial invasion in the mucosa by increasing the mucus gel
layer through the up-regulation of Muc2 mRNA expression, and thereby suppresses iNOS
induction, resulting in prevention of the occurrence of intestinal lesions following loxoprofen
treatment.
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response to loxoprofen. Furthermore, it was found that lafutidine increased the expression of
Muc2 mRNA in the small intestine and this response was totally mitigated by ablation of
capsaicin-sensitive sensory neurons. Muc2, one of important mucin genes, plays an important
role in the dimerization of secretory mucins, an essential step in the formation of the gastro‐
intestinal mucus-gels [30]. It is possible that lafutidine up-regulates Muc2 expression and
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to prevent bacterial invasion, probably by up-regulating Muc2/mucus expression, it would be
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1. Introduction
Capsaicin is an active ingredient of red pepper and paprika. These plants are well known and
used in every day of the culinary practice for about 9000-9500 years.
It was an important discovery that the capsaicin (capsaicin, dihydrocapsaicin, nordihydro‐
capsaicin and other capsaicinoids) specifically modify the function of certain nerves, later
named to capsaicin sensitive afferent nerves (Jancsó et al., 1967; 1968; 1970).
Capsaicin activates the capsaicin (vanilloid) receptor expressed a subgroup of primary afferent
nociceptive neurons (Szolcsányi, 2004). The capsaicin receptor has been cloned (Caterina et al.,
1997) and turned out to be a cation channel. It is gated besides capsaicin and other capsaicinoids
(some vanilloids) by low pH, noxious heat and various pains – producing endogenous and
exogenous chemicals. Thus, these sensory nerve endings equipped with these ion channels are
prone to be stimulated in gastric mucosa.
The action of capsaicin on the capsaicin sensitive afferent nerves is dose dependent (Szolcsányi
and Barthó, 1981; Szolcsányi, 1984; 1997; 2004; Abdel-Salam et al., 1999; 2001; Mózsik et al.,
2001). Szolcsányi indicated four different stages of capsaicin action (depending on the dose
and duration of the exposure of the compound): a. excitation (stage 1); b. sensory blocking
effect (stage 2); c. long-term selective neurotoxin impairment (stage 3) and d. irreversible cell
destruction (stage 4) (Szolcsányi, 1984). The stages 1 and 2 are reversible; meanwhile the stages
3 and 4 are irreversible compound-induced actions on the capsaicin sensitive afferent nerve.
These stages of capsaicin actions can be detected in the gastrointestinal (GI) tract (Mózsik et
al., 2001) in animal experiments.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
Capsaicin is an active ingredient of red pepper and paprika. These plants are well known and
used in every day of the culinary practice for about 9000-9500 years.
It was an important discovery that the capsaicin (capsaicin, dihydrocapsaicin, nordihydro‐
capsaicin and other capsaicinoids) specifically modify the function of certain nerves, later
named to capsaicin sensitive afferent nerves (Jancsó et al., 1967; 1968; 1970).
Capsaicin activates the capsaicin (vanilloid) receptor expressed a subgroup of primary afferent
nociceptive neurons (Szolcsányi, 2004). The capsaicin receptor has been cloned (Caterina et al.,
1997) and turned out to be a cation channel. It is gated besides capsaicin and other capsaicinoids
(some vanilloids) by low pH, noxious heat and various pains – producing endogenous and
exogenous chemicals. Thus, these sensory nerve endings equipped with these ion channels are
prone to be stimulated in gastric mucosa.
The action of capsaicin on the capsaicin sensitive afferent nerves is dose dependent (Szolcsányi
and Barthó, 1981; Szolcsányi, 1984; 1997; 2004; Abdel-Salam et al., 1999; 2001; Mózsik et al.,
2001). Szolcsányi indicated four different stages of capsaicin action (depending on the dose
and duration of the exposure of the compound): a. excitation (stage 1); b. sensory blocking
effect (stage 2); c. long-term selective neurotoxin impairment (stage 3) and d. irreversible cell
destruction (stage 4) (Szolcsányi, 1984). The stages 1 and 2 are reversible; meanwhile the stages
3 and 4 are irreversible compound-induced actions on the capsaicin sensitive afferent nerve.
These stages of capsaicin actions can be detected in the gastrointestinal (GI) tract (Mózsik et
al., 2001) in animal experiments.
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The vagal nerve has a key-role in the development of GI mucosal damage and prevention
(Mózsik et al., 1982). The potency of vagal nerve has been emphasized dominantly in the
aggressive processes to GI mucosa (such as peptic ulcer disease, gastric mucosal damage, etc.)
in both animal models and in human investigations. The „chemical” and „surgical” vagotomy
widely used in the treatment of patients with peptic ulcer disease in the years up to middle of
1970 (Karádi and Mózsik, 2000). By the other words, the primary aims of this therapy were to
decrease the activity of vagal nerve at the level of efferent nerves in the target organs.
The  application  of  capsaicin  in  the  animal  experiments  was  used  as  a  specific  tool  to
approach the group of primary afferent nociceptive neurons (Szolcsányi,  2004; Buck and
Burks, 1986; Holzer, 1988; 1991; Szállasi and Blumberg, 1999, Holzer, 2013) involved in the
different  physiological,  pathological  processes  and  medical  therapy  in  human  healthy
subjects and in patients with different GI disorders as well those treated with nonsteroi‐
dal anti-inflammatory drugs (NSAIDs).
Szolcsányi and Barthó (1981) were the firsts, who clearly indicated the beneficial and harmful
effect of capsaicin in the peptic ulcer disease in rats on dependence of applied doses of
capsaicin. Later, Holzer started with a very extensive research work with capsaicin in the field
of gastroenterology (Holzer, 1998; 1999; Buck and Burks, 1986; Szállasi and Blumberg, 1999,
Holzer, 2013). Our group also participated in the GI capsaicin research in animals experiments
from 1980 (Mózsik et al., 1997) (the historical background see the chapter written by Szolcsányi,
2014).
Even new drug, Lafutidine, was developed in the medical treatment of GI mucosal damage
(Ajioka et al., 2000; 2002; Onodera et al., 1995; 1999; Takeuchi, 2006). The Lafutidine is a
histamin-2-receptor (H2R) blocking compound showed typical capsaicin actions at the target
organ.
The new and interesting results obtained with capsaicin application in animal experiments
offered excellent tools to approach the different events of human GI physiology, pathology
and pharmacology and to produce new drug or new drug combinations in human healthy
subjects and patients with different GI and other diseases (myocardial infarction, thrombo‐
phylia, rheumatoid arthritis, chronic pain killer use).
We started clinical studies with capsaicin from 1997 (Mózsik et al., 1999; Debreceni et al.,
1999; Mózsik et al., 2004a; 2004b; 2005) and these studies incorporated the different regulatory
mechanisms of capsaicin in the human stomach, gastric mucosal preventive effects of capsai‐
cin(noids) on the NSAID-induced gastric mucosal damage, chronic gastritis with Helicobacter
pylori (H. pylori) positive and negative gastritis (with and without eradication treatment). We
performed immuno-histochemical examinations of capsaicin receptor (TRPV1), calcitonin-
gene-related peptide (CGRP), substance P (SP) in the human GI mucosa of patients with
various GI disorders, took significant steps in the development of capsaicin containing drug
and drug combinations (with aspirin, diclofenac, Naproxen), including the preparation of
protocols for human phase I. examinations [and to carried out these examinations after the
receiving permission from the National Institute of Pharmacy (Budapest, Hungary) and
National Clinical Pharmacological and Ethical Committee of Hungary].
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These studies were carried out as propective, randomized and multiclinical studies of human
healthy subjects and in patients with various gastrointestinal disorders including gastric
mucosal damage produced by application of NSAIDs or H. pylori infection.
The aims of this review are: (1) to give a short summary on the actions of capsaicin on the
human gastrointestinal tract (dominantly on the stomach), (2) to indicate some details of
gastroprotective actions of capsaicin in human healthy subjects; (3) to demonstrate the
capsaicin-induced gastric protective effects against the NSAID-(selective and non-selective
COX inhibitor) induced gastric microbleedings in human healthy subjects; (4) to prove the
independency of TRPV1 and CGRP expression from the presence of the H. pylori positive or
negative chronic gastritis, the efficacy of successfully carried out eradication treatment in
patients with H. pylori positive gastritis in patients; 5. to indicate the clinical pharmacological
problems of plant origin capsaicin in humans (in term of drug processing); (6). to point out
that the gastroprotective effects of capsaicin (given orally in stimulatory doses of capsaicin on
the capsaicin-sensitive afferent nerves) to human healthy subjects, and as treatment to patients
who are under chronic NSAID use (like patients with myocardial infarction, stroke, thrombo‐
phylia, rheumatic diseases, etc.).
In terms of classical pharmacology we would like to demonstrate clearly in the human
observations that the applied doses of capsaicin stimulate the capsaicin-sensitive afferent nerve
with a clear cut exclusion of the existence of capsaicin desensitation.
On the other hand, our research activity clearly demonstrates the different difficulties of
capsaicin(oids) application as new gastroprotective drug for healthy subjects and for patients
with different GI disorders and NSAIDs use in regards to toxicology plant cultivation, storage,
chemical detection and standardization questions as well as permission requests from
authorities needed prior the launch of industrial processing of plant-derived, orally applicable
drug or drug combinations.
2. Materials and methods
The observations were carried out in 198 healthy human subjects aged 25-65 years (40± 10
years) and in 178 patients with various GI disorders (gastritis, erosion, ulcer, polyps, cancer
and chronic inflammatory bowel diseases, polyps, precancerous states, colorectal cancer), aged
ranged 25-75 years (45±10), 69 patients with chronic gastritis 39-68 years (mean: 56.4 years)
(altogether 445 healthy persons and GI patients).
The observations were carried out at First Department of Medicine, Department of Pharma‐
cology and Pharmacotherapy and Institute of Pharmaceutical Chemistry, University of Pécs,
Hungary, in the Department of Gastroenterology of Petz Aladár Teaching Hospital, Győr,
Hungary, in the Department of Gastroenterology of Markusovszky Hospital, Szombathely,
Hungary (and their relevant Departments of Pathology), in Histopatology Ltd., Pécs, Hungary
and at our industrial research partner (PannonPharma Ltd., Pécsvárad, Hungary).
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performed immuno-histochemical examinations of capsaicin receptor (TRPV1), calcitonin-
gene-related peptide (CGRP), substance P (SP) in the human GI mucosa of patients with
various GI disorders, took significant steps in the development of capsaicin containing drug
and drug combinations (with aspirin, diclofenac, Naproxen), including the preparation of
protocols for human phase I. examinations [and to carried out these examinations after the
receiving permission from the National Institute of Pharmacy (Budapest, Hungary) and
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the capsaicin-sensitive afferent nerves) to human healthy subjects, and as treatment to patients
who are under chronic NSAID use (like patients with myocardial infarction, stroke, thrombo‐
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In terms of classical pharmacology we would like to demonstrate clearly in the human
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with a clear cut exclusion of the existence of capsaicin desensitation.
On the other hand, our research activity clearly demonstrates the different difficulties of
capsaicin(oids) application as new gastroprotective drug for healthy subjects and for patients
with different GI disorders and NSAIDs use in regards to toxicology plant cultivation, storage,
chemical detection and standardization questions as well as permission requests from
authorities needed prior the launch of industrial processing of plant-derived, orally applicable
drug or drug combinations.
2. Materials and methods
The observations were carried out in 198 healthy human subjects aged 25-65 years (40± 10
years) and in 178 patients with various GI disorders (gastritis, erosion, ulcer, polyps, cancer
and chronic inflammatory bowel diseases, polyps, precancerous states, colorectal cancer), aged
ranged 25-75 years (45±10), 69 patients with chronic gastritis 39-68 years (mean: 56.4 years)
(altogether 445 healthy persons and GI patients).
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The human healthy subjects and patients were included into the groups of different random‐
ized, prospective studies (see later).
The classical human clinical pharmacological phase I examinations were carried out in 15
healthy males in each protocol (additionally up today, 30 human healthy subjects for human
phase I examinations for aspirin plus capsaicin and diclofenac plus capsaicin) (some parts of
these observations are presented by the book chapter written Mózsik et al., 2014).
The physical, laboratory, and iconographic examinations were normal in the healthy human
subjects, in patients with various GI disorders.
The healthy persons were randomized into different groups of prospective, randomized and
prospective studies for evaluation the effects of capsaicin on:
1. gastric basal acid secretion (BAO) (Mózsik et al., 1999, 2005);
2. changes in cations, anions, albumin concentration (and outputs) of gastric secretory
responses (Mózsik et al., 2004a; 2005);
3. gastric emptying (Debreceni et al., 1999);
4. sugar (glucose) loading test (75 g given orally) (Dömötör et al., 2006b);
5. gastric transmucosal potential difference (GTPD) alone (Mózsik et al., 2005);
6. GTPD measurement after intragastric administration of ethanol and capsaicin application
(Mózsik et al., 2005);
7. indomethacin-induced gastric microbleedings without and with capsaicin (Fisher and
Hunt, 1976).
The different doses of capsaicin (1 – 8 µg/100 mL in saline solution) were intragastrically given
to identify the ED50 values on the gastric basal acid secretion. These doses of capsaicin were
used to determine direct action of capsaicin on the gastric transmucosal potential difference
(GTPD) (without and with intragastric administration of ethanol) and indomethacin-induced
gastric microbleedings.
The all of the healthy volunteers received capsaicin in doses with random allocation. In the
observations to study the gastric emptying, sugar loading test, the effect of the ED50 value (400
µg intragastrically given) of capsaicin was tested.
The 178 patients with different GI disorders were studied by immunohistochemical examina‐
tions of biopsy samples. The histological diagnosis was established on the opinion of inde‐
pendent pathologist. The immunohistochemical examinations for capsaicin receptor, CGRP,
SP were carried out on the same on paraffin-embedded tissues samples from which the
classical histological diagnosis was established by the independent pathologist (Dömötör et
al., 2005, 2006).
The patients with chronic gastritis (69 patients) were divided H. pylori positive and negative
groups. Smaller group of patients with H. pylori infection were studied further after classical
eradication treatment had been performed.
The observations were carried out according to the method of Good Clinical Practice (GCP).
The studies were carried out from 1997 up to now, which were permitted by the Regional
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Ethical Committee of University of Pécs, Hungary. Written informed consent was obtained
from all participants.
The following main methods were used in the human observations:
2.1. Determination of gastric basal acid out (BAO)
Determination of gastric basal acid out (BAO) in human healthy subjects: After an overnight
fasting, a nasogastric tube was introduced at 8.00 a.m., and the total gastric content was
suctioned. Than the newly secreted gastric juice was suctioned every 15 min for 1 h (BAO).
The healthy subjects received intragastrically capsaicin (100, 200, 400 and 800 µg ig.), atropine
(0.1-1.0 mg sc.), Pirenzepine 25-50 mg, famotidine (20-40 mg orally), ranitidine (150-300 mg
orally), cimetidine (100-1000 mg orally), Omeprazole (20 – 40 mg iv.) and Esomeprazole (20-40
mg orally) given for determinations their dose responses curves (Mózsik et al., 2005; 2007;
Szabó et al., 2013).
Gastric acid secretion was measured by titration of gastric juice with 0.1 N NaOH to pH 7.0
(pH titrimeter, Radelkis, Budapest). The gastric acid outputs were expressed as mmol/h (means
± SEM).
2.2. Determination of affinity and intrinsic activity curves
Determination of affinity and intrinsic activity curves for drugs inhibiting BAO in healthy
human subjects: The applied doses of drugs were expressed in molar values, which were used
to determine the affinity and intrinsic activity curves of the different drugs by the method of
Csáky (1969). For drawing the affinity and intrinsic activity curves the doses of various drugs
were expressed in [-] molar values, which offered to analyze the drug actions on the BAO
according to the classical molecular pharmacological methods. We identified the pD2 values
(necessary doses of drugs to produce 50 per cent inhibition on BAO values). The effect of
atropine (αatropine=1.00) in case of identification of intrinsic activity curves for other drugs and
capsaicin (Mózsik, 2006).
2.3. Chemical composition of gastric juice without and with capsaicin application
These observations were carried out in the same healthy human subjects. The concentrations
of Na+, K+and calcium2+in the gastric juice were measured flamephotometrically. The concen‐
tration of Mg2+was measured by atomic absorption spectrophotometrically, the chloride
concentration by colorimetric method, the protein content by the method of biuret reaction.
The 400 µg of capsaicin (as ED50 value) was used in these studies.
2.4. Calculation of „parietal” and „ non-parietal” components of gastric secretory responses
without and with capsaicin
The chloride linked to H+and sodium was calculated for the determination of „parietal”
(chloride linked to H+) and „non-parietal” (linked to sodium) components of gastric BAO
(Hollander, 1934).
Capsaicin-Sensitive Afferentation and Human Gastrointestinal Tract
http://dx.doi.org/10.5772/58360
217
The human healthy subjects and patients were included into the groups of different random‐
ized, prospective studies (see later).
The classical human clinical pharmacological phase I examinations were carried out in 15
healthy males in each protocol (additionally up today, 30 human healthy subjects for human
phase I examinations for aspirin plus capsaicin and diclofenac plus capsaicin) (some parts of
these observations are presented by the book chapter written Mózsik et al., 2014).
The physical, laboratory, and iconographic examinations were normal in the healthy human
subjects, in patients with various GI disorders.
The healthy persons were randomized into different groups of prospective, randomized and
prospective studies for evaluation the effects of capsaicin on:
1. gastric basal acid secretion (BAO) (Mózsik et al., 1999, 2005);
2. changes in cations, anions, albumin concentration (and outputs) of gastric secretory
responses (Mózsik et al., 2004a; 2005);
3. gastric emptying (Debreceni et al., 1999);
4. sugar (glucose) loading test (75 g given orally) (Dömötör et al., 2006b);
5. gastric transmucosal potential difference (GTPD) alone (Mózsik et al., 2005);
6. GTPD measurement after intragastric administration of ethanol and capsaicin application
(Mózsik et al., 2005);
7. indomethacin-induced gastric microbleedings without and with capsaicin (Fisher and
Hunt, 1976).
The different doses of capsaicin (1 – 8 µg/100 mL in saline solution) were intragastrically given
to identify the ED50 values on the gastric basal acid secretion. These doses of capsaicin were
used to determine direct action of capsaicin on the gastric transmucosal potential difference
(GTPD) (without and with intragastric administration of ethanol) and indomethacin-induced
gastric microbleedings.
The all of the healthy volunteers received capsaicin in doses with random allocation. In the
observations to study the gastric emptying, sugar loading test, the effect of the ED50 value (400
µg intragastrically given) of capsaicin was tested.
The 178 patients with different GI disorders were studied by immunohistochemical examina‐
tions of biopsy samples. The histological diagnosis was established on the opinion of inde‐
pendent pathologist. The immunohistochemical examinations for capsaicin receptor, CGRP,
SP were carried out on the same on paraffin-embedded tissues samples from which the
classical histological diagnosis was established by the independent pathologist (Dömötör et
al., 2005, 2006).
The patients with chronic gastritis (69 patients) were divided H. pylori positive and negative
groups. Smaller group of patients with H. pylori infection were studied further after classical
eradication treatment had been performed.
The observations were carried out according to the method of Good Clinical Practice (GCP).
The studies were carried out from 1997 up to now, which were permitted by the Regional
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside216
Ethical Committee of University of Pécs, Hungary. Written informed consent was obtained
from all participants.
The following main methods were used in the human observations:
2.1. Determination of gastric basal acid out (BAO)
Determination of gastric basal acid out (BAO) in human healthy subjects: After an overnight
fasting, a nasogastric tube was introduced at 8.00 a.m., and the total gastric content was
suctioned. Than the newly secreted gastric juice was suctioned every 15 min for 1 h (BAO).
The healthy subjects received intragastrically capsaicin (100, 200, 400 and 800 µg ig.), atropine
(0.1-1.0 mg sc.), Pirenzepine 25-50 mg, famotidine (20-40 mg orally), ranitidine (150-300 mg
orally), cimetidine (100-1000 mg orally), Omeprazole (20 – 40 mg iv.) and Esomeprazole (20-40
mg orally) given for determinations their dose responses curves (Mózsik et al., 2005; 2007;
Szabó et al., 2013).
Gastric acid secretion was measured by titration of gastric juice with 0.1 N NaOH to pH 7.0
(pH titrimeter, Radelkis, Budapest). The gastric acid outputs were expressed as mmol/h (means
± SEM).
2.2. Determination of affinity and intrinsic activity curves
Determination of affinity and intrinsic activity curves for drugs inhibiting BAO in healthy
human subjects: The applied doses of drugs were expressed in molar values, which were used
to determine the affinity and intrinsic activity curves of the different drugs by the method of
Csáky (1969). For drawing the affinity and intrinsic activity curves the doses of various drugs
were expressed in [-] molar values, which offered to analyze the drug actions on the BAO
according to the classical molecular pharmacological methods. We identified the pD2 values
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2.5. Measurement of gastric transmucosal potential difference (GTPD)
GTPD was measured during endoscopy. The exploring mucosal electrode was passed through
the biopsy channel of gastroscope and the reference electrode was placed on the volar surface
of the left forearm. The electrodes were connected to a digital voltmeter (Radelkis, Budapest,
Hungary, OP 211/1). GTPD measurements were done at the greater curvature of the gastric
body and the results were expressed in –mV (without and with intragastrically administration
of different doses of capsaicin) (Hossennbocus et al., 1975; Mózsik et al., 2005). Five mL
capsaicin (300 mL/L, diluted in saline) was intragastrically applied and only saline solution
was given to identify the baseline in GTPD. The ∆GTPD values were expressed in –mV, ΔGTPD
max was calculated at five minutes after intragastric application of capsaicin.
2.6. Effect of capsaicin on ethanol-induced changes GTPD changes
The GTPD baseline was identified. Then ethanol (5 mL, 300 mL/L) was intragastrically given.
The GTPD change was determined after the ethanol had been passed through the biopsy
channel of gastroscope without and with capsaicin administration (given in different doses in
the same pathway after 1 min of ethanol administration).
2.7. Measurements of gastric microbleeding produced by acute application of indomethacin
(without and with capsaicin administration) in healthy human subjects
Non-selective COX inhibitor, indomethacin (IND) was used to induce gastric microbleeding.
The extents of IND-induced gastric microbleeding were measured in healthy human subjects
by the method of hemoglobin concentration in the gastric juice respecting the value of gastric
emptying rate (Fisher and Hunt, 1976). The details of this method were described in one
previous paper (Mózsik et al., 2005).
2.7.1. Baseline of gastric mucosal microbleedings in acute observations with human healthy subjects
The baseline of gastric microbleeding was measured in the gastric juice without application of
any drug and/or capsaicin. The hemoglobin concentration was determined. The extent of
gastric emptying was measured with application of phenol red into the stomach (by the
method of Fisher and Hunt 1976; Nagy et al., 1984). The extent of gastric microbleeding was
expressed in mL/day (means ±SEM), and this value was taken as baseline (used as control for
other observations).
2.7.2. Capsaicin-induced acute mucosal protection on the IND-induced acute gastric microbleeding in
healthy human subjects
The healthy human subjects received IND (3x25 mg given orally for a day), and the forthcom‐
ing day the gastric microbleeding was measured on forthcoming day, when these healthy
human subjects also received 25 mg IND orally. The extent of gastric microbleeding was
measured as mentioned above, and its value was expressed as mL/ day (means ± SEM).
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2.8. Measurements of gastric emptying
The gastric emptying measurements were performed on two consecutive days by the same
protocol, without capsaicin on first day and with capsaicin (400 µg orally given, ED50 value)
on second day. The measurement procedure was the following. The healthy human subjects
went on an overnight starvation and the observations were started at 8.00 a.m. In total, 100 mL
of 13C-octanoid acid (Izinta, Budapest, Hungary) was given for the gastric emptying measure‐
ments. This material was given in 200 mL physiological saline and 75 g glucose was added to
the solution. The volunteers exhaled into a plastic bag with a volume of 0.5 L. The first air
sample was considered as reference. Then, the volunteers swallowed the test solution and gave
air samples in every 15 min. The IRIS performed the infrared spectroscopy (IRIS, Izinta,
Budapest, Hungary) measurements and calculated the delta over base (DOB) values. This
value was directly proportional to the ratio 13CO2 and 12CO2 (DOB is about 13CO2/12CO2) in the
air sample. When we respected the DOB values against to the time in the graph, we obtained
a gastric emptying curve. On this curve, we could consider the following four parameters to
characterize gastric emptying rate: 1. maximal value of DOB (DOBmax unit) (U); 2. the time at
DOBmax (U/min); 3. the slope of the rising part of the curve (U/min) and 4. the time at 50% of
area under curve (AUC50%, min). The DOBmax and slope are direct, meanwhile the time at
DOBmax and the time at AUC50% are inversely proportional to gastric emptying (Debreceni et
al., 1999; Mózsik et al., 2004a).
2.9. Sugar loading test in healthy human subjects
The glucose (75 g) was orally given in 100 mL water. The plasma level of glucose was measured
enzymatical (Boehringer, Germany). The plasma levels of insulin (µIU/mL) (Biochem Immun‐
system), C peptide and glucagon (pg/mL) (Byk-Sangtect Diagnostic GmbH) were measured
by RIA. The all measurements were carried out before and after administration repeatedly in
every 15 mins for 4 h period (Dömötör et al., 2006b).
2.10. Immunohistochemical examinations in the gastric and large bowel mucosa in patients
with various disorders
The classical pathological histological examinations were carried out by an independent
pathologist for giving the histopathological diagnosis of patients (besides the classical
laboratory, iconographic examinations).
The specific immunohistochemical examinations were used for the same biopsy specimens
used for pathological examination. Specific antisera were used for detection of vanilloid
(TRVP1) receptor (polyclonal anti-TRVP1, Abcam, Cambridge, UK), CGRP (polyclonal anti-
CGRP, Abcam, Cambridge, UK) and SP (monoclonal anti SP, Abcam, Cambridge, UK).
The TRVP1 and CGRP positive and/or negativity was detected, meanwhile SP staining was
evaluated by a semi-quantitave scale (Dömötör et. al., 2005).
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previous paper (Mózsik et al., 2005).
2.7.1. Baseline of gastric mucosal microbleedings in acute observations with human healthy subjects
The baseline of gastric microbleeding was measured in the gastric juice without application of
any drug and/or capsaicin. The hemoglobin concentration was determined. The extent of
gastric emptying was measured with application of phenol red into the stomach (by the
method of Fisher and Hunt 1976; Nagy et al., 1984). The extent of gastric microbleeding was
expressed in mL/day (means ±SEM), and this value was taken as baseline (used as control for
other observations).
2.7.2. Capsaicin-induced acute mucosal protection on the IND-induced acute gastric microbleeding in
healthy human subjects
The healthy human subjects received IND (3x25 mg given orally for a day), and the forthcom‐
ing day the gastric microbleeding was measured on forthcoming day, when these healthy
human subjects also received 25 mg IND orally. The extent of gastric microbleeding was
measured as mentioned above, and its value was expressed as mL/ day (means ± SEM).
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2.8. Measurements of gastric emptying
The gastric emptying measurements were performed on two consecutive days by the same
protocol, without capsaicin on first day and with capsaicin (400 µg orally given, ED50 value)
on second day. The measurement procedure was the following. The healthy human subjects
went on an overnight starvation and the observations were started at 8.00 a.m. In total, 100 mL
of 13C-octanoid acid (Izinta, Budapest, Hungary) was given for the gastric emptying measure‐
ments. This material was given in 200 mL physiological saline and 75 g glucose was added to
the solution. The volunteers exhaled into a plastic bag with a volume of 0.5 L. The first air
sample was considered as reference. Then, the volunteers swallowed the test solution and gave
air samples in every 15 min. The IRIS performed the infrared spectroscopy (IRIS, Izinta,
Budapest, Hungary) measurements and calculated the delta over base (DOB) values. This
value was directly proportional to the ratio 13CO2 and 12CO2 (DOB is about 13CO2/12CO2) in the
air sample. When we respected the DOB values against to the time in the graph, we obtained
a gastric emptying curve. On this curve, we could consider the following four parameters to
characterize gastric emptying rate: 1. maximal value of DOB (DOBmax unit) (U); 2. the time at
DOBmax (U/min); 3. the slope of the rising part of the curve (U/min) and 4. the time at 50% of
area under curve (AUC50%, min). The DOBmax and slope are direct, meanwhile the time at
DOBmax and the time at AUC50% are inversely proportional to gastric emptying (Debreceni et
al., 1999; Mózsik et al., 2004a).
2.9. Sugar loading test in healthy human subjects
The glucose (75 g) was orally given in 100 mL water. The plasma level of glucose was measured
enzymatical (Boehringer, Germany). The plasma levels of insulin (µIU/mL) (Biochem Immun‐
system), C peptide and glucagon (pg/mL) (Byk-Sangtect Diagnostic GmbH) were measured
by RIA. The all measurements were carried out before and after administration repeatedly in
every 15 mins for 4 h period (Dömötör et al., 2006b).
2.10. Immunohistochemical examinations in the gastric and large bowel mucosa in patients
with various disorders
The classical pathological histological examinations were carried out by an independent
pathologist for giving the histopathological diagnosis of patients (besides the classical
laboratory, iconographic examinations).
The specific immunohistochemical examinations were used for the same biopsy specimens
used for pathological examination. Specific antisera were used for detection of vanilloid
(TRVP1) receptor (polyclonal anti-TRVP1, Abcam, Cambridge, UK), CGRP (polyclonal anti-
CGRP, Abcam, Cambridge, UK) and SP (monoclonal anti SP, Abcam, Cambridge, UK).
The TRVP1 and CGRP positive and/or negativity was detected, meanwhile SP staining was
evaluated by a semi-quantitave scale (Dömötör et. al., 2005).
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2.11. Detection of Helicobacter pylori in patients with chronic gastritis
The presence of H. pylori was detected by 13C-urea breath test (Izinta, Hungary) and with
specific  histological  staining of  biopsy specimens.  The diagnosis  of  chronic gastritis  was
based on the classical pathological histology. The results of observations were expressed
as means ± SEM. The unpaired and paired Student’s t tests were used for the calculation
of results  between the identical  observations.  P value ≤  0.05 was considered statistically
significant.
2.12. Evaluation of capsaicin-stimulated gastric mucosal protection on IND-induced gastric
microbleeding and capsaicin-produced gastric mucosal protection on the IND-induced
gastric microbleeding before and after 2 weeks capsaicin treatment (based on randomized,
prospective and multi-clinical study in healthy subjects) (Mózsik et al., 2004 a; 2005; 2007)
2.12.1. Measurement of gastric microbleeding before and after 2 weeks capsaicin treatment
The baseline in gastric microbleeding was measured and carried out as those under the point
of 7.1. The gastric microbleeding was expressed in mL/ day (means ±SEM).
2.12.2. Measurement of IND-induced acute gastric microbleeding before and after 2-week capsaicin
treatment
These measurements were carried out in healthy human subjects as those were written under
7.2. These healthy subjects received 3x25 mg IND for one day and 25 mg IND on the next day
before the measurement of the extent of gastric microbleeding. The gastric microbleeding was
expressed in mL/day (means ±SEM).
2.12.3. Measurement of capsaicin-induced acute gastric mucosal protection against the IND-induced
acute gastric microbleeding before and after 2-week capsaicin treatment
The observations were carried out under the observational circumstances mentioned in 12.2,
however, different doses of capsaicin (200 and 400 µg given orally) were used. Two hundred
and 400 µg capsaicin were applied given orally before the measurement of IND-induced acute
gastric microbleeding before and after 2-week capsaicin treatment.
2.12.4. Evaluation of capsaicin’s effect by randomized, prospective, multi-clinical studies in patients
with chronic Helicobacter pylori positive gastritis before and after eradication treatment to capsaicin-
effect due to stimulation of capsaicin-sensitive neural afferentation (Lakner et al 2011)
These studies were carried out in 38 persons (including 20 healthy persons and 18 patients
with H. pylori positive gastritis). The histologically normal controls were in ages: 41 to 67 years,
mean: 52.1 years), meanwhile the ages of patients with chronic Helicobacter pylori infection
were 39 to 68 years, mean: 56.4 years) (Lakner et al., 2011).
The presence of H. pylori was determined by the methods mentioned above.
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The eradication therapy was involved a seven days treatment with double dose proton-pump
inhibitor consisting of PPI (pantoprazole 2x40 mg/day), amoxicillin (1000 mg twice daily) and
clarithromycin (500 mg twice daily), according to European guidelines (Malfertheiner et al.,
2007). Following this one week of eradication period, the patients further treated with normal
dose of PPI for other another week.
The gastroscopies, gastric biopsies, general and special immuno-histochemical examinations
were carried out at the time of entry of patients into the eradication treatment, after the
eradication treatment (Lakner et al., 2011).
2.13. Used drugs and compounds
Anticholinergic (atropine, Egis, Budapest, Hungary), antimuscarinic (Pirenzepine, Boehring‐
er, Ingelheim, Germany) agents; [histamine H2-receptor antagonists (Cimetidine, Pannon‐
Pharma, Hungary), ranitidine (Biogal-Teva, Hungary), famotidine (Richter Gedeon,
Hungary)], proton pump inhibitors (PPI) [(Omeprazole, Astra-Zeneca, Sweden), Esomepra‐
zole (Astra-Zeneca, Sweden)]; indomethacin (Chinoin, Budapest, Hungary) were used.
Capsaicin was applied in these studies obtained from Asian Herbex Ltd: Capsaicin USP as
manufactured in Andhra Pradesh, India). The Drug Master File (DMF) is signed in the
documentation of Drug and Food Administration (FDA) in the United States as only one
capsaicin preparation for orally applicable preparate (“ 17856 A II 26.10.2004 Asian Herbex
Ltd. : Capsaicin USP as manufactured in Andhra Pradesh, India”) (for further details, see
Mózsik et al. 2009b).
2.14. Statistical evaluation of results
The results were expressed as means ± SEM. The paired and unpaired Student’s t test and
ANOVA test were used for the statistical analysis of the results. The results were taken to be
significant when the P value was found ≤ 0.05. Special mathematical programs were applied
for the evaluation of results of human phase I. examinations.
3. Results
3.1. Capsaicin-induced BAO in healthy human subjects
The capsaicin (given in doses of 100, 200,400 and 800 µg orally) dose-dependently inhibited
the gastric acid output (Y=-0.13.X+1.164; r=0.97; n=16; P < 0.001) (Mózsik et al., 1999; Mózsik et
al., 2005). The ED50 value of capsaicin was obtained as 400 µg/person on the gastric BAO (in
case of administration of capsaicin in doses which stimulates the capsaicin-sensitive afferent
nerves) (Figures 1 and 2) (Mózsik et al., 1999; 2005).
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2.11. Detection of Helicobacter pylori in patients with chronic gastritis
The presence of H. pylori was detected by 13C-urea breath test (Izinta, Hungary) and with
specific  histological  staining of  biopsy specimens.  The diagnosis  of  chronic gastritis  was
based on the classical pathological histology. The results of observations were expressed
as means ± SEM. The unpaired and paired Student’s t tests were used for the calculation
of results  between the identical  observations.  P value ≤  0.05 was considered statistically
significant.
2.12. Evaluation of capsaicin-stimulated gastric mucosal protection on IND-induced gastric
microbleeding and capsaicin-produced gastric mucosal protection on the IND-induced
gastric microbleeding before and after 2 weeks capsaicin treatment (based on randomized,
prospective and multi-clinical study in healthy subjects) (Mózsik et al., 2004 a; 2005; 2007)
2.12.1. Measurement of gastric microbleeding before and after 2 weeks capsaicin treatment
The baseline in gastric microbleeding was measured and carried out as those under the point
of 7.1. The gastric microbleeding was expressed in mL/ day (means ±SEM).
2.12.2. Measurement of IND-induced acute gastric microbleeding before and after 2-week capsaicin
treatment
These measurements were carried out in healthy human subjects as those were written under
7.2. These healthy subjects received 3x25 mg IND for one day and 25 mg IND on the next day
before the measurement of the extent of gastric microbleeding. The gastric microbleeding was
expressed in mL/day (means ±SEM).
2.12.3. Measurement of capsaicin-induced acute gastric mucosal protection against the IND-induced
acute gastric microbleeding before and after 2-week capsaicin treatment
The observations were carried out under the observational circumstances mentioned in 12.2,
however, different doses of capsaicin (200 and 400 µg given orally) were used. Two hundred
and 400 µg capsaicin were applied given orally before the measurement of IND-induced acute
gastric microbleeding before and after 2-week capsaicin treatment.
2.12.4. Evaluation of capsaicin’s effect by randomized, prospective, multi-clinical studies in patients
with chronic Helicobacter pylori positive gastritis before and after eradication treatment to capsaicin-
effect due to stimulation of capsaicin-sensitive neural afferentation (Lakner et al 2011)
These studies were carried out in 38 persons (including 20 healthy persons and 18 patients
with H. pylori positive gastritis). The histologically normal controls were in ages: 41 to 67 years,
mean: 52.1 years), meanwhile the ages of patients with chronic Helicobacter pylori infection
were 39 to 68 years, mean: 56.4 years) (Lakner et al., 2011).
The presence of H. pylori was determined by the methods mentioned above.
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The eradication therapy was involved a seven days treatment with double dose proton-pump
inhibitor consisting of PPI (pantoprazole 2x40 mg/day), amoxicillin (1000 mg twice daily) and
clarithromycin (500 mg twice daily), according to European guidelines (Malfertheiner et al.,
2007). Following this one week of eradication period, the patients further treated with normal
dose of PPI for other another week.
The gastroscopies, gastric biopsies, general and special immuno-histochemical examinations
were carried out at the time of entry of patients into the eradication treatment, after the
eradication treatment (Lakner et al., 2011).
2.13. Used drugs and compounds
Anticholinergic (atropine, Egis, Budapest, Hungary), antimuscarinic (Pirenzepine, Boehring‐
er, Ingelheim, Germany) agents; [histamine H2-receptor antagonists (Cimetidine, Pannon‐
Pharma, Hungary), ranitidine (Biogal-Teva, Hungary), famotidine (Richter Gedeon,
Hungary)], proton pump inhibitors (PPI) [(Omeprazole, Astra-Zeneca, Sweden), Esomepra‐
zole (Astra-Zeneca, Sweden)]; indomethacin (Chinoin, Budapest, Hungary) were used.
Capsaicin was applied in these studies obtained from Asian Herbex Ltd: Capsaicin USP as
manufactured in Andhra Pradesh, India). The Drug Master File (DMF) is signed in the
documentation of Drug and Food Administration (FDA) in the United States as only one
capsaicin preparation for orally applicable preparate (“ 17856 A II 26.10.2004 Asian Herbex
Ltd. : Capsaicin USP as manufactured in Andhra Pradesh, India”) (for further details, see
Mózsik et al. 2009b).
2.14. Statistical evaluation of results
The results were expressed as means ± SEM. The paired and unpaired Student’s t test and
ANOVA test were used for the statistical analysis of the results. The results were taken to be
significant when the P value was found ≤ 0.05. Special mathematical programs were applied
for the evaluation of results of human phase I. examinations.
3. Results
3.1. Capsaicin-induced BAO in healthy human subjects
The capsaicin (given in doses of 100, 200,400 and 800 µg orally) dose-dependently inhibited
the gastric acid output (Y=-0.13.X+1.164; r=0.97; n=16; P < 0.001) (Mózsik et al., 1999; Mózsik et
al., 2005). The ED50 value of capsaicin was obtained as 400 µg/person on the gastric BAO (in
case of administration of capsaicin in doses which stimulates the capsaicin-sensitive afferent
nerves) (Figures 1 and 2) (Mózsik et al., 1999; 2005).
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Figure 1. Capsaicin-induced inhibition on gastric basal acid output (BAO) in 16 human healthy subject. The results
were expressed as per cent of untreated (control) group (means±SEM). The results of the mathematical analysis were
expressed as control vs. capsaicin treated groups. Abbreviations: NS=not significant;++=P<0.01;+++=P<0.001 (Mózsik









0 200 400 600 800 1000
BAO
mEq/ h
r=0.97; Y=-0.13*X+1.164; p<0.001; (n=16)
Capsaicin (μg i.g.)
Mean ± SE
Figure 2. Inhibition of gastric acid basal output (BAO) by capsaicin in 16 healthy human subjects (after Mózsik et al.:
World J Gastroenterol 11: 5180-83, 2005).
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3.2. Affinity and intrinsic affinity curves for the capsaicin, muscarinic agents, H2-receptor
antagonists and proton pump inhibitors on BAO in healthy human subjects
The action of the compounds inhibiting the gastric basal acid secretion is presented by Figure
3. The curve indicates that no competitive actions of these drugs exist on the gastric basal acid







Figure 3. Affinity curves for drugs inhibitory actions of different antisecretory drugs on the 
gastric basal acid output (BAO) in human healthy subjects. The absolute values were 
calculated as H
+
 output/h, the presentations of curves expressed in per cent value (total = 





Figure 4. Intrinsic activity curves for the inhibitory drugs of different antisecretory drugs and 
capsaicin (given in stimulatory doses of capsaicin-sensitive afferent nerves) on the gastric 
acid basal output (BAO) in human healthy subjects, which were expressed to action of 




 The intrinsic activity curves for the drugs inhibiting the gastric basal acid outputs in 
healthy human subjects were calculated. The intrinsic activity (αatropine = 1.00) was taken to be 
equal to 1.00, and the values for other drugs were expressed to action of atropine (Figure 4). 
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Figure 4. Intrinsic activity curves for the inhibitory drugs of different antisecretory drugs and capsaicin (given in stimu‐
latory doses of capsaicin-sensitive afferent nerves) on the gast ic acid basal output (BAO) in human healthy subjects,
which were expressed to action of atropine (1.00) (α atro ine) (mea s ±SEM). (Aft r Mózsik et al.: Inflammopharma‐
cology 15: 232-45, 2007).
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3.2. Affinity and intrinsic affinity curves for the capsaicin, muscarinic agents, H2-receptor
antagonists and proton pump inhibitors on BAO in healthy human subjects
The action of the compounds inhibiting the gastric basal acid secretion is presented by Figure
3. The curve indicates that no competitive actions of these drugs exist on the gastric basal acid
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Figure 4. Intrinsic activity curves for the inhibitory drugs of different antisecretory drugs and capsaicin (given in stimu‐
latory doses of capsaicin-sensitive afferent nerves) on the gast ic acid basal output (BAO) in human healthy subjects,
which were expressed to action of atropine (1.00) (α atro ine) (mea s ±SEM). (Aft r Mózsik et al.: Inflammopharma‐
cology 15: 232-45, 2007).
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The intrinsic activity curves for the drugs inhibiting the gastric basal acid outputs in healthy
human subjects were calculated. The intrinsic activity (αatropine=1.00) was taken to be equal to
1.00, and the values for other drugs were expressed to action of atropine (Figure 4). The pA2
values (50 % inhibition of intrinsic activity in [-] molar values) were calculated from the
intrinsic activity curves.
For the molecular pharmacological understanding the background of the action of drugs,
action the molecular weights, pD2 values, of the intrinsic activity (in comparison to atropine
action) and pA2 values were calculated and presented in Table 1.
Compounds M.W. pD2 Intrinsic activity pA2
Capsaicin 305,4 5,88 0,76 5,87
Atropine 289,38 5,40 1,00 5,40
Pirenzepine 424,34 3,93 0,89 3,93
Cimetidine 252,34 2,23 1,00 2,23
Ranitidine 314,41 3,33 1,00 3,33
Famotidine 337,43 3,77 1,00 3,77
Nizatidine 331,47 3,34 1,00 3,34
Omeprazole 345,42 3,97 1,00 3,97
Esomeprazole 345,42 3,97 1,00 3,97
Table 1. Summary of the affinity (pD2) and intrinsic activity (expressed in value of αatropine=1,00)(pA2) values of
capsaicin, atropine, Pirenzepine, cimetidine, ranitidine, famotidine, Omeprazole and Esomeprazole on the gastric
basal acid output (BAO) in healthy human subjects. (After Mózsik et al.: Inflammopharrmacology 15:232-45, 2007)
The Figures 3, 4 and Table 1 clearly indicate that the capsaicin acts in the smaller doses as those
drugs acting on the muscarinic (atropine, Pirenzepine), H2R receptor antagonists (cimetidine,
ranitidine, fomatidine, nizatidine) and proton pump inhibitors (Omeprazole, Esomeprazole).
3.3. Changes in the „parietal” and „non-parietal” components of gastric secretory responses
in healthy human subjects
The measurements of cations (H+, sodium, potassium, calcium, magnesium) and of chloride
offered the possibility to identify the „parietal” and „non-parietal” components of gastric
secretion in humans without and with administration of different drugs (or compounds)
(Hollander, 1934).
Using the Hollander’s method for the calculation and evaluation of cations, chloride in the
gastric juice indicated clearly the significant decrease of „parietal component” (∆-18±2 mmol/
L, P< 0.001) in association with significant increase of „ non-parietal component” (∆+19±2
mmol/L, P < 0.001) of the gastric secretion after application of 400 µg (given orally) of capsaicin
(n=10) (Mózsik et al., 2005).
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H+ Na+ K+ Ca2+ Mg2+
A B A B A B A B A B
43±3 25±1 73±4 89±2 13±1 8±0,6 0,98± 0,02 0,88± 0,01 0,49± 0,01 0,38± 0,01
P<0.001 P<0.001 P<0.001 P<0.001 P<0.001
100±7 58±2 100±5 122±3 100±8 62±5 100±2 90±1 100±2 78±2
"parietal" component "non-parietal" component albumin (g/L)
A B A B A B
43±3 25±2 126±4 145±4 1,23±0,001 1,650 ±0.02
P<0.001 P<0.001 P<0.001
100±7 58±5 100±3 115±3 100±1 131±2
Table 2. Chemical composition of gastric juice without (A) and with (B) application of capsaicin (ED50=400 µg orally
give) in healthy human subjects. The results are given as mmol/L or % (means ±SEM) (n=10). (After Mózsik et al.:
World J Gastroenterol 11: 5080-84, 2005)
3.4. Changes of albumin level in the gastric juice after capsaicin administration in healthy
human subjects
The albumin concentration increased from 1.24 ± 0.001 g/L vs. 1.63 ± 0.02 g/L (P < 0.001; n=10)
after 400 µg capsaicin (i.g. given) application (Mózsik et al., 2005).
Figure 5. Changes in gastric mucosal proteins (albumin) in the gastric basal output (BAO), without and with capsaicin,
in 10 healthy subjects (g/L) (means±SEM).
Capsaicin-Sensitive Afferentation and Human Gastrointestinal Tract
http://dx.doi.org/10.5772/58360
225
The intrinsic activity curves for the drugs inhibiting the gastric basal acid outputs in healthy
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values (50 % inhibition of intrinsic activity in [-] molar values) were calculated from the
intrinsic activity curves.
For the molecular pharmacological understanding the background of the action of drugs,
action the molecular weights, pD2 values, of the intrinsic activity (in comparison to atropine
action) and pA2 values were calculated and presented in Table 1.
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Atropine 289,38 5,40 1,00 5,40
Pirenzepine 424,34 3,93 0,89 3,93
Cimetidine 252,34 2,23 1,00 2,23
Ranitidine 314,41 3,33 1,00 3,33
Famotidine 337,43 3,77 1,00 3,77
Nizatidine 331,47 3,34 1,00 3,34
Omeprazole 345,42 3,97 1,00 3,97
Esomeprazole 345,42 3,97 1,00 3,97
Table 1. Summary of the affinity (pD2) and intrinsic activity (expressed in value of αatropine=1,00)(pA2) values of
capsaicin, atropine, Pirenzepine, cimetidine, ranitidine, famotidine, Omeprazole and Esomeprazole on the gastric
basal acid output (BAO) in healthy human subjects. (After Mózsik et al.: Inflammopharrmacology 15:232-45, 2007)
The Figures 3, 4 and Table 1 clearly indicate that the capsaicin acts in the smaller doses as those
drugs acting on the muscarinic (atropine, Pirenzepine), H2R receptor antagonists (cimetidine,
ranitidine, fomatidine, nizatidine) and proton pump inhibitors (Omeprazole, Esomeprazole).
3.3. Changes in the „parietal” and „non-parietal” components of gastric secretory responses
in healthy human subjects
The measurements of cations (H+, sodium, potassium, calcium, magnesium) and of chloride
offered the possibility to identify the „parietal” and „non-parietal” components of gastric
secretion in humans without and with administration of different drugs (or compounds)
(Hollander, 1934).
Using the Hollander’s method for the calculation and evaluation of cations, chloride in the
gastric juice indicated clearly the significant decrease of „parietal component” (∆-18±2 mmol/
L, P< 0.001) in association with significant increase of „ non-parietal component” (∆+19±2
mmol/L, P < 0.001) of the gastric secretion after application of 400 µg (given orally) of capsaicin
(n=10) (Mózsik et al., 2005).
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"parietal" component "non-parietal" component albumin (g/L)
A B A B A B
43±3 25±2 126±4 145±4 1,23±0,001 1,650 ±0.02
P<0.001 P<0.001 P<0.001
100±7 58±5 100±3 115±3 100±1 131±2
Table 2. Chemical composition of gastric juice without (A) and with (B) application of capsaicin (ED50=400 µg orally
give) in healthy human subjects. The results are given as mmol/L or % (means ±SEM) (n=10). (After Mózsik et al.:
World J Gastroenterol 11: 5080-84, 2005)
3.4. Changes of albumin level in the gastric juice after capsaicin administration in healthy
human subjects
The albumin concentration increased from 1.24 ± 0.001 g/L vs. 1.63 ± 0.02 g/L (P < 0.001; n=10)
after 400 µg capsaicin (i.g. given) application (Mózsik et al., 2005).
Figure 5. Changes in gastric mucosal proteins (albumin) in the gastric basal output (BAO), without and with capsaicin,
in 10 healthy subjects (g/L) (means±SEM).
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3.5. Action of capsaicin on the GTPD in the healthy human subjects
The capsaicin (given ig. in doses of 100, 200, 400 and 800 µg) dose-dependently increased the
GTPD alone [∆ value from to baseline 10 (-mV)] (Mózsik et al., 2005).
When we applied capsaicin in double dose (800 µg intragastrically given) than we received
the same increase in GTPD at the same time period (Hossenbocus et al., 1975; Mózsik et al.,
2005) (Figure 6).













 = 0 + A*exp(t/T0)
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Figure 6. Capsaicin (CAPS) dose-dependent gastric mucosal protective effect of capsaicin on gastric transmucosal po‐
tential difference (GTPD) in 10 healthy subjects (after Mózsik et al., World J Gastroenterol 11:5180-5184, 2005).
3.6. Action of ethanol on GTPD in healthy human subjects
The intragastrically applied ethanol immediately and significantly decreased the GTPD [∆ 25
(-mV)] (Mózsik et al., 2005).
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3.7. Preventive action of capsaicin on the ethanol-induced decrease of GTPD in healthy
human subjects
The intragastrically applied capsaicin (given in doses of 100, 200, 400 and 800 µg) dose-
dependently prevented the ethanol-induced decrease of GTPD in human healthy subjects
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Figure 7. The ethanol (30 v/v in 5 ml intragastrically given) immediately the GTPD in the gastric mucosal surface (in
comparison to baseline) (means±SEM) (n=14) (after Mózsik et al., World J Gastroenterol 11:5180-5184, 2005).
3.8. IND-induced acute gastric microbleeding and the acute gastric mucosal preventive
effect of capsaicin on the IND-induced acute gastric mucosal damage in healthy human
subjects (based on the results of prospective, randomized and multi-clinical study)
3.8.1. Extent of IND-induced acute gastric mucosal damage in healthy human subjects
The baseline of blood losing was 2.0 ± 0.2 mL/ day (n=14) without application of IND, which
was increased to 8.1 ± 0.2 mL/day (n= 14; P< 0.001) after application of indomethacin.
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3.8.2. Gastric mucosal preventive effect of capsaicin on the IND-induced acute gastric microbleeding in
healthy human subjects
The capsaicin was given in doses of 200, 400 and 800 µg orally before the administration of
indomethacin. The acutely applied capsaicin prevented by dose-dependent manner of IND-
induced gastric microbleeding in healthy human subjects (Y=-0.0071*X+7.78; r=-0.98, n=14; P<
0.001) (Mózsik et al., 2005; Sarlós et al., 2003).
Figure 8. Gastric mucosal protection demonstrated by reduced microbleeding after capsaicin treatment of indome‐
thacin (IND)-induced mucosal damage. (After Mózsik et al.: World J Gastroenterol 11.5180-83, 2005).
3.9. Effect of capsaicin on the gastric emptying in healthy human subjects
The capsaicin was intragastrically given in dose of ED50, which increased significantly the
gastric acid emptying: 1. Capsaicin (400 µg, ig=ED50)-induced changes in the maximal values
of DOB max decreased from 18±1 to 14±1 U (P<0.01); 2. the time to reach the DOB max decreased
from 148±13 to 70±12 min (P<0.01); 3. the slope (in U/min) increased from 0.11±0.01 to 14±0.001
(P<0.001); 4. the time to reach the AUC50 decreased from 115±10 to 80±8 (min) (n=10; P<0.01)
(Debreceni et al., 1999).
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Figure 9. Typical curce obtained by the IRIS (infra-red-spectocsopy) measurement and calculated the delta over base
(DOB) value. This value is directly proportional to ratio of 13CO2 and 12CO2 (DOB~13CO2/12CO2) in the air sample (Debre‐
ceni et al., J Physiol Paris 93: 455-460, 1999).
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Figure 10. Capsaicin (400 μg ig.given)-induced changes in the maximal values of Delta Over Base (DOB max) (U) in 14
human healthy subjects (means±SEM) (Debreceni et al., J Physiol Paris 93:455-460, 1999).
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Figure 11. Capsaicin (400 μg ig. given)-induced changes in time to reach the value of DOB max (min) in 14 human
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Figure 12. Capsaicin (400 μg ig. given) -induced changes in the slope in its rising part in 14 
human healthy subjects (means±SEM) (Debreceni et al., J Physiol Paris 93:455-460, 1999). 
 
Figure 12. Capsaicin (400 μg ig. given)-induced changes in the slope in its rising part in 14 human healthy subjects
(means±SEM) (Debreceni et al., J Physiol Paris 93:455-460, 1999).
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Figure 13. The time of 50% (in min) to rearch the AUC 50% in 14 healthy subjects (means±SEM) (U/min) in 14 human
healthy subjects means±SEM) (Debreceni et al., J Physiol Paris 93:455-460, 1999).
3.10. Increased glucose absorption from small intestine and of glucagon release by capsaicin
during the glucose loading test in healthy human subjects
During glucose loading test we measured the glucose absorption in the proximal part of the
small intestine, insulin, C peptide, glucagon using the plasma level of glucose as markers
substance (Dömötör et al., 2006).
Figure 14. Design of clinical observations with glucose observation and utilization in 14 healthy human subjects with‐
out and with (400 µg, ED50, orally given) capsaicin application. The measurement of glucose, insulin, C-peptide, gluca‐
gon was carried out from the plasma level in every 15 min period from the glucose application to 4 h. (After Mózsik et
al.: Inflammopharmacology 15:232-45, 2007).
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The absorption of glucose from the small intestine and glucagon release increased by capsaicin
administration; however no significant changes were obtained in neither insulin nor C peptide
release under these observational circumstances (Figure 15).
The plasma levels of glucose increased significantly 30 to 150 min and the plasma level of
glucagon increased from 90 to 180 min after capsaicin administration in human healthy
subjects given 75 g glucose orally. The plasma levels of insulin and C peptide increased from
75 to 165 min after glucose administration; however, levels did not differ significantly.
3.11. Results of the immunohistochemical examinations in the human gastric and large
bowel mucosa in healthy human subjects and in patients with different gastrointestinal
disorders
3.11.1. Demonstration of capsaicin receptors, CGRP and SP in the human gastric and large bowel
mucosa in healthy human subjects
The results of these observations were obtained in „ healthy human subjects”, who had
different functional complaints and the endoscopic examinations were carried out to exclude
the presence of any histologically proven disease (the clinical histological examinations were
carried out by the independent pathologist) and the opinion of pathologist gave normal
histology.
The immunohistochemical  examination demonstrated the  presence of  capsaicin  (TRVP1)
receptors in the gastric and large bowel mucosa obtained from biopsy samples. The location
of capsaicin receptor could be demonstrated near the nerve endings, vascular vessel and
in the epithelial layer (Figure 16) (Dömötör et al., 2005).The CGRP and SP could be observed
in gastric mucosa and these parts of large bowel mucosa as well (Figure 17) (Dömötör et
al., 2005).
3.11.2. Demonstration of capsaicin receptor, CGRP and SP in the gastric and large bowel mucosa in
patients with different disorders
The preliminary results of these observations were published by Dömötör et al. (2005).
These patients went over the clinical endoscopic and pathological examinations. The original
pathological diagnosis was given by an independent pathologist.
The capsaicin receptor, and released neuropeptides (CGRP and SP) could be detected in all
types of patients with different disorders (Table 3). The results of these preliminary clearly
indicated the following: 1. capsaicin could be demonstrated in patients with superficial
gastritis, erosive gastritis, stomach polyps, stomach cancer, inflammation of large bowel
disease, colon polyps with severe dysplasia and colorectal cancers.
The CGRP could be demonstrated in most of the all of the above mentioned diseases; mean‐
while the SP could not be demonstrated in these diseases (Table 3).
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Figure 15. Changes in plasma level of glucose, insulin, C-peptide and glucagon after oral administration of glucose
(75 g in 100 ml water) in 14 healthy human subjects. Capsaicin (400 µg) was orally given in gelatine capsule (Hungaro‐
pharma, Budapest, Hungary). The plasma levels of glucose, insulin, C-peptide and glucagon were measured every 15
min for 4 h. The results are expressed as means ±SEM. (After Dömötör et al.: Eur J Pharmacol 534: 280-83, 2006).
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STOMACH TRPV1 CGRP SP
Superficial gastritis + + -
Erosive gastritis + + -
Gastric ulcer -/+ -/+ -/+
Polyp + + -
Carcinoma + + -
LARGE BOWEL TRPV1 CGRP SP
Inflammation + + +
Polyp with moderate dysplasia - - -
Poly with severe dysplasia + spot-like - -
Carcinoma + spot-like + -
*The signs of+or – indicate the trend of expression in the specific immunohistochemical examinations in the mucosa specimens
(stomach and large bowel) in patient different disease.
Table 3. Immundistribution of capsaicin receptor (TRPV1), calcitonin-gene releted peptide (CGRP) and substance P
(SP) in the gastric and large bowel mucosa of patients with different GI disorders. (After Mózsik et al.:
Inflammopharmacology 15: 232-45, 2007)*
Figure 16. The immundistribution of TRPV1 (first row), CGRP (second row) and of SP (third row) in the gastric mucosa
of a healthy subject (A) and of patient with H. pylori negative (B) and H. pylori positive (C) chronic gastritis. Arrows
show the immunsigns in the mucosa. (After Mózsik et al.: Inflammopharmacology 15: 232-45, 2007).
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3.12. Capsaicin receptor, CGRP and SP in the patients with Helicobacter positive and
negative chronic gastritis
These observations were carried out in 57 patients with chronic gastritis (21 patients from them
were H. pylori positive and 30 patients were H. pylori negative).
The expression of capsaicin receptors and CGRP increased in the gastric mucosa with both
bacteria positive and negative chronic gastritis, meanwhile SP increased with a limited extent
Determined by a semi quantitative scale (Dömötör et al., 2006a). The expression of TRVP1,
CGRP, and SP increased significantly in the human gastric mucosa with chronic gastritis;
however, no difference was obtained in their expression in patients with H. pylori positive
and negative chronic gastritis (Dömötör et al., 2006a).
3.13. Measurements of the gastric microbleeding before and after 2-week capsaicin
treatment: Testing of the changes in baseline, IND-induced acute gastric microbleeding and
of capsaicin-stimulated gastric mucosal protective effect on the IND-induced acute gastric
microbleeding in healthy human subjects (Figures 18 and 19)
3.13.1. Baseline before and after 2 weeks IND treatment without application of any drug and/or
compound
The baseline of gastric microbleeding was detected 2.1 ± 0.1 vs. 2.0± 0.1 mL/day, before and
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Figure 17. The immundistribution f TRPV1 (first li e), CGRP (second line) and of SP (third line) in th  colon mucosa of
control person (A) and of patient with inflammatory bowel disease (B) and with severe dysplastic polyp (C). Arrows
show the immunsigns in the ucos . (After Mózsik et al.: Inflammopharmacology 15: 232-45, 2007)
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3.13.2. Measurement of IND-induced acute gastric mucosal microbleeding – before and after 2 weeks
capsaicin treatment – in healthy human subjects
The acute administration of IND significantly increased the extent of gastric microbleeding vs.
baseline (without administration of IND) (P<0.001; n=14) in healthy human subjects before
(baseline vs. IND., 2.1 ± 0.1 vs. 8.3 ± 0.2 mL/day) and after (baseline vs. IND., 2.0± 0.1 vs 7.8±0.3
mL/ day) 2 weeks capsaicin (3 x 400 µg orally given) treatment (Mózsik et al., 2005).
 
Figure 18. Clinical study design of a chronic capsaicin treatment in human healthy subjects. Abbreviations: CAPS: 
capsaicin, IND: indomethacin. 
 
Figure 19. Capsaicin (given 200 and 400 µg ig.) -induced gastric mucosal preventive effects on indomethacin 
(3x25 mg ig.) -produced gastric mucosal microbleeding before and after a chronic capsaicin (3x400 µg i.g. for 2 
weeks) in 14 human healthy subjects. The results were expressed as means ± SEM). 
3.13.3. Measurement of acutely applied capsaicin-induced gastric mucosal protective effect on the IND-
induced acute gastric microbleeding before and after 2 weeks capsaicin treatment in healthy human subjects 
The intragastrically applied capsaicin dose–dependently prevented the IND-induced gastric mucosal 
damage (Mózsik et al., 2003; 2004a; 2005) – before (Y = - 0.0087X + 9.18 , r = - 0.99: P<0.001) and after (Y = -0.0096 X 
+ 10.1 ; r= -.0.99 ; P<0.001) 2 weeks capsaicin treatment – when the capsaicin was acutely and intragastrically given 
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3.13.3. Measurement of acutely applied capsaicin-induced gastric mucosal protective effect on the IND-
induced acute gastric microbleeding before and after 2 weeks capsaicin treatment in healthy human
subjects
The intragastrically applied capsaicin dose–dependently prevented the IND-induced gastric
mucosal damage (Mózsik et al., 2003; 2004a; 2005) – before (Y=-0.0087X+9.18, r=-0.99: P<0.001)
and after (Y=-0.0096 X+10.1 ; r=-.0.99 ; P<0.001) 2 weeks capsaicin treatment – when the
capsaicin was acutely and intragastrically given (in doses of 200 and 400 µg) before the one
day IND treatment (see the description in the methods) (Mózsik et al., 2005).
3.14. Expression of capsaicin receptor, CGRP, and SP in patients with chronic gastritis
3.14.1. Capsaicin-sensitive afferentation in H. pylori positive and negative chronic gastritis
The symptoms of patient’s suffering from chronic gastritis with or without H. pylori infection
(20 H. pylori positive and 30 H. pylori negative) were nonspecific including epigastric
discomfort, nausea, loss of appetite and vomiting. The patients underwent physical, labora‐
tory, ultrasonographic, endoscopic and histological (including special immuno-histochemical)
examinations. Twenty people with functional dyspepsia (all of them underwent the afore‐
mentioned medical, laboratory, iconographic and histological examinations and all of these
examinations indicated negative results) were taken as healthy controls. The age of patients
was 39 to 68 years; there were 22 males and 29 females with chronic gastritis, and ten males
and ten females in the functional dyspepsia group.
The H. pylori infection was detected by 14C urea breath test, rapid urease test, Warthinn-Starry
silver staining and other specific histological examinations. The gastric tissue samples from
the stomach and antrum were examined by an independent histologist and classified of chronic
gastritis according to the Sydney System.
The immuno-histochemical studies were carried out on formalin fixed, paraffin embedded
tissue samples of gastric mucosa using the peroxidase-labeled polymer method (Lab Vision
Co., Fremont, USA). SP was detected by the NC1/34HL rat monoclonal antibody, the TRPV1
receptor and CGRP were labeled using polyclonal rabbit antisera (all from Alcam Ltd., UK,
Cambridge).
3.14.2. Capsaicin-sensitive afferentation in H. pylori positive chronic gastritis before and after
eradication treatment
These observations were carried out in 38 persons, including 20 healthy subjects and 18 patients
with H. pylori positive gastritis. The age of persons with histologically intact gastric mucosa
(controls) were 41 to 67 years (mean=52.2 years). The age of patients with chronic H. pylori
positive gastritis (6 males, 12 females) was 39 to 68 years (mean=56.4 years).
The time period between the first and control gastroscopy was 6 weeks after the starting of the
examinations. The biopsies were taken from the corpus and antrum of patients with chronic
gastritis, before and after eradication treatment and from healthy subjects.
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3.13.2. Measurement of IND-induced acute gastric mucosal microbleeding – before and after 2 weeks
capsaicin treatment – in healthy human subjects
The acute administration of IND significantly increased the extent of gastric microbleeding vs.
baseline (without administration of IND) (P<0.001; n=14) in healthy human subjects before
(baseline vs. IND., 2.1 ± 0.1 vs. 8.3 ± 0.2 mL/day) and after (baseline vs. IND., 2.0± 0.1 vs 7.8±0.3
mL/ day) 2 weeks capsaicin (3 x 400 µg orally given) treatment (Mózsik et al., 2005).
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3.13.3. Measurement of acutely applied capsaicin-induced gastric mucosal protective effect on the IND-
induced acute gastric microbleeding before and after 2 weeks capsaicin treatment in healthy human
subjects
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mucosal damage (Mózsik et al., 2003; 2004a; 2005) – before (Y=-0.0087X+9.18, r=-0.99: P<0.001)
and after (Y=-0.0096 X+10.1 ; r=-.0.99 ; P<0.001) 2 weeks capsaicin treatment – when the
capsaicin was acutely and intragastrically given (in doses of 200 and 400 µg) before the one
day IND treatment (see the description in the methods) (Mózsik et al., 2005).
3.14. Expression of capsaicin receptor, CGRP, and SP in patients with chronic gastritis
3.14.1. Capsaicin-sensitive afferentation in H. pylori positive and negative chronic gastritis
The symptoms of patient’s suffering from chronic gastritis with or without H. pylori infection
(20 H. pylori positive and 30 H. pylori negative) were nonspecific including epigastric
discomfort, nausea, loss of appetite and vomiting. The patients underwent physical, labora‐
tory, ultrasonographic, endoscopic and histological (including special immuno-histochemical)
examinations. Twenty people with functional dyspepsia (all of them underwent the afore‐
mentioned medical, laboratory, iconographic and histological examinations and all of these
examinations indicated negative results) were taken as healthy controls. The age of patients
was 39 to 68 years; there were 22 males and 29 females with chronic gastritis, and ten males
and ten females in the functional dyspepsia group.
The H. pylori infection was detected by 14C urea breath test, rapid urease test, Warthinn-Starry
silver staining and other specific histological examinations. The gastric tissue samples from
the stomach and antrum were examined by an independent histologist and classified of chronic
gastritis according to the Sydney System.
The immuno-histochemical studies were carried out on formalin fixed, paraffin embedded
tissue samples of gastric mucosa using the peroxidase-labeled polymer method (Lab Vision
Co., Fremont, USA). SP was detected by the NC1/34HL rat monoclonal antibody, the TRPV1
receptor and CGRP were labeled using polyclonal rabbit antisera (all from Alcam Ltd., UK,
Cambridge).
3.14.2. Capsaicin-sensitive afferentation in H. pylori positive chronic gastritis before and after
eradication treatment
These observations were carried out in 38 persons, including 20 healthy subjects and 18 patients
with H. pylori positive gastritis. The age of persons with histologically intact gastric mucosa
(controls) were 41 to 67 years (mean=52.2 years). The age of patients with chronic H. pylori
positive gastritis (6 males, 12 females) was 39 to 68 years (mean=56.4 years).
The time period between the first and control gastroscopy was 6 weeks after the starting of the
examinations. The biopsies were taken from the corpus and antrum of patients with chronic
gastritis, before and after eradication treatment and from healthy subjects.
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The H. pylori positive patients underwent 7-day eradication treatment with combination of
double dose of PPI (pantoprazole 2x40 mg/ day), amoxicillin (1000 mg twice daily) and
clarithromycin (500 mg twice daily) according to the European guidelines. After this one week
combination treatment, the patients continued to take normal dose of PPI for another week.
The H. pylori infection was detected before and after treatment. The results of eradication
treatment was successful in 89%, the gastric histology (by biopsy and by histology) indicated
normal picture in 22% of cases, and 78 % of patients showed moderate gastritis.
The expression of TRPV1 and CGRP increased significantly in the gastric mucosa of patients
with chronic gastritis – independently on the presence of H. pylori positive or negative status
and of successful eradication treatment in patients with H. pylori positive gastritis), meanwhile
no significant expression changes were obtained for SP in the gastric mucosa in these groups)
(Dömötör et al., 2005; Lakner et al., 2012, Mózsik et al., 2011; 2013, Czimmer et al., 2013) (Figures
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Figure 20. Changes in the immunhistochemical distribution of capsaicin receptor (TRPV1), CGRP and SP in patients
with H. pylori positive chronic gastritis before and after eradication therapy. (After Lakner et al., World J Gastrointest
Pharmacol Ther. 2: 36-41, 2011)
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Table 4. The summary of the changes in the immunhistochemical distribution of capsaicin receptor, calcitonin gene-
related peptide and substance P in patient with chronic H. pylori positive gastritis before and after eradication therapy.
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Figure 21. Changes in the expression of capsaicin receptor (TRPV1), calcitonin gene-related peptide (CGRP) and sub‐
stance P (SP) in the human gastric mucosa of healthy voluntaries (histologically intact) (A), H. pylori positive (B), H. py‐
lori negative (C) and H. pylori positive before (D) and after (E) eradication (pantoprazole 40, amoxicillin 1000 and
clarithromycin 500 mg, all two times per day, for seven days) (n=number of patients). (After Mózsik et al., 2014).
4. Discussion
The vagal nerve plays a key role in the gastrointestinal physiology, pathology and pharma‐
cology. The nerve fibres of vagus can be divided into afferent (about 90%) and efferent fibres
(10 %) based on animal observations. About 9 per cent of afferent fibres are capsaicin sensitive
afferent fibres (Gabella and Pease, 1973; Grijalva and Novin, 1990).
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The H. pylori positive patients underwent 7-day eradication treatment with combination of
double dose of PPI (pantoprazole 2x40 mg/ day), amoxicillin (1000 mg twice daily) and
clarithromycin (500 mg twice daily) according to the European guidelines. After this one week
combination treatment, the patients continued to take normal dose of PPI for another week.
The H. pylori infection was detected before and after treatment. The results of eradication
treatment was successful in 89%, the gastric histology (by biopsy and by histology) indicated
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with chronic gastritis – independently on the presence of H. pylori positive or negative status
and of successful eradication treatment in patients with H. pylori positive gastritis), meanwhile
no significant expression changes were obtained for SP in the gastric mucosa in these groups)
(Dömötör et al., 2005; Lakner et al., 2012, Mózsik et al., 2011; 2013, Czimmer et al., 2013) (Figures
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stance P (SP) in the human gastric mucosa of healthy voluntaries (histologically intact) (A), H. pylori positive (B), H. py‐
lori negative (C) and H. pylori positive before (D) and after (E) eradication (pantoprazole 40, amoxicillin 1000 and
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4. Discussion
The vagal nerve plays a key role in the gastrointestinal physiology, pathology and pharma‐
cology. The nerve fibres of vagus can be divided into afferent (about 90%) and efferent fibres
(10 %) based on animal observations. About 9 per cent of afferent fibres are capsaicin sensitive
afferent fibres (Gabella and Pease, 1973; Grijalva and Novin, 1990).
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Many observations on the field of Gastroenterology were based on the modification of efferent
fibres of vagal nerve, except the classical surgical vagotomy (both in the animal experiments
and in human observations with peptic ulcer disease). This standpoint was emphasized during
the research period performed by the application of different anticholinergic compounds
acting at the level of muscarinic receptor.
Since histamine also plays an essential role in the gastric acid secretion and in many other
immunological processes, various H2 receptor antagonist compounds were developed like
cimetidine, ranitidine, famotidine and nizatidine.
After recognition of the H+-K+-ATPase as biochemical structure of gastric acid secretion, the
so-called proton pump inhibitors (H+-K+-ATPase inhibitors) were developed and studied in
clinical practice with great efforts (Mózsik, 2006).
The principle problems for clinicians were that the research had not offered any possibilities
for studying capsaicin sensitive afferent fibres of vagal nerve in the human physiology,
pathology, pharmacology and in human medical therapy. The observations of Jancsó et al.
(1967; 1968; 1970) opened a new gate for evaluation of the potential roles of capsaicin sensitive
afferent fibres independently from other afferent nerves in various physiological, pharmaco‐
logical and pathological processes.
Szolcsányi and Barthó (1981) clearly demonstrated the dual actions of capsaicin in peptic
ulceration of rat: capsaicin – given in small doses – prevented; meanwhile this compound given
in higher doses aggravated peptic ulcer disease in rats. Following them Holzer studied the
details of capsaicin actions in the GI tract (see the reviews of Holzer 1998; 1999, 2013; Szolcsányi,
2014).
Our experimental studies with capsaicin have been carried out together with professor
Szolcsányi (Department of Pharmacology and Pharmacotherapy, Medical and Health Centre,
University of Pécs, Hungary) from 1980, understanding the actions of capsaicin in gastric
mucosal damage and protection have been our main focus (Mózsik et al., 1997).
My work team started with the human clinical pharmacological studies from the years of 1960
in patients with peptic ulcer disease (Mózsik et al., 1965; 1967; 1969a; 1969b). These studied
tried to reveal the details of absorption, metabolization and excretion of various anticholinergic
agents in patients with peptic ulcer before the starting of chronic treatment, after the regular
chronic treatment and after cessation of these drugs. The application of anticholinergic agents
to patients was used to approach the cholinergic mediated processes both in the development
and treatment of peptic ulcer diseases.
After the years of 1970, the H2R blocking compounds became deeply studied in human GI
physiology, pathology and pharmacology. Many clinical pharmacological studies with H2R
blockers have been carried out in patients with peptic ulcer disease (Mózsik et al., 1994; Patty
et al., 1984; Tárnok et al., 1979; 1983). In the last two decades the proton pump inhibitors were
deeply studied.
The problems, results and difficulties of our clinical pharmacology practice put down the bases
of a very clear research line for the observations of capsaicin. The results of the different animal
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observations offered a new possibility for evaluation of capsaicin sensitive afferent nerves (by
the application of capsaicin) during physiological, pathological, pharmacological and thera‐
peutic events of the GI tract (Mózsik et al., 2014).
The results from animal experiments with capsaicin which is widely used in the every-day
culinary practice, clearly indicated us that the stimulatory doses of capsaicin acting on
capsaicin-sensitive fibres produce gastric mucosal defensive actions and they are able to
prevent the NSAID-induced gastric mucosal damage. These scientifically carried out studies
with capsaicin in animals also offered a new tool to approach the capsaicin sensitive afferent
nerves in the healthy human beings, and to some extent in patients with different GI disorders.
Our studies with capsaicin in human healthy subjects and in patients with different gastroin‐
testinal disorders have been stated from 1997. These studies were permitted by the Regional
Ethical Committee of University of Pécs, Hungary, and these observations were carried out
according to Good Clinical Practice respecting the Helsinki Declaration.
The human observations were carried out according to the basic laws of human clinical
pharmacology (inclusion and exclusion criteria, randomization, prospective studies, generally
self-controlled group of healthy human subjects, etc).
We had five aims in these studies with the capsaicin:
1. To understand the main mechanisms of capsaicin sensitive afferent nerves in the gastric
functions;
2. To try to understand the potential role(s) of capsaicin sensitive afferent nerves in the
development of human physiological, pathological and pharmacological events;
3. To identify the dose range of capsaicin which stimulates only the capsaicin-sensitive
afferent nerves and to identify the classical molecular pharmacological parameters
(affinity and intrinsic activity curves, ED50 and pA2 values) in comparison the same
parameters obtained in cases of every day used drugs;
4. To exclude clearly the existence of desensitation of capsaicin-sensitive afferent nerves to
capsaicin (under different observation circumstances, namely in acute administration,
before and after two weeks capsaicin treatment, given in dose of 3 x 400 µg /day) to
capsaicin;
5. To process and even to produce a new capsaicin containing drug or drug combinations
to modify the capsaicin-sensitive afferentation in human healthy subjects and to treat
patients with GI mucosal damage against NSAIDs and H. pylori infection.
These aims determined us to use a significant number of the methodologies applied in the
human studies. However, we had to use classical molecular pharmacological methods to
compare and to understand some details of capsaicin-induced changes in the human physio‐
logical, pathological parameters.
The following main trends were applied in the capsaicin research:
1. To determine the dose-response curves for the various drugs and capsaicin.
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Many observations on the field of Gastroenterology were based on the modification of efferent
fibres of vagal nerve, except the classical surgical vagotomy (both in the animal experiments
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of a very clear research line for the observations of capsaicin. The results of the different animal
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observations offered a new possibility for evaluation of capsaicin sensitive afferent nerves (by
the application of capsaicin) during physiological, pathological, pharmacological and thera‐
peutic events of the GI tract (Mózsik et al., 2014).
The results from animal experiments with capsaicin which is widely used in the every-day
culinary practice, clearly indicated us that the stimulatory doses of capsaicin acting on
capsaicin-sensitive fibres produce gastric mucosal defensive actions and they are able to
prevent the NSAID-induced gastric mucosal damage. These scientifically carried out studies
with capsaicin in animals also offered a new tool to approach the capsaicin sensitive afferent
nerves in the healthy human beings, and to some extent in patients with different GI disorders.
Our studies with capsaicin in human healthy subjects and in patients with different gastroin‐
testinal disorders have been stated from 1997. These studies were permitted by the Regional
Ethical Committee of University of Pécs, Hungary, and these observations were carried out
according to Good Clinical Practice respecting the Helsinki Declaration.
The human observations were carried out according to the basic laws of human clinical
pharmacology (inclusion and exclusion criteria, randomization, prospective studies, generally
self-controlled group of healthy human subjects, etc).
We had five aims in these studies with the capsaicin:
1. To understand the main mechanisms of capsaicin sensitive afferent nerves in the gastric
functions;
2. To try to understand the potential role(s) of capsaicin sensitive afferent nerves in the
development of human physiological, pathological and pharmacological events;
3. To identify the dose range of capsaicin which stimulates only the capsaicin-sensitive
afferent nerves and to identify the classical molecular pharmacological parameters
(affinity and intrinsic activity curves, ED50 and pA2 values) in comparison the same
parameters obtained in cases of every day used drugs;
4. To exclude clearly the existence of desensitation of capsaicin-sensitive afferent nerves to
capsaicin (under different observation circumstances, namely in acute administration,
before and after two weeks capsaicin treatment, given in dose of 3 x 400 µg /day) to
capsaicin;
5. To process and even to produce a new capsaicin containing drug or drug combinations
to modify the capsaicin-sensitive afferentation in human healthy subjects and to treat
patients with GI mucosal damage against NSAIDs and H. pylori infection.
These aims determined us to use a significant number of the methodologies applied in the
human studies. However, we had to use classical molecular pharmacological methods to
compare and to understand some details of capsaicin-induced changes in the human physio‐
logical, pathological parameters.
The following main trends were applied in the capsaicin research:
1. To determine the dose-response curves for the various drugs and capsaicin.
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2. To introduce the classical molecular pharmacological methods for understanding the
capsaicin-induced action in comparison to others produced by anticholinergic drugs,
H2R antagonists or proton pump inhibitors.
3. The specific immunohistochemistry (for obtained morphological evidence) was incorpo‐
rated into the research.
4. Different parameters were simultaneously measured (e.g. plasma glucose, insulin, C-
peptide and glucagon were detected during the sugar loading test in the healthy human
subjects).
5. Capsaicin studies were carried out not only in acute administration and after a chronic
capsaicin administration.
6. The immunohistochemical studies were carried out in the GI mucosa of patients with
different GI disorders (acute gastric mucosal damage, chronic inflammation, precancer‐
ous state and cancers in the stomach and in the large bowel);
7. The human pathological diagnosis was given by an independent pathologist.
8. The ED5O (necessary doses of drugs to produce 50% inhibition) values were determined
and expressed in [-] molar values (pD2).
9. To evaluate the possible role of capsaicin afferentation in the prevention or treatment of
gastric mucosal damage produced by NSAIDs in healthy subjects and in patients who are
treated with these drugs (as pain killers, platelet aggregation, anti-inflammatory com‐
pounds, etc).
4.1. Capsaicin-sensitive efferent nerves vs. gastric secretion in healthy human subjects
The capsaicin dose-dependent manner decreased the gastric basal secretion (BAO) (Mózsik et
al., 1999; 2004a; 2005). The capsaicin was applied in very small doses (200 to 800 µg orally),
which stimulate the capsaicin-sensitive afferent nerves.
When we applied the molecular pharmacological approach the actions of capsaicin, anticho‐
linergic agents, H2R antagonists or proton pump inhibitors, we were surprised that capsaicin
was able to inhibit gastric acid secretion in smaller molar concentration than other clinically
widely used drugs (Figures 3 and 4). Analyzing the intrinsic activity of these drugs and
capsaicin by the molecular pharmacological methods (intrinsic activity of atropine was taken
to be 1.00), we found capsaicin’s action to be lesser than atropine’s (Figure 3).
The affinity curves of different drugs and capsaicin were molecular pharmacologically
determined and given as pD2 (the necessary doses of drugs and capsaicin to produce 50%
inhibition of gastric acid secretion (basal acid output), which expressed in [-] molar value) and
as intrinsic activity (pA2) (the necessary doses of drugs and capsaicin to produce 50% inhibi‐
tion, also expressed in [-] molar) values (Table 1).
The results of these molecular pharmacological studies clearly indicated the sensitivity of the
various regulatory targets of different drugs and capsaicin in comparison to possible physio‐
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logical roles of the target organs and the drug actions influence their functional activities and
states. There is no question that the stimulation of capsaicin-induced afferent sensitive nerves
plays a very significant effect in regulatory processes important for the maintenance of gastric
mucosal integrity in human beings (including in healthy subjects and patients with different
GI disorders or treated with different drugs, especially with NSAIDs).
The decrease of gastric acid secretion was explained by the increased H+back diffusion after
capsaicin application via the increased vasodilatator processes induced by the release of the
CGRP and SP in animal observations or by the increase of somatostatin secretion. The CGRP
and SP together with capsaicin receptor (TRVP1) can be detected by inmunohistological
methods in the gastric mucosa around nerves, vascular spaces, parietal cells and in epithelial
layer.
The increased gastric secretory responses are present along with increased gastric mucosal
blood flow. On the other hand, the increased gastric acid (H+) secretion is closely associated
with the increase of K+, Mg2+, Ca+and albumin in gastric juice. However, the decrease of gastric
acid secretion produced by antisecretory agents is associated with the decrease of H+, K+, Mg2+,
Ca2+and albumin (Myren, 1968).
Human observations with capsaicin do suggest presence of increased H+back diffusion during
capsaicin action (except when capsaicin was given in high doses):
1. The increased H+back diffusion suggests the decreased level of albumin in the gastric juice.
Our results cannot prove the existence of gastric H+back diffusion in human healthy
subjects during the capsaicin action:
2. We calculated the “parietal” and “non-parietal “components of gastric juice after Hol‐
lander’s original observation (Hollander 1934). Our results clearly indicate that the
decrease of gastric H+concentration (and output) is closely associated with the increased
extent of “non-parietal component” during the capsaicin action in the healthy human
subjects. The “non-parietal component” of the gastric juice is a buffering part, which
cannot be obtained in circumstance of passive metabolic processes. Earlier, the significant
increase of buffering (“non-parietal component”) secretion was obtained in 2-10 days after
cessation of a prolonged atropine treatment in patients with peptic ulcer disease (Antal
et al., 1966).
3. There are other arguments also exist against the existence of the passive H+back diffusion
in the stomach during capsaicin action in the healthy human subjects. When the capsaicin
was directly given to gastric mucosa (using gastroscope), then GTPD increased in a dose
dependent manner (Mózsik et al., 2005).
If ethanol was intragastrically given (using the biopsy channel), then GTPD immediately
decreased, which could be reversed by the topical application of capsaicin. This action is also
dose-dependent from capsaicin after ethanol application in the healthy human subjects
(Mózsik et al., 2005).
The capsaicin action on the gastric secretory responses can be explained by different ways:
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2. To introduce the classical molecular pharmacological methods for understanding the
capsaicin-induced action in comparison to others produced by anticholinergic drugs,
H2R antagonists or proton pump inhibitors.
3. The specific immunohistochemistry (for obtained morphological evidence) was incorpo‐
rated into the research.
4. Different parameters were simultaneously measured (e.g. plasma glucose, insulin, C-
peptide and glucagon were detected during the sugar loading test in the healthy human
subjects).
5. Capsaicin studies were carried out not only in acute administration and after a chronic
capsaicin administration.
6. The immunohistochemical studies were carried out in the GI mucosa of patients with
different GI disorders (acute gastric mucosal damage, chronic inflammation, precancer‐
ous state and cancers in the stomach and in the large bowel);
7. The human pathological diagnosis was given by an independent pathologist.
8. The ED5O (necessary doses of drugs to produce 50% inhibition) values were determined
and expressed in [-] molar values (pD2).
9. To evaluate the possible role of capsaicin afferentation in the prevention or treatment of
gastric mucosal damage produced by NSAIDs in healthy subjects and in patients who are
treated with these drugs (as pain killers, platelet aggregation, anti-inflammatory com‐
pounds, etc).
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which stimulate the capsaicin-sensitive afferent nerves.
When we applied the molecular pharmacological approach the actions of capsaicin, anticho‐
linergic agents, H2R antagonists or proton pump inhibitors, we were surprised that capsaicin
was able to inhibit gastric acid secretion in smaller molar concentration than other clinically
widely used drugs (Figures 3 and 4). Analyzing the intrinsic activity of these drugs and
capsaicin by the molecular pharmacological methods (intrinsic activity of atropine was taken
to be 1.00), we found capsaicin’s action to be lesser than atropine’s (Figure 3).
The affinity curves of different drugs and capsaicin were molecular pharmacologically
determined and given as pD2 (the necessary doses of drugs and capsaicin to produce 50%
inhibition of gastric acid secretion (basal acid output), which expressed in [-] molar value) and
as intrinsic activity (pA2) (the necessary doses of drugs and capsaicin to produce 50% inhibi‐
tion, also expressed in [-] molar) values (Table 1).
The results of these molecular pharmacological studies clearly indicated the sensitivity of the
various regulatory targets of different drugs and capsaicin in comparison to possible physio‐
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logical roles of the target organs and the drug actions influence their functional activities and
states. There is no question that the stimulation of capsaicin-induced afferent sensitive nerves
plays a very significant effect in regulatory processes important for the maintenance of gastric
mucosal integrity in human beings (including in healthy subjects and patients with different
GI disorders or treated with different drugs, especially with NSAIDs).
The decrease of gastric acid secretion was explained by the increased H+back diffusion after
capsaicin application via the increased vasodilatator processes induced by the release of the
CGRP and SP in animal observations or by the increase of somatostatin secretion. The CGRP
and SP together with capsaicin receptor (TRVP1) can be detected by inmunohistological
methods in the gastric mucosa around nerves, vascular spaces, parietal cells and in epithelial
layer.
The increased gastric secretory responses are present along with increased gastric mucosal
blood flow. On the other hand, the increased gastric acid (H+) secretion is closely associated
with the increase of K+, Mg2+, Ca+and albumin in gastric juice. However, the decrease of gastric
acid secretion produced by antisecretory agents is associated with the decrease of H+, K+, Mg2+,
Ca2+and albumin (Myren, 1968).
Human observations with capsaicin do suggest presence of increased H+back diffusion during
capsaicin action (except when capsaicin was given in high doses):
1. The increased H+back diffusion suggests the decreased level of albumin in the gastric juice.
Our results cannot prove the existence of gastric H+back diffusion in human healthy
subjects during the capsaicin action:
2. We calculated the “parietal” and “non-parietal “components of gastric juice after Hol‐
lander’s original observation (Hollander 1934). Our results clearly indicate that the
decrease of gastric H+concentration (and output) is closely associated with the increased
extent of “non-parietal component” during the capsaicin action in the healthy human
subjects. The “non-parietal component” of the gastric juice is a buffering part, which
cannot be obtained in circumstance of passive metabolic processes. Earlier, the significant
increase of buffering (“non-parietal component”) secretion was obtained in 2-10 days after
cessation of a prolonged atropine treatment in patients with peptic ulcer disease (Antal
et al., 1966).
3. There are other arguments also exist against the existence of the passive H+back diffusion
in the stomach during capsaicin action in the healthy human subjects. When the capsaicin
was directly given to gastric mucosa (using gastroscope), then GTPD increased in a dose
dependent manner (Mózsik et al., 2005).
If ethanol was intragastrically given (using the biopsy channel), then GTPD immediately
decreased, which could be reversed by the topical application of capsaicin. This action is also
dose-dependent from capsaicin after ethanol application in the healthy human subjects
(Mózsik et al., 2005).
The capsaicin action on the gastric secretory responses can be explained by different ways:
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1. direct cellular action of capsaicin on the parietal cells;
2. direct stimulatory action of capsaicin on the “non-parietal component” of gastric secretory
responses;
Figure 22. Changes of parietal and non-parietal components of gastric juice before (A) and after (B) capsaicin (400 µg
orally, ED50 value) administration.
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Figure 23. Changes in the contents of electrolytes of gastric juice with increase and decrease of H
+
 output, without 
(upper part) and with (below part) capsaicin application. 
If ethanol was intragastrically given (using the biopsy channel), then GTPD immediately decreased, 
which could be reversed by the topical application of capsaicin. This action is also dose-dependent from capsaicin 
after ethanol application in the healthy human subjects (Mózsik et al., 2005). 
The capsaicin action on the gastric secretory responses can be explained by different ways: 
1. direct cellular action of capsaicin on the parietal cells; 
2. direct stimulatory action of capsaicin on the “non-parietal component” of gastric secretory responses; 
3. the capsaicin (given in doses producing the stimulation of capsaicin-sensitive afferent nerves) results 
directly neural (or hormonal) influences on the gastric mucosa; 
4. other yet not known mechanism(s) existing in the regulation of the human gastric secretion. 
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3. the capsaicin (given in doses producing the stimulation of capsaicin-sensitive afferent
nerves) results directly neural (or hormonal) influences on the gastric mucosa;
4. other yet not known mechanism(s) existing in the regulation of the human gastric
secretion.
The capsaicin given in ED50 increased the gastric emptying (Debreceni et al, 1999; Mózsik et
al., 2004a, 2004b). This action of capsaicin on the gastric emptying can be explained at least by
two pathways:
1. decrease of gastric acid secretion;
2. direct action on muscular function of the stomach (pylorus).
Up to now, the acute action of capsaicin was evaluated dominantly by the measuring one or
two parameters.
4.2. Capsaicin action of glucose absorption from small intestine in human healthy subjects
and its hormonal and metabolic backgrounds
The sugar loading test was applied for measuring absolutely different physiological events,
e.g. glucose absorption from the proximal part of the small intestine and consequently the
produced hormonal regulations during the glucose loading test.
The response to glucose loading in healthy human subject can be divided into three different
periods on basis of physiological events after orally applied glucose in human healthy persons:
1. absorption (first period, from 30 to 90 min);
2. insulin (and other hormones) release (second period, from 60 to 150 min);
3. glycogen mobilization by the liver (third period, from 150 to 180 min) under adrenergic
neural influences.
The glucose can be absorbed from the proximal part of the small intestine by active transport
mechanism (in presence of Mg2+, mitochondrial ATP breakdown into ADP) (Dömötör et al.,
2006b). The monitoring of the glucose level was used as biological marker for the equilibrium
of the different physiological events. In the first period the plasma glucose level depends only
on the glucose absorption; in the second period the plasma level of glucose represents the
equilibrium between the absorption and hormone release; and in the third the glucose level
represents the mobilization of glucose by the liver in healthy human subjects. It is also
important that the insulin and glucagon act contra regulatory on glucose utilization in the
serum.
By studying the time sequence of changes in plasma levels of glucose, insulin, C-peptide and
glucagon after glucose loading in healthy human subjects without and with capsaicin (400 µg
orally), we found the followings:
1. The plasma level of glucose (from 30 to 150 min) and the glucagon (from 90 to 180 min)
increased significantly after glucose plus capsaicin administration.
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1. direct cellular action of capsaicin on the parietal cells;
2. direct stimulatory action of capsaicin on the “non-parietal component” of gastric secretory
responses;
Figure 22. Changes of parietal and non-parietal components of gastric juice before (A) and after (B) capsaicin (400 µg
orally, ED50 value) administration.
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directly neural (or hormonal) influences on the gastric mucosa; 
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3. the capsaicin (given in doses producing the stimulation of capsaicin-sensitive afferent
nerves) results directly neural (or hormonal) influences on the gastric mucosa;
4. other yet not known mechanism(s) existing in the regulation of the human gastric
secretion.
The capsaicin given in ED50 increased the gastric emptying (Debreceni et al, 1999; Mózsik et
al., 2004a, 2004b). This action of capsaicin on the gastric emptying can be explained at least by
two pathways:
1. decrease of gastric acid secretion;
2. direct action on muscular function of the stomach (pylorus).
Up to now, the acute action of capsaicin was evaluated dominantly by the measuring one or
two parameters.
4.2. Capsaicin action of glucose absorption from small intestine in human healthy subjects
and its hormonal and metabolic backgrounds
The sugar loading test was applied for measuring absolutely different physiological events,
e.g. glucose absorption from the proximal part of the small intestine and consequently the
produced hormonal regulations during the glucose loading test.
The response to glucose loading in healthy human subject can be divided into three different
periods on basis of physiological events after orally applied glucose in human healthy persons:
1. absorption (first period, from 30 to 90 min);
2. insulin (and other hormones) release (second period, from 60 to 150 min);
3. glycogen mobilization by the liver (third period, from 150 to 180 min) under adrenergic
neural influences.
The glucose can be absorbed from the proximal part of the small intestine by active transport
mechanism (in presence of Mg2+, mitochondrial ATP breakdown into ADP) (Dömötör et al.,
2006b). The monitoring of the glucose level was used as biological marker for the equilibrium
of the different physiological events. In the first period the plasma glucose level depends only
on the glucose absorption; in the second period the plasma level of glucose represents the
equilibrium between the absorption and hormone release; and in the third the glucose level
represents the mobilization of glucose by the liver in healthy human subjects. It is also
important that the insulin and glucagon act contra regulatory on glucose utilization in the
serum.
By studying the time sequence of changes in plasma levels of glucose, insulin, C-peptide and
glucagon after glucose loading in healthy human subjects without and with capsaicin (400 µg
orally), we found the followings:
1. The plasma level of glucose (from 30 to 150 min) and the glucagon (from 90 to 180 min)
increased significantly after glucose plus capsaicin administration.
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2. The plasma levels of insulin and C-peptide were increased from 90 to 165 min, however,
no significant changes were observed between subjects without and with capsaicin.
3. No significance in timing of insulin and glucagon release was observed, which clearly
excludes the existence of antagonism between insulin and glucagon release (short time).
4. The plasma level of glucagon was high for longer period than it was in case of insulin. It
should be noted that capsaicin increased the glucagon level.
The results clearly indicate that capsaicin sensitive afferent nerves have a key-role in the
regulation of glucose absorption from the small intestine (due to a local increase of blood flow),
glucose utilization, and release of neuropeptide (presently the glucagon release). This human
observation proved clear-cut the active participation of capsaicin sensitive afferent nerves in
the carbohydrate metabolism (by the ways of modification of sugar absorption, hormone
release). Up till now only the somatostatin release induced by capsaicin has been known
(Szolcsányi, 2004).
4.3. Capsaicin given orally in small doses prevents with IND-induced gastric
microbleedings in human healthy subjects
The IND was used in these studies as NSAID, which is a non-selective COX blocker (the ratio
of ED50 of IND on COX-1 /COX-2 = 0.30) (Kawai et al., 1998) (Table 5). The extent of gastric
microbleeding appears as consequence of COX-1 and COX-2 inhibition.
The results of our observations (Sarlós et al., 2003; Mózsik et al., 2003, 2004a; 2005) the capsaicin
(ig. given) dose dependently prevented the IND-induced gastric microbleeding before and
after 2 weeks capsaicin treatment.
Under the results of Kawai et al. (1998), we calculated the extents of gastric microbleeding
depending on COX-1 and COX-2 enzyme activity (Table 6). It was found that the capsaicin-
induced gastric mucosal protection remained unchanged – before and after 2 weeks capsaicin













Table 5. Comparison of inhibitory effects (IC50) of NSAIDs on COX-1 and COX-2 enzymes in human platelet synovial
cell (After Kawai et al.: Eur. J. Pharmacol. 347; 87-94, 1998).*
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Table 6. Correlation between the capsaicin actions, COX-1 and COX-2 systems and gastric 
microbleedings produced by indomethacin (IND) in human healthy subjects before and after 
2-week capsaicin (3x400µg orally) treatment. (After Mózsik et al.: Inflammmopharmacology 
15: 232-45, 2007)* 
 
• 400 µg CAPSAICIN (IG GIVEN) INDUCED DECREASE OF IND-GASTRIC 
MICROBLEEDING 
 
   6±0.2 mL/day           5.9±0.2 mL/day 





 VALUE OF INDOMETHACIN TO RATIO OF COX-1/COX-2 = 0,30 
(1: 3,25) 
• MICROBLEEDING IN THE STOMACH 
Before After 
←      2 weeks capsaicin treatment → 
Baseline 2,1 + 0,1 mL/day      2,0 + 0,1 mL/day 
After IND 8,25 + 0,25 mL/day      7,8 + 0,3 mL/day 
∆ IND-induced 6,15 + 0,2 mL/day                 5,8 + 0,3 mL/day 
(= inhibition on COX-1 + COX-2) (= 100%) 
 
COX-1:1.447±0.1 mL/day       1.364±0.1 mL/day 
COX-2: 4.70±0.2 mL/day       4.44±0.2 mL/day 
* means±SEM in 14 human healthy subjects.
Table 6. Correlation between the capsaicin actions, COX-1 and COX-2 systems and gastric microbleedings produced
by indomethacin (IND) in human healthy subjects before and after 2-week capsaicin (3x400µg orally) treatment.
(After Mózsik et al.: Inflammmopharmacology 15: 232-45, 2007)*
The orally given 200, 400 and 800 µg capsaicin dose dependently reduced the IND-induced
gastric microbleeding. All of the healthy persons included in this study received all the
mentioned doses of capsaicin in random allocation.
4.5. Questions of desensibilization in capsaicin receptor to capsaicin
4.5.1. Facts to exclude the presence of the desensibilization of capsaicin receptor to applied doses of
capsaicin in acute observation circumstances
When we applied the capsaicin twice in doses of 800 µg ig. after 5 min interval, then we received
the same extents of increase in difference of GTPD, indicating a very active metabolic action
under these observation circumstances.
The  same  extent  gastric  mucosal  protection  was  obtained  in  the  IND-induced  gastric
mucosal damage in human healthy subjects. The actions of gastric mucosal prevention was
dose-dependent on the IND-induced gastric microbleedings (please note that these human
observations  were  carried  out  in  prospective,  randomized  and  multiclinical  studies)
(Figures 18 and 19).
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2. The plasma levels of insulin and C-peptide were increased from 90 to 165 min, however,
no significant changes were observed between subjects without and with capsaicin.
3. No significance in timing of insulin and glucagon release was observed, which clearly
excludes the existence of antagonism between insulin and glucagon release (short time).
4. The plasma level of glucagon was high for longer period than it was in case of insulin. It
should be noted that capsaicin increased the glucagon level.
The results clearly indicate that capsaicin sensitive afferent nerves have a key-role in the
regulation of glucose absorption from the small intestine (due to a local increase of blood flow),
glucose utilization, and release of neuropeptide (presently the glucagon release). This human
observation proved clear-cut the active participation of capsaicin sensitive afferent nerves in
the carbohydrate metabolism (by the ways of modification of sugar absorption, hormone
release). Up till now only the somatostatin release induced by capsaicin has been known
(Szolcsányi, 2004).
4.3. Capsaicin given orally in small doses prevents with IND-induced gastric
microbleedings in human healthy subjects
The IND was used in these studies as NSAID, which is a non-selective COX blocker (the ratio
of ED50 of IND on COX-1 /COX-2 = 0.30) (Kawai et al., 1998) (Table 5). The extent of gastric
microbleeding appears as consequence of COX-1 and COX-2 inhibition.
The results of our observations (Sarlós et al., 2003; Mózsik et al., 2003, 2004a; 2005) the capsaicin
(ig. given) dose dependently prevented the IND-induced gastric microbleeding before and
after 2 weeks capsaicin treatment.
Under the results of Kawai et al. (1998), we calculated the extents of gastric microbleeding
depending on COX-1 and COX-2 enzyme activity (Table 6). It was found that the capsaicin-
induced gastric mucosal protection remained unchanged – before and after 2 weeks capsaicin
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Table 6. Correlation between the capsaicin actions, COX-1 and COX-2 systems and gastric microbleedings produced
by indomethacin (IND) in human healthy subjects before and after 2-week capsaicin (3x400µg orally) treatment.
(After Mózsik et al.: Inflammmopharmacology 15: 232-45, 2007)*
The orally given 200, 400 and 800 µg capsaicin dose dependently reduced the IND-induced
gastric microbleeding. All of the healthy persons included in this study received all the
mentioned doses of capsaicin in random allocation.
4.5. Questions of desensibilization in capsaicin receptor to capsaicin
4.5.1. Facts to exclude the presence of the desensibilization of capsaicin receptor to applied doses of
capsaicin in acute observation circumstances
When we applied the capsaicin twice in doses of 800 µg ig. after 5 min interval, then we received
the same extents of increase in difference of GTPD, indicating a very active metabolic action
under these observation circumstances.
The  same  extent  gastric  mucosal  protection  was  obtained  in  the  IND-induced  gastric
mucosal damage in human healthy subjects. The actions of gastric mucosal prevention was
dose-dependent on the IND-induced gastric microbleedings (please note that these human
observations  were  carried  out  in  prospective,  randomized  and  multiclinical  studies)
(Figures 18 and 19).
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The results of these mentioned observations clearly indicated that the doses of capsaicin in our
studies could not produce desensibilization of capsaicin receptors (these doses of capsaicin
only were able to stimulate the capsaicin-sensitive afferent nerve).
4.5.2. Facts to exclude the presence of desensibilization to capsaicin receptor by applied doses of capsaicin
during 2 weeks capsaicin treatments
The capsaicin exerts gastroprotective effect remained unchanged on IND-induced gastric
mucosal microbleeding before and after 2-week capsaicin (3x 400µg orally given) treatment








Figure 24. Schematic demonstration the possible pathways in changes of chronic capsaicin treatment from the 
side of the compound (upper part) and from the side of mucosal injury and complaints (lower part) in human 
healthy subjects and in patients with different (including gastrointestinal) disorders. 
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Figure 24. Schematic demonstration the possible pathways in changes of chronic capsaicin treatment from the side of
the compound (upper part) and from the side of mucosal injury and complaints (lower part) in human healthy sub‐
jects and in patients with different (including gastrointestinal) disorders.
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By other words, the gastric baseline microbleeding remained unchanged after the application
of different doses of capsaicin (200, 400 and 800 µg orally) induced gastric mucosal prevention.
The registration of these facts are very important, since a very wide scale of capsaicin doses
applied in human observations resulted very contradictory data (capsaicin were applied in
stimulatory doses to capsaicin sensitive afferent nerve and much higher doses producing
reversible and irreversible inhibitory actions in various animal experiments).
The capsaicin acts at the level of capsaicin receptor, which has been cloned (Caterina et al.,
1997). It is true that the capsaicin action depends on its doses proved by animal experiments
(Szolcsányi, 1984; Mózsik et al., 2001). The small dose (400 µg=ED50) was applied for two weeks
(in dose of 400 µg x 3 orally) in healthy subjects. The gastric mucosal microbleeding was
produced by orally given IND (Figure 19 and Table 6.
The following results were obtained:
1. The extent of baseline gastric microbleeding before and after 2 weeks capsaicin (without
application of any drug) remained unchanged.
2. The extent of acutely given IND-induced gastric microbleeding was also unchanged.
3. The extent of capsaicin-induced gastric mucosal protection was also found to be the same
(and dose dependent) before and after 2 weeks capsaicin treatment.
It has been concluded from these observations that the sensitivity of capsaicin receptor
(TRVP1) unchanged, and on the other hand, the orally applied capsaicin is capable to exert
gastric mucosal protection against IND.
Probably the applied small dose of capsaicin – used in our present studies – could not modify
the TRVP1 receptor sensitivity. We have no knowledge in this field by using higher dose(s) of
capsaicin in human healthy subjects.
These facts are very important from the point of selection of capsaicin containing drug, because
these dosages of capsaicin could exert beneficial effect (given orally in small doses), meanwhile
the capsaicin can produce reversible or irreversible damage on the human gastric mucosa.
Earlier similar types of observations were carried out with atropine and other parasympatho‐
lytics (Mózsik et al., 1965; 1967; 1969 a,b) and cimetidine (Wildersmith et al., 1990). Tolerance
developed to the drugs applied chronically in patients with peptic ulcer disease, and the
“pharmacological denervation hypersensibility“ occurred with a clinically detectable toler‐
ance (Mózsik et al., 1966; 1967; 1969). These clinical pharmacological examinations modified
the periodicity and dosage of applicable drugs (used in chronic treatment).
The careful analysis of the results with capsaicin actions, COX-1 and COX-2 systems and gastric
microbleedings produced by IND in human healthy subjects before and after two weeks
capsaicin (3 x 400 µg orally) treatment offered an excellent possibility to approach the capsaicin
actions on the COX-1 and COX-2 enzyme system (Table 6).
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The results of these mentioned observations clearly indicated that the doses of capsaicin in our
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mucosal microbleeding before and after 2-week capsaicin (3x 400µg orally given) treatment
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By other words, the gastric baseline microbleeding remained unchanged after the application
of different doses of capsaicin (200, 400 and 800 µg orally) induced gastric mucosal prevention.
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Probably the applied small dose of capsaicin – used in our present studies – could not modify
the TRVP1 receptor sensitivity. We have no knowledge in this field by using higher dose(s) of
capsaicin in human healthy subjects.
These facts are very important from the point of selection of capsaicin containing drug, because
these dosages of capsaicin could exert beneficial effect (given orally in small doses), meanwhile
the capsaicin can produce reversible or irreversible damage on the human gastric mucosa.
Earlier similar types of observations were carried out with atropine and other parasympatho‐
lytics (Mózsik et al., 1965; 1967; 1969 a,b) and cimetidine (Wildersmith et al., 1990). Tolerance
developed to the drugs applied chronically in patients with peptic ulcer disease, and the
“pharmacological denervation hypersensibility“ occurred with a clinically detectable toler‐
ance (Mózsik et al., 1966; 1967; 1969). These clinical pharmacological examinations modified
the periodicity and dosage of applicable drugs (used in chronic treatment).
The careful analysis of the results with capsaicin actions, COX-1 and COX-2 systems and gastric
microbleedings produced by IND in human healthy subjects before and after two weeks
capsaicin (3 x 400 µg orally) treatment offered an excellent possibility to approach the capsaicin
actions on the COX-1 and COX-2 enzyme system (Table 6).
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4.5.3. Gastric (gastrointestinal) cytoprotection vs. capsaicin actions (given in stimulatory doses of
capsaicin-sensitive afferent nerves)
Observations with different chemical agents (drugs, mediators, nutritive agents like retinoids,
prostaglandins and others) indicated a special gastric mucosal protection, which did not
depend on the gastric acid inhibition (see the reviews Mózsik et al. 2010, 2011). Later on, many
observations indicated that the so-called gastric cytoprotective agents are able to prevent the
development of injuries of numerous organs (produced by different actions) and they can
accelerate healing processes.
The existence of gastric cytoprotection was earlier proved in patients with peptic ulcer (Mózsik
et al., 1965, 2010, 2011) as it was nominated by André Robert (1979).
Only few points are interesting in our present position, namely: 1. the capsaicin-induced gastric
mucosal protection in human healthy subjects is accompanied by the decrease of gastric acid
secretion (that was one of the criteria differed from “classic“ gastric cytoprotection); 2.both
“classical cytopotective effects” as well as capsaicin-produced gastric mucosal protection
disappear after surgical vagotomy (but not after chemical vagotomy); 3. gastric cytoprotective
effect produced by different agents remained to be the same besides application of capsaicin
(given in doses to produce stimulation of capsaicin-sensitive afferent nerves) (Mózsik et al.,
1997). These results offer us to suggest that: 1. some part a gastric mucosal (cyto)protection is
very closely associated with the functional activity of capsaicin-sensitive afferent nerves; 2.
increased extent of gastric mucosal damage might develop in consequence of surgical ablation
of capsaicin-sensitive afferent nerves (Mózsik et al., 1982, 2011).
These lines of capsaicin and cytoprotection protection in some meaning are similar and differ
from each other (Szabó et al., 2012; Mózsik et al., 2011).
4.5.4. Distribution of capsaicin receptor, CGRP and SP in the gastric and large bowel mucosa of patients
with different gastrointestinal disorders
The use of specific antisera against TRVP1 receptor, CGRP and SP released by the stimulation
of capsaicin sensitive afferent nerve can immunohistochemical demonstrate their presence in
the GI mucosa. Please note, that mucosal biopsy cannot be performed in healthy human
subjects due to ethical regulations. So „healthy subjects”are represented by human subjects
with functional disorders having no endoscopic abnormalities and diagnosed by clinicians
and independent pathologist. There is another problem, namely the regular biopsy can be
offered a small tissue sample for its regular pathological histological evaluation. Our specific
immunohistochemical observations could be done only after successful routine histological
examination.
We studied l78 patients with different gastrointestinal disorders (complaints), and the persons,
who had normal histology based on the opinion of independent pathologist, were used as
normal (healthy) human subjects (Dömötör et al., 2007; Mózsik et al., 2007).
The TRVP1 receptor, CGRP and SP neuropeptides released by the stimulation of capsaicin
receptor can be shown by immonohistochemistry both in the human gastric and colon mucosa.
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The TRVP1 receptors and neuropetides (CGRP and SP) could be demonstrated in the GI
mucosa around the nerve endings, vascular elements, parietal cells, and also in epithelial layer.
The capsaicin application and the immunohistochemical demonstration of TRVP1 receptor in
the GI tract newly met in the healthy human subjects. We studied the immunohistochemical
distribution of TRVP1, CGRP and SP in the GI mucosa of patients with different disorders.
The TRVP1 receptor, CGRP and SP could be detected practically in all patients with different
acute, chronic diseases (including benignant, precancerous and cancerous diseases) (Dömötör
et al., 2005). The results of these observations can be taken only as preliminary results. Their
expression differed significantly in the GI mucosa of patients with acute and chronic disorders.
Of course, the critical evaluation of these immunohistochemical observations is extremely
hard, since we have only very limited information on the origin, stages, time periods of
diseases, drug therapies and suggested etiological backgrounds. The studies dealing with the
changes of individual patients with chronic GI disorders – in this research respect – are in
progress. We have to emphasize two different main points in these studies, namely 1. The
changes of the expressions of TRVP1, CGRP and SP are helpful from the point of development
of GI mucosal injury and prevention, and 2. probably the participations of TRVP1, CGRP and
SP differ in these GI pathological circumstances.
4.6. Immunohistochemical examinations in patients with chronic H. pylori positive and
negative gastritis
In model human observations, the possible participation of TRVP1, CGRP and SP were studies
in patients with chronic gastritis. The laboratory tests (quick urease test, urea breath test) and
specific histological staining widely used in every day medical practice for demonstration of
the presence of H. pylori infection were used, which suggested the presence of bacteria as the
etiological for chronic gastritis.
Our studies were carried out in patients with H. pylori positive and negative chronic gastritis.
The expression of TRVP1, CGRP and SP increased significantly in the gastric mucosa with
chronic gastritis; however, no difference was obtained their expression in patients with H.
pylori positive and negative chronic gastritis (Dömötör et al., 2006a).
The inflammation of the tissues does not represent a specific tissue reaction to inducing agents.
This statement can be concluded from our results obtained in patients with H. pylori positive
and negative chronic gastritis due the potential role of capsaicin sensitive afferent nerves. There
is no question that the so-called „neurogenic inflammation” participated in the „general
inflammatory processes” in patients with different gastrointestinal disorders.
4.7. Capsaicin sensitive afferentation in patients with chronic H. pylori positive gastritis
before and after eradication treatment
The last step of our observations indicated that capsaicin-sensitive afferentation did not differ
before and 6 weeks after successful eradication treatment in patients with chronic H. pylori
positive gastritis (meanwhile the control biopsy was normal in 22 %, in 78% of cases it indicated
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offered a small tissue sample for its regular pathological histological evaluation. Our specific
immunohistochemical observations could be done only after successful routine histological
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the presence of H. pylori infection were used, which suggested the presence of bacteria as the
etiological for chronic gastritis.
Our studies were carried out in patients with H. pylori positive and negative chronic gastritis.
The expression of TRVP1, CGRP and SP increased significantly in the gastric mucosa with
chronic gastritis; however, no difference was obtained their expression in patients with H.
pylori positive and negative chronic gastritis (Dömötör et al., 2006a).
The inflammation of the tissues does not represent a specific tissue reaction to inducing agents.
This statement can be concluded from our results obtained in patients with H. pylori positive
and negative chronic gastritis due the potential role of capsaicin sensitive afferent nerves. There
is no question that the so-called „neurogenic inflammation” participated in the „general
inflammatory processes” in patients with different gastrointestinal disorders.
4.7. Capsaicin sensitive afferentation in patients with chronic H. pylori positive gastritis
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The last step of our observations indicated that capsaicin-sensitive afferentation did not differ
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positive gastritis (meanwhile the control biopsy was normal in 22 %, in 78% of cases it indicated
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a moderate improvement of the histological picture of gastritis) (Lakner et al, 2011; Mózsik et
al., 2011, Mózsik et al., 2013; Czimmer et al., 2013).
After careful analysis of these results, it can be stated that the capsaicin-sensitive afferentation
represents as an essential pathway in the healing of chronic gastritis (probably without and
with H. pylori infection). These results suggest an independent mechanism in the healing of
chronic gastritis which differs from the eradication treatment. By other words, besides the H.
pylori infection other factors might exist. The H. pylori infection can be taken as one (but
probably most important) exogenous factor, however, the capsaicin-sensitive afferent fibres
of vagal nerve represents an endogenous factor in the injury and protection of gastric mucosa
(Mózsik et al., 2013).
Our results with capsaicin (in healthy human subjects and in patients with different gastroin‐
testinal disorders) are summarized in Figure 21. The vagal nerve is able to modify the GI tract
by regulatory steps at the central nervous system and at the level of target organ. The peripheral
action of capsaicin is a dose dependent action (Szolcsányi, 1984; Mózsik et al., 2001) (Table 5).
The capsaicin mobilizes the CGRP and SP (Inui et al., 1991; Dömötör et., 2005), which modifies
the vascular reactions in the GI mucosa (Sipos et al. 2006), recently demonstrated that the
existence of neuroimmune link between the CGRP, SP and immune cells in the gastric mucosa
of patients with chronic gastritis. Dömötör et al. (2006b) demonstrated the increased release
of glucagon during a sugar loading test in healthy human subjects, indicated a new step of
capsaicin-induced changes taking place between the capsaicin sensitive afferent nerves and
neurohormonal regulation. Dömötör et al. (2006b) gave a direct evidence for the role of
capsaicin in the carbohydrates metabolism.
There were a few very surprising matters due to capsaicin from the point of human classical
clinical pharmacology prior our observations:
1. no permitted orally applicable capsaicin preparation was available for humans;
2. no chronic toxicology was known to capsaicin by animal observations;
3. no direct clinical pharmacological study had been performed to determine germinative
function;
4. the capsaicin (Sigma-Aldrich, USA) chemically is not uniform due to its varying content
of dihydrocapsaicin, nordihydrocapsaicin and some other capsaicinoids;
5. no classical human clinical pharmacological study (human phase I and phase II) was
found in the literature;
6. no correct Drug Master File (DMF) for capsaicin preparation were developed for the
commercially obtained capsaicin (exception of a certain capsaicin preparation obtained
from India and used by us);
7. no human pharmacokinetic observations were available for capsaicin (please remember
that our capsaicin studies in human healthy subjects were started in 1997).
Bernard et al. (2008) were unable to create pharmacokinetic profile of capsaicinoids after
administration of 15 and 30 mg of capsaicin/person; meanwhile, the detection limit was 10 ng/
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ml. Chaiyasit et al. (2009) after the application of 5 gram of C. frurenscens orally (equivalent
to 26.6 mg pure capsaicin) found that the capsaicin could be detected in plasma after 10 min,
and the peak concentration (Cmax) was 2.47 ± 0.13 ng/mL, tmax was 47.1 ± 2.0 min and t½ was
24.9 ± 5.0 min. After 90 min, capsaicin could not be detected in the plasma. Chaiyasit et al.
(2009) explained the results of Bernard et al. (2008) by the time factor of pharmacokinetic
behaviors of capsaicin in humans. The results of these observations were mentioned in the
review paper by O’Neill et al. (2012).
We also received new information from the chronic toxicological studies in Beagle dogs (2008).
These animals were treated with different doses (0.1, 0.3 and 0.9 mg/kg body weight/day orally
given) of capsaicin(noids) for one month. No toxic effects were observed in these dogs during
the whole treatment periods. We noticed surprisingly that capsaicin and dihydocapsaicin
could not be detected in the sera of Beagle dogs by either high pressure chromatography with
the detection limit of 20 ng/mL serum or liquid chromatography-mass spectrometry with the
detectation was 26 fg/mL in the serum at any time after the oral administration (Mózsik et al.,
2008; Boros et al., 2008).
5. Main conclusion from our obervations on capsaicin application in
human healthy subjects and in patients with different disorders
1. The capsaicin (as a specific agent to stimulate the capsaicin-sensitive afferent nerves) plays
a special role in the regulation the gastric functions (decrease of gastric acid secretion,
increase of gastric emptying, increase in “buffering part” of the gastric secretion, increase
of GTDP), absorption of glucose (and in its metabolism as well as in increase of glycagon
release) in human healthy subjects, when it is applied in stimulatory doses;
2. The capsaicin given orally in stimulatory doses protects against the alcohol-and NSAID-
induced gastric mucosal damage in healthy human subjects;.
3. If the capsaicin is given in stimulatory doses to capsaicin-sensitive afferent nerves in
human healthy subjects, it will not produce desensibilization of its receptor (neither in
acute administrations nor in chronic administrations) in human healthy subjects ;
4. The presence of capsaicin receptor (also CGRP and SP, which are very close in physio‐
logical relation) can be shown by specific immuno-histochemical methods under various
GI disorders ;
5. The capsaicin-induced gastroprotection differs from the eradication treatment in patients
with chronic H. pylori positive gastritis (and probably the roles of capsaicin receptor and
CGRP differ from SP);
6. Very important to note that these gastroprotective actions can be obtained only by
administration of capsaicin in stimulatory doses to its sensitive afferent nerves.
After looking of this conclusion list, there are clear evidences that the capsaicin is an orally
applicable drug either alone or in combinations with different NSAIDs to human healthy
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existence of neuroimmune link between the CGRP, SP and immune cells in the gastric mucosa
of patients with chronic gastritis. Dömötör et al. (2006b) demonstrated the increased release
of glucagon during a sugar loading test in healthy human subjects, indicated a new step of
capsaicin-induced changes taking place between the capsaicin sensitive afferent nerves and
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6. Very important to note that these gastroprotective actions can be obtained only by
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After looking of this conclusion list, there are clear evidences that the capsaicin is an orally
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subjects and to patients. Its indication is wide from prevention against drug-induced gastric
mucosal damage, from patients under long term aspirin treatment (due to cardiovascular
disease, thrombophylia, rheumatoid arthritis), pain killer treatment, patients having chronic
H. pylori positive gastritis and to patient with different carbohydrate disorders.
We are of the opinion that we scientifically put down the clinical pharmacological bases of the
oral capsaicin or drug combination use. We are in need of competent pharmaceutical partners
for commercial introduction of these drug candidates into the everyday medical treatment
(Mózsik, 2014; Mózsik et al., 2014).
Of course, we are aware that many other observations are need to be carried out in according
to the regulations of international drug development, production and marketing for a capsaicin
containing drug to licensed for everyday medical treatment.
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subjects and to patients. Its indication is wide from prevention against drug-induced gastric
mucosal damage, from patients under long term aspirin treatment (due to cardiovascular
disease, thrombophylia, rheumatoid arthritis), pain killer treatment, patients having chronic
H. pylori positive gastritis and to patient with different carbohydrate disorders.
We are of the opinion that we scientifically put down the clinical pharmacological bases of the
oral capsaicin or drug combination use. We are in need of competent pharmaceutical partners
for commercial introduction of these drug candidates into the everyday medical treatment
(Mózsik, 2014; Mózsik et al., 2014).
Of course, we are aware that many other observations are need to be carried out in according
to the regulations of international drug development, production and marketing for a capsaicin
containing drug to licensed for everyday medical treatment.
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1. Introduction
Backgrounds. 1. The intact gastrointestinal mucosa is a result of excellently well regulated
equilibrium between the aggressive (physical and other stress, xenobiotics, wide scale of drugs,
chemicals, bacterial and viral infections) and defensive (bicarbonate secretion, mucus secre‐
tion, blood supply, prostaglandins, mucosal energy systems, etc.) factors, which are further
controlled by different neural, hormonal and pharmacological mechanisms. 2. The vagal nerve
takes an essential place both in the development of gastrointestinal mucosal damage and
protection. 3. The physicians have widely been applied the nonsteroidal antiinflammatory
drugs (such as aspirin, diclofenac, Naproxen, etc.) as antipyretic, anti-inflammatory, pain-
killer and platelet aggregation inhibitor agents in healthy humans and in patients with
different disorders (such as myocardial infaction, different forms of thrombophylia, rheuma‐
toid arthritis and arthrosis or trauma) in the everyday medical practice. The administration of
these drugs produces gastrointestinal complaints (mucosal damages, bleedings, perforations).
So in one hand, the applications of these drugs are absolutely indicated, on the other hand, the
1 Important note: The term “capsaicin“ is used in the text, however capsaicinoids of natural origin are used for during
different studies.Some times the term “capsaicinoids“ are used to emphasize their plant origin.
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applications of these drugs are contraindicated from the points of gastroenterologist. 4. We
earlier proved clearly that the small doses of capsaicin (given orally in doses of nanogram to
microgram / kg in animal experiments and 200 to 800 µg in human observations) prevents the
aspirin, indomethacin (a mixed COX-1 and COX-2 inhibitor)-induced gastrointestinal mucosal
damage.
Aims: 1. The development and pharmaceutically production of the planned production of new
gastrointestinal mucosal protective drug (capsaicin alone and/or capsaicin in combination with
different nonsteroidal anti-inflammatory drugs) for the use in human healthy beings and in
patients. 2. For the development and production of a new drug, we had to respect the following
aspects: a. the knowledge of the chemical composition of natural origin capsaicin(oids); b.
problems of the analytical measurements of capsaicin(oids) in the biological samples (in
animals and humans); c. correct and complete preclinical dossier; d. correct dossier of acute
and chronic toxicological studies with capsaicin (including the different tests) in two speci‐
ments of animal experiments; e. existence of a complete drug master file (DMF); f. the exclusion
of pesticides, fusariums, aflatoxin and other toxicological agents (which are used during the
plant cultivation in the different countries) from the capsaicin(oids) preparations used for drug
production; g. to collect the necessary permissions from the different international and national
authrorities before starting of pharmaceutical production of drug alone or in combinations;
h. different pharmaceutical controlling measurements and other pharmaceutical aspects of
planned drug or drug combinations (such as stability, drug preparation, different pharma‐
ceutical technologies, etc.); i. preparation of different protocols for human human phase
examinations (especially for human phase I.); j. to receive the permissions from the the
different national authorities to carried out the prepared protocols before starting of the
classical pharmacological studies; k. to gather the necessary numbers of experts from the very
different scientific fields, who are able to solve all of above mentioned scientific, pharmaceut‐
ical, research problems (in animal experiments and in human observations); l. to find accred‐
ited institutes to perform human clinical pharmacological (phase) examinations. 2. When we
solved all of above scientific problems, the human phase I. examinations with capsaicin alone
and with combination+aspirin and capsaicin+diclofenac, the human phase I. examinations
were in the Clinical Pharmacological Units of First Department of Medicine and of Institute of
Cardiology, Medical and Health Centre, University of Pécs, Hungary, meanwhile the phar‐
macokinetic measurements were done in the Laboratories of PannonPharma Pharmaceutical
Ltd., Pécsvárad, Hungary. 3. The aims of these human phase I. examinations were: a. to
measure of capsaicin in the plasma of male human healthy subjects, when the capsaicin was
given orally (in doses of 400 and 800 µg) alone or in combination with aspirin (500 mg orally)
and with diclofenac (100 mg orally); b. to measure the pharmacokinetic parameters (Cmax, Tmax,
AUC 0-tlast, AUC 0-∞, t½, MRT, mean residence time) of ASA and diclofenac given alone and after
in combinations with different doses (400 and 800 µg) of capsaicin; c. to study extents of
inhibitory effect on platelet aggregation of ASA and diclofenac on the epinephrine-induced
platelet aggregation.
The observations were carried out on volunteers of healthy male human subjects. The
volunteers were selected by special experts of human clinical pharmacology based on the strict
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criteria of inclusion and exclusion. The time period of phase I. examinations was maximally 8
weeks, from which two weeks for randomisation of the volunteers (15 in each study), the
clinical pharmacological study was done in five sequences during 5 weeks, and the post-study
procedure took one week after the closing the clinical pharmacological studies. The observa‐
tions were carried out in random allocation, and the human phase I. examinations covered
hospitalization (two days) and outpatients (4 days) periods. The observations were carried out
according to the written and permitted protocols (“Human phase I. single-blind study
comparing the pharmacokinetic properties of ASA after single administration alone and co-
administration with two different doses of capsaicin (400 and 800 µg) and evaluating their
safety in healthy male subjects“. Protocol number: 1.4.1; EudraCT number: 2008-007048-32 and
“ Human phase I. single-blind study comparing the pharmacokinetic properties of diclofenac
after single administration alone and co-administration with two different doses of capsaicin
(400 and 800 µg) and evaluating their safety in healthy male subjects“. Protocol number: 1.4.2;
EudraCT number: 2008-007050-36).
Our  observations  were  to  produce  clinically  and  pharmaceutically  a  new  capsaicin
containing  drug  and  drug  combinations  started  from  2005  as  an  “innovative  drug  re‐
search“,  meanwhile  the  human phase  I.  examinations  started  from March 10,  2011  and
finished  by  December  31,  2013  (including  the  examinations,  pharmacokinetic  measure‐
ments, mathematical analysis of obtained results, closing of written reports).
Main results and conclusions: 1. The presence of capsaicin and dihydrocapsaicin (after orally
given capsaicinoids of 400 and 800 µg) was not able to detect in the plasma of the healthy male
volunteers, who were treated with capsaicin(oids); 2. The capsaicin(oids) does (do) not modify
the absorption, metabolism and excretion of orally given ASA and diclofenac; 3. The capsai‐
cin(oids) does(do) not modify the epinephrine-induced platelet aggregation by ASA and
diclofenac, meanwhile the different doses of capsaicin(oids) alone has (have) no direct action
on the epinephrine-induced platelet aggregation; 4. We have learned a lot of new research,
juristic, patent, pharmaceutical and other clinical pharmacological problems (from basic
research problems, requisted animal toxicological examinations by the different authorities,
preparation of preclinical dossier, the different pathways for obtaining official permission from
the different authorities to carried out the human clinical phase examinations, chemical
qualification of capsaicin(oids) in the plasma in treated animals and human healthy subjects);
5. We were able to start with the development and production of pharmaceutical production
of gastroprotective capsacin(oids) containing drug alone and in combinations with ASA and
diclofenac based on the internationally accepted laws of human clinical pharmacology; 6.
We established the scientific basis of the capsaicin-sensitive afferentation vs. gastric mucosal
protection against the different noxious agents (including the nonsteroidal anti-inflammatory
drugs) in human healthy subjects and in patients treated with different anti-inflammatory
drugs.
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criteria of inclusion and exclusion. The time period of phase I. examinations was maximally 8
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preparation of preclinical dossier, the different pathways for obtaining official permission from
the different authorities to carried out the human clinical phase examinations, chemical
qualification of capsaicin(oids) in the plasma in treated animals and human healthy subjects);
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drugs) in human healthy subjects and in patients treated with different anti-inflammatory
drugs.




The biological regulation of living organ is very complex process, including the efferent nerves
as well as afferent nerves as recently discovered. These regulatory processes influence main
cellular physiological mechanisms. Of course, for the understanding these mechanisms we
have to learn the principal physiological laws at the level of cells (including the classical
physiology, biochemistry and in different pathological circumstances) (Mozsik, 2006).
The primary aim of pharmacology is to give different biological or chemical substances, which
are able to modify cell functions under normal and pathological conditions (Mózsik et al., 1997;
Mózsik, 2006). The field of pharmacology changed significantly nowdays by the application
of various research trends (chemical synthesis of new drugs, drugs of plant origin, molecular
biology plus immunology, etc).
We deal briefly in this paper with the interdisciplinary challenges in new drug (and drug
combinations) production of plant origin capsaicin (alone or in combination with NSAIDs)
modulating (used in doses, which have stimulatory actions on the capsaicin-sensitive afferent
nerves) pharmacologically the afferent nerves in the gastrointestinal (GI) tract. From that point
of views we carefully and critically evaluated the correlations between the plant origin
capsaicinoids, NSAIDs with GI mucosal damage and preventions in animals and human
healthy beings (Abdel Salam et al., 1994; 1995a,b,c,e,f,g; 1996a,b; 1997a,b,c,d; 1999; 2001; 2006 ;
Mózsik et al., 1999; 2006 a,b; 2005; 2007).
3. Main problems of pharmacological treatment in patient with different
diseases
The patients with myocardial infarction, thromboembolic episodes, stroke of central nervous
system, cancers and persons who have to be treat as preventions of different diseases (rein‐
farction after myocardial infarction, prevention of thromboembolic episodes produced by
atrial fibrillation, cancers, after different surgical intervention and immobilization) and in
healthy subjects treated with NSAIDs in order to prevent the development of colorectal
cancers. The number of these groups of patients reaches to 50-60 per cent of total population
in Hungary.
The majority of patients who underwent cardiac and other surgeries are treated permanently
with aspirin (in dose of 100 mg/day/person). This is a basic stand-point of the different
consensus meetings of Europe and of the World (Megettigan et al., 2006; Patrono et al., 2004;
Todd and Clisson, 1990).
The administration of aspirin in absolutely indicated from medical points of view in patients
mentioned above, accepting the opinion of cardiologists; however, we have to emphasize that
the aspirin very frequently produces GI bleeding (which do not favour gastroenterologists).
Really, there is a great and principal question from the general medical practice (and of
research), namely whether all patient can be taken as the same, in whom the medical science
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should offer medical treatment from the point of cardiology, which produces severe GI
disorders (bleedings, peptic ulcer). Consequently there is a contradictory medical (and
evidence-based proved) standpoint between the cardiologists vs. gastroenterologists (during
the treatment of one patient, and as well as in the treatment of populations of patients
mentioned above).
Another big population of patients suffers from different degenerative joint diseases, trauma
or from acute and chronic pain. These patients have to receive permanent treatment with
NSAIDs. The NSAIDs are not GI protective agents neither in healthy person and nor in patients
with these disorders. Large portion of patients appearing on gastrointestinal wards suffer from
the drug-induced side effects.
Patients with NSAIDs-induced gastrointestinal disorders (blood losing, bleeding, peptic ulcer)
represent a significant number of populations. Furthermore, these patients have to treat
permanently by different NSAIDs.
The actions of NSAIDs are associated with the selective and non-selective inhibitory properties
on cyclooxygenase system (emphasizing the key role of COX-1 and COX-2). Aspirin is a
specific COX-1 inhibitor; meanwhile other NSAIDs applied in the clinical practice represent
the compounds acting as non-selective COX-1 and COX-2 inhibitors. Recently, the specifically
acting compounds, inhibiting COX-2 enzyme, have been produced to reduce gastric mucosal
damage, however, the number of myocardial infarction was increase in such patients (Meget‐
tigan et al., 2006; Patrono et al., 2004; Tood and Clissold, 1990; Couzin 2004a,b; Lenzer, 2004).
We have to emphasize clearly, that the small doses of capsaicin are able to prevent gastric
mucosal bleeding induced by NSAIDs (both COX-1, COX-2 inhibitors). It is true that COX-2
inhibitors produce smaller side effects in GI tract of patients; however these compounds have
no inhibitory properties on the thrombocyte aggregation. When the patient with angina
pectoris and degenerative joint disease received only COX 2 inhibitors, than the number of
patients with myocardial infarctions and of cardiac origin death increased significantly
(“Vioxx story“) (Couzin, 2004a,b ; Lenzer, 2004; Green, 2005; Lawler, 2005; Tanne, 2006a,b,c).
Recently, the European and American Consensus Meetings uniformly accepted the salicylate
application in about dose of 100 mg/day and of 300 mg/day in cumarine resistant patient
(Megettigan et al., 2006; Patrono et al., 2004).
Our aim was to product a capsaicin containing drug or drug combinations with a NSAID for
the treatment of above mentioned groups of patients hoping that application of these com‐
pounds will be able to prevent the NSAIDs induced GI side effects in patients (Mózsik et al.,
2009a,b, 2010; Szabo et al., 2013).
4. Experts’ opinion up to 2008
We successfully applied funding for innovative academic pharmacological and pharmaceut‐
ical industrial research to the National Office for Research and Technology (Hungary) in 2005
(Regional University Science Centre Pécs, Hungary, MEDIPOLISZ, Pázmány Péter Pro‐
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gramme RET-II, 08/2005) for time period of 2006-2008, and later on BAROS GÁBOR Pro‐
gramme, Hungary (REG_DKI_O,CAPSATAB) for time period of 2010-2011.
The aims of these research programmes (in these time periods) were to produce new capsai‐
cin(oids) drug alone and in different combinations for patients with different gastrointestinal
disorders, for patients with myocardial infarctions (orally applicable combinations of capsai‐
cin(oids) with aspirin) and for those with chronic degenerative locomotive diseases (orally
applicable capsaicin(oids) with diclofenac and Naproxen).
Twenty-one researchers (chemist, pharmaceutical chemist, physicians, clinical pharmacolo‐
gists, pharmaceutics, laboratory experts, biologists, engineers and agricultural engineers) have
participated in this innovative pharmacological and pharmaceutical research.
The capsaicin(oids) are well-known species, which are able to modify the action of capsacin-
sensitive afferent nerves. Their actions are dose-depependent, and they are capable to modify
the neurogenic inflammantion, pain, and the defence of the various target organs against
different noxious agents.
The research of capsaicin is a traditional and internationally well accepted research line at Pécs
University, Hungary (Department of Pharmacology and Pharmacotherapy, First Department
of Medicine in a well successful cooperation) in the 50 years period. We arrived to the
production of orally given capsaicin(oids) new drug and capsaicin(oids) plus nonsteroidal
anti-inflammatory drugs in the time of our innovative pharmacological and pharmaceutical
research in the 2005.
The production of new drug or different drug combinations represented an interdisciplinary
challenge for all of us (which significantly differed from the traditional basic and clinical
research).
The first step of our common work was to write an interdisciplinary experts’ opinion based
on the most important research data from the capsaicin research to be used for the new drug
production, for receiving different permissions from the different authoritities to start with the
classical clinical pharmacological studies.
The experts’s opinion was prepared (Mózsik et al., 2007b), and this material was published in
Inflammopharmacology (Mózsik et al., 17:113-150, 2009a). This part of book chapter deals with
these experts’ opinion (subchapter of 3). The authors summarized their obtained significantly
different results in these studies from the years of 2005 to 2008 (Mózsik et al., 2009b).
4.1. Brief introduction
Capsaicin is an active ingredient of red pepper and paprika. These plants have been well
known in about 9500 years, and these have been applying in the every day of the culinary
practice.
It was an important discovery that the capsaicin (capsaicin, dihydrocapsaicin, nordihydro‐
capsaicin and other capsaicinoids) specifically modify the function of capsaicin sensitive
afferent nerves (Jancsó et al., 1967; 1968; 1970).
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The  action  of  capsaicin  on  the  capsaicin  sensitive  afferent  nerves  is  dose  dependent
(Szolcsányi and Barthó, 1981; Szolcsányi, 1984, 1997, 2004; Abdel-Salam et al., 1999; 2001;
Mózsik et al., 2001). Szolcsányi indicated four different stages of capsaicin action (depend‐
ing on the dose and duration of the exposure of the compound): a. excitation (stage 1); b.
sensory blocking effect (stage 2); c. long-term selective neurotoxin impairment (stage 3) and
d. irreversible cell destruction (stage 4) (Szolcsányi, 1984). The stages 1 and 2 are reversi‐
ble;  meanwhile  the  stages  3  and  4  are  irreversible  compound-induced  actions  on  the
capsaicin sensitive afferent nerve. These stages of capsaicin actions can be detected in the
gastrointestinal tract (Mózsik et al., 2001).
Capsaicin activates the capsaicin (vanilloid) receptor expressed by a subgroup of primary
afferent nociceptive neurons (Szolcsányi, 2004). The capsaicin receptor had been cloned
(Caterina et al., 1997) and turned out to be a cation channel. It is gated besides capsaicin and
other capsaicinoids (some vanilloids) by low pH, noxius heat and various pain-producing
endogenous and exogenous chemicals. Thus, these sensory nerve endings equipped with these
ion channels are prone to be stimulated in gastric mucosa.
The vagal nerve has a key role in the development of gastrointestinal mucosal damage and
prevention (Mózsik et al., 1982). The key role of vagal nerve has been emphasized dominantly
in the aggressive processes to gastrointestinal mucosa (such as peptic ulcer disease, gastric
mucosal damage, etc.) both in the GI research of animal models and as well as in human clinical
practice. The “chemical“ and “ surgical“ vagotomy widely used in the treatment of patients
with peptic ulcer disease in the years up to middle of 1970s (Karádi, Mózsik, 2000). By the other
words, the primary aims of this therapy were to decrease the activity of vagal nerve at the level
of efferent vagal nerve.
The application of capsaicin in the animals experiments was used as a specific tool to approach
to the group of primary afferent nociceptive neurones (Szolcsányi, 2004; Buck and Burks,
1986; Holzer, 1998; 1991; Szállasi and Blumberg, 1999) involved in the different physiological
and pathological processes.
Szolcsányi and Barthó (1981) were the firsts, who clearly indicated the beneficial and harmful
effect of capsaicin in the peptic ulcer disease in rats, on dependence of applied doses of
capsaicin. Later on, Holzer started with a very extensive research work with capsaicin in the
field of Gastroenterology (Holzer, 1998; 1999; Buck and Burks, 1986; Szállasi and Blumberg,
1999). We also participated in the GI capsaicin research in animals experiments from 1980
(Mózsik et al., 1997). Recently, the new drug, Lafutidine, was processed in the medical
treatment of GI mucosal damage (Ajioka et al., 2000; 2002; Onodera et al., 1999; 2002; Takeuchi,
2006). The Lafutidine is a H2R blocking compound together with typical capsaicin actions at
the target organ.
The new and interesting results obtained with capsaicin application in animal experiments
offered an excellent tool to approach the different events of human GI physiology, pathology
and pharmacology. Our clinical studies with capsaicin have been started from 1997 (Mózsik
et al., 1999; Debreceni et al., 1999; Mózsik et al., 2004a; 2004b; 2005).
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The aim of this  paper is  given a short  summary on the possibility of  capsaicin applica‐
tion as a new tool to understand the various steps of human physiology, pathology and
pharmacology.
4.2. Physiological and pharmacological research tool by capsaicin
4.2.1. The chemistry of capsaicinoids
4.2.1.1. Chemical composition of Natural Capsaicin
The degree of pungency (heat or bite) of the Capsicum fruits is determined by the amount of
compounds called capsaicinoids. These substances are responsible to produce the character‐
istic sensations associated with injestion of spicy cuisine as well as responsible for causing
severe irritation, inflammation, erythema, and transient hypo-and hyperalgesia at sites
exposed to capsaicinoids.
All capsaicinoids posses a 3-hydroxy-4-methoxy-benzylamide (vanilloid) pharmacophore, but
differ in their hydrophobic alkyl side chain. Differences in the side chain moiety include
saturation of the carbon carbon double bond, deletion of a methyl group and changes in the
lenght of the hydrocarbon chain (Figure 1). Previous structure-activity studies using models
for the study of acut pain and altered pain sensitivity in mice have demonstrated a strict
structural requiremenet for both the vanilloid pharmacophore and a hydrophobic alkyl chain
that may be saturted or unsaturated, branched or unbranched, and consisting of 8 to 12 carbon
atoms for optimal binding and activation of the capsaicin receptor, TRPV1 (Bevan and
Szolcsányi, 1990; Walpole et al., 1993a,b,c).
It is worth mentioning that there are some contradictions in meaning of the term “capsai‐
cin“ in different sources of literature. On one hand, the term capsaicin refers to one chemical
entity: (E)-8-Methyl-N-vanillyl-6-nonenamide (CAS-number: 404-86-4). On the other hand,
the term capsaicin is frequently used for Capsicum extracts containing capsaicin and related
capsaicinoids (e.g.,  see Capsaicin USP 29).  These latter preparations are frequently refer‐
red to as Natural Capsaicin. In addition to the natural capsaicin preparations, capsaicin can
be obtained by synthesis  as  well.  The synthesized capsaicin  is  frequently  referred to  as
trans-capsaicin, since during the syntheses not only the natural trans but the cis isomer can
also be obtained.
The two main components of Natural Capsaicin (a mixture of capsaicinoids of Capsicum
origin) are capsaicin and dihydrocapsaicin. There are, however, other structurally related
alkyl  vanillylamides  (capsaicinoids)  generally  found  in  smaller  amounts  in  Capsicum
extracts. The names and structures of the main components of Natural Capsaicin are shown
below (Figure 1).
Separation and quantitation of the components can be performed by gas chromatography (GC)
or liquid chromatography (HPLC). The GC and HPLC chromatograms of Natural Capsaicin
(Capsaicin USP 29) are shown on Figures 2 and 3, respectively.
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The aim of this  paper is  given a short  summary on the possibility of  capsaicin applica‐
tion as a new tool to understand the various steps of human physiology, pathology and
pharmacology.
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Figure 2. Gas-Chromatographic (GC-FID) analysis of capsaicin and dihydrocapsaicin of a Natural Capsaicin sample.
(Identification of the components was performed by GC-MS method.) (Kuzma M. et al., unpublished results)


























Figure 3. High Pressure Liquid Chromatography (HPLC-DAD) chromatogram of a Natural Capsaicin sample. (Retention
times: Capsaicin tR=10.29 min, DihydrocapsaicintR=15.59 min. Identification of the components was performed by
means of the respective USP standards.) (Kuzma M. et al., unpublished results)
4.2.1.2. Capsaicin USP 29




Capsaicin contains not less than 90.0 percent and not more than 110.0 percent of the labeled
percentage of total capsaicinoids. The content of capsaicin (C18H27NO3) is not less than 55
percent, and the sum of the contents of capsaicin and dihydrocapsaicin (C18H29NO3) is not less
than 75 percent, and the content of other capsaicinoids is not more than 15 percent, all
calculated on the dried basis.
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Packaging and storage: Preserve in tight containers, protected from light, and store in a cool
place.
Caution: Handle Capsaicin with care. Prevent inhalation of particles of it and prevent its
contact with any part of the body.
Solubility: It does not dissolve in water. It well dissolves in alcohols (methanol, ethanol 96%),
ethylacetate and acetonitrile.
Identification: Prepare a test solution of Capsaicin in methanol containing 1 mg/mL. Prepare
a Standard solution of USP Capsaicin RS in methanol containing 1 mg/mL. Separately apply
10-µL portions of the test solution and the Standard solution to a thin-layer chromatographic
plate coated with a 0.25-mm layer of chromatographic silica gel mixture.
Develop the chromatograms in a solvent system consisting of a mixture of ether and methanol
(19:1) until the solvent front has moved about three-fourths of the length of the plate. Remove
the plate from the chamber, and allow it to air-dry. Spray the plate with a 0.5% solution of 2,6-
dibromoquinone-chlorimide in methanol, allow to stand in a chamber containing ammonia
fumes, and examine the chromatograms: the blue color and the Rf value of the principal spot
obtained from the test solution correspond to those properties of the principal spot obtained
from the Standard solution.
Melting range: between 57° and 66°, but the range between beginning and end of melting does
not exceed 5°.
Loss on drying: Dry it in vacuum over phosphorus pentoxide at 40° for 5 hours: it loses not
more than 1.0% of its weight.
Residue on ignition: not more than 1.0%.
4.2.1.3. Stability of capsaicinoids
Stability of capsaicin and dihydrocapsaicin are different according to the respective MDSD
documents: The recommended storage temperature of capsaicin and dihydrocapsaicin are 2-8
oC and-20 oC, respectively. According to the MDSD sheet, the Sigma-Aldrich Capsaicin natural
(pruduct number 21750, CAS number: 404-86-4) ((~65 % capsaicin) should be stored at 2-8 oC.
Literature data only to capsaicin chemistry:
Kopec et al. tested the stability of 100 % ethanol solution of capsaicin of different concen‐
trations. It was found that the solutions of 4 mM or more concentrated solutions protect‐
ed from light and stored at 4 ºC have been proved to be stable for a period of 12 months
(Kopec et al., 2002).
While  investigating  stability  of  a  capsaicin  containing  ointment  Jaiarj  et  al.  found  the
preparation to show higher stability stored at 4 °C other than at ambient temperature (Jaiarj
et al., 2000).
Schweiggert et al. investigated stability of chilli powder. They found that the capsaicin,
dihydrocapsaicin and nordihydrocapsaicin content of the samples dropped by 6-11 %. Based
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on their experience it was recommended that paprika (pepper) samples should be heat-treated
before processing, in order to reduce the number of microorganisms producing enzymes with
peroxidase activity (Schweiggert et al., 2006).
Conclusions: The presence of phenolic hydroxyl gruop and that of the carbon carbon double
bond makes capsaicinoids sensitive to oxidation. Accordingly, natural capsaicin should be
protected from exposure to light, heat, moisture, and oxidizing agents, wich initiate and/or
catalyse the decomposition processes.
4.2.2. Capsaicin as a pharmacological tool in research
The term Capsicum refers to the fruit of numerous species of the solanaceous genus Capsicum.
The genus name Capsicum is either derived from Greek “Kapso“ meaning to bite, referring to
its purgency or from the Latin “Capso“ or box referring to the fruit pod. Members of the genus
vary widely in size, shape, flavor, and much more importantly in purgency. Red hot peppers,
also called chilies, paprika, and sweet non-purgent peppers are consumed widely by humans
(Maga, 1975; Rozin, 1990, Mózsik et al., 2007). Capsaicin (8-methyl-N-vanillyl-6-nonenamide)
is the major purgent ingredient of hot peppers.
4.2.3. Selective sensory effects of capsaicin
Apart from being used as a food additive, the compound has wide important pharmacological
actions. Capsaicin uniquely selective for mammalian small afferent neurons of dorsal root
ganglia C and Aδ fibers, a property which led to its use to investigate the role of these afferent
fibres in a number of physiological processes (Jancsó and Jancsó-Gábor, 1959; Szolcsányi,
1982; 1984). In the skin the polymodal sensory receptors, chemoreceptors and warm receptors
are affected by capsaicin (Szolcsanyi, 1977; 1982; 1993; 1996; Szolcsányi et al., 1994; Bevan and
Szolcsányi, 1990; Holzer, 1990; 1991a, 1992 a; 1992 b). Most of these afferents contain substance
P (SP) and /or calcitonin gene-related peptide (CGRP) (Holzer, 1991a; 1991 b; Maggi, 1995).
The action of capsaicin expresses itself as an initial short-lasting stimulation that can be
followed by desensibilization to capsaicin itself and to other stimuli of afferent sensory
neurons. Capsaicin in ng – µg/kg doses applied to the peripheral or central endings or cell
bodies of sensory neurons induces transient excitation of these sensory neurons. In response
to stimulation peptide mediators are released from the central and peripheral nerve endings
(Szolcsányi, 1984; 1996; Holzer, 1998; 1991a; Maggi, 1995).
In the periphery neuropeptide release exerts local neuroregulatory tissue responses (Szolcsá‐
nyi, 1984; 1991; 1996). Neuropeptides are stored in sensory vehicles (Gulbekian et al., 1986;
Merighi et al., 1988) and are released on stimulation with capsaicin by a Ca2+-dependent
manner (Maggi et al., 1989). In this way the peripheral terminals of capsaicin sensitive nerves
are not only sensory receptors for conveying impulses in the afferent direction but also effector
sites from where mediators are released for neurotransmission (Szolcsányi, 1984; 1996). With
large doses (mg /kg) there is an initial stimulation, the duration of which is not yet defined,
followed by sensory desensitization (Szolcsányi, 1984; 1993).
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Four response stages of the capsaicin-sensitive primary afferents to capsaicin have been
introduced by Szolcsányi (Szolcsányi, 1984; 1985) depending on the dose and duration of
exposure to the drug. These are excitation, sensory blocking effect, long-term selective
neurotoxic impairment and irreversible cell destruction.
4.2.4. Mechanism of action of capsaicin on sensory receptors
To explain the mechanism of these sensory effects of capsaicin it has been hypothetized that
in the polymodal nociceptive primary afferent neurons a capsaicin-gated cation channel exists
which operates at the peripheral receptive terminals as at the level cell body. Capsaicin exerts
its excitatory effect by activation of this cation channel which is permeable to a wide range of
cations as Na+, K+and Ca2+, but not to anions as Cl-(Winter, 1987; Wood et al., 1988). The influx
of Na+and Ca2+induces membrane depolarization which at a certain level, opens tetrotodotox‐
in-sensitive fast sodium channels at the regenerative region of the sensory receptor and in this
way triggers nerve terminal spike and direct stimulation of transmitter release by Ca2+.
Opening of the capsaicin-gated cation channel for shorter or longer periods of time triggers a
chain of intracellular events (Bevan and Szolcsányi, 1990). Functional blockage with reversible
intracellular molecular changes (stage 2) or neurotoxic degeneration (stages 3 and 4) develop
depending on the concentration and the contact time at the site of action on different parts
(receptor, axon, cell body, central terminal) of the capsaicin-sensitive primary afferent
neurones (Mózsik et al., 2001). Prolonged stimulation and consequently prolonged opening of
this cation channel results in osmotic swelling due to intracellular NaCl accumulation together
with intracellular accumulation of Ca2+at the exposed sites of the nerve terminal which will
activates Ca2+-dependent enzymes and impairs mitochondrial functions (Bevan and Szolcsá‐
nyi, 1990; Chard et al., 1995). Prolonged activation of Ca2+is therefore the first step in sequence
of events ultimately leading to cell death.
In mammals, the long-lasting sensory blocking or neurotoxic effects of capsaicin on primary
afferent neurones have been described following topical, perioxonal, or systemic pretreatment
in adults or neonates. Autonomic efferent neural mechanisms are not affected by drug (Maggi
and Meli, 1988; Szolcsányi, 1982; Holzer, 1991a). This selective sensory blocking effect of
capsaicin has been used as an experimental tool for the elimination of the capsaicin-sensitive
subset of primary afferent neurones and consequently for identifying those tissue responses
that are mediated by capsaicin-sensitive afferent (Szolcsányi, 1996; Mózsik et al. 1997c). The
later tissue responses being absent in sensory desensitized animals.
4.2.5. Capsaicin actions of the gastrointestinal tract in animals
In their experiments, Makara et al. (1965) found that intragastric capsaicin (1 mg/0.5 ml volume/
rat) enhanced the development of Shay ulcer at 12 hours. After four consecutive daily doses
of reserpine (1.0 mg/kg, sc.), the above dose of capsaicin given simultaneously enhanced gastric
ulceration by the latter. On the other hand, daily administration of paprika oil containing 1.0
mg/kg of capsaicin tended to accelerate rather than retard the healing process of reserpine-
induced gastric ulcer in rats.
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This  was  attributed  by  the  authors  to  the  capsaicin-induced  local  hyperaemia  or  the
carotenoids and other pigments present in paprika oil. When Lee (1963) kept rabbits for 12
months on various diets (high fat,high carbohydrate or high protein) supplemented with
large  doses  of  ground hot  pepper,  ulcers  developed in  the  stomach of  all  animals  and
cirrhosis  of  the  liver  occurred in  animals  fed with  either  high fat  or  high carbohydrate
supplemented with capsaicin.
In the study of Nopanitaya (1974), the effect of capsaicin (1.0 mg/kg) and its combination with
various diets on the morphology of duodenal mucosa of young rats was investigated for period
of 28 and 56 days. The author reported ultrastructural alterations in the mitochondria of the
absorptive cells of rats fed with low protein diet and also those supplemented with capsaicin.
The changes, however, were less pronounced at the 56th day than at 28th day, indicating some
sort of adaptation to capsaicin.
It was not known until 1981, that Szolcsányi and Barthó proved, namely that capsaicin protects
against experimental gastric ulcer. Introduction of capsaicin into the stomach of pylorus-
ligated rats (Shay)-rats in small doses (5 to 50 µg) and low concentration (10 µg/ mL) markedly
reduced the ulcer formation at 18 hours later. On the other hand, acute gastric ulceration
induced by pylorus-ligation (Shay-ulcer) or acid distension was aggravated in rats desensi‐
tized 2 weeks earlier with systematic capsaicin in high doses which selectively impairs
capsaicin sensitive sensory nerves.
In capsaicin desensitized rats the aggressive side of the balance remained apparently un‐
changed since hypersecretion of the pylorus-ligated rats did not differ from that of the controls
with respect to volume, H+and pepsin concentration. This suggested that it is the gastric
defense mechanism which was impaired in capsaicin desensitized rats. As a result of these
data a role of capsaicin sensitive afferents in modulating gastric mucosal defenses was
forwarded by the authors. In explaining the nature of this novel gastroprotective action of low
dose capsaicin, it was postulated that intragastric capsaicin exerts opposite effects on gastric
ulcer formation depending on the concentration in which it is introduced into the gastric
lumen. Low concentrations trend to inhibit the development of ulceration and high concen‐
trations promote ulcer formation. Release of vasodilator mediators from capsaicin-sensitive
sensory nerve endings with the consequent enhancement of the microcirculation was proposed
as the mechanism responsible for the mucosal protective effects on intragastrically adminis‐
tered capsaicin in low concentrations.
These mechanisms suggested a resistance or defense mechanism against ulcer formation
working under physiological conditions. In capsaicin desensitized rats, mucosal sensory
receptors will be unresponsive to stimuli, and consequently no release of vascular dilator
mediators will take place upon challenge with noxious agents. As a result gastric ulcer will be
aggravated (Szolcsányi and Barthó, 1981).
These  observations  and  the  drawn  conclusions  were  confirmed  by  other  investigators.
Intragastric application of capsaicin in small doses has been shown to protect rat gastric
mucosa  against  experimental  ulcerations  induced  by  ethanol  (Holzer  and  Lippe,  1988;
Esplugues and Whittle, 1989), acidified aspirin (Holzer et al., 1989) and indomethacin (Gray
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et al., 1994). Furthermore, after desensitization rats exhibited more severe gastric mucosal
damage than their sensory intact controls in response to chemical challenge with ethanol
(Holzer and Lippe, 1988; Lippe et al., 1989; Esplugues and Whittle, 1990; Esplugues et al.,
1992; Pabes et al., 1993), cysteamine (Holzer and Samettz, 1986; Gray et al., 1994), platelet
activating factor (Esplugues et al., 1989; Pique et al., 1990) and endothelin-1 (Whittle and
Lopez-Belmonte, 1991).
Capsaicin desensitation performed 6 days prior to cold restraint stress, however, was reported
to have a little effect on gastric ulcer formation. Only the number of lesions was higher in
capsaicin treated rats restrained for 3 hours (Dugani and Glavin, 1986). Acute intragastric
capsaicin (40 mg/kg) followed immediately by stress resulted in significantly more frequent
and more severe ulceration (Dugani and Glavin, 1985). Cysteamine-induced duodenal ulcers
(Holzer and Sametz, 1986) and gastric mucosal damage evoked by 0.6 M HCl (Takeuchi et al.,
1994) were not changed after capsaicin desensitization.
Studies have shown that gastric mucosal barrier disruption is accompanied with an increase
of gastric mucosal blood flow (GMBF), which appears to be triggered by H+rediffused through
the breached mucosal defenses (Bruggeman et al., 1979; Starlinger et al., 1981a). Such an
increase in GMBF is through to be a defense mechanism, whereby the increased blood flow
prevents the accumulation of injurious concentration of H+in the submucosa. Capsaicin-
sensitive nerves which are unduly sensitive to H+(Bevan and Yeats, 1991) have been shown to
respond to H+back-diffused through breached mucosal defenses and to signal for an increase
in gastric mucosal blood flow (Holzer et al., 1991b). This further strengthened the role of these
nerves in maintaining mucosal integrity. Holzer el al. (1991a, b) postulated that the acid-
induced mucosal hyperaemia results from local axon reflex between collaterals of afferent
nerve fibres within the gastric wall. Li et al. (1992) found that gastric mucosal hyperaemia in
response to perfusion of the rat stomach with 0.15 M HCl in 15 v/v ethanol to be completely
blocked by close arterial infusion of a hCGRP receptor antagonist.
Lippe and Holzer (1992) reported in rats that, N-nitro-L-arginine methyl ester (L-NANE) (an
inhibitor of endothelium derived nitric oxide formation) depressed the increase in GMBF
produced by gastric perfusion with ethanol diluted in 0.15 M HCl The loss of H+from the lumen
under these circumstances was also markedly enhanced by L-NAME. Considerable contro‐
versy still exists in the literature in regards to the mediators of the hyperaemic response to
back-diffusion of acid (Whittle, 1977; Ritchie, 1991; Gislason et al., 1995).
The involvement of capsaicin-sensitive sensory nerves in repair mechanisms of the injured
mucosa have also been investigated. In anaesthetized rats, 180 min after exposure to 50 v/v
ethanol, rapid repair of the injured mucosa (assessed by reduction of deep mucosal damage
and partial reepitheliazition of the denuted surface) was reported to be similar in sensory
denervated and sensory intact groups. This suggested that nociceptive neurones control
mechanisms of defense against acute gastric mucosal injury, but they are not required for the
rapid repair of the injured mucosa (Pabst et al., 1993). On contrary, sensory differention
delayed healing of gastric ulcers provoked in rats by 0.6 M HCl.
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This  was  attributed  by  the  authors  to  the  capsaicin-induced  local  hyperaemia  or  the
carotenoids and other pigments present in paprika oil. When Lee (1963) kept rabbits for 12
months on various diets (high fat,high carbohydrate or high protein) supplemented with
large  doses  of  ground hot  pepper,  ulcers  developed in  the  stomach of  all  animals  and
cirrhosis  of  the  liver  occurred in  animals  fed with  either  high fat  or  high carbohydrate
supplemented with capsaicin.
In the study of Nopanitaya (1974), the effect of capsaicin (1.0 mg/kg) and its combination with
various diets on the morphology of duodenal mucosa of young rats was investigated for period
of 28 and 56 days. The author reported ultrastructural alterations in the mitochondria of the
absorptive cells of rats fed with low protein diet and also those supplemented with capsaicin.
The changes, however, were less pronounced at the 56th day than at 28th day, indicating some
sort of adaptation to capsaicin.
It was not known until 1981, that Szolcsányi and Barthó proved, namely that capsaicin protects
against experimental gastric ulcer. Introduction of capsaicin into the stomach of pylorus-
ligated rats (Shay)-rats in small doses (5 to 50 µg) and low concentration (10 µg/ mL) markedly
reduced the ulcer formation at 18 hours later. On the other hand, acute gastric ulceration
induced by pylorus-ligation (Shay-ulcer) or acid distension was aggravated in rats desensi‐
tized 2 weeks earlier with systematic capsaicin in high doses which selectively impairs
capsaicin sensitive sensory nerves.
In capsaicin desensitized rats the aggressive side of the balance remained apparently un‐
changed since hypersecretion of the pylorus-ligated rats did not differ from that of the controls
with respect to volume, H+and pepsin concentration. This suggested that it is the gastric
defense mechanism which was impaired in capsaicin desensitized rats. As a result of these
data a role of capsaicin sensitive afferents in modulating gastric mucosal defenses was
forwarded by the authors. In explaining the nature of this novel gastroprotective action of low
dose capsaicin, it was postulated that intragastric capsaicin exerts opposite effects on gastric
ulcer formation depending on the concentration in which it is introduced into the gastric
lumen. Low concentrations trend to inhibit the development of ulceration and high concen‐
trations promote ulcer formation. Release of vasodilator mediators from capsaicin-sensitive
sensory nerve endings with the consequent enhancement of the microcirculation was proposed
as the mechanism responsible for the mucosal protective effects on intragastrically adminis‐
tered capsaicin in low concentrations.
These mechanisms suggested a resistance or defense mechanism against ulcer formation
working under physiological conditions. In capsaicin desensitized rats, mucosal sensory
receptors will be unresponsive to stimuli, and consequently no release of vascular dilator
mediators will take place upon challenge with noxious agents. As a result gastric ulcer will be
aggravated (Szolcsányi and Barthó, 1981).
These  observations  and  the  drawn  conclusions  were  confirmed  by  other  investigators.
Intragastric application of capsaicin in small doses has been shown to protect rat gastric
mucosa  against  experimental  ulcerations  induced  by  ethanol  (Holzer  and  Lippe,  1988;
Esplugues and Whittle, 1989), acidified aspirin (Holzer et al., 1989) and indomethacin (Gray
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et al., 1994). Furthermore, after desensitization rats exhibited more severe gastric mucosal
damage than their sensory intact controls in response to chemical challenge with ethanol
(Holzer and Lippe, 1988; Lippe et al., 1989; Esplugues and Whittle, 1990; Esplugues et al.,
1992; Pabes et al., 1993), cysteamine (Holzer and Samettz, 1986; Gray et al., 1994), platelet
activating factor (Esplugues et al., 1989; Pique et al., 1990) and endothelin-1 (Whittle and
Lopez-Belmonte, 1991).
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versy still exists in the literature in regards to the mediators of the hyperaemic response to
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The involvement of capsaicin-sensitive sensory nerves in repair mechanisms of the injured
mucosa have also been investigated. In anaesthetized rats, 180 min after exposure to 50 v/v
ethanol, rapid repair of the injured mucosa (assessed by reduction of deep mucosal damage
and partial reepitheliazition of the denuted surface) was reported to be similar in sensory
denervated and sensory intact groups. This suggested that nociceptive neurones control
mechanisms of defense against acute gastric mucosal injury, but they are not required for the
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In addition capsaicin-desensitized not sensory intact animals showed no hyperaemic respons‐
es in response to intragastric instillation of 50 mM HCl. The conclusion was that capsaicin-
sensitive sensory nerves contribute to healing of gastric ulcer (lesions) by mediating the
hyperaemic responses associated with acid back-diffusion following injury (Takeuchi et al.,
1994). Similarly sensory denervated rats showed marked increased area of acetic acid-induced
ulceration at 1 and 2 weeks following the acetic acid injection indicating that the sensory
function adversely affected the healing of gastric ulcer (Tramontana et al., 1994).
Capsaicin exerts protective effects on the chemical-induced mucosal injury not only in the
stomach, but also in the colon. Evangelista and Meli (1989) found that systemic capsaicin
neonatal pretreatment enhanced trinitrobenzene sulfonic acid-induced colitis (one week) in
rats. This pretreatment, however, had no acute affect (24 hours) on colitis caused by trinitro‐
benzene sulfonic acid, ethanol or acetic acid.
Reinshagen et al. (1994) employed systemic capsaicin pretreatment as a tool to investigate the
role of sensory nerves in an immune-complex model of colitis in rabbits. They found that
capsaicin pretreatment per se caused no histological inflammation. Meanwhile, colitis was
more severe in sensory denervated state than in sensory intact rabbits. The increase in ulcer
index and neutrophyl infiltration was more marked in the capsaicin pretreated control group
at both 48 and 96 hours.
The difference in neutrophyl infiltration between the two groups was, however, more marked
at 48 than at 96 hours (Reinshagen et al., 1994). Endoh and Leung (1990) reported that topical
capsaicin application protected against acetic acid-induced colitis. In the trinitrobenzene
sulfonic acid-induced colitis rat model, however, only partial and transient protective effect
was seen by Goso et al. (1993) after topical capsaicin administration. Co-administration of 640
µM capsaicin reduced the ulcerative area from 91% to 64% only when colon was examined l
hour later. An approximatically 8 fold higher dose of capsaicin (5000 µM) yielded similar
protection, while 100 µM had no protective effect. No protection by capsaicin was however
seen when the colon was examined 24 hours after noxious challenge.
4.2.6. Capsaicin-sensitive sensory nerves and gastric acid secretion
Several studies in rats have indicated the involvement of capsaicin-sensitive sensory nerves in
the regulation of gastric acid secretion; however, contradictory data were reported. In most
studies, the indirect approach through functional ablation of capsaicin-sensitive afferent
nerves with systemic neonatal (Evangelista et al., 1989; Esplugues et al., 1990), adult (Alföldi
et al., 1986; 1987; Dugani and Glavin, 1986; Robert et al., 1991) or peripheral capsaicin
(Raybould and Taché, 1989) treatment was used as a tool to investigate the role of capsaicin-
sensitive afferent nerves in the regulation of gastric acid secretion.
Adult rats treated with systemic capsaicin (60 mg/kg, sc.) showed depressed pentagastrin-
stimulated gastric acid secretion (Dugani and Glavin, 1986). On the contrary, adult systemic
capsaicin pretreatment with 300 mg/kg sc. did not modify gastric acid secretion elicited by
pentagastrin, carbachol or by small dose of histamine (0.1 mg/kg). However, the gastric acid
secretory response to 0.5 and 5.0 mg/kg histamine was greatly reduced in capsaicin desensi‐
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside280
tized rats. It was suggested that the histamine-induced increase in gastric acid secretion
involves a capsaicin-sensitive mechanism, while these mechanisms are not required for
pentagastrin or cholinergic stimulation of gastric acid secretion (Alföldi et al., 1986; 1987).
Similar data were reported by Raybould and Taché (1989) using topical capsaicin application
into the cervical vagus. The gastric acid secretory response to distension (5 ml for 6 min) was
reduced in capsaicin-treated rats. This mechanism by which capsaicin-sensitive vagal afferent
fibres play a role in the secretory response to histamine was explained by histamine acting in
part by increasing vagal C-fibres discharge resulting in a vago-vagal reflex increase in gastric
acid secretion or by that histamine stimulates vagal afferent C-fibres resulting the release of
peptides from sensory nerves terminals.
A peptide increasing gastric acid secretion and would be localized in vagal afferent nerves has
not been identified. In contrast that adult rats treated with systemic capsaicin (300 mg/kg, sc.)
at neonate age did not show any reduction in their gastric acid secretory to histamine,
pentagastrin or carbachol, while acid secretion in response to distension was abolished. On
the other hand, capsaicin desensitation (neonatal treatment) substantially reduced the gastric
acid secretion to 2-deoxy-D-glucose (Evangelista et al., 1989), while it did not modify when
stimulated by insulin (Esplugues et al., 1990).
The conflicting observations regarding the effect of capsaicin continue to be seen when it
was  given  into  the  stomach.  It  was  reported  that  intraduodenal  (but  not  intragastric)
instillation of capsaicin (1.0 mg in 2 ml saline solution) in pylorus-ligated rats induced a
significant rise in total acidity 12 hours later (Makara et al.,1965). The results with capsai‐
cin  indicated  in  some  meaning  contradictory  results  in  the  gastrointestinal  tract  men‐
tioned  above.  Relatively  same  attention  was  played  to  the  applied  doses  of  capsaicin.
Szolcsányi and Barthó (1981), however, emphasized well that capsaicin protects against the
chemical induced gastric ulcer formation, when the capsaicin was given in 5 and 50 µg
doses (10 µg/mL concentration) intragastrically, meanwhile capsaicin in high dose aggravat‐
ed the ulcer formation by the induction of desensitazion.
Very systematic observations were carried out by us with capsaicin on dependence of its
concentration (or pretreatment produced desensitization of capsaicin sensitive afferent nerves)
on different experimental models (aspirin, HCl, indomethacin, ethanol, cysteamine). The
changes of gastric acid secretion, gastric mucosal damage, gastric H+back-diffusion, gastric
mucosal blood flow were measured and calculated, when the capsaicin was applied in small
doses and in high doses producing desensitization (Mózsik et al., 1997c). The results of these
observations clearly demonstrated that: 1. capsaicin, given in small doses, dose-dependently
inhibited all of the parameters in all experimental models; 2.the gastric mucosal protective
effects of capsaicin remained at the level of other drugs (acting on efferent nerves, eg. atropine,
and cimetidine or at topically such as sucralfate, retinoids). Consequently, the capsaicin
enhanced the other drug-induced gastric mucosal protective effects (Mózsik et al., 1997c); 3.
after denervated states of capsaicin-sensitive afferent nerves (produced by pretreatment of
high dose of capsaicin) the gastric mucosal lesion formation was enhanced. These results
offered to conclude that the gastric mucosal protective effects can be obtained only capsaicin,
when it is given in small doses, however this gastric mucosal protective effect of capsaicin can
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In addition capsaicin-desensitized not sensory intact animals showed no hyperaemic respons‐
es in response to intragastric instillation of 50 mM HCl. The conclusion was that capsaicin-
sensitive sensory nerves contribute to healing of gastric ulcer (lesions) by mediating the
hyperaemic responses associated with acid back-diffusion following injury (Takeuchi et al.,
1994). Similarly sensory denervated rats showed marked increased area of acetic acid-induced
ulceration at 1 and 2 weeks following the acetic acid injection indicating that the sensory
function adversely affected the healing of gastric ulcer (Tramontana et al., 1994).
Capsaicin exerts protective effects on the chemical-induced mucosal injury not only in the
stomach, but also in the colon. Evangelista and Meli (1989) found that systemic capsaicin
neonatal pretreatment enhanced trinitrobenzene sulfonic acid-induced colitis (one week) in
rats. This pretreatment, however, had no acute affect (24 hours) on colitis caused by trinitro‐
benzene sulfonic acid, ethanol or acetic acid.
Reinshagen et al. (1994) employed systemic capsaicin pretreatment as a tool to investigate the
role of sensory nerves in an immune-complex model of colitis in rabbits. They found that
capsaicin pretreatment per se caused no histological inflammation. Meanwhile, colitis was
more severe in sensory denervated state than in sensory intact rabbits. The increase in ulcer
index and neutrophyl infiltration was more marked in the capsaicin pretreated control group
at both 48 and 96 hours.
The difference in neutrophyl infiltration between the two groups was, however, more marked
at 48 than at 96 hours (Reinshagen et al., 1994). Endoh and Leung (1990) reported that topical
capsaicin application protected against acetic acid-induced colitis. In the trinitrobenzene
sulfonic acid-induced colitis rat model, however, only partial and transient protective effect
was seen by Goso et al. (1993) after topical capsaicin administration. Co-administration of 640
µM capsaicin reduced the ulcerative area from 91% to 64% only when colon was examined l
hour later. An approximatically 8 fold higher dose of capsaicin (5000 µM) yielded similar
protection, while 100 µM had no protective effect. No protection by capsaicin was however
seen when the colon was examined 24 hours after noxious challenge.
4.2.6. Capsaicin-sensitive sensory nerves and gastric acid secretion
Several studies in rats have indicated the involvement of capsaicin-sensitive sensory nerves in
the regulation of gastric acid secretion; however, contradictory data were reported. In most
studies, the indirect approach through functional ablation of capsaicin-sensitive afferent
nerves with systemic neonatal (Evangelista et al., 1989; Esplugues et al., 1990), adult (Alföldi
et al., 1986; 1987; Dugani and Glavin, 1986; Robert et al., 1991) or peripheral capsaicin
(Raybould and Taché, 1989) treatment was used as a tool to investigate the role of capsaicin-
sensitive afferent nerves in the regulation of gastric acid secretion.
Adult rats treated with systemic capsaicin (60 mg/kg, sc.) showed depressed pentagastrin-
stimulated gastric acid secretion (Dugani and Glavin, 1986). On the contrary, adult systemic
capsaicin pretreatment with 300 mg/kg sc. did not modify gastric acid secretion elicited by
pentagastrin, carbachol or by small dose of histamine (0.1 mg/kg). However, the gastric acid
secretory response to 0.5 and 5.0 mg/kg histamine was greatly reduced in capsaicin desensi‐
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tized rats. It was suggested that the histamine-induced increase in gastric acid secretion
involves a capsaicin-sensitive mechanism, while these mechanisms are not required for
pentagastrin or cholinergic stimulation of gastric acid secretion (Alföldi et al., 1986; 1987).
Similar data were reported by Raybould and Taché (1989) using topical capsaicin application
into the cervical vagus. The gastric acid secretory response to distension (5 ml for 6 min) was
reduced in capsaicin-treated rats. This mechanism by which capsaicin-sensitive vagal afferent
fibres play a role in the secretory response to histamine was explained by histamine acting in
part by increasing vagal C-fibres discharge resulting in a vago-vagal reflex increase in gastric
acid secretion or by that histamine stimulates vagal afferent C-fibres resulting the release of
peptides from sensory nerves terminals.
A peptide increasing gastric acid secretion and would be localized in vagal afferent nerves has
not been identified. In contrast that adult rats treated with systemic capsaicin (300 mg/kg, sc.)
at neonate age did not show any reduction in their gastric acid secretory to histamine,
pentagastrin or carbachol, while acid secretion in response to distension was abolished. On
the other hand, capsaicin desensitation (neonatal treatment) substantially reduced the gastric
acid secretion to 2-deoxy-D-glucose (Evangelista et al., 1989), while it did not modify when
stimulated by insulin (Esplugues et al., 1990).
The conflicting observations regarding the effect of capsaicin continue to be seen when it
was  given  into  the  stomach.  It  was  reported  that  intraduodenal  (but  not  intragastric)
instillation of capsaicin (1.0 mg in 2 ml saline solution) in pylorus-ligated rats induced a
significant rise in total acidity 12 hours later (Makara et al.,1965). The results with capsai‐
cin  indicated  in  some  meaning  contradictory  results  in  the  gastrointestinal  tract  men‐
tioned  above.  Relatively  same  attention  was  played  to  the  applied  doses  of  capsaicin.
Szolcsányi and Barthó (1981), however, emphasized well that capsaicin protects against the
chemical induced gastric ulcer formation, when the capsaicin was given in 5 and 50 µg
doses (10 µg/mL concentration) intragastrically, meanwhile capsaicin in high dose aggravat‐
ed the ulcer formation by the induction of desensitazion.
Very systematic observations were carried out by us with capsaicin on dependence of its
concentration (or pretreatment produced desensitization of capsaicin sensitive afferent nerves)
on different experimental models (aspirin, HCl, indomethacin, ethanol, cysteamine). The
changes of gastric acid secretion, gastric mucosal damage, gastric H+back-diffusion, gastric
mucosal blood flow were measured and calculated, when the capsaicin was applied in small
doses and in high doses producing desensitization (Mózsik et al., 1997c). The results of these
observations clearly demonstrated that: 1. capsaicin, given in small doses, dose-dependently
inhibited all of the parameters in all experimental models; 2.the gastric mucosal protective
effects of capsaicin remained at the level of other drugs (acting on efferent nerves, eg. atropine,
and cimetidine or at topically such as sucralfate, retinoids). Consequently, the capsaicin
enhanced the other drug-induced gastric mucosal protective effects (Mózsik et al., 1997c); 3.
after denervated states of capsaicin-sensitive afferent nerves (produced by pretreatment of
high dose of capsaicin) the gastric mucosal lesion formation was enhanced. These results
offered to conclude that the gastric mucosal protective effects can be obtained only capsaicin,
when it is given in small doses, however this gastric mucosal protective effect of capsaicin can
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not be obtained by the application of higher doses (Abdel-Salam et al., 1994, 1995a, 1995b,
1995c, 1995d, 1995e, 1995f, 1995g, 1996a, 1996b, 1997a, 1997b, 1997c, 1997d; Mózsik et al.,1993,
1996a, 1996b, 1997a, 1997b, 1997)
4.2.7. Molecular-pharmacological studies
The molecular pharmacological observations were carried out (and calculated based on the
dose-response curves of drugs) with capsaicin, atropine, cimetidine, omeprazole, PGI2, vitamin
A, β-carotene, studying their effects on the gastric acid secretion in 2 and 4 hours pylorus-
ligated rats alone, or in combination of betanechol (7.6 and 15.4 nmol/kg), histamine (2.7 and
13.6 µmol/kg) and pentagastrin (65.1 and 325.6 nmol/kg) and on the gastric mucosal damage
produced by intragastrically applied ethanol, HCl, acidified aspirin and subcutaneously applied
indomethacin (alone and in combinated with application of 7.6 and 15.2 µmol/ kg betanechol,
13.6 and 54.3 µmol/kg histamine and 6.51 and 325.6 nmol/kg pentagastrin) (calculated the
number and severity of gastric mucosal damage) in rats (Figures 4-7, Tables 1-7).
The doses of the necessary for the producing 50% inhibition on the gastric acid secretion and
gastric mucosal damage were calculated in molar values/kg body weight (ED50).
The values for affinity (pD) and intrinsic (α-values) were calculated according to standard
procedures employed in molecular pharmacology (Csáky, 1969). The values of the pD2
(necessary dose to inhibit the gastric acid secretion and gastric mucosal damage in 50%) and
pA2 (necessary dose to produce 50% in gastric acid secretion and on gastric mucosal damage)
were calculated from the affinity and intrinsic activity curves.
The doses of drugs (compounds) were calculated as molar values for the determination of their
biological effects. The affinity (pD2 values) and intrinsic activity (α-values) are shown as molar
values. The intrinsic activity of atropine (α) was taken as 1.00 for comparing the effects of
agents on gastric acid secretion and gastric mucosal damage (Figures 4-7, Tables 1-7) (Mózsik
et al., 2006).
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Figure 4. Affinity curves for different drugs, compounds inhibiting the gastric acid secretion of 4 h pylorus-
ligated rats (Mózsik et al., 2006b). For further details of the observations see the cited paper. 
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Table 1. Inhibitory effects of capsaicin and resiniferatoxin on basal gastric acid 
secretion in rats.* 
Compounds Models ED50 values 
Capsaicin 2 h pylorus ligated rats 3.27 nmol/kg 
Capsaicin 4 h pylorus ligated rats 3.27 nmol/kg 
RTX 4 h pylorus ligated rats 0.954 nmol/kg 
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Table 2. Inhibitory effects of resiniferatoxin on stimulated gastric acid secretion in rats.* 
Compounds Models ED50 values 
Capsaicin 1 h pylorus ligated rats + betanechol (7.6 µmol/kg)  0.954 nmol/kg 
Capsaicin 1 h pylorus ligated rats + betanechol (15.2 µmol/kg) 0.954 nmol/kg 
Capsaicin 1 h pylorus ligated rats+ histamine (13.6 µmol/kg) 0.954 nmol/kg 
Capsaicin 1 h pylorus ligated rats + histamine (54.3 µmol/kg) 0.954 nmol/kg 
Capsaicin 1 h pylorus ligated rats + pentagastrin (65.1 nmol/kg) 0.954 nmol/kg 
Capsaicin 1 h pylorus ligated rats  pentagastrin (325.6 nmol/kg) 0.954 nmol/kg 
RTX 4 h pylorus ligated rats + betanechol (7.6 nmol/kg) 0.954 nmol/kg 
RTX 4 h pylorus ligated rats+ betanechol (15.2 nmol/kg) 0.954 nmol/kg 
RTX 4 h pylorus ligated rats + histamine (2.7 µmol/kg) 0.954 nmol/kg 
RTX 4 h pylorus ligated rats + histamine (13.6 µmol/kg) 0.954 nmol/kg 
RTX 4 h pylorus ligated rats + pentagastrin (65.1 nmol/kg) 0.954 nmol/kg 
RTX 4 h pylorus ligated rats  pentagastrin (325.6 nmol/kg) 0.954 nmol/kg 
* (Mózsik et al., 2006b) 
 







































Figure 7. Intrinsic activity curves for different drugs, compounds inhibiting the gastric mucosal damage produced by
chemical agents which were expressed relative to that of atropine (αatropine=1,00) in rats (Mózsik et al., 2006b). For fur‐
ther details of the observations see t e cited paper.
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not be obtained by the application of higher doses (Abdel-Salam et al., 1994, 1995a, 1995b,
1995c, 1995d, 1995e, 1995f, 1995g, 1996a, 1996b, 1997a, 1997b, 1997c, 1997d; Mózsik et al.,1993,
1996a, 1996b, 1997a, 1997b, 1997)
4.2.7. Molecular-pharmacological studies
The molecular pharmacological observations were carried out (and calculated based on the
dose-response curves of drugs) with capsaicin, atropine, cimetidine, omeprazole, PGI2, vitamin
A, β-carotene, studying their effects on the gastric acid secretion in 2 and 4 hours pylorus-
ligated rats alone, or in combination of betanechol (7.6 and 15.4 nmol/kg), histamine (2.7 and
13.6 µmol/kg) and pentagastrin (65.1 and 325.6 nmol/kg) and on the gastric mucosal damage
produced by intragastrically applied ethanol, HCl, acidified aspirin and subcutaneously applied
indomethacin (alone and in combinated with application of 7.6 and 15.2 µmol/ kg betanechol,
13.6 and 54.3 µmol/kg histamine and 6.51 and 325.6 nmol/kg pentagastrin) (calculated the
number and severity of gastric mucosal damage) in rats (Figures 4-7, Tables 1-7).
The doses of the necessary for the producing 50% inhibition on the gastric acid secretion and
gastric mucosal damage were calculated in molar values/kg body weight (ED50).
The values for affinity (pD) and intrinsic (α-values) were calculated according to standard
procedures employed in molecular pharmacology (Csáky, 1969). The values of the pD2
(necessary dose to inhibit the gastric acid secretion and gastric mucosal damage in 50%) and
pA2 (necessary dose to produce 50% in gastric acid secretion and on gastric mucosal damage)
were calculated from the affinity and intrinsic activity curves.
The doses of drugs (compounds) were calculated as molar values for the determination of their
biological effects. The affinity (pD2 values) and intrinsic activity (α-values) are shown as molar
values. The intrinsic activity of atropine (α) was taken as 1.00 for comparing the effects of
agents on gastric acid secretion and gastric mucosal damage (Figures 4-7, Tables 1-7) (Mózsik
et al., 2006).
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ligated rats (Mózsik et al., 2006b). For further details of the observations see the cited paper. 
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Figure 7. Intrinsic activity curves for different drugs, compounds inhibiting the gastric mucosal damage produced by
chemical agents which were expressed relative to that of atropine (αatropine=1,00) in rats (Mózsik et al., 2006b). For fur‐
ther details of the observations see t e cited paper.
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Compounds Models ED50 values
Capsaicin 2 h pylorus ligated rats 3.27 nmol/kg
Capsaicin 4 h pylorus ligated rats 3.27 nmol/kg
RTX 4 h pylorus ligated rats 0.954 nmol/kg
*(Mózsik et al., 2006b)
Table 1. Inhibitory effects of capsaicin and resiniferatoxin on basal gastric acid secretion in rats.*
Compounds Models ED50 values
Capsaicin 1 h pylorus ligated rats + betanechol (7.6 μmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats + betanechol (15.2 μmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats+ histamine (13.6 μmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats + histamine (54.3 μmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats + pentagastrin (65.1 nmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats pentagastrin (325.6 nmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats + betanechol (7.6 nmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats+ betanechol (15.2 nmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats + histamine (2.7 μmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats + histamine (13.6 μmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats + pentagastrin (65.1 nmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats pentagastrin (325.6 nmol/kg) 0.954 nmol/kg
* (Mózsik et al., 2006b)
Table 2. Inhibitory effects of resiniferatoxin on stimulated gastric acid secretion in rats.*
Compounds Models ED50 values
Capsaicin 0.6 M HCl (2 ml) (4 h) 0.135 μmol/kg
Capsaicin aspirin (200 mg/kg) + 0.15 M HCl (4 h) 0.13 μmol/kg
Capsaicin ethanol (96% in 1 ml) (1 h) 0.13 μmol/kg
Capsaicin 4 h pylorus ligated rats+ IND (20 mg/kg) 1.98 nmol/kg
RTX 4 h pylorus ligated rats + IND (20 mg/kg) 0.95 nmol/kg
Capsaicin 4 h pylorus ligated rats +IND (20 mg/kg) + 0.15 N HCl (2 ml) 0.25 μmol/kg
RTX 4 h pylorus ligated rats + IND (20 mg/kg)+ 0.15 N HCl (2 ml) 0.95 nmol/kg
Capsaicin 4 h pylorus ligated rats+ IND (20 mg/kg) 0.3 N HCl (2 ml) 2.78 μmol/kg
RTX 4 h pylorus ligated rats + IND (20 mg/kg) 0.3 N HCl (2 ml) 0.15 μmol/kg
*(Mózsik et al., 2006b)
Table 3. Protective effects of capsaicin and resiniferatoxin on gastric mucosal damage caused by exogenous agents in
rats.*
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Compounds Models ED50 values
RTX 4 h pylorus ligated rats+ bethanechol (7.6 μmol/kg) + IND (20 mg/kg) 0.20 μmol/kg
RTX 4 h pylorus ligated rats+ bethanechol (15.2 μmol/kg) + IND (20 mg/kg) 0.20 μmol/kg
RTX 4 h pylorus ligated rats+ histamine (13.6 μmol/kg) + IND (20 mg/kg) 0.13 μmol/kg
RTX 4 h pylorus ligatedrats + histamine (54.3 μmol/kg) + IND (20 mg/kg) 0.13 μmol/kg
RTX 4 h pylorus ligated rats+ pentagastrin (6.51 nmol/kg)+ IND (20 mg/kg) 0.13 μmol/kg
RTX 4 h pylorus ligated rats+ pentagastrin (325.6 nmol/kg) + IND (20 mg/kg) 0.13 μmol/kg
*(Mózsik et al., 2006b)
Table 4. Protective effects of resiniferatoxin on gastric mucosal damage caused by exo-, and endogenous agents in
rats.*
Compounds pD2 Intrinsic activity pA2
Capsaicin 8.48 0.76 8.50
Atropine 5.75 1.00 5.80
Cimetidine 3.00 0.64 3.20
Omeprazole 4.88 1.00 4.90
* For further information, see Figures 1 and 2 (Mózsik et al., 2006b)
Table 5. The pD2, intrinsic activity (αatropine=1.00) and pA2 values for different drugs (compound) inhibiting the gastric
acid outputs in 4 h pylorus-ligated rats.*
Vitamin A: 3.49 x 10-8 – 3.49 x 10-5 (0.01-10.0 mg/kg): no inhibitory action on the gastric acid secretion
β-carotene: 1.86 x 10-8 – 1.86 x 10-5 (0.01-10.0 mg/kg): no inhibitory action on the gastric acid secretion
PGI2 : 2.8 x 10-9 – 1.42 x 10-8 (1.0-5.0 µg/kg): no inhibitory action on the gastric acid secretion
PGE2 : 1.33-1.99 x 10-7 (50.0-150.0 µg/kg): no inhibitory action on the gastric acid secretion
*(Mózsik et al., 2006b)
Table 6. Dose ranges of the tested nutritional compounds (vitamin A and β-carotene), PGI2 and PGE2 on the gastric
acid secretion of 4 h pylorus-ligated rats, without presence any inhibitory actions.*
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Compounds Models ED50 values
Capsaicin 2 h pylorus ligated rats 3.27 nmol/kg
Capsaicin 4 h pylorus ligated rats 3.27 nmol/kg
RTX 4 h pylorus ligated rats 0.954 nmol/kg
*(Mózsik et al., 2006b)
Table 1. Inhibitory effects of capsaicin and resiniferatoxin on basal gastric acid secretion in rats.*
Compounds Models ED50 values
Capsaicin 1 h pylorus ligated rats + betanechol (7.6 μmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats + betanechol (15.2 μmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats+ histamine (13.6 μmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats + histamine (54.3 μmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats + pentagastrin (65.1 nmol/kg) 0.954 nmol/kg
Capsaicin 1 h pylorus ligated rats pentagastrin (325.6 nmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats + betanechol (7.6 nmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats+ betanechol (15.2 nmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats + histamine (2.7 μmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats + histamine (13.6 μmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats + pentagastrin (65.1 nmol/kg) 0.954 nmol/kg
RTX 4 h pylorus ligated rats pentagastrin (325.6 nmol/kg) 0.954 nmol/kg
* (Mózsik et al., 2006b)
Table 2. Inhibitory effects of resiniferatoxin on stimulated gastric acid secretion in rats.*
Compounds Models ED50 values
Capsaicin 0.6 M HCl (2 ml) (4 h) 0.135 μmol/kg
Capsaicin aspirin (200 mg/kg) + 0.15 M HCl (4 h) 0.13 μmol/kg
Capsaicin ethanol (96% in 1 ml) (1 h) 0.13 μmol/kg
Capsaicin 4 h pylorus ligated rats+ IND (20 mg/kg) 1.98 nmol/kg
RTX 4 h pylorus ligated rats + IND (20 mg/kg) 0.95 nmol/kg
Capsaicin 4 h pylorus ligated rats +IND (20 mg/kg) + 0.15 N HCl (2 ml) 0.25 μmol/kg
RTX 4 h pylorus ligated rats + IND (20 mg/kg)+ 0.15 N HCl (2 ml) 0.95 nmol/kg
Capsaicin 4 h pylorus ligated rats+ IND (20 mg/kg) 0.3 N HCl (2 ml) 2.78 μmol/kg
RTX 4 h pylorus ligated rats + IND (20 mg/kg) 0.3 N HCl (2 ml) 0.15 μmol/kg
*(Mózsik et al., 2006b)
Table 3. Protective effects of capsaicin and resiniferatoxin on gastric mucosal damage caused by exogenous agents in
rats.*
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Compounds Models ED50 values
RTX 4 h pylorus ligated rats+ bethanechol (7.6 μmol/kg) + IND (20 mg/kg) 0.20 μmol/kg
RTX 4 h pylorus ligated rats+ bethanechol (15.2 μmol/kg) + IND (20 mg/kg) 0.20 μmol/kg
RTX 4 h pylorus ligated rats+ histamine (13.6 μmol/kg) + IND (20 mg/kg) 0.13 μmol/kg
RTX 4 h pylorus ligatedrats + histamine (54.3 μmol/kg) + IND (20 mg/kg) 0.13 μmol/kg
RTX 4 h pylorus ligated rats+ pentagastrin (6.51 nmol/kg)+ IND (20 mg/kg) 0.13 μmol/kg
RTX 4 h pylorus ligated rats+ pentagastrin (325.6 nmol/kg) + IND (20 mg/kg) 0.13 μmol/kg
*(Mózsik et al., 2006b)
Table 4. Protective effects of resiniferatoxin on gastric mucosal damage caused by exo-, and endogenous agents in
rats.*
Compounds pD2 Intrinsic activity pA2
Capsaicin 8.48 0.76 8.50
Atropine 5.75 1.00 5.80
Cimetidine 3.00 0.64 3.20
Omeprazole 4.88 1.00 4.90
* For further information, see Figures 1 and 2 (Mózsik et al., 2006b)
Table 5. The pD2, intrinsic activity (αatropine=1.00) and pA2 values for different drugs (compound) inhibiting the gastric
acid outputs in 4 h pylorus-ligated rats.*
Vitamin A: 3.49 x 10-8 – 3.49 x 10-5 (0.01-10.0 mg/kg): no inhibitory action on the gastric acid secretion
β-carotene: 1.86 x 10-8 – 1.86 x 10-5 (0.01-10.0 mg/kg): no inhibitory action on the gastric acid secretion
PGI2 : 2.8 x 10-9 – 1.42 x 10-8 (1.0-5.0 µg/kg): no inhibitory action on the gastric acid secretion
PGE2 : 1.33-1.99 x 10-7 (50.0-150.0 µg/kg): no inhibitory action on the gastric acid secretion
*(Mózsik et al., 2006b)
Table 6. Dose ranges of the tested nutritional compounds (vitamin A and β-carotene), PGI2 and PGE2 on the gastric
acid secretion of 4 h pylorus-ligated rats, without presence any inhibitory actions.*
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Compounds pD2 Intrinsic activity pA2
Capsaicin 8.48 0.76 8.50
PGI2 7.45 1.00 7.44
Atropine 5.75 1.00 5.80
Cimetidine 3.00 0.64 3.20
Omeprazole 4.88 1.00 4.90
Vitamin A 5.45 1.00 5.44
β-carotene 5.73 1.00 5.73
* For further information, see Figures 4-7. (Mózsik et al., 2006b)
Table 7. The pD2, intrinsic activity (αatropine=1.00) and pA2 values for different drugs, compounds inhibiting the gastric
mucosal damage produced by chemical agents in rats.*
The results obtained demonstrated the following conclusions:
1. Only the values of pD2 and pA2 (expressed in [-] molar doses) can be used for the evalu‐
ation of physiological and pharmacological regulations of the target organ(s) in animal‐
experiment(s) (Mózsik et al., 2006).
2. The following pD2 (ED50%) values were obtained for the different drugs (compounds) for
actions in inhibiting gastric acid secretion: atropine 5.75; omeprazole 4.88; cimetidine 3.00;
capsaicin 8.50,whereas no effects were observed with PGI2, vitamin A and β-carotene.
3. The intrinsic activity values (αatropine=1.00) obtained in relation to atropine were 0.64 for
cimetidine, 0.75 for capsaicin, 1.00 for omeprazole; no effects were observed for PGI2,
vitamin A and β-carotene.
4. The following pD2 (ED50) values were obtained for he different drugs or compounds
inhibiting the gastric mucosal damage produced by chemicals: capsaicin 8.48, PGI2 7.45,
atropine 5.75, cimetidine 3.00, omeprazole 4.88, vitamin A 5.45 and β-carotene 5.73.
5. The intrinsic activity values (αatropine=1.00) were obtained: capsaicin 0.76, cimetidine 0.64,
of other components were 1.00 on the gastric mucosal damage.
6. The values of pA2 values were obtained as follows: capsaicin 8.50, PGI2 7.44, atropine 5.80,
cimetidine 3.00, omeprazole 4.90, vitamin A 5.44 and β-carotene 5.70.
The results of these molecular pharmacological observations clearly indicated (proved) that
the capsaicin-sensitive afferent nerves have essential role both in the regulation of gastric acid
secretion and in the defense of the gastric mucosal damage produced by the different chemical
agents. It has been emphasizing that the capsaicin exerts the gastric acid inhibitory and the
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gastric mucosal protective effect in smaller molar concentrations than other compounds
(atropine, cimetidine, omeprazole and other compounds without any gastric acid inhibitory
effects). That is a clear explanation for why the essential role of capsaicin-sensitive afferent
nerves is deeply emphasized in the physiological and pharmacological regulation of gastro‐
intestinal tract.
4.2.8. Capsaicin actions in human healthy subjects and in patients with different gastrointestinal
disorders
Early work regarding the effect of peppers on the human stomach has yielded conflicting
results. In peptic ulcer patients, Schneider et al., (1956) studied the influence of a variety of
spices on sensation of pain and healing peptic ulcer. Ulcer patients placed on established
treatment with anticholinergics and diet were given different purgent species in capsules that
contained the average quantity habitually consumed by Americans with three of their daily
meals for six weeks. With the exception of black pepper, which resulted in distressing pain
after one or two days, none of the tested spices have modified pain sensation or delayed healing
of ulcers.
In other study, instillation of red chilli powder was reported to be associated with significant
increase of DNA from gastric aspirates (Desai et al., 1973). Viranuvatti et al. (1972) studies the
local effect of capsicum in twenty human subjects by instillation a 3% capsicum solution
through an intragastric tube or via the lumen of gastrofiberscope. There was no change in 13
cases, oedema and/or hyperaemia developed in three cases, haemorrhagic spots occurred in
another three cases and bleeding occurred in one case.
Capsaicin was reported to increase the gastric acidity in human subjects receiving intragas‐
trically aqueous suspensions from hot peppers (Berkessy, 1934; Varga, 1936; Ketusinh et al.,
1966; Solanke, 1973). Solanke (1973) studied the effect of red pepper suspension (200 ml of 4%
solution) instilled through a nasogastric tube on gastric acid secretion in patients with
duodenal ulcer and non-duodenal ulcer. Patients were allocated into two treatments: fresh red
pepper suspension and a red pepper suspension with pH adjusted to 7.4 with 0.01 N sodium
hydroxyde. They found a significant increase in gastric acid secretion after treatment with
either form of the red pepper suspension. Many other observations were carried out in human
beings with different extractions of chilli, paprika. Consequently we have no scientifically well
controlled human studies on the applied doses of capsaicin. On the other hand, these studies
were carried out in sporadic pathways.
The Good Clinical Practice (GCP) was introduced in the clinical research of human beings and
patients.
From the years of 1997, the clinical studies with capsaicin were carried out in prospective and
randomized, multiclinical conditions as those had been officially accepted in the multiclinical
pharmacological studies in all over the World.
The following observation facts were accepted in these human observations:
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Compounds pD2 Intrinsic activity pA2
Capsaicin 8.48 0.76 8.50
PGI2 7.45 1.00 7.44
Atropine 5.75 1.00 5.80
Cimetidine 3.00 0.64 3.20
Omeprazole 4.88 1.00 4.90
Vitamin A 5.45 1.00 5.44
β-carotene 5.73 1.00 5.73
* For further information, see Figures 4-7. (Mózsik et al., 2006b)
Table 7. The pD2, intrinsic activity (αatropine=1.00) and pA2 values for different drugs, compounds inhibiting the gastric
mucosal damage produced by chemical agents in rats.*
The results obtained demonstrated the following conclusions:
1. Only the values of pD2 and pA2 (expressed in [-] molar doses) can be used for the evalu‐
ation of physiological and pharmacological regulations of the target organ(s) in animal‐
experiment(s) (Mózsik et al., 2006).
2. The following pD2 (ED50%) values were obtained for the different drugs (compounds) for
actions in inhibiting gastric acid secretion: atropine 5.75; omeprazole 4.88; cimetidine 3.00;
capsaicin 8.50,whereas no effects were observed with PGI2, vitamin A and β-carotene.
3. The intrinsic activity values (αatropine=1.00) obtained in relation to atropine were 0.64 for
cimetidine, 0.75 for capsaicin, 1.00 for omeprazole; no effects were observed for PGI2,
vitamin A and β-carotene.
4. The following pD2 (ED50) values were obtained for he different drugs or compounds
inhibiting the gastric mucosal damage produced by chemicals: capsaicin 8.48, PGI2 7.45,
atropine 5.75, cimetidine 3.00, omeprazole 4.88, vitamin A 5.45 and β-carotene 5.73.
5. The intrinsic activity values (αatropine=1.00) were obtained: capsaicin 0.76, cimetidine 0.64,
of other components were 1.00 on the gastric mucosal damage.
6. The values of pA2 values were obtained as follows: capsaicin 8.50, PGI2 7.44, atropine 5.80,
cimetidine 3.00, omeprazole 4.90, vitamin A 5.44 and β-carotene 5.70.
The results of these molecular pharmacological observations clearly indicated (proved) that
the capsaicin-sensitive afferent nerves have essential role both in the regulation of gastric acid
secretion and in the defense of the gastric mucosal damage produced by the different chemical
agents. It has been emphasizing that the capsaicin exerts the gastric acid inhibitory and the
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside286
gastric mucosal protective effect in smaller molar concentrations than other compounds
(atropine, cimetidine, omeprazole and other compounds without any gastric acid inhibitory
effects). That is a clear explanation for why the essential role of capsaicin-sensitive afferent
nerves is deeply emphasized in the physiological and pharmacological regulation of gastro‐
intestinal tract.
4.2.8. Capsaicin actions in human healthy subjects and in patients with different gastrointestinal
disorders
Early work regarding the effect of peppers on the human stomach has yielded conflicting
results. In peptic ulcer patients, Schneider et al., (1956) studied the influence of a variety of
spices on sensation of pain and healing peptic ulcer. Ulcer patients placed on established
treatment with anticholinergics and diet were given different purgent species in capsules that
contained the average quantity habitually consumed by Americans with three of their daily
meals for six weeks. With the exception of black pepper, which resulted in distressing pain
after one or two days, none of the tested spices have modified pain sensation or delayed healing
of ulcers.
In other study, instillation of red chilli powder was reported to be associated with significant
increase of DNA from gastric aspirates (Desai et al., 1973). Viranuvatti et al. (1972) studies the
local effect of capsicum in twenty human subjects by instillation a 3% capsicum solution
through an intragastric tube or via the lumen of gastrofiberscope. There was no change in 13
cases, oedema and/or hyperaemia developed in three cases, haemorrhagic spots occurred in
another three cases and bleeding occurred in one case.
Capsaicin was reported to increase the gastric acidity in human subjects receiving intragas‐
trically aqueous suspensions from hot peppers (Berkessy, 1934; Varga, 1936; Ketusinh et al.,
1966; Solanke, 1973). Solanke (1973) studied the effect of red pepper suspension (200 ml of 4%
solution) instilled through a nasogastric tube on gastric acid secretion in patients with
duodenal ulcer and non-duodenal ulcer. Patients were allocated into two treatments: fresh red
pepper suspension and a red pepper suspension with pH adjusted to 7.4 with 0.01 N sodium
hydroxyde. They found a significant increase in gastric acid secretion after treatment with
either form of the red pepper suspension. Many other observations were carried out in human
beings with different extractions of chilli, paprika. Consequently we have no scientifically well
controlled human studies on the applied doses of capsaicin. On the other hand, these studies
were carried out in sporadic pathways.
The Good Clinical Practice (GCP) was introduced in the clinical research of human beings and
patients.
From the years of 1997, the clinical studies with capsaicin were carried out in prospective and
randomized, multiclinical conditions as those had been officially accepted in the multiclinical
pharmacological studies in all over the World.
The following observation facts were accepted in these human observations:
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1. The pure capsaicin (Sigma, USA, later on Sigma-Aldrich, USA) was used in the studies
with healthy human subjects and in patients with different diseases (instead of different
extractions of different capsaicin containing plants),
2. The clinical observations were carried out according to the medical laws of clinical
pharmacology (in random allocation and in prospective and randomized studies),
3. The clinical observations were carried out according to the criteria of GCP,
4. All of the persons participating received all doses of capsaicin in random allocation.
We have to emphasize that the classical pharmacological studies were carried out with
capsaicin obtained from the firm of Sigma (USA), or later from Sigma-Aldrich (USA).
The main results of the human multiclinical pharmacological studies with capsaicin:
1. The capsaicin (in range of 100 to 800 µg dose orally given to each person) dose-depend‐
ently inhibited the gastric basal acid output (BAO) in healthy human subjects (Fig. 8.)
(Mózsik et al., l999; Mózsik et al., 2005).
2. The capsaicin dose-dependently enhanched the the gastric transmucosal potential
difference (GTPD) in healthy human subjects (Fig. 9) (Mózsik et al., 2005).
3. The ethanol-induced decrease of GTPD can be dose-dependently reversed by topical
application of capsaicin (given it in doses of 100, 200,400 and 800 µg orally) (Fig. 10)
(Mózsik et al., 2005).
4. The indomethacin (3x 25 mg/day given orally,plus 25 mg given immediately before
measuring of gastric blood losing) produced a significant increase of gastric microbleed‐
ing in comparison to control (untreated) conditions (Fig. 11) (Mózsik et al., 2005; Mózsik
et al., 2006).
5. The extent basal and indomethacin-induced gastric microbleeding unchanged before and
after weeks treatment with capsaicin (3x 400 µg/ person/day) (Mózsik et al., 2005; Mózsik
et al., 2007).
6. The dose-dependent gastroprotective effect of capsaicin on the indomethacin-induced
gastric microbleeding remained the same after two weeks (3 x 400 µg given orally /day/
person) of capsaicin treatment (Mózsik et al., 2005; Mózsik et al., 2006).
These  observations  proved  that  the  capsaicin  (dose-dependently)  prevents  the  ethanol-
and indomethacin-induced gastric mucosal damage in healthy human subjects (Mózsik et
al., 2005; Mózsik et al., 2007) before and after two weeks treatment with capsaicin (3x 400
µg orally  /day/  person)  (Mózsik  et  al.,  2005;  Mózsik  et  al.,  2006),  however,  we have  to
emphasize that  the indomethacin (3x25 mg given orally,  plus 25 mg given immediately
before  the  measuring  of  gastric  microbleeding)  produced  the  same  extent  of  gastric
microbleeding. We also have to emphasize that the extent of baseline of gastric microbleed‐
ing remained the same before and after two week treatment with capsaicin (Mózsik et al.,
2005; Mózsik et al., 2007).
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Figure 8. Dose-response curve of capsaicin on the gastric basal acid output (BAO) in healthy human subjects (Mózsik
Gy. et al., 2005). The determination was carried out at one hour after the beginning of the human observations.
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Effect of capsaicin on GTPD (-∆mV)  in healthy human subjects 
Figure 9. Dose-response curve of capsaicin on the gastric transmucosal potential difference (GTPD) in healthy human
subjects (Mózsik Gy. et al., 2005), when the different doses were directly intragastrically via endoscopic chanel. The
GTPD measurements were carried out t 1, 2, 3, 4, a d 5 minutes. The results are expressed at 5 min after capsai in
intragastric application.
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Figure 11. Dose-response curve of c psaicin on the Indomethacin (3x25+25mg given orally in pills) induced gastric
microbleeding in healthy huma  subjects. The different doses 200, 400, 800 µg capsaicin was intragastrically applied
in gelatin capsule (Mózsik Gy., et al., 2005).
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4.2.8.1. Results of the comparative molecular-pharmacological studies of capsaicin, atropine,
Omeprazole, Famotidine, Ranitidine and Cimetidine on the gastric basal acid output (BAO) in human
subjects
The affinity (pD values) and intrinsic activity (pA values) curves of capsaicin, atropine,
Omeprazole, Famitidine, ranitidine and cimetidine (used in their physiological and human
therapeutic doses) were determined in patients with gastrointestinal disorders, according to
the method of Csáky (1969) (Figures 12 and 13, Table 8).
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2007c). For further explanation see the cited paper. 
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Compounds M.W. pD2 Intrinsic activity pA2
Capsaicin 305,4 5,88 0,76 5,87
Atropine 289,38 5,40 1,00 5,40
Pirenzepine 424,34 3,93 0,89 3,93
Cimetidine 252,34 2,23 1,00 2,23
Ranitidine 314,41 3,33 1,00 3,33
Famotidine 337,43 3,77 1,00 3,77
Nizatidine 331,47 3,34 1,00 3,34
Omeprazole 345,42 3,97 1,00 3,97
Esomeprazole 345,42 3,97 1,00 3,97
Table 8. Summary of the affinity (pD2) and intrinsic activity (expressed in value of αatropine=1,00)(pA2) values of
capsaicin, atropine, Pirenzepine, cimetidine, ranitidine, famotidine, Omerazole and Esomeprazole on the gastric basal
acid output (BAO) in healthy human subjects
4.2.9. Side effects of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in the
gastrointestinal tract of patients
The patients with myocardial infarction, thromboembolic episodes, stroke of central nervous
system, cancers and persons who have to be under secondary preventional terapy (against
reinfarction after myocardial infarction, prevention of thromboembolic episodes produced by
atrial fibrillation, cancers, after different surgical intervention and immobilization) and in
healthy subject treated with NSAIDs in order to prevent the development of colorectal cancers
were randomized for further study.
The number of these groups of patients reaches to 50-60 per cent of total population in
Hungary; however, an extremely big number of patients with these diseases is included in the
different countries of the World.
The patients who underwent cardiac and other surgeries we have to treat permanently with
aspirin (in dose around 100 mg / day / person). This is a basic staind-point of the different
consensus meetings of Europe and of the World (Mcgettigan and Henry, 2006; Expert Con‐
sensus Document on the Use of Antiplatelet Agents 2004; Todd, and Clissold, 1990).
The administration of aspirin is absolutely indicated from medical points of view in patients
with mentioned disorders, accepting the opinion of cardiologists we have to emphasize that
the aspirin very frequently produces harmful gastrointestinal bleeding (which is not accepted
by gastroenterologists). Really, there is a great and principal question from the general medical
practice (and of research), namely wheather all patients can be taken uniformally, in whom
the medical science offers such medical treatment from the point of cardiology, which produces
severe gastrointestinal disorders (bleedings, peptic ulcer). Consequently, there is a contradic‐
tion medically (and evidence-based proved) in standpoint of cardiologists and gastroenterol‐
ogists (during the treatment only one patient, and as well as in the treatment of populations
of patients mentioned above).
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Another big population of patients suffers from different degenerative joint diseases, trauma,
acute and chronic pain producing states.These patients have to receive permanently treatment
with NSAIDs. The NSAIDs are not gastrointestinal protective agents neither in healthy person
and nor in patients with these diseases. The patients appearing at ambulance of Gastrointes‐
tinal Units are suffered from the drug-induced side effects in gastrointestinal tract
The number of patients with NSAIDs-induced gastrointestinal disorders (blood losing,
bleeding, peptic ulcer) also represents a significant number of populations. Furthermore, these
patients have to be treated permanenly by different NSAIDs.
The actions of NSAIDs are associated with the selective and non-selective inhibitory properties
on cycloxygene system (emphasizing the key role of COX-1 and COX-2). Aspirin represents
as a specific COX-1 inhibitor; meanwhile the other NSAIDs applied in the clinical practice
represent the compounds acting as non selective COX-1 and COX-2 inhibitors. Recently, the
specifically acting compounds, inhibiting COX-2 enzyme, have been produced, however, it
was also observed that during the treatment an extremely big number of patients received
myocardial infraction (Couzin, 2004a, 2004b; Lenzer, 2004; McGettigan, and Henry, 2006).
We have to emphasize clearly, that the small doses of capsaicin are able to prevent gastric
mucosal bleeding in humans, which are able to inhibit both the COX-1 and COX-2 enzymes.
This discovery opened a new pathway in the physiological and pharmacological regulation of
different tissues (see later).
4.3. Animal observations
4.3.1. Acute toxicology studies of capsaicin in animal experiments
During acute toxicity study with capsaicin eight of 17 rats died in which capsaicin was
administered in four increasing s.c. doses to a cumulative amount of 21.0 – 66.0 mg/ rat
(Cabanac et al., 1976). Additionally, Molnár (1965), Molnár and György (1967) reported that
capsaicin administered i.v. at a dose higher than 10 µg/ kg to cats caused a rapid fall in the
mean arterial pressure which was followed by either a pressor phase or death.These results
called our attention to methods of administration of capsaicin (intravenously or orally in
animal observations.
The LD50 dose of capsaicin (given i.p.) was calculated as 7.65 mg/kg in adult female and male
mice (please to note that capsaicin was not given in as pure agents, however as extracts)
(Glinsukon et al., 1980). The toxicity of capsaicin present in the capsicum extract was approx‐
imately four fold higher than that of pure capsaicin given intraperitoneally to mice. Capsaicin
had a sligtly LD50 in weanking female rats administred in propylene glycol of those observed
when administered intraperitoneally in dimethylsulfoxyde (DMSO) (P< 0.05) (Glinsukon et
al., 1980). Guinea pigs are the most susceptible species to capsaicin toxicity with LD50 of 1.10
mg/mg, whereas hamsters and rabbits are less susceptible (Glinsukon et al., 1980).
The main results of these toxicological observations were as follows: LD50 values were 7.65
(5.28 – 11.09) for male and 6.50 (4.33-9.75) mg /kg for female mice; 10.40 (9.71 – 18.12) mg/ kg
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Pirenzepine 424,34 3,93 0,89 3,93
Cimetidine 252,34 2,23 1,00 2,23
Ranitidine 314,41 3,33 1,00 3,33
Famotidine 337,43 3,77 1,00 3,77
Nizatidine 331,47 3,34 1,00 3,34
Omeprazole 345,42 3,97 1,00 3,97
Esomeprazole 345,42 3,97 1,00 3,97
Table 8. Summary of the affinity (pD2) and intrinsic activity (expressed in value of αatropine=1,00)(pA2) values of
capsaicin, atropine, Pirenzepine, cimetidine, ranitidine, famotidine, Omerazole and Esomeprazole on the gastric basal
acid output (BAO) in healthy human subjects
4.2.9. Side effects of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in the
gastrointestinal tract of patients
The patients with myocardial infarction, thromboembolic episodes, stroke of central nervous
system, cancers and persons who have to be under secondary preventional terapy (against
reinfarction after myocardial infarction, prevention of thromboembolic episodes produced by
atrial fibrillation, cancers, after different surgical intervention and immobilization) and in
healthy subject treated with NSAIDs in order to prevent the development of colorectal cancers
were randomized for further study.
The number of these groups of patients reaches to 50-60 per cent of total population in
Hungary; however, an extremely big number of patients with these diseases is included in the
different countries of the World.
The patients who underwent cardiac and other surgeries we have to treat permanently with
aspirin (in dose around 100 mg / day / person). This is a basic staind-point of the different
consensus meetings of Europe and of the World (Mcgettigan and Henry, 2006; Expert Con‐
sensus Document on the Use of Antiplatelet Agents 2004; Todd, and Clissold, 1990).
The administration of aspirin is absolutely indicated from medical points of view in patients
with mentioned disorders, accepting the opinion of cardiologists we have to emphasize that
the aspirin very frequently produces harmful gastrointestinal bleeding (which is not accepted
by gastroenterologists). Really, there is a great and principal question from the general medical
practice (and of research), namely wheather all patients can be taken uniformally, in whom
the medical science offers such medical treatment from the point of cardiology, which produces
severe gastrointestinal disorders (bleedings, peptic ulcer). Consequently, there is a contradic‐
tion medically (and evidence-based proved) in standpoint of cardiologists and gastroenterol‐
ogists (during the treatment only one patient, and as well as in the treatment of populations
of patients mentioned above).
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Another big population of patients suffers from different degenerative joint diseases, trauma,
acute and chronic pain producing states.These patients have to receive permanently treatment
with NSAIDs. The NSAIDs are not gastrointestinal protective agents neither in healthy person
and nor in patients with these diseases. The patients appearing at ambulance of Gastrointes‐
tinal Units are suffered from the drug-induced side effects in gastrointestinal tract
The number of patients with NSAIDs-induced gastrointestinal disorders (blood losing,
bleeding, peptic ulcer) also represents a significant number of populations. Furthermore, these
patients have to be treated permanenly by different NSAIDs.
The actions of NSAIDs are associated with the selective and non-selective inhibitory properties
on cycloxygene system (emphasizing the key role of COX-1 and COX-2). Aspirin represents
as a specific COX-1 inhibitor; meanwhile the other NSAIDs applied in the clinical practice
represent the compounds acting as non selective COX-1 and COX-2 inhibitors. Recently, the
specifically acting compounds, inhibiting COX-2 enzyme, have been produced, however, it
was also observed that during the treatment an extremely big number of patients received
myocardial infraction (Couzin, 2004a, 2004b; Lenzer, 2004; McGettigan, and Henry, 2006).
We have to emphasize clearly, that the small doses of capsaicin are able to prevent gastric
mucosal bleeding in humans, which are able to inhibit both the COX-1 and COX-2 enzymes.
This discovery opened a new pathway in the physiological and pharmacological regulation of
different tissues (see later).
4.3. Animal observations
4.3.1. Acute toxicology studies of capsaicin in animal experiments
During acute toxicity study with capsaicin eight of 17 rats died in which capsaicin was
administered in four increasing s.c. doses to a cumulative amount of 21.0 – 66.0 mg/ rat
(Cabanac et al., 1976). Additionally, Molnár (1965), Molnár and György (1967) reported that
capsaicin administered i.v. at a dose higher than 10 µg/ kg to cats caused a rapid fall in the
mean arterial pressure which was followed by either a pressor phase or death.These results
called our attention to methods of administration of capsaicin (intravenously or orally in
animal observations.
The LD50 dose of capsaicin (given i.p.) was calculated as 7.65 mg/kg in adult female and male
mice (please to note that capsaicin was not given in as pure agents, however as extracts)
(Glinsukon et al., 1980). The toxicity of capsaicin present in the capsicum extract was approx‐
imately four fold higher than that of pure capsaicin given intraperitoneally to mice. Capsaicin
had a sligtly LD50 in weanking female rats administred in propylene glycol of those observed
when administered intraperitoneally in dimethylsulfoxyde (DMSO) (P< 0.05) (Glinsukon et
al., 1980). Guinea pigs are the most susceptible species to capsaicin toxicity with LD50 of 1.10
mg/mg, whereas hamsters and rabbits are less susceptible (Glinsukon et al., 1980).
The main results of these toxicological observations were as follows: LD50 values were 7.65
(5.28 – 11.09) for male and 6.50 (4.33-9.75) mg /kg for female mice; 10.40 (9.71 – 18.12) mg/ kg
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for rats; 1.10 (0.79 – 1, 52) mg /kg for guinea pig; > 50 mg/kg for rabbits and > 120 mg/kg for
hamsters (Glinsukon et al., 1980).
The relative lethality of capsaicin administered by various routes in the mouse:
• 0.56 (0.36 – 0.87) mg/ kg intravenously,
• 1.60 (1.03-2.48) mg/kg intratracheally,
• 7.65 (5.28 – 11.09) mg/ kg intraperitoneally,
• 7.80 (5.53 – 10.99) mg/kg subcutaneusly,
• 60 to 190 mg/kg intragastrically,
• > 218 mg/kg intrarectally and
• > 512 mg/kg dermally (Glinsukon et al., 1980).
At the autopsy, only hyperemia without hemorrhage was observed in the visceral organs and
the muscular wall of the peritoneal cavity with a slight increase in the amount of peritoneal
fluid in the rats treated intraperitotoenally treated with capsaicin. A similar observation was
also found in mice treated intraperitoneally with capsaicin. Histopathologic changes seen in
the gastric mucosa of mice treated intragastrically with capsaicin was desquamatic necrosis
with increase mucus material (PAS’s Schiff stain). Some of the chief and parietal cells showed
an appearance of pale basophylic cytoplasm and vacuolization. No significant histopatholog‐
ical changes were observed in other organs.
The pattern of the electrocardiogram and heart rate did not change for 5 min after capsaicin
adminsitration. Respiratory rates were slightly increased during the first min, whereas a small
increase of the tidal volume was also observed. The tidal volume then decreased to 10 to 20
per cent of the control whithin 3-4 min and the respiration stopped. During this time, heart
rate gradually decreased and electrocardiograph signals disappeared much later (in about 6-14
min). Mean arterial pressure was variable in the rats treated with capsaicin. At the beginning,
capsaicin causes a transient hypotension and followed by hypertensive period. Mean arterial
pressure gradually decreased along with the decrease in the tidal volume. Convulsions were
not observed in these anesthetized with a lethal dose of capsaicin. This finding was confirnmed
in mice anesthetized with sodium barbital and subsequently given a single lethal dose of
capsaicin.
The LD50 values indicate a high susceptibility, in guinea pigs, rats and mice, whereas hamsters
and rabbits are less susceptible to capsaicin. Capsaicin is a highly toxic compound when
administered by all routes except gastric, rectal and dermal. Cabanac et al. (1976) published a
report on the acute toxicity of capsaicin in which adult male rats were given four increasing
subcutaneosly doses of capsaicin (cumulative amount of 21.0 to 66.0 mg/kg).
The letality of capsaicin administered gastrically to the mouse is much more less than that of
the intraperitoneal adminsitration route. The minimum lethal dose of capsaicin per kg was 100
mg, which would be contained in 32.4 g dry weigth of fruits. For a 60 kg person, this toxic level
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would be comparable to the consumption of about 1.94 kg of dry weet of capsinum fruits, this
prevents the over consumption of this spice (Molnar, 1965).
4.3.2. Acute toxicity studies with pure trans-capsaicin derivated to dogs after intravenous
administration
The trans-geometric isomer of capsaicin, or trans-8-methyl-N-vanillyl-6-nonenamide, is the
most abundant pungent molecule in chilli peppers and thus represents the most important
ingredient in spicy foods. Although there are two geometric isomers of capsaicin (trans and
cis), only trans-capsaicin occurs naturally (Cordell and Araujo, 1993). The capsaicin content of
chilli peppers ranges from 0.1 to 1.0 % w/w (Govindajarajan and Sathyanarayna, 1991).
Furthermore, this food addidive has been widely used to evaluate the different physiological
or pathological regulatory mechanisms in the human observation in the form of non-prescrip‐
tion (in USA) or prescribtion (in the Europe) topical analgetics, and self-defense products (e.g.
pepper spray).
The trans-geometric isomer of capsaicin is a highly selective agonist for the transient receptor
potential vanilloid receptor 1 (TRVP1 or also known as VR1 according to older nomenclature)
(Caterina et al., 1997).
TRVP1 is a ligand-gated, non-selective, cation channel preferentially expressed in small-
diameter in primary afferent neurones (C-fibres and Aδ-fibres), especially nociceptive sensory
nerves. TRPV1 responds to noxious stimuli including capsaicin, heat and extracellular
acidification, and integrates simultaneous exposures to these stimuli (Tominaga et al., 1998).
Based on the highly selective agonistic property of capsaicin toward TRVP1 receptors, drug
products containing pure synthetic trans-capsaicin are under evaluation as topical and
injectable therapies (Bley, 2004).
Formal studies of the toxicological potential of capsaicin in vivo began in 1935, when De Lille
and Ramirez (1935) reported that administration of a capsaicin extract into dogs produces a
fall in blood pressure accompanied by variable effect on the respiration, an increase is salivary
secretion, and a relatively small increase in gastric secretion. The capsaicin can really be
increased the buffering (“non-periatal component“ of the gastric secretion, in association with
the decrease of “parietal component“ of gastric secretion by the application of pure capsaicin
(Sigma, USA) in the human healthy subjects (Mózsik et al., 2007).
The capsaicin materials tested in the studies cited above were generally natural extracts and
may not exhibit the same toxicological profile as pure synthetic trans-capsaicin. Although the
extract content and nature of impurities in the test articles used in these studies are often not
explicitly stated, a typical capsaicin extract is a mixture of trans-capsaicin (cis-capsaicin does
not occur naturally) and other capsaicinoids (including capsaicin, nordyhydrocapsaicin,
dihydrocapsaicin, homocapsaicin and homodihydrocapsaicin). Earlier Burk et al. (1986)
clearly proved that there is no physiological difference of between the application of capsaicin
or dihydrocapsaicin in animal experiments.
The actual percent of capsaicin and other capsaicinoids will vary depending on the peppers
used and method of extraction. In fact, the United States Pharmacopoecia definies capsaicin
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for rats; 1.10 (0.79 – 1, 52) mg /kg for guinea pig; > 50 mg/kg for rabbits and > 120 mg/kg for
hamsters (Glinsukon et al., 1980).
The relative lethality of capsaicin administered by various routes in the mouse:
• 0.56 (0.36 – 0.87) mg/ kg intravenously,
• 1.60 (1.03-2.48) mg/kg intratracheally,
• 7.65 (5.28 – 11.09) mg/ kg intraperitoneally,
• 7.80 (5.53 – 10.99) mg/kg subcutaneusly,
• 60 to 190 mg/kg intragastrically,
• > 218 mg/kg intrarectally and
• > 512 mg/kg dermally (Glinsukon et al., 1980).
At the autopsy, only hyperemia without hemorrhage was observed in the visceral organs and
the muscular wall of the peritoneal cavity with a slight increase in the amount of peritoneal
fluid in the rats treated intraperitotoenally treated with capsaicin. A similar observation was
also found in mice treated intraperitoneally with capsaicin. Histopathologic changes seen in
the gastric mucosa of mice treated intragastrically with capsaicin was desquamatic necrosis
with increase mucus material (PAS’s Schiff stain). Some of the chief and parietal cells showed
an appearance of pale basophylic cytoplasm and vacuolization. No significant histopatholog‐
ical changes were observed in other organs.
The pattern of the electrocardiogram and heart rate did not change for 5 min after capsaicin
adminsitration. Respiratory rates were slightly increased during the first min, whereas a small
increase of the tidal volume was also observed. The tidal volume then decreased to 10 to 20
per cent of the control whithin 3-4 min and the respiration stopped. During this time, heart
rate gradually decreased and electrocardiograph signals disappeared much later (in about 6-14
min). Mean arterial pressure was variable in the rats treated with capsaicin. At the beginning,
capsaicin causes a transient hypotension and followed by hypertensive period. Mean arterial
pressure gradually decreased along with the decrease in the tidal volume. Convulsions were
not observed in these anesthetized with a lethal dose of capsaicin. This finding was confirnmed
in mice anesthetized with sodium barbital and subsequently given a single lethal dose of
capsaicin.
The LD50 values indicate a high susceptibility, in guinea pigs, rats and mice, whereas hamsters
and rabbits are less susceptible to capsaicin. Capsaicin is a highly toxic compound when
administered by all routes except gastric, rectal and dermal. Cabanac et al. (1976) published a
report on the acute toxicity of capsaicin in which adult male rats were given four increasing
subcutaneosly doses of capsaicin (cumulative amount of 21.0 to 66.0 mg/kg).
The letality of capsaicin administered gastrically to the mouse is much more less than that of
the intraperitoneal adminsitration route. The minimum lethal dose of capsaicin per kg was 100
mg, which would be contained in 32.4 g dry weigth of fruits. For a 60 kg person, this toxic level
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would be comparable to the consumption of about 1.94 kg of dry weet of capsinum fruits, this
prevents the over consumption of this spice (Molnar, 1965).
4.3.2. Acute toxicity studies with pure trans-capsaicin derivated to dogs after intravenous
administration
The trans-geometric isomer of capsaicin, or trans-8-methyl-N-vanillyl-6-nonenamide, is the
most abundant pungent molecule in chilli peppers and thus represents the most important
ingredient in spicy foods. Although there are two geometric isomers of capsaicin (trans and
cis), only trans-capsaicin occurs naturally (Cordell and Araujo, 1993). The capsaicin content of
chilli peppers ranges from 0.1 to 1.0 % w/w (Govindajarajan and Sathyanarayna, 1991).
Furthermore, this food addidive has been widely used to evaluate the different physiological
or pathological regulatory mechanisms in the human observation in the form of non-prescrip‐
tion (in USA) or prescribtion (in the Europe) topical analgetics, and self-defense products (e.g.
pepper spray).
The trans-geometric isomer of capsaicin is a highly selective agonist for the transient receptor
potential vanilloid receptor 1 (TRVP1 or also known as VR1 according to older nomenclature)
(Caterina et al., 1997).
TRVP1 is a ligand-gated, non-selective, cation channel preferentially expressed in small-
diameter in primary afferent neurones (C-fibres and Aδ-fibres), especially nociceptive sensory
nerves. TRPV1 responds to noxious stimuli including capsaicin, heat and extracellular
acidification, and integrates simultaneous exposures to these stimuli (Tominaga et al., 1998).
Based on the highly selective agonistic property of capsaicin toward TRVP1 receptors, drug
products containing pure synthetic trans-capsaicin are under evaluation as topical and
injectable therapies (Bley, 2004).
Formal studies of the toxicological potential of capsaicin in vivo began in 1935, when De Lille
and Ramirez (1935) reported that administration of a capsaicin extract into dogs produces a
fall in blood pressure accompanied by variable effect on the respiration, an increase is salivary
secretion, and a relatively small increase in gastric secretion. The capsaicin can really be
increased the buffering (“non-periatal component“ of the gastric secretion, in association with
the decrease of “parietal component“ of gastric secretion by the application of pure capsaicin
(Sigma, USA) in the human healthy subjects (Mózsik et al., 2007).
The capsaicin materials tested in the studies cited above were generally natural extracts and
may not exhibit the same toxicological profile as pure synthetic trans-capsaicin. Although the
extract content and nature of impurities in the test articles used in these studies are often not
explicitly stated, a typical capsaicin extract is a mixture of trans-capsaicin (cis-capsaicin does
not occur naturally) and other capsaicinoids (including capsaicin, nordyhydrocapsaicin,
dihydrocapsaicin, homocapsaicin and homodihydrocapsaicin). Earlier Burk et al. (1986)
clearly proved that there is no physiological difference of between the application of capsaicin
or dihydrocapsaicin in animal experiments.
The actual percent of capsaicin and other capsaicinoids will vary depending on the peppers
used and method of extraction. In fact, the United States Pharmacopoecia definies capsaicin
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as a product which contains >55% capsaicin and in combination of capsaicin and dihydro‐
capsaicin to be >75%; total capsainoid content may be as little as 90% (United States Phar‐
macopoeica, 2005). Additionally, each extracts are expected to contain chemical entities other
than vanilloid compounds.
Chanda et al. (2005) performed observation with pure trans-capsaicin in dogs. The objectives
of their study were to evaluate the possible cardivascular and respiratory effects of the pure
capsaicin, and to evaluate the potential of any target organ toxicity and that might occur as a
result of introduction of the pure trans-capsaicin given into the systemic circulation in dogs.
These studies were carried out in approximatively 10-17 months old dogs weighed between
19 and 21.8 kg at the time of observations. Capsaicin for this study was dissolved in 10 % w/v
hydroxypropyl-β-cyclodextrin (Aldrich Chemical Gillingham, UK). Doses of capsaicin used
in the main study were 0.03, 0.1 and 0.3 mg/kg given intravenously. The studies were carried
out in acute observations and after two weeks of capsaicin (in doses of 0.03, 0.1 and 0.3 given
intravenously) treatment as well. Different biochemical parameters (glucose, urea nitrogen,
creatinine, total protein, albumin, albumin/globulin ratio, cholesterol, alanine aminotransfer‐
ase, alkaline phosphatae, calcium, gamma glutamyltransferase, inorganic phosphorus,
sodium, potassium, chloride, total bilirubin), hematological parameters (red blood count,
hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean
corpuscular hemoglobin concentration, platelet count, leucocyte count, different blood cell
count, blood smear, prothombin time, activated partial thromboplastin time). Urine sapmles
were tested for appearance/color, volume, specific gravidity, pH, protein, glucose, ketones,
bilirubin, blood, microscopic examination of urine sediments, and urobilinogen. At the
necropsy, the macroscopic observations were recorded, the organs were weighed, and selected
tissues were collected and preserved. Microscopic examinations were carried out from all the
tissue samples.
The capsaicin concentration of the plasma samples was determined by high performance
liquid chromatography (HPLC).
• All of these observations were carried out in acute and after two weeks capsaicin treatment.
• The studies reported were conducted according to the priciples of Good Laboratory Practice
(GLP). The trans-capsaicin (CAS 404-86-4) used in both the studies decribed was manufac‐
tured under the Current Good Manufacturing Practice (CGMP) conditions. The two batches
of trans-capsaicin used for the studies had > 99%.
• The main results of these observations with trans-capsaicin in acute administration (before
a chronic capsaicin treatment) are the followings:
4.3.2.1.Acute effects on cardiovascular and respiratory parameters
Administration of capsaicin (given in vehicle, 0.03 and 0.1 mg/kg) had no detectable effect on
the cardiac and respiratory systems. However, after administration of 0.3 mg/kg trans-
capsaicin elicited a rise in mean arterial blood pressure from a baseline of 96±7 to 138±21 mmHg
whithin 2 min of starting the infusion. This effect peaked at 146±17 mmHg at the end of infusion
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(15 min). The administration of the vehicle, capsaicin from 0.03 mg/kg to 0.1 mg/kg had no
measurable effectc on arterial blood pressure, change in force of ventricular contraction (dP/
dtmax), heart rate ECG waveform, and femoral blood flow. However, administration of 0.3 mg/
kg capsaicin elicited a rise in mean arterial blood pressure from a base line of 96±7 to 138±21
mmHg within 2min of starting the infusion. The hypertensive effect was accompanied by
increases in heart rate (from 71±3 at baseline to 119±25 bpm), dP/dtmax (from 4050±91 at baseline
to 6679±1027 mmHg/s) and femoral blood flow (from 117±27 at baseline to 174±34 mL/min).
These changes were statistically significant (P) in comparison with the results obtained after
application of vehicle, 0.03 or 0.1 mg/kg capsaicin injection.
The change in heart rate was also associated with decreases in the RR and QT intervals of the
ECG. However the corrected QT intervals (both QTCF and QTCB) were unchanged.
The administration of the vehicle elicited a decrease in deep of respiration. This was reflected
as decreases at 30 min post-infusion in tidal volume (TV) (from 143±19 to 118±20 mL), peak
inspiratory flow (PIF) (from 253 ±12 to 198±10 mLs) and peak expiratory flow (PEF) (from
297±47 to 246±24 mL/s). The rate of respiration was unaffected. After administration of 0.03
and 0.1 mg/kg trans-capsaicin did not elicit any further changes in respiration. After admin‐
istration of high (0.3 mg/kg) dose of trans-capsaicin (given intravenously) elicited increases in
PIF, PEF and TV. The increase of in PIF and PEF following 0.3 mg/kg trans-capsaicin is
significantly different from the decrease in these parameters following the vehicle treatment
(P<0.05). However, these increases were transients, lasting for only 5 to 10 min following the
infusion.
4.3.2.2. Plasma levels of capsaicin
No detectable levels of capsaicin were found 5 min after administration of 0.05 mg/kg
capsaicin. Following the administration of the intermediate dose (0.1 mg/kg i.v.), two and four
dogs showed detectable levels of capsacinin (in ranges approximatively 17 and 11 ng/mL). The
high dose (0.3 mg/kg) produced an increase in the plasma levels in all dogs (ranging 32.2 to
65.6 ng/mL, mean of 47.9±6.4 ng/mL).
4.3.3. Results of subacute toxicology of capsaicin in dogs
4.3.3.1. Two weeks treatment with trans-capsaicin
All dogs survived until scheduled termination on Day 15. Only capsaicin solution-related
clinical sign observed during the study was vacualization during dosing, which was noted in
all dogs.
In general, the observation was noted more frequently in male dogs than in female dogs. Clear
nasal discharge was seen across all groups, and the daily incidence was slighly higher in male
than in females given 0.3 mg/kg trans-capsaicin (intravenously), althought the daily incidence
in males given 0.1 or 0.3 mg/kg/day of trans-capsaicin and in females given 0.3 mg/kg/day was
slightly higher than controls. Slight tremors (head, limbs and/or body) were seen across all
groups during this study. The majority of these observations were noted during the study.
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as a product which contains >55% capsaicin and in combination of capsaicin and dihydro‐
capsaicin to be >75%; total capsainoid content may be as little as 90% (United States Phar‐
macopoeica, 2005). Additionally, each extracts are expected to contain chemical entities other
than vanilloid compounds.
Chanda et al. (2005) performed observation with pure trans-capsaicin in dogs. The objectives
of their study were to evaluate the possible cardivascular and respiratory effects of the pure
capsaicin, and to evaluate the potential of any target organ toxicity and that might occur as a
result of introduction of the pure trans-capsaicin given into the systemic circulation in dogs.
These studies were carried out in approximatively 10-17 months old dogs weighed between
19 and 21.8 kg at the time of observations. Capsaicin for this study was dissolved in 10 % w/v
hydroxypropyl-β-cyclodextrin (Aldrich Chemical Gillingham, UK). Doses of capsaicin used
in the main study were 0.03, 0.1 and 0.3 mg/kg given intravenously. The studies were carried
out in acute observations and after two weeks of capsaicin (in doses of 0.03, 0.1 and 0.3 given
intravenously) treatment as well. Different biochemical parameters (glucose, urea nitrogen,
creatinine, total protein, albumin, albumin/globulin ratio, cholesterol, alanine aminotransfer‐
ase, alkaline phosphatae, calcium, gamma glutamyltransferase, inorganic phosphorus,
sodium, potassium, chloride, total bilirubin), hematological parameters (red blood count,
hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean
corpuscular hemoglobin concentration, platelet count, leucocyte count, different blood cell
count, blood smear, prothombin time, activated partial thromboplastin time). Urine sapmles
were tested for appearance/color, volume, specific gravidity, pH, protein, glucose, ketones,
bilirubin, blood, microscopic examination of urine sediments, and urobilinogen. At the
necropsy, the macroscopic observations were recorded, the organs were weighed, and selected
tissues were collected and preserved. Microscopic examinations were carried out from all the
tissue samples.
The capsaicin concentration of the plasma samples was determined by high performance
liquid chromatography (HPLC).
• All of these observations were carried out in acute and after two weeks capsaicin treatment.
• The studies reported were conducted according to the priciples of Good Laboratory Practice
(GLP). The trans-capsaicin (CAS 404-86-4) used in both the studies decribed was manufac‐
tured under the Current Good Manufacturing Practice (CGMP) conditions. The two batches
of trans-capsaicin used for the studies had > 99%.
• The main results of these observations with trans-capsaicin in acute administration (before
a chronic capsaicin treatment) are the followings:
4.3.2.1.Acute effects on cardiovascular and respiratory parameters
Administration of capsaicin (given in vehicle, 0.03 and 0.1 mg/kg) had no detectable effect on
the cardiac and respiratory systems. However, after administration of 0.3 mg/kg trans-
capsaicin elicited a rise in mean arterial blood pressure from a baseline of 96±7 to 138±21 mmHg
whithin 2 min of starting the infusion. This effect peaked at 146±17 mmHg at the end of infusion
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(15 min). The administration of the vehicle, capsaicin from 0.03 mg/kg to 0.1 mg/kg had no
measurable effectc on arterial blood pressure, change in force of ventricular contraction (dP/
dtmax), heart rate ECG waveform, and femoral blood flow. However, administration of 0.3 mg/
kg capsaicin elicited a rise in mean arterial blood pressure from a base line of 96±7 to 138±21
mmHg within 2min of starting the infusion. The hypertensive effect was accompanied by
increases in heart rate (from 71±3 at baseline to 119±25 bpm), dP/dtmax (from 4050±91 at baseline
to 6679±1027 mmHg/s) and femoral blood flow (from 117±27 at baseline to 174±34 mL/min).
These changes were statistically significant (P) in comparison with the results obtained after
application of vehicle, 0.03 or 0.1 mg/kg capsaicin injection.
The change in heart rate was also associated with decreases in the RR and QT intervals of the
ECG. However the corrected QT intervals (both QTCF and QTCB) were unchanged.
The administration of the vehicle elicited a decrease in deep of respiration. This was reflected
as decreases at 30 min post-infusion in tidal volume (TV) (from 143±19 to 118±20 mL), peak
inspiratory flow (PIF) (from 253 ±12 to 198±10 mLs) and peak expiratory flow (PEF) (from
297±47 to 246±24 mL/s). The rate of respiration was unaffected. After administration of 0.03
and 0.1 mg/kg trans-capsaicin did not elicit any further changes in respiration. After admin‐
istration of high (0.3 mg/kg) dose of trans-capsaicin (given intravenously) elicited increases in
PIF, PEF and TV. The increase of in PIF and PEF following 0.3 mg/kg trans-capsaicin is
significantly different from the decrease in these parameters following the vehicle treatment
(P<0.05). However, these increases were transients, lasting for only 5 to 10 min following the
infusion.
4.3.2.2. Plasma levels of capsaicin
No detectable levels of capsaicin were found 5 min after administration of 0.05 mg/kg
capsaicin. Following the administration of the intermediate dose (0.1 mg/kg i.v.), two and four
dogs showed detectable levels of capsacinin (in ranges approximatively 17 and 11 ng/mL). The
high dose (0.3 mg/kg) produced an increase in the plasma levels in all dogs (ranging 32.2 to
65.6 ng/mL, mean of 47.9±6.4 ng/mL).
4.3.3. Results of subacute toxicology of capsaicin in dogs
4.3.3.1. Two weeks treatment with trans-capsaicin
All dogs survived until scheduled termination on Day 15. Only capsaicin solution-related
clinical sign observed during the study was vacualization during dosing, which was noted in
all dogs.
In general, the observation was noted more frequently in male dogs than in female dogs. Clear
nasal discharge was seen across all groups, and the daily incidence was slighly higher in male
than in females given 0.3 mg/kg trans-capsaicin (intravenously), althought the daily incidence
in males given 0.1 or 0.3 mg/kg/day of trans-capsaicin and in females given 0.3 mg/kg/day was
slightly higher than controls. Slight tremors (head, limbs and/or body) were seen across all
groups during this study. The majority of these observations were noted during the study.
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As the study progressed, dogs given 0.3 mg/kg trans-capsaicin demonstrated an apparent
tolerance to the general anesthetic and analgesic, as indicated by a general vacualization during
the dosing period.
There were no statistically significant differences in the body weights and food consumption
values, among the groups of dogs treated with capsaicin chronically. The body weights,
however, were slightly lower (in about 7 %) in males treated with 0.3 mg/kg trans-capsaicin
for 14 days. Over the duration of the study, males lost approximately 0.4 kg, whereas the
control gained 0.1 kg. Through this value statistically was not significant, the food consump‐
tion of males and females given 0.3 mg/kg/ day was sligthly lower than that of controls
(approximately 11 and 12 per cent, respectively).
4.3.3.2. Clinical chemistry and hematology
The only the difference considered related to test article was minimally higher ALT for males
and females given 0.3 mg/kg/day trans-capsaicin intravenously after l4-day treatment. Other
statistically significant differences for clinical chemistry test results were considered incidental,
because they did not exhibit dose relatioship and they were present before the initiation of
treatment. In hematology, WBC was statistically significant (P< 0.05) lower in female dogs in
the 0.3 mg/kg/day treated group. A few animals, including controls, had notably high
neutrophil counts, which were likely secondary to inflammated lesions at injection sites.
4.3.3.3. Organ weights, macroscopic and microscopic observations
There were no capsaicin solution-related organ weight changes, macroscopic or microscopic
observations.
The statistically significant differences with respect to controls of prostate, brain and adrenal
weight values were considered incidental because there were no correlating macroscopic and
microscopic findings. Thrombosis, due to administration of vehicle, was noted at the intrave‐
nous injection sites in all groups. Other lesions observed with the thrombosis induced
inflammmation, fibrosis, edema and hemorrhage.
4.3.3.4. Pharmacokinetic data after 14-day treatment with trans-capsaicin in dogs
After intravenous administration, peak of the plasma concentration (Cmax) was obtained in all
cases immediately at the end of infusion. Capsaicin was rapidly eliminated and measurable
values were only obtained immediately after the end of infusion (0.25 h) in 0.03, 0.1 and 0.3
mg/kg/day dose groups. In the 0.3 mg/kg/day group, measurable values were obtained at 0.5
h in all dogs on Day 1, but they were very close to the limit of quantitation (10 ng/mL). On Day
15, only one dog still had a measurable value at this timepoint.
Females generally had higher or similar mean Cmax values compared to males, but the largest
difference did not exceed 44%. The increases in mean Cmax for males and females were
throughly proportional to the increase of dose level from 0.03 to 0.3 mg/kg/day.
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4.3.4. Absorption and metabolism of oral application of the capsaicinoids in animal experiments
Due to the increasing experimental use and planned drug production in humans of capsaicin
in a very wide field of medical research and medical treatment, we have to know correct facts
on the absorption, metabolism and excretion of capsaicinoids.
It is known that capsaicin given directly into the stomach of rats has only minimal excitatory
effects on immediate blood pressure responses (Lippe et al., 1989) in contrast to intravascular
or subcutaneous administration (Donnerer and Lembeck, 1983). On the other hand it has been
shown that capsaicin disappears from the intestinal lumen whithin a rather short time
(Kawada et al., 1984) and should therefore reach the circulation.
Since biotransformed products of capsaicin are difficult to detect, the use of [3H]-labelled
dihydrocapsaicin ([3H]-DHC) allowed us to determine the percentage of unchanged com‐
pound in the total ectracted radioactivity. Dihydrocapsaicin (DHC) has been shown to display
pharmacodynamic and pharmacokinetic properties compared with those of capsaicin (Burk
et al., 1982; Kawada et al., 1984).
[3H]-dihydrocapsacin ([3H]-DHC) and unlabelled capsaicin were readily absorbed from the
gastrointestinal tract but were almost completely metabolized before reaching the general
circulation. A certain degree of biotransformation already took place in the intestinal lumen.
Unchanged compounds (identified by chromatography) were present in the portal vein blood.
These seem to be result of a saturable absorption and degradation process in the gastrointes‐
tinal tract and a very effective metabolism limit of the liver (Donnerer et al., 1990).
Less than 5% of the total amount of extracted radioactivity consisted of unchanged [3H]-DHC
in truck blood and brain 15 min after gastrointestinal application. On the other hand, approx‐
imatively 50% unchanged [3H]-DHC was detected in these tissues in 3 min after intravenously
application or 90 min after subcutaneously application of capsaicinoids (Donnerer et al.,
1990). Dihydrocapsaicin (DHC) or [3H]-DHC were metabolized when incubated in vitro with
liver tissue but not with brain tissue (Donnerer et al., 1990). The metabolic product(s) did not
show capsaicin-like biological activity (Donnerer et al., 1990). These results clearly indicate
that the rapid hepatic metabolization limits systemic pharmacological effects of enterally
absorbed capsaicin in rats (Donnerer et al., 1990)
4.3.5. Toxicological studies with pure trans-capsaicin derivated to dogs after intravenous administration
in acute and after subacute experimental circumstances
4.3.5.1. Chemistry of capsaicin
Trans-capsaicin, or trans-8-methyl-N-vanillyl-6-nonenamide, is the most abundant pungent
molecule in chilli peppers and thus represents the most important ingredient in spicy foods.
Although there are two geometric isomers of capsaicin, only the trans-isomer occurs in natural
sources (Cordell and Araujo, 1993). The capsaicin content of chilli peppers ranges from 0.1 to
1.0 % w/w (Govindajarajan and Sathyanarayna, 1991). Furthermore, this food addidive has
been widely used to evaluate the different physiological or pathological regulatory mecha‐
Clinical Pharmacological Approach of Capsaicin Action in GI Tract
http://dx.doi.org/10.5772/58359
299
As the study progressed, dogs given 0.3 mg/kg trans-capsaicin demonstrated an apparent
tolerance to the general anesthetic and analgesic, as indicated by a general vacualization during
the dosing period.
There were no statistically significant differences in the body weights and food consumption
values, among the groups of dogs treated with capsaicin chronically. The body weights,
however, were slightly lower (in about 7 %) in males treated with 0.3 mg/kg trans-capsaicin
for 14 days. Over the duration of the study, males lost approximately 0.4 kg, whereas the
control gained 0.1 kg. Through this value statistically was not significant, the food consump‐
tion of males and females given 0.3 mg/kg/ day was sligthly lower than that of controls
(approximately 11 and 12 per cent, respectively).
4.3.3.2. Clinical chemistry and hematology
The only the difference considered related to test article was minimally higher ALT for males
and females given 0.3 mg/kg/day trans-capsaicin intravenously after l4-day treatment. Other
statistically significant differences for clinical chemistry test results were considered incidental,
because they did not exhibit dose relatioship and they were present before the initiation of
treatment. In hematology, WBC was statistically significant (P< 0.05) lower in female dogs in
the 0.3 mg/kg/day treated group. A few animals, including controls, had notably high
neutrophil counts, which were likely secondary to inflammated lesions at injection sites.
4.3.3.3. Organ weights, macroscopic and microscopic observations
There were no capsaicin solution-related organ weight changes, macroscopic or microscopic
observations.
The statistically significant differences with respect to controls of prostate, brain and adrenal
weight values were considered incidental because there were no correlating macroscopic and
microscopic findings. Thrombosis, due to administration of vehicle, was noted at the intrave‐
nous injection sites in all groups. Other lesions observed with the thrombosis induced
inflammmation, fibrosis, edema and hemorrhage.
4.3.3.4. Pharmacokinetic data after 14-day treatment with trans-capsaicin in dogs
After intravenous administration, peak of the plasma concentration (Cmax) was obtained in all
cases immediately at the end of infusion. Capsaicin was rapidly eliminated and measurable
values were only obtained immediately after the end of infusion (0.25 h) in 0.03, 0.1 and 0.3
mg/kg/day dose groups. In the 0.3 mg/kg/day group, measurable values were obtained at 0.5
h in all dogs on Day 1, but they were very close to the limit of quantitation (10 ng/mL). On Day
15, only one dog still had a measurable value at this timepoint.
Females generally had higher or similar mean Cmax values compared to males, but the largest
difference did not exceed 44%. The increases in mean Cmax for males and females were
throughly proportional to the increase of dose level from 0.03 to 0.3 mg/kg/day.
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4.3.4. Absorption and metabolism of oral application of the capsaicinoids in animal experiments
Due to the increasing experimental use and planned drug production in humans of capsaicin
in a very wide field of medical research and medical treatment, we have to know correct facts
on the absorption, metabolism and excretion of capsaicinoids.
It is known that capsaicin given directly into the stomach of rats has only minimal excitatory
effects on immediate blood pressure responses (Lippe et al., 1989) in contrast to intravascular
or subcutaneous administration (Donnerer and Lembeck, 1983). On the other hand it has been
shown that capsaicin disappears from the intestinal lumen whithin a rather short time
(Kawada et al., 1984) and should therefore reach the circulation.
Since biotransformed products of capsaicin are difficult to detect, the use of [3H]-labelled
dihydrocapsaicin ([3H]-DHC) allowed us to determine the percentage of unchanged com‐
pound in the total ectracted radioactivity. Dihydrocapsaicin (DHC) has been shown to display
pharmacodynamic and pharmacokinetic properties compared with those of capsaicin (Burk
et al., 1982; Kawada et al., 1984).
[3H]-dihydrocapsacin ([3H]-DHC) and unlabelled capsaicin were readily absorbed from the
gastrointestinal tract but were almost completely metabolized before reaching the general
circulation. A certain degree of biotransformation already took place in the intestinal lumen.
Unchanged compounds (identified by chromatography) were present in the portal vein blood.
These seem to be result of a saturable absorption and degradation process in the gastrointes‐
tinal tract and a very effective metabolism limit of the liver (Donnerer et al., 1990).
Less than 5% of the total amount of extracted radioactivity consisted of unchanged [3H]-DHC
in truck blood and brain 15 min after gastrointestinal application. On the other hand, approx‐
imatively 50% unchanged [3H]-DHC was detected in these tissues in 3 min after intravenously
application or 90 min after subcutaneously application of capsaicinoids (Donnerer et al.,
1990). Dihydrocapsaicin (DHC) or [3H]-DHC were metabolized when incubated in vitro with
liver tissue but not with brain tissue (Donnerer et al., 1990). The metabolic product(s) did not
show capsaicin-like biological activity (Donnerer et al., 1990). These results clearly indicate
that the rapid hepatic metabolization limits systemic pharmacological effects of enterally
absorbed capsaicin in rats (Donnerer et al., 1990)
4.3.5. Toxicological studies with pure trans-capsaicin derivated to dogs after intravenous administration
in acute and after subacute experimental circumstances
4.3.5.1. Chemistry of capsaicin
Trans-capsaicin, or trans-8-methyl-N-vanillyl-6-nonenamide, is the most abundant pungent
molecule in chilli peppers and thus represents the most important ingredient in spicy foods.
Although there are two geometric isomers of capsaicin, only the trans-isomer occurs in natural
sources (Cordell and Araujo, 1993). The capsaicin content of chilli peppers ranges from 0.1 to
1.0 % w/w (Govindajarajan and Sathyanarayna, 1991). Furthermore, this food addidive has
been widely used to evaluate the different physiological or pathological regulatory mecha‐
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nisms in the human observation in the form of non-prescription (in the USA) or prescribtion
(in Europe) topical analgetics, and self-defense products (e.g. pepper spray).
The trans-geometric isomer of capsaicin is a highly selective agonist for the transient receptor
potential vanilloid receptor 1 (TRVP1 or as known VR1 according to older nomenclature)
(Caterina et al., 1997).
TRVP1 is a ligand-gated, non-selective, cation channel preferentially expressed in small-
diameter, primary afferent neurones (C-fibres and Aδ-fibres), especially nociceptive sensory
nerves. TRPV1 responds to noxious stimuli including capsaicin, heat and extracellular
acidification, and integrates simultaneous exposures to these stimuli (Tominaga et al., 1998).
Based on the highly selective agonistic property of capsaicin toward TRVP1 receptors, drug
products containing pure synthetic trans-capsaicin are under evaluation as topical and
injectable therapies (Bley, 2004).
Formal studies of the toxicological potential of capsaicin in vivo began in 1935, when De Lille
and Ramirez (1935) reported that administration of a capsaicin extract into dogs produced a
fall in blood pressure accompanied by variable effect on the respiration, an increase is salivary
secretion, and a relatively small increase in gastric secretion. The capsaicin really can increase
the buffering (“non-perietal component“ of the gastric secretion, in association with the
decrease of “parietal component“ of gastric secretion by the application of pure capsaicin
(Sigma, USA) in human healthy subjects (Mózsik et al., 2007a).
The capsaicin materials tested in the studies cited above were either natural extracts or racemic
mixtures, and may not exhibit the same toxicological profile as pure trans-capsaicin. Although
the extract content and nature of impurities in the test articles used in these studies are often
not explicitly stated, a typical capsaicin extract is a mixture of trans-capsaicin (cis-capsaicin
does not occur naturally) and other capsaicinoids (including capsaicin, nordyhydrocapsaicin,
dihydrocapsaicin, homocapsaicin and homodihydrocapsaicin). Earlier Burk et al. (1986)
clearly proved that there is no physiological difference between the applications of capsaicin
and dihydrocapsaicin in animal experiments).
4.3.5.2. Observations in acute experiments in the dogs
The actual percent of capsaicin and other capsaicinoids will vary depending on the peppers
used and method of extraction: In fact, the United States Pharmacopocia definies capsaicin as
a product which contains >55% capsaicin and in combination of capsaicin and dihydrocap‐
saicin to be >75%; total capsainoid content may be as little as 90% (United States Pharmaco‐
poeica, 2005). Additionally, per extracts are expected to contain chemical entities other than
vanilloid compounds.
Chanda et al. (2005) did observation with pure trans-capsaicin in dogs.The objectives of this
study were to evaluate the possible cardiovascular and respiratory effects of the pure capsaicin,
and to evaluate the potential of any target organ toxicity and that might occur as a result of
introduction of the pure trans-capsaicin given into the systemic circulation in dogs.
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These studies were carried out in dogs, approximatively 10-l7 months old and weighed
between 19 and 21.8 kg at the time of observations. Capsaicin for this study was dissolved in
10 % w/v hydroxypropyl-β-cyclodextrin (Aldrich Chemical, Gillingham, UK). Doses of
capsaicin used in the main study were 0.03, 0.1 and 0.3 mg/kg given intravenously. The studies
were carried out in acute observations, and after two weeks capsaicin (in doses of 0.03, 0,1 0nd
0,3 mg/ kg given intravenously) treatment. Different biochemical parameters (glucose,urea
nitrogen, creatinine, total protein, albumin, albumin / globulin ratio, cholesterol, alanine
aminotransferase, alkaline phosphatae, calcium, gamma glutamyltransferase, inorganic
phosphorus, sodium, potassium, chloride, total bilirubin), hematological parameters (red
blood count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglo‐
bin, mean corpuscular hemoglobin concentration, platelet count, leucocyte count, differenrt
blood cell count, blood smear, prothombin time, activated partial thromboplastin time). Urine
samples were tested for appearance/color parameters, volume, specific gravidity, pH, protein,
glucose, ketones, bilirubin, blood, microscopic examination of urine sediments, and urobili‐
nogen. At the necropsy, the macroscopic observations were recorded, the organs were
weighted, and selected tissues were colected ans presenved. Microscopic examinations were
carried out from all the tissue samples.
The capsaicin concentration of the plasma samples was determined by high performance
liquid chromatography (HPLC).
All of these observations were carried out in acute and after two weeks capsaicin treatment.
The studies reported were conducted according to the priciples of Good Laboratory Practice
(GLP). The trans-capsaicin (CAS 404-86-4) used in both the studies decribed was manufactured
under the Current Good Manufacturing Practice (CGMP) conditions. The two batches of trans-
capsaicin used for the studies had > 99%.
The main results of these observations with trans-capsaicin in acute administration (before a
chronic capsaicin treatments) are as follows:
Administration of capsaicin (given in vehicle, 0.03 and 0.1 mg/kg) had no detectable effect on
the cardiac and respiratory systems. However, after administration of 0.3 mg/kg trans-
capsaicin elicited a rise in mean arterial blood pressure from a baseline of 96±7 to 138±21 mm
Hg whithin 2 min of starting the infusion. This effect peaked at 146±17 mmHg at the end of
infusion (15 min). The hypertensive effect was accompanied by increases in heart rate (from
71±3 at baseline to 119±25 bpm) left ventricular pressure and derivitave (dP/dtmax) (from
4050±91 at baseline to 6679± 1079 mmHgs), and femoral blood flow (from 117±27 at baseline
to 174±35 mL/min). These changes were statistically significant in comparison with the results
obtained after vehicle, 0.03 or 0.1 mg/ kg capsaicin injection
Administration of the vehicle elicited a decrease in deep of respiration. This was reflected as
decreases at 30 min post-infusion in tidal volume (TV) (from 143±19 to 118±20 mL), peak
inspiratory flow (PIF) (from 253 ±12 to 198±10 mLs) and peak expiratory flow (PEF) (from
297±47 to 246±24 mL/s).The rate of respiration was unaffected. After administration of 0.0.3
and 0.1 mg / kg trans-capsaicin did not elicit any further changes in respiration. After admin‐
istration of high (0.3 mg/kg) dose of trans-capsaicin (given intravenously) elicited increases in
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nisms in the human observation in the form of non-prescription (in the USA) or prescribtion
(in Europe) topical analgetics, and self-defense products (e.g. pepper spray).
The trans-geometric isomer of capsaicin is a highly selective agonist for the transient receptor
potential vanilloid receptor 1 (TRVP1 or as known VR1 according to older nomenclature)
(Caterina et al., 1997).
TRVP1 is a ligand-gated, non-selective, cation channel preferentially expressed in small-
diameter, primary afferent neurones (C-fibres and Aδ-fibres), especially nociceptive sensory
nerves. TRPV1 responds to noxious stimuli including capsaicin, heat and extracellular
acidification, and integrates simultaneous exposures to these stimuli (Tominaga et al., 1998).
Based on the highly selective agonistic property of capsaicin toward TRVP1 receptors, drug
products containing pure synthetic trans-capsaicin are under evaluation as topical and
injectable therapies (Bley, 2004).
Formal studies of the toxicological potential of capsaicin in vivo began in 1935, when De Lille
and Ramirez (1935) reported that administration of a capsaicin extract into dogs produced a
fall in blood pressure accompanied by variable effect on the respiration, an increase is salivary
secretion, and a relatively small increase in gastric secretion. The capsaicin really can increase
the buffering (“non-perietal component“ of the gastric secretion, in association with the
decrease of “parietal component“ of gastric secretion by the application of pure capsaicin
(Sigma, USA) in human healthy subjects (Mózsik et al., 2007a).
The capsaicin materials tested in the studies cited above were either natural extracts or racemic
mixtures, and may not exhibit the same toxicological profile as pure trans-capsaicin. Although
the extract content and nature of impurities in the test articles used in these studies are often
not explicitly stated, a typical capsaicin extract is a mixture of trans-capsaicin (cis-capsaicin
does not occur naturally) and other capsaicinoids (including capsaicin, nordyhydrocapsaicin,
dihydrocapsaicin, homocapsaicin and homodihydrocapsaicin). Earlier Burk et al. (1986)
clearly proved that there is no physiological difference between the applications of capsaicin
and dihydrocapsaicin in animal experiments).
4.3.5.2. Observations in acute experiments in the dogs
The actual percent of capsaicin and other capsaicinoids will vary depending on the peppers
used and method of extraction: In fact, the United States Pharmacopocia definies capsaicin as
a product which contains >55% capsaicin and in combination of capsaicin and dihydrocap‐
saicin to be >75%; total capsainoid content may be as little as 90% (United States Pharmaco‐
poeica, 2005). Additionally, per extracts are expected to contain chemical entities other than
vanilloid compounds.
Chanda et al. (2005) did observation with pure trans-capsaicin in dogs.The objectives of this
study were to evaluate the possible cardiovascular and respiratory effects of the pure capsaicin,
and to evaluate the potential of any target organ toxicity and that might occur as a result of
introduction of the pure trans-capsaicin given into the systemic circulation in dogs.
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These studies were carried out in dogs, approximatively 10-l7 months old and weighed
between 19 and 21.8 kg at the time of observations. Capsaicin for this study was dissolved in
10 % w/v hydroxypropyl-β-cyclodextrin (Aldrich Chemical, Gillingham, UK). Doses of
capsaicin used in the main study were 0.03, 0.1 and 0.3 mg/kg given intravenously. The studies
were carried out in acute observations, and after two weeks capsaicin (in doses of 0.03, 0,1 0nd
0,3 mg/ kg given intravenously) treatment. Different biochemical parameters (glucose,urea
nitrogen, creatinine, total protein, albumin, albumin / globulin ratio, cholesterol, alanine
aminotransferase, alkaline phosphatae, calcium, gamma glutamyltransferase, inorganic
phosphorus, sodium, potassium, chloride, total bilirubin), hematological parameters (red
blood count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglo‐
bin, mean corpuscular hemoglobin concentration, platelet count, leucocyte count, differenrt
blood cell count, blood smear, prothombin time, activated partial thromboplastin time). Urine
samples were tested for appearance/color parameters, volume, specific gravidity, pH, protein,
glucose, ketones, bilirubin, blood, microscopic examination of urine sediments, and urobili‐
nogen. At the necropsy, the macroscopic observations were recorded, the organs were
weighted, and selected tissues were colected ans presenved. Microscopic examinations were
carried out from all the tissue samples.
The capsaicin concentration of the plasma samples was determined by high performance
liquid chromatography (HPLC).
All of these observations were carried out in acute and after two weeks capsaicin treatment.
The studies reported were conducted according to the priciples of Good Laboratory Practice
(GLP). The trans-capsaicin (CAS 404-86-4) used in both the studies decribed was manufactured
under the Current Good Manufacturing Practice (CGMP) conditions. The two batches of trans-
capsaicin used for the studies had > 99%.
The main results of these observations with trans-capsaicin in acute administration (before a
chronic capsaicin treatments) are as follows:
Administration of capsaicin (given in vehicle, 0.03 and 0.1 mg/kg) had no detectable effect on
the cardiac and respiratory systems. However, after administration of 0.3 mg/kg trans-
capsaicin elicited a rise in mean arterial blood pressure from a baseline of 96±7 to 138±21 mm
Hg whithin 2 min of starting the infusion. This effect peaked at 146±17 mmHg at the end of
infusion (15 min). The hypertensive effect was accompanied by increases in heart rate (from
71±3 at baseline to 119±25 bpm) left ventricular pressure and derivitave (dP/dtmax) (from
4050±91 at baseline to 6679± 1079 mmHgs), and femoral blood flow (from 117±27 at baseline
to 174±35 mL/min). These changes were statistically significant in comparison with the results
obtained after vehicle, 0.03 or 0.1 mg/ kg capsaicin injection
Administration of the vehicle elicited a decrease in deep of respiration. This was reflected as
decreases at 30 min post-infusion in tidal volume (TV) (from 143±19 to 118±20 mL), peak
inspiratory flow (PIF) (from 253 ±12 to 198±10 mLs) and peak expiratory flow (PEF) (from
297±47 to 246±24 mL/s).The rate of respiration was unaffected. After administration of 0.0.3
and 0.1 mg / kg trans-capsaicin did not elicit any further changes in respiration. After admin‐
istration of high (0.3 mg/kg) dose of trans-capsaicin (given intravenously) elicited increases in
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PIF, PEF and TV. The increase of in PIF and PEF folloowing 0.3 mg/kg trans-capsaicin is
significantly different from the decrease in these parameters following the vehicle treatment
(P<0.05). However, these increases were transients, lasting only 5 to 10 min after the end of
infusion.
No detectable levels of capsaicin were found in the plasma level at 5 min after administration
of 0.05 mg/kg capsaicin. Following the administration of the intermediate dose (0.1 mg/kg i.v.),
two and four dogs showed detectable levels of capsacinin (in ranges approximatively 17 and
11 ng/mL). The high dose (0.3 mg/kg) produced an increase in the plasma levels in all dogs
(ranging 32.2 to 65.6 ng/mL, mean of 47.9±6.4 ng /mL).
4.3.5.3. Results of the subacute and chronic toxicology of capsaicinoid in dogs
All dogs survived until the scheduled termination on day 15. Only capsaicin solution-related
clinical sign observed during the study was vacualization during dosing, which was noted in
all dogs.
In general, the observation was noted more frequently in male dogs than in female dogs. Clear
nasal discharge was seen across all groups, and the daily incidence was slighly higher in male
than in females given 0.3 mg/kg trans-capsaicin (intravenously), althought the daily incidence
in males given 0.1 or 0.3 mg/kg/ day of trans-capsaicin and in females 0.3 mg/kg/day was
slightly higher than controls. Slight tremors (head,l imbs, and/or body) were seen across all
groups during this study. The majority of these observations were noted during the study.
As the study progressed, dogs given 0.3 mg/kg trans-capsaicin demonstrated an apparent
tolerance to the general anesthetic and analgesic, as indicated by a general vacualization during
the dosing period.
There were no statistically significant differences in the body weights and food consumption
values, among the groups of dogs treated chronically. The body weights, however, were
slightly lower (in about 7 %) in males treated with 0.3 mg/kg trans-capsaicin for 14 days. Over
the duration of the study, males in this group lost approximately 0.4 kg, whereas the control
gained 0.1 kg. Altough it was statistically not significant, the food consumption of males and
females given 0.3 mg/kg/day was sligthly lower than that of controls (approximately 11 and
12 per cent, respectively) (Changa et al., 2005).
4.3.5.4. Clinical chemistry and hematology
The results of the clinical chemistry [aminotransferase (ALT), aspartate aminotransferase
(AST) and alkaline phosphatase], and hematology (RBC, count of MCV, MCV, platelet
count,WBC) tests from days – 1 and 15 only are measured. There were few statistically
significant or otherwise notable differences for clinical chemistry test results between the
control and treated animals.
The only the difference considered related to test article was minimally higher ALT for males
and females given 0.3 mg/kg/day trans-capsaicin intravenously after l4 days treatment. Other
significant differences for clinical chemistry test results were considered incidental because
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they exhibited no dose relationship or were present before initiation of the treatment. In
hematology, female dogs in the 0.3 mg/kg/day treated group the WBC was statistically
significant (P< 0.05) lower. A few animals, including controls, had notably high neutrophil
counts, which were like secondary to inflammated lesions at injection sites.
4.3.5.5. Organ weights, macroscopic and microscopic observations
There were no capsaicin solution-related organ weight changes in macroscopic or microscopic
observations.
The statistically significant differences with respect to controls of prostate, brain and adrenal
weight values were considered incidental because there were no correlating macroscopic and
microscopic findings.
Thrombosis, due to administration of vehicle, was noted at the intravenous injection sites in
all groups. Other lesions observed with the thrombosis induced inflammation, fibrosis, edema
and hemorrhage.
4.3.5.6. Pharmacokinetic data after 14 days treatment with trans-capsaicin in dogs
After intravenous administration, peak plasma concentration (Cmax) was attained in all cases
immediately after the end of infusion. Capsaicin was rapidly eliminated and measurable
values were only obtained immediately after the end of infusion (0.25 hour) in 0.03, 0.1 and
0.3 mg/kg/day dosage groups. In the 0.3 mg/kg/day group, measurable values were obtained
out to 0.5 hour in all dogs on day 1, but they were very close to the limit of quantitation (10
ng/mL). On day 15, only one dog still had a measurable value at this timepoint.
Females generally had higher or similar mean Cmax values compared to males, but the largest
difference did not exceed 44%. The increases in mean Cmax for males and females were
throughly proportional to the increase of dose level from 0.03 to 0.3 mg/kg/day. Mean Cmax
values for males increased 1: 3.3: 10-fold on Day 1 and 1: 2.9: 9.2 fold on Day 14. These results
clearly indicate that no acumulation exists to capsaicin after multiple dosing by this route of
its administration (Chanda et al., 2005).
4.3.5.7. Summary and conclusions of the administration of trans-capsaicin in its acute and subacute
experiments in dogs (on dependence of different doses of trans-capsaicin)
In the acute study, surface lead II ECG was monitored to determine the QTc intevals and the
duration of cardiac repolarization. However, there were no observable changes in the QTCF
(Fridericia’s correlation QTCF, QTCF=QT/3√ (RR intervall)). Such a change would have been
theoretically possible, as capsaicin has been reported to block voltage-activated potassium
channels in rat ventricular myocytes (Castle, 1992). Because many drugs are able to block
voltage-activated channels actuallly shorten the duration of cardiac action potentials, there are
limited correlations between the potassium channel blocking activity and QT interval prolon‐
gation (Martin et al., 2004). The lack of measurable effects on the cardiac action potential make
it likely that the hemodynamic effects of capsaicin measured during the acute study with 0.3
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PIF, PEF and TV. The increase of in PIF and PEF folloowing 0.3 mg/kg trans-capsaicin is
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(P<0.05). However, these increases were transients, lasting only 5 to 10 min after the end of
infusion.
No detectable levels of capsaicin were found in the plasma level at 5 min after administration
of 0.05 mg/kg capsaicin. Following the administration of the intermediate dose (0.1 mg/kg i.v.),
two and four dogs showed detectable levels of capsacinin (in ranges approximatively 17 and
11 ng/mL). The high dose (0.3 mg/kg) produced an increase in the plasma levels in all dogs
(ranging 32.2 to 65.6 ng/mL, mean of 47.9±6.4 ng /mL).
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All dogs survived until the scheduled termination on day 15. Only capsaicin solution-related
clinical sign observed during the study was vacualization during dosing, which was noted in
all dogs.
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and females given 0.3 mg/kg/day trans-capsaicin intravenously after l4 days treatment. Other
significant differences for clinical chemistry test results were considered incidental because
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they exhibited no dose relationship or were present before initiation of the treatment. In
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(Fridericia’s correlation QTCF, QTCF=QT/3√ (RR intervall)). Such a change would have been
theoretically possible, as capsaicin has been reported to block voltage-activated potassium
channels in rat ventricular myocytes (Castle, 1992). Because many drugs are able to block
voltage-activated channels actuallly shorten the duration of cardiac action potentials, there are
limited correlations between the potassium channel blocking activity and QT interval prolon‐
gation (Martin et al., 2004). The lack of measurable effects on the cardiac action potential make
it likely that the hemodynamic effects of capsaicin measured during the acute study with 0.3
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mg/kg/kay capsaicin due to agonistic activity on TRVP1 receptors. This is probably due to the
reported potency of capsaicin being severalfold higher than for either calcium and potassium
ion channels (Castle, 1992); Cheng et al., 2003). Thus, it is likely that capsaicin receptors
expressed on pericardiac sensory nerves induced the transient increases in the heart rate
observed during the acute dosing study, in the course of performing their role to sense cardiac
ischemia (Pan and Chem, 2004). For longer administration of capsaicin, it is possible that the
putative antihypertensive actions of capsaicin result from either prolonged desensitation of
pericardiac sensory fibres, or including the release of vasoactive peptides (CGRP and SP) from
the perivascular C-fibres, or activating and endogenous system with counterbalances hyper‐
tension caused by sodium salt loading (Vaishnava and Wang, 2003).
Other than cardiac effects,  capsaicin has also been studied in animals for other possible
target organ toxicity. Almost all of these studies used pepper plant extracts, which are likely
to  display  varying  degrees  of  capsaicinoids  content  and  possible  diverse  impurity  pro‐
files. These impurities may be the contributing factor in some of toxicities observed. Chanda
et al.  (2004) observed that pure capsaicin displays a different genotocity profil  than that
described in some previous literature. Additionally, in contrast to the high dose levels used
in toxicological studies, human exposure to dietary capsaicinoids (a mixture of capsaicin,
dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin and homodihydrocapsaicin) in the
USA and  in  European  countries  is  about  1.5  mg/  day,  which  translates  into  0.025  mg/
day/ day dose (Chanda et al., 2005).
When  capsaicin  was  dissolved  in  diethylene  gycol  monoethyl  eher  and  Dulbecco’s
phosphate-buffered saline and administered intravenous infusion for14 days (in a 15 min
time period to anesthetized dogs), the vehicle itself caused marked vascular irritation at the
administration sites.  There were no deaths,  no test  article-related organ weight changes,
and no macroscopic and microscopic observations. The only test article-related clinical sign
observed in the study was vacualization by the dogs treated with 0.3 mg/kg /day dose. The
only test article-related clinical pathology finding was maximal higher in ALT for male and
female dogs receiving 0.3 mg/kg/day capsaicin. This may indicate the liver as a possible
target organ when capsaicin is delivered at high doses directly into the systemic circula‐
tion. When the capsaicin was given in dose of 0.1 mg/kg/day for 14 days, capsaicin was
rapidly eliminated in dogs.
Capsaicin dissolved in dimethyl sulfoxide (DMSO) has been studied by Glinsukon et al.
(1980) for determination of LD50 values using several administration routes in mice. The
authors also determined the LD50 values of capsaicin for one administration route (intraper‐
itoneal) in different species. The oreder of sensitivity (LD5O values) for species, from at least
to most, by the intraperitoneal route using DMSO as the delivery vehicle was repoted to
be: hamsters (>120 mg/kg), rabbit (>50 mg/kg), rat (9.5 mg/kg), mouse (6.5 to 7.65 mg/kg)
and guinea pig (1.1 mg/kg). This study and those described above were mixed with respect
to gender. Electrocardiograms (ECGs), mean arterial presure and resporiratory rates were
also measured by Glinsukon et al. (1980) in anesthetized rats after treatment with a lethal
intraperitoneal dose of capsaicin. Saito and Yamamoto (1996) reported the oral LD50 values
for capsaicin extract for both genders in mice and rats from experiment, where propylene
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glycol was used as vehicle. They did not found any significance in the LD50 values in both
genders.  The  major  toxic  signs  in  mice  and  rats  included  salivation,  straggering  gait,
bradypnoe and cyanosis.  Tremor,  clonic  convulsion,  dyspnoe and lateral  or  prone posi‐
tion were observed,  and then the animals died in time period of  4  to 26 min after  oral
dosing by gavage.
The cause of death was proposed to be due to hypotension and respiratory paralysis in rats
and mice although the authors noted that the pathophsiology of these deaths was not clearly
understood.
In a study with Monsereenusorn (1983), 50 mg /kg capsaicin was given orally by gavage to rats
for up to 60 days. The effects of capsaicin on body weight, rectal temperature, food and water
consumption, hematological parameters, plasma biochemistry, urine concentration and
dilution tests were evaluated at 10, 20, 30, 40, 50 and 60 days. The major finding was decreased
body weight gain starting at 40 days, despite an increase in food cosumption. Minor changes
in the clinical chemistry (reduced plasma urea nitrogen, glucose, phospholipids, triglycerides,
total cholesterol, free fatty acids, glutaminic piruvic transaminase and alkalic phosphatase)
were noted after one month treatment, however, these differences were not biologically
significant,
The results of observations done by Chanda et al. (2005) indicate that trans-capsaicin given
into the sytemic circulation, induces transient increases in heart rate and blood pressure
without the alterations in cardiac repolarization.
4.3.6. Metabolism of capsaicin
Early studies by Lee and Kumar (1980) showed that phenobarbital-induced rat liver micro‐
somes converted the capsaicin and dihydrocapsaicin to corresponsing catechol metabolites,
N-(4,5-dihydroxyl-3-methoxybenzyl)-acetamides via hydroxylation on the vanillyl moiety.
This finding was further confirmed by Miller et al. (1983) who demonstrated the covalent
binding of [3H]-dihydrocapsaicin to hepatic microsomal proteins following in vitro incubation
or administration to rats. Based on these results, it has been postulated that capsaicin is
activated by the liver mixed-function oxidase system to an electrophilic intermediate, most
likely a ring epoxide, capable of covalently interactiving with nucleophilic sites of hepatic
protein (Figure 14).
This irreversible interaction of capsaicin with liver microsomal protein may account for its
impact binding of capsaicin observed in spinal cord or brain, and it was concluded that
capsaicin-induced neuropathy in rodents might be mediated by mechanisms other than
covalent intercation (Miller et al.,1983). The alkyl side chain of capsaicin is also considered to
be susceptible to enzymatic oxidation. Thus, when capsaicin was incubated with NADPH and
the liver S9 fraction from phenobarbital pretreated rats, it was hydroxylated at the terminal
carbon of the side chain (Surh et al., 1995).
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for capsaicin extract for both genders in mice and rats from experiment, where propylene
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside304
glycol was used as vehicle. They did not found any significance in the LD50 values in both
genders.  The  major  toxic  signs  in  mice  and  rats  included  salivation,  straggering  gait,
bradypnoe and cyanosis.  Tremor,  clonic  convulsion,  dyspnoe and lateral  or  prone posi‐
tion were observed,  and then the animals died in time period of  4  to 26 min after  oral
dosing by gavage.
The cause of death was proposed to be due to hypotension and respiratory paralysis in rats
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consumption, hematological parameters, plasma biochemistry, urine concentration and
dilution tests were evaluated at 10, 20, 30, 40, 50 and 60 days. The major finding was decreased
body weight gain starting at 40 days, despite an increase in food cosumption. Minor changes
in the clinical chemistry (reduced plasma urea nitrogen, glucose, phospholipids, triglycerides,
total cholesterol, free fatty acids, glutaminic piruvic transaminase and alkalic phosphatase)
were noted after one month treatment, however, these differences were not biologically
significant,
The results of observations done by Chanda et al. (2005) indicate that trans-capsaicin given
into the sytemic circulation, induces transient increases in heart rate and blood pressure
without the alterations in cardiac repolarization.
4.3.6. Metabolism of capsaicin
Early studies by Lee and Kumar (1980) showed that phenobarbital-induced rat liver micro‐
somes converted the capsaicin and dihydrocapsaicin to corresponsing catechol metabolites,
N-(4,5-dihydroxyl-3-methoxybenzyl)-acetamides via hydroxylation on the vanillyl moiety.
This finding was further confirmed by Miller et al. (1983) who demonstrated the covalent
binding of [3H]-dihydrocapsaicin to hepatic microsomal proteins following in vitro incubation
or administration to rats. Based on these results, it has been postulated that capsaicin is
activated by the liver mixed-function oxidase system to an electrophilic intermediate, most
likely a ring epoxide, capable of covalently interactiving with nucleophilic sites of hepatic
protein (Figure 14).
This irreversible interaction of capsaicin with liver microsomal protein may account for its
impact binding of capsaicin observed in spinal cord or brain, and it was concluded that
capsaicin-induced neuropathy in rodents might be mediated by mechanisms other than
covalent intercation (Miller et al.,1983). The alkyl side chain of capsaicin is also considered to
be susceptible to enzymatic oxidation. Thus, when capsaicin was incubated with NADPH and
the liver S9 fraction from phenobarbital pretreated rats, it was hydroxylated at the terminal
carbon of the side chain (Surh et al., 1995).
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4.3.6.1. The potential routes of metabolism in capsaicin
4.3.6.1.1. Enzymatic oxidatic metabolism of capsaicin
One-electron oxidation of capsaicin has been investigated by means of electrochemical,
enzymatic and chemical procedures (Lawson and Gannett, 1989; Boersch et al., 1991). Lawson
and Gannett (1989) reported that incubation of capsaicin with microsomes or non-enzymatic
reaction with potassium ferricyanide resulted in the formation of a dimer, 5,5’-bis-capsaicin.
Figure 14. Metabolism of natural capsaicin in the experimental animals. After Surh and Lee, 1995 with modification.
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A phenoxy radical was proposed to be involved in the mutagenesis by capsaicin. Formation
of phenoxy radical has often been observed with certain plant phenolics (Newmark, 1984;
1987), which plays a critical role of in lignin biosynthesis in the process of wood formation
(Freudenberg, 1960). Formation of dimetric tyrosine by oxidation of tyrosine with horseradish
peroxidase-catalized coupling reaction has been proposed as a mechanism for the dimerization
of two diiodotyrosyl residues in thyroglobin to form the thyroid hormone, thyroxine (Taurog
et al., 1994). Boersch et al. (1991) have demonstrated that incubation of capsaicin with perox‐
idase and hydrogen peroxide produced a flouescent dimer analogue similar to that previously
reported by Lawson and Gannett (1989). The formation of this flourescent oxidation product
was also observed by chemical or electrochemical oxidation of capsaicin (Lawson and Gunnett,
1989). Gunnett et al. (1990) has shown that the liver cytochrome P450 2E1 (CYP2E1) activity is
responsible for conversion to the reactive phenoxy radical which, in turn, dimerizes or
covalently binds to CYP2E1, thereby interacting the enzyme (Figure 14).
4.3.6.1.2. Non-oxidative metabolism of capsaicin
Cell-free extracts of various tissues of rats contained enzyme activity for hydrolyzing capsaicin
or its dihydro analoque at the acid-amide bond to produce vanillylamine and the correspond‐
ing fatty acyl moieties (Kawada and Iwai, 1985; Tawada et al., 1992; Oi et al., 1992) (Table 1).
The highest enzyme activity was found in the liver followed by such extrahepatic tissues as
kidney, lung and small intestine (Kawada and Iwai, 1985). It is of oral administration of
capsaicin (Oi et al., 1992). The splitting of the side chain of dihydrocapsaicin also occurred in
vivo (Kawada and Iwai, 1985), which is considered to be rate-limiting step in the overall
metabolism of this compound. Hydrolysis of the amide linkage of capsaicinoids will thus lead
to the formation of vanillylamine as a common metabolite regardless of the fatty acid type in
their side chain. Indeed, the systhemic vanilloid, olvanil [N-(3-methoxy-4-hydroxybenzyl)ole‐
amide] having longer side chain than capsaicin, has been found to be susceptible to hydrolysis
of the amide bond as determined in various metabolic model systems including cell-free
extracts of liver and intestine, isolated hepatocytes, enterocytes, and perfused isolated
intestine, and also in whole animal studies (Wehmeyer et al., 1990). Oxydative deamination of
the resulting vanillylamine produces the aromatic alcohol for excretion as a free form or a
glucoronic conjugate (Kawada and Iwai, 1985; Wehmeyer et al., 1990). Capsaicin hydrolyzing
enzymes have been purified from the rat hepatic microsomes (Park and Lee, 1994), and
identified as previously known isoenzymes of carbylesterase based on such biochemical and
biophysical parameters as Mr, pI value, pH-dependency, mode of inhibition and subcellular
toxicity. The enzymes are likely to be present either free in the lumen of endoplasmatic
reticulum or loosely bound to the terminal surface of the membrane (Park and Lee, 1994).
Capsaicinoids administered to rats intragastrically were readily absorbed from the gastroin‐
testinal tract, and further metabolized to a great extent in the liver before reaching the general
circulation (Park and Lee, 1994). As a result, gastrointestinally absorbed capsaicinoids are
expected to reach the central nervous system or other extrahepatic organs almost exclusively
as degradation products (Donnerer et al., 1990).
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4.3.6.2. Role of metabolic activation in capsaicin-induced toxicity
There is no clear-cut mechanism which can solely explain the toxicity exerted by capsaicin.
Bioactivation to an electrophylic intermediate with subsequent covalent modification of critical
cellular macromolecules such as DNA, RNA and proteins has been thought to play a role in
cell death (Miller et al., 1983; Anonymous, 1986), fueling interest in towards the role of these
observed metabolic processes. Based on the results of previous metabolic studies, the following
activation pathways can be postulated which may account for the capsaicin-induced cellular
damage (Figure 15):
a. cytochrome P450-catalyzed epoxidation of the vanillyl moiety to produce an arene oxide;
b. one-electron oxidation of the hydroxyl group to form a phenoxy radical;
c. O-demethylation at the aromatic ring and subsequent oxidation of the resulting catechol
to the semiquinone and quinone derivates.
The possible involvement of an electrophilic epoxide by others (Miller et al., 1983), but the
presumed oxirane epoxidation of capsaicin is expected to occur since the formation of arene
oxide. Nonetheless, ring epoxidation of capsaicin is expected to occur since the formation of
arene oxide intermediates is a best general phenomenon in the monooxigenase-catalized
metabolism of aromatic compounds. The best evidence for the epoxidation of capsaicin might
be the actual isolation of the presumed arene oxide, but the chemical reactivity of such species
precludes its direct isolation from incubation mixtures or from the biological fluids or tissues
of treated animals. The advances in the development of novel mild oxidating agents such as
dimethyl dioxirane have made it possible to prepare the extremely reactive epoxides of certain
chemical carcinogens including alflatoxin B1-8,9 oxide (Baertschi et al., 1988). A similar
synthetic approach could be applied to synthesis of the benzoepoxide derivate of capsaicin for
testing its biological activity as well as chemical reactivity. The covalent binding of tritium-
labeled capsaicin to hepatic microsomal protein was significantly inhibited by reduced
glutathione, which implies the formation of a reactive intermediate (epoxide) during metab‐
olism of capsaicin (Miller et al., 1983). Since glutathione is relatively nonspecific in terms of
interacting with reactive intermediates including not only oxiranes but also of capsaicin does
not necessarily suggest the aforementioned arene oxide as a sole electrophilic epoxide
hydrolase being more sensitive approach in exploring the possible involvement of an epoxi
metabolite in the toxification processes induced by capsaicin.
The intermediacy of the phenoxy radical of capsaicin has been investigated by using the
electrochemical or chemical methods (Lawson and Gannett, 1989; Boiesch et al., 1991; Gannett
et al., 1990). Furthermore, horseradish peroxidase plus the phenoxy radical intermediate
(Boesch et al., 1991; Gunnett et al., 1990). Likewise, hepatic microsomal cytochrom P450
(particularly CYP2E1) might generate the same reactive radical species that is capable of
attacking the nucleophilic sites of the enzyme or the target cell protein (Gunnett et al., 1990)
leading to the loss of catalytic activity in other crutial biological functions.
A quinone type intermediate also represents a potential ultimate electrophilic metabolite of
capsaicin. The formation of such intermediate could proceed via O-demethylation of the 3-
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methoxy group on the vanillyl moiety with concomittant oxidation to the semiquinone and
ortho-quinone derivates. The same of ortho-quinone metabolite could be generally through O-
demethylation of the aforementioned phenoxy radical intermediate of capsaicin (Table 1). This
process will also lead to the formation of an extremely reactive CH3 radical, which is wel known
to alkylate cellular nucleic acids and proteins. The above mentioned reactions are likely to
occur in presence of microsomal O-demethylase activity and relatively high reactivity of the
catechols. The antineoplastic agent, etoposide, for instance, has been known to exert its
cytotoxic effect by enzymic O-demethylation of one of its methoxy groups to the ortho-quinone
derivative capable for binding covalently to cellular macromolecules (Haim et al., 1987a;
1987b; Mans et al., 1991; Relling et al., 1992; 1994). Similarly, initial ring epoxidation of capsaicin
and subsequent NIH shift resulting benzoepoxide derivate would generate a catechol inter‐
mediate without O-demethylation
Figure 15. Structures of selected compounds containing cathecol moieties, including capsaicin. (Chanda et al., 2004)
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4.3.6.2. Role of metabolic activation in capsaicin-induced toxicity
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observed metabolic processes. Based on the results of previous metabolic studies, the following
activation pathways can be postulated which may account for the capsaicin-induced cellular
damage (Figure 15):
a. cytochrome P450-catalyzed epoxidation of the vanillyl moiety to produce an arene oxide;
b. one-electron oxidation of the hydroxyl group to form a phenoxy radical;
c. O-demethylation at the aromatic ring and subsequent oxidation of the resulting catechol
to the semiquinone and quinone derivates.
The possible involvement of an electrophilic epoxide by others (Miller et al., 1983), but the
presumed oxirane epoxidation of capsaicin is expected to occur since the formation of arene
oxide. Nonetheless, ring epoxidation of capsaicin is expected to occur since the formation of
arene oxide intermediates is a best general phenomenon in the monooxigenase-catalized
metabolism of aromatic compounds. The best evidence for the epoxidation of capsaicin might
be the actual isolation of the presumed arene oxide, but the chemical reactivity of such species
precludes its direct isolation from incubation mixtures or from the biological fluids or tissues
of treated animals. The advances in the development of novel mild oxidating agents such as
dimethyl dioxirane have made it possible to prepare the extremely reactive epoxides of certain
chemical carcinogens including alflatoxin B1-8,9 oxide (Baertschi et al., 1988). A similar
synthetic approach could be applied to synthesis of the benzoepoxide derivate of capsaicin for
testing its biological activity as well as chemical reactivity. The covalent binding of tritium-
labeled capsaicin to hepatic microsomal protein was significantly inhibited by reduced
glutathione, which implies the formation of a reactive intermediate (epoxide) during metab‐
olism of capsaicin (Miller et al., 1983). Since glutathione is relatively nonspecific in terms of
interacting with reactive intermediates including not only oxiranes but also of capsaicin does
not necessarily suggest the aforementioned arene oxide as a sole electrophilic epoxide
hydrolase being more sensitive approach in exploring the possible involvement of an epoxi
metabolite in the toxification processes induced by capsaicin.
The intermediacy of the phenoxy radical of capsaicin has been investigated by using the
electrochemical or chemical methods (Lawson and Gannett, 1989; Boiesch et al., 1991; Gannett
et al., 1990). Furthermore, horseradish peroxidase plus the phenoxy radical intermediate
(Boesch et al., 1991; Gunnett et al., 1990). Likewise, hepatic microsomal cytochrom P450
(particularly CYP2E1) might generate the same reactive radical species that is capable of
attacking the nucleophilic sites of the enzyme or the target cell protein (Gunnett et al., 1990)
leading to the loss of catalytic activity in other crutial biological functions.
A quinone type intermediate also represents a potential ultimate electrophilic metabolite of
capsaicin. The formation of such intermediate could proceed via O-demethylation of the 3-
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside308
methoxy group on the vanillyl moiety with concomittant oxidation to the semiquinone and
ortho-quinone derivates. The same of ortho-quinone metabolite could be generally through O-
demethylation of the aforementioned phenoxy radical intermediate of capsaicin (Table 1). This
process will also lead to the formation of an extremely reactive CH3 radical, which is wel known
to alkylate cellular nucleic acids and proteins. The above mentioned reactions are likely to
occur in presence of microsomal O-demethylase activity and relatively high reactivity of the
catechols. The antineoplastic agent, etoposide, for instance, has been known to exert its
cytotoxic effect by enzymic O-demethylation of one of its methoxy groups to the ortho-quinone
derivative capable for binding covalently to cellular macromolecules (Haim et al., 1987a;
1987b; Mans et al., 1991; Relling et al., 1992; 1994). Similarly, initial ring epoxidation of capsaicin
and subsequent NIH shift resulting benzoepoxide derivate would generate a catechol inter‐
mediate without O-demethylation
Figure 15. Structures of selected compounds containing cathecol moieties, including capsaicin. (Chanda et al., 2004)
Clinical Pharmacological Approach of Capsaicin Action in GI Tract
http://dx.doi.org/10.5772/58359
309
4.3.6.3. Effects of capsaicin on xenobiotic metabolism and chemically induced mutagenesis and
carcinogenesis
Capsaicin has been suggested to exert such chemopreventive effects through modulation of
metabolism of carcinogens and their interactions with tareget cell DNA. It has been reported
that capsaicin displays a dose-related inhibition of the activity of rat epithelial aryl hydrocar‐
bon hydroxylase (Modly et al., 1986), a marker enzyme for metabolism of polycyclic aromatic
hydrocarbons such as benzo(α)pyrene. Furthermore, capsaicin suppressed the metabolism
and covalent DNA binding of benzo(α)pyrene and human as well as murine keratocytes
(Modly et al., 1986). The results of different studies suggested the interaction of capsaicinoids
with microsomal mixed-function oxidases.Thus, the pretreatment of rats with subcutaneous
dosages of capsaicin resulted in pronounced prolongation of fenobarbital or hexobarbital
sleeping time (Miller et al., 1983; Surh et al., 1995; Rauf et al., 1985). Capsaicin also competitively
inhibited the ethylmorphine demethylase activity in rat liver microsomes and produced a type
I spectral change (Miller et al., 1980). Oral administration of capsaicin (50 mg/kg) together with
10% ethanol in drinking materials resulted much greater xenobitic metabolizing enzyme
activity, than that induced by ethanol alone (Iwama et al., 1989). Capsaicin pretreatment also
induced 4-hydroxylation of biphenyl in the rat liver (Rauf et al., 1985).
Yagi has reported that capsaicin and dihydrocapsaicin repress the energy-transducing NADH-
quinone oxidoreductase activity (Yagi, 1990). This finding confirms an earlier observation by
investigations of inhibitory effects of capsaicin on rat hepatic mitochondial energy metabolism
through supression of energy flow from NADH to coenzyme Q (Chudapongse and Jathana‐
soot, 1881). Capsaicin was shown to inhibit calmodulin-mediated oxidative burst in rat
macrophages as determined by attenuetion of Ca2+ionophore-triggered production of super‐
oxide anion and hydrogen peroxide (Savitha et al., 1990). Joe and Lokesh (1994) have also
shown that capsaicin can strongly block the generation of reactive oxygen species in rat
peritoneal macrophages in vitro. Capsaicin fed to animals was also inhibitory onto these
macrophages (Joe and Lokesh, 1994). Pretreatment of rats with capsaicin (1.68 mg/kg, intra‐
peritoeally) for three consequeutive days resulted in enhancement of activities of pulmonary
antioxidant enzymes such as superoxide dismutase, catalase and peroxidase while long-term
treatment caused an opposite effect on the latter two enzymes (De and Ghosh, 1989). Since
reactive oxygen species are known to play an important role in phorbol-12-myristate-13-
acetate (PMA)-mediated tumor promotion as well as in inflammation (Kensler and Trush,
1989), it would be worth determining whether capsaicin with potential anti-inflammatory
activity (Joe and Lokesh, 1994; Flynn and Rafferty, 1986) could act as an anti-tumor promoter.
It is noteworthy that the inhibition of prostaglandin synthesis by curcumin, the product of
tumeric, correlates well with its protective activity against curcumin by inactivate xanthine
dehydrogenase/oxigenase, which may account for its anti-promotional activity.
Capsaicinoids have also been found to retain inhibitory effects on liver microsomal CYP2E1
activity (Gannett el al., 1990; Lee et al., 1994; Shlyankevich et al., 1995). Capsaicin inhibits the
metabolism and mutagenicity (Guengerich et al., 19991; Koop, 1992; Espinosa-Aguirre et al.,
1993), which is known to be activated by CYP2E1. The vinyl carbamate-induced CYP2E1-
mediated mutagenicity and tumorigenicity has been showns to be reduced by capsaicin (Lee
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et al., 1995). The initiation of papillomas in mouse skin by benzo(α)pyrene was also signifi‐
cantly reduced by topical application of capsaicin prior to the carcinogen (Lee et al., 1995). This
finding is in agreement with in vitro inhibition of rodent epidermal arylhydrocarbon hydrox‐
ylase activity by capsaicin as previously reported by Moody et al. (1986). Chilli extracts have
been found to modulate the mutagenic activity of particulate organic matter in urban air
samples (Espinosa-Aquuirre et al., 1993).
In a series of observations, it has been observed that capsaicin has a protective effect on the
metabolism, DNA binding, and/or mutagenicity of some carcinogens [aflatoxin Bl, tobacco-
specific nitrosoamine and 4-(methylnitroso)-1-(3-pyridyl)-1-butanone)]. These findings
suggest that capsaicin might act as a chemoprotective agent by modulating the activities of
microsomal mixed-function oxidases which play key roles in metabolic activation as well as
detoxication of a wide array of chemical carcinogens and mutagens (Surh and Lee, 1995).
4.3.6.4. Hepatoprotection of capsaicin in rats
Recently Abdel Salam et al. observed in details the dose dependent hepatoprotective effect of
orally given capsacin (2 mL/kg followed by 1 mL/kg after one week) in rats treated with carbon
tetrachloride (CCl4) (2006). Capsaicin at three dose levels (10,100 and 1000 µg/kg) or silymarin
(22 mg/kg) was administered orally for 10 days, starting at the time of administration of CCl4.
The daily administration of capsaicin conferred significant protection against the hepatotoxic
effect of CCl4 in rats. It decreased the increases of of serum alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) and also prevented the development of histological
hepatic necrosis caused by CCl4 as determined 10 days after drug administration. Thus,
compared with CCl4 control group, serum ALT decreased by 39.3, 59.3 and 71.1 %, while AST
decreased by 14.3, 21.5 and 23.3%, after the capsaicin administration (given it in doses
mentioned above), respectively. Serum bilirubin was decreased by 10 and 100 µg/kg (46.4 and
66.5% reduction, respectively), but an increased bilirubin and ALP was observed after the
highest dose of capsaicin. Meanwhile, silymarin reduced serum ALT by 65.3%, AST by 18.9%,
ALP by 22% and bilirubin by 13.4%, compared to controls. Serum proteins were significantly
increased by 16.9 to 22.9% after treatment with capsaicin compared, whilst marked increased
in serum glucose by 66.9% was observed after highest dose of capsaicin compared with vehicle-
treated group.
Quantitative analysis of the area of damage by image analysis technique showed a reduced
area of damage from 13.6% to 7.5, 4.3 and 2.8% by application of capsaicin (used in the above
mentioned doses) respectively (Abdel-Salam et al., 2006). Haematoxylin-eosin staining
indicated markedly less hepatic necrosis in rats treated with capsaicin or silymarin. Histo‐
chemical alterations such as decreased nuclear DNA, cell glycogen and proteins contents
caused by CCl4 in hepatocytes were prevented by capsaicin as well as by silymarin.
It has been concluded from these results that orally applied capsaicin exerts beneficial effects
on liver histopathologic changes and enzymatic release caused by CCl4 in rats, but high doses
are likely to result cholestasis (Abdel Salam et al., 2006).
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4.3.7. Genotoxicity studies of capsaicin or trans-capsaicin
Published information on the potential genotoxicty of capsaicin is inconsistent, both positive
and negative effects have been found in classic genetic toxicology assays (Surh and Lee, 1995;
Azazan and Blevins, 1995).
Eight bacterial point mutation tests (including Ames assays) were performed from 1981 to 1995
on capsaicin of carying origins, using variuos strains of S.typhimurium. Variopus forms of S9
activation were provided seven of the eight assays. Four of these tests resulted in a positive
responses and four resulted in a negative response. Point mutation tests in Chinese hamster
V79 cells were conducted twice, resulting in positive and one negative response. The in vivo
micronucleus test was conducted once in mice and it was positive (Nagabhushan and Bhide,
1985). Data from one micronucleus and sister chromatid exchange study in human lympho‐
cytes was interpreted to show that capsaicin is genotoxic (Marques et al., 2002). Capsaicin was
also reported to induce DNA strand breaks in human neuroblastoma cells (Richeus et al., 1999).
The most of these studies were carried out with natural extracts, and these may not exhibit the
same toxicological profile with pure capsaicin.
Recently different studies were carried out to evaluate the genotoxic potential of trans-
capsaicin using different genotoxic assays used by international regulatory agencies to
evaluate drug product safety (Chanda et al., 2004). These included the Ames assay, mouse
lymphoma cell mutations assay, mouse in vivo bone marrow micronucleus assay and chro‐
mosomal aberration assay in human peripheral blood lymphocytes (HPBL). All studies were
conducted accoring to the Organization of Economic Cooperation and Development (OECD)
principles Good Laboratory Practice (GLP)
4.3.7.1. Ames assay
Ames assay described in the paper of Chanda et al. (2004) was based on the method described
by Ames et al. (1975). The thimidi kinase (TK) heterozygote system was described by Clive et
al. (1972), in which tk+tk-is mutated to tk-tk-. It’s measured on the L5178Y mouse lymphoma
cell line established by Fischer (1958).
In this assay, cell deficient tk+/ tk-to tk-tk-are resistant to cytotoxic effects of pyrimidine
analoque triflurothymidine (TFT). Thymidin kinase proficient cells are sensitive to TFT, which
causes the inhibtion of cellular metabolism and stops further cell division. Thus, the mutant
cells are able to proliferate in the presence of TFT, whereas normal cells containing thymidine
kinase are not (Moore et al., 2002).
Salmonella typhimurium TA 1535, TA 1537, TA 98 and TA 100 were used. The assays were
performed in presence and absence of S9, using the direct method and preincubation method.
Capsaicin did not induce mutagenic activity in any of bacterial strains.
4.3.7.2 Mouse lymphoma cell mutation assay
The tk+/tk-3.7.2C heterozygote of L5178Y mouse lymphoma cells were used in these studies
(details of the methods used, see in paper of Chanda et al., 2004).
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Both assays in presence of S9 mix gave weak mutagenic responses. Both assays contained at
least two treatment groups of capsaicin that tested sinificant (for log mutant fraction) at the
level of 5%. Both assays showed linear trend (of mutant fraction with concentration) that was
significant at P< 0.001. The increases in the mutant fraction obtained were small, the largest
was 190 mutants per million above the control value obtained at near the maximum acceptable
level of toxicity (12% relative total growth).
In the absence of S9 mix, the 4 hour exposure assay gave a very weak mutagenic response,
while the 24 hour assay gave no significant responses at dose levels resulting acceptable level
of genotoxicity, throughout the test linear trend was significant (P=0.022).
Colony size distribution patterns were difficult to assess due to the very small sample sizes.
The same situation occurs for vehicle control groups, which show a high level of variation
between the experiments, and within experiments. The numbers of mutant colonies assessed
in the capsaicin treatments resulting significant increases were found very low.
4.3.7.3. Mouse in vivo micronucleus assay
For details of this methodology, see the paper of Chanda et al. (2004). At least 2000 polychro‐
matic erythrocytes were scored for frequency of micronucleated cells. The numbers of
mironucleated normochromic erythrocytes (NCE), which were observed within the same
microscope fields, were similarly recorded. The PCE/NCE ratio was assessed by scoring a total
of at least 500 PCE+NCE. All assessment was performed on coded slides.
In preliminary toxicity tests the maximum tolerated dose of capsaicin was determined to be
around 800 mg/kg per day in males and around 200 mg/kg per day in females. Three groups
of male mice were dosed with 200, 400 and 800 mg/kg per day and one group of females was
dosed with 200 mg/kg per day of capsaicin at 0 and 24 hours. Five mice per sex from each test
material dose groups were selected to provide the normal assessment base. Current vehicle
and positive groups were included.
Treatment-related animal deaths and clinical signs were observed in the middle and high dose
level groups. One death occurred in the male vehicle control group, immediately after dosing
and was considered to be as a result of a dosing error.
The frequencies of micronucleated polychromatic erythrocytes (MN-PCE) in the capsaicin-
treated groups were 0.04, 0.10, 0.09 % (males) and 0.05% (females). All of these frequencies
were within the historical control range for negative responses (0.01-0.23 % for a group of five
mice). The frequencies of MN-PCE in the concurrent vehicle control groups were 0.07% (males)
and 0.11% (females), whereas the MN-PCE frequency in the positive control group was 1.57%,
demonstrating the sensitivity of the test system.
4.3.7.4. Chromosomal aberration in human peripheral blood lymphocytes (HPBL)
Human venous blood from healthy, adult donors (nonsmokers without any history of
radiotherapy, chemotherapy or drug usage and lacking current viral infections) was used. The
whole blood cultures were initiated in 15 ml centrifuge tubes by adding 0.6 mL of fresh
heparinized blood and the final volume of culture medium and test arcticle was 10 mL.
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level groups. One death occurred in the male vehicle control group, immediately after dosing
and was considered to be as a result of a dosing error.
The frequencies of micronucleated polychromatic erythrocytes (MN-PCE) in the capsaicin-
treated groups were 0.04, 0.10, 0.09 % (males) and 0.05% (females). All of these frequencies
were within the historical control range for negative responses (0.01-0.23 % for a group of five
mice). The frequencies of MN-PCE in the concurrent vehicle control groups were 0.07% (males)
and 0.11% (females), whereas the MN-PCE frequency in the positive control group was 1.57%,
demonstrating the sensitivity of the test system.
4.3.7.4. Chromosomal aberration in human peripheral blood lymphocytes (HPBL)
Human venous blood from healthy, adult donors (nonsmokers without any history of
radiotherapy, chemotherapy or drug usage and lacking current viral infections) was used. The
whole blood cultures were initiated in 15 ml centrifuge tubes by adding 0.6 mL of fresh
heparinized blood and the final volume of culture medium and test arcticle was 10 mL.
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Cultures were incubated with loose caps at 37±2 ºC in a humidified atmosphere of 5± 1.5 ºC in
air. The medium was RPMI 1640 supplemented with HEPES buffer (25 mM), about 20% heat-
activated fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin 100 µg/mL, L-
glutamine (2 mM) and 2% phytohemagglutinin-M (PGA-M). Negative (untreated controls)
and vehicle controls (cultures treated with 10 µL of DMS0/mL) were used. The positive control
agents used in the assays were mitomycin-C (MMMC) for the nonactivation series and CP
(cyclophosphamide) in the metabolic activation series.
The in vitro metabolic activation system (Maron and Ames, 1983) consisted of liver post-
mitochondrial fraction (S9) and an energy-producing system (NADP at 1.5 mg/mL (1.8 mM)
and isocitric acid at 2.7 mg/mL (10.5 mM). S9 was prepared 5 days after a single dose of 500
mg/kg of Aroclor® 1254.
Two trials were conducted. In the initial trial, cultures were treated for about 3 hours with and
without S9 and harvested about 22 hours after initiation of treatment. In the second trial,
cultures were treated for about 22 hours without S9 and about 3 hours with S9 and harvested
about 22 hours after initiation of treatment. This harvested time corresponds to 1.5 times a cell
cycle time (Galloway et al., 2004). The time of cell cycle is approximatively 15 h after the
lymphocytes was included to divide by the addition of PHA-M. At harvest, cells were swollen
by 75 mM KCl hypotonic solution and fixed with absolute methanol-glacial acetic acid (3:1 v/
v). Cells were selected from each duplicate culture were analyzed for the different types of
chromosomal aberrations (Evans, 1962; Evans, 1976). Mitotic index was evaluated from the
negative control, vehicle control and a range of test article concentrations and this was used
for measurement of toxicity and selection of doses for analysis. Percent of polyploidy and
endoreduplication were also analyzed. For control of bias, all slides were coded prior to
analysis and read blind.
In the first trial, 6.78, 9.69, 13.8, 19.8, 28. 2, 40.4, 57.6, 82.4, 118, 168, 240, 343, 490, 700 and 1000
µg/mL of capsaicin were evaluated with and without metabolic activation by S9. The highest
concentration was limited due to the presence of a precipitate dosing. In the first trial, a
precipitate was observed at > 240 µg/mL, and hemolysis was observed prior to washing and
harvesting of these cultures. Only dead cells were present on slides prepared from cultures
treated with > 343 µg/mL due to excessive toxicity (Chanda et al., 2004). Chromosomal
aberrations were analyzed from the cultures treated with 82.4, 118, 168 and 240 µg/mL. The
high concentration had > 50% reduction in mitotic index. No increase in structural or numerical
chromosomal aberrations was observed (Chanda et al., 2004).
Based on the results from the initial assay, the second trial was conducted at concentrations of
6.15, 12.3, 24.6, 49.2, 98.4, 154, 192, 240 and 320 µg/mL without metabolic activation and 49.2,
98.4, 123, 154, 192, 240 and 320 µg/mL with metabolic activation. Treatment periods were for
about 22 and about 3 h without and with metabolic activation, respectively, and the cultures
were harvested at 22 h from the initiation of treatment. In the assay without metabolic activa‐
tion, a precipitate was observed in cultures treated with > 92 µg/mL and hemolysis was found
prior to harvest of the cultures treated with > 240 g/mL. Only dead cells were present on slides
prepared from cultures treated with > 192 µg/mL, due to excessive toxicity. Severe toxicity was
observed also in case of 98.4 µg/mL dose (92% reduction in mitotic index). Chromosomal
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aberrations were analyzed from the cultures treated with 24.6, 49.2 and 123 µg/mL. Due to
toxicity, < 100 metaphases were available for analysis in the duplicate cultures treated with 123
µg/mL dose. The highest tested concentration (240 µg/mL) had > 50% reduction on mitotix
index. No increase in structural or numerical chromosomal aberrations was observed.
In the assay with metabolic activation, a precipitate was observed after dosing at > 192 µg/mL
and hemolysis was observed prior to harvest of the cultures treated with 320 µg/mL. Since the
cultures treated with 240 µg/mL had excessive toxicity (100% reduction in mitotic index) and
the slides prepared from cultures treated with 192 µg/mL were selected as the highest
concentration for analysis. Chromosomal aberrations were analyzed from the cultures treated
with 98.4, 123, 154 and 192 µg/mL. No increase in structural or numerical chromosomal
aberrations was observed (Chanda et al., 2004).
Although there are a number of publications focussing on genotoxic potential of capsaicin or
spicy pepper extracts, the test substances used in these studies were various according to
source,purity and impurity profile. Consequently, there has not been any systemic observation
of the genotoxic potential of trans-capsaicin.
The majority of the studies found in the literature (Marques et al., 2002; Richeux et al., 1999;
Ames et al., 1975; Fischer, 1972) used the Ames assay. There was one study using either
micronucleus assay, the sister chromatoid exchange assay or the assay investigating DNA
strand breaks in human neuroblastoma cells (Surh and Lee, 1995; Azizan and Blevins,1995;
Nagabhushan and Bhide, 1985; Marques et al., 2002; Ames et al., 1999). None of the studies
were conducted using systematically pure capsaicin preparations, and it is very important to
be able to attribute the results of capsaicin alone, not the impurities.Chanda et al. (2004) applied
synthetic capsaicin alone (the purity > 99%) to perform to genotoxicity studies.
In the Ames assay with pure synthetic capsaicin, no increase in mutation frequency was
observed in any assays, with and without S9. It was concluded from these studies that the
capsaicin is not genotoxic in the bacterial assay, with and without metabolic activation (at the
highest concentrations that could be tested).
Capsaicin was found to be weakly mutagenic in mouse lymphoma L5178Y cells, in presence of
S9, when it was dissolved in DMSO at concentrations that extended into the toxic range. The
lowest positive concentration in the presence of S9 in any individual test was 12 µg/mL. Limited
evidence of very weak activity was also noted in the absence of S9.The lowest positive concen‐
tration in absence of S9 was 65 µg/mL. Although criteria for the determinations a positive
response in the lymphoma assay remained controversial according to the criteria used by the
laboratory that conducted in these studies (Clive et al., 1979; Moore et al., 2003). These results
can be interpreted as week toxicity. With longer exposures (about 24 hours), higher capsaicin
concentrations were too toxic for analysis and the mutant fractions were not significantly
different from the controls at the usable concentrations.Thus, it can be concluded that capsai‐
cin is non-mutagenic at concentrations up 28 µg/mL after 24 h exposure in the absence of S9.
In the in vivo micronucleus study in mice, the frequency of MN-PCEs was 0.04-0.10 % in the
treated group compared to 0.07-0.11% in the vehicle treated control mice. Both were within
the historical control range, which was started to be 0.07 ± 0.08%. The frequency of MN-PCE
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without S9 and harvested about 22 hours after initiation of treatment. In the second trial,
cultures were treated for about 22 hours without S9 and about 3 hours with S9 and harvested
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µg/mL of capsaicin were evaluated with and without metabolic activation by S9. The highest
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precipitate was observed at > 240 µg/mL, and hemolysis was observed prior to washing and
harvesting of these cultures. Only dead cells were present on slides prepared from cultures
treated with > 343 µg/mL due to excessive toxicity (Chanda et al., 2004). Chromosomal
aberrations were analyzed from the cultures treated with 82.4, 118, 168 and 240 µg/mL. The
high concentration had > 50% reduction in mitotic index. No increase in structural or numerical
chromosomal aberrations was observed (Chanda et al., 2004).
Based on the results from the initial assay, the second trial was conducted at concentrations of
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98.4, 123, 154, 192, 240 and 320 µg/mL with metabolic activation. Treatment periods were for
about 22 and about 3 h without and with metabolic activation, respectively, and the cultures
were harvested at 22 h from the initiation of treatment. In the assay without metabolic activa‐
tion, a precipitate was observed in cultures treated with > 92 µg/mL and hemolysis was found
prior to harvest of the cultures treated with > 240 g/mL. Only dead cells were present on slides
prepared from cultures treated with > 192 µg/mL, due to excessive toxicity. Severe toxicity was
observed also in case of 98.4 µg/mL dose (92% reduction in mitotic index). Chromosomal
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside314
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index. No increase in structural or numerical chromosomal aberrations was observed.
In the assay with metabolic activation, a precipitate was observed after dosing at > 192 µg/mL
and hemolysis was observed prior to harvest of the cultures treated with 320 µg/mL. Since the
cultures treated with 240 µg/mL had excessive toxicity (100% reduction in mitotic index) and
the slides prepared from cultures treated with 192 µg/mL were selected as the highest
concentration for analysis. Chromosomal aberrations were analyzed from the cultures treated
with 98.4, 123, 154 and 192 µg/mL. No increase in structural or numerical chromosomal
aberrations was observed (Chanda et al., 2004).
Although there are a number of publications focussing on genotoxic potential of capsaicin or
spicy pepper extracts, the test substances used in these studies were various according to
source,purity and impurity profile. Consequently, there has not been any systemic observation
of the genotoxic potential of trans-capsaicin.
The majority of the studies found in the literature (Marques et al., 2002; Richeux et al., 1999;
Ames et al., 1975; Fischer, 1972) used the Ames assay. There was one study using either
micronucleus assay, the sister chromatoid exchange assay or the assay investigating DNA
strand breaks in human neuroblastoma cells (Surh and Lee, 1995; Azizan and Blevins,1995;
Nagabhushan and Bhide, 1985; Marques et al., 2002; Ames et al., 1999). None of the studies
were conducted using systematically pure capsaicin preparations, and it is very important to
be able to attribute the results of capsaicin alone, not the impurities.Chanda et al. (2004) applied
synthetic capsaicin alone (the purity > 99%) to perform to genotoxicity studies.
In the Ames assay with pure synthetic capsaicin, no increase in mutation frequency was
observed in any assays, with and without S9. It was concluded from these studies that the
capsaicin is not genotoxic in the bacterial assay, with and without metabolic activation (at the
highest concentrations that could be tested).
Capsaicin was found to be weakly mutagenic in mouse lymphoma L5178Y cells, in presence of
S9, when it was dissolved in DMSO at concentrations that extended into the toxic range. The
lowest positive concentration in the presence of S9 in any individual test was 12 µg/mL. Limited
evidence of very weak activity was also noted in the absence of S9.The lowest positive concen‐
tration in absence of S9 was 65 µg/mL. Although criteria for the determinations a positive
response in the lymphoma assay remained controversial according to the criteria used by the
laboratory that conducted in these studies (Clive et al., 1979; Moore et al., 2003). These results
can be interpreted as week toxicity. With longer exposures (about 24 hours), higher capsaicin
concentrations were too toxic for analysis and the mutant fractions were not significantly
different from the controls at the usable concentrations.Thus, it can be concluded that capsai‐
cin is non-mutagenic at concentrations up 28 µg/mL after 24 h exposure in the absence of S9.
In the in vivo micronucleus study in mice, the frequency of MN-PCEs was 0.04-0.10 % in the
treated group compared to 0.07-0.11% in the vehicle treated control mice. Both were within
the historical control range, which was started to be 0.07 ± 0.08%. The frequency of MN-PCE
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for the positive control (50 mg/kg of cyclophosphamide) was 1.5%. However, in this study a
difference was observed between the maximum tolerated doses estimated for males (800 mg/
kg) and females (200 mg/kg). These values are higher than previous reports in the literature
(Glinsukon et al., 198O; Saito and Yamamoto, 1996), which probably may reflect the quality of
the current drug substance, and do not reflect to sex difference.
Capsaicin was evaluated for its ability to induce clastogenicity in cultured human lymphocytes
with and without an exogenous metabolic activation system. Clastogenecity was evaluated at
concentrations that induced severe toxicity to no toxicity. Cultures were harvested within 22
hours from the initiation of treatment. Capsaicin did not induce structural and numerical
chromosomal aberrations.
It can be concuded from the rsults of genotocity observations with pure trans-capsaicin that
its genotocity potential is very limited and differs when the impured capsaicin or chilli extracts
were used in assays.
These data have important implications for analysis of risks associated with dietary or
environmental capsaicin exposures. Although the majority of epidemiological data suggests
that dietary capsaicin consumption is not associated with enhanced risk of cancer (Surh and
Lee, 1995). It is true that a positive matematical correlation can be observed between the intake
of Chilli pepper and the gastric cancer in Mexico (Lopez-Carrilo et al., 2003), other factors than
capsaicin should be investigated as the causal link in such epidemiological evaluation (Table 9).
Test compound Animal/Cells tested
Hepatic S9 for metabolic
activation
Endpoint Response
CAP, Chilli S. typhimurium Aroclor 1254-induced rat His+ reversion +
CAP, Chilli Chinese hamster V79 Aroclor 1254-induced rat Azaguanine resistance -
CAP, Chilli Swiss mice In vivo Micronuclei formation + CAP(only)
CAP S. typhimurium TA98 Aroclor 1254-induced rat His+ reversion +
CAP, DHC, typhimurium TA98, Aroclor 1254-induced rat His+ reversion -
ChilliS TA1535
CAP, DHC, Chilli Chinese hamster V79 Azaguanine resistence +
CAP, Chilli S. typhimurium Phenobarbital-induced rat His+ reversion -
CAP, Chilli S. typhimurium Streptomycin-resistance + (Chilli); -(CAP)
CAP, DHC, S. typhimurium TA98, + (source unclear) His+ reversion - or + (CAP)
Chilli TA100
Chilli Mouse bone marrow In vivo Micronuclei formation +
CAP Albino mice In vivo Pregnancy frequency -
CAP Mouse epididymis In vivo Sperm abnormality -
CAP Human lymphocytes Chromosome aberrations +
CAP, capsaicin; DHC, dihydrocapsaicin; Chilli, planet extract (after Surh J., Lee S.S. Life Science 56: 1845-1855, 1995) (with modi‐
fication)
Table 9. Genotoxicity of chilli extracts and its major pungent constituents capsaicin and dihydrocapsaicin up to 1995
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4.3.8. Chronic toxicity studies in animals
The chronic toxicological studies are absolutely required to drug candidate in species (one
from the  rodents  and  dog)  for  6  months  time  period.  None  of  these  types  of  observa‐
tions could be found in the literature,  consequently these studies should be done in the
fourthcoming time with our preparation.
4.3.9. Brief summary of the main results of observations with capsaicin in animals
Capsaicin  is  a  very  active  compound acting  at  the  levels  of  capsaicin  sensitive  afferent
nerves.  Capsaicin has dual  action,  namely given in small  doses it  produces a  biological
significant gastrointestinal mucosal protective effect, meanwhile it enhances the gastrointes‐
tinal mucosal damages to different chemical, osmotic and pressure stimuli.
It is important to note that the doses (10 to 100 µg/kg) produce gastrointestinal mucosal
defensive actions are significantly lower than those (100-200 mg/kg) induce gastrointesti‐
nal mucosal damage.
The capsaicin is absorbed well from gastrointestinal tract in animals, and its metabolization is
carried out by the liver (in pathways of enzymatic oxidation and non enzymatic oxidation).
The production of epoxyns (arene) is suggested; however, it was not clearly proven.
There is specific and important observation that the capsaicin dose-dependently prevents the
CCl4-induced hepatic injury during one week treatment.
The genotoxicity studies indicated a very limited positivity, which dominantly depends on the
extents of capsaicin purity from plants.
No chronic toxicological studies have been published in two species (rodent, dog) and applied
for 6 months.
4.4. Human observations with capsaicin
4.4.1. Observations with capsaicin in healthy human subjects
The capsaicin studies were carried out from 1997, by the permission of Regional Ethical
Committee of Pécs University, Hungary. These studies were carried out in randomized,
prospective manner, respecting the Helsinki Declaration. The observations were carried out
according to the Good Clinical Practice (GCP), at the same methods as those are required to
classical drug (or drug candidate) studies.
The First Department of Medicine, Medical and Health Centre, University of Pécs, Hungary,
is  one  of  the  Hungarian  Accreditated  Centres  for  the  studies  of  the  human phase  I-II.
examinations. This institute has been participating in the drug developments since 1968.
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4.4.1.1. Dose-response curves of capsaicin in the human stomach acute observations
The dose-response curves were identified on the gastric basal acid secretion (BAO) in healthy
human subjects, and on the measurements in gastric transmucosal potential difference (GTPD)
without and with topically (intragastrically) applied ethanol (Mózsik et al., 2005). We tested
100, 200, 400 and 800 µg capsaicin dissolved in 100 saline solution given intragastrically via
nasogastric tube on the gastric BAO values and on GTPD.
In other  series  of  observations,  the gastric  microbleeding was produced by orally given
indomethacin (3x25, plus 25 mg at the starting of examinations) in healthy human subjects.
Indomethacin was given alone, or in combination of capsaicin (200, 400 and 800 µg). The
results  were  compared  with  the  results  obtained  without  application  of  indomethacin
(baseline).
The effect of capsaicin given in smaller dose than 100 µg, no effect was observed. The ED5O
value was obtained in experiments using 400 µg dose on the gastric BAO, GTPD (without and
with topically applied ethanol), and Indomethacin-induced gastric microbledings (Mózsik et
al., 2005; Mózsik et al., 2007).
It was also observed that gastric microbleeding produced by both inhibition of COX-1 and
COX-2 was completely prevented by the application of 400 µg capsaicin (Mózsik et al., 2007;
Sarlos et al., 2003).
When capsaicin was given in dose of ED50 intragastrically, the “parietal component“ decreased
(P < 0.001), meanwhile the “non-parietal component“ (buffering secretion) and gastric
emptying increased significantly (P< 0.001) in human healthy subjects (Mózsik et al., 2004;
2005; 2007; Debreceni et al., 2001). Recently, it was observed that capsaicin (given in dose of
400 µg orally) enhanced the glucose absorption and glucagon release during standard glucose
loading test in human healthy subjects (Dömötör et al., 2006).
4.4.1.2 Changes in laboratory parameters and complaints of human healthy subjects during the study
with capsaicin
No systemic laboratory changes were noted in the biochemical parameters except the obser‐
vations with gastric juice (Mózsik et al., 2004; 2005), glucose loading test (Dömötör et al.,
2006). No subjective complains were observed in patients (pain, diarrhoea, vomit).
4.4.2. Subchronic observations with capsaicin in human healthy subjects
4.4.2.1. Two weeks treatment with capsaicin
The group of healthy human subjects received capsaicin treatment for two weeks (3 x 400 µg
given orally) in prospective, randomized study. The gastric microbleeding was produced by
indomethacin application before and after the two-week capsaicin treatment. At baseline
indomethacin-induced gastric microbleedings applied without and with different doses of
capsaicin were measured before and after two-week capsaicin treatment.
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No changes were obtained at baseline, indomethacin-induced gastric microbleding, and on
the other hand, the gastric mucosal protective effects of capsaicin remained the same after the
two-week capsaicin treatment as those were found at baseline (Mózsik et al., 2005; Mózsik et
al., 2007a).
4.4.2.2. Biochemical meaurements and complaints in human healthy subjects during two weeks
capsaicin treatment
No changes were noted in the biochemical parameters and no complaints registered in the
human healthy subjects.
4.4.3. Human chronic observations with capsaicinoids
In a case-control study in Mexico City included 220 cases of gastric cancer and 752 controls
randomly selected from the general population. Chilli pepper consumers were found to be
having a 5.5 fold greater risk for gastric cancer than non-consumers. Persons who stated
themselves as heavy consumers of chilli peppers were at a 17 fold greater risk. However, when
chilli consumption was measured as frequency per day, a significant dose-response relation‐
ship was not observed (Lopez-Carrillo et al., 1994).
In another case-control study in India, red chilli powder was found to be a risk factor for cancer
of the oral cavity, pharynx, esophageus and laryngx compared with population controls, but
not with hospital controls (Notani and Jayant, 1987).
In an Italian case-control study, chilli was briefly mentioned as being protective against
stomach cancer (Buiiatti et al., 1989). Chilli pepper, however, are not heavily consumed in
Northern Italy, where this study was conducted, and it is possible that chilli consumption
rather correlated with other used protecting spices such as onions and garlic, which are heavily
consumed in Italy.
The Committee of Experts on Flavouring Substances of the Council of Europe concluded that
the available data do not allow to establish a safe exposure level of capsaicinoids for foods
(Opinion of the Scientific Committee on Food on Capsaicin, adopted on 26 February, 2002).
It was also observed that the non-selective COX-1 and COX-2 inhibiting nonsteroidal anti-
inflammatory drug-induced gastric microbleeding can completely be prevented by 400 µg
capsaicin administrations in human healthy subjects (Mózsik et al., 2007).
4.4.4. Preventive effects of capsaicin against the selective and nonselective inhibitory actions produced
by nonsteroidal anti-inflammatory drugs on COX-1 and COX-2 enzymes
The indomethacin (as non selective COX inhibitor) was used to provoke gastric microbleeding
in healthy human subjects, and capsaicin itself, as a specific stimulator of capsaicin receptor
(TRVP1) was applied in small doses to healthy human subjects. The capsaicin treatment was
carried out for two weeks, it was given in 3 x 400µg dose orally daily (400 µg capsaicin dose
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was obtained to be equal to ED50 value in previous human observations) (Mózsik et al., 1999;
2004; 2005) (Table 10-11).
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Table 10. Comparison of inhibitory effects (IC50) by giving the COX-1 and the various NSAIDs using human platelet
COX-1 and synovial cell COX-2*
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Table 11. Correlation between the capsaicin actions, COX-1 and COX-2 systems and gastric 
microbleedings produced by indomethacin in human healthy subjects before and after 2 
weeks capsaicin (3x400µg orally) treatment.* 
 
 
• 400 µg CAPSAICIN (IG GIVEN) INDUCED DECREASE OF IND-GASTRIC 
MICROBLEEDING 
                                     6±0.2 mL/day        5.9±0.2 mL/day 
* means±SEM in 14 human healthy subjects. 
(1: 3.25) 
• MICROBLEEDING IN THE STOMACH 
                      Before After 
←      2 weeks capsaicin treatment → 
Baseline  2,1 + 0,1 mL/day     2,0 + 0,1 mL/day 
After IND  8,25 + 0,25 mL/day     7,8 + 0,3 mL/day 
∆ IND-induced  6,15 + 0,2 mL/day     5,8 + 0,3 mL/day 
(= inhibition on COX-1 + COX-2) (= 100%) 
 
COX-1:1.447±0.1 mL/day       1.364±0.1 mL/day 
COX-2: 4.70±0.2 mL/day       4.44±0.2 mL/day 
NSAID    Ratio COX-1 : COX-2 
Aspirin          0.12 
Diclofenac           38.00 
Etodolac      179.00  
Ibuprofen          0.86 
Indomethacin                     0.30 
Loxoprofen-SRS         3.20 
NS-398    1263.00 
Oxaprozin          0.061 




 VALUE OF INDOMETHACIN TO RATIO OF COX-1/COX-2 = 0,30 
* means±SEM in 14 human healthy subjects.
Table 11. Correlation between the capsaicin actions, COX-1 and COX-2 systems and gastric microbleedings produced
by indomethacin in human healthy subjects before and after 2 weeks capsaicin (3x400µg orally) treatment.*
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4.5. Summary of the observation with capsaicin alone or in combination with selectively
and non-selectively inhibition of COX-1 and COX-2 enzymes by nonsteroidal anti-
inflammatory compounds in animal experiments and in human observations
The capsaicin chemically representing a mixture of compounds of capsaicinoid (capsaicin,
dihydrocapsaicin, norcapsacin, nordihydrocapsaicin) has been widely used in the population
nutrition of different countries for the last 9000-9500 years.
It was a significant internationally accepted discovery that capsaicin (capsaicinoids) signifi‐
cantly stimulates (stimulate) a subgroup of the afferent nerves (named under as “capsaicin-
sensitive afferent nerves“) responding upon various chemical agents, heat, pH gradients in
animal experiments and human observations.
The doses of capsaicin (capsaicinoids) are significant in the biological actions, because when
it (those) is (are) given in small doses then it (those) prevents (prevent) tissue protection
(including the gastrointestinal tract), however, capsaicin (capsaicinoids) enhances (enhance)
the organ’s damage (including the gastrointestinal tract). The capsaicin (capsaicinoids)
produces (produce) organ damaging effects as a consequence of capsacin-induced desensita‐
tion proceeded by the application of capsaicin (capsaicinoids) in higher doses. The existence
of these principle observations was scientifically proven in animal experiments and human
observation.
The application of capsaicin has been carried out as a tool to approach the different physio‐
logical and pharmacological regulation of different diseases and their prevention.
The study of the afferent nerves has been carried out from the years of 1970. The results of this
research clearly proved the principle and important role of the afferent nerves in the physio‐
logical regulation of various organs and as well as in the development of damage and
prevention of these different organs.
The human observations with capsaicin were carried out randomized, prospective studies by
the permission of Regional Ethical Committee of our Univesity of Pecs, Hungary. These studies
were carried out in accordance of the Good Clinical Practice (GCP) together with respect of
the Helsinki Declaration.
The results of the animal experiments and human observations clearly proved the gastroin‐
testinal protection by application of small doses of capsaicin (capsaicinoids) (including the
application of nonsteroidal anti-inflammatory drugs).
The  anti-inflammatory  drugs  (acting  by  the  properties  of  drugs  of  selective  and  non-
selective inhibitions of COX-1 and COX-2 enzymes) are widely used in the prevention of
thromboembolic  episodes,  in  the  prevention  of  reinfarction  in  patients  who  underwent
myocardial  infaction,  in  the  treatment  of  patients  with  acute  and  chronic  pains  with
degerative chronic joint diseases,  malignant diseases and healthy persons for preventing
gastrointestinal cancers, etc.
Capsaicinoids absorbs well from the gastrointestinal tract. They are metabolized in the
pathways of enzymatic oxidation of liver and as well as non enzymatic oxidation. It is very
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was obtained to be equal to ED50 value in previous human observations) (Mózsik et al., 1999;
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The study of the afferent nerves has been carried out from the years of 1970. The results of this
research clearly proved the principle and important role of the afferent nerves in the physio‐
logical regulation of various organs and as well as in the development of damage and
prevention of these different organs.
The human observations with capsaicin were carried out randomized, prospective studies by
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were carried out in accordance of the Good Clinical Practice (GCP) together with respect of
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The results of the animal experiments and human observations clearly proved the gastroin‐
testinal protection by application of small doses of capsaicin (capsaicinoids) (including the
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The  anti-inflammatory  drugs  (acting  by  the  properties  of  drugs  of  selective  and  non-
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important that capsaicin alone dose-dependently prevents the hepatic damage produced by
carbon tetrachloride (in a significantly higher level that it was found for silymarin). The studies
with genotoxicity clearly indicated that the pure capsaicin has a very limited toxicity (this value
is higher if the capsaicin preparation is not chemically clear and contaminated with different
toxicological agents of plants, e.g. aflatoxin, pesticides).
The human observations also clearly indicated that capsaicin actions can be reproduced well
in human healthy subjects. The capsaicin application produces an dose-dependent increase in
GTPD (without and with combined ethanol), decreases BAO, and totally prevents the indo‐
methacin-induced gastric mucosal microbleedings (in range of 100 to 800 µg given intragas‐
trically). Furthermore two weeks treatment with capsaicin (3x 400 µg given intragastrically)
did not modify the sensitivity of the gastric mucosa to capsaicin-sensitive afferent nerves and
the gastric mucosal protective effects against indomethacin remained at the same dose-
dependent level after 2-week capsaicin treatment.
The conclusions of these animal and human observations clearly proved that the application
of capsaicin in small doses is completely able to prevent the nonsteroidal anti-inflammatory
drug-induced gastrointestinal side effects. By the other ways capsaicin is able to inhibit the
functions of COX-1 and COX-2 enzymes in animal experiments and in human observations.
The further scientific research may offer an absolutely new pathway(s) for the development
of drug (s) by the stimulation of capsaicin-sensitive afferent nerves by the usage of small doses
of capsaicinoids to patients, who have to be treated with nonsteroidal anti-inflammatory drugs
and for other diseases requiring cyclooxygenase inhibition (inflammations, tumors).
4.6. Summary of expters’ opinion
The plant  origin capsaicinoids (capsaicin,  dihydrocapsaicin,  norcapsaicin,  dihydrocapsai‐
cin, homocapsaicin, homodihydrocapsaicin) are well known and used as nutritional additive
agents in the every day nutrional practice from the last 7000 years, however, we have a
very little scientifically based knowledge of their chemistry, physiology, pharmacology in
animal observations, and in humans up till the end of 20th century. Our knowledge from
their chemistry, physiology and pharmacology entered to be scientifically based evidence
from the years of 1980s, dominantly upon animal observations. The human observations
with capsaicin (capsaicinoids), in terms of good clinical practice, have been started only in
the last ten years in randomized, prospective, multiclinical studies. The name of “capsai‐
cin“ used only in the physiological and pharmacological research both in animal experi‐
ments  and  in  human  observations.  The  “capsaicin“ (as  a“chemically“  used  natural
compound) modifies the “so-called“ capsaicin-sensitive afferent nerves, depending on their
doses of application.
Aims: The specific action of capsaicin (capsaicinoids) on sensory afferent nerves modifying
gastrointestinal (GI) function offers a possibility for the production of an orally applicable drug
or drug combinations, which can to be used for human medical therapy. The production of a
new drug needs to be based on the critical interdisciplinary review of the results obtained with
capsaicinoids.
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Materials and methods: This paper gives an interdisciplinary and critical overview on the
chemical, physiological, pharmacological and toxicological actions of the natural origin
capsaicinoids (from the point of drug production) under conditions of acute, subacute and
chronic administration in animal experiments and human observations for toxicology and
pharmacokinetics.
This interdisciplinary review covers the following main chapters: 1. Physiological and
pharmacological research tool by capsaicin in the animals and human beings; 2. capsaicin
research in animals (including the acute, subacute and chronic toxicology, metabolism as well
as genotoxicology); 3. Pharmacological observation with capsaicin in human beings.
Conclusion: 1. The capsaicin used in the physiological and pharmacological observations (in
animals and human beings) chemically represents heterogenous chemical compounds, which
can be obtained from the plants (paprika, chilli, etc). 2. Capsaicinoids are able to modify the
capsaicin-sensitive afferent nerves, which play principle roles in the defence of various organs
(including the gastrointestinal tract (against heat, stress, chemical-induced damage). 3. The
beneficial effects of capsaicin (capsaicinoids) application on gastrointestinal tract obtained in
animal experiments can be converted for humans observations. After this interdisciplinary
and critical review, this paper demonstrates well-planned research pathways of discoveries
on capsaicinoid chemistry, physiology, pharmacology and toxicology in animal experiments
and human observations.
5. Some general scientific problems in the application of the plant origin
compounds in the every used foods and drugs
The evaluation of effectiveness and safety of chemically produced compound(s) is very strickly
regulated testing program both in animals and in humans.
After very careful and critical overview of plant origin compounds, it was very surprising to
see that health and scientific requirements differ so much in regards of their application as
dietary (Response to EMEA Consultation Document CPMP/QWP/2819/00 REV 1 AKA EMEA/
CVMP/814/00 REV 1: Guideline on Quality of Herbal Medicinal Products/Traditional Herbal
Medicinal Products (Released 21 July 2001/Consultation Date 30th September 2005) and as a
drug terapy (this Notice to Applicants (NTA) prepared by the European Commission in
consultation with the competent authorities of the Member States, the European Medicines
Agency and interested parties in order to fulfil the Commission’s obligations with respect to
article 6 of Regulation (EC) No. 726/2004, and with respect to the Annex I to Directive 2001/83/
EC as amended (Directive 2003/63/EC, OJ L 159 27.6.2003 p.46 NTA, Vol. 2B-CTD, foreword
& introduction, edition June 2006).
We, the authors of this review could not understand the extremely high number of application
of plant origin compounds needed to be applied for foods, food additive agents, health
modification compounds and classical drugs (especially orally applicable preparations).
Clinical Pharmacological Approach of Capsaicin Action in GI Tract
http://dx.doi.org/10.5772/58359
323
important that capsaicin alone dose-dependently prevents the hepatic damage produced by
carbon tetrachloride (in a significantly higher level that it was found for silymarin). The studies
with genotoxicity clearly indicated that the pure capsaicin has a very limited toxicity (this value
is higher if the capsaicin preparation is not chemically clear and contaminated with different
toxicological agents of plants, e.g. aflatoxin, pesticides).
The human observations also clearly indicated that capsaicin actions can be reproduced well
in human healthy subjects. The capsaicin application produces an dose-dependent increase in
GTPD (without and with combined ethanol), decreases BAO, and totally prevents the indo‐
methacin-induced gastric mucosal microbleedings (in range of 100 to 800 µg given intragas‐
trically). Furthermore two weeks treatment with capsaicin (3x 400 µg given intragastrically)
did not modify the sensitivity of the gastric mucosa to capsaicin-sensitive afferent nerves and
the gastric mucosal protective effects against indomethacin remained at the same dose-
dependent level after 2-week capsaicin treatment.
The conclusions of these animal and human observations clearly proved that the application
of capsaicin in small doses is completely able to prevent the nonsteroidal anti-inflammatory
drug-induced gastrointestinal side effects. By the other ways capsaicin is able to inhibit the
functions of COX-1 and COX-2 enzymes in animal experiments and in human observations.
The further scientific research may offer an absolutely new pathway(s) for the development
of drug (s) by the stimulation of capsaicin-sensitive afferent nerves by the usage of small doses
of capsaicinoids to patients, who have to be treated with nonsteroidal anti-inflammatory drugs
and for other diseases requiring cyclooxygenase inhibition (inflammations, tumors).
4.6. Summary of expters’ opinion
The plant  origin capsaicinoids (capsaicin,  dihydrocapsaicin,  norcapsaicin,  dihydrocapsai‐
cin, homocapsaicin, homodihydrocapsaicin) are well known and used as nutritional additive
agents in the every day nutrional practice from the last 7000 years, however, we have a
very little scientifically based knowledge of their chemistry, physiology, pharmacology in
animal observations, and in humans up till the end of 20th century. Our knowledge from
their chemistry, physiology and pharmacology entered to be scientifically based evidence
from the years of 1980s, dominantly upon animal observations. The human observations
with capsaicin (capsaicinoids), in terms of good clinical practice, have been started only in
the last ten years in randomized, prospective, multiclinical studies. The name of “capsai‐
cin“ used only in the physiological and pharmacological research both in animal experi‐
ments  and  in  human  observations.  The  “capsaicin“ (as  a“chemically“  used  natural
compound) modifies the “so-called“ capsaicin-sensitive afferent nerves, depending on their
doses of application.
Aims: The specific action of capsaicin (capsaicinoids) on sensory afferent nerves modifying
gastrointestinal (GI) function offers a possibility for the production of an orally applicable drug
or drug combinations, which can to be used for human medical therapy. The production of a
new drug needs to be based on the critical interdisciplinary review of the results obtained with
capsaicinoids.
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside322
Materials and methods: This paper gives an interdisciplinary and critical overview on the
chemical, physiological, pharmacological and toxicological actions of the natural origin
capsaicinoids (from the point of drug production) under conditions of acute, subacute and
chronic administration in animal experiments and human observations for toxicology and
pharmacokinetics.
This interdisciplinary review covers the following main chapters: 1. Physiological and
pharmacological research tool by capsaicin in the animals and human beings; 2. capsaicin
research in animals (including the acute, subacute and chronic toxicology, metabolism as well
as genotoxicology); 3. Pharmacological observation with capsaicin in human beings.
Conclusion: 1. The capsaicin used in the physiological and pharmacological observations (in
animals and human beings) chemically represents heterogenous chemical compounds, which
can be obtained from the plants (paprika, chilli, etc). 2. Capsaicinoids are able to modify the
capsaicin-sensitive afferent nerves, which play principle roles in the defence of various organs
(including the gastrointestinal tract (against heat, stress, chemical-induced damage). 3. The
beneficial effects of capsaicin (capsaicinoids) application on gastrointestinal tract obtained in
animal experiments can be converted for humans observations. After this interdisciplinary
and critical review, this paper demonstrates well-planned research pathways of discoveries
on capsaicinoid chemistry, physiology, pharmacology and toxicology in animal experiments
and human observations.
5. Some general scientific problems in the application of the plant origin
compounds in the every used foods and drugs
The evaluation of effectiveness and safety of chemically produced compound(s) is very strickly
regulated testing program both in animals and in humans.
After very careful and critical overview of plant origin compounds, it was very surprising to
see that health and scientific requirements differ so much in regards of their application as
dietary (Response to EMEA Consultation Document CPMP/QWP/2819/00 REV 1 AKA EMEA/
CVMP/814/00 REV 1: Guideline on Quality of Herbal Medicinal Products/Traditional Herbal
Medicinal Products (Released 21 July 2001/Consultation Date 30th September 2005) and as a
drug terapy (this Notice to Applicants (NTA) prepared by the European Commission in
consultation with the competent authorities of the Member States, the European Medicines
Agency and interested parties in order to fulfil the Commission’s obligations with respect to
article 6 of Regulation (EC) No. 726/2004, and with respect to the Annex I to Directive 2001/83/
EC as amended (Directive 2003/63/EC, OJ L 159 27.6.2003 p.46 NTA, Vol. 2B-CTD, foreword
& introduction, edition June 2006).
We, the authors of this review could not understand the extremely high number of application
of plant origin compounds needed to be applied for foods, food additive agents, health
modification compounds and classical drugs (especially orally applicable preparations).
Clinical Pharmacological Approach of Capsaicin Action in GI Tract
http://dx.doi.org/10.5772/58359
323
A lot of chemical compounds are used during the culturation of different plants, which are be
used as sources of various compounds of food or drug preparations. Furthermore, during the
preparation of the cultivated plant are treated with different chemicals to result aimed chemical
compounds (we can use only “Drugs Master File“, surprisingly up to now no “Food Master
File“). These aspects are remained out off the scientific area up till present time.
The medical sciences emphasize the prevention of different diseases. Our main question is
why these aspects remained out of the scope of science?
In case of capsaicin, we have the following main problems:
1. The research of physiology and pharmacology only “capsaicin“ is mentioned all the time,
while the capsaicin as a plant source compound chemically does not represent one
chemical entity;
2. The content of capsaicin (Sigma-Aldrich, USA) is also not standard, because its content of
capsaicin, dihydrocapsaicin, nordihydrocapsaicin and other capsaicinoids can vary;
3. No correct Drug Master File (DMF) for capsaicin (capsaicinoids) has been prepared;
4. No classical animal toxicological (including the germinative function) examinations have
been carried out for capsaicin (capsaicinoids);
5. No classical preclinical dossier exists for capsaicin;
6. No classical human clinical pharmacological study (human phase I-II) exists in the
international literature.
Our research team works in capsaicin research from 1980 using mostly animal experiments,
but starting form 1997 we are studiing capsaicin physiology in human investigations (under
permission of the the Regional Ethical Committee of Pécs University, Hungary).
We actively participated in innovative research of capsaicin (capsaicinoids) to produce a new
drug or new drug combinations affecting capsaicin sensitive afferent nerve function offering
an absolutely new gate for gastrointestinal pharmacology (Mózsik et al., 2009a,b; 2010)
6. Chemical composition of capsaicinoids originated from plants and their
botanical backgrounds
In physiological and pharmacological research capsaicin is generally used as “one chemical
compound“. Capsaicin (capsaicinoids) is (are) active chemical substance(s) extracted from
paprika, chilli, chillies, which is (are) able to modify the capsaicin-sensitive afferent nerves.
This (these) compound(s) stimulates (stimulate) in smaller doses and inhibits (inhibit) in higher
doses of capsaicin-sensitive afferent nerves.
Szolcsányi and Barthó demonstrated first that capsaicin given in doses of 5-50 µg/mL inhibits
the development of gastrointestinal mucosal damage (Szolcsányi and Barthó, 1981). Similar
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results were obtained in systematic research on gastrointestinal tract in animals (Mózsik et al.,
1997) and human healthy subjects treated with indomethacin (Mózsik et al. 2005; Mózsik et
al., 2009a,b).
The action of capsaicin expresses itself as an initial short-lasting stimulation that can be
followed by desensitation to capsaicin itself and to other stimuli of afferent sensory neurons.
Capsaicin applied in ng to µg/ kg doses to the peripheral or central endings or cell bodies of
sensory neurons induces transient excitation. In response to stimulation peptide mediators are
released from the central and peripheral nerve endings (Szolcsányi, 1984; Maggi, 1995). These
four response stages could be separated: 1. excitation, 2. sensory-blocking, 3. long-term
selective neurotoxic impairment and 4. irreversible cell destruction. From the point of gastro‐
intestinal mucosal protection only the small doses of capsaicin have clinical relevancy (these
doses 200-1200 µg/person) (Mózsik et al., 2005; Mózsik et al., 1997; Mózsik et al., 2009a,b; 2010,
Szabó et al., 2013).
Seven  capsaicinoids  and  their  chemical  structures  have  been  identified  from  different
Capsicum  species:  C. annuum; C.  frutescens;  C.  chinese;  C.  baccatum; C. pubescens)  (Table 9)
(Basu and De, 2003; Anu and Peter, 2000; Jurenitsch et al., 1979): capsaicin, dihydrocapsicin,
nordihydrocapsaicin,  homodihydrocapsicin;  homocapsaicin;  nonanoic  acid  vanillylamide  and
decanoid acid vanillylamide (Basu and De, 2003, Anu and Peter, 2000; Jurenitsch et al., 1979).
The first five compounds represent capsaicin homologues, meanwhile the last two represent
capsaicin analogues (Fig. 16).
The fine chemical trading firms (including Sigma Aldrich and others) obtain the capsaicin from
plants (Capsicum). According to the chemotaxonomic key, the different species of Capsicums
contain different amounts of capsaicin homologues and analogues (Jurenitsch et al., 1979)
(Table 13).
Species Flower colour Number flw/node Seed colour Calyx constriction
C. annuum white 1 tan absent
C. frutescens greenish 2–5 tan absent
C. chinese white/greenish 2-5 tan present
C. baccatum white with yellow spot 1–2 tan absent
C. pubescens purple 1–2 black absent
* For further informations, see Ref. Mózsik et al.(2009b)
Table 12. The morphological identification of the five major species*
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A lot of chemical compounds are used during the culturation of different plants, which are be
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Figure 16. Structure of capsaicin and natural capsaicinoids (Mózsik et al, 2009b).
Accordingly, the commercially available natural capsaicin preparations are mixtures of
capsaicin and natural capsaicinoids (Fig. 17).
The capsaicin preparation can be used as an active pharmaceutical ingredient (Capsaicin
Natural) is described by the United States Pharmacopeia (USP). The 2006 edition of USP30-
NF25 described its definition, identification, melting range and the content of capsaicin,
dihydrocapsicin and other capsaicinoids. According to the USP requirements Capsaicin
Natural should contain not less than 90 percent of total capsaicinoids. The content of capsaicin
and dihydrocapsaicin should not be less than 75 percent, and the content of other capsaicinoids
should not be more than 15 percent calculated on dried basis [USP30-NF25 Page 1609].
The principal requirements of the European Authorities for capsaicinoid content of natural
capsaicin preparations usable in medical therapy are the same as those of USP30-NF25.
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1. NDHC fraction over 9.5 %
1.1 Cfraction over 56 % Capsicum baccatum var. pendulum
1.2 C fraction under 56% Capsicum annum var. annum
2. NDHC C Fraction 9,5 % Capsicum annum var. annum
2.1 C fraction, 42 to 57 %
2.2 C fraction under 42 % Capsicum baccatum var. pendulum
2.3 C fraction, 57 to 73 %
DHC fraction 26 to 34 %
Total capsaicinoids, under 0,35 % Capsicum baccatum var. pendulum
2.4 C fraction over 63%
DHC Fraction under32 %
Total capsaicinoids, over 0,35 % Capsicum fritescens – Capsicum chinense complex
Abbreviations: C, capsaicin; NDHC, nordihydrocapsaicin; DHC, dihydrocapsaicin
* For further I nfromations, see Ref. Mózsik et al.(2009b).
Table 13. A chemotaxonomic key to the identification of cultivated Capsicums*
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Figure 17. Gas-chromatographic (GC-MS) analysis of a commercially available natural capsaicin preparation. Reten‐
tion times: 16.8 min: nordihydrocapsaicin, 17.5 min: capsaicin, 17.7 min: dihydrocapsaicin [36].
For pharmaceutical industry and human clinical pharmacology the presence of several
components of natural capsaicin preparations represent special technological and clinical
pharmacological difficulties. Namely, we have to quantify these components of capsicum
extract in the pharmaceutical preparations as well as in the human biological blood samples,
consequently we have to use specific and sensitive analytical methods.
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Figure 17. Gas-chromatographic (GC-MS) analysis of a commercially available natural capsaicin preparation. Reten‐
tion times: 16.8 min: nordihydrocapsaicin, 17.5 min: capsaicin, 17.7 min: dihydrocapsaicin [36].
For pharmaceutical industry and human clinical pharmacology the presence of several
components of natural capsaicin preparations represent special technological and clinical
pharmacological difficulties. Namely, we have to quantify these components of capsicum
extract in the pharmaceutical preparations as well as in the human biological blood samples,
consequently we have to use specific and sensitive analytical methods.
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7. Drug Master File (DMF)
To receive permission for human use of capsaicin preparations from the National and
International Regulatory Authorities we have to present the following details: 1. specification
of the Capsicum species; 2. climatic regulations of places of Capsicum cultivation; 3. chemical
treatments of Capsicum plants during their cultivation; 4. details of treatment of Capsicum plants
(their collections, drying, extractions storages, etc.), analytical results supporting the chemical
composition of the plant origin capsaicinoids extract; 6. chemical stability of the natural
capsaicin (capsaicinoids); 7. analytical results showing the (possible) contamination of the
natural capsaicin product with organic phosphates, pesticides, fusariums, aflatoxin; 8.
international certification (including Food and Drug Administration, FDA) on capsaicin
(capsaicinoids) content of the natural preparation. Data of above mentioned facts need to be
given by internationally accredited laboratories. These data are collected in the Drug Master
File (DMF).
The leading chemical trading firms-concerning capsaicin supply-had no DMF for their
capsaicin preparations. Independently, several trading firms keep the natural capsaicin
(capsaicinoids) preparation on the market without the exact knowledge on the circumstances
of cultivation, details of extraction and stability of the product. They have no exact information
on the quantities of residues of organic phosphates, pesticides, fusariums, aflatoxin in their
preparation of capsaicin (proved by certifications of various internationally accredited
laboratories).
According to the observations of Foodnews Enviromental Working Group (food‐
news.org;http://www.drgreene.org/body.cfm?xyzpdqabc=21&action=detail& ref=1920), the
most sweet peppers are contaminated with more than one pesticide. Pesticides were not
detected only in 32 % of the samples, and 7 pesticides were observed in 1 % of tested samples.
The samples of Sweet Bell Peppers contain acephate, dicophol, dimethoate, diphenylamine,
fenvalerate, metalaxyl, methamidophos, methomyl, fermethrin; malathion, endosulfanes, azinphos-
methyl, o-phenylphenol, which may produce animal carcinogens, birth defects, brain and
nervous system damage as well as the damage of immune system and endocrine system
(Report Card www.ewg.org).
In our case we found only one natural capsaicin preparation with Drug Master File (DMF)
from India, which signed by the Food and Drug Administration, USA. Along with this
preparation, we could not exact information from the manufacturer on above mentioned data
to be incorporated into the DMF.
8. Preparation of human clinical pharmacological studies
We wanted to use capsaicinoid preparation as an orally applicable drug or part of a drug
combination in human beings.
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We compiled the below listed documentations for the National Institute of Pharmacy to apply
permission for human clinical pharmacological studies with capsaicin preparation
1. experts’ opinion; 2. results of all toxicological studies; 3. chemical stability of the natural
capsaicin preparation; 4. results of pharmaceutical industrial formulation from the natural
capsaicin; 5. various permissions from our University; 6. documentation of health insurance
of volunteers; 7. preclinical dossiers; 8. documented valid permission on the accreditation of
Clinical Pharmacological Unit for human phase I and II examinations (accreditation controlled
by the National Institute of Pharmacy in Hungary); 9. exact protocols for human clinical
pharmacological studies; 10. written information on the planned examinations for the volun‐
teers; 11. request for authorization of a clinical trial on medical product for human use to the
competent authorities and ethical committees in the community; 12. lists of investigators
(together with their CV), data of involved institutes (departments participating in the study).
9. The National Instute of Pharmacy in Hungary requested additional
exmainations with natural capsaicin (capsaicum natural usp 27) obtained
from India on geno-and other toxicological examinations
The National Institute of Pharmacy in Hungary requested additional examinations with
natural capsaicin (Capsaicin Natural USP 27) obtained form India on geno-and other toxico‐
logical studies due to having limited knowledge of circumstances of cultivation, collection,
storage, stability and preparation. In the literature some data were available supporting
genotoxic property of some natural capsaicin preparations by different researchers. Some
positivities were indicated with natural capsaicin on its genotoxicity and the different re‐
searchers suggested that these mostly depend on various enviromental factors of natural
capsaicin, since these tests were negative with synthetic capsaicin.
These requisted studies with the natural capsaicin obtained from India were 1. testing of
natural capsaicin with bacterial reverse mutation assay; 2. testing of mutagenic effect of natural
capsaicin by mouse micronucleus test; 3. 14-day oral average dose range finding study with
natural capsaicin in rats (30–60 and 120 mg/ kg. b. w. orally for 14 days); 4. oral dose range
finding toxicity study of natural capsaicin in Beagle dogs (0.3 – 0.6 – 0.9 mg /kg. b. w. /day
orally for 14 days); 5. 28-day oral toxicity study of natural capsaicin in rats (placebo, 5, 15 and
30 mg/kg b. w orally for 28 days); 6. 28-day oral toxicity study of test item natural capsaicin in
Beagle dogs (placebo, 0.1 – 0.3 – 0.9 mg/kg b. w/day orally for 28 days) (together with capsaicin
kinetics).
Determination of LOD and LOQ (Reilly et al.,2002).: Limit of detection (LOD) was determined
experimentally, and taken as the concentration producing a detector signal that could be
clearly distinguished from the baseline noise (3 times baseline noise). The limit of quantifica‐
tion (LOQ) taken as the concentration that produced a detector signal ten times greater than
the baseline noise. The LOD and LOQ values of capsaicin and dihydrocapsaicin in dog's
plasma were found to be 2 ng/mL and 10 ng/mL, respectively.
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clearly distinguished from the baseline noise (3 times baseline noise). The limit of quantifica‐
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The sensitivity of the present method exceeds that of the HPLC-MS methods previously
reported for determination of the two main capsaicinoids in rat plasma and tissues (Reilly et
al., 2002). Furthermore, the method is practical and less expensive than current methodology.
In our experience, after per os administration of Capsaicin natural (USP 29) in dogs neither
capsaicin nor dihydrocapsaicin could be detected in the plasma samples. Our HPLC-FLD
results were confirmed by investigation of the samples by HPLC-MS. Ex vivo animal investi‐
gation of pharmacokinetics of per os administered capsaicinoids are under way by means of
the present method for better understanding of the gastrointestinal fate of capsaicinoids.
In the 2005-2008 time period our innovative drug research produced the following main
subjects: 1. developed and validated methods for testing of drug active agents, and for testing
of biological samples: 7 methods; 2. developed of a validated liquid chromatography-mass
spectrometry (LC-MS) method for testing of drug(s) (and their metabolites) in biological
samples; 3. developed other validated analytical protocols: 7 protocols; 4. validated genotox‐
icity examinations were carried out with natural capsaicin; 5. internationally validated 14-day
oral gavage range finding studies were carried out with natural capsaicin in rats and dogs; 6
internationally validated complete 28-day oral toxicity studies were carried out with natural
capsaicin in rats and Beagle dogs (Mózsik et al., 2008 a,b,c,d,e,f,g,h).
After compilation of the results of these observations we received permissions from the
National Institute of Pharmacy in Hungary for human phase I. clinical pharmacological studies
for natural capsaicin (Capsaicin Natural USP27) used alone and natural capsaicin plus NSAID
combinations. Our industrial partner was PannonPharma Ltd., Pécsvárad Hungary, who did
the pharmaceutical industrial research in the field.
10. Human phase I. single-blind study comparing the pharmacokinetic
properties of asa and its platelet aggregation after single administration
alone and co-administration with two different doses of capsaicin (400 and
800 µG) and evaluating their safety in healty male jubjects
(protocol number: 1.4.1; EudraCT number: 2008-007048-32)
10.1. Main aims of these studies
We planned to produce various drugs combinations, in which ASA, diclofenac, Naproxen (as
NSAIDs) were combined with capsaicin(oids) in tablet [suggesting that the NSAIDs induced
GI mucosa damage can be prevented by the capsaicin(oids)].
1. To plan the chemical compositions of these drug combinations for their pharmaceutical
industrial productions (dosages, bioadhesive compounds of tablets) and to produce them.
We wanted to start with a human clinical pharmacological phase I. examinations (respec‐
tive all the national and international experts’ requirements and necessary permissions
form different (18) Authorities) (Mózsik et al., 2010).
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2. We wanted to study whether the capsaicin(oids) (orally given in different doses, which
only stimulate the capsaicin-sensitive afferent nerves) is(are) able to modify the absorp‐
tion, metabolism, excretion of NSAIDs and their specific pharmacological actions (e.g. the
platelet aggregation in case of ASA) in human healthy subjects.
This book chapter deals with the problems and results of ASA+capsaicin(oids) combination in
healthy male subjects during “classical human pharmacological phase I. examinations“.
Inclusion and exclusion of so-called healthy persons for the human phase I. examination
(according the principals of clinical pharmacology) and characterizations of different somatic
parameters of included healthy subjects into the phase I. study,
3. Schedule of the protocol for whole study (including the clinical phase, detections of
capsaicin(oids), measurements of ASA – and salicylic acid (as one of the metabolites) of
ASA and platelet aggregation produced by capsaicin(noids) (given in two doses) alone or
in combination with ASA),
4. The registrate the tolerance and safety of these combinations in these clinical pharmaco‐
logical studies,
5. Definitive results of measurements of plasma capsaicin and dihydrocapsaicin, and their
evaluation,
6. Pharmacokinetic measurements of ASA, salicylic acid after application of ASA alone and
in combinations with capsaicin(oids) (given orally in two doses),
7. Platelet aggregation studies with capsaicin(oids) alone and capsaicin(oids) in combination
with ASA.
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2. We wanted to study whether the capsaicin(oids) (orally given in different doses, which
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The following doses of drugs were studied in this human phase I. examination:
• ASA : 500 mg,
• Capsaicin(oids) : 400 µg and 800 µg,
• ASA placebo,
• Capsaicin(oids) placebo.
”Human phase I. single-blind study comparing the pharmacokinetic properties of ASA after
single administration alone and co-administration with two different doses of capsaicin (400
and 800 µg) and evaluating their safety in healthy male subjects”
Protocol number: 1.4.1
EudraCT number:2008-007048-32
The study for human clinical phase I. examination was permitted by
the Hungarian Institute of Pharmacy (Budapest, Hungary) (dated by June 4, 2009),
the National Ethics Commitee for Clinical Pharmacology, Medical Research Council (Buda‐
pest, Hungary) (dated by March 11, 2009).
The clinical pharmacological study was carried out at Clinical Pharmacological Unit of the
First Department of Medicine, Medical and Health Centre, University of Pécs, Hungary.
The pharmacokinetic measurements were done at PannonPharma Pharmaceutical Ltd.,
Pécsvárad, Hungary.
The initiation date: March 10, 2011 and finished (including the clinical examinations, pharma‐
cokinetic measurements, mathematical analysis, closing of written reports) by December 6,
2012.
[Selected references to the preparation of protocols:
1. Declaration of Helsinki (1964) as revised in Tokyo (1975), Venice (1983), Hong Kong (1989),
Somerset West, RSA (1996) and Edinburg, Scotland (2000) with the Note of Clarification
on Paragraph 29,Washington (2002),
2. ICH Topics E3. Structure and Content of Clinical Study Reports. Step 4, Consensus
Guidelines from 30,11, 1995.Note for Guidance on Structure and Content of Clinical Study
Reports (CPMP/ICH/137/95). July 1996.
3. ICH Topics E6. Guidelione for Good Clinical Practice. Step 5. Consolidated Guideline from
01.05.1996.Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). January
1997.
4. R.H.B. Meyboom, Y.A. Hekster, A.C.G. Egberts, F.W.J. Gribnau, R. Edwards: Causal or
Causal? The Role of Causality Assessment in Pharmacovigilance – Drug Safety.
17.12.1997.
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside332
5. ICH Topic E2. A Clinical Safety data Management: Definitions and Standards for Expe‐
diting Reporting Step 5. 01.06.1995. Note for Guidance on Clinical Data Management:
Definitions and Standards for Expecditing Reporting (CPMP/ICH/377/95),
6. ICH Topic E9. Statistical Principles for Clinical Trials Step 4. Consensus Guideline
05.02.1998. Note for Guidance on Statistical Principles for Clinical Trials (CPMP/ICH/
363/96),
7. CPMP/PhVWP (III/3445/91): Causality classification in pharmacovigilance in the Euro‐
pean Community.]
10.3. Requested permissions from the different authorities before the start of human phase
I. examinations
We compiled the documentations for the National Institute of Pharmacy in Hungary to ask
for human clinical pharmacological studies with this capsaicin preaparation (all the documents
listed below were requested for receiving permissions):
1. Experts’ opinion (Mózsik et al., 2007b; Mózsik et al.,2009b´),
2. Results of all toxicological studies,
3. Chemical stability of the natural capsaicin preparation,
4. Results of pharmaceutical industrial formulation from the natural capsaicin,
5. Different permissions from University (Regional Ethics of Committee),
6. Documentation of health insurance of volunteers,
7. Preclinical dossiers (protocols for the planned clinical pharmacological studies),
8. Documented valid permission on the accrediation of Clinical Pharmacological Unit for
human phase I. and II. examinations – which accrediatation controlled by the National
Institute of Pharmacy – was prepared for the National Institue of Pharmacy in Hungary,
9. Exacts protocols for the human clinical pharmacoligical studies,
10. Written information on the planned examinations, for the volunteers,
11. Request for authorization of a clinical trial on medical product use to the competent
authoririties and for of opinion of the ethical committees in the community,
12. Lists of investigators (together with their CV), place institutes (departments) participating
in the study and of course, the all written agreements and permissions.
10.4. Collection, screening of the healthy male volunteers Selection on volunteers:
• In this study fifteen healthy male subjects, age between 18-55, BMI 18-29.9 kg/m2 were
involved,
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• A person is healthy if medical examination did not find any pathological signs and other
screening test parameters stated in this protocol were within the normal range and the
subject did not mention any significant disease when taking the case history,
• If, in the course of initial screening, some pathological values would be observed, these
findings had to be regarded as an exclusion criterion.  Having a laboratory parameter
out of the normal range could generally not regarded as an exclusion criterion provid‐
ed that:
• they were not accompanied by clinical symptoms,
• the context of related laboratory values gave no indication of pathological process and
• the Investigator regarded them as clinically irrelevant in a written form in the Case Report
File (CRF) from the accepted protocoll.
Inclusion criteria:
The subject could be involved in the trial if the following criteria had been fulfilled:
• Voluntary participation after given information (Informed Consent signed and dated before
the start of the screening period),
• Age between 18 and 55 years,
• Healthy male subjects,
• BMI: 18-29.9 kg/m2,
• Negative physical status by physical examinations,
• Laboratory parameters within the normal range,
• Normal ECG findings – standard 12 leads.
Exclusion criteria:
• Unwillingness or incapacity to sign the written Informed Consent Form,
• Any clinically significant acute or chronic abnormalities during the physical examinations
at screening,
• Clinically significant history or presence of any clinically significant gastrointestinal
pathology (e.g. gastric or duodenal ulcer, gastro-oesophageal reflux, chronic diarrhoea,
IBD), unresolved gastrointestinal symptoms (diarrhoea, vomiting),
• Clinically significant liver or kidney disease, or other condition which known to interfere
with the absorption, metabolism and excretion of the study drug,
• Clinically significant cardiac and neurological disease in the medical history,
• Any clinically significant changes of laboratory tests from blood and/or urine,
• Donation of blood within 3 months prior to the study,
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• Acute infection,
• Positive virological testing,
• Pathological findings on the standard 12 lead ECG,
• Hypertension (blood pressure higher than 140/90 mmHg (systolic/diastolic),
• Heart rate outside the range of 50-100 beats per minute,
• History of psychiatric diseases and treatment,
• Known hypersensitivity to any component of the study drugs,
• Use of any drugs known to induce or inhibit  hepatic metabolism (inducers for exam‐
ple:  barbiturates,  carbamazepine,  phenytoin,  glucocorticoids omeprazole;  examples for
inhibitors:  SSRIs,  cimetidine,  diltiazem,  macrolides,  imidazoles,  neuroleptics,  verapa‐
mil, flouroquinolones, and antihistamines) within 1 month prior to study drug adminis‐
tration,
• Use of any prescribed medication within 14 days or over-the-counter medication within 7
days prior to study drug administration,
• Any depo injection or medication implant within 3 months prior to administration of study
medication,
• Any food allergy, intolerance, restriction or special diet i.e. vegetarian, which in the opinion
of the investigator could contraindicate the subject to participate in the study,
• Participation in another clinical trial within 3 months prior to this study,
• Positive screen on drug abuse,
• Positive alcohol breath test (at time of hospitalisation),
• Known drug or chronic alcohol abuse, drug addiction,
• Malignant disease,
• Smoking more than 10 cigarettes/day (or comparable),
• Excessive caffeine drinking (more than 3 cups a day),
• Legal incapacity and/or other circumstances rendering the volunteer unable to understand
the nature, scope and possible consequences of the study,
• Evidence of an uncooperative attitude,
• Vulnerable subject.
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10.6. Clinical parameters of included healthy male volunteers (Table 14)
Age of subjects from 20 to 44 years (average is 34.5± 6.7 years),
Body heights form 170 to 196 cm) (average is 180.8± 6.9 cm),
Body weights from 69.5 to 101 kg) (average is 84.8± 9.6 kg),
Body Mass Index (BMI) from 20.77 to 29.68 kg/m2 (average is 25.97 ± 2.87 kg/m2).
Table 14. Clinical parameters of included healthy male subjects in our human phase I. studies. (Number of
volunteers=15) (average ± SD):
10.7. Study design (Figure 18)
Figure 18. Study design of human phase I.examination of capsaicin alone or co-adminsiration with Aspirin (ASA)
10.8. Study procedures and treatment periodes – Study procedure in both treatment periods
Hospitalisation of subjects:
Subjects were required to attend the Unit on the evening preceding dose administration not
later than 8:00 p.m. Subjects should fast for 10 hours (9:00 p.m. – 7:00 a.m.) prior to dosing.
Only water may be drunk after the evening meal until 6:00 a.m. and then no fluids will be
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taken prior dosing. Subjects had to remain in upright position (i.e. sitting, standing) for 30
minutes after dosing. Meals were provided within the Unit. Subjects were allowed to leave the
clinic after the last blood sampling post dose or after blood drawing for safety laboratory tests.
Daily activities during the trial:
Period 1:
Day 0: This day was the day before administration of the study medication and had to be not
later than 2 weeks after screening. Subjects had to report to the clinic at 8 p.m. on the day before
dosing. The subjects received an evening snack which had to be consumed until 9 p.m.,
• Short interview for possible presence of exclusion criteria,
• Physical examination, temperature, blood pressure, pulse rate ECG,
• Alcohol breath test,
• Urine drug test was performed.
Day 1-2: The following procedures were carried out or checked prior to the drug administration
in all subjects:
• Insertion of the intravenous canule, if applicable,
• Blood sampling for pharmacokinetic analysis before dose (0:00 h),
• Study drug administration between 7 and 9 a.m. according to the randomization list.
Compliance check had to be performed. Subjects took the medication with 150 ml water in
upright position and remained upright for 30 minutes after dosing.
• Additional 150 ml water had to be drunken 2 hours after drug administration,
• Blood sampling (4 ml) for pharmacokinetic analysis up to 24:00 h after administration (pre-
dose and 0:10, 0:20, 0:40, 1:00, 1:30, 2, 4, 6, 10, 12, 16, and 24 hours post dose) with separation
of plasma,
• 12-lead ECG examination after the 4 hour blood sample, and before the meal,
• Standard meal 4 hours post dose,
• Questioning for and registration of adverse events.
• Wash-out period: A wash-out period of at least 3 days followed the all but one each
treatment period; registration of adverse events.
• Following study periods: Procedures over 3 days (please see day 0 to 1 in period 1) identical
with period 1. After the last study period completed final examinations were carried out.
• Water intake: During the period from two hours prior to dose administration until after the
4 hour blood sample was taken, each subject took 150 ml of water with the dose and 150 ml
of water after the 2 hour blood sample. No other fluid was permitted during this time.
Subjects were allowed to drink water ad libitum.
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• Diet: Four hours after the drug treatment, subjects consumed a standard meal, well-
balanced in carbohydrates, lipids and proteins and resume their normal rate of fluid intake.
Concomitant medication:
• Concomitant medication was generally not allowed for the duration of the study. If this was
considered to be necessary for the volunteer’s welfare it could be given at the discretion of
the Investigator. The volunteers had to inform the Investigator about any intake of other
medicine in the course of the trial. Any intake of concomitant medication had to be docu‐
mented in the Case Report Form (CRF).
• Additional intake of acetylsalicylic acid was considered as exclusion criteria.
Post-study procedure:
• Within one week after the last blood sampling time point of the last treatment period follow-
up examinations was performed:
• Physical examination (incl.: blood pressure, heart rate, body weight, temperature), ECG,
• Laboratory test: haematology, blood chemistry and urine (after 10 hours fasting condition),
• Clinically relevant deviations of laboratory parameters (with the exception of those
measured during the screening period) were regarded as adverse events.
10.9. Drug administration schedule and randomization of healthy male volunteers included
into the study
Treatments
Sequence 1 400 400+ASA 800 800+ASA ASA
Sequence 2 400 400+ASA 800 ASA 800+ASA
Sequence 3 400 400+ASA ASA 800 800+ASA
Sequence 4 400 ASA 400+ASA 800 800+ASA
Sequence 5 ASA 400 400+ASA 800 800+ASA
The table above indicates only the active drugs. The remaining drugs are placebos.
It means the following:
400:1 tablet of 400 µg capsaicin+1 ASA placebo+1 capsaicin placebo
800:2 tablets of 400 µg capsaicin+1 ASA placebo
ASA:1 tablet of ASA+2 capsaicin placebo
ASA+400:1 tablet of ASA+1 tablet of capsaicin 400 µg+1 capsaicin placebo
ASA+800:1 tablet of ASA+2 tablets of capsaicin 400 µg
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10.10. Randomization of volunteers for this pharmacokinetic study (Table 16).
Sequence 1 Sequence 2 Sequence 3 Sequence 4 Sequence 5
Subject
number
6 4 3 2 1
10 8 11 9 5
13 14 12 15 7
The numbers in the table indicates the order of volunteers in time of inclusion. The time of the study was five
weeks (3 days for the kinetic measurements, 3 days for wash-out) (see later)
Table 16. Random allocation of healthy male volunteers in this study
10.11. Chemical composition of “capsaicin“ (capsaicinoids)
The United States Pharamcopeia defines capsaicin as product with contains >55% capsaicin,
and combination of capsaicin and dihydrocapsaicin >75%; total capsaicinoids may be as little
as 90% (United States Pharmacopoeia, 2005; USP 37).
This capsaicin definition is used as capsaicin in the animal researches and as well as in human
observations.
The measurements of capsaicin and dihydrocapsaicin are accepted in the animal and human
pharmakokinetic observations.
10.12. Measurements of Capsaicin and Dihydrocapsaicin from the plasma of volunteers
Measurements were performed:
• by High Pressure Chromatography (HPLC)-limit of detection by HPLC is 20
nanogram /mL plasma,
• by Liquid Chromatography – Mass Spectromery (LC-MS)-limit of detection is 26 fentogram/
mL for capsaicin and 20 fentogram/mL for dihydrocapsaicin.
Results:
No capsaicin and no dihydrocapsaicin could be detected in any samples of plasma of volun‐
teers, after oral application of capsaicin (given orally in doses of 400 µg and 800 µg) in time
period of 0 to 24 hours. If we applied the capsaicinoids externally to the equipments, then we
were able to detect both capsaicin and dihydrocapsaicin.
(Similar negativ results were obtained in Beagle dogs treated different doses (0.1, 0.3 and 0.9
mg/kg/body weight orally in every day for one month period) (Mózsik et al. 2008; Boros et al.,
2008).
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• Diet: Four hours after the drug treatment, subjects consumed a standard meal, well-
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Concomitant medication:
• Concomitant medication was generally not allowed for the duration of the study. If this was
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medicine in the course of the trial. Any intake of concomitant medication had to be docu‐
mented in the Case Report Form (CRF).
• Additional intake of acetylsalicylic acid was considered as exclusion criteria.
Post-study procedure:
• Within one week after the last blood sampling time point of the last treatment period follow-
up examinations was performed:
• Physical examination (incl.: blood pressure, heart rate, body weight, temperature), ECG,
• Laboratory test: haematology, blood chemistry and urine (after 10 hours fasting condition),
• Clinically relevant deviations of laboratory parameters (with the exception of those
measured during the screening period) were regarded as adverse events.
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10.13. Pharmacokinetic measurements of ASA alone and in combination with
capsaicin(oids)
∙ ASA*
∙ ASA* + capsaicin(oids)** (400µg)
∙ ASA* + capsaicin(oids)** (800µg)
*500 mg orally given, ** orally given
ASA metabolism in humans
by ASA esterase
ASA → salicylic acid + acetic acid
Measurements: ASA and Salicylic acid
Table 17. Combinations of pharmacokinetic measurements of human phase I. examinations
Blood sampling:
• Blood samples of 4 ml were taken from the forearm vein at the following times: pre-dose
and 0:10, 0:20, 0:30, 0:40, 1:00, 1:30, 2, 4, 6, 10, 12, 16, and 24 hours post dose,
• Blood samples (14 in each period) were taken by vein puncture. Samples (4 ml) were
collected into tubes using anticoagulation agent (potassium fluorid). The total amount of
blood taken from each volunteer was not exceed 500 ml,
• After taking the blood sample for pharmacokinetic analysis, it was immediately transferred
to a bath of melting ice and remained there for not more than 20 minutes. After centrifugation
(1600 g, 4°C, 10 min), the separated plasma from each sample was divided into two aliquots
(not less than 1 ml in each tube) using transparent, polypropylene tubes and they were
immediately frozen and stored at a temperature below –20°C until analysis,
• Tubes were labelled. Each label contained the following information: study number, period
and sample number, blood sampling time point, subject’s randomisation number.
• After the end of clinical part, samples were transferred frozen directly to the analytical
facility. Samples were packed with dry ice for transport, no interruption of the freeze cycle
is allowed.
Pharmacokinetic and statistical evaluation:
The following pharmacokinetic parameters for the salicylic acid were calculated (by Prof.
Mihály Klincsik, Department of Mathematics, Pollack Mihály Faculty of Engineering Univer‐
sity of Pécs, Hungary) for each subject using model – independent approaches as follows:
• Cmaxobserved maximal concentration,
• Tmaxtime corresponding to the observed maximal concentration,
• AUC0-tlastarea under the plasma concentration time-curve, calculated by means of log-linear
trapezoidal rule from time zero to the last data point above quantitation limit,
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• AUC0-∞ area under the plasma concentration time-curve extrapolated from zero to infinity:
AUC0-∞=AUC0-last+Clast, calc./ λz, where Clast, calc represents the estimated plasma concentration
by the regression line at the last sampling time point with measured concentration above
the limit of quantitation, and
• λz represents the rate constant calculated from the regression line,
• t1/2 terminal half-life calculated from the terminal elimination constant λz : t1/2=ln2/ λz,
• MRT(mean residence time): MRT=AUMC0-∞/AUC0-∞, where AUMC is the area under the first
moment curve, calculated by the trapezoidal rule and extrapolated to infinit
Changes in pharmacokinetics of ASA metabolism:
Figure 19. Mean concentration curves of aspirin (ASA)(left figure) and salicylic acid (SA)(right figure) plasma concen‐
trations after oral administration of 500 mg ASA and co-administration of 400 and 800 μg capsaicin tablets in 15
healthy male volunteers
Figure 20. Log-linear plot curves of aspirin (ASA)(left figure) and salicylic acid (SA)(right figure) plasma concentrations
after oral administration of 500 mg ASA and co-administration of 400 and 800 μg capsaicin tablets in 15 healthy male
volunteers
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Figure 21. Changes of AUC0-tlast, AUC0-∞ and Cmax values for aspirin (ASA)(left figure) and salicylic acid (SA)(right figure)
detected in plasma of 15 healthy male volunteers after oral administration of 500 mg ASA and co-administration of
400 and 800 µg capsaicin tablets
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Table 18. P values from NOVA table comparing the mean values of the PK parameters
10.14. Platelet aggregation studies with ASA alone and in combination with capsaicin(oids)
10.14.1. Acetylsalicylic acid (ASA, Aspirin)
• high doses (500 mg) decreases pain, fever and inflammation,
• continuously taken low doses (75-325 mg) cause effective inhibition of platelet aggregation
prevention of cardiovascular and cerebrovascular diseases,
• the incidence of coronary heart disease among ASA nonuser high cardiovascular risk
patients is more than 15 cases per 1000 person-years,
• among low risk patients without ASA medication the incidence is less than 5 cases per 1000
person-years,
• high or low risk patients take low dose ASA everyday, the incidence of ACS became in the
high risk group 4, in the low risk group only 1 event per 1000 patient-years.
10.14.2. Upper gastrointestinal tract complications (UGIC) (peptic ulcer, bleeding, perforation)
• among the general population 1 case / 1000 person-years,
• endpoints are 5-10%,
• UGIC among patients on ASA is 2-3 cases / 1000 person-years,
• endpoints are 10-20%,
• daily-users of low doses ASA have a 3-5 fold increased RR for UGIC as non-users.
10.14.3. Study design
• 15 healthy male volunteers,
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• prescreening procedure demographic data BMI, medical history, physical examination
laboratory blood tests, urine test, urine drug test and viral serology (HBsAg, Anti HCV,
HIV),
• subjects were 18-55 years old and had a BMI of 18-29.9 kg/m2.
Treatments
Tablets
400 µg capsaicin 500 mg ASA capsaicin placebo ASA placebo
400 µg capsaicin 1 1 1
800 µg capsaicin 2 1
500 mg ASA 1 2
400 µg capsaicin +
500 mg ASA
1 1 1
800 µg capsaicin +
500 mg ASA
2 1
Table 19. Treatment protocol for ASA induced platelet aggregation on the epinephrine-induced platelet aggreagtion
10.14.4. Study of capsaicinoids alone, ASA and their combinations ont he epinephrine-induced platelet
aggregation int he healthy male volunteers.
Materials: following the drug administration (according to the randomized schedule of the
permitted human phase I. protocol) 8.1 ml blood was collected for platelet aggregation
measurements before drug administration (0.0) (as control) and in 1.0, 2.0, 6.0 and 24.0 hours
after drug administration.
Aggregation measurements: the epinephrine-induced platelet aggregation was studied by
CARAT TX4 optical aggregometer (Carat Diagnostics Ltd, Budapest, Hungary at 37 ºC based
on Born’ method (Born, 1962; Koltai et al.,2008).
Method of evaluation of the obtained results: aggregation index below 40% was considered
as clinically significant and effective inhibition of platelet aggregation.
Mathematical analysis of the obtained results was done by parired Student’s t test (after using
Kolmogonov-Smirnov’ test to check the normality of the data distribution), one-way ANOVA
test, Dunnett’s post-hoc test.
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Figure 22. The platelet aggregation after oral capsaicin alone in two doses (400, 800 μg) and after co-administration
of ASA (500 mg) in 15 male healthy subjects
10.15. Summaries and conclusions
• The human clinical pharmacological phase I. study (protocol number: 1.4.1; EudraCT
number: 2008-007048-32) was successfully carried out in human healthy male volunteers.
• The capsaicin (oids) with using biodhesive compound was successfully pharmaceutically
produced by PannonPharma Pharmaceutical Ltd. (Pécsvárad, Hungary
• The presence of capsaicin and dihydrocapsaicin (from the orally given capsaicinoids) was
not able to detect in the plasma of healthy male volunteers, who were treated with capsaicin
(oids) (in doses of 400 and 800 µg orally given).
• The capsaicin (oids) (given in doses of 400 and 800 µg orally does (do) not modify the
absorption, metabolism and excretion of orally given ASA.
• The capsaicin (oids) does (do) not modify the epinephrine-induced aggregation by ASA,
meanwhile the different doses of capsaicin(oids) alone have no direct action on the epi‐
nephrine-induced platelet aggregation.
• The capsaicin(oids) acts (act) locally in the gastrointestinal tract (indicating a good selection
of bioadhesive compounds during the pharmaceutical technological preparation of our ASA
+capsaicin(oids) combination.
• The results of these phase I. examinations offer us further possibility to carried out the
forthcoming phase II. and phase III. examinations in patients.
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